<SEC-DOCUMENT>0000320017-22-000016.txt : 20220322
<SEC-HEADER>0000320017-22-000016.hdr.sgml : 20220322
<ACCEPTANCE-DATETIME>20220322161046
ACCESSION NUMBER:		0000320017-22-000016
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220322
DATE AS OF CHANGE:		20220322

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CALADRIUS BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0000320017
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				222343568
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33650
		FILM NUMBER:		22759620

	BUSINESS ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920
		BUSINESS PHONE:		908-229-2590

	MAIL ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Caladrius Biosciences, Inc.
		DATE OF NAME CHANGE:	20150608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NeoStem, Inc.
		DATE OF NAME CHANGE:	20060906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHASE III MEDICAL INC/DE
		DATE OF NAME CHANGE:	20030819
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>clbs-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:845060b2-4e37-482c-8ae9-0e23a5d9619a,g:0f1463a6-505b-4611-9f37-25c6b798c5c1,d:7d049288b82e438c85d504cc3e9dc500--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:clbs="http://www.caladrius.com/20211231" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>clbs-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF80L2ZyYWc6NTdlN2Q3Njc4YjBjNGM2Mjk0M2FjNjA2NmU3MTM1ZDcvdGFibGU6YzU4ZjIzMTJhYjdmNDY4YWJhMGQwMjc3ZTA4Y2NiZGYvdGFibGVyYW5nZTpjNThmMjMxMmFiN2Y0NjhhYmEwZDAyNzdlMDhjY2JkZl8yLTEtMS0xLTcyMDI_54270153-0f69-4d14-b3dd-a275be190f36">0000320017</ix:nonNumeric><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF80L2ZyYWc6NTdlN2Q3Njc4YjBjNGM2Mjk0M2FjNjA2NmU3MTM1ZDcvdGFibGU6YzU4ZjIzMTJhYjdmNDY4YWJhMGQwMjc3ZTA4Y2NiZGYvdGFibGVyYW5nZTpjNThmMjMxMmFiN2Y0NjhhYmEwZDAyNzdlMDhjY2JkZl80LTEtMS0xLTcyMDI_448b8522-5499-4acb-b183-08fe66ca97fb">2021</ix:nonNumeric><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF80L2ZyYWc6NTdlN2Q3Njc4YjBjNGM2Mjk0M2FjNjA2NmU3MTM1ZDcvdGFibGU6YzU4ZjIzMTJhYjdmNDY4YWJhMGQwMjc3ZTA4Y2NiZGYvdGFibGVyYW5nZTpjNThmMjMxMmFiN2Y0NjhhYmEwZDAyNzdlMDhjY2JkZl81LTEtMS0xLTcyMDI_771dec68-0a83-4721-8b20-76028c070ccb">FY</ix:nonNumeric><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF80L2ZyYWc6NTdlN2Q3Njc4YjBjNGM2Mjk0M2FjNjA2NmU3MTM1ZDcvdGFibGU6YzU4ZjIzMTJhYjdmNDY4YWJhMGQwMjc3ZTA4Y2NiZGYvdGFibGVyYW5nZTpjNThmMjMxMmFiN2Y0NjhhYmEwZDAyNzdlMDhjY2JkZl82LTEtMS0xLTcyMDI_af1f2014-b355-451b-b9b5-f1123bf8d701">false</ix:nonNumeric><ix:nonNumeric contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzItMC0xLTEtNzIwMg_0a058abe-d734-4c31-a82c-efb4e8bc4aad">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzItMC0xLTEtNzIwMg_d0558917-552f-48e0-95eb-612098e4b721">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzYtMC0xLTEtNzIwMg_3827fe5c-6ee8-4d37-a233-c3c99088f192">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzYtMC0xLTEtNzIwMg_bfd3c824-688d-44a3-a795-98776d67c466">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzctMC0xLTEtNzIwMg_430fdfa5-3899-44a5-b33b-301b103d665c">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzctMC0xLTEtNzIwMg_95df09b8-b8ab-49d7-988b-87cfc081e730">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i3c06d396aa1143d3b027ef1142d83cb5_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEyNTk4_1483d86e-ff2f-4b87-a4f3-f6e1bf4d50d7">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i58d1afa2bd9346fc97c1b81a5e0a4fd1_I20210131" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTIvZnJhZzpkNWMwNjExYmY2OWQ0MzEzODVhZWJiYTQ1YjY2MjNkYi90ZXh0cmVnaW9uOmQ1YzA2MTFiZjY5ZDQzMTM4NWFlYmJhNDViNjYyM2RiXzExMw_4eca3aec-2590-4ec9-a97a-9cf0403bfa89">P5Y6M</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="clbs-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if90ca5338733460a971066d59766dc81_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ibab4128b577c44a6906698d794637dfa_I20220322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4277098eb8e941d8849e8e36535b5f36_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f6e5136b8641cfa6b0a6033d36e4f2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib68115849dea4da8a299b880b533d09e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85f50c88c76b46fb9a9fdce9451675bd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i121f073fba6944229ad70a1d2216e933_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0b6071a73644d039603573d50440ef9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib80ecf1156d64c119d881173740ad234_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaaa7498b3d44ce1bcad37ed96000058_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22fd97027cb3412289b307029b9c5d44_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i348737336b4d46088a36ffcdbf611676_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic33cdb661db24963b1bfc647608c3a94_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ec6574cc7fc442f846e686e0a84ff71_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35b1729b0f074c18b9bceadc165d9549_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0ff61bf14d841cc822f4506607be1ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief8aba9cebaa4b98af858420b6d60b7f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i041d14ec45c44c8fb3cc8034c61ca2ed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b6458eb2d574b56bd1552b4ca244e6f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09a9631d583b4e668c5ba6e87d883e35_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf75562bf4d943e689edffa4d6485601_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3f51b0ee3ea49bba7a5f4081d6ded24_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if085aac894864f8a99c23eb6f47d40df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0e019f45caf44e48d650bf1abbafe32_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic49793f351ee420aad500948204d4e30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b3b4197bf6b40bd9ea38bf539ff4783_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb8d59a888234a98a095e58d9743487f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i590074ecb1084218835cf2d097815608_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c4ae4fba6464ce49a9062a34c2c26ce_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1d500671ff149bcba1096235d4f0351_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08c8bd3f15da40f487ae7ccc5cd6ce0b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85b3581054004614935d85f02ba032eb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i138b992a9f394701a484d131a2d03699_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4300a282ab74c7fafc35eaf54a4d1b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i281d8d9652bf482bb56d77de34f2b394_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9b7f001d8d64dcf8ca8ba24c50737f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb79bfd702f54177906acce5d83f1c8d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd0fb63052524135af561bfff992a6c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66d93ded2f34467d936905ead482129f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8805752994c49a8983ffea360e4c657_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62dba77d3e2d4497b9f85f984cfba083_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">clbs:CLBS16TreatmentOfCMDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71b84bd2ef5e48a7bdb1280f312427a2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0be130c99cf043d29b10c289f1311bf5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66e36ae7aaf0456e850ea8fbf00533f0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c6296c462c944e98b58dc2225093cca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bd83120aa4846998e97a3591fb90ade_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccc34d3422ed44678794bda76d2eaf4b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bb11fcb1dc24116a57364c1887e3eee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5468258328d0445fae4d4028b71bf1d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dc62f8ee9d94752a5a99f633d893ab6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea9f8dda92dc4bd8a85d72b68a1c2034_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if63b1c1c78bf4e0282c0521dfe489b5b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i048ee8e3bbb048d3a2c27c95245f5f26_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">clbs:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ce00799bd1b413ea234f8cba5445fa0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">clbs:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a31510bd7f84ebd8c107e3f8ae7e451_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd367f49394e4ab892e5ef3d131cbacb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i310aef3fef4244c585bf799759419229_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib92b79ab0ccd455ead408147f405a076_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d9629ce58cd4f72b9770fbf37dff34a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44c2bc8d551a45f1ac6ddf183da926e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia36b0d5241f648078a95606bbd0ff79d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56f86dd405f8453396a3f70388a0570d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bccb0f475cc4d218304cd754913183a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0919bea6d44b4365b7bf14cfc4143c4f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecc81b9b2d6b49b0b19a54a285242744_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id672da1b89c34c4e9eff23a1f19e2531_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9772fdb5cd8471f96f384eb173d43ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63e392b1e77d4c5eac2465ca78a69cbd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4584a12f69824f27abd288e3a1a3d90f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26b465f7839c460fad563a663abb5e53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5830c986cd0e460abfdcf8d771b6070f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b6161f803dd4b47b8ed44fadd5ac665_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c5d1caf1a754f32a2b36182140d1778_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fda5905c1054d06a90a8cbf51b93a97_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="office"><xbrli:measure>clbs:office</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ia3d14c5a5f224864ad0dabc919f68696_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EquityIncentiveCompensationPlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic520fa50fa274ec688df80ce26839e93_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EquityIncentiveCompensationPlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib349cdd63be447d58d8816ef0e5c45d5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EquityIncentiveCompensationPlan2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6839ac3846014921bbf0418907b17b41_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EquityIncentiveCompensationPlan2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c3abe0816124623859688fce308ef7d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EquityIncentiveCompensationPlan2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ea30e24d2234509b67b4bb09c8f3d27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EquityIncentiveCompensationPlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i125c01a6899241f092b94c8c6d510bcb_I20130101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EmployeeStockPurchasePlan2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2c17509e40c431c93f98142b8bee4f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="offering_period"><xbrli:measure>clbs:offering_period</xbrli:measure></xbrli:unit><xbrli:context id="i28542dcef1334e33863c7a40beba93ac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5adb43718d3c4cdf96885dcfb77648d0_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EmployeeStockPurchasePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia54075aa02684beb8ab89afa65b0d48d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EmployeeStockPurchasePlan2017AmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27caf2e77bc5468785bb299e95eb6191_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EmployeeStockPurchasePlan2017AmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81fbec32b886419d9100b66971330fc6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EmployeeStockPurchasePlan2017AmendedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaffc3258262f48dcbbf5775b82cf558e_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:LincolnParkAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec24a6e53385419d9edb327599fc7c12_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:LincolnParkAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5e26195328b4591826e01006d17f63d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:LincolnParkAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0ab769fd5384e5c8fa1c574d03e7274_I20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:H.C.WainwrightSalesAmendedAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18cb5d7872684b26a43eaec5bc10e4bb_D20180801-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:H.C.WainwrightSalesAmendedAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe7b2ea590f64edea9436bb291dddfe3_D20180201-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:H.C.WainwrightSalesAmendedAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2959d4ff885948268aa6c8327cf31262_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:H.C.WainwrightSalesAmendedAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib26b46410f1947caaa269dc8c84bc533_I20210604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieba8f73a7897435fbc5b3392cb6478cf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ba1e218994d4ff1b3b3d3cdd3ea83a2_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:InstitutionalPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9992345fcbc5433492a910eba1965518_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:InstitutionalPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib537ee905795476eb1a4ed13cf5100b1_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AdditionalPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i064784dc58ac445ab8485a53331724c5_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AdditionalPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39237a1f42304c68bc922379c5cafbc9_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic237f5a9d962463dab8bf38d6a802419_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:January2021PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58d1afa2bd9346fc97c1b81a5e0a4fd1_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:January2021PurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82ea1a2d86944a1c93f15ae19da0bc8e_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6d2e0cb9f694fe7a859d47739e7393e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i806c337fb61d4e69a7df6495c7be9795_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c06d396aa1143d3b027ef1142d83cb5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i079cc5701e904396b3b89403166d381c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60f3653ff42d4f0eaacf9c26102cfd38_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bbaca2f02cc464a87710b12e3b26046_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie912ebfc1b8b4a6aa5f2e375f861d2c2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ca74538c1c54566b186f58a6caf61e1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1373d5ad1834c4abef25fae33e3348e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife71a6468a004189ad68cb01a4d67fcf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab051a0f20f54b90a2c3a2ae838bb8ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieba28787ca6743bebdb732d522992e81_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8097329850104783b37c8ae588e3f1f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1262c5aee83e44218db30c90579c58ff_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f25e23ccf5e4e8b9996111cff5b1f1f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee4c1259461b4d82a4ed9b9423814c93_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b81cf0af0d549cc9704b163fd97825f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0424a8b4b4e74dd6a974d18e483a0683_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib31c704f4b3d4411913b83a05612f827_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifac165fbd5294cbbae45708def42554a_I20170228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61ed912a36714a0f8fa66f5c6f03cc72_D20170501-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08b10f0993ca498595bc8f6e22708cd3_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31c91a3c922742a393bcaf2e5965f1af_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb2942cf4b2d4251b0227854fee06098_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa54ec01303049c2ac24d543660aa65d_D20190501-20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id909ba1c9804438aafc38ea943a32300_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb3d98988e62496d9a95ec85932a553d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd538497ecb94882951d52a7b78a623a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib03213178c1c439fbbcd57ce65f84a0a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3273942991694dcbb5315ec3f95ef5c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4ffabf75b224124baa59142f55d7740_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i208a56199ea240e189c18fe67bc1738e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9412c3333444df08e11f620932bee49_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacc61b5e28ba4a56b04bcf5fece477a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63593eb72a0c4883b9e50df4be109be4_D20210412-20210412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-12</xbrli:startDate><xbrli:endDate>2021-04-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i7d049288b82e438c85d504cc3e9dc500_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION   </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FORM <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zODk5_871cffc5-3e7f-4bee-aa87-2c79dc98e390">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Mark One)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6Nzk3NTc2NWM1OWYzNDc5Y2EwNDU1MjNlYzFmNjM4NDcvdGFibGVyYW5nZTo3OTc1NzY1YzU5ZjM0NzljYTA0NTUyM2VjMWY2Mzg0N18wLTAtMS0xLTcyMDI_eea465b7-3980-4f57-bb66-1ec7ee0331a4">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FOR THE FISCAL YEAR ENDED <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8xMzM_6116db35-ce55-4d66-a9a1-61bbb5716f48"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8xMzM_373a2eba-88d9-450e-8b4d-82d1ac282f1b">December&#160;31</ix:nonNumeric>, 2021</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6NjMzZjQzYWJmODM5NDFiY2JiZWQwMDYxYjQ5NDYzZTkvdGFibGVyYW5nZTo2MzNmNDNhYmY4Mzk0MWJjYmJlZDAwNjFiNDk0NjNlOV8wLTAtMS0xLTcyMDI_510c0fae-4804-4193-861a-14ebccaa5d0b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Transition Period from __________________&#160;&#160;&#160;to _________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zOTA4_6878cf28-a763-49e5-a537-e9d91059d4ac">001-33650</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zODk2_d9e972e9-4d07-4aeb-9f6f-72a41369d405">CALADRIUS BIOSCIENCES, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6NzRhNWE2MjNkYjNiNGQzMzlkOGE4ZjdjMzA5ZGNiNjcvdGFibGVyYW5nZTo3NGE1YTYyM2RiM2I0ZDMzOWQ4YThmN2MzMDlkY2I2N18wLTAtMS0xLTcyMDI_79c6f02a-caac-460d-856a-b1877692afb4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6NzRhNWE2MjNkYjNiNGQzMzlkOGE4ZjdjMzA5ZGNiNjcvdGFibGVyYW5nZTo3NGE1YTYyM2RiM2I0ZDMzOWQ4YThmN2MzMDlkY2I2N18wLTEtMS0xLTcyMDI_f43b6460-e480-4411-b259-c8e919726be6">22-2343568</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6NzRhNWE2MjNkYjNiNGQzMzlkOGE4ZjdjMzA5ZGNiNjcvdGFibGVyYW5nZTo3NGE1YTYyM2RiM2I0ZDMzOWQ4YThmN2MzMDlkY2I2N180LTAtMS0xLTcyMDIvdGV4dHJlZ2lvbjo4MmI1MzNiODlkZDk0Nzc3YWViMDBiYTIzNjUxNGVhY180_dba644f1-f0ba-47cc-8f72-395474a29021">110 Allen Road, 2nd Floor</ix:nonNumeric>, <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6NzRhNWE2MjNkYjNiNGQzMzlkOGE4ZjdjMzA5ZGNiNjcvdGFibGVyYW5nZTo3NGE1YTYyM2RiM2I0ZDMzOWQ4YThmN2MzMDlkY2I2N180LTAtMS0xLTcyMDIvdGV4dHJlZ2lvbjo4MmI1MzNiODlkZDk0Nzc3YWViMDBiYTIzNjUxNGVhY184_d6221c47-428d-4ae5-99fe-a0a58cd9b350">Basking Ridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6NzRhNWE2MjNkYjNiNGQzMzlkOGE4ZjdjMzA5ZGNiNjcvdGFibGVyYW5nZTo3NGE1YTYyM2RiM2I0ZDMzOWQ4YThmN2MzMDlkY2I2N180LTAtMS0xLTcyMDIvdGV4dHJlZ2lvbjo4MmI1MzNiODlkZDk0Nzc3YWViMDBiYTIzNjUxNGVhY18xMg_9ffb8daa-2f48-4379-92e8-4714ba79f269">New Jersey</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6NzRhNWE2MjNkYjNiNGQzMzlkOGE4ZjdjMzA5ZGNiNjcvdGFibGVyYW5nZTo3NGE1YTYyM2RiM2I0ZDMzOWQ4YThmN2MzMDlkY2I2N180LTEtMS0xLTcyMDI_fd6bb5b9-1c3e-489b-9757-f455838d6664">07920</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(zip code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zODk3_b2307616-1b6e-4641-a506-61bb8703c110">908</ix:nonNumeric>-<ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zOTEx_57314f80-f343-4dcc-950a-1c720cd8d6f3">842-0100</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3.3pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities Registered Pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:40.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.103%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol (s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Each Exchange On Which Registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6YjA2YjdlNjlmNzVmNDc0YmE0ZmQ2NzgwNGZmYjA1ZGIvdGFibGVyYW5nZTpiMDZiN2U2OWY3NWY0NzRiYTRmZDY3ODA0ZmZiMDVkYl8yLTAtMS0xLTcyMDI_e5e362d9-1d8a-4dd4-8820-f04cac56957e">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6YjA2YjdlNjlmNzVmNDc0YmE0ZmQ2NzgwNGZmYjA1ZGIvdGFibGVyYW5nZTpiMDZiN2U2OWY3NWY0NzRiYTRmZDY3ODA0ZmZiMDVkYl8yLTEtMS0xLTcyMDI_a21b8309-7abe-425e-bcf8-49a4a6513d3f">CLBS</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6YjA2YjdlNjlmNzVmNDc0YmE0ZmQ2NzgwNGZmYjA1ZGIvdGFibGVyYW5nZTpiMDZiN2U2OWY3NWY0NzRiYTRmZDY3ODA0ZmZiMDVkYl8yLTItMS0xLTcyMDIvdGV4dHJlZ2lvbjo2YWQ2OTMwNmFkOWM0OTAxODlhNzcxNjViNmUyMjFjY184_5b2a71d7-f20a-4f97-b71d-1e9bdd6b805c">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3.3pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> None</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zOTA2_7a76e9af-b6a7-4943-bdc2-4ddf80a958ac">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zOTAx_87bd0584-84e5-4d05-adf2-124382b4cf76">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zOTA3_d3c1a926-3e31-4b40-b86d-0ffaf15c6f34">Yes</ix:nonNumeric> &#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No &#9744;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files). <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zOTAy_a894b943-8a6e-4945-9b57-ddbeac56aea6">Yes</ix:nonNumeric> &#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No &#9744;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a </span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">smaller reporting company, or an emerging growth company. See the definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6YWYyMTM3ZTc5MDY0NGZhOGJkNjVjZTEwMGFiODY5ZjUvdGFibGVyYW5nZTphZjIxMzdlNzkwNjQ0ZmE4YmQ2NWNlMTAwYWI4NjlmNV8xLTAtMS0xLTcyMDI_412bd350-96e2-436a-92c1-ca36ba097f48">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6YWYyMTM3ZTc5MDY0NGZhOGJkNjVjZTEwMGFiODY5ZjUvdGFibGVyYW5nZTphZjIxMzdlNzkwNjQ0ZmE4YmQ2NWNlMTAwYWI4NjlmNV8xLTQtMS0xLTcyMDI_80172f6b-c7fd-4186-9a86-19e80214e274">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6YWYyMTM3ZTc5MDY0NGZhOGJkNjVjZTEwMGFiODY5ZjUvdGFibGVyYW5nZTphZjIxMzdlNzkwNjQ0ZmE4YmQ2NWNlMTAwYWI4NjlmNV8yLTQtMS0xLTcyMDI_426a75fc-fdd7-4cfd-a31c-fbd0642b4838">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:20.16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#9744;</span></div><div style="text-indent:20.16pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  &#160;&#160;<ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zOTAz_9fc5602c-871a-4c83-ad18-25837678100c">&#9744;</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes&#160;&#160;&#9744;&#160;&#160;&#160;No&#160;<ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zODk4_f2152671-2393-47d9-8cd7-6eebe36e31f3">&#9746;</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the Registrant's voting and non-voting common stock held by non-affiliates of the Registrant (without admitting that any person whose shares are not included in such calculation is an affiliate) computed by reference to June 30, 2021 (the last business day of the Registrant's most recently completed second fiscal quarter) was approximately $<ix:nonFraction unitRef="usd" contextRef="if90ca5338733460a971066d59766dc81_I20210630" decimals="-6" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8yOTUw_a255e2d4-dc55-4d39-bab4-931f908bd4d6">95</ix:nonFraction> million, computed by reference to the last sale price of $1.61 for the common stock on the Nasdaq Capital Market reported for such date. Shares held by executive officers, directors and persons owning directly or indirectly more than 10% of the outstanding common stock have been excluded from the preceding number because such persons may be deemed to be affiliates of the Registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></div><div style="margin-bottom:3.3pt;padding-right:2.25pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:3.3pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date. </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:63.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.471%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of March 22, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $0.001 par value per share</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibab4128b577c44a6906698d794637dfa_I20220322" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6NmZmMmU3YmZkOWQ3NDM5Yjk2OTFiYzQxMjIwYjFhZjUvdGFibGVyYW5nZTo2ZmYyZTdiZmQ5ZDc0MzliOTY5MWJjNDEyMjBiMWFmNV8xLTEtMS0xLTcyMDI_bd061cd1-04aa-4254-9ce6-3b6156f4469b">60,533,064</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">shares</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zOTA0_33512705-d1e3-4404-bc7f-fa079448d139" escape="true">The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant's Proxy Statement for the 2022 Annual Meeting of Stockholders. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant's fiscal year ended December 31, 2021.</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i7d049288b82e438c85d504cc3e9dc500_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:3.3pt;padding-right:2.25pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All references in this Annual Report on Form 10-K to &#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company&#8221; and &#8220;Caladrius&#8221; mean Caladrius Biosciences, Inc., including subsidiaries and predecessors, except where it is clear that the term refers only to Caladrius Biosciences, Inc. This Annual Report on Form 10-K contains forward-looking statements, which involve risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those set forth under &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; and under &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. </span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:15.75pt"><span><br/></span></div><div style="margin-bottom:3.3pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:3.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i7d049288b82e438c85d504cc3e9dc500_34">PART I</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 1. BUSINESS</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_16">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 1A. RISK FACTORS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_19">18</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 1B. UNRESOLVED STAFF COMMENTS</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_22">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 2. PROPERTIES</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_25">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 3. LEGAL PROCEEDINGS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_28">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 4. MINE SAFETY DISCLOSURES</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_31">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_37">51</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 6. [RESERVED]</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_40">52</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 7.&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_43">53</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_55">60</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_58">61</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_133">88</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 9A. CONTROLS AND PROCEDURES</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_136">88</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 9B. OTHER INFORMATION</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_139">89</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_1407">89</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART III</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_145">90</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3.3pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 11. EXECUTIVE COMPENSATION</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_148">90</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_151">90</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_154">90</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_157">90</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART IV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3.3pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_163">90</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 16. FORM 10-K SUMMARY</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_163">94</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i7d049288b82e438c85d504cc3e9dc500_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This annual report (this &#8220;Annual Report&#8221;) contains &#8220;forward-looking&#8221; statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. When used in this Annual Report, statements that are not statements of current or historical fact may be deemed to be forward-looking statements, including, without limitation, all statements&#160;related to any expectations of revenues, expenses, cash flows, earnings or losses from operations, cash required to maintain current and planned operations, capital or other financial items; any statements of the plans, strategies and objectives of management for future operations; any plans or expectations with respect to product research, development and commercialization, including regulatory approvals; any other statements of expectations, plans, intentions or beliefs; and any statements of assumptions underlying any of the foregoing. Without limiting the foregoing, the words &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;forecast,&#8221; &#8220;outlook,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;likely,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;continue&#8221; or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements, although some forward-looking statements are expressed differently. We remind readers that forward-looking statements are merely predictions and therefore inherently subject to uncertainties and other factors and involve known and unknown risks that could cause the actual results, performance, levels of activity or our achievements or industry results, to be materially different from any future results, performance, levels of activity or our achievements or industry results expressed or implied by such forward-looking statements. Factors that could cause our actual results to differ materially from anticipated results expressed or implied by forward-looking statements include, among others:</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain sufficient capital or strategic business arrangements to fund our operations and expansion plans, including meeting our financial obligations under various licensing and other strategic arrangements, the funding of our clinical trials for product candidates, and the commercialization of the relevant technology;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to build and maintain the management and human resources infrastructure necessary to support the growth of our business;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether a market is established for our cell-based products and services and our ability to capture a meaningful share of this market;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scientific, regulatory and medical developments beyond our control;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain, as applicable, appropriate governmental licenses, accreditations or certifications or to comply with healthcare laws and regulations or any other adverse effect or limitations caused by government regulation of our business;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether any of our current or future patent applications result in issued patents, the scope of those patents and our ability to obtain and maintain other rights to technology required or desirable for the conduct of our business;&#160;and our ability to commercialize products without infringing upon the claims of third-party patents;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether any potential strategic or financial benefits of various licensing agreements will be realized;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to diversify our pipeline of development product candidates, which could include an acquisition, merger, business combination, in-license or other strategic transaction, and whether any of such efforts will result in us entering into or completing any transaction or that any such transaction, if completed, will add to shareholder value;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our development activities;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to complete our other planned clinical trials (or initiate other trials) in accordance with our estimated timelines due to delays associated with enrolling patients due to the novelty of the treatment, the size of the patient population and the need of patients to meet the inclusion criteria of the trial or otherwise; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which the COVID-19 pandemic may impact our business, including our clinical trials and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The factors discussed herein, including those risks described in &#8220;Item 1A. Risk Factors&#8221; and in our other periodic filings with the SEC, which are available for review at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, could cause actual results and developments to be materially different from those expressed or implied by such statements. All forward-looking statements attributable to us are expressly qualified in their entirety by these and other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they were made. Except as required by law, we undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i7d049288b82e438c85d504cc3e9dc500_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_16"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. BUSINESS.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caladrius Biosciences, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Caladrius&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. We are developing what are intended to be first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Our technology is intended to leverage these cells to enable the body's natural repair mechanisms using formulations unique to each medical indication.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leadership team has decades of collective biopharmaceutical development experience. Our goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. Our current product candidates include: </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CLBS16), the subject of both a completed positive Phase 2a study (ESCaPE-CMD) and an ongoing follow-on Phase 2b study (FREEDOM Trial) in the United States for the treatment of coronary microvascular dysfunction (&#8220;CMD&#8221;); </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CLBS12), recipient of SAKIGAKE designation pursuant to which early conditional approval in Japan for the treatment of critical limb ischemia (&#8220;CLI&#8221;) and Buerger&#8217;s disease is being sought based on the current results of a clinical trial executed in Japan. CLBS12 was the recipient of orphan drug designation in March 2021 from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for Buerger's disease; and </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with chronic kidney disease related to type 2 diabetes (diabetic kidney disease or &#8220;DKD&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporated in 1980</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as a Delaware corporation and our principal executive offices are located at 110 Allen Road, Second Floor, Basking Ridge, NJ 07920. Our telephone number is (908) 842-0100 and the corporate website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.caladrius.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our website address in this Annual Report on Form&#160;10-K is included only as an inactive textual reference and is not intended to be an active link to our website. The information on the website is not incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to those reports, as well as other documents filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), are available free of charge through the Investors section of the website as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC. The public can obtain documents that are filed with the SEC at&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K includes the following trademarks owned by us: Caladrius</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These trademarks are the property of Caladrius. This Annual Report on Form 10-K also includes other trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and traded names included herein are the property of their respective owners. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ischemic Repair (CD34 Cell Technology) </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CD34+ cell was discovered as a result of the deliberate search for a cell capable of stimulating the development and/or repair of blood vessels. All tissues in the body maintain their function by replacing cells over time. In addition to the maintenance function, the body must also be capable of building new blood vessels after injury. A CD34+ cell is an endothelial progenitor cell that has the ability to stimulate new blood vessel formation at the level of the microvasculature. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary cell technology using autologous (a patient&#8217;s own naturally occurring) CD34+ cells has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted or reduced. Through the administration of CD34+ cells, we seek to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted area. We believe that a number of conditions caused by underlying ischemic injury can be improved through our CD34+ cell technology including, but not limited to, Buerger's disease, CLI, CMD, and DKD.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of Coronary Microvascular Dysfunction</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, with the assistance of a $1.9&#160;million grant from the National Institutes of Health (Award Number R44HL135889), we initiated our program for XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of CMD, a disease that afflicts as many as 1.6 million patients in the United States alone, with no current targeted treatment options. That study, the ESCaPE-CMD Trial, was a Phase 2a proof-of-concept open label study that enrolled patients at the Mayo Clinic in Rochester, MN and Cedars-Sinai Medical Center in Los Angeles, CA. Those data showed a positive therapeutic effect with a statistically significant improvement in angina frequency, coronary flow reserve, Canadian Cardiovascular Society Angina Class and Seattle Angina Questionnaire scores, as well as an acceptable safety profile. The full data set from that study was presented at the SCAI 2020 Scientific Sessions Virtual Conference on May 14, 2020 by Dr. Timothy Henry, FACC, of the Christ Hospital in Cincinnati, Ohio. In December 2020, we commenced enrollment in our Phase 2b FREEDOM Trial of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a double-blind, randomized and placebo-controlled clinical trial designed to further evaluate the efficacy and safety of intracoronary artery delivery of autologous CD34+ cells in subjects with CMD and without obstructive coronary artery disease. While early enrollment proceeded to plan with the first patient treated in January 2021, the impact of the COVID-19 pandemic contributed to a general slowing of enrollment. Protocol amendments to the initial FREEDOM Trial protocol, as agreed to by the FDA, were implemented with the goal of enhancing breadth and speed of subject enrollment.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of Critical Limb Ischemia</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our randomized, open-label, registration-eligible study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan for the treatment of CLI and Buerger's disease has, to date, demonstrated positive trends in both safety and efficacy. The HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> study's enrollment, however, has been significantly curtailed by the COVID-19 pandemic's impact in Japan, including the States of Emergency in Japan that have persisted for much of the past 18 months. Due to the significant and continued operational and financial burden incurred as a result of these COVID-19 delays, coupled with the unpredictability of the timing of site enrollment re-initiation, we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suspended further enrollment and are focusing our efforts on consummating a partnership for the product in Japan. Such a partnership may become the basis for the completion of development and registration of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan and may include the completion of enrollment of the four remaining no-option CLI subjects stipulated in the original protocol, if necessary, and/or exploration of submitting the existing data to Japan's Pharmaceuticals and Medical Devices Agency (&#8220;PMDA&#8221;) under Japan's regenerative medicine regulations, which allow for conditional approval of innovative regenerative medicine products. Despite receipt from FDA in March 2021 of orphan designation in the United States for CLBS12 as a potential treatment for Buerger's disease, based on a response from the FDA in October 2021 regarding a development plan for U.S. registration, we have decided not to pursue U.S. development in Buerger's disease at this time.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CLBS201 for Treatment of Diabetic Kidney Disease</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progressive kidney failure is associated with attrition of the microcirculation of the kidney. Pre-clinical studies in kidney disease and injury models have demonstrated that protection or replenishment of the microcirculation results in improved kidney function. Based on these observations, we have elected to move forward with a Phase 1, open-label, proof-of-concept trial evaluating CLBS201 dosed via intra-renal artery injections in subjects with DKD. This protocol, as approved by an Institutional Review Board (&#8220;IRB&#8221;), is expected to include six subjects in total with the first two subjects sequentially dosed and followed for a two-week safety observation period. Clearance by an independent Data Safety Monitoring Board (&#8220;DSMB&#8221;) overseeing the study will then permit the treatment of the next four patients, with all patients being followed for safety and therapeutic effect. A read-out of data will occur after the six-month follow-up visit for all patients. A key criterion for continued development of CLBS201 will be our ability to demonstrate a therapeutic effect that will make it competitive in the field of DKD treatment, i.e., kidney function regeneration, as indicated by increased glomerular filtration rate.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Out-licensing Opportunities and Pipeline Diversification</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. Our current long-term strategy focuses on advancing our therapies through development with the ultimate objective of obtaining market authorizations and entering commercialization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. We believe that we are well-positioned to realize potentially meaningful value increases within our own proprietary pipeline if we are successful in advancing our product candidates to their next significant development milestones.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we further desire to diversify our pipeline of development product candidates and are exploring a range of strategic transactions in furtherance of that goal. We have taken, and intend to continue to take, active steps to identify assets and/or companies for acquisition and/or partnership that would complement our current development programs and de-risk our overall development portfolio. Such assets potentially could target indications beyond cardiovascular disease as well as product categories outside of cell therapy. The range of possible</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transactions includes an acquisition, merger, business combination, in-license or other strategic transaction, any of which could result in the issuance of securities that could significantly dilute the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of our existing stockholders. There can be no assurance that this exploration of strategic alternatives will result in us entering into or completing any transaction or that such transaction, if completed, will add to shareholder value.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Considerations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of coronavirus (SARS-CoV-2), which causes COVID-19, was reported to have surfaced in China. In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic, and the world's economies began to experience pronounced effects. Despite the FDA approval of multiple COVID-19 vaccines, there remains uncertainty around the extent and duration of disruption and any future related financial impact cannot reasonably be estimated at this time. In response to the COVID-19 pandemic, we implemented a universal work from home policy as well as stringent social distancing and other hygiene policies for employees when they must be in the office. Our clinical study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan has experienced significant delays in enrollment due to the States of Emergency in effect in Japan for most of 2020 and re-implemented from January 7, 2021 through March 21, 2021 covering Tokyo and other regions in response to an increased number of COVID-19 infections. Due to reported increases in COVID-19 cases and a low rate of vaccination in Japan, States of Emergency were renewed on April 25, 2021 through May 11, 2021 and then re-implemented in Tokyo from July 12, 2021 through September 30, 2021. With our expectation that COVID-19 in Japan would continue to impact negatively enrollment of patients in the HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trial, we have elected to suspend trial enrollment, seek a development partner and consult with the Japanese regulatory authorities regarding the submission of patient data already accrued. Our phase 2b trial of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States has also experienced delays in enrolling patients as a result of COVID-19.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE FIELD OF CELL THERAPY</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regenerative medicine is defined as the process of replacing or regenerating human cells, tissues or organs to restore normal function. Among the categories of therapeutic technology platforms within this field are cell therapy, gene therapy, tissue engineering, tools, device diagnostics and aesthetic medicine. All living complex organisms start as a single cell that replicates and then individual groups of cells differentiate (mature into complex cell types), thereby yielding the diversity of organs and organ systems in an adult organism. Cell therapy is a process that uses cells to prevent, treat or cure disease, or to regenerate damaged or aged tissue. Since the 1970s, bone marrow, blood and umbilical cord-derived stem cells have been used to restore bone marrow, as well as blood and immune system cells damaged by the chemotherapy and radiation historically used to treat many cancers. Notably, this approach holds certain curative potential for patients with otherwise fatal conditions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are two general classes of cell therapies: autologous and allogeneic. When cells are collected from a person (donor) and transplanted or used to develop a treatment solely for that same person (recipient or patient) with or without modification, the treatment paradigm is known as &#8220;autologous&#8221; cell therapy.  For long-term repair of cardiovascular tissues, evidence indicates that the repair cells must remain in the target tissue for a period of time. Since autologous cells are not destroyed by the immune system, autologous cell therapy can be expected to result in long-term residence of the administered cells. When the donor and the recipient are not the same individual, however, the procedures are referred to as &#8220;allogeneic&#8221; cell therapy. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various cell therapies are in clinical development for an array of human diseases, including autoimmune, oncologic, cardiovascular, neurologic and orthopedic diseases, among other indications. While no assurances can be given regarding future medical developments, we believe that the field of cell therapy holds the promise to better the human experience and minimize or ameliorate the pain and suffering from many common and often life-threatening diseases. The FDA has been investing significant resources into policies and organizational changes to advance the cell and gene therapy fields in recent years through what the agency has labeled its &#8220;comprehensive regenerative medicine policy framework,&#8221; as first announced in late 2017 and incrementally developed since that time through various agency actions. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TECHNOLOGY OUT-LICENSING OPPORTUNITIES</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ischemic Repair (CD34+ Cell Technology)</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our CD34+ Cell Technology is an autologous cell platform technology with potential application to a broad array of ischemic conditions and we will seek to out-license the technology in geographies and/or indications in which we do not intend to pursue development ourselves. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property Platform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our developed and owned ischemic repair patent portfolio comprises the following:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.68pt">Nine U.S. patents, three European Union (&#8220;EU&#8221;) patents (each filed in 5 individual countries) and ten other patents in Japan, Canada, Russia and Hong Kong;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Claims cover, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter alia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a pharmaceutical composition that contains a therapeutic concentration of non-expanded CD34+ stem cells that move in response to SDF-1 or VEGF, together with a stabilizing amount of serum, that can be delivered to repair an injury caused by vascular insufficiency;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Issued and pending claims can be applied to a broad range of conditions caused by underlying ischemia, including acute myocardial infarction, chronic myocardial ischemia post-AMI, chronic heart failure, critical limb ischemia, and ischemic brain injury and DKD; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">One pending patent application in the United States; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">One pending patent application outside the United States.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Market Opportunity for CLI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In Japan, there are approximately 300,000 patients with CLI, of whom approximately 51,000 are not candidates for revascularization, together with an addressable population of approximately 560,000 patients in the EU and 300,000 in the United States. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The field of cardiovascular cell therapy development is competitive. There are a number of companies that are developing cell-based therapies for cardiovascular diseases. These companies are utilizing a number of different therapeutic approaches in their development efforts. There are both autologous and allogeneic based competitive therapies that derive cells principally from four sources: fat, peripheral blood, cord blood, and bone marrow.  HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is an autologous therapy that derives its cells from the peripheral blood of the patient via apheresis. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Market Opportunity for CMD</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the United States there is an addressable population of approximately 400,000 to 1,600,000 patients with CMD, while the addressable population is roughly 1,200,000 to 4,800,000 in the EU and between 43,000 and 166,000 in Japan.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Market Opportunity for DKD</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, stage 3 and 4 DKD patients represent an addressable population of approximately 7,000,000 and there is an estimated addressable population of 12,000,000 patients in the EU.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEASONALITY</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that our operations are seasonal in nature.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">GOVERNMENT REGULATION </span></div><div style="margin-bottom:8pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry is one of the most highly regulated industries in the United States and abroad. Various governmental regulatory authorities, as well as private accreditation organizations, oversee and monitor the activities of individuals and businesses engaged in the development, manufacture and delivery of health care products and services. The following is a general description of certain current laws and regulations that are relevant to our business:</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premarket Review and Approval of Pharmaceutical and Biological Products in the United States</span></div><div style="margin-bottom:8pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, pharmaceutical and biological products, including cellular therapies, are subject to extensive pre- and post-market regulation by the FDA. The Federal Food, Drug, and Cosmetic Act (&#8220;FD&amp;C Act&#8221;) and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products, including biological products, intended for therapeutic uses. Biological products are approved for marketing under provisions of the Public Health Service Act (&#8220;PHS Act&#8221;). However, biological products that also meet the definition of &#8220;drugs&#8221; under the FD&amp;C Act are also subject to regulation under FD&amp;C Act provisions and to applicable provisions from two sets of FDA implementing regulations, those for biological products and those for drugs. Another distinction between pharmaceuticals and cellular therapies is that the PHS Act requires the submission of a Biological Licensing Application (&#8220;BLA&#8221;), rather than a New Drug Application (&#8220;NDA&#8221;), for market authorization of a cellular therapy candidate like ours. Generally, the application process and requirements for product approval under BLA is similar to those for an NDA, and the review process for biological products is associated with similar approval risks and application costs as for chemical entity drug products.</span></div><div style="margin-bottom:8pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as the FDA refusal to approve pending NDAs or BLAs, withdrawal of an approval, issuance of warning letters and other types of enforcement letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the Department of Justice, or DOJ, or other governmental entities. Under certain circumstances, individual members of company management may also be subject to civil or criminal penalties related to company violations of applicable legal requirements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An applicant seeking approval to market and distribute a new pharmaceutical or biological product in the United States typically must undertake the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA's good laboratory practice or GLP regulations;</span></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an IND, which includes the detailed clinical protocol, which must take effect before human clinical trials can commence;</span></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">approval of the clinical trial protocol and the sponsor's safeguards for human subjects by one or more institutional review boards, or &#8220;IRBs,&#8221; depending on the numbers of clinical sites and other features of the study design, before each clinical trial may be initiated;</span></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or &#8220;GCPs,&#8221; to establish the safety and efficacy of the proposed drug or biological product for each proposed indication for which FDA approval is sought;</span></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;</span></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparation and submission to the FDA of an NDA or BLA, as appropriate;</span></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review of the product by an FDA advisory committee, where appropriate or if applicable, as determined by the FDA at its discretion;</span></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with the regulations establishing current Good Manufacturing Practices, or &#8220;cGMPs,&#8221; and current Good Tissue Practices or &#8220;cGTPs&#8221; (if applicable), and to assure that the facilities, methods and controls used for the manufacture, processing and packing of the drug or biological product are adequate to preserve the product&#8217;s identity, strength, quality and purity; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payment of applicable user fees and securing FDA approval of the NDA or BLA. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease. Moreover, submission of an IND may not result in FDA authorization to initiate a clinical trial if the FDA raises concerns or questions about the design of the clinical trial or the preclinical or manufacturing information supporting it, including concerns that human research subjects will be exposed to unreasonable health risks. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development. After a trial is initiated, the FDA may order the temporary or permanent discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial is not being conducted in accordance with FDA requirements, or presents an unacceptable risk to the clinical trial patients.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted in compliance with federal regulations and GCPs, which are meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors. In addition, sponsors of most clinical trials involving FDA regulated products, including drugs and biologics, are required to register and disclose certain clinical trial information on a public registry and results database managed by the National Institutes of Health called ClinicalTrials.gov. Registration information that must be submitted includes information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial. Sponsors are also obligated to disclose the results of their clinical trials after completion. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs. Failure to comply with applicable clinical trial registration or results reporting obligations can result in&#160;civil monetary penalties or the withholding of grant funds from a federally funded grantee.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials to support NDAs or BLAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap or may be combined. Under certain circumstances, a fourth post-approval phase may be required.</span></div><div style="margin-bottom:8pt;padding-left:36pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Trials in this phase are initially conducted in a limited population of healthy volunteers to test the product candidate for safety, dose tolerance, absorption, metabolism, distribution and excretion in healthy humans or, on occasion, in patients, such as cancer patients, when the drug or biologic is too toxic to be ethically given to healthy individuals.</span></div><div style="margin-bottom:8pt;padding-left:36pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: These clinical trials are generally conducted in a limited patient population to determine the presence and approximate magnitude of therapeutic effect of the product for specific targeted indications and to identify </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">appropriate therapeutic dose and dose frequency as well as any corresponding additional possible adverse effects and safety risks. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></div><div style="margin-bottom:8pt;padding-left:36pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: These are commonly referred to as pivotal or registration studies. When Phase 2 evaluations demonstrate that a dose range of the product is effective and has an acceptable safety profile, Phase 3 clinical trials are typically undertaken in a larger patient population to further evaluate dosage, to provide substantial evidence of clinical efficacy and to further test for safety in an expanded and diverse patient population at multiple and geographically-dispersed clinical trial sites. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug or biologic as a requirement for marketing authorization.</span></div><div style="margin-bottom:8pt;padding-left:36pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In some cases, the FDA may condition approval of an NDA or BLA for a product candidate on the sponsor's agreement to conduct additional clinical trials after NDA or BLA approval. In other cases, a sponsor may voluntarily carry out additional trials post approval to gain more information about the drug or biologic.</span></div><div style="margin-bottom:8pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Submission of an NDA or BLA to the FDA</span></div><div style="margin-bottom:8pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA or BLA seeking approval to market the drug product for one or more indications. FDA approval of the NDA or BLA is required before marketing of the product may begin in the United States. The cost of preparing and submitting an NDA or BLA is substantial. Under federal law, most NDA or BLA submissions are additionally subject to a substantial application user fee. The current fee for FY2022 is $3,117,218 (some small businesses may qualify for a waiver under certain circumstances) and an annual program fee, currently $369,413, must also be paid for each approved prescription drug or biological product. These fees are typically adjusted annually.</span></div><div style="margin-bottom:8pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has 60 days from its receipt of an NDA or BLA to determine whether the application will be accepted for filing based on the Agency's threshold determination that the application is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. If the application is not sufficiently complete, the FDA may issue a Refusal to File, or RTF, letter, although the FDA may permit an applicant to correct certain easily correctable deficiencies in the NDA/BLA before filing without taking an official RTF action. Under certain NDA and BLA review performance goals to which the FDA has agreed, most applications for standard review of drug or biological products are reviewed within ten to twelve months, and most applications for priority review drugs or biologics are reviewed within six to eight months. If a sponsor submits a major amendment to a filed NDA or BLA at any time during the review cycle, the FDA may extend these reviews by three months although only one such extension is permitted during a review cycle. Priority review can be applied to drugs or biologics that, in the FDA's determination, offer major advances in treatment or provide a treatment for a disease or condition for which no adequate therapy exists. For biologics, priority review is further limited to products intended to treat a serious or life-threatening disease relative to currently approved products. Priority review requests must be submitted in conjunction with the original NDA/BLA for which the sponsor is seeking the designation, and the FDA decision will be made in conjunction with its official action to file the application and begin the substantive review process.</span></div><div style="margin-bottom:8pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA or BLA, the FDA will typically inspect one or more clinical trial sites to ensure compliance with GCPs. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. These pre-approval inspections cover all facilities associated with an NDA or BLA submission, including drug component manufacturing (such as active pharmaceutical ingredients), finished drug product manufacturing, and control testing laboratories. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with applicable cGMP and cGTP requirements and are adequate to assure consistent production of the drug or biological product within required specifications and the NDA or BLA contains data that provide substantial evidence that the drug or biologic is safe and effective for the proposed indication.</span></div><div style="margin-bottom:8pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer applications for novel drug or biological products, or drug or biological products that present difficult questions of safety or efficacy, to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but the FDA will carefully consider them.</span></div><div style="margin-bottom:8pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA fully evaluates the NDA or BLA and the relevant manufacturing facilities, the FDA will issue either an approval/licensure letter or a complete response letter (&#8220;CRL&#8221;). A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA's satisfaction in a resubmitted NDA or BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions within two or six months, depending on the type of information being provided to address the deficiencies in the CRL. Even with the submission of this additional information, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">however, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></div><div style="margin-bottom:8pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA approves a drug or biological product for marketing in the United States, it may limit the approved indications for use for the product; require that contraindications, warnings or precautions be included in the product labeling; require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug&#8217;s safety after approval; require testing and surveillance programs to monitor the product after commercialization; or impose other conditions, including distribution restrictions or other risk management mechanisms, such as a risk evaluation and mitigation strategy or &#8220;REMS,&#8221; which can materially affect the potential market and profitability of the product. The FDA also may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications or patient populations, making certain types of manufacturing changes or seeking to make additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></div><div style="margin-bottom:8pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One potential condition of approval is that the FDA may require an applicant to develop a REMS to ensure that the benefits of the drug outweigh its risks.&#160; To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity. REMS requirements are tailored to the specific risk/benefit profile of a drug and can include requirements such as medication guides for patients, detailed communication plans for health care professionals, and elements to assure safe use, or &#8220;ETASU.&#8221; ETASU may include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, restricted distribution, and the use of patient registries. The FDA may require a REMS as a condition of approval or may add such a requirement at any point post-approval if it becomes aware of a serious risk associated with use of the product. The requirement for a REMS and the specific components that are involved can materially affect the potential market and profitability of a product. If the FDA concludes a REMS plan is needed, the sponsor of the NDA or BLA must submit a proposed REMS. The FDA will not approve an NDA without a REMS, if required.</span></div><div style="margin-bottom:8pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expedited Review Programs (Fast Track, Breakthrough, RMAT) and Accelerated Approval Pathways</span></div><div style="margin-bottom:8pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is authorized to facilitate the development and expedite the review of certain drugs or biologics that are intended for the treatment of a serious or life-threatening disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Under the Fast Track Program, the sponsor of an IND for a drug candidate may request that the FDA designate the drug candidate for a specific indication as a Fast Track drug concurrent with, or after, the submission of the IND for the drug candidate. The FDA must determine if the drug candidate qualifies for Fast Track designation within 60&#160;days of receipt of the sponsor&#8217;s request. In addition to other benefits such as the ability to engage in more frequent interactions with the FDA, the FDA may initiate review of sections of a Fast Track drug&#8217;s NDA or BLA before the application is complete. This &#8220;rolling review&#8221; is available if the applicant provides, and the FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. The FDA&#8217;s time period goal for reviewing an application, however, does not begin until the last section of the NDA/BLA is submitted. Additionally, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</span></div><div style="margin-bottom:8pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, under the FDA&#8217;s accelerated approval regulations, the FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients beyond existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments.</span></div><div style="margin-bottom:8pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase&#160;4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow the FDA to withdraw approval of the drug such that accelerated approval is also referred to as U.S. &#8220;conditional&#8221; approval. Products granted accelerated approval also are subject to additional requirements for the pre-dissemination review by the FDA of proposed promotional materials both during the NDA review process and for 120 days after marketing approval.</span></div><div style="margin-bottom:8pt;padding-right:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above, the FDA may designate an investigational product as a Breakthrough Therapy or as a Regenerative Medicine Advanced Therapy (&#8220;RMAT&#8221;), depending on the type of investigational product and its ability to meet applicable eligibility criteria. Breakthrough Therapy designation is a process designed to expedite the development and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-right:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s). The RMAT designation requires similar eligibility criteria to be met, but it is available only to cell therapies, tissue therapies, and other products that meet the statutory definition of a &#8220;regenerative medicine therapy.&#8221; Specifically, a biological product is eligible for RMAT designation if: (a) the product candidate is a regenerative medicine therapy, which is defined in the FD&amp;C Act as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, except for those regulated solely under the PHS Act (that is, excluding those biological products that are not also regulated as &#8220;drugs&#8221; under the FD&amp;C Act); (b) the product candidate is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (c) preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. Both Breakthrough Therapy and RMAT designations are intended to help accelerate product development by allowing more frequent interactions with the FDA and receiving intensive FDA guidance on efficient drug development.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Information</span></div><div style="margin-bottom:8pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act (&#8220;PREA&#8221;), NDAs or BLAs or supplements to NDAs or BLAs must contain data that are adequate to assess the safety and effectiveness of the drug or biologic for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. Sponsors must also submit pediatric trial plans prior to the assessment data, and those plans must contain an outline of the proposed pediatric trial or trials the applicant plans to conduct, including trial objectives and design, any deferral or waiver requests and other information required by regulation. The applicant, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. The FDA may grant full or partial waivers or deferrals for submission of data. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation, although the FDA has recently taken steps to limit what it considers abuse of this statutory exemption in PREA by announcing that it does not intend to grant any additional orphan drug designations for rare pediatric subpopulations of what is otherwise a common disease.</span></div><div style="margin-bottom:6pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Best Pharmaceuticals for Children Act (&#8220;BPCA&#8221;) provides approved NDA and BLA holders a six-month extension of any exclusivity that attaches to the end of all existing marketing exclusivities and patents for the drug or biologic. Conditions for exclusivity include the FDA&#8217;s determination that information relating to the use of a new drug or biologic in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA's request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drugs</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may designate a candidate as an orphan drug if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States) Orphan drug designation must be requested by an applicant before submitting an NDA or BLA for the relevant drug candidate. If the FDA grants orphan drug designation, the FDA will publicly disclose the generic identity of the drug candidate and its potential orphan use. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve any other applications for the same product for the same indication for seven&#160;years, except in certain limited circumstances comprising methods by which a second sponsor can demonstrate clinical superiority of its drug in comparison to the first approved orphan drug. Regardless of the orphan drug designation, a competitor may receive FDA approval for a different product (i.e., a different therapeutic agent from the orphan drug) for the same indication for which the orphan product has exclusivity and may obtain approval for the same product (i.e., the same therapeutic agent as the orphan drug) but for a different indication. If a designated orphan drug ultimately receives marketing approval for an indication broader than what was described in its orphan drug designation request, it may not be entitled to exclusivity under the Orphan Drug Act. Among the other benefits of orphan drug designation, the sponsor receives a waiver of the NDA or BLA application user fee and is eligible for tax credits for certain research (although the amount of this potential tax credit was decreased from 50% to 25% of qualified clinical testing expenses with the 2017 overhaul of the U.S. Tax Code, effective in 2018).</span></div><div style="margin-bottom:8pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drugs and biological products manufactured, marketed or distributed pursuant to FDA approval decisions are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion, and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to FDA review and approval before they can be implemented. There also are continuing, annual program fee requirements for any marketed, approved prescription products, as well as new application fees for supplemental applications.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, drug manufacturers and other entities involved in the manufacture of approved drugs are required to register their facilities with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA for compliance with cGMP/cGTP requirements. Prescription drug distribution facilities are also subject to state licensure, including inspections, by the relevant local regulatory authority. Changes to the manufacturing process, specifications or container closure system for an approved drug or biologic are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP or cGTP and impose reporting and documentation requirements upon the sponsor and others involved in the product&#8217;s manufacturing process. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations that require, among other things, quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP/cGTP compliance and ensure ongoing compliance with other statutory requirements the FD&amp;C Act, such as the requirements for making manufacturing changes to an approved NDA or BLA.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after a new drug or biologic approval is granted, the FDA may withdraw that approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. If a previously unknown problem, including adverse events of unanticipated severity or frequency, or with manufacturing processes, is discovered or the manufacturer fails to comply with regulatory requirements, the FDA may require revisions to the approved labeling to add new safety information; may impose additional post-market studies or clinical trials to assess new safety risks; or may impose distribution or other restrictions under a REMS program. Other potential consequences of regulatory non-compliance include, among other things:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on post-approval clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending NDAs/BLAs or supplements to approved NDAs/BLAs, or suspension or revocation of product license approvals;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consent degrees, corporate integrity agreements, debarment, or exclusion from federal health care programs; or</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mandated modification of promotional materials and labeling and the issuance of corrective information.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising and promotion of prescription drug and biological products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant penalties. In addition, the distribution of prescription pharmaceutical products is subject to a variety of federal and state laws, the most recent of which is still in the process of being phased into the U.S. supply chain and regulatory framework.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. Most recently, the Drug Supply Chain Security Act, or DSCSA, was enacted with the aim of building an electronic system to identify and trace certain prescription drugs distributed in the United States, including most biological products. The DSCSA mandates phased-in and resource-intensive obligations for pharmaceutical manufacturers, wholesale distributors, and dispensers over a 10&#8209;year period that is expected to culminate in November&#160;2023. From time to time, new legislation and regulations may be implemented that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by the FDA. It is impossible to predict whether further legislative or regulatory changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Health Care Regulations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates are approved in the United States, we will have to comply with various U.S. federal and state laws, rules&#160;and regulations pertaining to health care fraud and abuse, including anti-kickback laws and physician self-referral laws, rules&#160;and regulations. Violations of the fraud and abuse laws are punishable by criminal and civil sanctions, including, in some instances, exclusion from participation in federal and state health care programs, including Medicare and Medicaid. Other federal and state laws and regulations that could directly or indirectly affect our ability to operate the business and/or financial performance include:</span></div><div style="margin-bottom:8pt;padding-left:36pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">state and local licensure, applicable to the processing and storage of human cells and tissues;</span></div><div style="margin-bottom:8pt;padding-left:36pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">laws and regulations administered by the United States Department of Health and Human Services, including the Office for Human Research Protections and the Office of Inspector General;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">state laws and regulations governing human subject research;</span></div><div style="margin-bottom:8pt;padding-left:36pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">federal and state coverage and reimbursement laws and regulations, including laws and regulations administered by the Centers for Medicare &amp; Medicaid Services and state Medicaid agencies;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the federal Medicare and Medicaid Anti-Kickback Law and similar state laws and regulations;</span></div><div style="margin-bottom:8pt;padding-left:36pt;padding-right:4.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act and similar state laws and regulations;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the federal physician self-referral prohibition commonly known as the Stark Law, and state equivalents of the Stark Law;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the federal transparency requirements under the Physician Payments Sunshine Act that require manufacturers of FDA-approved drugs, devices, biologics and medical supplies covered by Medicare or Medicaid to report, on an annual basis, to the Department of Health and Human Services information related to payments and other transfers of value physicians, teaching hospitals, and certain advanced non-physician health care practitioners and physician ownership and investment interests;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Occupational Safety and Health Administration requirements;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">state and local laws and regulations dealing with the handling and disposal of medical waste; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;padding-right:4.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the Intermediate Sanctions rules of the IRS providing for potential financial sanctions with respect to &#8220;Excess Benefit Transactions&#8221; with tax-exempt organizations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines, or the relevant compliance guidance promulgated by the federal government, in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures to the extent that those laws impose requirements that are more stringent than the Physician Payments Sunshine Act. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Japan's Pharmaceutical and Medical Device Authority Regulation of Regenerative Medicine </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2014, there was no specific regulatory oversight of regenerative medicine products in Japan.  However, in November 2013, the Japanese authorities revised the Pharmaceutical Affairs Law and renamed it the Pharmaceuticals, Medical Devices, and Other Therapeutic Products Act (the &#8220;PMD Act&#8221;). The new legislation became effective on November 25, 2014 and provides for a timely introduction of innovative regenerative medicine products. The new legislation formalizes a legal basis for development of regenerative medicine therapies. The new legislation defines regenerative medicine products as processed human cells that are intended to be used for either (1) the reconstructive repair, or formation of structures or functions of the human body; (2) the treatment or prevention of human diseases; or (3) gene therapy.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legislation allows the PMDA/Ministry of Health, Labour and Welfare (&#8220;MHLW&#8221;) to award conditional approval to a regenerative medicine therapy if there is evidence of adequate safety and results which predict likely efficacy. The evidence for efficacy may be based on surrogate endpoints and may come from an exploratory study. This conditional approval is time-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">limited, and there must be an agreement with PMDA/MHLW as to follow-up collection of information which confirms efficacy and safety, similar to a post-marketing commitment in the United States.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the PMD Act, products under consideration may also be given a SAKIGAKE designation (similar to an FDA &#8220;Breakthrough&#8221; or &#8220;RMAT&#8221; designation in certain respects) with a priority six month review period. Additionally, there is a commitment that the PMDA will facilitate research and development by giving scientific and regulatory advice to sponsors from the early stage of development.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the new legislation, the sponsor prepares a marketing authorization application which is submitted for review to the PMDA. The PMDA reviews the application and prepares a review report and recommendation which is submitted to the MHLW. The MHLW reviews the recommendation and makes a decision regarding approval of the product. This procedure is followed for both a conditional approval and subsequently for a full approval after the post-marketing commitments have been fulfilled.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF RISK FACTORS</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business, financial condition, operating results and cash flows are subject to numerous risks and uncertainties that are summarized below. The below summary of risk factors should be read together with the more detailed discussion of risks set forth following this section under the heading &#8220;Risk Factors,&#8221; as well as elsewhere in this Annual Report on Form 10-K. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have incurred substantial losses and negative cash flow from operations in the past and expect to continue to incur losses and negative cash flow for the foreseeable future. Additionally, we anticipate that we will need substantial additional financing to continue our operations; if we are unable to raise additional capital, we may be forced to delay, reduce or eliminate one or more of our product development programs, and our business will be harmed.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If our status as a smaller reporting company changes, Section 404(b) of the Sarbanes-Oxley Act of 2002 may require an independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. Any delays or difficulty in satisfying these requirements could adversely affect our future results of operations and our stock price.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our future success may be dependent on the timely and successful partnering and/or commercialization of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our experimental product candidate for CLI and Buerger's Disease that is in clinical development in Japan, CLBS16 (XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for CMD in clinical development in the United States, and CLBS201 for DKD in the United States, and if we encounter delays or further difficulties in the development of these product candidates, our business prospects would be significantly harmed.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business has been and may continue to be adversely affected by the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have experienced and may continue to experience delays in completing our clinical trials and in enrolling patients in our clinical trials, which could delay or prevent the receipt of necessary regulatory approvals.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable to manage multiple late stage clinical trials for a variety of product candidates simultaneously.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The development of cell therapy product candidates is subject to uncertainty because autologous cell therapy is inherently variable.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Any disruption to our access to the reagents we are using in the clinical development of our cell therapy product candidates could adversely affect our ability to perform clinical trials and seek future regulatory submissions.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The initiation of pivotal Phase 3 clinical trials for cell therapy product candidates requires the validation and establishment of manufacturing controls that may delay product development timelines.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If serious or unacceptable side effects are identified during the development of any of our product candidates, we may need to abandon or limit our development of that product candidate.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Fast Track designation by the FDA and other similar regulatory designations may not lead to a faster development, regulatory review, or approval process.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our clinical trials may fail to demonstrate adequately the safety and efficacy of our product candidates, which failure would prevent or delay regulatory approval and commercialization.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We presently rely on contract manufacturing organizations to produce our product candidates at development and commercial scale quantities and have not yet qualified an alternate manufacturing supply, which could negatively impact our ability to meet any future demand for the products.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may enter into collaborations, strategic alliances, additional licensing arrangements, acquisitions, business combinations and/or other strategic transactions in the future, any of which could require us to issue securities that could significantly dilute the shares of our existing stockholders, and we may not realize the benefits of any such alliances, licensing arrangements, acquisitions, business combinations or strategic transactions, if completed. . </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our cell therapy business is based on novel technologies that are inherently expensive, risky and may not be understood by or accepted in the marketplace, which could adversely affect our future value.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If competitors develop and market products that are more effective, safer, or less expensive than our product candidates or offer other advantages, our commercial prospects will be limited.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may be subject to significant product liability claims and litigation, including potential exposure from the use of our product candidates in human subjects, and our insurance may be inadequate to cover claims that may arise.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may be unable to retain key officers or employees or hire new key officers or employees needed to implement our business strategy and develop our products and businesses.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our internal computer systems, or those used by our clinical investigators, clinical research organizations or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of development programs for our product candidates. Additionally, the increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Contract development and manufacturing organizations have a finite cell manufacturing capacity, which limitations could inhibit the long-term growth prospects of our business such that it will need to improve manufacturing efficiency at our contract manufacturers in order to establish cost of goods levels that will permit approved products to succeed commercially.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The development and commercialization of our product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the United States and abroad, and the failure to receive regulatory approvals for cell therapy product candidates would likely have a material and adverse effect on our business and prospects.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may be subject to numerous and varying privacy and security laws, and our failure to comply could result in penalties and reputational damage.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will continue to be subject to extensive regulation following any product approvals, and if we fail to comply with these regulations, we may suffer a significant setback in our business.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health care companies have been the subject of federal and state investigations, and we could become subject to investigations in the future.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">It is uncertain to what extent government, private health insurers and third-party payors will approve coverage or provide reimbursement for the therapies and products to which our research and development relate. Availability for such reimbursement may be further limited by an increasing uninsured population and reductions in Medicare and Medicaid funding in the United States.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competitor companies or hospitals may be able to take advantage of EU rules permitting sales of unlicensed medicines for individual patients to sell competing products without marketing authorization.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may be unable to obtain or maintain patent protection for our products and product candidates, which could have a material adverse effect on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation and third-party claims relating to intellectual property are expensive, time-consuming and uncertain, and we may be unsuccessful in our efforts to protect against infringement by third parties or defend ourselves against claims of infringement.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In certain countries, patent holders may be required to grant compulsory licenses, which would likely have a significant and detrimental effect on any future revenues in such country.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stock price has been, and will likely continue to be, highly volatile.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may fail to comply with the continued listing requirements of the Nasdaq Capital Market, such that our common stock may be delisted and the price of our common stock and its ability to access the capital markets could be negatively impacted.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">In addition to potential dilution associated with potential future fundraising and strategic transactions, we currently have a significant number of securities outstanding that are exercisable for our common stock, which exercise could result in significant additional dilution and downward pressure on the stock's price.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Provisions in our amended and restated certificate of incorporation and by-laws and Delaware law may inhibit a takeover of us, which could limit the price investors might be willing to pay in the future for our common stock and could entrench management.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business and stock price.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HUMAN CAPITAL RESOURCES</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had 27 full-time employees. Senior management and professional employees have had prior experience in pharmaceutical or biotechnology companies. None of our employees are covered by collective bargaining agreements. We believe that our relations with our employees are good.  Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees, advisors and consultants. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the granting of equity-based compensation awards in order to increase shareholder value and our success by motivating such individuals to perform to the best of their abilities and achieve our objectives.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize that our industry is specialized and dynamic, and a significant aspect of our success is our continued ability to execute our human capital strategy of attracting, engaging, developing and retaining highly skilled talent. There is fierce competition both within our industry and in the geographic locations in which we have offices for highly skilled talent, and we offer a robust set of benefits, career-enhancing learning experiences and initiatives aligned with our mission, vision, and values in order to attract qualified prospective employees and to retain and motivate our employees. We offer competitive compensation for our employees and strongly embrace a pay for performance philosophy in setting and adjusting compensation. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Code of Business Conduct and Ethics clearly outlines our commitment to diversity and inclusion, where all employees are welcomed in an environment designed to make them feel comfortable, respected, and accepted regardless of their age, race, national origin, gender, religion, disability or sexual orientation. We have a set of policies explicitly setting forth our expectations for nondiscrimination and a harassment-free work environment. We are also a proud equal opportunity employer and cultivate a highly collaborative and entrepreneurial culture.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i7d049288b82e438c85d504cc3e9dc500_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business, financial condition, operating results and cash flows can be affected by a number of factors, including, but not limited to, those set forth below, any one of which could cause our actual results to vary materially from recent results or from our anticipated future results. The risks described below are not the only ones we face, but those we currently consider to be material. There may be other risks which we now consider immaterial, or which are unknown or unpredictable, with respect to our business, our competition, the regulatory environment or otherwise that could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL REQUIREMENTS</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred substantial losses and negative cash flow from operations in the past and expect to continue to incur losses and negative cash flow for the foreseeable future.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a limited operating history, limited capital, and limited sources of revenue. Since our inception in 1980 through December&#160;31, 2021, we have incurred aggregate net losses of approximately $453.0 million. Our net losses from continuing operations attributable to common stockholders for the years ended December&#160;31, 2021 and December&#160;31, 2020 were approximately $27.5 million and $8.2 million, respectively. As of December&#160;31, 2021, our cash and cash equivalents and marketable securities were $95.0 million. Our current business has not generated revenues in the past and for the foreseeable future we do not expect it to generate revenue to be sufficient to cover costs attributable to that business or to our operations as a whole, including our development activities associated with our product candidates. Ultimately, we may never generate sufficient revenue from our business to reach profitability, generate positive cash flow or sustain, on an ongoing basis, our current or projected levels of product development and other operations. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We anticipate that we will need substantial additional financing to continue our operations; if we are unable to raise additional capital, we may be forced to delay, reduce or eliminate one or more of our product development programs, and our business will be harmed.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current operating plan will require significant levels of additional capital to fund the continued development of our cell therapy product candidates and our clinical development activities.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical activities are expected to continue to grow as our programs are advanced and they will require significant investment over a period of several years before they could potentially be approved by the FDA and commercialized by us or a partner, if ever. Even if data from our current clinical trials for our product candidates were deemed positive, we may be required to conduct additional clinical trials of the product candidates, including larger and more expensive pivotal Phase 3 trials, to pursue commercialization of the candidates. To do so, we will need to raise additional capital, enter into collaboration agreements with third parties or undertake any combination thereof. If we are unsuccessful in our efforts to raise capital or find collaborative partners, we will likely need to otherwise delay or abandon the trials.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount and timing of our future capital requirements also will likely depend on many other factors, including:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results, costs, timing and outcomes of our cell therapy research and development programs and product candidates;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into any collaboration agreements with third parties for our product candidates and the timing and terms of any such agreements; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with the consummation of one or more strategic transactions;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of, and the costs involved in obtaining, regulatory approvals for our product candidates, a process which could be particularly lengthy, or complex given the FDA's limited experience with marketing approval for cell therapy products; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of maintaining, expanding and protecting our intellectual property portfolio, including potential litigation costs and liabilities relating thereto; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of expansion of our development operations and personnel; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of, or our access to, state or federal government awards.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To both fund our clinical trials and support our future operations, we would likely seek to raise capital through a variety of different public and/or private financings vehicles. This could include, but not be limited to, utilization of our at-the-market (&#8220;ATM&#8221;) offering agreement with H.C. Wainwright &amp; Co., LLC (&#8220;HCW&#8221;), equity sales pursuant to our purchase agreement with Lincoln Park Capital Fund, LLC potential issuances of other debt or equity securities in public or private financings and/or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sale or licensing of assets. If we raise capital through the sale of equity, or securities convertible into equity, it will result in dilution to our then-existing stockholders. Servicing the interest and principal repayment obligations under debt we incur, or whether any such debt is called, would divert funds that might otherwise be available to support research and development, clinical or commercialization activities. In addition, debt financing involves covenants that restrict our ability to operate our business. In certain cases, we also may seek funding through collaborative arrangements that would likely require us to relinquish certain rights to our technology or product candidates and diminish our share in the future revenues associated with the partnered product. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ultimately, we may be unable to raise capital or enter into collaborative relationships on terms that are acceptable to us, if at all. Our inability to obtain necessary capital or financing to fund our future operating needs could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never generated any revenue from product sales and our ability to generate revenue from product sales and become profitable depends significantly on our success in a number of factors. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale, have not generated any revenue from product sales, and do not anticipate generating any revenue from product sales until sometime after we have received regulatory approval for the commercial sale of a product candidate, which may never occur. Our ability to generate revenue from product sales and achieve profitability depends significantly on our success in many factors, including: </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completing research regarding, and nonclinical and clinical development of, our current and future product candidates; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining regulatory approvals and marketing authorizations for product candidates for which we complete clinical trials; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing a sustainable and scalable manufacturing process for our product candidates;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying and contracting with contract manufacturers that have the ability and capacity to manufacture our development products and make them at an acceptable cost;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launching and commercializing product candidates for which we obtain regulatory approvals and marketing authorizations, either directly or with a collaborator or distributor; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining market acceptance of our product candidates as viable treatment options; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ensuring ongoing regulatory compliance post-approval and with respect to sales and marketing of future products;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressing any competing technological and market developments; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying, assessing, acquiring and/or developing new product candidates; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trade secrets, and know-how; and </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attracting, hiring, and retaining qualified personnel. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the FDA, or other regulatory agencies, domestic or foreign, to change our manufacturing processes or assays, or to perform clinical, nonclinical, or other types of studies in addition to those that we currently anticipate. If we are successful in obtaining regulatory approvals to market one or more of our product candidates, our revenue will depend, in part, upon the size of the markets in the territories for which we obtain regulatory approval, the accepted price for the product, the ability to receive reimbursement at any price, and whether we own the commercial rights for that territory. If the number of our addressable disease patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. If we are not able to generate revenue from the sale of any approved products, we may never become profitable. </span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our status as a smaller reporting company changes, Section 404(b) of the Sarbanes-Oxley Act of 2002 may require an independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. Any delays or difficulty in satisfying these requirements could adversely affect our future results of operations and our stock price. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 404(b) of the Sarbanes-Oxley Act of 2002 requires an independent registered public accounting firm to test the internal control over financial reporting of public companies, and to report on the effectiveness of such controls, for each fiscal year ending after June 15, 2010. Under the Dodd Frank Wall Street Reform and Consumer Protection Act of 2010, we are exempt from Section 404(b) as long as we remain a smaller reporting company or a non-accelerated filer. If our status as a smaller reporting company changes, we may be required to comply with this auditor attestation requirement. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may in the future discover areas of our internal controls that need improvement, particularly with respect to businesses that we may acquire. If so, we cannot be certain that any remedial measure we take will ensure that we have adequate internal controls over our financial processes and reporting in the future. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could harm our operating results or cause us to fail to meet our reporting obligations. If we are unable to conclude that we have effective internal controls over financial reporting, or if it becomes necessary for our independent registered public accounting firm to provide us with an unqualified report regarding the effectiveness of our internal control over financial reporting and it is unable to do so, investors could lose confidence in the reliability of our financial statements. This could result in a decrease in the value of our common stock. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR CELL THERAPY PRODUCT DEVELOPMENT EFFORTS</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success may be dependent on the timely and successful continued development and commercialization of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, our experimental product candidate for CLI and Buerger's Disease that has been in clinical development in Japan, XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or CLBS16 for CMD, and CLBS201 for DKD, and if we encounter delays or further difficulties in the development of these product candidates, our business prospects would be significantly harmed.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent upon the successful development, approval and commercialization of our product candidates. Before we are able to seek regulatory approval of our product candidates, we must conduct and complete extensive clinical trials to demonstrate their safety and efficacy in humans. We have never taken a product through the regulatory approval process or successfully to U.S. or international commercialization.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2018, we treated the first patient in a clinical trial in Japan for HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for use in CLI taking advantage of the paradigm of potential conditional approval for regenerative medicine products established by new regulations in Japan for products that show sufficient safety evidence and some evidence of efficacy. Because of difficulty enrolling the remaining patients in the trial and the costs of continued delays in such, we suspended enrollment of the trial at the end of 2021 and commenced talks with development partners as well as with PMDA to consider paths forward. There can be no assurance that we will find a partner or that PMDA will consider the drug for approval without completing enrollment of the trial, such that HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may be delayed indefinitely or never commercialized.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late 2020 we began enrolling patients in the FREEDOM trial using CD34+ cells to treat CMD (CLBS16). That trial also has been delayed significantly by COVID-19-related challenges to enrollment. Additionally, we currently have an open investigational new drug application (&#8220;IND&#8221;) for CLBS201 in a pilot study examining the effectiveness of CD34+ cells to treat diabetic kidney disease.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive, difficult to design and implement, and can take many years to complete. Importantly, a failure of one or more of these or any other clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of clinical trials that could delay or prevent our ability to complete our clinical trials, receive regulatory approval or commercialize our cell therapy product candidates, including the following:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspensions, delays or changes in the design, initiation, enrollment, implementation or completion of required clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse changes in our financial position or significant and unexpected increases in the cost of our clinical development program;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes or uncertainties in, or additions to, the regulatory approval process that require us to alter our current development strategy;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial results that are negative, inconclusive or even less than desired as to safety and/or efficacy, which could result in the need for additional clinical trials or the termination of the product's development;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in our ability to manufacture our product candidates in quantities or in a form that is suitable for any required </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property constraints that prevent us from making, using, or commercializing any of our cell therapy product candidates;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of our product candidates or other materials or equipment necessary to conduct clinical trials of these product candidates may be no longer available for purchase, insufficient or inadequate;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation of clinical trials; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in reaching agreement on acceptable terms with prospective contract research organizations (&#8220;CROs&#8221;), contract manufacturing organizations (&#8220;CMOs&#8221;), and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs, CMOs and clinical trial sites; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in obtaining required IRB approval at each clinical trial site; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to file INDs with the FDA for our development candidates or comparable clinical trial applications with other regulatory authorities outside of the United States;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of a temporary or permanent clinical hold by the FDA or similar restrictions by other regulatory agencies for a number of reasons, including after review of an IND or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical trial operations or clinical trial sites; developments on trials conducted by competitors or approved products post-market for related technology that raises FDA concerns about risk to patients of the technology broadly; or if the FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty collaborating with patient groups and investigators; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by our CROs, CMOs other third parties, or us to adhere to clinical trial requirements; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to perform in accordance with the FDA or international GCP requirements; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to reach agreement with the FDA on a satisfactory development path of our development candidates;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in having patients qualify for or complete participation in a trial or return for post-treatment follow-up; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients dropping out of a clinical trial; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">occurrence of adverse events associated with the product candidate; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials or abandoning existing trials; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">transfer of manufacturing processes from our academic collaborators to larger-scale facilities operated by either a contract manufacturing organization, or CMO, or by us, and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may not accept clinical data from trials that are conducted in countries where the standard of care is potentially different from the United States. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to successfully complete nonclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to, or we may elect to, conduct bridging studies to demonstrate the equivalence of our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business has been and may continue to be adversely affected by the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has affected our operations and may materially affect our business. In response to the pandemic, we have limited in-office operations, including implementing work from home and social distancing policies. We risk a delay, default and/or nonperformance under our existing agreements arising from force majeure. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, COVID-19 has resulted in significant governmental measures being implemented to control the spread of the virus, including quarantines, travel restrictions, social distancing and business shutdowns. We have taken temporary precautionary measures intended to help minimize the risk of the virus to our employees, including temporarily allowing all employees to work remotely. These measures could negatively affect our business. For instance, temporarily requiring all employees to work remotely may induce absenteeism, disrupt our operations, or increase the risk of a cybersecurity incident. COVID-19 has also caused volatility in the global financial markets and threatened a slowdown in the global economy, which may negatively affect our ability to raise additional capital on attractive terms or at all.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trials have suffered and may continue to suffer from delays and lower than anticipated patient recruitment or enrollment. Our clinical study of HONEDRA&#174; in Japan has experienced significant delays in enrollment due to the States of Emergency in effect in Japan for most of 2020 and re-implemented from January 7, 2021 through March 21, 2021 covering Tokyo and other regions in response to an increased number of COVID-19 infections. Due to reported increases in COVID-19 cases and a low rate of vaccination in Japan, States of Emergency were renewed on April 25, 2021 through May 11, 2021 and then re-implemented in Tokyo from July 12, 2021 through September 30, 2021. With our expectation that COVID-19 in Japan would continue to impact negatively enrollment of patients in the HONEDRA&#174; clinical trial, we elected to suspend trial enrollment, seek a development partner and consult with the Japanese regulatory authorities regarding the submission of patient data already accrued. Our phase 2b trial of XOWNA&#174; in the United States has also experienced delays in enrolling patients as a result of COVID-19.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 will continue to impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, the severity of COVID-19 or new variants or the effectiveness of actions to contain and treat COVID-19 and its variants, particularly in the geographies where we or our third party suppliers, contract manufacturers, or contract research organizations operate. We cannot presently predict the scope and severity of any potential business shutdowns or disruptions. If we or any of the third parties with whom we engage, however, were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our business and our results of operations and financial condition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to successfully complete our clinical development programs for our product candidates and receive regulatory approval to market one or more of the products, if the commercial opportunities are smaller than we anticipate, our future revenues may be adversely affected, and our business may suffer.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the size of the commercial opportunities in any of our target indications is smaller than we anticipate, or if the FDA grants our candidates approval to treat only specific subpopulations or otherwise approves the products for more narrow indications for use than we are seeking, we may not be able to achieve profitability and growth.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to successfully complete our clinical development program for our product candidates, and ultimately receive regulatory approval to market one or more of the products, we may, among other things:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval for indications that are not as broad as the indications we sought;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have the product removed from the market after obtaining marketing approval;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">encounter problems with respect to the manufacturing of commercial supplies;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be subject to additional post-marketing testing requirements; and/or</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be subject to restrictions on how the product is distributed or used.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience delays in enrolling patients in our clinical trials, which could delay or prevent the receipt of necessary regulatory approvals.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate or complete as planned any clinical trials if we are unable to identify and enroll a sufficient number of eligible patients to participate in the clinical trials required by the FDA or other regulatory authorities. We also may be unable to engage a sufficient number of clinical trial sites to conduct our trials. Moreover, our ability to conduct trials outside of the United States may be constrained by our inability to transport trial materials to foreign destinations within the expiry period of such materials unless and until we commence operation outside of the United States or find another source of supply.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face continuing challenges in enrolling patients to participate in our clinical trials due to the novelty of our cell-based therapies, the size of the patient populations, the eligibility criteria for enrollment in the trial and COVID-19 impact. Moreover, changes to enrollment criteria may be prohibited by regulating agencies, may have no impact on enrollment rates and may change or harm the outcome of the study. In addition, some patients may have concerns or negative perceptions regarding cell therapy that may affect their decision to enroll in the trials. Furthermore, patients suffering from diseases within target indications may enroll in competing clinical trials, which could negatively affect our ability to complete enrollment of our trials. Enrollment challenges in clinical trials often result in increased development costs for a product candidate, significant delays and potentially the abandonment of the clinical trial.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the unique aspects of conducting a clinical trial for a cell therapy candidate, patient enrollment in general is affected by many factors, including:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">size of the target patient population;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">severity of the disease or disorder under investigation;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eligibility criteria for the clinical trial in question;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other clinical trials being conducted at the same time involving patients who have the disease or disorder under investigation;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceived risks and benefits of the product candidate under study;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval and availability of other therapies to treat the disease or disorder that is being investigated in the clinical trial;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">willingness or unwillingness to participate in a placebo controlled clinical trial;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient referral practices of physicians;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to monitor patients adequately during and after treatment; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proximity and availability of clinical trial sites for prospective patients.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to enroll a sufficient number of patients in any of our planned clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may have other delays in completing our clinical trials and we may not complete them at all.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not completed the clinical trials necessary to obtain FDA approval to market HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or CLBS201 or any of our other product candidates in development. Our operational team lacks significant experience in completing Phase&#160;3 pivotal clinical trials and bringing a drug or biological product through commercialization. Clinical trials for products in development may be delayed or terminated as a result of many factors, including the following:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients failing to complete clinical trials due to dissatisfaction with the treatment, side effects or other reasons;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by regulators, IRBs, or independent ethics committees to authorize us or our investigators at individual sites to commence a clinical trial;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or termination by regulators of clinical research for many reasons, including concerns about patient safety or failure of our contract manufacturers to comply with applicable cGMP/cGTP requirements for the clinical supplies of the cell therapy candidate;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or failure to obtain clinical supply for our product candidates necessary to conduct clinical trials from contract manufacturers, including commercial grade clinical supply for our trials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">treatment candidates demonstrating a lack of efficacy during clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to continue to fund clinical trials or to find a partner to fund the clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition with ongoing clinical trials and scheduling conflicts with participating clinicians; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in completing data collection and analysis for clinical trials.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay or failure to complete clinical trials and obtain FDA approval for our product candidates could have a material adverse effect on our cost to develop and commercialize, and our ability to generate revenue from, a particular product candidate.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to manage multiple late stage clinical trials for a variety of product candidates simultaneously.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our current clinical trials progress, we may need to manage multiple late stage clinical trials simultaneously in order to continue developing all of our current product candidates. Our management team does not have significant experience in completing late stage clinical trials and the management of late stage clinical trials is more complex and time consuming than early stage trials. Typically, early stage trials involve several hundred patients in no more than 30 clinical sites. Late stage (Phase&#160;3) trials may involve up to several thousand patients in up to several hundred clinical sites and may require facilities in several countries. Therefore, the project management required to supervise and control such an extensive program is substantially larger than early stage programs. As the need for these resources is not known until some months before the trials begin, it is necessary to recruit large numbers of experienced and talented individuals very quickly. If the labor market does not allow this team to be recruited quickly, the sponsor is faced with a decision to delay the program or to initiate it with inadequate management resources. This may result in recruitment of inappropriate patients, inadequate monitoring of clinical investigators and inappropriate handling of data or data analysis. Consequently, it is possible that conclusions of efficacy or safety may not be acceptable to permit submission of a BLA for any one of the above reasons or a combination of several.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The development of our cell therapy product candidates is subject to uncertainty because autologous cell therapy is inherently variable.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When manufacturing an autologous cell therapy, the number and the composition of the cell population varies from patient to patient. Such variability in the number and composition of these cells could adversely affect our ability to manufacture autologous cell therapies in a cost-effective or profitable manner and meet acceptable product release specifications for use in a clinical trial or, if approved, for commercial sale. As a consequence, the development and regulatory approval process for autologous cell therapy products could be delayed or may never be completed. Our product development costs will also increase if manufacturing processes and controls require unexpected investments, which could harm our business and results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any disruption to our access to the reagents, devices, material or equipment we are using in the clinical development of our cell therapy product candidates could adversely affect our ability to perform clinical trials and seek future regulatory submissions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reagents, devices, materials and systems that we are using in our clinical trials, that we intend to use in our planned clinical trials and that we may need or use in commercial production, are provided by&#160;unaffiliated third parties. Any lack of continued availability of these reagents, devices, materials and systems for any reason would have a material adverse effect on our ability to complete these&#160;studies and could adversely impact our ability to achieve commercial manufacture of our planned therapeutic products.&#160;Although other available sources for these reagents, devices, materials and systems may exist in the marketplace, we have not evaluated their cost, effectiveness, or intellectual property foundation and therefore cannot guarantee the suitability or availability of such other potential sources.&#160; </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The initiation of pivotal Phase 3 clinical trials for cell therapy product candidates requires the validation and establishment of manufacturing controls that may delay product development timelines.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To conduct pivotal Phase 3 clinical trials, we are required to have certain validated and established manufacturing controls with respect to the safety, purity and potency of our product candidates when administered to patients. If we determine that the results of any Phase 2 clinical trial we may conduct supports Phase 3 development, we expect to initiate and complete one or more pivotal Phase 3 clinical trials for such programs and would need to address any outstanding chemistry, manufacturing and control CMC issues raised by the FDA prior to initiating such trials. We may not be successful in our efforts to address any CMC issues raised by the FDA. If we cannot initiate, or if we are delayed in initiating, a pivotal Phase 3 clinical program as a result of our failure to satisfy the FDA's CMC concerns or otherwise, the timing of regulatory submission for commercialization of our product candidates would be delayed, or we may be unable to seek regulatory approval to commercialize our products at all.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product candidates that appear promising in research and development may be delayed or may fail to reach later stages of clinical development.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development of pharmaceutical product candidates is highly uncertain. Product candidates that appear promising in research and development and early clinical trials may be delayed or fail to reach later stages of development. Decisions regarding the further development of product candidates must be made with limited and incomplete data, which makes it difficult to ensure or even accurately predict whether the allocation of limited resources and the expenditure of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional capital on specific product candidates will result in desired outcomes. Preclinical and clinical data can be interpreted in different ways, and negative or inconclusive results or adverse events during a clinical trial could delay, limit or prevent the development of a product candidate.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Exploratory trends and results observed in earlier stage clinical trials, particularly trends and results observed for small subsets that were not pre-specified, may not be replicated in later stage clinical trials. Product candidates in Phase&#160;3 clinical trials may fail to demonstrate sufficient efficacy despite having progressed through initial clinical trials, even if certain exploratory subset analyses of primary or secondary endpoints in those early trials showed trends toward efficacy or, in some analyses, nominal statistical significance. The results of clinical trials in one set of patients or line of treatment may not be predictive of those obtained in another.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If serious or unacceptable side effects are identified during the development of any of our product candidates, we may need to abandon or limit our development of that product candidate.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are in clinical development and their risk of failure is high. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive marketing approval. If our product candidates are associated with undesirable side effects or have other unexpected, unacceptable characteristics, we may need to abandon their development or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many investigational products that initially showed promise in clinical or earlier stage testing have later been found to cause side effects or other safety issues that prevented further development. Even if we receive regulatory approval for a candidate with a known safety risk, such an approved product may not achieve market acceptance by physicians, patients, third-party payors or others in the medical community, which would materially and adversely affect our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A Fast Track designation by the FDA and other similar regulatory designations may not lead to a faster development, regulatory review or approval process.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were granted SAKIGAKE designation in Japan and Advanced Therapeutic Medicinal Product (&#8220;ATMP&#8221;) designation in Europe for HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of CLI and Buerger's Disease. However, SAKIGAKE and ATMP designations do not ensure that we will experience a faster development, regulatory review or approval process compared to conventional FDA or Japan PMDA procedures. Additionally, a regulatory authority may withdraw a designation if it believes that the designation is no longer supported by data from the clinical development program. Moreover, award of a particular designation does not imply a higher probability of success of a product in the approval process.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may fail to demonstrate adequately the safety and efficacy of our product candidates, which would prevent or delay regulatory approval and commercialization. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical trials of our product candidates are, and the manufacturing and marketing of our products will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test and market our product candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. In particular, because our cell therapy candidates are subject to regulation as biological drug products, we will need to demonstrate that they are safe, pure, and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. The risk/benefit profile required for product licensure will vary depending on these factors and may include adequate duration of response, a delay in the progression of the disease, and/or an improvement in survival. For example, response rates from the use of our product candidates may not be sufficient to obtain regulatory approval unless we can also show an adequate duration of response.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect there may be greater variability in results for products processed and administered on a patient-by-patient basis, as anticipated for our product candidates, than for &#8220;off-the-shelf&#8221; products, like many other drugs. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data from earlier studies conducted by the third-party research institutions should not be relied upon as evidence that later or larger-scale clinical trials will succeed. Some future trials may have different patient populations than current studies and will test our product candidates in different indications, among other differences. In addition, our proposed manufacturing processes </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for our product candidates include what we believe will be process improvements that are not part of the production processes that were previously used in the earlier conducted clinical trials being conducted by the research institutions. Accordingly, our results with our product candidates may not be consistent with the results of the clinical trials. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if such trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as do we, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We presently rely on contract manufacturing organizations to produce our product candidates at development and commercial scale quantities and have not yet qualified an alternate manufacturing supply, which could negatively impact our ability to meet any future demand for the products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on one contract manufacturer, Cognate Bioservices, a Charles River Company (&#8220;Cognate&#8221;), to provide the cell processing services necessary for clinical production for our various CD34+ cell therapy product candidates. To date, Cognate has not produced any products at commercial scale quantities and we expect that Cognate would need to significantly expand its manufacturing capabilities to meet potential commercial demand for XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and CLBS201 and any other of our product candidates, if approved, as well as any of our other product candidates that might attain regulatory approval. Such expansion would require additional regulatory approvals. Even if they increase their manufacturing capabilities, it is possible that they may still lack sufficient capacity to meet demand. At present we have no contract manufacturer for the production of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan. Ultimately, if we are unable to supply our products to meet commercial demand, whether because of processing constraints or other disruptions, delays or difficulties that we experience, sales of the products and their long-term commercial prospects could be significantly damaged.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not presently have redundant suppliers for any of our product candidates. If the facilities where our product candidates are being manufactured and/or the associated equipment were significantly damaged or destroyed, or if there were other disruptions, delays or difficulties affecting manufacturing capacity, our planned and future clinical trials and commercial production for these product candidates would likely be significantly disrupted and delayed. It would be both time consuming and expensive to replace this capacity with third parties, particularly since any new facility would need to comply with regulatory requirements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ultimately, if we are unable to supply our cell therapy product candidates to meet commercial demand, were commercial approval to be obtained, whether because of processing constraints or other disruptions, delays or difficulties that we experience, our production costs could increase dramatically, and sales of the product and its long-term commercial prospects could be significantly damaged.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, as a result of the current geopolitical tensions and the conflict between Russia and Ukraine following the recent and ongoing Russian invasion of Ukraine, the governments of the United States, the European Union, Japan and other jurisdictions have recently announced the imposition of sanctions on certain industry sectors and parties in Russia, as well as enhanced export controls on certain products and industries. These and any additional sanctions and export controls, as well as any counter responses by the governments of Russia or other jurisdictions, could adversely affect, directly or indirectly, the global supply chain, with negative implications on the availability and prices of raw materials, energy prices, and our customers, as well as the global financial markets and financial services industry.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial potential and profitability of our product candidates are unknown and subject to significant risk and uncertainty.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we successfully develop and obtain regulatory approval for our cell therapy product candidates, the market may not understand or accept the products, which could adversely affect both the timing and level of future sales. Ultimately, the degree of market acceptance of our product candidates (or any of our future product candidates) will depend on a number of factors, including:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and potential advantages compared to alternative treatments or competitive products; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">physician acceptance of our cell therapy approach to our target disease indications, include the ease or difficulty of administering the future products; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on how the product is distributed or used;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of our marketing and distribution support, including whether we receive support from any patient advocacy groups;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the adequacy of product supply in light of complex manufacturing and distribution processes; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to distinguish our products (which involve adult cells) from any ethical and political controversies associated with stem cell products derived from human embryonic or fetal tissue; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of the product, the reimbursement policies of government and third-party payors and our ability to obtain sufficient third-party coverage or reimbursement.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in achieving sales of our product candidates, it is not clear to what extent, if any, the products will be profitable. The costs of goods associated with production of cell therapy products are significant. While we are working to improve the speed and efficiency and lower the cost of our manufacturing processes, there can be no assurance that we will be successful in these efforts. In addition, some changes in manufacturing processes or procedures generally require FDA or foreign regulatory authority review and approval prior to implementation. Thus, we may need to conduct additional nonclinical studies and clinical trials to support approval of any such changes. Furthermore, this review process could be costly and time-consuming and could delay or prevent the commercialization of product candidates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may enter into collaborations, strategic alliances, additional licensing arrangements, acquisitions, business combinations or other strategic transactions in the future, any of which could require us to issue securities that could significantly dilute the shares of our existing stockholders, and we may not realize the benefits of such alliances or licensing arrangements, acquisitions, business combinations or strategic transactions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into collaborations, strategic alliances, additional licensing arrangements, acquisitions, business combinations or other strategic transactions with third parties that we believe are essential to product commercialization or will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that could significantly dilute the shares of our existing stockholders, or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and/or acquisition candidates and the negotiation process can be time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. Furthermore, there can be no assurance that our exploration of potential acquisitions, business combinations or strategic alternatives will result in us entering or completing any transaction or that such transaction, if completed, will add to shareholder value.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, collaborations involving our product candidates, such as our collaborations with third-party research institutions, are subject to numerous risks, which may include the following: </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in their strategic focus due to the acquisition of competitive products, availability of funding, or other external factors, such as a business combination that diverts resources or creates competing priorities; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to their marketing and distribution; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; and </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, if we enter into collaboration agreements and strategic partnerships or license our products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited experience in the development and marketing of cell therapies and may be unsuccessful in our efforts to establish a profitable business. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience in the areas of cell therapy product development and marketing, and in the related regulatory issues and processes. Although we have recruited a team that has experience with designing and conducting clinical trials, as a company we have limited experience in conducting clinical trials and no experience in conducting clinical trials through to regulatory approval of any product candidate.&#160; In part because of this lack of experience, we cannot be certain that ongoing or planned clinical trials will begin or be completed on time, if at all. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our cell therapy business is based on novel technologies that are inherently expensive, risky and may not be understood by or accepted in the marketplace, which could adversely affect our future value.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical development, commercialization and marketing of cell and tissue-based therapies are at an early stage, substantially research-oriented and financially speculative. To date, very few companies have been successful in their efforts to develop and commercialize a cell therapy product. In general, cell-based or tissue-based products may be susceptible to various risks, including undesirable and unintended side effects, unintended immune system responses, inadequate therapeutic efficacy, or other characteristics that may prevent or limit their approval or commercial use. Regulatory approval of novel product candidates such as HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and CLBS201, which are each manufactured having novel and proprietary formulations, can be more complex and expensive and take longer than other, more well-known or extensively studied pharmaceutical or biopharmaceutical products, due to the FDA&#8217;s lack of experience with them. To our knowledge, the FDA has only approved five autologous cell therapy products to date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This lack of experience may lengthen the regulatory review process, require us to conduct additional studies or clinical trials, which would increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these product candidates or lead to significant post-approval limitations or restrictions. Furthermore, the number of people who may use cell or tissue-based therapies is difficult to forecast with accuracy. Our future success is dependent on the establishment of a large global market for cell and tissue-based therapies and our ability to capture a share of this market with our product candidates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If competitors develop and market products that are more effective, safer, or less expensive than our product candidates or offer other advantages, our commercial prospects will be limited.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cell therapy development programs now face, and will continue to face, intense competition from pharmaceutical, biopharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies engaged in drug discovery activities or funding, both in the United States and abroad. Some of these competitors are pursuing the development of drugs and other therapies that target the same diseases and conditions that we are targeting with our product candidates.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a general matter, we also face competition from many other companies that are researching and developing cell therapies. Many of these companies have financial and other resources substantially greater than ours. In addition, many of these competitors have significantly greater experience in testing pharmaceutical and other therapeutic products, obtaining FDA and other regulatory approvals, and marketing and selling FDA-approved products in highly regulated commercial health care markets. If we ultimately obtain regulatory approval for any of our product candidates, we also will be competing with respect to manufacturing efficiency and marketing capabilities, areas in which we have limited or no commercial-scale experience. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in resources being even more concentrated by our competitors. Competition may increase further as a result of advances made in the commercial applicability of our technologies and greater availability of capital for investment in these fields.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our cell therapy product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated pathway for licensure of so-called biosimilar and interchangeable biological products, both of which have specific defined meanings under the law. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an existing reference product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original reference product is approved for marketing in the United States a stand-alone BLA. The law is complex and is still being interpreted and implemented by the FDA. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a risk that the FDA will not consider any of our therapeutic candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Additionally, this period of regulatory exclusivity does not apply to companies pursuing regulatory approval via their own traditional BLA, rather than via the abbreviated pathway. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing, as well as unique state laws and government/private policies.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to significant product liability claims and litigation, including potential exposure from the use of our product candidates in human subjects, and our insurance may be inadequate to cover claims that may arise.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business exposes us to potential product liability risks inherent in the testing, processing and marketing of cell therapy products. Such liability claims may be expensive to defend and result in large judgments against us. We face an inherent risk of product liability exposure related to the testing of our current and any future product candidates in human clinical trials and will face an even greater risk with respect to any commercial sales of our products should they be approved. None of our product candidates have been widely used over an extended period of time, and therefore relevant safety data are limited. Cell therapy companies also derive the raw materials for manufacturing of product candidates from human cell sources, and therefore the manufacturing process and handling requirements, including ensuring compliance with cGTPs, are extensive, which increases the risk of quality failures and subsequent product liability claims. We presently have product liability insurance limited to $10 million per incident and $10 million in annual aggregate. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to increase our insurance coverage when we begin commercializing product candidates, if ever. At that time, we may not be able to obtain or maintain product liability insurance on acceptable terms with adequate coverage or at all, or if claims against us substantially exceed our coverage, then our financial position could be significantly impaired.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether or not we are ultimately successful in any product liability litigation that may arise, such litigation could consume substantial amounts of our financial and managerial resources, decrease demand for our products and injure our reputation.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to maintain errors and omissions, directors and officers, workers' compensation and other insurance at levels we believe to be appropriate to our business activities. If, however, we were subject to a claim in excess of this coverage or to a claim not covered by our insurance and the claim succeeded, we would be required to pay the claim from our own limited resources, which could have a material adverse effect on our financial condition, results of operations and business. Additionally, liability or alleged liability could harm our business by diverting the attention and resources of our management and damaging our reputation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to retain key officers or employees or hire new key officers or employees needed to implement our business strategy and develop our products and businesses.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the specialized nature of cell therapy and that it is a relatively new field, there is an inherent scarcity of experienced personnel in the field. We are substantially dependent on the skills and efforts of current senior management for their management and operations, as well as for the implementation of our business strategy. In addition, our future success depends upon our ability to attract and retain additional qualified personnel (including medical, scientific, technical, commercial, business and administrative personnel) necessary to support our anticipated growth, develop our business, perform our contractual obligations to third parties and maintain appropriate licensure. There can be no assurance that we will be successful in attracting or retaining personnel required by us to continue to grow our operations. The loss of a key employee, the failure of a key employee to perform in his or her current position or our inability to attract and/or retain skilled employees, as needed, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could result in our inability to continue to grow our business or to implement our business strategy, or may have a material adverse effect on our business, financial condition and operating results.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those used by our clinical investigators, clinical research organizations or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of development programs for our product candidates. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on information technology systems to keep financial records, maintain laboratory and corporate records, communicate with staff and external parties and operate other critical functions. Any significant insufficiency degradation or failure of these computer systems could cause us to inaccurately calculate or lose our data. Despite the implementation of security measures, these internal computer systems and those used by our clinical investigators, clinical research organizations, and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical failures. The techniques that could be used by criminal elements or foreign governments to attack these computer systems are sophisticated, change frequently and may originate from less regulated and remote areas of the world. Furthermore, there is an increased risk of cybersecurity attacks by state actors due to the current conflict between Russia and Ukraine. Recently, Russian ransomware gangs have threatened to increase hacking activity against critical infrastructure of any nation or organization that retaliates against Russia for its invasion of Ukraine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any such increase in such attacks on our third-party provider or other systems could adversely affect our network systems or other operations. While we have not experienced any such system failure, theft of information, accident or security breach to date, if such an event were to occur and cause interruptions in its operations, it could result in a material disruption of our clinical development activities. For example, the loss of clinical trial data from historical or future clinical trials could result in delays in regulatory approval efforts and significantly increase costs to recover or reproduce the data. To the extent that any disruption, theft of information, or security breach were to result in a loss of or damage to data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the clinical development, and the future development of our product candidates could be delayed.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks&#160;and challenges.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate information about our product candidates and the diseases that our therapies are designed to treat. Social media practices in our industry continue to evolve and regulations related to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients and others may use social media channels to comment on the effectiveness of a product candidate or to report an alleged adverse event. When such disclosures occur, we may fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend against political and market pressures generated by social media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO MANUFACTURING OUR DEVELOPMENT PRODUCT CANDIDATES</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no internal capacity to manufacture our development product candidates and have no assurance that we will continue to have access to manufacturers in our industry that can effectively make our development products or make them at an affordable, salable or otherwise commercially reasonable price or quantity. </span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract development and manufacturing organizations have a finite cell manufacturing capacity, which could inhibit the long-term growth prospects of our business.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have minimal manufacturing contracts to produce materials for our clinical trials in the United States. It is possible that the demand for our products could exceed existing manufacturing capacity. We expect that, as our own cell therapy development programs progress and demand for cell therapy services in the industry expand, it may become necessary or desirable for us to expand our manufacturing vendors for cell therapy services and products in the future, which may require us to invest significant amounts of capital and to obtain regulatory approvals. If manufacturers are unable to meet our rising demand for products and services on a timely basis or unable to maintain cGMP/cGTP compliance standards, then it is likely that the progress of our own programs will be impaired which could materially and adversely affect the overall success of our development programs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of therapeutic products approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMPs and manufacturers of cell-based product candidates must comply with cGTPs. In addition, manufacturers of therapeutic products may be required to modify their manufacturing processes from time to time in response to regulatory requests. The manufacture of live cellular-based products is complex and imposes significant regulatory burdens </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that may change over time. We may encounter difficulties in the production of our product candidates due to our limited manufacturing experience.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to improve manufacturing efficiency at our contract manufacturers in order to establish cost of goods levels that will permit approved products to succeed commercially.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMOs cannot provide assurances that they will be able to develop process enhancements that are acceptable to regulators or other comparable regulatory authorities, on a timely basis, on commercially reasonable terms, or at all, or that any expected improvement in profitability will be realized. If they are unsuccessful in their efforts to develop necessary improvements, we may be unable to develop commercially viable products, which would impair our ability to continue our operations.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lack of access to safe, reliable, and effective transportation options could adversely affect our ability to meet our needs.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To effectively and efficiently deliver our cell therapy product, we also need to establish and maintain cost-effective relationships with reliable and experienced transportation carriers. Most existing transportation carriers are not optimally designed for the transportation of cell therapy products. For example, these carriers generally lack a true point-to-point chain of control, may have non-controlled X-ray and inspection, do not guarantee package orientation, handling or storage conditions and, in many cases, lack a standard, documented and tracked operating procedures. While reliable ground carriers with experience in the transport of blood products exist in major U.S. metropolitan areas, air carriers meeting such needs are limited. If carriers we currently use should cease medical shipping operations or otherwise become unable to properly meet our transportation needs or comply with applicable customs and import regulations, the lack of access to safe, reliable and effective transportation options could adversely affect our ability to meet our needs.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO GOVERNMENT REGULATION </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The development and commercialization of our product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the United States and abroad, and the failure to receive regulatory approvals for our cell therapy product candidates would likely have a material and adverse effect on our business and prospects.</span></div><div style="margin-bottom:8pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state and local level, and in other countries, extensively regulate, among other things, the research, development, testing, manufacture, including any manufacturing changes, packaging, storage, recordkeeping, labeling, advertising and promotion, distribution, marketing, import and export of pharmaceutical and biological products, such as HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and CLBS201. The process of obtaining required regulatory approvals and the subsequent compliance with appropriate statutes and regulations requires the expenditure of substantial time and money, and there is no guarantee that we will successfully complete the steps needed to obtain regulatory approval of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and CLBS201 or any future product candidates. There also are extensive and ongoing post-marketing compliance obligations to which we would be subject following FDA approval of any of our product candidates. In addition, these federal regulations may change, and our product candidates may be subject to new laws or regulations due to the rapid advancement of the regenerative medicine field and legislators'/regulators' interest in it.</span></div><div style="margin-bottom:8pt;padding-right:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not received regulatory approval to market any of our product candidates in any jurisdiction. If we seek approval of any of our cell therapy product candidates, we will be required to submit to FDA, Japan's PMDA, and potentially other regulatory authorities, extensive preclinical and clinical data supporting the safety and efficacy of such product candidates, as well as information about the manufacturing process and to undergo inspection of manufacturing facilities, among other things. The process of obtaining FDA and other regulatory approvals is expensive, typically takes many years and is subject to numerous risks and uncertainties, particularly with complex and/or novel product candidates such as our cell-based product candidates. Changes in regulatory approval policies during the clinical research and development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application or may make it easier for our competitors to gain regulatory approval to enter the marketplace. Ultimately, the FDA and other regulatory agencies have substantial discretion in the approval/licensure process and may refuse to accept any application or may decide that our product candidate data are insufficient for approval without the submission of additional preclinical, clinical or other time-consuming studies. In addition, varying agency interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent regulatory approval of a product candidate. Any regulatory approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the following factors, among others, could cause regulatory approval for our product candidates to be delayed, limited or denied:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product candidates require significant clinical testing to demonstrate safety and effectiveness before applications for marketing approval can be submitted to the FDA and other regulatory authorities;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">data obtained from animal testing and other nonclinical testing and clinical trials can be interpreted in different ways, and regulatory authorities may not agree with our respective interpretations or may require us to conduct additional testing;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative or inconclusive results or the occurrence of serious or unexpected adverse events during a clinical trial could cause us to delay and/or terminate development efforts for a product candidate; and/or</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA and other regulatory authorities may require expansion of the size and scope of the clinical trials.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any difficulties or failures that we encounter in securing regulatory approval for our product candidates would likely have a substantial adverse impact on our ability to generate product sales and could make any search for a collaborative partner more difficult.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unsuccessful in our efforts to comply with applicable federal, state and international laws and regulations, which could result in loss of licensure, certification or accreditation or other government enforcement actions or impact our ability to secure regulatory approval of our product candidates.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we seek to conduct our business in compliance with applicable laws and regulations, these laws and regulations are exceedingly complex and often subject to varying interpretations. The cell therapy industry is the topic of significant government interest, and thus the laws and regulations applicable to our business are subject to frequent change and/or reinterpretation. As such, there can be no assurance that we will be able, or will have the resources, to maintain compliance with all applicable biopharmaceutical and health care laws and regulations. Failure to comply with such biopharmaceutical and health care laws and regulations could result in significant enforcement actions, civil or criminal penalties, which along with the costs associated with such compliance or with enforcement of such biopharmaceutical and health care laws and regulations, may have a material adverse effect on our operations or may require restructuring of our operations or impair our ability to operate profitably.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities engaged in the recovery, processing, storage, labeling, packaging or distribution of any human cells, tissues or cellular- and tissue-based products, or the screening or testing of a donor, are required to register with the applicable regulatory agencies. Any third party retained by us to process our samples must be similarly registered with regulators and comply with applicable regulations as well as applicable cGTP regulations and any failure to comply with these requirements could adversely affect our business. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cGTPs, cGMP regulations govern the manufacture, processing, packaging and holding of cell therapy products that are regulated as drugs. Any third-party manufacturers that prepare our products must comply with cGMP requirements including quality control, quality assurance and the maintenance of records and documentation for certain products. They may be unable to comply with these cGMP requirements and with other national regulators and state and local regulatory requirements. These requirements may change over time and we or third-party manufacturers may be unable to comply with the revised requirements.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to conduct clinical trials in accordance with regulations and accepted standards, we may be delayed in receiving, or may never receive, regulatory approvals of our product candidates from the FDA and other regulatory authorities.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain marketing approvals for our product candidates in the United States and abroad, we must, among other requirements, complete adequate and well-controlled clinical trials sufficient to demonstrate to the FDA and other regulatory bodies that the product candidate is safe and effective for each indication for which approval is sought. If the FDA finds that patients enrolled in the trial are or would be exposed to an unreasonable and significant risk of illness or injury due to, among other things, occurrence of one or more serious adverse events in an ongoing clinical trial, the FDA can place one or more of our clinical trials on partial or full clinical hold. If safety concerns develop, we may, or the FDA, a foreign regulatory authority, or an IRB may require us to pause or stop the affected trials before completion. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The completion of our clinical trials also may be delayed or terminated for a number of other reasons, including if:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party clinical investigators do not perform the clinical trials on the anticipated schedule or consistent with the clinical trial protocol, GCPs required by the FDA and other regulatory requirements, or other third parties do not perform data collection and analysis in a timely or accurate manner;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inspections of clinical trial sites by the FDA or by IRBs of research institutions participating in the clinical trials, reveal regulatory violations that require the sponsor of the trial to undertake corrective action, suspend or terminate one or more sites, or prohibit use of some or all of the data in support of marketing applications; or</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or one or more IRBs suspends or terminates the trial at an investigational site or precludes enrollment of additional subjects.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development costs will increase if there are material delays in our clinical trials, or if we are required to modify, suspend, terminate, or repeat a clinical trial. If we are unable to conduct our clinical trials properly, we may never receive regulatory approval to market our product candidates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to numerous and varying privacy and security laws, and our failure to comply could result in penalties and reputational damage.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to laws and regulations covering data privacy and the protection of personal information including health information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which may affect our business. In the United States, we may be subject to state security breach notification laws, state health information privacy laws and federal and state consumer protections laws which impose requirements for the collection, use, disclosure and transmission of personal information. Each of these laws are subject to varying interpretations by courts and government agencies, creating complex compliance issues for us. If we fail to comply with applicable laws and regulations we could be subject to penalties or sanctions, including criminal penalties if we knowingly obtain individually identifiable health information from a covered entity in a manner that is not authorized or permitted by HIPAA or for aiding and abetting the violation of HIPAA.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous other countries have, or are developing, laws governing the collection, use and transmission of personal information as well. EU member states and other jurisdictions have adopted data protection laws and regulations, which impose significant compliance obligations. In May 2016, the European Union formally adopted the General Data Protection Regulation (&#8220;GDPR&#8221;), which applies to all EU member states from May 25, 2018 and replaced the EU Data Protection Directive The regulation introduces stringent new data protection requirements in the European Union and substantial fines for breaches of the data protection rules. It has increased our responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the new EU data protection rules. The GDPR is a complex law and the regulatory guidance is still evolving, including with respect to how the GDPR should be applied in the context of clinical studies.&#160; Furthermore, many of the countries within the European Union are still in the process of drafting supplementary data protection legislation in key fields where the GDPR allows for national variation, including the fields of clinical study and other health-related information.&#160; These variations in the law may raise our costs of compliance and result in greater legal risks.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will continue to be subject to extensive regulation following any product approvals, and if we fail to comply with these regulations, we may suffer a significant setback in our business.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in obtaining regulatory approval of our product candidates, we will continue to be subject to the requirements of and review by, the FDA and comparable regulatory authorities in the areas of manufacturing processes, quality assurance, post-approval clinical data, adverse event reporting, labeling, advertising and promotional activities, among other things. In addition, any marketing approval we receive may be limited in terms of the approved product indication or require costly post-marketing testing and surveillance. Discovery after approval of previously unknown problems with a product, manufacturer or manufacturing process, or a failure to comply with regulatory requirements, may result in actions such as:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning letters or untitled letters or other actions requiring changes in product manufacturing processes or restrictions on product marketing or distribution;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls or seizures or the temporary or permanent withdrawal of a product from the market; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, restitution, or disgorgement of profits or revenue, the imposition of civil penalties or criminal prosecution.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of these actions would likely cause a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if we or others identify undesirable side effects, or other previously unknown problems, caused by our product candidates after obtaining U.S. or foreign regulatory approval or other products with the same or related active ingredients, a number of potential consequences could result, including:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of the product;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require a recall of the product or we may voluntarily recall a product;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of warnings or contradictions in the product labeling, narrowing of the indication in the product label or issuance of field alerts to physicians and pharmacies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients or institute a REMS;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to limitation as to how we promote the product;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way the product is administered or modify the product in some other way;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or applicable foreign regulatory authority may require additional clinical trials or costly post-marketing testing and surveillance to monitor the safety or efficacy of the product;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of the product may decrease significantly;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; and </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our brand and reputation may suffer.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health care companies have been the subject of federal and state investigations, and we could become subject to investigations in the future.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both federal and state government agencies have heightened civil and criminal enforcement efforts. There are numerous ongoing investigations of health care companies, including drug, biologic and medical device companies, as well as their executives and managers. In addition, amendments to the Federal False Claims Act, including under health care reform, have made it easier for private parties to bring &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; (whistleblower) lawsuits against companies under which the whistleblower may be entitled to receive a percentage of any money paid to the government. The Federal False Claims Act provides, in part, that an action can be brought against any person or entity that has knowingly presented, or caused to be presented, a false or fraudulent request for payment from the federal government, or who has made a false statement or used a false record to get a claim approved. The government has taken the position that claims presented in violation of the federal anti-kickback law, Stark Law or other health care-related laws, including laws enforced by the FDA, may be considered a violation of the Federal False Claims Act. Penalties include substantial fines for each false claim, plus three times the amount of damages that the federal government sustained because of the act of that person or entity and/or exclusion from the Medicare program. In addition, a majority of states have adopted similar state whistleblower and false claims provisions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not aware of any government investigations involving any of our facilities or management. While we believe that we are in material compliance with applicable governmental health care laws and regulations, any future investigations of our business or executives could cause us to incur substantial costs, and result in significant liabilities or penalties, as well as damage to our reputation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is uncertain to what extent government, private health insurers and third-party payors will approve coverage or provide reimbursement for the therapies and products to which our research and development relate. Availability for such reimbursement may be further limited by an increasing uninsured population and reductions in Medicare and Medicaid funding in the United States.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that health care providers cannot obtain coverage or reimbursement for our therapies and products, they may elect not to provide such therapies and products to their patients and, thus, may not need our services. Further, as cost containment pressures are increasing in the health care industry, government and private payors may adopt strategies designed to limit the amount of reimbursement paid to health care providers. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, the trend toward managed health care and bundled pricing for health care services in the United States, could significantly influence the purchase of health care services and products, resulting in lower prices and reduced demand for our therapeutic products under development.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may receive a portion of our revenues from services rendered to patients enrolled in federal health care programs, such as Medicare, and we may also directly or indirectly receive revenues from federal health care programs. Federal health care programs are subject to changes in coverage and reimbursement rules and procedures, including retroactive rate adjustments. These contingencies could materially decrease the range of services covered by such programs or the reimbursement rates paid directly or indirectly for our products and services. To the extent that any health care reform favors the reimbursement of other therapies over our therapeutic products under development, such reform could affect our ability to sell our services, which may have a material adverse effect on our revenues.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The limitation on reimbursement available from private and government payors may reduce the demand for, or the price of, our services, which could have a material adverse effect on our revenues. Additional legislation or regulation relating to the health care industry or third-party coverage and reimbursement may be enacted in the future which could adversely affect the revenues generated from the sale of our products and services.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, there has been a trend in recent years towards reductions in overall funding for Medicare and Medicaid. There has also been an increase in the number of people who do not have any form of health care coverage in recent years and who are not eligible for or enrolled in Medicare, Medicaid or other governmental programs. The extent to which the reforms brought about under health care reform may be successful in reducing the number of such uninsured is unclear, and the reduced funding of governmental programs and increase in uninsured populations could have a negative impact on the demand for our services to the extent they relate to products and services which are reimbursed by government and private payors.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unintended consequences of health care reform legislation in the United States may adversely affect our business.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health care industry is undergoing fundamental changes resulting from political, economic and regulatory influences. In the United States, comprehensive programs are under consideration that seek to, among other things, increase access to health care for the uninsured and control the escalation of health care expenditures within the economy. In March 2010, the Patient Protection and Affordable Care Act (&#8220;PPACA&#8221;), as amended by the Health Care and Education Reconciliation Act, or the Affordable Care Act, was passed, which substantially changes the way health care is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry.&#160;While we do not believe this legislation will have a direct impact on our business, the legislation requires the adoption of implementing regulations, which may have unintended consequences or indirectly impact our business. For instance, the scope and implications of the amendments pursuant to the Fraud Enforcement and Recovery Act of 2009 (&#8220;FERA&#8221;), have yet to be fully determined or adjudicated and as a result it is difficult to predict how future enforcement initiatives may impact our business. Also, in some instances our clients may be health insurers that will be subject to limitations on their administrative expenses and federal review of &#8220;unreasonable&#8221; rate increases that could impact the prices they pay for our services. If the legislation causes such unintended consequences or indirect impact, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, creates the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect on April 1, 2013. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. &#160;Strong, partisan disagreement in Congress has prevented implementation of various PPACA provisions, and the Trump Administration had made the repeal of the PPACA a priority.&#160;One of the first executive orders of the Trump administration granted federal agencies broad powers to unwind regulations under the PPACA. On January 11, 2017, the Senate voted to approve a &#8220;budget blueprint&#8221; allowing Republicans to repeal parts of the law while avoiding Democrat filibuster.&#160;The &#8220;Obamacare Repeal Resolution&#8221; passed 51-48.&#160; Certain legislators are continuing their efforts to repeal the PPACA, although there is little clarity on how such a repeal would be implemented and what a PPACA replacement might look like.&#160; For the immediate future, there is significant uncertainty regarding the health care, health care coverage and health care insurance markets.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. government has in the past considered, is currently considering and may in the future consider health care policies and proposals intended to curb rising health care costs, including those that could significantly affect both private and public reimbursement for health care services. State and local governments, as well as a number of foreign governments, are also considering or have adopted similar types of policies. Future significant changes in the health care systems in the United States or elsewhere, and current uncertainty about whether and how changes may be implemented, could have a negative impact on the demand for our products. We are unable to predict whether other health care policies, including policies stemming from legislation or regulations affecting our business, may be proposed or enacted in the future; what effect such policies would have on our business; or the effect ongoing uncertainty about these matters will have on the purchasing decisions of our customers.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that additional state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services, which could result in reduced demand for our products or additional pricing pressures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries, particularly the member states of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries where we may seek to market </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our product candidates in the future, we may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidate to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on prices or reimbursement levels within the country of publication and other countries. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be adversely affected.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, upon completion of this offering and in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competitor companies or hospitals may be able to take advantage of EU rules permitting sales of unlicensed medicines for individual patients to sell competing products without a marketing authorization.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU medicines rules allow individual member states to permit the supply of a medicinal product without a marketing authorization to fulfill special needs, where the product is supplied in response to a bona fide unsolicited order, formulated in accordance with the specifications of a health care professional and for use by an individual patient under his direct personal responsibility.&#160; This may in certain countries also apply to products manufactured in a country outside the EU and imported to treat specific patients or small groups of patients.&#160; In addition, designated advanced therapy medicinal products do not need a marketing authorization if they are prepared on a non-routine basis and are used within the same EU member state in a hospital in accordance with a medical prescription for an individual patient.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These exemptions could allow our competitors to make sales in the EU without having obtained a marketing authorization and without undergoing the expense of clinical trials, especially if those competitors have cell processing facilities in the relevant EU member state.&#160; Similarly, certain hospitals may be able to compete with us on the basis of these rules.&#160; Because any such sales would be made without a marketing authorization, there would be no need for the competitor company or hospital to refer to the clinical data in our marketing authorization dossiers, and so any data exclusivity protection that we may obtain for our products would not prevent such competing sales.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A variety of risks associated with operating our business internationally could materially adversely affect our business. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek regulatory approval of our product candidates outside of the United States and, accordingly, we expect that we, and any potential collaborators in those jurisdictions, will be subject to additional risks related to operating in foreign countries, including: </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing regulatory requirements in foreign countries; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing coverage and reimbursement requirements in foreign countries;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers, price and exchange controls, and other regulatory requirements; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign taxes, including withholding of payroll taxes; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties staffing and managing foreign operations; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign laws, such as the U.K. Anti-Bribery Act; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the continued threat of terrorism and the impact of military and other action, including military actions involving Russia and Ukraine;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad, including as a result of COVID-19 or the recent military actions involving Russia and Ukraine; and  </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geo-political actions, including war and terrorism. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;These and other risks associated with our planned international operations may materially adversely affect our ability to attain or maintain profitable operations. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR INTELLECTUAL PROPERTY</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to obtain or maintain patent protection for our products and product candidates, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend, in part, on obtaining and maintaining patent protection for new technologies, product candidates, products and processes and successfully defending such patents against third-party challenges. To that end, we file patent applications, and have been issued patents, that are intended to cover certain methods and uses of human cells as well as compositions and methods relating to hematopoietic stem cells. These patent applications may never result in the issuance of patents.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of biotechnology companies can be highly uncertain and involve complex legal, scientific and factual questions and recent court decisions have introduced significant uncertainty regarding the strength of patents in the industry. Moreover, the legal systems of some foreign countries do not favor the aggressive enforcement of patents and may not protect our intellectual property rights to the same extent as the laws of the United States. Any of the issued patents we own or license may be challenged by third parties and held to be invalid, unenforceable or with a narrower or different scope of coverage than what we currently believe, effectively reducing or eliminating protection we believed we had against competitors with similar products or technologies. If we ultimately engage in and lose any such patent disputes, we could be subject to competition and/or significant liabilities, we could be required to enter into third-party licenses or we could be required to cease using the disputed technology or product. In addition, even if such licenses are available, the terms of any license requested by a third party could be unacceptable or unaffordable to us. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product development and approval timelines in the biotechnology industry are very lengthy. As such, it is possible that any patents that may cover an approved product may have expired at the time of commercialization or only have a short remaining period of exclusivity, thereby reducing the commercial advantages of the patent. In such case, we would then rely solely on other forms of exclusivity, such as regulatory exclusivity provided by the FD&amp;C Act, which may provide less protection to our competitive position.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation relating to intellectual property is expensive, time-consuming and uncertain, and we may be unsuccessful in our efforts to protect against infringement by third parties or defend ourselves against claims of infringement. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To protect our intellectual property, we may initiate litigation or other proceedings. In general, intellectual property litigation is costly, time-consuming, diverts the attention of management and technical personnel and could result in substantial uncertainty regarding our future viability, even if we ultimately prevail. Some of our competitors may be able to sustain the costs of such litigation or other proceedings more effectively than can we because of their substantially greater financial resources. The loss or narrowing of our intellectual property protection, the inability to secure or enforce our intellectual property rights or a finding that we have infringed the intellectual property rights of a third party could limit our ability to develop or market our products and services in the future or adversely affect our revenues. Furthermore, any public announcements related to such litigation or regulatory proceedings could adversely affect the price of our common stock.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may allege that the research, development and commercialization activities we conduct infringe patents or other proprietary rights owned by such parties. While we do not believe any of our current activities infringe the rights of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">others, we have not conducted an exhaustive search or analysis of third-party patent rights to determine whether our pre-clinical or clinical research and development or activities may infringe or be alleged to infringe any third-party patent rights. If we are found to have infringed the patents of a third party, we may be required to pay substantial damages; we also may be required to seek from such party a license, which may not be available on acceptable terms, if at all, to continue our activities. A judicial finding or infringement or the failure to obtain necessary licenses could prevent us from commercializing our products, which would have a material adverse effect on our business, operating results and financial condition. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain our licenses, patents or other intellectual property we could lose important protections that are material to continuing our operations and our future prospects.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain and maintain patent protection and licensing rights under certain of our license agreement, we must, among other things, ensure the timely payment of all applicable filing and maintenance fees. Any failure to do so could result in the loss of some or all of our rights to proprietary technology or the inability to secure or enforce intellectual property protection. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our license agreements require us to meet certain diligence obligations in the development of the licensed products. Our failure to meet these diligence obligations could result in the loss of some or all of our rights, which could materially and adversely affect our business and future prospects.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of trade secrets, our competitive position could be impaired.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant amount of our technology, especially regarding manufacturing processes, is unpatented and is maintained as trade secrets and /or know-how. We expend significant energy, resources and know-how in an effort to protect these trade secrets and know-how, including through the use of confidentiality agreements. Even so, improper use or disclosure of our confidential information could occur, and in such case, adequate remedies may not exist. The disclosure of trade secrets and know-how could impair our competitive position.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In certain countries, patent holders may be required to grant compulsory licenses, which would likely have a significant and detrimental effect on any future revenues in such country. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries, including some countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, most countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may be limited to monetary relief and may be unable to enjoin infringement, which could materially diminish the value of the patent. Compulsory licensing of life-saving products is also becoming increasingly common in developing countries, either through direct legislation or international initiatives. Such compulsory licenses could be extended to our product candidates, which may limit our potential revenue opportunities, including with respect to any future revenues that may result from our product candidates.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes to U.S. patent law may have a material adverse effect on our intellectual property rights.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs, and may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and any licensed patents. Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (the Leahy-Smith Act), signed into law on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.  In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the U.S. Patent and Trade Office (the &#8220;USPTO&#8221;) and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement of the patents, trademarks and proprietary rights of third parties. There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, and reexamination proceedings before the USPTO and corresponding foreign patent offices and trademark violations. Numerous </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing products and services. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our products and services may be subject to claims of infringement of the patent rights of third parties.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to devices, materials, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our products and services. We have conducted freedom to operate analyses with respect to only certain of our products and services, and therefore we do not know whether there are any third-party patents that would impair our ability to commercialize these products and services. We also cannot guarantee that any of our analyses are complete and thorough, nor can we be sure that we have identified each and every patent and pending application in the United States and abroad that is relevant or necessary to the commercialization of our products and services. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our products or services may infringe upon.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover aspects of our products or services, the holders of any such patents may be able to block our ability to commercialize such products or services unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our products or services. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR CAPITAL STOCK</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been, and will likely continue to be, highly volatile.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock has been, and in the future may continue to be, highly volatile. For example, from January 1, 2021 through March&#160;22, 2022 our common stock traded as low as $0.63 per share and as high as $4.89 per share.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price for our common stock is highly dependent on, among other things, stock market conditions in general, our clinical development efforts and the growth of our business in general, the amount of our available cash and investments and our level of cash utilization. Future events could increase the volatility seen in our common stock and ultimately cause a significant decline in the price of our common stock and ultimately impact our ability to raise additional capital in the future. These events could include the following, among others:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">low levels of trading volume for our shares;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capital-raising or other transactions that are, or may in the future be, dilutive to existing stockholders or that involve the issuance of debt securities;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in our clinical trials, negative clinical trial results or adverse regulatory decisions relating to our product candidates; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse fluctuations in our revenues or operating results or financial results that otherwise fall below the market's expectations;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disappointing developments concerning our cell therapy product candidates; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">positive developments concerning our cell therapy product candidates that lead to the need for additional capital to complete the development process; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">legal challenges, disputes and/or other adverse developments impacting our patents or other proprietary rights that protect our products.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, broader external events, such as news concerning economic or market conditions in the general economy or within our industry, the activities of our competitors, changes (or the threat of changes) in U.S. or foreign government regulations impacting the life sciences industry or the movement of capital into or out of our industry, are likely to affect the price of our common stock. Geopolitical events, including the continued threat of terrorism and the impact of military and other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">action, including military actions involving Russia and Ukraine, could impact our stock price as well. There can be no assurance that the market price of our common stock will not continue to fluctuate or decline significantly in the future.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to comply with the continued listing requirements of the Nasdaq Capital Market, such that our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed for trading on the Nasdaq Capital Market. We must satisfy Nasdaq&#8217;s continued listing requirements, including, among other things, a minimum closing bid price requirement of $1.00 per share for 30 consecutive business days (the "Minimum Bid Price Requirement"). If a company trades for 30 consecutive business days below the $1.00 minimum closing bid price requirement, Nasdaq will send a deficiency notice to the company advising that it has been afforded a &#8220;compliance period&#8221; of 180 calendar days to regain compliance with the applicable requirements.We received such notice on February 18, 2022 and thus risk delisting unless we are able to regain compliance in a timely fashion.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have a grace period of 180 calendar days, or until August 17, 2022, to regain compliance with the Minimum Bid Price Requirement. Compliance can be achieved automatically and without further action if the closing bid price of our stock is at or above $1.00 for a minimum of 10 consecutive business days at any time during the 180-day compliance period, in which case Nasdaq will notify us of our compliance and the matter will be closed. If, however, we do not achieve compliance with the Minimum Bid Price Requirement by August 17, 2022, we may be eligible for additional time to comply. In order to be eligible for such additional time, we will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and must notify Nasdaq in writing of our intention to cure the deficiency during the second compliance period. There can be no assurance that we will regain compliance with the Minimum Bid Price Requirement, that we will maintain compliant with other Nasdaq listing requirements or that we will be granted a second compliance period.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A delisting of our common stock from Nasdaq could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, employees and fewer business development opportunities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In addition to potential dilution associated with potential future fundraising and strategic transactions, we currently have significant numbers of securities outstanding that are exercisable for our common stock, which could result in significant additional dilution and downward pressure on our stock price. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there were 59,789,712 shares of our common stock outstanding. In addition, there were outstanding stock options, restricted stock units and warrants representing the potential issuance of an additional 24,093,000 shares of our common stock. The issuance of these shares in the future would result in significant dilution to our current stockholders and could adversely affect the price of our common stock and the terms on which we could raise additional capital. In addition, the issuance and subsequent trading of shares could cause the supply of our common stock available for purchase in the market to exceed the purchase demand for our common stock. Such supply in excess of demand could cause the market price of our common stock to decline. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our amended and restated certificate of incorporation and by-laws and Delaware law may inhibit a takeover of us, which could limit the price investors might be willing to pay in the future for our common stock and could entrench management.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and by-laws contain provisions that may discourage unsolicited takeover proposals that stockholders may consider to be in their best interests. Our board of directors is divided into three classes, each of which will generally serve for a term of three years with only one class of directors being elected in each year. As a result, at a given annual meeting only a minority of the board of directors may be considered for election. Since our staggered board of directors may prevent our stockholders from replacing a majority of our board of directors at any given annual meeting, it may entrench management and discourage unsolicited stockholder proposals that may be in the best interests of stockholders. Moreover, our board of directors has the ability to designate the terms of and issue new series of preferred stock without stockholder approval.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to anti-takeover provisions under Delaware law, which could delay or prevent a change of control. Together, these provisions may make more difficult the removal of management and may discourage transactions that otherwise could involve payment of a premium over prevailing market prices for our securities.</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business and stock price.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the course of testing our disclosure controls and procedures and internal control over financial reporting, we may identify and disclose material weaknesses or significant deficiencies in internal control over financial reporting that will have to be remedied. Implementing any appropriate changes to our internal control may require specific compliance training of our directors, officers and employees, entail substantial costs to modify our existing accounting systems, and take a significant period of time to complete. Such changes may not, however, be effective in maintaining the adequacy of our internal control over financial reporting, and any failure to maintain that adequacy or inability to produce accurate financial statements on a timely basis could result in our financial statements being unreliable, increase our operating costs and materially impair our ability to operate our business.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to achieve and maintain effective internal control over financial reporting could result in a loss of investor confidence in our financial reports and could have a material adverse effect on our stock price. Additionally, failure to maintain effective internal control over our financial reporting could result in government investigation or sanctions by regulatory authorities. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_22"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B. UNRESOLVED STAFF COMMENTS.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="margin-bottom:6pt"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_25"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. PROPERTIES.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are in Basking Ridge, New Jersey. The space is approximately 11,600 rentable square feet and the base monthly rent is approximately $25,700 through May 31, 2022. In November 2021 we executed a lease amendment to reduce the space to approximately 8,100 rentable square feet effective June 1, 2022 through September 30, 2025 (three years and four months).  The new base monthly rent is approximately $15,900 with the first four months free.  In addition, there are two five-year renewal options.  In July 2019, we executed a three-year lease extension for the approximately 3,400 rentable square feet in our Rye Brook, New York office, which extension expires in March 2023. The base monthly rent for our Rye Brook office is approximately $9,000. We believe the total leased space is sufficient for the near future.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_28"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. LEGAL PROCEEDINGS.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to certain legal proceedings in the ordinary course of business. We do not believe that any current legal proceedings are likely to have a material effect on our business, financial condition or results of operations.<br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_31"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i7d049288b82e438c85d504cc3e9dc500_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_37"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market for Our Common Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on The Nasdaq Capital Market under the symbol &#8220;CLBS.&#8221; </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;22, 2022, there were approximately 570 stockholders of record of our common stock. The number of record holders was determined from the records of our transfer agent and does not include beneficial owners of our common stock whose shares are held in the names of various security brokers, dealers, and registered clearing agencies. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends and Dividend Policy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not paid cash dividends on our common stock. The holders of our common stock are each entitled to receive dividends when and if declared by the board of directors out of funds legally available therefor, subject to the terms of any outstanding series of preferred stock. We intend to retain any future earnings to fund the development and growth of our business, and therefore we do not anticipate paying any cash dividends on our common stock in the foreseeable future. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information as of December&#160;31, 2021 regarding shares of our common stock that may be issued under our existing equity compensation plans, including our 2018 Equity Incentive Compensation Plan (the &#8220;2018 Plan&#8221;), our 2015 Equity Compensation Plan (the &#8220;2015 Plan&#8221;), our 2009 Stock Option and Incentive Plan (the &#8220;2009 Plan&#8221;), and our amended 2017 Employee Stock Purchase Plan (the &#8220;Amended 2017 ESPP&#8221;).</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.561%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Compensation Plan Information</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of securities</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">to be issued upon exercise</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of outstanding options (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price of</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">outstanding options</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">and rights</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of securities</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining available for</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">future issuance under equity</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">compensation plan</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(excluding securities</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">referenced in column (a))</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders (2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,131,849</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5.64</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,886,238</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity compensation plans not approved by security holders</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:1pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Includes stock options only; does not include purchase rights accruing under the Amended 2017 ESPP Plan because the purchase price (and therefore the number of shares to be purchased) will not be determined until the end of the purchase period.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Consists of the 2018 Plan, the 2015 Plan, the 2009 Plan, and the Amended 2017 ESPP.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Includes shares available for future issuance under the 2018 Plan and the Amended 2017 ESPP. </span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_40"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. [RESERVED].</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i7d049288b82e438c85d504cc3e9dc500_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; herein. The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Annual Report. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies designed to reverse disease and/or promote the regeneration of damaged tissue. We are developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Our technology leverages these cells to enable the body's natural repair mechanisms using formulations unique to each medical indication.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leadership team has decades of collective biopharmaceutical development experience. Our goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. The Company&#8217;s current product candidates include: </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CLBS16), the subject of both a completed positive Phase 2a study (ESCaPE-CMD) and an ongoing follow-on Phase 2b study (FREEDOM Trial) in the United States for the treatment of coronary microvascular dysfunction (&#8220;CMD&#8221;); </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (&#8220;CLI&#8221;) and Buerger&#8217;s disease is being sought based on the current results of a clinical trial executed in Japan. CLBS12 was the recipient of orphan drug designation in March 2021 from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for Buerger's disease; and </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with chronic kidney disease related to type 2 diabetes (diabetic kidney disease or &#8220;DKD&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we also desire to diversify our pipeline of development product candidates and are exploring a range of strategic transactions in furtherance of that goal. We have taken, and intend to continue to take, active steps to identify diligence-suitable assets and/or companies that would complement and de-risk our current development programs. Such assets could potentially include indications beyond cardiovascular as well as product categories outside of cell therapy and transactions could include an acquisition, merger, business combination, in-license or other strategic transaction, any of which could result in the issuance of securities that could significantly dilute the shares of our existing stockholders. There can be no assurance that this exploration of strategic alternatives will result in us entering into or completing any transaction or that such transaction, if completed, will add to shareholder value. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to present substantial public health and economic challenges around the world, and to date has led to the implementation of various responses, including government-imposed quarantines, stay-at-home orders, travel restrictions, mandated business closures and other public health safety measures.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to closely monitor the impact of the COVID-19 pandemic on all aspects of our business, including how it has and will continue to impact our operations and the operations of our suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required by federal, state or local authorities. In addition, we have taken steps to minimize the current environment&#8217;s impact on our business and strategy, including devising contingency plans and securing additional resources from third party service providers. For the safety of our employees and families, we implemented a universal work from home policy as well as stringent social distancing and other hygiene policies for employees when they must be in the office. Our clinical study of HONEDRA&#174; in Japan has experienced significant delays in enrollment due to the States of Emergency in effect in Japan for most of 2020 and reimplemented from January 7, 2021 through March 21, 2021 covering Tokyo and other regions in response to an increased number of COVID-19 infections. Due to reported increases in COVID-19 cases and a low rate of vaccination in Japan, States of Emergency were renewed on April 25, 2021 through May 11, 2021 and then reimplemented in Tokyo from July 12, 2021 through September 30, 2021. With our expectation that COVID-19 in Japan would continue to impact negatively enrollment of patients in the HONEDRA&#174; clinical trial, we elected to suspend trial enrollment, seek a development partner and consult with the Japanese regulatory authorities regarding the submission of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patient data already accrued. In addition, our phase 2b trial of XOWNA&#174; in the United States has also experienced delays in enrolling patients as a result of COVID-19.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond its impact on our development pipeline described above, the extent to which COVID-19 ultimately impacts our business, results of operations and financial condition will depend on future developments, which remain highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, the emergence of new variants, new information that may emerge concerning the severity of COVID-19 or the effectiveness of actions taken to contain COVID-19 or treat its impact, including vaccination campaigns, among others. If we or any of the third parties with whom we engage, however, were to experience any additional shutdowns or other prolonged business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially or negatively affected, which could have a material adverse impact on our business, financial condition and results of operations. It is possible that our clinical development timelines could continue to be negatively affected by COVID-19, which could materially and adversely affect our business, financial condition and results of operations. See &#8220;Risk Factors&#8221; for additional discussion of the potential adverse impact of the COVID-19 pandemic on our business, financial condition and results of operations.<br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_46"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2021 Compared to Year Ended December&#160;31, 2020 </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the years ended December&#160;31, 2021 and 2020:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"></td><td style="width:60.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.172%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,050)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,145)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,905)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27,466)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,141)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,325)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, net losses were $27.5 million and $8.1 million for the years ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2021, operating expenses totaled $29.1 million compared to $19.1 million for the year ended December&#160;31, 2020, representing an increase of $9.9 million or 52%. Operating expenses comprise the following:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Research and development expenses were approximately $17.7 million for the year ended December&#160;31, 2021 compared to $9.3 million for the year ended December&#160;31, 2020, representing an increase of approximately $8.4 million, or 91%. This increase was primarily due to an increase in expenses associated with the enrollment of our XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Phase 2b study (the FREEDOM Trial). Research and development in both periods focused on the advancement of our ischemic repair platform and related to:</span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">expenses associated with our XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Phase 2b study (the FREEDOM Trial) which commenced in the fourth quarter of 2020 with the first patient in the study treated in January 2021; </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">ongoing registration-eligible study expenses for HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in CLI in Japan which focused on patient enrollment completion. The study's enrollment has been significantly curtailed by the COVID-19 pandemic's impact in Japan, including the States of Emergency that have persisted there for over 18 months. Due to the significant and continued operational and financial burden incurred as a result of these COVID-19 delays, coupled with the complete unpredictability of the timing of site enrollment re-initiation, we have suspended enrollment efforts and will focus on consummating a partnership with a Japanese company in order to complete the study enrollment as well as to explore the possibility of submitting the existing data to PMDA under the SAKIGAKE designation; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses associated with the preparation for filing an IND for the clinical study of CLBS201 for treatment of DKD. A Phase 1, open-label, proof-of-concept trial has been initiated recently and is expected to include six subjects in total.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were approximately $11.4 million for the year ended December&#160;31, 2021, compared to $9.9 million for the year ended December&#160;31, 2020, representing an increase of approximately $1.5 million, or 15%. This increase was primarily due to an increase in directors and officers insurance premiums and strategic consulting expenses.  Our general and administrative expenses focus on general corporate-related activities.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, to minimize our use of cash, we have used a variety of equity and equity-linked instruments as compensation to employees, consultants, directors and other service providers. The use of these instruments has resulted in charges to the results of operations, which has been significant in the past. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense) is comprised primarily of investment income on cash, cash equivalents and marketable securities and a loss on sale of $0.1 million related to the sale of our New Jersey net operating losses (&#8220;NJ NOLs&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Benefit</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we received approval from the New Jersey Economic Development Authority (&#8220;NJEDA&#8221;) to participate in the Technology Business Tax Certificate Transfer Program (the &#8220;Program&#8221;), whereby we qualified to sell a percentage of its New Jersey net operating losses (&#8220;NJ NOLs&#8221;). We subsequently sold a portion of our NJ NOLs to a qualifying and approved buyer pursuant to the Program for net proceeds of $10.9 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we received final approval from the NJEDA under the Program to sell a portion of our NJ NOLs, which subsequently were sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $1.4 million. The $1.5 million of our NJ NOL tax benefits have been recorded as a benefit from income taxes and the loss on sale of $0.1 million recorded in other income (expense).</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_49"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Analysis of Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, we had cash, cash equivalents, and marketable securities of approximately $95.0 million, working capital of approximately $91.7 million, and stockholders&#8217; equity of approximately $92.3 million. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, we met our immediate cash requirements through existing cash balances.  Additionally, we used equity and equity-linked instruments to pay for services and compensation. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by or used in operating, investing and financing activities were as follows (in thousands):</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.778%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,245)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,823)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,896)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in operating activities during the year ended December&#160;31, 2021 totaled approximately $22.2 million, comprising (i) our net loss of $27.5 million, as adjusted for non-cash income and expenses totaling $4.6 million (which includes adjustments for equity-based compensation, depreciation and amortization, and amortization/accretion of marketable securities), and (ii) changes in operating assets and liabilities of approximately $0.6 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in operating activities during the year ended December&#160;31, 2020 totaled approximately $8.8 million, which is the sum of (i) our net loss of $8.1 million, as adjusted for non-cash income and expenses totaling $1.6 million (which includes adjustments for equity-based compensation, depreciation and amortization, and amortization/accretion of marketable securities), and (ii) changes in operating assets and liabilities of approximately $2.3 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in investing activities during the year ended December&#160;31, 2021 totaled approximately $54.9 million and was primarily due to net purchases of marketable securities (net of sales of marketable securities).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in investing activities during the year ended December&#160;31, 2020 totaled approximately $7.3 million and was primarily due to net purchases of marketable securities (net of sales of marketable securities).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash provided by financing activities during the year ended December&#160;31, 2021, primarily consisted of (i) net proceeds of $23.1 million through the issuance of common shares and warrants in our January 2021 private placement, (ii) net proceeds of $1.8 million in connection with warrant exercises, (iii) net proceeds of $60.6 million through the issuance of common shares and warrants in both of our February 2021 registered direct offerings which was partially offset by tax withholding-related payments on net share settlement equity awards to employees. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash provided by financing activities during the year ended December&#160;31, 2020 primarily consisted of (i) net proceeds of $4.5 million through the issuance of common shares and warrants in our April 2020 registered direct offering, (ii) net proceeds of $3.8 million through the issuance of common shares and warrants in our May 2020 registered direct offering, and (iii) net proceeds of $1.9&#160;million through the issuance of common shares and warrants in our July 2020 private placement offering, and (iv) net proceeds of $8.4&#160;million through the issuance of common shares under our common stock sales agreement with HCW, which was partially offset by tax withholding-related payments on net share settlement equity awards to employees. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Requirements Outlook</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet our short and long-term liquidity needs, we expect to use existing cash balances and a variety of other means. Other sources of liquidity could include additional potential issuances of debt or equity securities in public or private financings, partnerships and/or collaborations and/or sale of assets. Our history of operating losses and liquidity challenges may make it difficult for us to raise capital on acceptable terms or at all. The demand for the equity and debt of biopharmaceutical companies like ours is dependent upon many factors, including the general state of the financial markets. During times of extreme market volatility, capital may not be available on favorable terms, if at all. Our inability to obtain such additional capital could materially and adversely affect our business operations. We will also continue to seek, as appropriate, grants for scientific and clinical studies from various governmental agencies and foundations, and other sources of non-dilutive funding. We believe that our cash on hand will enable us to fund operating expenses for at least the next 12 months following the issuance of our financial statements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, we entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with HCW, as sales agent, in connection with an &#8220;at the market offering&#8221; under which we may, from time to time offer and sell shares of our common stock, having an aggregate offering price of up to $50.0 million. As of December&#160;31, 2021, we had not issued any shares under the ATM Agreement. Pursuant to the ATM Agreement, HCW is only obligated to make sales when we are in compliance with all Nasdaq listing standards. On February 18, 2022, we received a deficiency notice from Nasdaq informing us that we are not in compliance with the Minimum Bid Price Requirement. As such, we will not be able to sell shares under the ATM Agreement until we regain compliance, if ever.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we received preliminary approval from the NJEDA to participate in the Program. The Program permits qualified companies to sell a percentage of their NJ NOLs to unrelated profitable corporations. On April 12, 2021, we received final approval from NJEDA to sell $1.5 million of our NJ NOLs, which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $1.4 million. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we entered into a Securities Purchase Agreement (the &#8220;Institutional Purchase Agreement&#8221;) with certain institutional investors (the &#8220;Institutional Purchasers&#8221;). Pursuant to the terms of the Institutional Purchase Agreement, we sold to the Institutional Purchasers in a registered direct offering an aggregate of 24,906,134 shares of our common stock and warrants to purchase an aggregate of 12,453,067 shares of our common stock at a combined purchase price equal to $2.45 per share and associated warrant. Each warrant features an exercise price equal to $2.90 per share, is exercisable immediately upon issuance and will expire five years from the issuance date. Additionally, in a concurrent non-brokered registered direct offering, we entered into a Securities Purchase Agreement (the &#8220;Additional Purchase Agreement&#8221;) with certain accredited investors (the &#8220;Additional Purchasers&#8221;). Pursuant to the terms of the Additional Purchase Agreement, we sold to the Additional Purchasers an aggregate of 1,632,652 shares of our common stock and warrants to purchase an aggregate of 816,326 shares of our common stock at a combined purchase price equal to $2.45 per share and associated warrant. Each warrant features an exercise price equal to $2.90 per share, is exercisable immediately upon issuance and will expire five years from the issuance date. The closing of the offerings occurred on February 17, 2021. In connection with the registered direct offerings, we received gross proceeds of approximately $65.0 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, we suspended the use of the at-the-market transactions facility (the &#8220;ATM&#8221;) and terminated the continuous offering pursuant to the Common Stock Sales Agreement (&#8220;Sales Agreement&#8221;) entered into in February 2018 with HCW. As of termination date of February 12, 2021, we had sold an aggregate of 3,784,912 shares of our common stock pursuant to the Sales Agreement for aggregate net proceeds of $9.5 million.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a Securities Purchase Agreement (the &#8220;January Purchase Agreement&#8221;) with certain institutional and accredited investors (the &#8220;January Purchasers&#8221;), pursuant to which the Company issued and sold to the January Purchasers in a private placement an aggregate of (i) 12,500,000 shares of common stock, and (ii) warrants exercisable for up to an aggregate of 6,250,000 shares of common stock at a combined offering price of $2.00 per share of common stock and associated warrant. The warrants have an exercise price of $2.90 per share. Each warrant will be immediately exercisable and will expire five and one-half years from the issuance date.  The closing of the offering occurred on January 25, 2021. We received gross proceeds of $25.0 million in connection with the private placement, before deducting placement agent fees and related offering expenses.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, we and Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to which we have the right to sell to Lincoln Park shares of our common stock having an aggregate value of up to $26 million, subject to certain limitations and conditions set forth in the Purchase Agreement (the &#8220;Offering&#8221;). As consideration for entering into the Purchase Agreement, we issued to Lincoln Park an additional 181,510 shares of common stock as commitment shares. Pursuant to the Purchase Agreement, Lincoln Park purchased 250,000 shares of common stock, at a price of $4.00 per share, for a total gross purchase price of $1.0 million (the &#8220;Initial Purchase&#8221;) upon commencement. Thereafter, as often as every business day from and after one business day following the date of the Initial Purchase and over the 36-month term of the Purchase Agreement, we have the right, from time to time, at our sole discretion and subject to certain conditions, to direct Lincoln Park to purchase up to 100,000 shares of common stock, with such amount increasing as the closing sale price of the common stock increases; provided Lincoln Park&#8217;s obligation under any single such purchase will not exceed $2,500,000, unless we and Lincoln Park mutually agree to increase the maximum amount of such single purchase (each, a &#8220;Regular Purchase&#8221;). If we direct Lincoln Park to purchase the maximum number of shares of common stock we then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, we may direct Lincoln Park in an &#8220;accelerated purchase&#8221; to purchase an additional amount of common stock that may not exceed the lesser of (i) 300% the number of shares purchased pursuant to the corresponding Regular Purchase or (ii)&#160;30% of the total number of shares of our common stock traded during a specified period on the applicable purchase date as set forth in the Purchase Agreement. Under certain circumstances and in accordance with the Purchase Agreement, we may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day. As of December&#160;31, 2021, the Company had not made any sales of common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and our negotiating position in capital generating efforts may worsen as existing resources are used. Additional equity financing may be dilutive to our stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict our ability to operate as a business; our stock price may not reach levels necessary to induce option or warrant exercises; and asset sales may not be possible on terms we consider acceptable. If we are unable to access capital necessary to meet our long-term liquidity needs, we may have to delay the expansion of our business or raise funds on terms that we currently consider unfavorable. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_52"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and judgments that affect the amounts reported in the financial statements. We evaluate our estimates and assumptions on an ongoing basis. We base our estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An accounting policy is considered to be critical if it is important to our financial condition and results of operations and if it requires management&#8217;s most difficult, subjective and complex judgments in its application. For a summary of all of our significant accounting policies, see Note 2 to our Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, we estimate the probability of achievement of the performance criteria and recognize compensation expense related to those awards expected to vest. We determine the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of our restricted stock and restricted stock units is based on the closing market price of our common stock on the date of grant. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_55"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_58"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements and notes thereto required to be filed under this Item are presented commencing on page 51</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="i7d049288b82e438c85d504cc3e9dc500_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Caladrius Biosciences, Inc. and Subsidiaries</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_64">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(PCAOB ID Number </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82MS9mcmFnOjU5YTZkZjk5MGQxODRlNTFhNTg4Y2QyMzM1YWFlYzM1L3RhYmxlOmU1M2ZiZjIyNTBmYTQzNjU5ZmVjYjJmYzYyNmY2OTg2L3RhYmxlcmFuZ2U6ZTUzZmJmMjI1MGZhNDM2NTlmZWNiMmZjNjI2ZjY5ODZfMC0wLTEtMS0xMjkyMS90ZXh0cmVnaW9uOjVlM2M1MjllMWZiMzQzYmI4OGM0ZTdhNTg2MGVlMWZkXzEzMTk0MTM5NTMzNDY4_007ce07f-9a17-4335-857d-70190d316da9">248</ix:nonNumeric></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_64">49</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_67">Consolidated Balance Sheets at December 31, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_67">50</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_70">Consolidated Statements of Operations - Years Ended December 31, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_70">51</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_73">Consolidated Statements of Comprehensive Loss - Years Ended December 31, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_73">52</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_76">Consolidated Statements of Equity - Years Ended December 31, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_76">53</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_79">Consolidated Statements of Cash Flows - Years Ended December 31, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_79">54</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_82">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_82">70</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i7d049288b82e438c85d504cc3e9dc500_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-bottom:3.3pt;padding-right:2.25pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Board of Directors and Stockholders of Caladrius Biosciences, Inc.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the financial statements </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We have audited the accompanying consolidated balance sheets of Caladrius Biosciences, Inc. (a Delaware corporation) and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive loss, equity, and cash flows for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for opinion </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical audit matters </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82NC9mcmFnOmNhNjQzOTI4ZjY1ZjQxYTBhNDI0ZmI3YWZlODE2OTFjL3RleHRyZWdpb246Y2E2NDM5MjhmNjVmNDFhMGE0MjRmYjdhZmU4MTY5MWNfMTMxOTQxMzk1NDYwNjk_78db1303-200a-48d6-827c-f3ccf4e6da78">GRANT THORNTON LLP</ix:nonNumeric> </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2011.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82NC9mcmFnOmNhNjQzOTI4ZjY1ZjQxYTBhNDI0ZmI3YWZlODE2OTFjL3RleHRyZWdpb246Y2E2NDM5MjhmNjVmNDFhMGE0MjRmYjdhZmU4MTY5MWNfMTMxOTQxMzk1NDYwNjg_554520cf-e204-43fc-bd1b-00bfecf9e64c">New York, New York</ix:nonNumeric><br/>March&#160;22, 2022</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i7d049288b82e438c85d504cc3e9dc500_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands, except share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:75.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.468%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt 0 12.25pt"><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMy0xLTEtMS03MjAy_1829b215-977c-4777-bd0b-29addddba4f2">24,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMy0zLTEtMS03MjAy_1e56dad7-5364-4800-a0b7-ee58607ffcd2">16,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfNC0xLTEtMS03MjAy_4175be86-e8d2-4755-9c99-91f539207516">70,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfNC0zLTEtMS03MjAy_2f3f7d6f-63e5-4b76-9bf2-2b4db0f5692c">18,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfNS0xLTEtMS03MjAy_af4df0ac-d721-4dc5-a17f-8226b1dd78c1">1,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfNS0zLTEtMS03MjAy_5b218329-6d9e-40aa-a5f7-327c94fd3ec3">758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfNi0xLTEtMS03MjAy_4f2165cd-7883-4c92-9a46-207d21a26d87">96,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfNi0zLTEtMS03MjAy_76b199b0-0b45-44d9-a04b-c04b76e29d1d">35,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfNy0xLTEtMS03MjAy_74d2a8ef-bfce-4a50-bff6-2b81a2789a02">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfNy0zLTEtMS03MjAy_74984b72-5098-4a31-9875-beed7d849b85">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfOS0xLTEtMS03MjAy_63644c24-e2ba-4f38-b8af-8900280d7a2e">764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfOS0zLTEtMS03MjAy_e32e1a80-04e6-4ebd-9029-c29dd7d65291">614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTAtMS0xLTEtNzIwMg_5e2d8a75-8e44-47d2-9679-b230533433a2">97,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTAtMy0xLTEtNzIwMg_44a6b26f-3214-472a-b739-2ee8b9a71e0b">36,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES, NON-CONTROLLING INTERESTS AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTMtMS0xLTEtNzIwMg_ec32a6b1-ae6c-4554-8aee-6c58393c3155">1,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTMtMy0xLTEtNzIwMg_401c9c7b-e551-4d24-bb3a-ef766dd42266">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTQtMS0xLTEtNzIwMg_4ec6ade4-0e5e-4d7e-8ad1-f862438a9341">2,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTQtMy0xLTEtNzIwMg_a7452ac9-0d95-4b56-b6a3-871855d7d43e">2,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTYtMS0xLTEtNzIwMg_8a0f545c-8158-4aed-b999-effe1d8508b4">4,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTYtMy0xLTEtNzIwMg_f9ba36cc-dece-4e7d-aa61-d1315e3a9e69">3,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTctMS0xLTEtNzIwMg_482f09df-968a-45fe-a46d-40512813fee8">485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTctMy0xLTEtNzIwMg_8008a4a3-eb3f-4f35-b0c3-0f96fb001495">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTgtMS0xLTEtNzIwMg_b22c4346-7283-4eb6-8d39-f6be089d964e">5,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTgtMy0xLTEtNzIwMg_2177e7ac-a707-4572-8b40-358e0d1da8c5">3,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commitments and Contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTktMS0xLTEtNzIwMg_a9020830-dd10-44d4-a904-4c703ebc787d"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTktMy0xLTEtNzIwMg_b10fd789-cbe1-4ced-8fe3-5cc571cd8d88"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock; authorized, <ix:nonFraction unitRef="shares" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzMz_3061b504-6e2b-40e7-b40f-9660cb5b1603"><ix:nonFraction unitRef="shares" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzMz_5411d509-9867-4299-b838-89e18aa7f6e6">20,000,000</ix:nonFraction></ix:nonFraction> shares</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series B convertible redeemable preferred stock liquidation value, <ix:nonFraction unitRef="shares" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="INF" name="clbs:PreferredStockLiquidationPreferenceShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzExMA_144356d0-c693-4600-a8cb-53b2fd722878"><ix:nonFraction unitRef="shares" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="INF" name="clbs:PreferredStockLiquidationPreferenceShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzExMA_4ebb7a17-5b2b-43f1-b27f-b41e1280a9af">0.001</ix:nonFraction></ix:nonFraction> share of common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzEzNg_7a9cf515-337c-42a3-92d5-e213bbe680cf"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzEzNg_a5148ae2-a334-4844-9feb-c7844f008ab0">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="INF" name="clbs:PreferredStockSharesDesignated" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzE1MA_61e855f6-3d20-4c9b-a0b6-4ad65f762de4"><ix:nonFraction unitRef="shares" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="INF" name="clbs:PreferredStockSharesDesignated" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzE1MA_cde9a514-289b-4918-82f0-3efc301dc8a6">825,000</ix:nonFraction></ix:nonFraction> shares designated; issued and outstanding, <ix:nonFraction unitRef="shares" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzE5Ng_1d466493-e600-457a-aab9-6605d682fe7d"><ix:nonFraction unitRef="shares" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzE5Ng_5304de99-9c0b-4dc9-821c-b81a0a70ec9b"><ix:nonFraction unitRef="shares" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzE5Ng_7107ad7e-0a2b-4fe7-b8c3-c1e32fe61f5f"><ix:nonFraction unitRef="shares" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzE5Ng_72e373e8-a044-4e0f-9f05-f732c5037dd9">10,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares at December 31, 2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMS0xLTEtNzIwMg_77f7c30b-65f5-4621-a832-2c93a10efab1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMy0xLTEtNzIwMg_56012285-6440-46cc-984f-c0db5d5dfdf7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjItMC0xLTEtNzIwMi90ZXh0cmVnaW9uOmJlZmE5ZTkyOTBjMzQyNWY4MWVjMGVjNmIxOTBmOGY3XzI0_2c0b95c3-8a20-401f-b5a0-e563082eb006"><ix:nonFraction unitRef="usdPerShare" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjItMC0xLTEtNzIwMi90ZXh0cmVnaW9uOmJlZmE5ZTkyOTBjMzQyNWY4MWVjMGVjNmIxOTBmOGY3XzI0_38d45406-2da3-421e-ad59-4bd3eafa1f9b">0.001</ix:nonFraction></ix:nonFraction> par value, authorized <ix:nonFraction unitRef="shares" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjItMC0xLTEtNzIwMi90ZXh0cmVnaW9uOmJlZmE5ZTkyOTBjMzQyNWY4MWVjMGVjNmIxOTBmOGY3XzQ5_6741c13e-4012-4308-b014-5bb8fa3a598a"><ix:nonFraction unitRef="shares" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjItMC0xLTEtNzIwMi90ZXh0cmVnaW9uOmJlZmE5ZTkyOTBjMzQyNWY4MWVjMGVjNmIxOTBmOGY3XzQ5_9cb4e145-4f4c-4190-821a-7049ce97b4db">500,000,000</ix:nonFraction></ix:nonFraction> shares; issued <ix:nonFraction unitRef="shares" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjItMC0xLTEtNzIwMi90ZXh0cmVnaW9uOmJlZmE5ZTkyOTBjMzQyNWY4MWVjMGVjNmIxOTBmOGY3XzY3_e970de89-0094-41b8-9073-e0e12bf2b2ab">59,800,792</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjItMC0xLTEtNzIwMi90ZXh0cmVnaW9uOmJlZmE5ZTkyOTBjMzQyNWY4MWVjMGVjNmIxOTBmOGY3Xzc0_4da4ca45-57c2-44ab-9baa-e92cf2921f6a">19,389,413</ix:nonFraction> shares, at December 31, 2021 and December 31, 2020, respectively; and outstanding, <ix:nonFraction unitRef="shares" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjItMC0xLTEtNzIwMi90ZXh0cmVnaW9uOmJlZmE5ZTkyOTBjMzQyNWY4MWVjMGVjNmIxOTBmOGY3XzE2MA_e5bd38e3-f0b3-4d72-872c-d054354199b6">59,789,712</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjItMC0xLTEtNzIwMi90ZXh0cmVnaW9uOmJlZmE5ZTkyOTBjMzQyNWY4MWVjMGVjNmIxOTBmOGY3XzE2Nw_ce66d863-21ae-4cbc-9a13-11e724cfaf52">19,378,333</ix:nonFraction> shares, at December 31, 2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjItMS0xLTEtNzIwMg_53723f01-3709-4091-9efb-8ed4b3857f11">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjItMy0xLTEtNzIwMg_3f2d0f60-be30-4400-b2c1-9b6cfa2ee0d1">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjMtMS0xLTEtNzIwMg_ca5fb698-697d-4435-8f54-fe03756f154f">545,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjMtMy0xLTEtNzIwMg_828b8cb0-a5c8-421a-b4c2-e014b5e6fc92">458,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost; <ix:nonFraction unitRef="shares" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjQtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOmQzYmYyMGY4NjA5NDQ1ZTI4YTgxYmZkZDVkYjA2MGRhXzI5_d300fdae-3974-4b48-bd0d-2ca38771a6e4"><ix:nonFraction unitRef="shares" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjQtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOmQzYmYyMGY4NjA5NDQ1ZTI4YTgxYmZkZDVkYjA2MGRhXzI5_ee06c93a-41c2-4d7e-8507-059ed789c98f">11,080</ix:nonFraction></ix:nonFraction> shares at December 31, 2021 and December 31, 2020 respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjQtMS0xLTEtNzIwMg_52254bbd-c746-4765-a239-0726c8296b7e">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjQtMy0xLTEtNzIwMg_56f6c304-e468-4e6a-8fb5-bf87b469b5be">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjUtMS0xLTEtNzIwMg_1d395478-f7d9-4693-a9c0-dfbd09c5f383">453,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjUtMy0xLTEtNzIwMg_8a6dbd7c-6878-44ac-a590-f7a341adff12">425,550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjYtMS0xLTEtNzIwMg_e43fa66c-4dc6-4cf2-9944-af6101053a7b">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjYtMy0xLTEtNzIwMg_889e3c7b-2c55-4476-ac9b-b595aa964d00">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Caladrius Biosciences, Inc. stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjctMS0xLTEtNzIwMg_60c1447c-ed59-4f63-bc47-d2c0c300302e">92,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjctMy0xLTEtNzIwMg_38e6893e-d71b-4d70-99e0-5b048e73013d">32,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjgtMS0xLTEtNzIwMg_02749332-4d3d-4305-8e96-e75a59c1c88c">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjgtMy0xLTEtNzIwMg_327cf681-58bb-4021-bed1-53c5a8de4754">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjktMS0xLTEtNzIwMg_c7f37f10-0a17-4e5e-b7b7-556bcdd1908a">92,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjktMy0xLTEtNzIwMg_57b95d17-9cb0-4657-bceb-709d96e6fe19">32,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities, non-controlling interests and equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMzAtMS0xLTEtNzIwMg_cd6ab75e-89f5-4694-9d56-ca33e54b3d8d">97,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMzAtMy0xLTEtNzIwMg_ba51c384-65c6-4866-89a2-5ec8728b5b38">36,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i7d049288b82e438c85d504cc3e9dc500_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands, except per share data)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:75.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.191%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMy0xLTEtMS03MjAy_0f6b600f-fcdc-4553-95f7-f5e993edd747">17,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMy0zLTEtMS03MjAy_7d6064e0-5905-45ea-9ba6-d92709561407">9,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfNC0xLTEtMS03MjAy_565e5af9-59ee-484a-8b98-8cf097095b92">11,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfNC0zLTEtMS03MjAy_7cdcaf72-7083-4f5c-abc3-f645029de3bc">9,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfNS0xLTEtMS03MjAy_e5eef8f9-fc42-47e9-b9f1-55ff8423d469">29,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfNS0zLTEtMS03MjAy_6a07bb36-fa7b-45e6-a309-4dc3f7721dd9">19,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfNy0xLTEtMS03MjAy_d02f3b4f-dedc-4f93-9f3e-4074a90491a3">29,050</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfNy0zLTEtMS03MjAy_731a7340-aaeb-49b9-90ec-68dddfb57e0b">19,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMTAtMS0xLTEtNzIwMg_00e5cb04-7108-4d1d-86d5-2930e03e466c">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMTAtMy0xLTEtNzIwMg_58c3ba68-23b0-4780-8e43-3561d4e21bd7">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMTEtMS0xLTEtNzIwMg_675db0ff-13ad-479f-be5b-9046543ce4f0">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMTEtMy0xLTEtNzIwMg_2598f97b-b61d-446a-8f6a-ae994bd515b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMTItMS0xLTEtNzIwMg_8922a02c-ecf9-4f32-a354-6da939ed5ce9">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMTItMy0xLTEtNzIwMg_d8bfe987-c38d-41ef-8d5f-e02cf43223da">132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss before benefit from income taxes and noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMTgtMS0xLTEtNzIwMg_aedc7ac2-3efe-4f23-af10-3b6589d1103f">28,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMTgtMy0xLTEtNzIwMg_3e9830b1-6c6a-4310-b003-048806b4c059">19,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMTktMS0xLTEtNzIwMg_d9448699-b128-431d-9b20-3e8c878ce0cd">1,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMTktMy0xLTEtNzIwMg_633a8c09-cfb6-4c25-a9b3-0311674e13d2">10,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMjAtMS0xLTEtNzIwMg_ffe5aba0-1996-4681-954f-6090a17ec80d">27,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMjAtMy0xLTEtNzIwMg_a0ca2d3c-411c-4b46-97cc-70c7119c38cf">8,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less - net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMjEtMS0xLTEtNzIwMg_6921d416-0478-4029-9e1a-a771a0f65451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMjEtMy0xLTEtNzIwMg_19a16e50-9033-4362-a317-e2e89da9b9e5">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Caladrius Biosciences, Inc. common shareholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMjMtMS0xLTEtNzIwMg_525d3f9b-ad9f-4a07-8853-cb921023b42b">27,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMjMtMy0xLTEtNzIwMg_975be8da-9b78-4b9c-a4d8-4a1999cf1059">8,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic and diluted loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Caladrius Biosciences, Inc. common shareholders</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMzQtMS0xLTEtNzIwMg_294888d0-f896-41ff-b838-30f11a501f24"><ix:nonFraction unitRef="usdPerShare" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMzQtMS0xLTEtNzIwMg_2df6e165-7a5c-41b3-8d32-8c1ea67e67fb">0.50</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMzQtMy0xLTEtNzIwMg_3f62333d-e1a9-4033-bde6-b40c4f9e987f"><ix:nonFraction unitRef="usdPerShare" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMzQtMy0xLTEtNzIwMg_63e299b7-937f-43bc-a82d-8a5e0666f8de">0.53</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfNDItMS0xLTEtNzIwMg_2aa0aae4-4859-4169-a94c-02dc970118d5"><ix:nonFraction unitRef="shares" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfNDItMS0xLTEtNzIwMg_8e443810-0c41-4712-99f3-8d305e1efeb4">55,313</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfNDItMy0xLTEtNzIwMg_2327bdc0-577e-4214-b88c-9b3720881096"><ix:nonFraction unitRef="shares" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfNDItMy0xLTEtNzIwMg_c5c6eca3-795d-4b47-8b6a-cf3fef99c9a8">15,440</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i7d049288b82e438c85d504cc3e9dc500_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:75.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.029%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfMi0xLTEtMS03MjAy_c5c1ea15-7b6b-422c-8115-4b68b9847315">27,466</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfMi0zLTEtMS03MjAy_7db494ec-0b29-4e98-8e15-907ace3a1794">8,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale securities - net unrealized loss </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfNS0xLTEtMS03MjAy_e9833dc7-eb32-4403-91a4-320d5ee4b4cc">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfNS0zLTEtMS03MjAy_d6061ee6-b820-4094-a7bd-cdcae151d89e">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfNi0xLTEtMS03MjAy_0db41f86-6fdc-40af-a3cf-bbc4a4896cf6">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfNi0zLTEtMS03MjAy_b30b51f7-92a4-4fac-a37e-c69225719427">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfOC0xLTEtMS03MjAy_0776ffa1-a759-481c-bedc-edfe5e79e118">27,523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfOC0zLTEtMS03MjAy_50da0e76-41d6-488e-b0c6-b2834e10ce48">8,156</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfMTAtMS0xLTEtNzIwMg_9605dc5d-ddae-498c-84ab-f8d1f5b34f37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfMTAtMy0xLTEtNzIwMg_f90569c0-fe48-4c7b-99b1-2f92dd49b0a9">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfMTItMS0xLTEtNzIwMg_fe66077a-6fe9-49f6-9b86-65ef72ade123">27,523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfMTItMy0xLTEtNzIwMg_330127ea-1dc7-48d7-bbc5-b576f0e11d6a">8,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i7d049288b82e438c85d504cc3e9dc500_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.553%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.934%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.934%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.510%"></td><td style="width:0.1%"></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series B Convertible<br/>Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Caladrius Biosciences,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity<br/></span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79f6e5136b8641cfa6b0a6033d36e4f2_I20191231" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi0xLTEtMS03MjAy_0a5007c0-d70d-45a5-aff3-8b31832e331b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f6e5136b8641cfa6b0a6033d36e4f2_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi0zLTEtMS03MjAy_c8b110b9-8ec1-4210-a408-68c9992e17f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib68115849dea4da8a299b880b533d09e_I20191231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi01LTEtMS03MjAy_191ad754-b856-42a4-92f2-f4d6aa105f3f">10,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib68115849dea4da8a299b880b533d09e_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi03LTEtMS03MjAy_0d9e81aa-dc71-4ee8-983f-051315d961df">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85f50c88c76b46fb9a9fdce9451675bd_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi05LTEtMS03MjAy_e4f26d34-fb70-412e-8aef-f248e5c2fadb">438,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i121f073fba6944229ad70a1d2216e933_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi0xMS0xLTEtNzIwMg_c5d9a4e4-b044-49e8-bfc0-6de97db72c1a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0b6071a73644d039603573d50440ef9_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi0xMy0xLTEtNzIwMg_01e172bf-928f-4f7a-a9d6-9921fa27422d">417,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib80ecf1156d64c119d881173740ad234_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi0xNS0xLTEtNzIwMg_4846e2c4-90a4-4b24-b0d0-4a1922555844">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaaa7498b3d44ce1bcad37ed96000058_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi0xNy0xLTEtNzIwMg_14f2be10-4825-4bd9-89da-b222301ca5e1">20,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22fd97027cb3412289b307029b9c5d44_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi0xOS0xLTEtNzIwMg_a76c2a38-f13f-43d8-ac31-196f79e104b5">263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i348737336b4d46088a36ffcdbf611676_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi0yMS0xLTEtNzIwMg_13fde5e3-38d8-44a1-ac32-8bb230bc96fc">20,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic33cdb661db24963b1bfc647608c3a94_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNC0xMy0xLTEtNzIwMg_afb23392-9a7f-4f6d-9fcb-ff8a0d220636">8,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ec6574cc7fc442f846e686e0a84ff71_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNC0xNy0xLTEtNzIwMg_586e4c6e-d5a0-4c3e-9fae-06250b4a6e76">8,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35b1729b0f074c18b9bceadc165d9549_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNC0xOS0xLTEtNzIwMg_8d0516e2-9a60-4192-a2c8-6a07149f6585">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNC0yMS0xLTEtNzIwMg_aa0536bb-3f09-463e-8f68-f3df4fe3a5e8">8,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0ff61bf14d841cc822f4506607be1ee_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNS0xMS0xLTEtNzIwMg_5a7054bf-c30a-415d-8281-fa7a08c9b427">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ec6574cc7fc442f846e686e0a84ff71_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNS0xNy0xLTEtNzIwMg_660a5b0f-6806-46ba-a65e-a54517f02098">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNS0yMS0xLTEtNzIwMg_cff0ab4d-c7ff-49f0-b480-c3b9b45f92f9">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief8aba9cebaa4b98af858420b6d60b7f_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNi01LTEtMS03MjAy_8c01dadf-2842-4287-b131-718aa0cb4831">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief8aba9cebaa4b98af858420b6d60b7f_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNi03LTEtMS03MjAy_3fece92f-fb91-427e-9cba-cf74e1fc9ce3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i041d14ec45c44c8fb3cc8034c61ca2ed_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNi05LTEtMS03MjAy_3f0f7ba7-daf1-40a9-b90c-745261e8df5d">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ec6574cc7fc442f846e686e0a84ff71_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNi0xNy0xLTEtNzIwMg_461cb7f0-2f1b-47da-ae45-1cb716111846">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNi0yMS0xLTEtNzIwMg_b340e89c-47ac-420c-b976-01ae2cbfa892">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief8aba9cebaa4b98af858420b6d60b7f_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNy01LTEtMS03MjAy_5c3fedf6-6bd4-4d36-9bf3-0b50c359fb84">8,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief8aba9cebaa4b98af858420b6d60b7f_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNy03LTEtMS03MjAy_11aa347c-3843-4d2b-8cec-e3dacb8abc36">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i041d14ec45c44c8fb3cc8034c61ca2ed_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNy05LTEtMS03MjAy_202251f9-84d2-46d3-a626-b143494390fd">18,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ec6574cc7fc442f846e686e0a84ff71_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNy0xNy0xLTEtNzIwMg_b922c6ca-896e-4b33-93c1-8f7a79068605">18,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNy0yMS0xLTEtNzIwMg_32605de1-36a9-415e-99d6-e65d78e333d9">18,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b6458eb2d574b56bd1552b4ca244e6f_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtMS0xLTEtNzIwMg_0684afc1-41f1-4763-97cc-4fe8eac8fadb">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b6458eb2d574b56bd1552b4ca244e6f_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtMy0xLTEtNzIwMg_36b787d5-ed20-40d0-a06c-7347e1e4cc29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09a9631d583b4e668c5ba6e87d883e35_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtNS0xLTEtNzIwMg_51184ff8-87c4-4868-b238-2b1eb9aa83a8">19,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09a9631d583b4e668c5ba6e87d883e35_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtNy0xLTEtNzIwMg_c9602770-7461-4a9e-acc4-206f7c7724d8">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf75562bf4d943e689edffa4d6485601_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtOS0xLTEtNzIwMg_073120f9-ef4b-44e9-8ea4-ad6da25a6192">458,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3f51b0ee3ea49bba7a5f4081d6ded24_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtMTEtMS0xLTcyMDI_40c47b16-de23-4fb3-8881-fb09ae16e4e0">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if085aac894864f8a99c23eb6f47d40df_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtMTMtMS0xLTcyMDI_c167eb6d-b4d5-4cd2-a23d-14d4b7ab4e2f">425,550</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0e019f45caf44e48d650bf1abbafe32_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtMTUtMS0xLTcyMDI_b284ae83-c4e7-494f-a341-6aaf685abf27">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic49793f351ee420aad500948204d4e30_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtMTctMS0xLTcyMDI_b848987d-e359-4ee5-ab45-b62580a0102a">32,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b3b4197bf6b40bd9ea38bf539ff4783_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtMTktMS0xLTcyMDI_5ebe1e58-3e85-4884-b83e-b7750f514aa7">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtMjEtMS0xLTcyMDI_fafc4106-f329-4f45-94c0-9e7b1d097529">32,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb8d59a888234a98a095e58d9743487f_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTEtMTMtMS0xLTcyMDI_44740d76-40b6-41a4-b005-4064d0d2f739">27,466</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i590074ecb1084218835cf2d097815608_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTEtMTctMS0xLTcyMDI_99d3abbe-5300-4e7e-86dc-7d1ae70db473">27,466</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c4ae4fba6464ce49a9062a34c2c26ce_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTEtMTktMS0xLTcyMDI_2b10789c-56b9-48a7-8810-02480a4c0c86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTEtMjEtMS0xLTcyMDI_40984fd6-2e16-43d3-a416-ffae47c181e2">27,466</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1d500671ff149bcba1096235d4f0351_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTItMTEtMS0xLTcyMDI_0fe89163-d404-43fb-af75-b4293b2b3923">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i590074ecb1084218835cf2d097815608_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTItMTctMS0xLTcyMDI_34522ed5-72d3-4700-a412-7cfc982a5085">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTItMjEtMS0xLTcyMDI_f709be12-f635-45e1-aaa8-de951746140e">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08c8bd3f15da40f487ae7ccc5cd6ce0b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTMtNS0xLTEtNzIwMg_99194cd7-033b-47d1-99a4-8e9acb5914f4">517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c8bd3f15da40f487ae7ccc5cd6ce0b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTMtNy0xLTEtNzIwMg_b12899af-205e-4be1-af34-77870268e260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85b3581054004614935d85f02ba032eb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTMtOS0xLTEtNzIwMg_69b04176-6420-4bc1-9ca5-6526f8c37696">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590074ecb1084218835cf2d097815608_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTMtMTctMS0xLTcyMDI_f8f39ced-b5d8-4ef2-9956-fcbe29734c9c">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTMtMjEtMS0xLTcyMDI_6c19304f-7d13-43fb-8219-56b0de9d9437">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08c8bd3f15da40f487ae7ccc5cd6ce0b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTQtNS0xLTEtNzIwMg_f1d7b697-8241-4c54-8b62-430314275f7a">39,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c8bd3f15da40f487ae7ccc5cd6ce0b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTQtNy0xLTEtNzIwMg_e9cb7bb9-46aa-4231-8695-7907caa1ccd5">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85b3581054004614935d85f02ba032eb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTQtOS0xLTEtNzIwMg_9e9fe7c3-a12d-4b44-b5f6-0a30523ff51b">85,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590074ecb1084218835cf2d097815608_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTQtMTctMS0xLTcyMDI_f501d3a4-4774-429e-b275-021295273425">85,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTQtMjEtMS0xLTcyMDI_ab375e35-62ed-44bc-9dcd-a45c5c013931">85,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proceeds from option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08c8bd3f15da40f487ae7ccc5cd6ce0b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTUtNS0xLTEtNzIwMg_63a25f5f-aa22-4ecb-b047-adf91b14efbe">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c8bd3f15da40f487ae7ccc5cd6ce0b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTUtNy0xLTEtNzIwMg_71ef0bce-7ed4-43ed-94a6-b75ac00c0b04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85b3581054004614935d85f02ba032eb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTUtOS0xLTEtNzIwMg_9b71d1e9-189e-4e00-be1c-0e59e9d16db0">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590074ecb1084218835cf2d097815608_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTUtMTctMS0xLTcyMDI_85098b12-82c1-4455-bd01-15d7b1edbd52">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTUtMjEtMS0xLTcyMDI_5762f466-7b37-4736-ae69-f6cf434fe699">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i138b992a9f394701a484d131a2d03699_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctMS0xLTEtNzIwMg_304b7957-8ce6-4f17-9bfa-941c94ea50ca">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i138b992a9f394701a484d131a2d03699_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctMy0xLTEtNzIwMg_46d2584d-d8df-404d-b206-820f585bf50d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4300a282ab74c7fafc35eaf54a4d1b1_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctNS0xLTEtNzIwMg_be18ec12-940e-445b-a1e6-269a18a36f49">59,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4300a282ab74c7fafc35eaf54a4d1b1_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctNy0xLTEtNzIwMg_dc859366-c028-4611-afc2-7a1923db3b47">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i281d8d9652bf482bb56d77de34f2b394_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctOS0xLTEtNzIwMg_9f521cc5-0793-4c63-bd03-88bdf9a650dc">545,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9b7f001d8d64dcf8ca8ba24c50737f0_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctMTEtMS0xLTcyMDI_1caea614-3bcd-4add-ae92-ffe8e4dd7488">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb79bfd702f54177906acce5d83f1c8d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctMTMtMS0xLTcyMDI_db429daa-8ef7-43e6-8e5b-ff50d035d159">453,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd0fb63052524135af561bfff992a6c8_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctMTUtMS0xLTcyMDI_3ce72f2c-e3dc-4b9a-8a8f-fe40455f7edd">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66d93ded2f34467d936905ead482129f_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctMTctMS0xLTcyMDI_99996e2c-a3ef-4761-a2c2-9c47278bc3f0">92,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8805752994c49a8983ffea360e4c657_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctMTktMS0xLTcyMDI_91e9236a-729c-4ac5-b17b-31f5ce9e81c1">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctMjEtMS0xLTcyMDI_1fc49951-5019-4ecc-889d-d51abe2687dd">92,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i7d049288b82e438c85d504cc3e9dc500_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:77.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.247%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMy0xLTEtMS03MjAy_0b36cb8e-dc6a-4d1a-81b3-e7094226c105">27,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMy0zLTEtMS03MjAy_55f738d8-5abf-42c6-a56a-a190a51b68ca">8,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfNS0xLTEtMS03MjAy_8b0f2da9-508c-4238-9188-0cbc2422495c">2,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfNS0zLTEtMS03MjAy_7036d2f2-576d-4c3c-ade1-98b8cff3713d">1,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfNi0xLTEtMS03MjAy_e97dc218-422c-4f36-b0fd-c551aa18e027">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfNi0zLTEtMS03MjAy_d58ffb2b-6228-4200-8faa-81f7d14440e5">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization/accretion on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTAtMS0xLTEtNzIwMg_25ec92a2-bb1c-4a3d-9f79-89c5f41b2be2">2,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTAtMy0xLTEtNzIwMg_60678175-d84f-4741-998a-637fcfe5efc7">307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTItMS0xLTEtNzIwMg_54cfb696-3423-407d-8c50-0df9e72a9367">453</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTItMy0xLTEtNzIwMg_354a24a6-be40-4183-89eb-2361c3f0d91c">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTMtMS0xLTEtNzIwMg_9b875a74-092f-4755-bc3a-830299ed87e4">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTMtMy0xLTEtNzIwMg_46070325-6c4c-4cc0-aa19-d5f7fa5e07fe">466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTQtMS0xLTEtNzIwMg_1ab1d32b-d793-40b5-bcb8-653bb61349ca">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTQtMy0xLTEtNzIwMg_52747d7c-4173-4fce-aa76-ffaeefc6f445">2,839</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTUtMS0xLTEtNzIwMg_a7476dc0-eaf4-4023-80dd-b669f15ed602">22,245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTUtMy0xLTEtNzIwMg_be3e9817-b806-4e9d-8cb8-205c2958bbe9">8,823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTctMS0xLTEtNzIwMg_6309eaf2-7e9f-4e4f-8ab6-074271590848">179,775</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTctMy0xLTEtNzIwMg_2a36cf43-bc9b-4217-b5c5-cf07b4c428e9">34,799</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTgtMS0xLTEtNzIwMg_afc05e60-68f3-4064-8482-1d549e5f35d1">124,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTgtMy0xLTEtNzIwMg_09a8c76e-b600-4e4f-bfb7-033693ccef17">27,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjAtMS0xLTEtNzIwMg_17c6cdac-ab91-438c-99b8-f30c1590f57e">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjAtMy0xLTEtNzIwMg_419c174b-f9cf-4206-82e0-847cb4f4491c">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjEtMS0xLTEtNzIwMg_7cb6aef7-6144-46d4-a3db-7a69a966c417">54,896</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjEtMy0xLTEtNzIwMg_e3827f2a-29c9-4970-9563-40c285750a6d">7,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjMtMS0xLTEtNzIwMg_6f74b533-257a-48c2-a6c9-7943c77c0bb1">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjMtMy0xLTEtNzIwMg_3ae57c77-02f7-419e-bba4-f7293476df81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax withholding payments on net share settlement equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjQtMS0xLTEtNzIwMg_2e1c7b96-d343-455c-a670-6593c1ea32ed">248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjQtMy0xLTEtNzIwMg_ad660cc2-cb9c-4946-8372-1ef9ac1057ff">148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from issuance of capital stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjUtMS0xLTEtNzIwMg_4671ea32-28ea-4a0f-ba58-8a63c1b564e3">85,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjUtMy0xLTEtNzIwMg_fa5f3063-54ca-43d9-a83d-e594b2434e52">18,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjktMS0xLTEtNzIwMg_46883d25-c869-40bd-ae7f-b756d5130570">85,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjktMy0xLTEtNzIwMg_a19164b4-f753-4200-a5d4-3a5bff4f012c">18,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMzAtMS0xLTEtNzIwMg_e169f9a3-fe8b-48fc-836a-403a7cbfc000">8,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMzAtMy0xLTEtNzIwMg_bac09731-c558-4849-b69b-c654bb5ec376">2,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMzEtMS0xLTEtNzIwMg_8ac64f41-8586-4be2-8af9-38f2f90ff364">16,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i348737336b4d46088a36ffcdbf611676_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMzEtMy0xLTEtNzIwMg_d4e505d0-b730-435b-bc0f-dcf47b8c6306">14,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMzItMS0xLTEtNzIwMg_b918a782-ab9f-41cb-9c22-b54bf1ff9361">24,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMzItMy0xLTEtNzIwMg_cedac9c1-3e9a-4dd6-8ff2-37c7c1e95c53">16,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Cash Flow Information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid during the period for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMzYtMS0xLTEtNzIwMg_64f9d92a-deb8-4515-ad37-d336f563b896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMzYtMy0xLTEtNzIwMg_85677d9d-1342-4591-b33c-95b46139d851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMzctMS0xLTEtNzIwMg_e10a5ae5-e047-4b9e-9eec-6085805d5db5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMzctMy0xLTEtNzIwMg_4864084d-83ca-463a-8bd8-bce8f975667f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i7d049288b82e438c85d504cc3e9dc500_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CALADRIUS BIOSCIENCES, INC. AND SUBSIDIARIES</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_85"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 1&#160;&#8211; <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="clbs:BusinessTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84NS9mcmFnOjEwMDRkMDFiZGM5MTRmYzQ4N2Y0MjhjMDVhMTFlMzIyL3RleHRyZWdpb246MTAwNGQwMWJkYzkxNGZjNDg3ZjQyOGMwNWExMWUzMjJfNDA5MA_d6286a51-bf67-4862-b53f-173997c60bec" continuedAt="i499a99a9f10b465e9b356e5149173181" escape="true">The Business</ix:nonNumeric></span></div><ix:continuation id="i499a99a9f10b465e9b356e5149173181" continuedAt="i2688e5c7c5424a8e9cae2bbb32edb6a4"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">OVERVIEW</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caladrius Biosciences, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Caladrius&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The Company is developing what are intended to be first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Its technology is intended to leverage these cells to enable the body's natural repair mechanisms using formulations unique to each medical indication.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's leadership team has decades of collective biopharmaceutical development experience. Its goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. The Company's current product candidates include: </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CLBS16), the subject of both a completed positive Phase 2a study (ESCaPE-CMD) and an ongoing follow-on Phase 2b study (FREEDOM Trial) in the United States for the treatment of coronary microvascular dysfunction (&#8220;CMD&#8221;); </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CLBS12), recipient of SAKIGAKE designation pursuant to which early conditional approval in Japan for the treatment of critical limb ischemia (&#8220;CLI&#8221;) and Buerger&#8217;s disease is being sought based on the current results of a clinical trial executed in Japan. HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was the recipient of orphan drug designation in March 2021 from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for Buerger's disease; and </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with chronic kidney disease related to type 2 diabetes (diabetic kidney disease or &#8220;DKD&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ischemic Repair (CD34 Cell Technology)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CD34+ cell was discovered as a result of the deliberate search for a cell capable of stimulating the development and/or repair of blood vessels. All tissues in the body maintain their function by replacing cells over time. In addition to the maintenance function, the body must also be capable of building new blood vessels after injury. A CD34+ cell is an endothelial progenitor cell that has the ability to stimulate new blood vessel formation at the level of the microvasculature. No other native cell discovered to date has demonstrated this same capability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's proprietary cell technology using autologous (a patient&#8217;s own naturally occurring) CD34+ cells has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted or reduced. Through the administration of CD34+ cells, Caladrius seeks to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted area. The Company believes that a number of conditions caused by underlying ischemic injury can be improved through its CD34+ cell technology including, but not limited to, Buerger's disease, CLI, CMD, and DKD.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of Coronary Microvascular Dysfunction</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, with the assistance of a $<ix:nonFraction unitRef="usd" contextRef="i62dba77d3e2d4497b9f85f984cfba083_I20171231" decimals="-5" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84NS9mcmFnOjEwMDRkMDFiZGM5MTRmYzQ4N2Y0MjhjMDVhMTFlMzIyL3RleHRyZWdpb246MTAwNGQwMWJkYzkxNGZjNDg3ZjQyOGMwNWExMWUzMjJfMTY0OTI2NzQ1MDU4Mw_8ae55f51-0778-4d0b-994e-61f262ce463c">1.9</ix:nonFraction>&#160;million grant from the National Institutes of Health (Award Number R44HL135889), the Company initiated its program for XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of CMD, a disease that afflicts as many as 1.6 million patients in the United States alone, with no current targeted treatment options. That study, the ESCaPE-CMD Trial, was a Phase 2a proof-of-concept open label study that enrolled patients at the Mayo Clinic in Rochester, MN and Cedars-Sinai Medical Center in Los Angeles, CA. Those data showed a positive therapeutic effect with a statistically significant improvement in angina frequency, coronary flow reserve, Canadian Cardiovascular Society Angina Class and Seattle Angina Questionnaire scores, as well as an acceptable safety profile. The full data set from that study was presented at the SCAI 2020 Scientific Sessions Virtual Conference on May 14, 2020 by Dr. Timothy Henry, FACC, of the Christ Hospital in Cincinnati, Ohio. In December 2020, the Company commenced enrollment in its Phase 2b FREEDOM Trial of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a double-blind, randomized and placebo-controlled clinical trial designed to further evaluate the efficacy and safety of intracoronary artery delivery of autologous CD34+ cells in subjects with CMD and without obstructive coronary artery disease. While early enrollment proceeded to plan with the first patient treated in January 2021, the impact of the COVID-19 pandemic contributed to a general slowing of enrollment. Protocol amendments to the initial FREEDOM Trial protocol, as agreed to by the FDA, were implemented with the goal of enhancing breadth and speed of subject enrollment.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><ix:continuation id="i2688e5c7c5424a8e9cae2bbb32edb6a4" continuedAt="i0afa521d26ed4a7bbf109b2a9bd7d1f9"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of Critical Limb Ischemia</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's randomized, open-label, registration-eligible study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan for the treatment of CLI and Buerger's disease has, to date, demonstrated positive trends in both safety and efficacy. The HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> study's enrollment, however, has been significantly curtailed by the COVID-19 pandemic's impact in Japan, including the States of Emergency in Japan that have persisted for much of the past 18 months. Due to the significant and continued operational and financial burden incurred as a result of these COVID-19 delays, coupled with the unpredictability of the timing of site enrollment re-initiation, Caladrius</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suspended further enrollment and is focusing its efforts on consummating a partnership for the product in Japan. Such a partnership may become the basis for the completion of development and registration of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan and may include the completion of enrollment of the four remaining no-option CLI subjects stipulated in the original protocol, if necessary, and/or exploration of the possibility of submitting the existing data to Japan's Pharmaceuticals and Medical Devices Agency (&#8220;PMDA&#8221;) under Japan's regenerative medicine regulations, which allow for conditional approval of innovative regenerative medicine products. Despite receipt from FDA in March 2021 of orphan designation in the U.S. for CLBS12 as a potential treatment for Buerger's disease, based on a response from the FDA in October 2021 regarding a development plan for U.S. registration the Company decided not to pursue United States development in Buerger's disease at this time.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CLBS201 for Treatment of Diabetic Kidney Disease</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progressive kidney failure is associated with attrition of the microcirculation of the kidney. Pre-clinical studies in kidney disease and injury models have demonstrated that protection or replenishment of the microcirculation results in improved kidney function. Based on these observations, the Company has elected to move forward with a Phase 1, open-label, proof-of-concept trial evaluating CLBS201 dosed via intra-renal artery injections in subjects with DKD. This protocol, as approved by an Institutional Review Board (the &#8220;IRB&#8221;), is expected to include six subjects in total with the first two subjects sequentially dosed and followed for a two-week safety observation period. Clearance by the independent Data Safety Monitoring Board (&#8220;DSMB&#8221;) overseeing the study will then permit the treatment of the next four patients, with all patients being followed for safety and therapeutic effect. A read-out of data will occur after at the six-month follow-up visit for all patients. A key criterion for continued development of CLBS201 will be its ability to demonstrate a therapeutic effect that will make it competitive in the field of DKD treatment, i.e., kidney function regeneration, as indicated by increased glomerular filtration rate.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Out-licensing Opportunities and Pipeline Diversification</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. The Company's current long-term strategy focuses on advancing its therapies through development with the ultimate objective of obtaining market authorizations and entering commercialization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. The Company believes that it is well-positioned to realize potentially meaningful value increases within its own proprietary pipeline if it is successful in advancing its product candidates to their next significant development milestones.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company further desires to diversify its pipeline of development products candidates and is exploring a range of strategic transactions in furtherance of that goal. The Company has taken, and intends to continue to take, active steps to identify assets and/or companies for acquisition and/or partnership that would complement its current development programs and de-risk its overall development portfolio. Such assets potentially could target indications beyond cardiovascular disease as well as product categories outside of cell therapy. The range of possible transactions includes an acquisition, merger, business combination, in-license or other strategic transaction, any of which could result in the issuance of securities that could significantly dilute the shares of its existing stockholders. There can be no assurance that this exploration of strategic alternatives will result in Caladrius entering into or completing any transaction or that such transaction, if completed, will add to shareholder value.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus Considerations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of coronavirus (SARS-CoV-2), which causes COVID-19, was reported to have surfaced in China. In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic, and the world's economies began to experience pronounced effects. Despite the FDA approval of multiple COVID-19 vaccines in late 2020, there remains uncertainty around the extent and duration of disruption and any future related financial impact cannot reasonably be estimated at this time. In response to the COVID-19 pandemic, the Company implemented a universal work from home policy as well as stringent social distancing and other hygiene policies for employees when they must be in the office. The Company's clinical study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan has experienced significant delays in enrollment due to the States of Emergency in effect in Japan for most of 2020 and re-implemented from January 7, 2021 through March 21, 2021 covering Tokyo and other regions in response to an increased number of COVID-19 infections. Due to reported increases in COVID-19 cases and a low rate of vaccination in Japan, States of Emergency were renewed on April 25, 2021 through May 11, 2021 and then re-implemented in Tokyo from July 12, 2021 through September 30, 2021. With the Company's expectation that </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><ix:continuation id="i0afa521d26ed4a7bbf109b2a9bd7d1f9"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 in Japan would continue to impact negatively enrollment of patients in the HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trial, it elected to suspend trial enrollment, seek a development partner and consult with the Japanese regulatory authorities regarding the submission of patient data already accrued. Caladrius' phase 2b trial of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. has also experienced delays in enrolling patients as a result of COVID-19.</span></div><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84NS9mcmFnOjEwMDRkMDFiZGM5MTRmYzQ4N2Y0MjhjMDVhMTFlMzIyL3RleHRyZWdpb246MTAwNGQwMWJkYzkxNGZjNDg3ZjQyOGMwNWExMWUzMjJfMTMxOTQxMzk1ODkzNzE_fce396f1-0b53-4a12-b100-fe68df6870eb" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div></ix:nonNumeric><div style="text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84NS9mcmFnOjEwMDRkMDFiZGM5MTRmYzQ4N2Y0MjhjMDVhMTFlMzIyL3RleHRyZWdpb246MTAwNGQwMWJkYzkxNGZjNDg3ZjQyOGMwNWExMWUzMjJfMTMxOTQxMzk1ODkzNzI_51d40ebe-5414-4624-94f2-f371c7d7d354" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes  critical estimate and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84NS9mcmFnOjEwMDRkMDFiZGM5MTRmYzQ4N2Y0MjhjMDVhMTFlMzIyL3RleHRyZWdpb246MTAwNGQwMWJkYzkxNGZjNDg3ZjQyOGMwNWExMWUzMjJfMTMxOTQxMzk1ODkzNzM_113d00ae-e5c8-4241-93c6-be166b02019a" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_88"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 2 &#8211; <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODYzNg_754c2519-43dc-439f-a599-7b952b10ca3c" continuedAt="ibbe26bfe783841248769e9c6e915bb87" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ibbe26bfe783841248769e9c6e915bb87" continuedAt="i08e2f219722a4e93adf296dfbbda51e1"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODYzMA_1cd1e456-9731-425d-bc8d-c3c695585a87" continuedAt="i274a77cdd5d34d7ab7ce17a6433339ae" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i274a77cdd5d34d7ab7ce17a6433339ae">Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.</ix:continuation> </span></div><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODYwMg_7f712317-ff99-46c6-a873-4f7ad3e30315" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States.  Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODU5OA_e0a328d9-721c-49ef-83d4-865c5a15984d" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><ix:continuation id="i08e2f219722a4e93adf296dfbbda51e1" continuedAt="i85443bbaa53b420faed63d2eee451ce0"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODU4Nw_75efcbcd-5222-4fc7-a6de-5c66bc4d8ea2" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODU3Mw_11bef7c0-88d3-47ab-bbd7-6ecc2e4332df" continuedAt="i0796909b31bf4b3c960a3cbc7d6530a6" escape="true">The estimated useful lives of property and equipment are as follows:</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:center"><ix:continuation id="i0796909b31bf4b3c960a3cbc7d6530a6" continuedAt="i5efaf7567e0a41f392bf88455fae630d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i71b84bd2ef5e48a7bdb1280f312427a2_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RhYmxlOjEzNjNjNWViNTY0YjQ1YTY5ZmRjOGQ1YTM0MDZiZjVhL3RhYmxlcmFuZ2U6MTM2M2M1ZWI1NjRiNDVhNjlmZGM4ZDVhMzQwNmJmNWFfMC0xLTEtMS03MjAy_178bab3b-e3a0-47d1-b3cb-c105bbe262d6">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0be130c99cf043d29b10c289f1311bf5_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RhYmxlOjEzNjNjNWViNTY0YjQ1YTY5ZmRjOGQ1YTM0MDZiZjVhL3RhYmxlcmFuZ2U6MTM2M2M1ZWI1NjRiNDVhNjlmZGM4ZDVhMzQwNmJmNWFfMS0xLTEtMS03MjAy_daa60343-6758-469d-8f0b-391651d22c7b">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i66e36ae7aaf0456e850ea8fbf00533f0_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RhYmxlOjEzNjNjNWViNTY0YjQ1YTY5ZmRjOGQ1YTM0MDZiZjVhL3RhYmxlcmFuZ2U6MTM2M2M1ZWI1NjRiNDVhNjlmZGM4ZDVhMzQwNmJmNWFfMi0xLTEtMS03MjAy_3a016b7c-289b-499a-a029-417f58e01350">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table></ix:continuation></div></ix:nonNumeric><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentImpairment" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODYyNg_21f6ad2b-c34d-4dab-8f39-e3807130ad02" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODY0NA_7c1832a2-d4ab-4df1-998a-7214ec204666" continuedAt="ib3894295b9ed4d24b7cd325e6fff24be" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></ix:nonNumeric></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib3894295b9ed4d24b7cd325e6fff24be">The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant.</ix:continuation> </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODYzNQ_bad21df0-4011-492e-a1f4-13c912cd7425" continuedAt="i85e3ac19664b4b31aae61bb5e36e60d2" escape="true">Loss Per Share</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i85e3ac19664b4b31aae61bb5e36e60d2">Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.</ix:continuation> </span></div><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="clbs:TreasuryStockPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODYwNw_8e184f07-d6bc-4684-a696-e01888ac79ea" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODU4OA_6cfe580a-1bbb-45a7-8b87-0c92527ad824" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (&#8220;R&amp;D&#8221;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive the Company&#8217;s cell therapy initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#8217;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="i85443bbaa53b420faed63d2eee451ce0" continuedAt="i3496560c825c4830b36999dca92bfe5a"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODYyOA_7f79040a-731c-4375-8fa1-d7829d1acb65" continuedAt="iac9e9d5c289e4effb95cb5f7c421f249" escape="true">New Accounting Pronouncements</ix:nonNumeric></ix:continuation></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3496560c825c4830b36999dca92bfe5a"><ix:continuation id="iac9e9d5c289e4effb95cb5f7c421f249">In October 2019, the FASB issued ASU 2019-12, which affects general principles within Topic 740, Income Taxes. The amendments of&#160;ASU 2019-12&#160;are meant to simplify and reduce the cost of accounting for income taxes. For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company believes that the adoption of this new accounting guidance has not had a material impact on its financial statements and footnote disclosures.</ix:continuation></ix:continuation>&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_91"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 3 &#8211; <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RleHRyZWdpb246ZTM5YjE1ZjdhZjY4NGVlZmJiYjJiNWRjMDU2MTJlMDRfNjMx_5e67da7d-fa5a-473c-b979-62df5d92e937" continuedAt="i60c8eb0b0c07441ea832815555ee3fd5" escape="true">Available-for-Sale-Securities</ix:nonNumeric></span></div><ix:continuation id="i60c8eb0b0c07441ea832815555ee3fd5"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RleHRyZWdpb246ZTM5YjE1ZjdhZjY4NGVlZmJiYjJiNWRjMDU2MTJlMDRfNjQ1_c981522d-9cc1-4d43-b7db-6108aa29c4d3" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or debt marketable securities in the Company's Consolidated Balance Sheets (in thousands):</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:19.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6296c462c944e98b58dc2225093cca_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMi0xLTEtMS03MjAy_65629fb4-0282-4258-98a0-1653acb64348">53,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6296c462c944e98b58dc2225093cca_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMi0zLTEtMS03MjAy_e99b07c2-9701-42ee-bf54-9acd0121da17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6296c462c944e98b58dc2225093cca_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMi01LTEtMS03MjAy_bf4e095c-fb5a-4d00-96fe-7da87d3850e1">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6296c462c944e98b58dc2225093cca_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMi03LTEtMS03MjAy_be98369b-c63e-48b6-8c85-cff21ccbe6a2">53,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd83120aa4846998e97a3591fb90ade_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMi05LTEtMS03MjAy_d26a6da5-4594-41fc-b974-eae84580634d">8,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd83120aa4846998e97a3591fb90ade_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMi0xMS0xLTEtNzIwMg_aad57d91-79ca-4681-a635-7f227be806d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bd83120aa4846998e97a3591fb90ade_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMi0xMy0xLTEtNzIwMg_80abbfff-4560-4b0d-a219-80714d40331a">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd83120aa4846998e97a3591fb90ade_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMi0xNS0xLTEtNzIwMg_0b353c84-e3c7-4df3-83ba-9e86a0ea7df9">8,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc34d3422ed44678794bda76d2eaf4b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMy0xLTEtMS03MjAy_f385c253-061d-406d-b6b5-5a33043c0964">18,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc34d3422ed44678794bda76d2eaf4b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMy0zLTEtMS03MjAy_ced57992-bcf6-43e8-ad7a-1d06159674ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc34d3422ed44678794bda76d2eaf4b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMy01LTEtMS03MjAy_31cbfe07-f7b4-43a7-a280-60b6ab75774e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccc34d3422ed44678794bda76d2eaf4b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMy03LTEtMS03MjAy_c84ca915-e08d-4c07-8f5b-7823f1bfc067">18,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb11fcb1dc24116a57364c1887e3eee_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMy05LTEtMS03MjAy_3f7d558f-f562-4e64-9a84-683d2c3df419">7,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb11fcb1dc24116a57364c1887e3eee_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMy0xMS0xLTEtNzIwMg_5be41360-e891-4c67-ae95-13c08e00e7be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb11fcb1dc24116a57364c1887e3eee_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMy0xMy0xLTEtNzIwMg_f4010b28-daf9-4ee9-bc60-c6fcc217afbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb11fcb1dc24116a57364c1887e3eee_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMy0xNS0xLTEtNzIwMg_def6a1d3-02b3-49bc-8f46-faac66791372">7,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5468258328d0445fae4d4028b71bf1d0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNC0xLTEtMS03MjAy_57c5c4a8-e408-4662-8a95-cb297decce94">20,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5468258328d0445fae4d4028b71bf1d0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNC0zLTEtMS03MjAy_ff9c2bf0-e3c2-4ac2-ac07-80be7b7a17f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5468258328d0445fae4d4028b71bf1d0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNC01LTEtMS03MjAy_90d17830-c6e3-43fe-8022-3515b00a989b">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5468258328d0445fae4d4028b71bf1d0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNC03LTEtMS03MjAy_cd2e4ff7-48d7-4745-8143-54a2f39a16d8">20,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc62f8ee9d94752a5a99f633d893ab6_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNC05LTEtMS03MjAy_ff63e3c3-0cc7-4437-9025-a0b4810b7d45">14,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc62f8ee9d94752a5a99f633d893ab6_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNC0xMS0xLTEtNzIwMg_b9f19011-8c18-4e85-81e8-69e4b522e429">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc62f8ee9d94752a5a99f633d893ab6_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNC0xMy0xLTEtNzIwMg_a52432ed-8faf-458f-8773-6dd6eb498e57">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc62f8ee9d94752a5a99f633d893ab6_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNC0xNS0xLTEtNzIwMg_a03b854a-8469-4bb4-ad85-3c6bd1a8be5d">14,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNi0xLTEtMS03MjAy_86850d59-4337-4543-83d4-d6d1ab60762b">91,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNi0zLTEtMS03MjAy_0eac2b26-5b81-460a-b9ec-adec240e833c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNi01LTEtMS03MjAy_869dd0a8-35a8-4582-80c8-f36bf5b11316">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNi03LTEtMS03MjAy_95f6b48d-161d-4120-8c23-95bd8c23f193">91,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNi05LTEtMS03MjAy_8a6a1baf-9a07-451b-b867-37c4dfb4066c">30,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNi0xMS0xLTEtNzIwMg_f7b7988a-cd8b-452b-91c3-91d24552739d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNi0xMy0xLTEtNzIwMg_21687c01-53fa-4900-9598-9454a3e5db6c">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNi0xNS0xLTEtNzIwMg_6bf46668-eff3-4cdc-b33d-d25c81f2244f">30,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RleHRyZWdpb246ZTM5YjE1ZjdhZjY4NGVlZmJiYjJiNWRjMDU2MTJlMDRfNjM0_8df7e313-f217-4eb2-bf6b-5ba71c7f98b8" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on the Company's Consolidated Balance Sheets (in thousands):</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:67.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea9f8dda92dc4bd8a85d72b68a1c2034_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjdhMDRlM2VhODI1NTQwZTI5NjQ1YjVhNDFhMGU0MTYwL3RhYmxlcmFuZ2U6N2EwNGUzZWE4MjU1NDBlMjk2NDViNWE0MWEwZTQxNjBfMS0xLTEtMS03MjAy_00d47f30-387a-414b-8052-12214feec53e">21,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if63b1c1c78bf4e0282c0521dfe489b5b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjdhMDRlM2VhODI1NTQwZTI5NjQ1YjVhNDFhMGU0MTYwL3RhYmxlcmFuZ2U6N2EwNGUzZWE4MjU1NDBlMjk2NDViNWE0MWEwZTQxNjBfMS0zLTEtMS03MjAy_3a997405-17de-4fcf-aadc-908b66347d85">12,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048ee8e3bbb048d3a2c27c95245f5f26_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjdhMDRlM2VhODI1NTQwZTI5NjQ1YjVhNDFhMGU0MTYwL3RhYmxlcmFuZ2U6N2EwNGUzZWE4MjU1NDBlMjk2NDViNWE0MWEwZTQxNjBfMi0xLTEtMS03MjAy_76f7aaef-4d1f-430e-89dc-d4aa51083794">70,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce00799bd1b413ea234f8cba5445fa0_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjdhMDRlM2VhODI1NTQwZTI5NjQ1YjVhNDFhMGU0MTYwL3RhYmxlcmFuZ2U6N2EwNGUzZWE4MjU1NDBlMjk2NDViNWE0MWEwZTQxNjBfMi0zLTEtMS03MjAy_14764d2c-24df-40ee-9232-fccf59b7e38f">18,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjdhMDRlM2VhODI1NTQwZTI5NjQ1YjVhNDFhMGU0MTYwL3RhYmxlcmFuZ2U6N2EwNGUzZWE4MjU1NDBlMjk2NDViNWE0MWEwZTQxNjBfMy0xLTEtMS03MjAy_746c542a-b2ca-4873-b776-e47869be79bd">91,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjdhMDRlM2VhODI1NTQwZTI5NjQ1YjVhNDFhMGU0MTYwL3RhYmxlcmFuZ2U6N2EwNGUzZWE4MjU1NDBlMjk2NDViNWE0MWEwZTQxNjBfMy0zLTEtMS03MjAy_a8adb5fe-60a1-4550-bca0-ee517d65c140">30,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RleHRyZWdpb246ZTM5YjE1ZjdhZjY4NGVlZmJiYjJiNWRjMDU2MTJlMDRfNjI2_8def9d69-5967-4d17-a6e4-89e17d2a6a49" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfMi0xLTEtMS03MjAy_479b0601-0119-483d-baab-79add56aa8dc">91,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfMi0zLTEtMS03MjAy_840fdafb-73dd-420c-870a-85b25c2b7278">91,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfMi01LTEtMS03MjAy_0b526aaa-b396-4e8d-958c-202ec977bb76">30,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfMi03LTEtMS03MjAy_a2a44d4b-f697-42a3-b0d3-6440bee0bc7f">30,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfMy0xLTEtMS03MjAy_e9238660-3ddf-4183-a484-f27dd81b0791">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfMy0zLTEtMS03MjAy_c7592e9b-b315-41cb-90af-e91925d00f25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfMy01LTEtMS03MjAy_1edd269e-aeda-4052-8645-3251c3ca67b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfMy03LTEtMS03MjAy_9c7487a3-9e75-4661-a4a3-efb0ed2d7da9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfNC0xLTEtMS03MjAy_7f712e69-ecc6-40ba-b961-808548f8899d">91,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfNC0zLTEtMS03MjAy_90f162f3-6b48-49ea-8256-78c70d7da2c7">91,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfNC01LTEtMS03MjAy_55ed9dc7-7b4b-4852-a1e6-49ffd8b7f7a1">30,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfNC03LTEtMS03MjAy_632613ee-1ee8-4976-9e25-77900606d266">30,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i7d049288b82e438c85d504cc3e9dc500_94"></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 4 &#8211; <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RleHRyZWdpb246Y2RjYzg4YmEwZWQyNGNjYjliNWFmNjJlNDBiNzRlOTNfMjQw_ead9ea18-9797-42fc-9a97-4c47fa4655ad" continuedAt="i3fc1c559ea794a6190e57d0855fb5c26" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i5efaf7567e0a41f392bf88455fae630d"><ix:continuation id="i3fc1c559ea794a6190e57d0855fb5c26" continuedAt="i60615bc09e124beb83759c2dcdc09f64"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:73.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a31510bd7f84ebd8c107e3f8ae7e451_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfMi0xLTEtMS03MjAy_f590a1a5-ec1e-4fad-994c-be7741e7b78c">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd367f49394e4ab892e5ef3d131cbacb_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfMi0zLTEtMS03MjAy_c266c418-902a-4d0e-966d-14f12f0f8486">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i310aef3fef4244c585bf799759419229_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfMy0xLTEtMS03MjAy_eb3982da-3b63-47e9-80d9-3f1a970f15a4">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92b79ab0ccd455ead408147f405a076_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfMy0zLTEtMS03MjAy_4cc2b86d-b744-40b4-bdbc-966f052bdd67">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d9629ce58cd4f72b9770fbf37dff34a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfNC0xLTEtMS03MjAy_557ad84c-e3eb-4e76-940e-cdafdfa02132">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44c2bc8d551a45f1ac6ddf183da926e5_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfNC0zLTEtMS03MjAy_9132265b-a7ce-41fe-831a-02c3dac30217">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfNS0xLTEtMS03MjAy_fc796252-1e3c-4a36-9efb-2aab9b50a292">430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfNS0zLTEtMS03MjAy_e9d72128-4c0b-4d4b-969a-39c7cffe2e5b">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfNi0xLTEtMS03MjAy_6f4493fb-e8eb-456f-bec3-25fb71bc9f11">368</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfNi0zLTEtMS03MjAy_6545758e-edbc-4cbb-bc36-03c0add7ad2c">313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfNy0xLTEtMS03MjAy_80555a15-1895-4f2a-b186-29a968621a8e">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfNy0zLTEtMS03MjAy_15b24868-f12d-4972-b8f1-b410ce5de180">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-top:1pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i60615bc09e124beb83759c2dcdc09f64">The Company&#8217;s results included depreciation expense of approximately $<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RleHRyZWdpb246Y2RjYzg4YmEwZWQyNGNjYjliNWFmNjJlNDBiNzRlOTNfMTc3_c1d2737e-4edf-4d46-8d2b-8007a7463049">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RleHRyZWdpb246Y2RjYzg4YmEwZWQyNGNjYjliNWFmNjJlNDBiNzRlOTNfMTg0_92533f08-d7a7-4672-bdea-58eb55dea6e8">0.1</ix:nonFraction> million for the years ended December&#160;31, 2021 and 2020, respectively.</ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_97"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 5 &#8211; <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85Ny9mcmFnOjFkODkyOWM5YTE1MDQ2NDk5Nzk5N2Y2ZmUzM2Y2MWEyL3RleHRyZWdpb246MWQ4OTI5YzlhMTUwNDY0OTk3OTk3ZjZmZTMzZjYxYTJfMzM0_ede7e22f-e61b-4c9b-a7dc-78a39f77eb05" continuedAt="i2e274adb1ddc4f5986dd027031c82a98" escape="true">Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="i2e274adb1ddc4f5986dd027031c82a98"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021 and 2020, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss per share a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s they are anti-dilutive in the periods presented. <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85Ny9mcmFnOjFkODkyOWM5YTE1MDQ2NDk5Nzk5N2Y2ZmUzM2Y2MWEyL3RleHRyZWdpb246MWQ4OTI5YzlhMTUwNDY0OTk3OTk3ZjZmZTMzZjYxYTJfMzQw_34753760-fbaa-45f9-be6a-1e65adc04551" continuedAt="ifa36bfc0ce24448da661d2d1ed4a6001" escape="true">At December&#160;31, 2021 and 2020, the Company excluded the following potentially dilutive securities (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><ix:continuation id="ifa36bfc0ce24448da661d2d1ed4a6001"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:69.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia36b0d5241f648078a95606bbd0ff79d_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85Ny9mcmFnOjFkODkyOWM5YTE1MDQ2NDk5Nzk5N2Y2ZmUzM2Y2MWEyL3RhYmxlOmEwMThjNTQxNjI2ZTRlZTViZTBjY2JlYjc2ODk0YmZhL3RhYmxlcmFuZ2U6YTAxOGM1NDE2MjZlNGVlNWJlMGNjYmViNzY4OTRiZmFfMi0xLTEtMS03MjAy_60df90b6-3d3a-4553-bcf2-2bc54d2e185a">2,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56f86dd405f8453396a3f70388a0570d_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85Ny9mcmFnOjFkODkyOWM5YTE1MDQ2NDk5Nzk5N2Y2ZmUzM2Y2MWEyL3RhYmxlOmEwMThjNTQxNjI2ZTRlZTViZTBjY2JlYjc2ODk0YmZhL3RhYmxlcmFuZ2U6YTAxOGM1NDE2MjZlNGVlNWJlMGNjYmViNzY4OTRiZmFfMi0zLTEtMS03MjAy_74291e67-50a6-40ce-9769-902011dfee4f">964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3bccb0f475cc4d218304cd754913183a_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85Ny9mcmFnOjFkODkyOWM5YTE1MDQ2NDk5Nzk5N2Y2ZmUzM2Y2MWEyL3RhYmxlOmEwMThjNTQxNjI2ZTRlZTViZTBjY2JlYjc2ODk0YmZhL3RhYmxlcmFuZ2U6YTAxOGM1NDE2MjZlNGVlNWJlMGNjYmViNzY4OTRiZmFfMy0xLTEtMS03MjAy_e331cbc7-a960-4c6f-8304-f63a6bcd1cb6">21,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0919bea6d44b4365b7bf14cfc4143c4f_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85Ny9mcmFnOjFkODkyOWM5YTE1MDQ2NDk5Nzk5N2Y2ZmUzM2Y2MWEyL3RhYmxlOmEwMThjNTQxNjI2ZTRlZTViZTBjY2JlYjc2ODk0YmZhL3RhYmxlcmFuZ2U6YTAxOGM1NDE2MjZlNGVlNWJlMGNjYmViNzY4OTRiZmFfMy0zLTEtMS03MjAy_79b0afc0-94bc-4593-b6e1-136db647601d">2,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecc81b9b2d6b49b0b19a54a285242744_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85Ny9mcmFnOjFkODkyOWM5YTE1MDQ2NDk5Nzk5N2Y2ZmUzM2Y2MWEyL3RhYmxlOmEwMThjNTQxNjI2ZTRlZTViZTBjY2JlYjc2ODk0YmZhL3RhYmxlcmFuZ2U6YTAxOGM1NDE2MjZlNGVlNWJlMGNjYmViNzY4OTRiZmFfNC0xLTEtMS03MjAy_0f9021d7-7708-43ef-aa02-4d64c144bd83">604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id672da1b89c34c4e9eff23a1f19e2531_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85Ny9mcmFnOjFkODkyOWM5YTE1MDQ2NDk5Nzk5N2Y2ZmUzM2Y2MWEyL3RhYmxlOmEwMThjNTQxNjI2ZTRlZTViZTBjY2JlYjc2ODk0YmZhL3RhYmxlcmFuZ2U6YTAxOGM1NDE2MjZlNGVlNWJlMGNjYmViNzY4OTRiZmFfNC0zLTEtMS03MjAy_5a41fe39-26e5-49c9-87b4-a437946f18e7">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_100"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 6 &#8211; <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90ZXh0cmVnaW9uOmRlNjEyNWI1ZGE2MjQzMDk4OWZlZDc1MTgwNzA2ZDkzXzE1OTU_cea12cf1-ce91-4cb7-96d1-7fd752daa0ba" continuedAt="i0a72f7844f6b482ba33dbf0b0ececb8b" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i0a72f7844f6b482ba33dbf0b0ececb8b"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</span></div><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90ZXh0cmVnaW9uOmRlNjEyNWI1ZGE2MjQzMDk4OWZlZDc1MTgwNzA2ZDkzXzE2MDA_aebce384-b5e6-46f5-8d7b-edb8c5bac5e6" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of December&#160;31, 2021 and December&#160;31, 2020 were as follows (in thousands):</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:21.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9772fdb5cd8471f96f384eb173d43ab_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzMtMi0xLTEtNzIwMg_933a21fd-4ac6-498d-9ce6-1aee9bbdd65d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e392b1e77d4c5eac2465ca78a69cbd_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzMtNC0xLTEtNzIwMg_928b00b0-a92f-4e1d-8a0e-aac9101f0ce1">70,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4584a12f69824f27abd288e3a1a3d90f_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzMtNi0xLTEtNzIwMg_68d667cb-c200-416b-a242-b175b5b6be33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b465f7839c460fad563a663abb5e53_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzMtOC0xLTEtNzIwMg_a982c655-d843-46de-a8f5-43fb8fd54146">70,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5830c986cd0e460abfdcf8d771b6070f_I20201231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzMtMTAtMS0xLTcyMDI_d60691f1-ee0c-4e19-a08f-cbe6393bbe95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b6161f803dd4b47b8ed44fadd5ac665_I20201231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzMtMTItMS0xLTcyMDI_83f4e301-34ca-4e3b-ad20-9e908a5bb04e">18,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c5d1caf1a754f32a2b36182140d1778_I20201231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzMtMTQtMS0xLTcyMDI_6e901d66-ced3-479a-8b09-668763c72318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fda5905c1054d06a90a8cbf51b93a97_I20201231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzMtMTYtMS0xLTcyMDI_ff70e175-15e7-46ff-a78e-6ffeefdacd34">18,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9772fdb5cd8471f96f384eb173d43ab_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzQtMi0xLTEtNzIwMg_4685d3c2-47cc-45e8-8cbf-f9cc199d4b08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e392b1e77d4c5eac2465ca78a69cbd_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzQtNC0xLTEtNzIwMg_5dfa0cb1-93a2-4453-aec0-8ed9bb7427af">70,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4584a12f69824f27abd288e3a1a3d90f_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzQtNi0xLTEtNzIwMg_0491a358-6734-47ee-8d75-38a476c4f1ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b465f7839c460fad563a663abb5e53_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzQtOC0xLTEtNzIwMg_e09c55e7-0bf9-445c-80f0-74c9cf052e54">70,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5830c986cd0e460abfdcf8d771b6070f_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzQtMTAtMS0xLTcyMDI_dca30e38-5f4f-4da4-9b0b-83950227064b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b6161f803dd4b47b8ed44fadd5ac665_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzQtMTItMS0xLTcyMDI_b7b0b64f-40d3-4ba4-8562-24d74a80a264">18,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c5d1caf1a754f32a2b36182140d1778_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzQtMTQtMS0xLTcyMDI_2fb61183-2089-479c-9bbc-a62ab28e108b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fda5905c1054d06a90a8cbf51b93a97_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzQtMTYtMS0xLTcyMDI_4ca19da6-0071-4766-9654-c681fa9e2983">18,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash, cash equivalents, accounts payable and accrued expenses approximate fair value at December&#160;31, 2021 and December&#160;31, 2020, due to the short maturity nature of these items.</span></div></ix:continuation><div><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_103"></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 7&#160;&#8211;&#160;<ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDMvZnJhZzo0M2ZhODNlYjk1NmY0YTVkYTQ3ZTU4NDMxYjU3MGZiNC90ZXh0cmVnaW9uOjQzZmE4M2ViOTU2ZjRhNWRhNDdlNTg0MzFiNTcwZmI0Xzg4_9f85c440-ad81-47cd-b427-4679a819a08e" continuedAt="ia97d312ad3454cb4b0f19030aaf3daf6" escape="true">Accrued Liabilities </ix:nonNumeric></span></div><ix:continuation id="ia97d312ad3454cb4b0f19030aaf3daf6"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDMvZnJhZzo0M2ZhODNlYjk1NmY0YTVkYTQ3ZTU4NDMxYjU3MGZiNC90ZXh0cmVnaW9uOjQzZmE4M2ViOTU2ZjRhNWRhNDdlNTg0MzFiNTcwZmI0XzEwMA_d9cb8a1c-2cf2-4dbb-98ac-fd520fd82586" escape="true"><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities were as follow (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDMvZnJhZzo0M2ZhODNlYjk1NmY0YTVkYTQ3ZTU4NDMxYjU3MGZiNC90YWJsZTpmNzQ0NjA1NWM5YjE0Y2I4OTRkZTk5MGQ2YzhlYzE2Zi90YWJsZXJhbmdlOmY3NDQ2MDU1YzliMTRjYjg5NGRlOTkwZDZjOGVjMTZmXzItMS0xLTEtNzIwMg_01280cd3-4fd5-4fe2-8a9c-4a3904ced28d">2,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDMvZnJhZzo0M2ZhODNlYjk1NmY0YTVkYTQ3ZTU4NDMxYjU3MGZiNC90YWJsZTpmNzQ0NjA1NWM5YjE0Y2I4OTRkZTk5MGQ2YzhlYzE2Zi90YWJsZXJhbmdlOmY3NDQ2MDU1YzliMTRjYjg5NGRlOTkwZDZjOGVjMTZmXzItMy0xLTEtNzIwMg_b6fd3c9a-ac70-4f59-8782-46fbdbcf8856">1,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDMvZnJhZzo0M2ZhODNlYjk1NmY0YTVkYTQ3ZTU4NDMxYjU3MGZiNC90YWJsZTpmNzQ0NjA1NWM5YjE0Y2I4OTRkZTk5MGQ2YzhlYzE2Zi90YWJsZXJhbmdlOmY3NDQ2MDU1YzliMTRjYjg5NGRlOTkwZDZjOGVjMTZmXzMtMS0xLTEtNzIwMg_097e2522-e62f-454f-8377-b11c2327ca84">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDMvZnJhZzo0M2ZhODNlYjk1NmY0YTVkYTQ3ZTU4NDMxYjU3MGZiNC90YWJsZTpmNzQ0NjA1NWM5YjE0Y2I4OTRkZTk5MGQ2YzhlYzE2Zi90YWJsZXJhbmdlOmY3NDQ2MDU1YzliMTRjYjg5NGRlOTkwZDZjOGVjMTZmXzMtMy0xLTEtNzIwMg_188f6f46-60c3-4fd2-999c-0738df01b023">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDMvZnJhZzo0M2ZhODNlYjk1NmY0YTVkYTQ3ZTU4NDMxYjU3MGZiNC90YWJsZTpmNzQ0NjA1NWM5YjE0Y2I4OTRkZTk5MGQ2YzhlYzE2Zi90YWJsZXJhbmdlOmY3NDQ2MDU1YzliMTRjYjg5NGRlOTkwZDZjOGVjMTZmXzUtMS0xLTEtNzIwMg_018ea700-600e-4d34-a0f8-26fdb9588c5d">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDMvZnJhZzo0M2ZhODNlYjk1NmY0YTVkYTQ3ZTU4NDMxYjU3MGZiNC90YWJsZTpmNzQ0NjA1NWM5YjE0Y2I4OTRkZTk5MGQ2YzhlYzE2Zi90YWJsZXJhbmdlOmY3NDQ2MDU1YzliMTRjYjg5NGRlOTkwZDZjOGVjMTZmXzUtMy0xLTEtNzIwMg_d55ffeb6-1602-4d03-ac90-51f28a5b5999">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDMvZnJhZzo0M2ZhODNlYjk1NmY0YTVkYTQ3ZTU4NDMxYjU3MGZiNC90YWJsZTpmNzQ0NjA1NWM5YjE0Y2I4OTRkZTk5MGQ2YzhlYzE2Zi90YWJsZXJhbmdlOmY3NDQ2MDU1YzliMTRjYjg5NGRlOTkwZDZjOGVjMTZmXzYtMS0xLTEtNzIwMg_98abc898-5426-4ec4-8a65-446346556cac">2,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDMvZnJhZzo0M2ZhODNlYjk1NmY0YTVkYTQ3ZTU4NDMxYjU3MGZiNC90YWJsZTpmNzQ0NjA1NWM5YjE0Y2I4OTRkZTk5MGQ2YzhlYzE2Zi90YWJsZXJhbmdlOmY3NDQ2MDU1YzliMTRjYjg5NGRlOTkwZDZjOGVjMTZmXzYtMy0xLTEtNzIwMg_7912595f-5bc7-4ee0-9d16-5a1c763cc38a">2,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i7d049288b82e438c85d504cc3e9dc500_106"></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 8 &#8211; <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90ZXh0cmVnaW9uOjc2NzhiNDM5YjNjYjRiMjk4NmExMDE5OTdiNmY4ZDNjXzEzNTI_0b3742c9-d44c-46f2-990f-9d62571bb2a5" continuedAt="i4fa24cffcd6e41d08312322867ce0738" escape="true">Operating Leases</ix:nonNumeric></span></div><ix:continuation id="i4fa24cffcd6e41d08312322867ce0738"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and recognized leases with duration greater than 12 months on the balance sheet using the modified retrospective approach. The Company has operating leases for <ix:nonFraction unitRef="office" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="INF" name="clbs:NumberOfOfficesUnderOperatingLeases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90ZXh0cmVnaW9uOjc2NzhiNDM5YjNjYjRiMjk4NmExMDE5OTdiNmY4ZDNjXzEzMTk0MTM5NTM0NzE4_03ebe2ec-3da4-4b24-b412-e424ec87823e">two</ix:nonFraction> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ffices with terms that expire in 2023 and 2025, respectively. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. Each of the Company's leases includes options for the Company to extend the lease term and/or sub-lease space in whole or in part.</span></div><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90ZXh0cmVnaW9uOjc2NzhiNDM5YjNjYjRiMjk4NmExMDE5OTdiNmY4ZDNjXzEzNTM_2b2515c7-c597-44c7-9992-ef60afd40c88" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzItMC0xLTEtNzIwMg_0a058abe-d734-4c31-a82c-efb4e8bc4aad"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzItMC0xLTEtNzIwMg_d0558917-552f-48e0-95eb-612098e4b721">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzItMS0xLTEtNzIwMg_67e6fba0-c331-4a84-83df-9a7082db7589">724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzItMi0xLTEtNzIwMg_7440058f-fc57-4ef4-85c4-d14e4992562e">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzMtMS0xLTEtNzIwMg_ea07574d-11d8-4cd0-9497-9cfbc27defe6">724</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzMtMi0xLTEtNzIwMg_8b914bec-45ca-4667-883a-a1eb01929a65">574</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzYtMC0xLTEtNzIwMg_3827fe5c-6ee8-4d37-a233-c3c99088f192"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzYtMC0xLTEtNzIwMg_bfd3c824-688d-44a3-a795-98776d67c466">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzYtMS0xLTEtNzIwMg_12504b25-d517-47fc-b32c-e886be790001">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzYtMi0xLTEtNzIwMg_6cffd52c-ed0a-4a32-a81b-d1732201b8e2">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzctMC0xLTEtNzIwMg_430fdfa5-3899-44a5-b33b-301b103d665c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzctMC0xLTEtNzIwMg_95df09b8-b8ab-49d7-988b-87cfc081e730">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzctMS0xLTEtNzIwMg_888bded4-0151-4e95-897e-2fd53eb5741c">485</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzctMi0xLTEtNzIwMg_26acc78b-ca91-4c07-940d-7c59bdea48c2">254</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzgtMS0xLTEtNzIwMg_6614b690-0296-4cda-bf1f-6389ac740f54">714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzgtMi0xLTEtNzIwMg_20722765-b52e-4a92-81ce-01f7c0b9fc36">624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the weighted average remaining lease term for our operating leases was <ix:nonNumeric contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90ZXh0cmVnaW9uOjc2NzhiNDM5YjNjYjRiMjk4NmExMDE5OTdiNmY4ZDNjXzExNzY_46d3749e-cb26-4bf3-9ca8-812da47f9a47">2.50</ix:nonNumeric> years, and the weighted average discount rate for our operating leases was <ix:nonFraction unitRef="number" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="5" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90ZXh0cmVnaW9uOjc2NzhiNDM5YjNjYjRiMjk4NmExMDE5OTdiNmY4ZDNjXzEyNDg_12508e1c-b4eb-4812-815c-cbd9823bb75d">9.625</ix:nonFraction>%. <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90ZXh0cmVnaW9uOjc2NzhiNDM5YjNjYjRiMjk4NmExMDE5OTdiNmY4ZDNjXzEzNjQ_36d9773f-5fb5-4a32-806d-c4a4aad4a59a" continuedAt="i728dad66d750494abe55196625d5bd55" escape="true">Future minimum lease payments under the lease agreements as of December&#160;31, 2021 were as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:justify"><ix:continuation id="i728dad66d750494abe55196625d5bd55"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.181%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpmOTdlM2E2YmIyNDk0OTI3ODkyOGY4YmFjOGFkMDg5ZC90YWJsZXJhbmdlOmY5N2UzYTZiYjI0OTQ5Mjc4OTI4ZjhiYWM4YWQwODlkXzEtMS0xLTEtNzIwMg_0df7ed8d-4f9b-4971-8e4c-97efc7733bbd">286</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpmOTdlM2E2YmIyNDk0OTI3ODkyOGY4YmFjOGFkMDg5ZC90YWJsZXJhbmdlOmY5N2UzYTZiYjI0OTQ5Mjc4OTI4ZjhiYWM4YWQwODlkXzItMS0xLTEtNzIwMg_5d85e546-ab91-478b-be42-92a577d29725">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpmOTdlM2E2YmIyNDk0OTI3ODkyOGY4YmFjOGFkMDg5ZC90YWJsZXJhbmdlOmY5N2UzYTZiYjI0OTQ5Mjc4OTI4ZjhiYWM4YWQwODlkXzMtMS0xLTEtNzIwMg_258819e6-48b2-409c-a83c-93f17bd5bf82">190</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpmOTdlM2E2YmIyNDk0OTI3ODkyOGY4YmFjOGFkMDg5ZC90YWJsZXJhbmdlOmY5N2UzYTZiYjI0OTQ5Mjc4OTI4ZjhiYWM4YWQwODlkXzQtMS0xLTEtOTQ3NQ_a5f166ab-3e66-4cb6-b8fe-07c3b72df433">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpmOTdlM2E2YmIyNDk0OTI3ODkyOGY4YmFjOGFkMDg5ZC90YWJsZXJhbmdlOmY5N2UzYTZiYjI0OTQ5Mjc4OTI4ZjhiYWM4YWQwODlkXzQtMS0xLTEtNzIwMg_e6c68fae-7f4f-4ae2-ba82-c58a9612746a">836</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpmOTdlM2E2YmIyNDk0OTI3ODkyOGY4YmFjOGFkMDg5ZC90YWJsZXJhbmdlOmY5N2UzYTZiYjI0OTQ5Mjc4OTI4ZjhiYWM4YWQwODlkXzUtMS0xLTEtNzIwMg_0c069fff-175d-42b2-8502-44049a4833fd">122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpmOTdlM2E2YmIyNDk0OTI3ODkyOGY4YmFjOGFkMDg5ZC90YWJsZXJhbmdlOmY5N2UzYTZiYjI0OTQ5Mjc4OTI4ZjhiYWM4YWQwODlkXzYtMS0xLTEtNzIwMg_da76d0d0-549f-45a2-b04a-4437f4d52721">714</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i7d049288b82e438c85d504cc3e9dc500_109"></div><div style="margin-bottom:8pt;text-align:justify;text-indent:14.4pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 9 &#8211; <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEzMTkw_2aba03d8-c95f-4670-8d06-732a61120cbc" continuedAt="ifc4fb9f220c2463198a4de7cb73eb51f" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="ifc4fb9f220c2463198a4de7cb73eb51f" continuedAt="i104c3be9c3a344fe8c75b6d2c1298115"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has used long-term incentive plans for the purpose of granting equity awards to employees of the Company, including officers, and nonemployees, including consultants and nonemployee members of the Company's board of directors </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><ix:continuation id="i104c3be9c3a344fe8c75b6d2c1298115" continuedAt="i21375e848d2b474ebff4390a463d1e27"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(collectively, the &#8220;Participants&#8221;). The Participants may receive awards as determined by a committee of independent members of the Company's board of directors or, to the extent authorized by such committee with respect to certain Participants, a duly authorized employee (collectively, the &#8220;Committee&#8221;). The incentive plan currently used by the Company is the 2018 Equity Incentive Compensation Plan (the &#8220;2018 Plan&#8221;), as adopted by the stockholders of the Company in June 2018, and subsequently increased by the stockholders of the Company in June 2021 with <ix:nonFraction unitRef="shares" contextRef="ia3d14c5a5f224864ad0dabc919f68696_I20210630" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzExNTQ0ODcyMTIyNDc5_82c8b080-8a01-4e56-8a86-ac5a49d3b685">6,000,000</ix:nonFraction> shares authorized for issuance thereunder and in June of 2020 with&#160;<ix:nonFraction unitRef="shares" contextRef="ic520fa50fa274ec688df80ce26839e93_I20200630" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzg1Mw_cb905265-4cef-486f-94bd-0c603e7d8524">2,500,000</ix:nonFraction>&#160;shares authorized for issuance thereunder, plus any shares awarded under the 2015 Equity Compensation Plan (the &#8220;2015 Plan&#8221;) or the Amended and Restated 2009 Equity Compensation Plan (the &#8220;2009 Plan&#8221;) that are not issued due to their subsequent forfeiture, cancellation, or other settlement thereof. Concurrent with the adoption of the 2018 Plan, no future awards will occur under the 2015 Plan or the 2009 Plan. The awards that may be made under the 2018 Plan include: (a) incentive stock options and nonqualified stock options, (b) shares of restricted stock, (c) restricted stock units, and (d) other kinds of equity-based compensation awards. All stock options under the 2015 Plan and 2009 Plan were granted and the 2018 Plan are granted at the fair market value of the common stock at the grant date. Stock options vest either on the date of grant, ratably over a period determined at time of grant, or upon the accomplishment of specified business milestones, and generally expire <ix:nonNumeric contextRef="ib349cdd63be447d58d8816ef0e5c45d5_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzE4NDM_bf3f8212-5857-4cf5-b49e-3b0293972592">2</ix:nonNumeric>, <ix:nonNumeric contextRef="i6839ac3846014921bbf0418907b17b41_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzE4NDc_7f945314-5677-480e-a45e-2d71d84614f2">3</ix:nonNumeric>, or <ix:nonNumeric contextRef="i5c3abe0816124623859688fce308ef7d_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzE4NTQ_58eb4cf1-7da6-42c5-8fa2-cab4eed49b80">10</ix:nonNumeric> years from the grant date depending on the status of the recipient as a nonemployee, employee or director of the Company. As of December&#160;31, 2021, there were&#160;<ix:nonFraction unitRef="shares" contextRef="i4ea30e24d2234509b67b4bb09c8f3d27_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzIwMDA_73ee18ba-915e-472a-9d62-7da83bf5c1d3">5,585,661</ix:nonFraction>&#160;shares available for future grants under the 2018 Plan.&#160;No&#160;additional awards may be made under the 2015 Plan or the 2009 Plan.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted an employee stock purchase plan effective January 1, 2013 and authorized <ix:nonFraction unitRef="shares" contextRef="i125c01a6899241f092b94c8c6d510bcb_I20130101" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzIyMjM_8207457e-ec9a-453e-ba1c-886c6773ef92">50,000</ix:nonFraction> shares under the plan (the &#8220;2012 ESPP&#8221;). The plan has <ix:nonFraction unitRef="offering_period" contextRef="id2c17509e40c431c93f98142b8bee4f8_I20211231" decimals="INF" name="clbs:NumberofOfferingPeriodsEmployeeStockPurchasePlan" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzIyODA_125a1e10-30e1-44e8-aae8-51a0b59af823">two</ix:nonFraction> <ix:nonNumeric contextRef="i28542dcef1334e33863c7a40beba93ac_D20210101-20211231" name="clbs:OfferingPeriodsEmployeeStockPurchasePlanTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEzMTky_93a11fc7-235b-4dfa-bf6b-1caa2890a015">six-month</ix:nonNumeric> offering periods per year under which eligible employees may contribute up to <ix:nonFraction unitRef="number" contextRef="i28542dcef1334e33863c7a40beba93ac_D20210101-20211231" decimals="2" name="clbs:EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzIzNzA_2cbcbcc3-01d2-42e6-b2d1-0540d38b88a6">15</ix:nonFraction>% of their compensation toward the purchase of the Company's common stock per offering period (with a $<ix:nonFraction unitRef="usd" contextRef="i28542dcef1334e33863c7a40beba93ac_D20210101-20211231" decimals="0" name="clbs:EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzI0NzM_89a3288c-3122-45a0-acea-ea824d8a188f">25,000</ix:nonFraction> cap per calendar year). The employee's purchase price is equal to (i) <ix:nonFraction unitRef="number" contextRef="i28542dcef1334e33863c7a40beba93ac_D20210101-20211231" decimals="2" name="clbs:EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzI1NDY_215ec332-2d51-4323-9e90-fb1bf5e3c00d">85</ix:nonFraction>% of the closing price of a share of the Company's common stock on the enrollment date of such offering period or (ii) <ix:nonFraction unitRef="number" contextRef="i28542dcef1334e33863c7a40beba93ac_D20210101-20211231" decimals="2" name="clbs:EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzI2NjY_39249a8d-1d53-4e0d-8097-ec322bd17571">85</ix:nonFraction>% of the closing price of a share of the Company's common stock on the Exercise Date of such Offering Period, whichever is lower. In May 2017, the Company's stockholders approved an amendment and restatement to the 2012 ESPP (the &#8220;2017 ESPP&#8221;) in order to effect an increase of authorized shares from <ix:nonFraction unitRef="shares" contextRef="i125c01a6899241f092b94c8c6d510bcb_I20130101" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzI5Njc_e7bb43dc-d53f-4312-986e-dc131419bb3b">50,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="i5adb43718d3c4cdf96885dcfb77648d0_I20170531" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzI5NzM_df3035da-e391-497f-bc28-9106dc6fa804">100,000</ix:nonFraction>. In June 2018, the Company's stockholders approved an amendment to the 2017 ESPP  (the &#8220;Amended 2017 ESPP&#8221;) in order to effect an increase of authorized shares from <ix:nonFraction unitRef="shares" contextRef="i5adb43718d3c4cdf96885dcfb77648d0_I20170531" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzMxNDE_6a3d5561-43a2-4a37-aa51-e51acf18220d">100,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="ia54075aa02684beb8ab89afa65b0d48d_I20200630" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzMxNDc_4ccb7d6b-371e-4b2f-86e0-4936b71d4e69">500,000</ix:nonFraction>. During the year ended December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="i27caf2e77bc5468785bb299e95eb6191_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzMxNzc_7c4314da-1f68-4354-b737-00dea991ed2b">47,132</ix:nonFraction> shares were issued under the Amended 2017 ESPP. At December&#160;31, 2021, the Company had <ix:nonFraction unitRef="shares" contextRef="i81fbec32b886419d9100b66971330fc6_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzMyNTE_d15841e1-b535-4e4a-a03a-1dc4596c5836">300,577</ix:nonFraction> shares of the Company's common stock available for future grant in connection with this plan.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Issuances</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Agreement </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March&#160;2019, the Company and Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&#8217;s common stock having an aggregate value of up to $<ix:nonFraction unitRef="usd" contextRef="iaffc3258262f48dcbbf5775b82cf558e_I20190331" decimals="-5" name="clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzM3NDA_85ecf67c-b140-443d-87f1-9dd6f952d062">26.0</ix:nonFraction> million, subject to certain limitations and conditions set forth in the Purchase Agreement (the &#8220;Offering&#8221;). As consideration for entering into the Purchase Agreement, the Company issued to Lincoln Park an additional <ix:nonFraction unitRef="shares" contextRef="iec24a6e53385419d9edb327599fc7c12_D20190301-20190331" decimals="INF" name="clbs:StockIssuedDuringPeriodSharesIssuedAsConsideration" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzM5NTI_688ec698-7550-462e-8db0-2d42afad7551">181,510</ix:nonFraction> shares of common stock as commitment shares.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Purchase Agreement, upon commencement Lincoln Park purchased <ix:nonFraction unitRef="shares" contextRef="iec24a6e53385419d9edb327599fc7c12_D20190301-20190331" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzQwNTk_1d5cbe89-b0ff-4903-9d30-fa832dde5db5">250,000</ix:nonFraction> shares of common stock, at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iaffc3258262f48dcbbf5775b82cf558e_I20190331" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzQxMDA_3f75bbd1-fdae-4ba7-981c-7f16b5b12d55">4.00</ix:nonFraction> per share for a total gross purchase price of $<ix:nonFraction unitRef="usd" contextRef="iec24a6e53385419d9edb327599fc7c12_D20190301-20190331" decimals="0" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzQxNTA_7ff27509-0a85-4ba5-9929-796738f4a207">1,000,000</ix:nonFraction> (the &#8220;Initial Purchase&#8221;) upon commencement. Thereafter, as often as every business day from and after one business day following the date of the Initial Purchase and over the <ix:nonNumeric contextRef="iec24a6e53385419d9edb327599fc7c12_D20190301-20190331" name="clbs:TermOfAgreement" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzQzMjg_67e9b392-b372-49ee-bc29-c6ecf221a648">36</ix:nonNumeric>-month term of the Purchase Agreement, the Company has the right, from time to time, at its sole discretion and subject to certain conditions, to direct Lincoln Park to purchase up to <ix:nonFraction unitRef="shares" contextRef="iaffc3258262f48dcbbf5775b82cf558e_I20190331" decimals="INF" name="clbs:SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzQ1MTM_82aad2e0-b6de-4ac1-9f0a-cfaaef15cfc6">100,000</ix:nonFraction> shares of common stock, with such amount increasing as the closing sale price of the common stock increases; provided Lincoln Park&#8217;s obligation under any single such purchase will not exceed $<ix:nonFraction unitRef="usd" contextRef="iaffc3258262f48dcbbf5775b82cf558e_I20190331" decimals="INF" name="clbs:SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzQ3MDc_72825566-cdb3-4d9e-ab7f-52597399803c">2,500,000</ix:nonFraction>, unless the Company and Lincoln Park mutually agree to increase the maximum amount of such single purchase (each, a &#8220;Regular Purchase&#8221;).&#160;If the Company directs Lincoln Park to purchase the maximum number of shares of common stock it then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, the Company may direct Lincoln Park in an &#8220;accelerated purchase&#8221; to purchase an additional amount of common stock that may not exceed the lesser of (i)&#160;<ix:nonFraction unitRef="number" contextRef="iaffc3258262f48dcbbf5775b82cf558e_I20190331" decimals="2" name="clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzUyNTI_00967e5a-cd9d-4121-9bb3-714a456e01c4">300</ix:nonFraction>% the number of shares purchased pursuant to the corresponding Regular Purchase or (ii)&#160;<ix:nonFraction unitRef="number" contextRef="iaffc3258262f48dcbbf5775b82cf558e_I20190331" decimals="2" name="clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzUzNDI_23790afb-f07b-4c89-9edb-2724f82bc4c8">30</ix:nonFraction>% of the total number of shares of the Company&#8217;s common stock traded during a specified period on the applicable purchase date as set forth in the Purchase Agreement (each, an "Accelerated Purchase"). Under certain circumstances and in accordance with the Purchase Agreement, the Company may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company controls the timing and amount of any sales of its common stock to Lincoln Park.&#160;There is no upper limit on the price per share that Lincoln Park must pay for its common stock under the Purchase Agreement, but in no event will shares be sold to Lincoln Park on a day the closing price is less than the floor price specified in the Purchase Agreement. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the purchase agreement if it would result in Lincoln Park beneficially owning more than <ix:nonFraction unitRef="number" contextRef="iaffc3258262f48dcbbf5775b82cf558e_I20190331" decimals="4" name="clbs:RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzYyNDI_5a5e52c4-b15d-4957-9346-228b08b56198">9.99</ix:nonFraction>% of its common stock.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><ix:continuation id="i21375e848d2b474ebff4390a463d1e27" continuedAt="ic3b72ebc58284341863a2f3c7392c16d"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Purchase Agreement does not limit the Company&#8217;s ability to raise capital from other sources at the Company&#8217;s sole discretion, except that (subject to certain exceptions) the Company may not enter into any Variable Rate Transaction (as defined in the Purchase Agreement, including the issuance of any floating conversion rate or variable priced equity-like securities) during the <ix:nonNumeric contextRef="iec24a6e53385419d9edb327599fc7c12_D20190301-20190331" name="clbs:TermOfAgreement" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzExNTQ0ODcyMTIyNDk5_167e26bc-c393-465c-bf6a-e000860bccd9">36</ix:nonNumeric> months after the date of the Purchase Agreement. The Company has the right to terminate the Purchase Agreement at any time, at no cost to the Company.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had not made any sales of common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase. In addition, the Company may not direct Lincoln Park to make Accelerated Purchases under the Purchase Agreement if the stock is below the specified floor price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic5e26195328b4591826e01006d17f63d_I20211231" decimals="2" name="clbs:PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzExNTQ0ODcyMTIyNTA2_e37210eb-e498-4550-a025-b790bb67bb33">1.00</ix:nonFraction>.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock Sales Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a common stock sales agreement with H.C. Wainwright &amp; Co., LLC (&#8220;HCW&#8221;) as sales agent, which was subsequently amended in August 2018 (the &#8220;Sales Agreement&#8221;), in connection with an &#8220;at the market offering&#8221; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of not more than $<ix:nonFraction unitRef="usd" contextRef="ib0ab769fd5384e5c8fa1c574d03e7274_I20180831" decimals="INF" name="clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzczNjA_5b53ccb0-df8b-4556-be14-f5eda6181020">25.0</ix:nonFraction> million. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provided HCW with customary indemnification rights, and HCW was entitled to a commission at a fixed commission rate equal to <ix:nonFraction unitRef="number" contextRef="i18cb5d7872684b26a43eaec5bc10e4bb_D20180801-20180831" decimals="INF" name="clbs:SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzE2NDkyNjc0NTUwMTM_c45cbe6c-8803-4e02-b6c6-310d2a2d40de">3.0</ix:nonFraction>% of the gross proceeds per share sold. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, the Company suspended the use of the at-the-market transactions facility and terminated the continuous offering pursuant to the Sales Agreement.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of the termination of the Sales Agreement on February 12, 2021, the Company had sold an aggregate <ix:nonFraction unitRef="shares" contextRef="ibe7b2ea590f64edea9436bb291dddfe3_D20180201-20210212" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzkwMTI_ea10e8b6-0e66-4400-89b1-adafe286b068">3,784,912</ix:nonFraction> shares of its common stock pursuant to the Sales Agreement for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ibe7b2ea590f64edea9436bb291dddfe3_D20180201-20210212" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzkwODQ_c976dbd6-5aba-4694-a206-182bc0fbe86f">9.5</ix:nonFraction> million since inception. For the year ended December&#160;31, 2021, the Company had <ix:nonFraction unitRef="shares" contextRef="i2959d4ff885948268aa6c8327cf31262_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzE2NDkyNjc0NTgxOTI_eedf1093-0a2b-41b9-96d3-5c5e6ff5d202">no</ix:nonFraction>t issued any shares under the Sales Agreement.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">At The Market Offering Agreement</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with HCW, as sales agent, in connection with an &#8220;at the market offering&#8221; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="ib26b46410f1947caaa269dc8c84bc533_I20210604" decimals="-5" name="clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzE2NDkyNjc0NTg4NzA_029b0950-b37d-4632-aea8-90059bd9ad7c">50.0</ix:nonFraction>&#160;million. During the twelve months ended December&#160;31, 2021, the Company had <ix:nonFraction unitRef="shares" contextRef="ieba8f73a7897435fbc5b3392cb6478cf_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzE2NDkyNjc0NTg5MTI_c15f1bcc-a80e-4c22-9fa3-85ddf3a8fdf0">no</ix:nonFraction>t issued any shares under the ATM Agreement. Having received a listing deficiency notice from Nasdaq on February 18, 2022 after the Company&#8217;s shares traded below $1.00 for 30 consecutive trading days, the Company will not be permitted to sell additional shares under the ATM Agreement until it re-establishes timely compliance. Compliance may be reestablished by various mechanisms, including stock price appreciation at or above $1.00 for a requisite period of time and reverse stock split.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Registered Direct Offerings</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company entered into a Securities Purchase Agreement (the &#8220;Institutional Purchase Agreement&#8221;) with certain institutional investors (the &#8220;Institutional Purchasers&#8221;). Pursuant to the terms of the Institutional Purchase Agreement, the Company sold to the Institutional Purchasers in a registered direct offering an aggregate of <ix:nonFraction unitRef="shares" contextRef="i1ba1e218994d4ff1b3b3d3cdd3ea83a2_D20210201-20210228" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI4NzI_cdf3c1b4-e789-4c96-bff5-7d76064a6dee">24,906,134</ix:nonFraction> shares of its common stock and warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i9992345fcbc5433492a910eba1965518_I20210228" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI4NzY_ae35b36a-70b9-45aa-bf1d-2101ec3d9181">12,453,067</ix:nonFraction> shares of its common stock at a combined purchase price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i9992345fcbc5433492a910eba1965518_I20210228" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI4ODA_e7c0a4cb-1b28-46c0-8f1d-6bddab46191b">2.45</ix:nonFraction> per share and associated warrant. Each warrant features an exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i9992345fcbc5433492a910eba1965518_I20210228" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI4ODQ_259ce8c1-e2c5-466e-a908-67c117370bf8">2.90</ix:nonFraction> per share, is exercisable immediately upon issuance and will expire <ix:nonNumeric contextRef="i9992345fcbc5433492a910eba1965518_I20210228" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI4ODg_07e3bff7-36ba-45df-90d8-f487b55e725d">five years</ix:nonNumeric> from the issuance date. Additionally, in a concurrent non-brokered registered direct offering, the Company entered into a Securities Purchase Agreement (the &#8220;Additional Purchase Agreement&#8221;) with certain accredited investors (the &#8220;Additional Purchasers&#8221;). Pursuant to the terms of the Additional Purchase Agreement, the Company sold to the Additional Purchasers an aggregate of <ix:nonFraction unitRef="shares" contextRef="ib537ee905795476eb1a4ed13cf5100b1_D20210201-20210228" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI4OTI_d006e41d-39b9-4360-9e15-6ca8d0bc1565">1,632,652</ix:nonFraction> shares of its common stock and warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i064784dc58ac445ab8485a53331724c5_I20210228" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI4OTY_2a7eaa33-e662-4643-acfd-9971e2e62e92">816,326</ix:nonFraction> shares of its common stock at a combined purchase price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i064784dc58ac445ab8485a53331724c5_I20210228" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI5MDA_c1fd4c93-bbb1-479f-b51e-381e17085251">2.45</ix:nonFraction> per share and associated warrant. Each warrant features an exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i064784dc58ac445ab8485a53331724c5_I20210228" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI5MDQ_c4614554-7008-4cdd-928b-1b97f2827e4c">2.90</ix:nonFraction> per share, is exercisable immediately upon issuance and will expire <ix:nonNumeric contextRef="i064784dc58ac445ab8485a53331724c5_I20210228" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI5MDg_af8cc0b7-0a27-44b1-962c-2cdcecf3ba00">five years</ix:nonNumeric> from the issuance date. In connection with the registered direct offerings, the Company received gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i39237a1f42304c68bc922379c5cafbc9_D20210201-20210228" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI5MTI_f9fbf785-9e09-42bc-afbc-fedc850504f9">65.0</ix:nonFraction> million.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Private Placement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a securities purchase agreement (the &#8220;January Private Placement&#8221;) with certain investors (the &#8220;January Purchasers&#8221;). Pursuant to the terms of the January Private Placement, the Company agreed to sell to the January Purchasers an aggregate of <ix:nonFraction unitRef="shares" contextRef="ic237f5a9d962463dab8bf38d6a802419_D20210101-20210131" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTQzOTE_5ea8a029-bc59-4004-a7a8-8d8d82220bc2">12,500,000</ix:nonFraction> shares of its common stock at a purchase price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i58d1afa2bd9346fc97c1b81a5e0a4fd1_I20210131" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTQzOTU_514623fb-e1ef-4166-907c-b56959ed171d">2.00</ix:nonFraction> per share, along with warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i58d1afa2bd9346fc97c1b81a5e0a4fd1_I20210131" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTQzOTk_84f5e517-c1db-487c-b420-b34c828c6559">6,250,000</ix:nonFraction> shares of its common stock. In connection with the January Private Placement, the Company received gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ic237f5a9d962463dab8bf38d6a802419_D20210101-20210131" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTQ0MDM_00917366-6416-401f-9af1-5bd33b8ebdab">25.0</ix:nonFraction> million. Each warrant is exercisable for <ix:nonFraction unitRef="shares" contextRef="i58d1afa2bd9346fc97c1b81a5e0a4fd1_I20210131" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzE2NDkyNjc0NjM0MTQ_eea51aad-e0d9-4474-8457-dfd1b025f56e">one</ix:nonFraction> share of common stock </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><ix:continuation id="ic3b72ebc58284341863a2f3c7392c16d" continuedAt="i090cb7e6ee124947b1d96aa2be7d8431"><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and features an exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i58d1afa2bd9346fc97c1b81a5e0a4fd1_I20210131" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTQ0MDk_4850fb8b-cd3a-4c3c-86eb-273a37c399cd">2.90</ix:nonFraction> per share. The warrants are exercisable immediately upon issuance and will expire five and one-half years from the issuance date.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Exercises</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="i82ea1a2d86944a1c93f15ae19da0bc8e_D20210101-20210131" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTU1ODQ_ce13a409-47cc-4c3d-8e03-b326b05eb60f">801,148</ix:nonFraction> shares of common stock for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i82ea1a2d86944a1c93f15ae19da0bc8e_D20210101-20210131" decimals="-5" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTU1ODg_ef5de574-1cf5-4742-b20a-ec27ec9d630e">1.8</ix:nonFraction> million in connection with warrant exercises associated with the April 23, 2020 securities purchase agreement and the May 25, 2020 securities purchase agreement.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Warrants</span></div><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEzMTgx_38fa45d3-824d-45b3-907c-f4e099edbd82" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for stock options and warrants for the year ended December&#160;31, 2021:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:22.248%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.716%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzItMS0xLTEtNzIwMg_e0efc85e-e4c5-4a91-9e82-87c2d60a3aad">963,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzItMy0xLTEtNzIwMg_edf03c84-799a-451e-b993-998ea36731d2">14.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzItNS0xLTEtNzIwMg_9f6aae10-39b2-47ef-8f7a-b4151d8464f7">5.86</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzItNy0xLTEtNzIwMg_4800b5bd-4fb8-42fe-8f86-b20f3b0de18f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="INF" name="clbs:CommonStockWarrantsShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzItOS0xLTEtNzIwMg_8fb13ff1-9331-4f08-b685-95f8522b6e82">2,638,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzItMTEtMS0xLTcyMDI_6df2a77f-9409-41ee-8e26-ec8365f51be9">2.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" name="clbs:WeightedAverageRemainingContractualTermwarrantoutstanding" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzItMTMtMS0xLTcyMDI_d41143c6-36f0-44fa-abbf-f9ee4c367dd3">4.98</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="clbs:AggregateIntrinsicValueWarrantsOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzItMTUtMS0xLTcyMDI_c21a3efe-2a22-4cf4-88ed-73d302731aff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the Year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzUtMS0xLTEtNzIwMg_22ff3b5f-37f3-439a-a81b-be65437a83fe">1,314,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzUtMy0xLTEtNzIwMg_cb37a7a2-acde-474c-aacd-566c1acfc19f">1.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="INF" name="clbs:WarrantsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzUtOS0xLTEtNzIwMg_8991cdd2-2e10-441a-b72c-f071e6bc589d">19,519,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzUtMTEtMS0xLTcyMDI_b1f7ffef-ae0f-4eaa-a0bf-381d490d1d27">2.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzYtMS0xLTEtNzIwMg_cc251a3d-1331-4d08-9811-583c57308634">7,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzYtMy0xLTEtNzIwMg_1b49e23c-ddd4-4122-9b38-a64756b0c4e5">3.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="clbs:AggregateIntrinsicValueOptionExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzYtNy0xLTEtODcxNQ_d7419e73-1b49-44f3-84bf-a60245056e0d">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="INF" name="clbs:WarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzYtOS0xLTEtNzIwMg_1a482080-e0fb-40d4-aec5-c4764386decc">801,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzYtMTEtMS0xLTcyMDI_5d2945c4-62f2-487b-9ce9-48972e23a364">2.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzctMS0xLTEtNzIwMg_efeb9dbe-ad0f-45ee-8775-9215f0fabf8f">29,842</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzctMy0xLTEtNzIwMg_992f4862-d2d9-4984-8963-f5ce4575e416">2.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="INF" name="clbs:WarrantsCanceled" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzctOS0xLTEtNzIwMg_895f6527-726c-4bcd-8706-df906e9cfffc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsCanceled" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzctMTEtMS0xLTcyMDI_f6bc8693-d475-4d7a-ae51-068658164a73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzgtMS0xLTEtNzIwMg_063577c7-6d1b-497c-98b0-c146e8d490e2">109,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzgtMy0xLTEtNzIwMg_47e4dc5a-abac-4ef0-b486-3fe5688332a4">34.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="INF" name="clbs:WarrantsExpired" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzgtOS0xLTEtNzIwMg_5472e446-a83b-4cb3-8807-f386cb67f33b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsExpired" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzgtMTEtMS0xLTcyMDI_fe172177-f9ad-4a15-bcc4-3ff88ea53184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzktMS0xLTEtNzIwMg_0ac24c13-0b36-4e6d-a873-017c470bb83d">2,131,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzktMy0xLTEtNzIwMg_998bd3e3-7d9e-4cb4-97ac-caa29895963e">5.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzktNS0xLTEtNzIwMg_b08a03c5-6dc9-4f69-876c-b1ad67140591">7.97</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzktNy0xLTEtNzIwMg_0bd2a6d8-908f-4908-aeb8-d311b9d2bdc7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="INF" name="clbs:CommonStockWarrantsShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzktOS0xLTEtNzIwMg_2c612eea-3c3b-4e03-9817-c48182b5b476">21,356,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzktMTEtMS0xLTcyMDI_c75965c3-2647-4c62-9d24-e20342ad2f2c">2.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="clbs:WeightedAverageRemainingContractualTermwarrantoutstanding" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzktMTMtMS0xLTcyMDI_613da3a1-438a-4b6b-9a5f-a90c17bbe741">4.37</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="clbs:AggregateIntrinsicValueWarrantsOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzktMTUtMS0xLTcyMDI_8586a7b1-f426-419f-a928-889fdb2de997">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at December 31, 2021 or expected to vest in the future</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzEwLTEtMS0xLTcyMDI_dd67c59a-ca98-4863-831a-acbed45bffda">2,120,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzEwLTMtMS0xLTcyMDI_ce503352-9511-4712-aee4-e21c74794438">5.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzEwLTUtMS0xLTcyMDI_25741715-9ab6-4d3d-a165-10b495f8e4ac">7.96</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzEwLTctMS0xLTcyMDI_25866074-ccdd-490d-8179-0bdb7f652cb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="INF" name="clbs:Sharesvestedandexpectedtovest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzEwLTktMS0xLTcyMDI_3bedcc28-4435-4bd9-a8c1-754c880f0a9c">21,356,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzEwLTExLTEtMS03MjAy_86e624a8-a0e8-4d3e-9575-1477d413ef98">2.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="clbs:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzEwLTEzLTEtMS03MjAy_61e3e56b-4fb2-4f3c-a15b-8b0128095d77">4.37</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="clbs:AggregateIntrinsicValueWarrantsvestedandexpectedtovest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzEwLTE1LTEtMS03MjAy_29ca8cb6-c4a4-419c-88c8-b01cff9a8c11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzExLTEtMS0xLTcyMDI_0dd2d2ae-6e3e-4c1d-a263-fc010bd1e322">1,122,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzExLTMtMS0xLTcyMDI_7b73cd2f-c715-48b9-b591-c8df3d38da7f">9.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzExLTUtMS0xLTcyMDI_c856564e-618a-4c0f-8d22-c5f1a55685a8">6.70</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzExLTctMS0xLTcyMDI_bab381b0-6c7f-4f25-8614-e123f15ff3ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="INF" name="clbs:WarrantsVested" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzExLTktMS0xLTcyMDI_768cf14e-60ad-4fc4-b8be-313f73235d33">21,356,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzExLTExLTEtMS03MjAy_a1ef60d8-ea71-4a94-9c68-37067953b60f">2.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="clbs:WeightedAverageRemainingContractualTermwarrantsvested" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzExLTEzLTEtMS03MjAy_a6eafec9-8f0f-4592-836b-f99e1a5b0bae">4.37</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="clbs:AggregateIntrinsicValueWarrantsvested" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzExLTE1LTEtMS03MjAy_d87af769-964e-4238-8ad8-35fe8f5a93e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEzMTgz_bf559167-9e78-4adc-8996-9adabde0d729" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the Company issued restricted stock for services as follows ($ in thousands, except share data):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:69.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.187%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Restricted Stock Issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6d2e0cb9f694fe7a859d47739e7393e_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTpjOTQ5ODlmN2MwNTk0ZGQ0OGEyZjRjMmIzMTcxYzg3OS90YWJsZXJhbmdlOmM5NDk4OWY3YzA1OTRkZDQ4YTJmNGMyYjMxNzFjODc5XzItMS0xLTEtNzIwMg_f73618ee-0faf-4c65-828e-7783f3cbc535">612,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i806c337fb61d4e69a7df6495c7be9795_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTpjOTQ5ODlmN2MwNTk0ZGQ0OGEyZjRjMmIzMTcxYzg3OS90YWJsZXJhbmdlOmM5NDk4OWY3YzA1OTRkZDQ4YTJmNGMyYjMxNzFjODc5XzItMy0xLTEtNzIwMg_d1f72a05-1e70-4296-bbc9-54ae187bd515">156,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of Restricted Stock Issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6d2e0cb9f694fe7a859d47739e7393e_D20210101-20211231" decimals="-2" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTpjOTQ5ODlmN2MwNTk0ZGQ0OGEyZjRjMmIzMTcxYzg3OS90YWJsZXJhbmdlOmM5NDk4OWY3YzA1OTRkZDQ4YTJmNGMyYjMxNzFjODc5XzMtMS0xLTEtNzIwMg_b7b861b7-c97a-49fc-8c07-313d3b2ab36d">877.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i806c337fb61d4e69a7df6495c7be9795_D20200101-20201231" decimals="-2" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTpjOTQ5ODlmN2MwNTk0ZGQ0OGEyZjRjMmIzMTcxYzg3OS90YWJsZXJhbmdlOmM5NDk4OWY3YzA1OTRkZDQ4YTJmNGMyYjMxNzFjODc5XzMtMy0xLTEtNzIwMg_c7670a38-665e-49df-b3e1-8e010f20ccb1">512.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average estimated fair value of restricted stock issued for services in the years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ib6d2e0cb9f694fe7a859d47739e7393e_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzMyOTg1MzQ5MTIyMTU_4736de4c-747c-4ddc-bb04-6523131c1c50">1.43</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i806c337fb61d4e69a7df6495c7be9795_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzMyOTg1MzQ5MTIyMTA_93e6ac87-e810-4064-a7b8-a74f392d32b5">3.28</ix:nonFraction> per share, respectively. The fair value of the restricted stock was determined using the Company&#8217;s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEyNTk4_1483d86e-ff2f-4b87-a4f3-f6e1bf4d50d7">one</span> to <ix:nonNumeric contextRef="i079cc5701e904396b3b89403166d381c_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEyNjA0_b5c38a3e-c0ac-4d9c-b43c-77448f89e169">four years</ix:nonNumeric>.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEzMTc2_6da9cf63-35c3-4f13-a0c6-64cbb9a8587a" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the Company issued restricted stock units for services as follows ($ in thousands, except share data):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:69.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.187%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Restricted Stock Units Issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60f3653ff42d4f0eaacf9c26102cfd38_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTpiZmRmODk2NGYwYjM0ZDViYjc4OTU3YTIwZjBmN2Y0NS90YWJsZXJhbmdlOmJmZGY4OTY0ZjBiMzRkNWJiNzg5NTdhMjBmMGY3ZjQ1XzItMS0xLTEtNzIwMg_a74a8be9-f9cc-4e9a-b7ce-a33e2b077d86">458,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6bbaca2f02cc464a87710b12e3b26046_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTpiZmRmODk2NGYwYjM0ZDViYjc4OTU3YTIwZjBmN2Y0NS90YWJsZXJhbmdlOmJmZGY4OTY0ZjBiMzRkNWJiNzg5NTdhMjBmMGY3ZjQ1XzItMy0xLTEtNzIwMg_a35fe29e-c059-4033-a1f7-812ba82df58f">325,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of Restricted Stock Units Issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60f3653ff42d4f0eaacf9c26102cfd38_D20210101-20211231" decimals="-2" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTpiZmRmODk2NGYwYjM0ZDViYjc4OTU3YTIwZjBmN2Y0NS90YWJsZXJhbmdlOmJmZGY4OTY0ZjBiMzRkNWJiNzg5NTdhMjBmMGY3ZjQ1XzMtMS0xLTEtNzIwMg_62dde020-0189-4a8d-949e-4f39de031fed">728.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bbaca2f02cc464a87710b12e3b26046_D20200101-20201231" decimals="-2" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTpiZmRmODk2NGYwYjM0ZDViYjc4OTU3YTIwZjBmN2Y0NS90YWJsZXJhbmdlOmJmZGY4OTY0ZjBiMzRkNWJiNzg5NTdhMjBmMGY3ZjQ1XzMtMy0xLTEtNzIwMg_45cf5a9e-c51e-4514-92e0-009959acc038">863.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average estimated fair value of restricted stock units issued for services in the years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i60f3653ff42d4f0eaacf9c26102cfd38_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEyODc1_c6dab52a-d428-4d5b-82b4-0dc1136149a3">1.59</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i6bbaca2f02cc464a87710b12e3b26046_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEyODgy_062154fa-546b-4508-94db-7055e2237528">2.65</ix:nonFraction> per share, respectively. The fair value of the restricted stock units was determined using the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i090cb7e6ee124947b1d96aa2be7d8431">Company&#8217;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally <ix:nonNumeric contextRef="i60f3653ff42d4f0eaacf9c26102cfd38_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEzMTAy_ab5704c6-aff4-42d5-bc6b-d77c43d18e51">one year</ix:nonNumeric>, or upon the achievement of performance-based milestones.</ix:continuation> </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_115"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 10 &#8211; <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90ZXh0cmVnaW9uOjFkYjNlYzgyYWNhNTRlYjg5ZWZjZjhjMjEyYWFkYTFhXzExMjg_1dfd5731-76f0-40a4-97e7-d65d8cce61da" continuedAt="i7f19e3122ccc44c091355e4e58dfcbb2" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i7f19e3122ccc44c091355e4e58dfcbb2"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes share-based compensation in the form of stock options, restricted stock, and restricted stock units. <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90ZXh0cmVnaW9uOjFkYjNlYzgyYWNhNTRlYjg5ZWZjZjhjMjEyYWFkYTFhXzExMzg_99f6d5b9-b8c6-4549-8804-797232e611ec" continuedAt="i7f4b2ffc2364423caa11e56c9f96f889" escape="true">The following table summarizes the components of share-based compensation expense for the years ended December&#160;31, 2021 and 2020 ($ in thousands):</ix:nonNumeric></span></div><ix:continuation id="i7f4b2ffc2364423caa11e56c9f96f889"><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:76.206%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.882%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie912ebfc1b8b4a6aa5f2e375f861d2c2_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkY2E3YTQ4NDE4ZmI0N2Y3OWRmNTllZTAzZmI1MjIwMi90YWJsZXJhbmdlOmRjYTdhNDg0MThmYjQ3Zjc5ZGY1OWVlMDNmYjUyMjAyXzItMS0xLTEtNzIwMg_21551374-2e83-4472-97c2-82e1cd457194">760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca74538c1c54566b186f58a6caf61e1_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkY2E3YTQ4NDE4ZmI0N2Y3OWRmNTllZTAzZmI1MjIwMi90YWJsZXJhbmdlOmRjYTdhNDg0MThmYjQ3Zjc5ZGY1OWVlMDNmYjUyMjAyXzItMy0xLTEtNzIwMg_8a3bbf3a-1ccb-4677-91aa-414df30572cb">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1373d5ad1834c4abef25fae33e3348e_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkY2E3YTQ4NDE4ZmI0N2Y3OWRmNTllZTAzZmI1MjIwMi90YWJsZXJhbmdlOmRjYTdhNDg0MThmYjQ3Zjc5ZGY1OWVlMDNmYjUyMjAyXzMtMS0xLTEtNzIwMg_5a0773db-7e27-4aa7-a614-c30973d1c9cc">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife71a6468a004189ad68cb01a4d67fcf_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkY2E3YTQ4NDE4ZmI0N2Y3OWRmNTllZTAzZmI1MjIwMi90YWJsZXJhbmdlOmRjYTdhNDg0MThmYjQ3Zjc5ZGY1OWVlMDNmYjUyMjAyXzMtMy0xLTEtNzIwMg_82f0dd99-a231-4637-a59d-c4244e4b84c2">1,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkY2E3YTQ4NDE4ZmI0N2Y3OWRmNTllZTAzZmI1MjIwMi90YWJsZXJhbmdlOmRjYTdhNDg0MThmYjQ3Zjc5ZGY1OWVlMDNmYjUyMjAyXzUtMS0xLTEtNzIwMg_67c4ecbe-e33a-4346-94f2-cb4d7dac47e7">2,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkY2E3YTQ4NDE4ZmI0N2Y3OWRmNTllZTAzZmI1MjIwMi90YWJsZXJhbmdlOmRjYTdhNDg0MThmYjQ3Zjc5ZGY1OWVlMDNmYjUyMjAyXzUtMy0xLTEtNzIwMg_a42f4fc1-0562-4a55-9019-9bda9848e303">1,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at December&#160;31, 2021 were as follows ($ in thousands):</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab051a0f20f54b90a2c3a2ae838bb8ca_I20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTo5ZTczYmIwMDRmYTA0ZjhmODZjYWUwN2FkZDY5YjhmYi90YWJsZXJhbmdlOjllNzNiYjAwNGZhMDRmOGY4NmNhZTA3YWRkNjliOGZiXzEtMS0xLTEtNzIwMg_8f237aaf-45aa-4d46-8325-9447378a846b">757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieba28787ca6743bebdb732d522992e81_I20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTo5ZTczYmIwMDRmYTA0ZjhmODZjYWUwN2FkZDY5YjhmYi90YWJsZXJhbmdlOjllNzNiYjAwNGZhMDRmOGY4NmNhZTA3YWRkNjliOGZiXzEtMy0xLTEtNzIwMg_6fa5e7b7-9f76-4bdd-9625-788e4e3d6a98">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8097329850104783b37c8ae588e3f1f5_I20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTo5ZTczYmIwMDRmYTA0ZjhmODZjYWUwN2FkZDY5YjhmYi90YWJsZXJhbmdlOjllNzNiYjAwNGZhMDRmOGY4NmNhZTA3YWRkNjliOGZiXzEtNy0xLTEtNzIwMg_229f723f-c285-4849-9677-1bcc4d87f579">546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1262c5aee83e44218db30c90579c58ff_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTo5ZTczYmIwMDRmYTA0ZjhmODZjYWUwN2FkZDY5YjhmYi90YWJsZXJhbmdlOjllNzNiYjAwNGZhMDRmOGY4NmNhZTA3YWRkNjliOGZiXzItMS0xLTEtNzIwMg_55745c11-dc43-4bbe-8069-c3cb89618666">1.64</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60f3653ff42d4f0eaacf9c26102cfd38_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTo5ZTczYmIwMDRmYTA0ZjhmODZjYWUwN2FkZDY5YjhmYi90YWJsZXJhbmdlOjllNzNiYjAwNGZhMDRmOGY4NmNhZTA3YWRkNjliOGZiXzItMy0xLTEtNzIwMg_e8ec741f-8eeb-4268-b624-24e3caf9509f">1.57</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib6d2e0cb9f694fe7a859d47739e7393e_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTo5ZTczYmIwMDRmYTA0ZjhmODZjYWUwN2FkZDY5YjhmYi90YWJsZXJhbmdlOjllNzNiYjAwNGZhMDRmOGY4NmNhZTA3YWRkNjliOGZiXzItNy0xLTEtNzIwMg_4532583f-3645-4d23-9bba-e16da0f1eceb">1.70</ix:nonNumeric></span></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90ZXh0cmVnaW9uOjFkYjNlYzgyYWNhNTRlYjg5ZWZjZjhjMjEyYWFkYTFhXzExMTQ_2e93c0a7-6a7f-4978-8963-a580edce8e9f" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the years ended December&#160;31, 2021 and 2020 were as follows ($ in thousands):</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:75.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.883%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1262c5aee83e44218db30c90579c58ff_D20210101-20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTo0NDkyMWNmMGMyY2I0NGZkOTk0MGIzZTc3NDc0NzM3ZS90YWJsZXJhbmdlOjQ0OTIxY2YwYzJjYjQ0ZmQ5OTQwYjNlNzc0NzQ3MzdlXzMtMi0xLTEtNzIwMg_0d6b6f19-d7af-498a-89d3-ae4b4d006c9c">757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f25e23ccf5e4e8b9996111cff5b1f1f_D20200101-20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTo0NDkyMWNmMGMyY2I0NGZkOTk0MGIzZTc3NDc0NzM3ZS90YWJsZXJhbmdlOjQ0OTIxY2YwYzJjYjQ0ZmQ5OTQwYjNlNzc0NzQ3MzdlXzMtNC0xLTEtNzIwMg_c6a84fb9-004b-479d-ad24-cdbe4435f8cb">536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1262c5aee83e44218db30c90579c58ff_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTo0NDkyMWNmMGMyY2I0NGZkOTk0MGIzZTc3NDc0NzM3ZS90YWJsZXJhbmdlOjQ0OTIxY2YwYzJjYjQ0ZmQ5OTQwYjNlNzc0NzQ3MzdlXzQtMi0xLTEtNzIwMg_42f7c96f-4adb-4483-a650-7a035ae33d23">0.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2f25e23ccf5e4e8b9996111cff5b1f1f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTo0NDkyMWNmMGMyY2I0NGZkOTk0MGIzZTc3NDc0NzM3ZS90YWJsZXJhbmdlOjQ0OTIxY2YwYzJjYjQ0ZmQ5OTQwYjNlNzc0NzQ3MzdlXzQtNC0xLTEtNzIwMg_97769c79-47aa-4e19-af2b-2b77113ee2ef">2.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Assumptions </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#8217;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. </span></div><div style="margin-bottom:8pt;margin-top:6pt;text-indent:18pt"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90ZXh0cmVnaW9uOjFkYjNlYzgyYWNhNTRlYjg5ZWZjZjhjMjEyYWFkYTFhXzExMTk_2c1984fb-6fe9-44d5-b5dd-ac7f4c3a6edb" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of assumptions made in calculating the fair values of stock options was as follow:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:75.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.191%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - minimum (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iee4c1259461b4d82a4ed9b9423814c93_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzMtMS0xLTEtNzIwMg_af52719d-c37f-42f1-a139-ba639460ad14">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b81cf0af0d549cc9704b163fd97825f_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzMtMy0xLTEtNzIwMg_abf61e9b-c372-43af-a594-5a9f55490f94">6</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - maximum (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0424a8b4b4e74dd6a974d18e483a0683_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzQtMS0xLTEtNzIwMg_530a22c7-7b95-4708-b96c-9d0beb04ae5b">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib31c704f4b3d4411913b83a05612f827_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzQtMy0xLTEtNzIwMg_f596b326-0b37-40bf-8b87-f2de9017ea06">6</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility - minimum</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1262c5aee83e44218db30c90579c58ff_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzUtMS0xLTEtNzIwMg_cbfa6ced-6d3a-445e-bda1-b8f1a9987b2a">79</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f25e23ccf5e4e8b9996111cff5b1f1f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzUtMy0xLTEtNzIwMg_61c6b8a6-0e15-4ed6-9b34-b3cb0babd9fc">75</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility - maximum</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1262c5aee83e44218db30c90579c58ff_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzYtMS0xLTEtNzIwMg_19e3e3dc-b04a-42c9-94b2-3f7fcf682e45">84</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f25e23ccf5e4e8b9996111cff5b1f1f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzYtMy0xLTEtNzIwMg_1fd4629c-e4ab-46c4-93e6-3632383f1fdf">79</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1262c5aee83e44218db30c90579c58ff_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzctMS0xLTEtNzIwMg_41f69a6c-7500-4401-bdbd-4ca23cbe1540">81</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f25e23ccf5e4e8b9996111cff5b1f1f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzctMy0xLTEtNzIwMg_969fc01f-13d9-4e2d-8fc9-77c4a18157e5">75</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1262c5aee83e44218db30c90579c58ff_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzgtMS0xLTEtNzIwMg_c5ae4000-1044-4fbf-b9ac-3587f2b9fd7e">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f25e23ccf5e4e8b9996111cff5b1f1f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzgtMy0xLTEtNzIwMg_10f5f9bd-229b-46d8-a8e7-47fba98e977a">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate - minimum</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1262c5aee83e44218db30c90579c58ff_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzktMS0xLTEtNzIwMg_8a1af986-618e-4817-8116-6c2e18c37668">0.63</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f25e23ccf5e4e8b9996111cff5b1f1f_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzktMy0xLTEtNzIwMg_51d1380d-e5cb-4680-a8be-61c168cae061">0.40</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate - maximum</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1262c5aee83e44218db30c90579c58ff_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzEwLTEtMS0xLTcyMDI_52d6245f-b6e1-45df-9d1c-fded2fc89198">1.16</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f25e23ccf5e4e8b9996111cff5b1f1f_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzEwLTMtMS0xLTcyMDI_69b4fbe7-13e9-4e94-9620-3424c7109d16">1.71</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i7d049288b82e438c85d504cc3e9dc500_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 11 &#8211; <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzEyNTA_3eb915c1-48fe-49a1-b74c-dfcb31bc0bc0" continuedAt="i8e640c49a2644de0b46f991502e32d29" escape="true">Research Funding</ix:nonNumeric></span></div><ix:continuation id="i8e640c49a2644de0b46f991502e32d29" continuedAt="ifa06bab069e8463f9a67b65853d1e636"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">California Institute of Regenerative Medicine Grant Award</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) awarded the Company funds of up to $<ix:nonFraction unitRef="usd" contextRef="ifac165fbd5294cbbae45708def42554a_I20170228" decimals="-5" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzIwNA_0963d191-470f-44c7-8cc7-ba4c22c1d81a">12.2</ix:nonFraction> million to support The Sanford Project: T-Rex Study, a prospective, randomized, placebo-controlled, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of CLBS03 as a treatment for recent-onset type 1 diabetes. The funding is based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. Based on the actual number of subjects enrolled in California, the total amount of funding was revised to $<ix:nonFraction unitRef="usd" contextRef="ifac165fbd5294cbbae45708def42554a_I20170228" decimals="-5" name="clbs:FundingAmountAwarded" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzUzOQ_04c8f222-1c48-4ffe-9248-b1c1ae0dffaf">8.6</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="i61ed912a36714a0f8fa66f5c6f03cc72_D20170501-20200930" decimals="-5" name="clbs:FundingOfGrantAwardCashReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzU1Mg_c9802143-4ff1-40ef-9eb7-ea2654997a4f">8.2</ix:nonFraction> million has been received through the grant project period completion. </span></div></ix:continuation><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifa06bab069e8463f9a67b65853d1e636">The Company received $<ix:nonFraction unitRef="usd" contextRef="i08b10f0993ca498595bc8f6e22708cd3_D20170501-20170531" decimals="-5" name="clbs:FundingOfGrantAwardCashReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzEwOTk1MTE2MzEwNzQ_4284f7bf-ba94-4792-a430-e4520d1a9ee7">5.7</ix:nonFraction>&#160;million in initial funding in May 2017, a $<ix:nonFraction unitRef="usd" contextRef="i31c91a3c922742a393bcaf2e5965f1af_D20171201-20171231" decimals="-5" name="clbs:MilestonePaymentOnGrantAwardCashReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzEwOTk1MTE2MzEwODE_71fb2653-68d2-4193-8c4e-30e6b06757ac">1.9</ix:nonFraction>&#160;million milestone payment in December 2017, a $<ix:nonFraction unitRef="usd" contextRef="icb2942cf4b2d4251b0227854fee06098_D20180301-20180331" decimals="-5" name="clbs:ProgressPaymentOnGrantAwardCashReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzEwOTk1MTE2MzEwODg_7cab4979-2607-428f-ab3d-5dcccbd88a03">0.3</ix:nonFraction>&#160;million progress payment in March 2018, and a $<ix:nonFraction unitRef="usd" contextRef="iaa54ec01303049c2ac24d543660aa65d_D20190501-20190531" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzEwOTk1MTE2MzEwOTU_6d222ed9-45b4-42c4-aba1-183c484ec90a">0.2</ix:nonFraction>&#160;million progress payment in May 2019, of which the total was amortized over the estimated award period through July 2020 as a reduction to the related research and development expenses, with the final true up payment of $<ix:nonFraction unitRef="usd" contextRef="id909ba1c9804438aafc38ea943a32300_D20200901-20200930" decimals="-3" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzEwOTk1MTE2MzExMDI_c22eedab-21c2-4a1a-ac56-b303358b3d60">46</ix:nonFraction>&#160;thousand received in September 2020 and recorded as a reduction to the related research and development expenses. During the year ended December&#160;31, 2021 and December&#160;31, 2020 the Company amortized and recognized $<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-5" name="clbs:AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzMyOTg1MzQ4ODczNzM_f12a1062-03dc-4aef-a033-bcb80e85b065">0.0&#160;million</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-5" name="clbs:AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzMyOTg1MzQ4ODczNDI_8fae7543-3de9-49a9-8eab-61f309fe9d99">1.6</ix:nonFraction>&#160;million in credits, respectively, to research and development related to CIRM funds received.</ix:continuation>  </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_121"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 12 &#8211; <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzQxNDQ_742c2ede-9519-4dd2-966b-7af982be2a9f" continuedAt="i9698ed66d0844dbe93427cd3555435e9" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i9698ed66d0844dbe93427cd3555435e9" continuedAt="i32ad39255523486aae412856dce4bb77"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzQxNDE_2da0c0fe-920d-4adf-9090-187497fc0167" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision (benefit) for income taxes is based on loss from operations before provision for income taxes and noncontrolling interests as follows ($ in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax book income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyZWUxOGUwZjc5Mjk0YjUwOGEyNjIyMWEzMDlhMzQ3NS90YWJsZXJhbmdlOjJlZTE4ZTBmNzkyOTRiNTA4YTI2MjIxYTMwOWEzNDc1XzItMS0xLTEtNzIwMg_f3a314e5-190c-42fc-b2d5-4c2c8fb6fc5c">28,974</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyZWUxOGUwZjc5Mjk0YjUwOGEyNjIyMWEzMDlhMzQ3NS90YWJsZXJhbmdlOjJlZTE4ZTBmNzkyOTRiNTA4YTI2MjIxYTMwOWEzNDc1XzItMy0xLTEtNzIwMg_6deb6e21-b2a1-43df-b41b-751a25bbaeb8">19,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyZWUxOGUwZjc5Mjk0YjUwOGEyNjIyMWEzMDlhMzQ3NS90YWJsZXJhbmdlOjJlZTE4ZTBmNzkyOTRiNTA4YTI2MjIxYTMwOWEzNDc1XzMtMS0xLTEtNzIwMg_60b1425e-d4d3-4e5b-b3fd-f0b79135a607">28,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyZWUxOGUwZjc5Mjk0YjUwOGEyNjIyMWEzMDlhMzQ3NS90YWJsZXJhbmdlOjJlZTE4ZTBmNzkyOTRiNTA4YTI2MjIxYTMwOWEzNDc1XzMtMy0xLTEtNzIwMg_6e0162aa-b40b-4956-aed2-25b537a569dc">19,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzQxNDM_37337b80-761f-48cc-b514-32e4e7a03758" escape="true"><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision (benefit) from income taxes was as follows ($ in thousands):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:73.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Federal   </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzMtMi0xLTEtNzIwMg_a66ead18-f672-450f-be1b-13f82a0d8769">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzMtNC0xLTEtNzIwMg_6959d9b4-cd46-47f4-8237-a4564582ea56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;State and local</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzQtMi0xLTEtNzIwMg_e8ecac32-3515-4ec7-93b6-b730e1393062">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzQtNC0xLTEtNzIwMg_54a33d1a-7696-4b02-acda-a8e8733d4155">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzUtMi0xLTEtNzIwMg_5013c63e-44ed-44ad-afdd-7f40a9cf4f17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzUtNC0xLTEtNzIwMg_4cfea0a7-7794-4f45-8863-e5bc7023045b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Federal   </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzgtMi0xLTEtNzIwMg_9fc3103f-131d-4da0-9eb1-2caeb2d67f70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzgtNC0xLTEtNzIwMg_36dc2664-dfbd-4a31-ad83-7baa42a57b3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;State and local</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzktMi0xLTEtNzIwMg_f2e75f46-73f9-43fc-ba8d-fe5a29889563">1,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzktNC0xLTEtNzIwMg_24e65d5d-97c7-462a-aecf-b40a6c5a16dc">10,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzEwLTItMS0xLTcyMDI_243b40a6-d4aa-468e-84c2-3c956af60c17">1,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzEwLTQtMS0xLTcyMDI_fa2a95f2-4d3e-4e11-8927-c02329055a38">10,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Federal   </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzEzLTItMS0xLTcyMDI_0015fd12-0684-4826-aa43-c5c46226fb47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzEzLTQtMS0xLTcyMDI_f4f46982-568e-45f9-99e1-cd45dec2397a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;State and local</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzE0LTItMS0xLTcyMDI_37b04e9f-61c9-4537-b7c4-fa9219623784">1,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzE0LTQtMS0xLTcyMDI_c0fe9aa4-afde-4053-83ed-e61f45e1c362">10,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzE1LTItMS0xLTcyMDI_9cc56e88-89f5-4bec-bdc6-74898363472f">1,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzE1LTQtMS0xLTcyMDI_b8969d52-b214-4c1c-ba5f-049c0ba13425">10,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><ix:continuation id="i32ad39255523486aae412856dce4bb77" continuedAt="iec9dc8586ce1412591bf1f0f15cea9d7"><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzQxMjU_c66143b1-faff-4061-a730-dfbc434d4158" escape="true"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The provision (benefit) for income taxes is determined by applying the U.S. Federal statutory rate of <ix:nonFraction unitRef="number" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzM4MQ_36af79e1-9d39-430a-a5b8-b7e831abb0e8">21</ix:nonFraction>% to income before income taxes, and the components are set forth below ($ in thousands): </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:73.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal benefit at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzItMi0xLTEtNzIwMg_e7c27c39-7c18-46e4-bd74-5b1cbbd69a1b">6,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzItNC0xLTEtNzIwMg_1defef64-aa70-4102-96e9-e8c5e56844df">3,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent non deductible expenses for U.S. taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzQtMi0xLTEtNzIwMg_3eb94609-8997-4ba5-b921-ec6852cb5573">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzQtNC0xLTEtNzIwMg_27daa9be-9f7f-4da9-8026-f7d28378e1b5">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in state deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="clbs:EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzYtMi0xLTEtNzIwMg_bd2933eb-dbbf-4186-b77a-997fc7a255a1">622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="clbs:EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzYtNC0xLTEtNzIwMg_0ee67cc4-0f71-44ed-a0ef-e34285a01741">5,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to actual</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzctMi0xLTEtNzIwMg_c1fb0aea-4837-4d45-a508-a6a0a7ada667">2,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzctNC0xLTEtNzIwMg_f8b0f803-799d-4a29-a905-1b416617a4de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other true ups</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzgtMi0xLTEtNzIwMg_93125633-b82f-4843-b109-10fc5d81f7a5">1,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzgtNC0xLTEtNzIwMg_6946e46a-45ba-4c1b-883e-c4f42fac4dca">387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 382 NOL Limitation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" name="clbs:EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzktMi0xLTEtNzIwMg_04ba94c4-10b2-4bdd-bbf9-a16928fc4b12">35,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" name="clbs:EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzktNC0xLTEtNzIwMg_e9f636f9-3a9e-4829-9bda-328e81e37522">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of New Jersey State NOLs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="clbs:EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzEwLTItMS0xLTcyMDI_2cc570c0-fbe3-4de2-be89-5a3b71b8b75b">1,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="clbs:EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzEwLTQtMS0xLTcyMDI_7ffb6980-d57a-4c56-bf1d-ea338a712ff6">10,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzExLTItMS0xLTcyMDI_df5ef0a4-5768-4aae-8647-193be52a9809">33,979</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzExLTQtMS0xLTcyMDI_37b6620f-d49c-49ee-8f61-6b4e6b3887fb">1,521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax provision (benefit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzEyLTItMS0xLTcyMDI_5331e562-5bac-492c-9424-498cda5920ff">1,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzEyLTQtMS0xLTcyMDI_9b4bd4c3-1db8-4e8a-9d64-04cc81c2b983">10,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzQxMTk_fda8b5a3-3471-4eb4-82b1-33dcaf1ffa84" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes at December&#160;31, 2021 and 2020 consist of the following ($ in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:73.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Tax Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated net operating losses (tax effected)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzMtMi0xLTEtNzIwMg_cab80750-a9a8-444a-b12b-72543b3f2c54">36,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzMtNC0xLTEtNzIwMg_9d64f9dc-4930-4991-be68-839ed8f410ca">68,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="clbs:DeferredTaxAssetsRightOfUseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzYtMi0xLTEtNzIwMg_67e34ebc-ea9a-45af-bb40-b8d7d227618b">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="clbs:DeferredTaxAssetsRightOfUseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzYtNC0xLTEtNzIwMg_d0845d19-8bb4-4579-9bfc-ca6b425f7b20">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzctMi0xLTEtNzIwMg_8c345ae0-c704-4948-8a40-c62d09041454">3,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzctNC0xLTEtNzIwMg_b6e57fd5-283e-4f61-8e90-0cd90d3dc479">5,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzgtMi0xLTEtNzIwMg_7cf023ae-dc89-4d79-a43c-6c2be3e68759">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzgtNC0xLTEtNzIwMg_2992f53a-baf5-4572-b09c-cea426a8cf0b">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="clbs:DeferredTaxAssetsAccumulatedDepreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzEzLTItMS0xLTcyMDI_3d9cc81c-cc98-48ab-9083-800ea6bbe734">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="clbs:DeferredTaxAssetsAccumulatedDepreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzEzLTQtMS0xLTcyMDI_a1b87fea-f003-4235-8ad6-4cac821dfb2f">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzE0LTItMS0xLTcyMDI_390d5779-26f7-4dcf-ab56-17145178eb75">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzE0LTQtMS0xLTcyMDI_79ff3eda-ad16-48a1-a2f5-9a3f18bbba03">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzE2LTItMS0xLTcyMDI_c277bf18-1228-4b8b-9f58-21dfebaa9e3f">526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzE2LTQtMS0xLTcyMDI_1836fd46-60ff-4f62-912e-c1037e2866ef">526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzE3LTItMS0xLTcyMDI_121efa7f-2522-4f7d-a569-a4bd5e44282f">40,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzE3LTQtMS0xLTcyMDI_129906d8-dcce-4d70-8b7d-592f468e4c64">74,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Tax Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzIwLTItMS0xLTcyMDI_a60b2a18-f910-4998-a1f4-ace96bc12b0e">204</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzIwLTQtMS0xLTcyMDI_04146628-ec2a-4a1c-8a3d-585525785a88">161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzIyLTItMS0xLTcyMDI_567a507c-5393-4e94-857d-73e3c5f03984">204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzIyLTQtMS0xLTcyMDI_d6312b64-0aab-4c33-ab18-6ee6b40963d0">161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="clbs:NetDeferredTaxAssetsAndLiabilitiesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzIzLTItMS0xLTcyMDI_82cefcd2-9c69-4dfc-bfb0-fd302437483b">40,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="clbs:NetDeferredTaxAssetsAndLiabilitiesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzIzLTQtMS0xLTcyMDI_f8809987-339c-4f46-ae5f-26625a94592c">74,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzI0LTItMS0xLTcyMDI_c1dd8bbf-3a31-47e1-acae-98e70c31433e">40,189</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzI0LTQtMS0xLTcyMDI_47a65d2d-1240-4f75-910f-6f5e30c09487">74,169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzI1LTItMS0xLTcyMDI_db59d379-be45-46bc-a316-b6adf4ab038b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzI1LTQtMS0xLTcyMDI_aa0fcb44-1eb9-49f5-9b89-304f8a134cf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, and 2020, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="ibb3d98988e62496d9a95ec85932a553d_I20211231" decimals="-6" name="clbs:OperatingLossCarryforwardsBeforeWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzEwNTk_9bbc6090-f910-4ddc-ab29-ecefa7c24a85">281</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icd538497ecb94882951d52a7b78a623a_I20201231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzEwNjY_92f51f01-dfea-4a3b-bbc6-c757d5746c4e">264</ix:nonFraction> million, respectively, of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an ownership change of greater than 50% over a 3-year testing period on January 25, 2021.  As a result, $<ix:nonFraction unitRef="usd" contextRef="ibb3d98988e62496d9a95ec85932a553d_I20211231" decimals="-6" name="clbs:OperatingLossCarryforwardsSetToExpireWrittenDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzExNTQ0ODcyMTAxNDA2_772de455-684c-4e45-9030-4b1767aa5aa8">169</ix:nonFraction>&#160;million of the $<ix:nonFraction unitRef="usd" contextRef="ibb3d98988e62496d9a95ec85932a553d_I20211231" decimals="-6" name="clbs:OperatingLossCarryforwardsBeforeWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzEyMDk0NjI3OTE1MTcy_a57d6a38-dae6-49d5-864b-5b9d4aaee26f">281</ix:nonFraction>&#160;million of Federal NOLs will expire unutilized.  The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $<ix:nonFraction unitRef="usd" contextRef="ibb3d98988e62496d9a95ec85932a553d_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzExNTQ0ODcyMTAxNDIw_58698af1-d5c8-481e-b884-8c65d3030a50">112</ix:nonFraction>&#160;million of remaining Federal NOL.  The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on January 25, 2021 will be subject to an annual limitation of $173k under Internal Revenue Code Section 382, while losses incurred after January 25, 2021 will not be subject to limitations. The Company may be able to utilize additional NOLs of approximately $<ix:nonFraction unitRef="usd" contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231" decimals="-5" name="clbs:OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzEyMDk0NjI3OTE1MTg2_31ea7e6a-db4e-48a0-aa28-301cd59ea6e3">1.1</ix:nonFraction>&#160;million per year for the first five years after this ownership change as a result of the application of the Net Unrealized Built-in Gain rules.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><ix:continuation id="iec9dc8586ce1412591bf1f0f15cea9d7"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company had State NOLs available in New Jersey of $<ix:nonFraction unitRef="usd" contextRef="ib03213178c1c439fbbcd57ce65f84a0a_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzEyNDg_b9f3a244-2359-4892-b3ef-80349071a68c">97</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3273942991694dcbb5315ec3f95ef5c1_I20201231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzEyNTU_799bbb9d-1d14-4b29-a212-e435c3de1d2c">99</ix:nonFraction> million, respectively, California of $<ix:nonFraction unitRef="usd" contextRef="ib4ffabf75b224124baa59142f55d7740_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzEyODc_397c923e-c6fd-4b9b-af61-f8fb90e23f38">70</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i208a56199ea240e189c18fe67bc1738e_I20201231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzEyOTQ_3a456e65-729b-4c4d-8a5e-8d83d509ee57">70</ix:nonFraction> million, respectively, and New York City of $<ix:nonFraction unitRef="usd" contextRef="ie9412c3333444df08e11f620932bee49_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzEzMzM_21491302-ffaa-4fec-8540-e0196dfc6be2">13</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iacc61b5e28ba4a56b04bcf5fece477a5_I20201231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzEzNDA_a5c58796-d057-4bc9-88d3-f7bd13c28d6a">13</ix:nonFraction>&#160;million, respectively, to offset future taxable income expiring from 2031 through 2041. In accordance with Section 382 of the Internal Revenue code, the usage of the Company&#8217;s state NOLs would be limited given the change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the FASB&#8217;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For years prior to 2018 the federal statute of limitations is closed for assessing tax. The Company&#8217;s state tax returns remain open to examination for a period of three to four years from date of filing.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company received preliminary approval from the New Jersey Economic Development Authority (&#8220;NJEDA&#8221;) to participate in the Technology Business Tax Certificate Transfer Program (the &#8220;Program&#8221;). The Program permits qualified companies to sell a percentage of their New Jersey net operating losses (&#8220;NJ NOLs&#8221;) to unrelated profitable corporations. On April 12, 2021, the Company received final approval from NJEDA to sell a portion of our NJ NOLs, which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i63593eb72a0c4883b9e50df4be109be4_D20210412-20210412" decimals="-5" name="clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzE2NDkyNjc0NDY0Mzc_932ee4f7-a606-4364-9b6b-d5c016ce2112">1.4</ix:nonFraction>&#160;million. The $<ix:nonFraction unitRef="usd" contextRef="i63593eb72a0c4883b9e50df4be109be4_D20210412-20210412" decimals="-5" name="clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzE2NDkyNjc0NDY0NDY_2f36abab-612c-4531-8b1a-e03dbcb0d565">1.5</ix:nonFraction>&#160;million of our NJ NOL related tax benefits (&#8220;NJ NOL Tax Benefits&#8221;) have been recorded as a benefit from income taxes and the loss on sale of $<ix:nonFraction unitRef="usd" contextRef="i63593eb72a0c4883b9e50df4be109be4_D20210412-20210412" decimals="-5" name="clbs:LossOnSaleOfNetOperatingLosses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzE2NDkyNjc0NDY1ODM_75defb42-e85b-4e49-b679-2650ac24c459">0.1</ix:nonFraction>&#160;million recorded in other income (expense) in the consolidated financial statements.</span></div></ix:continuation><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_124"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 13 &#8211; <ix:nonNumeric contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjQvZnJhZzplMTBiYjU0NzUyY2Y0ZmNkYWEwMDZlOWYwOWJiNDY3OC90ZXh0cmVnaW9uOmUxMGJiNTQ3NTJjZjRmY2RhYTAwNmU5ZjA5YmI0Njc4XzQyMw_530f351e-ecd9-4dec-82d5-f10cacac53c2" continuedAt="i8b737bec28cf42e2abcbe95f88c3c9ea" escape="true">Contingencies</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8b737bec28cf42e2abcbe95f88c3c9ea">From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.</ix:continuation> </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_133"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_136"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.&#160;&#160;CONTROLS AND PROCEDURES. &#160;</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures are the Company&#8217;s controls and other procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934), as amended (the &#8220;Exchange Act&#8221;) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file under the Exchange Act is accumulated and communicated to management, including the Chief Executive Officer/Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitations of control systems, not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Controls and procedures can only provide reasonable, not absolute, assurance that the above objectives have been met.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 7, 2022, the Company evaluated, with the participation of its management, including our Chief Executive Officer and Chief Legal Officer, the effectiveness of the Company&#8217;s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on that evaluation, our Chief Executive Officer/Principal Financial Officer concluded that the Company&#8217;s disclosure controls and procedures were effective, at the reasonable assurance level, in ensuring that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms and is accumulated and communicated to management, including the Chief Executive Officer and Chief Legal Officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that: </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and the board of directors of the Company; and </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the financial statements. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to risk that controls may become inadequate because of changes in conditions or because of declines in the degree of compliance with policies or procedures. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed the effectiveness of its internal control over financial reporting as of December&#160;31, 2021. In making this assessment, they used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control-Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, based on management&#8217;s assessment, the Company&#8217;s internal control over financial reporting was effective. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in the Company&#8217;s internal control over financial reporting that occurred during the quarter ended December&#160;31, 2021 that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></div><div id="i7d049288b82e438c85d504cc3e9dc500_139"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/>ITEM 9B. OTHER INFORMATION.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i7d049288b82e438c85d504cc3e9dc500_1407"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i7d049288b82e438c85d504cc3e9dc500_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_145"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Management and Corporate and Governance Matters,&#8221; &#8220;Section 16(a) Beneficial Ownership Reporting Compliance,&#8221; and &#8220;Code of Conduct and Ethics&#8221; in the Company's Proxy Statement for the 2022 Annual Meeting of Stockholders.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_148"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11. EXECUTIVE COMPENSATION</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Executive Compensation&#8221; and &#8220;Caladrius Director Compensation,&#8221; in the Company&#8217;s Proxy Statement for the 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual Meeting of Stockholders.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_151"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the caption &#8220;Security Ownership of Management and Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information&#8221; in the Company&#8217;s Proxy Statement for the 2022 Annual Meeting of Stockholders.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_154"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Management and Corporate Governance Matters&#8221; in the Company&#8217;s Proxy Statement for the 2022 Annual Meeting of Stockholders.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_157"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the caption &#8220;Accounting Fees and Other Accounting Matters&#8221; in the Company&#8217;s Proxy Statement for the 2022 Annual Meeting of Stockholders.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i7d049288b82e438c85d504cc3e9dc500_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_163"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are being filed as part of this Report:</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(1) FINANCIAL STATEMENTS:</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference is made to the Index to Financial Statements on Page 48 of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other schedules have been omitted because the required information is not present or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the Financial Statements or Notes thereto.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i7d049288b82e438c85d504cc3e9dc500_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="-sec-extract:summary;margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)(3) EXHIBITS: </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a list of exhibits filed (or furnished, where specified) as part of this Annual Report on Form 10-K. Exhibits that were previously filed are described below and are incorporated by reference. For exhibits incorporated by reference, the location of the exhibit in the previous filing is indicated.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.550%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:45pt;text-align:right;text-indent:-45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001716000143/exhibit31arcertofincorpeff.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Certificate of Incorporation of Caladrius Biosciences, Inc., as amended, effective July 27, 2016 (filed as Exhibit 3.1 to the Company&#8217;s on Form 10-Q for the quarter ended June 30, 2016, filed with the SEC on August 9, 2016).</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-align:right;text-indent:-45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001716000143/exhibit32arbylawseff072720.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated By-Laws of the Caladrius Biosciences, Inc. as amended, effective as of July 27, 2016 (filed as Exhibit 3.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, filed with the SEC on August 9, 2016).</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-align:right;text-indent:-45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001717000082/exhibit31092017.htm">3.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendments to Amended and Restated Bylaws of Caladrius Biosciences, Inc., effective as of September 18, 2017 (filed as Exhibit 3.1 to the Company's Current Report on Form 8-K, filed with the SEC on September 21, 2017).</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:45pt;text-align:right;text-indent:-45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001721000043/exh432020.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of Capital Stock.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001720000022/ex41.htm">4.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Warrant (filed as Exhibit 4.1 to the Company's Current Report on Form 8-K, filed with the SEC on April 24, 2020).</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001720000039/ex41.htm">4.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Warrant (filed as Exhibit 4.1 to the Company's Current Report on Form 8-K, filed with the SEC on May 26, 2020).</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001720000060/pipe20200710ex41.htm">4.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Warrant (filed as Exhibit 4.1 to the Company's Current Report on Form 8-K, filed with the SEC on July 10, 2020).</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001721000006/a20210121ex41formofwarrant.htm">4.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Warrant (filed as Exhibit 4.1 to the Company's Current Report on Form 8-K, filed with the SEC on January 25, 2021).</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-align:right;text-indent:-45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001718000021/exhibit101directorcompensa.htm">10.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director Compensation Policy (filed as Exhibit 10.1 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 22, 2018 and amended on April 2, 2018).</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-align:right;text-indent:-45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001715000050/def14a-2015.htm">10.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015 Equity Compensation Plan (filed as Annex A to the Company&#8217;s Definitive Proxy Statement filed on Schedule 14A, filed with the SEC on June 8, 2015).</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-align:right;text-indent:-45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001717000060/clbs-ex1012017employeestoc.htm">10.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Employee Stock Purchase Plan (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2017).</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-align:right;text-indent:-45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001715000013/exh1045.htm">10.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Indemnification Agreement for executive officers (filed as Exhibit 10.44 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 as filed with the SEC on March 2, 2015).</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001715000002/exhibit102dm.htm">10.5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement, dated as of January 5, 2015 and effective on January 5, 2015, by and between the Company and David J. Mazzo, Ph.D. (filed as Exhibit 10.2 to the Company's Current Report on Form 8-K filed on January 5, 2015).</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001715000008/exh102dm.htm">10.6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment, dated as of January 16, 2015, to Employment Agreement, dated as of January 5, 2015 and effective on January 5, 2015, by and between the Company and David J. Mazzo, Ph.D. (filed as Exhibit 10.2 to the Company's Current Report on Form 8-K filed on January 16, 2015).</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001716000143/exhibit101djmamendment.htm">10.7</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment to Employment Agreement, dated as of July 25, 2016, by and between the Company and David J. Mazzo, PhD (filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q. for the quarter ended June 30, 2016, filed with the SEC on August 9, 2016).</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001717000082/exhibit101amendedemploymen.htm">10.8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment to Employment Agreement with David J. Mazzo, effective September 18, 2017 (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on September 21, 2017).</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.550%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000114420418063631/tv508609_ex10-1.htm">10.9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment to Employment Agreement with David J. Mazzo, dated December 6, 2018 (filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on December 7, 2018).</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001720000022/ex101.htm">10.10</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form of Purchase Agreement, dated April 23, 2020, by and between Caladrius Biosciences, Inc. and each purchaser identified on the signature pages thereto (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K, filed with the SEC on April 24, 2020).</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001720000039/ex102.htm">10.11</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Placement Agent Agreement, dated November 5, 2019, as subsequently amended on each of March 11, 2020, April 23, 2020 and May 25, 2020, by and between Caladrius Biosciences, Inc. and H.C. Wainwright &amp; Co., LLC (filed as Exhibit 10.2 to the Company's Current Report on Form 8-K, filed with the SEC on May 26, 2020).</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001720000039/ex101.htm">10.12</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Purchase Agreement, dated May 25, 2020, by and between Caladrius Biosciences, Inc. and each purchaser identified on the signature pages thereto (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K, filed with the SEC on May 26, 2020).</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001720000060/pipe20200710ex101.htm">10.13</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Purchase Agreement, dated July 10, 2020, by and between Caladrius Biosciences, Inc. and each purchaser identified on the signature pages thereto (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K, filed with the SEC on July 10, 2020).</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001720000060/pipe20200710ex102.htm">10.14</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Registration Rights Agreement, dated July 10, 2020, by and between Caladrius Biosciences, Inc. and each purchaser identified on the signature pages thereto (filed as Exhibit 10.2 to the Company's Current Report on Form 8-K, filed with the SEC on July 10, 2020).</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001721000006/a20210121ex101formofsecpur.htm">10.15</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Purchase Agreement, dated January 21, 2021, by and between Caladrius Biosciences, Inc. and certain Investors, as defined therein (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K, filed with the SEC on January 25, 2021).</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001721000006/a20210121ex102formofregrts.htm">10.16</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Registration Rights Agreement, dated January 21, 2021, by and between Caladrius Biosciences, Inc. and each purchaser identified on the signature pages thereto (filed as Exhibit 10.2 to the Company's Current Report on Form 8-K, filed with the SEC on January 25, 2021).</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001721000032/exhibit10120210212.htm">10.17</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Form of Institutional Securities Purchase Agreement, by and between Caladrius Biosciences, Inc. and each purchaser identified on the signature pages thereto (incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Form 8-K filed on February 16, 2021).</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001721000032/exhibit10220210212.htm">10.18</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Institutional Additional Securities Purchase Agreement, by and between Caladrius Biosciences, Inc. and each purchaser identified on the signature pages thereto (incorporated by reference to Exhibit 10.2 of the Registrant&#8217;s Form 8-K filed on February 16, 2021).</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-align:right;text-indent:-45pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001719000024/exhibit141.htm">14.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Code of Ethics for Senior Financial Officers (filed as Exhibit 14.1 to the Company's Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on March 14, 2019).</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001720000016/exh2112019.htm">21.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subsidiaries of Caladrius Biosciences, Inc.</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh23120211231.htm">23.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of Grant Thornton LLP</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="clbs-ex311_20211231xq4.htm">31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="clbs-ex32_20211231.htm">32</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant Section 302 of the Sarbanes-Oxley Act of 2002</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-align:right;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-align:right;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-align:right;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:36pt;text-align:right;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:36pt;text-align:right;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.550%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:36pt;text-align:right;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or compensatory plan, contract or arrangement required to be filed as an exhibit to this Form 10-K pursuant to Item 15(b) of Form 10-K.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:right;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:right;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain portions of this exhibit were omitted based upon a request for confidential treatment, and the omitted portions were filed separately with the SEC on a confidential basis.</span></div></td></tr></table></div><div><span><br/></span></div><div id="i7d049288b82e438c85d504cc3e9dc500_169"></div><div style="-sec-extract:summary;margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.  FORM 10-K SUMMARY</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i7d049288b82e438c85d504cc3e9dc500_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i7d049288b82e438c85d504cc3e9dc500_7">Index</a></span></div></div><div style="margin-bottom:6pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;padding-right:2.25pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in Basking Ridge (Bernards Township), State of New Jersey, on March&#160;22, 2022. </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.742%"><tr><td style="width:1.0%"></td><td style="width:48.488%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.623%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.489%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CALADRIUS BIOSCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ David J. Mazzo, PhD</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name: David J. Mazzo</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title: President and Chief Executive Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</span></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:27.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.966%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.587%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ David J. Mazzo</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David J. Mazzo, PhD</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director, and President and Chief Executive Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 22, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Gregory B. Brown</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory B. Brown, MD</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 22, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Michael H. Davidson</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael H. Davidson</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 22, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Cynthia L. Flowers</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cynthia L. Flowers</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 22, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Steven M. Klosk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steven M. Klosk</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 22, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Steven S. Myers</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steven S. Myers</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 22, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Peter G. Traber, MD</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter G. Traber, MD</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 22, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Anne C. Whitaker</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anne C. Whitaker</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 22, 2022</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>2
<FILENAME>exh23120211231.htm
<DESCRIPTION>EX-23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icabcec64beeb47a2a1afb79a600c417f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 23.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%">We have issued our report dated March 22, 2022, with respect to the consolidated financial statements included in the Annual Report of Caladrius Biosciences, Inc. on Form 10-K for the year ended December 31, 2021. We consent to the incorporation by reference of said report in the Registration Statements of Caladrius Biosciences, Inc. on Form S-1 (File No 333-239302), Forms S-3 (File No. 333-196702, File No. 333-206175, File No. 333-210664, File No. 333-214607, File No. 333-220354, File No. 333-226319, File No. 333-248100, and File No. 333-252560) and on Forms S-8 (File No. 333-107438, File No. 333-144265, File No. 333-159282, File No. 333-162733, File No. 333-173854, File No. 333-181365, File No. 333- 184927, File No. 333-191572, File No. 333-205662, File No. 333-212202, File No. 333-215455, File No. 333-218642, File No. 333-222410, File No. 333-225743, File No. 333-225744, File No. 333-248101, File No. 333-257560, and File No. 333-254971).</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%">&#47;s&#47;GRANT THORNTON LLP</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%">New York, New York</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%">March 22, 2022</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>clbs-ex311_20211231xq4.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i74fcb94ae89a463d85abc715c6182255_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS UNDER SECTION 302</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David J. Mazzo, certify that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.  I have reviewed this annual report on Form 10-K of Caladrius Biosciences, Inc.&#59;</font></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.  The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;a)  designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;b)  designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;c) evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.  The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;a)  all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;b)  any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;22, 2022 </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; David J. Mazzo</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David J. Mazzo, PhD</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>clbs-ex32_20211231.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2c04bd05395b449192bb3cee3fe94f28_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 32</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS UNDER SECTION 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Caladrius Biosciences, Inc. a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Annual Report for the year ended December&#160;31, 2021 (the &#8220;Form 10-K&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:16.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 22, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; David J. Mazzo</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David J. Mazzo, PhD</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>clbs-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:845060b2-4e37-482c-8ae9-0e23a5d9619a,g:0f1463a6-505b-4611-9f37-25c6b798c5c1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:clbs="http://www.caladrius.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.caladrius.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clbs-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clbs-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clbs-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clbs-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.caladrius.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.caladrius.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004006 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofEquity">
        <link:definition>1005007 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheBusiness" roleURI="http://www.caladrius.com/role/TheBusiness">
        <link:definition>2101101 - Disclosure - The Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheBusinessDetails" roleURI="http://www.caladrius.com/role/TheBusinessDetails">
        <link:definition>2402401 - Disclosure - The Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecurities" roleURI="http://www.caladrius.com/role/AvailableforSaleSecurities">
        <link:definition>2107103 - Disclosure - Available-for-Sale-Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesTables" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables">
        <link:definition>2308302 - Disclosure - Available-for-Sale-Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesSummaryDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails">
        <link:definition>2409403 - Disclosure - Available-for-Sale-Securities - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesClassificationonConsolidatedBalanceSheetsDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationonConsolidatedBalanceSheetsDetails">
        <link:definition>2410404 - Disclosure - Available-for-Sale-Securities - Classification on Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesContractualMaturitiesDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails">
        <link:definition>2411405 - Disclosure - Available-for-Sale-Securities - Contractual Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.caladrius.com/role/PropertyandEquipment">
        <link:definition>2112104 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.caladrius.com/role/PropertyandEquipmentTables">
        <link:definition>2313303 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentSummaryDetails" roleURI="http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails">
        <link:definition>2414406 - Disclosure - Property and Equipment - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNarrativeDetails" roleURI="http://www.caladrius.com/role/PropertyandEquipmentNarrativeDetails">
        <link:definition>2415407 - Disclosure - Property and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShare" roleURI="http://www.caladrius.com/role/LossPerShare">
        <link:definition>2116105 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShareTables" roleURI="http://www.caladrius.com/role/LossPerShareTables">
        <link:definition>2317304 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShareDetails" roleURI="http://www.caladrius.com/role/LossPerShareDetails">
        <link:definition>2418408 - Disclosure - Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.caladrius.com/role/FairValueMeasurements">
        <link:definition>2119106 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.caladrius.com/role/FairValueMeasurementsTables">
        <link:definition>2320305 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails">
        <link:definition>2421409 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilities" roleURI="http://www.caladrius.com/role/AccruedLiabilities">
        <link:definition>2122107 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.caladrius.com/role/AccruedLiabilitiesTables">
        <link:definition>2323306 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesDetails" roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails">
        <link:definition>2424410 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeases" roleURI="http://www.caladrius.com/role/OperatingLeases">
        <link:definition>2125108 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesTables" roleURI="http://www.caladrius.com/role/OperatingLeasesTables">
        <link:definition>2326307 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesNarrativeDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails">
        <link:definition>2427411 - Disclosure - Operating Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesBalanceSheetPresentationDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails">
        <link:definition>2428412 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails">
        <link:definition>2429413 - Disclosure - Operating Leases - Future Minimum Lease Payments Under Lease Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails_1" roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails_1">
        <link:definition>2429413 - Disclosure - Operating Leases - Future Minimum Lease Payments Under Lease Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.caladrius.com/role/StockholdersEquity">
        <link:definition>2130109 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.caladrius.com/role/StockholdersEquityTables">
        <link:definition>2331308 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityEquityPlanDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails">
        <link:definition>2432414 - Disclosure - Stockholders' Equity - Equity Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityEquityIssuancesDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails">
        <link:definition>2433415 - Disclosure - Stockholders' Equity - Equity Issuances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionsandWarrantsDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails">
        <link:definition>2434416 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails">
        <link:definition>2435417 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.caladrius.com/role/ShareBasedCompensation">
        <link:definition>2136110 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.caladrius.com/role/ShareBasedCompensationTables">
        <link:definition>2337309 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>2438418 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationCompensationCostNotYetRecognizedDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails">
        <link:definition>2439419 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails">
        <link:definition>2440420 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationValuationAssumptionsDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails">
        <link:definition>2441421 - Disclosure - Share-Based Compensation - Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchFunding" roleURI="http://www.caladrius.com/role/ResearchFunding">
        <link:definition>2142111 - Disclosure - Research Funding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchFundingDetails" roleURI="http://www.caladrius.com/role/ResearchFundingDetails">
        <link:definition>2443422 - Disclosure - Research Funding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.caladrius.com/role/IncomeTaxes">
        <link:definition>2144112 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.caladrius.com/role/IncomeTaxesTables">
        <link:definition>2345310 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesLossfromOperationsBeforeProvisionforIncomeTaxesDetails" roleURI="http://www.caladrius.com/role/IncomeTaxesLossfromOperationsBeforeProvisionforIncomeTaxesDetails">
        <link:definition>2446423 - Disclosure - Income Taxes - Loss from Operations Before Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails" roleURI="http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails">
        <link:definition>2447424 - Disclosure - Income Taxes - Components of Benefit from Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesEffectiveIncomeTaxReconciliationDetails" roleURI="http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails">
        <link:definition>2448425 - Disclosure - Income Taxes - Effective Income Tax Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofDeferredIncomeTaxesDetails" roleURI="http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails">
        <link:definition>2449426 - Disclosure - Income Taxes - Components of Deferred Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.caladrius.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2450427 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.caladrius.com/role/Contingencies">
        <link:definition>2151113 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" abstract="false" name="SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsCanceled" abstract="false" name="WeightedAverageExercisePriceWarrantsCanceled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_AdditionalPurchaseAgreementMember" abstract="true" name="AdditionalPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan" abstract="false" name="NumberofOfferingPeriodsEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" abstract="false" name="WeightedAverageRemainingContractualTermwarrantoutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_LincolnParkAgreementMember" abstract="true" name="LincolnParkAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" abstract="false" name="IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WarrantsVested" abstract="false" name="WarrantsVested" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_CLBS16TreatmentOfCMDMember" abstract="true" name="CLBS16TreatmentOfCMDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_WarrantsOtherDisclosuresAbstract" abstract="true" name="WarrantsOtherDisclosuresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="clbs_PreferredStockLiquidationPreferenceShare" abstract="false" name="PreferredStockLiquidationPreferenceShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_FundingOfGrantAwardCashReceived" abstract="false" name="FundingOfGrantAwardCashReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_EmployeeStockPurchasePlan2017Member" abstract="true" name="EmployeeStockPurchasePlan2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" abstract="false" name="LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice" abstract="false" name="PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent" abstract="false" name="SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_TermOfAgreement" abstract="false" name="TermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent" abstract="false" name="EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_LossOnSaleOfNetOperatingLosses" abstract="false" name="LossOnSaleOfNetOperatingLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsGranted" abstract="false" name="WeightedAverageExercisePriceWarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_DeferredTaxAssetsAccumulatedDepreciation" abstract="false" name="DeferredTaxAssetsAccumulatedDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" abstract="false" name="WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_NumberOfOfficesUnderOperatingLeases" abstract="false" name="NumberOfOfficesUnderOperatingLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsExercisable" abstract="false" name="WeightedAverageExercisePriceWarrantsExercisable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_AggregateIntrinsicValueWarrantsvested" abstract="false" name="AggregateIntrinsicValueWarrantsvested" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" abstract="false" name="SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" abstract="false" name="SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" abstract="false" name="OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_H.C.WainwrightSalesAmendedAgreementMember" abstract="true" name="H.C.WainwrightSalesAmendedAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_AggregateIntrinsicValueOptionExercised" abstract="false" name="AggregateIntrinsicValueOptionExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" abstract="false" name="RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" abstract="false" name="AggregateIntrinsicValueWarrantsvestedandexpectedtovest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_January2021PurchaseAgreementMember" abstract="true" name="January2021PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense" abstract="false" name="AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_ProgressPaymentOnGrantAwardCashReceived" abstract="false" name="ProgressPaymentOnGrantAwardCashReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WarrantsWeightedAverageExercisePriceRollForward" abstract="true" name="WarrantsWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="clbs_PreferredStockSharesDesignated" abstract="false" name="PreferredStockSharesDesignated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_EmployeeStockPurchasePlan2017AmendedMember" abstract="true" name="EmployeeStockPurchasePlan2017AmendedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_EquityIncentiveCompensationPlan2018Member" abstract="true" name="EquityIncentiveCompensationPlan2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" abstract="false" name="SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee" abstract="false" name="EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_BusinessTextBlock" abstract="false" name="BusinessTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract" abstract="true" name="RestrictedStockAndRestrictedStockUnitsIssuedAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="clbs_OperatingLeaseRightOfUseAssetAbstract" abstract="true" name="OperatingLeaseRightOfUseAssetAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WarrantsCanceled" abstract="false" name="WarrantsCanceled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_WarrantsExercised" abstract="false" name="WarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_MarketableSecuritiesMember" abstract="true" name="MarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_WarrantsExpired" abstract="false" name="WarrantsExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" abstract="false" name="ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses" abstract="false" name="EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_Sharesvestedandexpectedtovest" abstract="false" name="Sharesvestedandexpectedtovest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_FundingAmountAwarded" abstract="false" name="FundingAmountAwarded" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsExercised" abstract="false" name="WeightedAverageExercisePriceWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" abstract="false" name="WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsOutstanding" abstract="false" name="WeightedAverageExercisePriceWarrantsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_WarrantsGranted" abstract="false" name="WarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_AtTheMarketOfferingAgreementMember" abstract="true" name="AtTheMarketOfferingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate" abstract="false" name="EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" abstract="false" name="ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_AggregateIntrinsicValueWarrantsOutstanding" abstract="false" name="AggregateIntrinsicValueWarrantsOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm" abstract="false" name="OfferingPeriodsEmployeeStockPurchasePlanTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_EmployeeStockPurchasePlan2012Member" abstract="true" name="EmployeeStockPurchasePlan2012Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate" abstract="false" name="EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_TreasuryStockPolicyPolicyTextBlock" abstract="false" name="TreasuryStockPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="clbs_CommonStockWarrantsShares" abstract="false" name="CommonStockWarrantsShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" abstract="false" name="OperatingLossCarryforwardsSetToExpireWrittenDown" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" abstract="false" name="StockIssuedDuringPeriodSharesIssuedAsConsideration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_WeightedAverageRemainingContractualTermwarrantsvested" abstract="false" name="WeightedAverageRemainingContractualTermwarrantsvested" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_NetDeferredTaxAssetsAndLiabilitiesGross" abstract="false" name="NetDeferredTaxAssetsAndLiabilitiesGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_MilestonePaymentOnGrantAwardCashReceived" abstract="false" name="MilestonePaymentOnGrantAwardCashReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" abstract="false" name="SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsExpired" abstract="false" name="WeightedAverageExercisePriceWarrantsExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_InstitutionalPurchaseAgreementMember" abstract="true" name="InstitutionalPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_OperatingLossCarryforwardsBeforeWriteDown" abstract="false" name="OperatingLossCarryforwardsBeforeWriteDown" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_DeferredTaxAssetsRightOfUseLiability" abstract="false" name="DeferredTaxAssetsRightOfUseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>clbs-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:845060b2-4e37-482c-8ae9-0e23a5d9619a,g:0f1463a6-505b-4611-9f37-25c6b798c5c1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="clbs-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1609d703-af18-4029-aa28-27118e38a242" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4194a5af-fd67-45c6-8dff-b63f40e18cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1609d703-af18-4029-aa28-27118e38a242" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4194a5af-fd67-45c6-8dff-b63f40e18cf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_18191b49-9404-4bd2-9df5-b783b1110400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1609d703-af18-4029-aa28-27118e38a242" xlink:to="loc_us-gaap_MarketableSecurities_18191b49-9404-4bd2-9df5-b783b1110400" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d8c5c393-b4a3-46b0-8242-fa7f27c36ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1609d703-af18-4029-aa28-27118e38a242" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d8c5c393-b4a3-46b0-8242-fa7f27c36ebb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2492d284-779b-42e7-9f6d-82e4aea9dd19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c014bae0-c550-40da-8c54-38cb841a7b61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2492d284-779b-42e7-9f6d-82e4aea9dd19" xlink:to="loc_us-gaap_PreferredStockValue_c014bae0-c550-40da-8c54-38cb841a7b61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9c631564-813a-4bd1-bca0-f6d4f18eccf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2492d284-779b-42e7-9f6d-82e4aea9dd19" xlink:to="loc_us-gaap_CommonStockValue_9c631564-813a-4bd1-bca0-f6d4f18eccf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_47bb13a5-05f8-4e85-8c0e-28f1e1b3ecac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2492d284-779b-42e7-9f6d-82e4aea9dd19" xlink:to="loc_us-gaap_AdditionalPaidInCapital_47bb13a5-05f8-4e85-8c0e-28f1e1b3ecac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_5fedd603-e740-42ff-9f59-7a7b48c11397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2492d284-779b-42e7-9f6d-82e4aea9dd19" xlink:to="loc_us-gaap_TreasuryStockValue_5fedd603-e740-42ff-9f59-7a7b48c11397" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6028a73c-57bb-4edd-9e0a-fccdd5aa422a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2492d284-779b-42e7-9f6d-82e4aea9dd19" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6028a73c-57bb-4edd-9e0a-fccdd5aa422a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_846f9226-5838-4ea8-9ffc-b532b1c13216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2492d284-779b-42e7-9f6d-82e4aea9dd19" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_846f9226-5838-4ea8-9ffc-b532b1c13216" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0378cabd-3ad0-4847-a7c9-756473603a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7b14d62d-e6cd-4692-bdec-3ad3f7e06552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0378cabd-3ad0-4847-a7c9-756473603a3a" xlink:to="loc_us-gaap_AssetsCurrent_7b14d62d-e6cd-4692-bdec-3ad3f7e06552" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d306f825-94b5-4a8a-bf26-a1eb35b1794c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0378cabd-3ad0-4847-a7c9-756473603a3a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d306f825-94b5-4a8a-bf26-a1eb35b1794c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fcb2bd0f-ec98-485f-88d9-e3483688c76e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0378cabd-3ad0-4847-a7c9-756473603a3a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fcb2bd0f-ec98-485f-88d9-e3483688c76e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2e8496c4-b88a-44bd-a9be-744ca7214d69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6bddcdbd-adac-40c4-89fc-2ecfb9beafc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2e8496c4-b88a-44bd-a9be-744ca7214d69" xlink:to="loc_us-gaap_StockholdersEquity_6bddcdbd-adac-40c4-89fc-2ecfb9beafc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_ed13a8e3-7e6a-49f1-b58c-95a509ba6195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2e8496c4-b88a-44bd-a9be-744ca7214d69" xlink:to="loc_us-gaap_MinorityInterest_ed13a8e3-7e6a-49f1-b58c-95a509ba6195" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_376f59d0-6950-4523-af7e-ebc634ec9733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6481062e-ef2c-4051-9d18-4a99b0cf583e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_376f59d0-6950-4523-af7e-ebc634ec9733" xlink:to="loc_us-gaap_LiabilitiesCurrent_6481062e-ef2c-4051-9d18-4a99b0cf583e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d8216fff-2a57-4ebe-855e-f58c732ea0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_376f59d0-6950-4523-af7e-ebc634ec9733" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d8216fff-2a57-4ebe-855e-f58c732ea0d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_54898cc4-63f3-4bfd-a10b-fb2ce894d9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d4ad0977-27e4-4aea-bc34-eff3227ad7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_54898cc4-63f3-4bfd-a10b-fb2ce894d9ea" xlink:to="loc_us-gaap_Liabilities_d4ad0977-27e4-4aea-bc34-eff3227ad7dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e1441130-c797-477f-9043-084f664d7dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_54898cc4-63f3-4bfd-a10b-fb2ce894d9ea" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e1441130-c797-477f-9043-084f664d7dce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3cd585bb-a8a9-405b-b723-befefeac0dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_54898cc4-63f3-4bfd-a10b-fb2ce894d9ea" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3cd585bb-a8a9-405b-b723-befefeac0dd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cd5d3419-0376-4fc9-b107-db8ad444aaba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ba12aeb1-4eec-4ba0-aa82-589d4a58d5db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cd5d3419-0376-4fc9-b107-db8ad444aaba" xlink:to="loc_us-gaap_AccountsPayableCurrent_ba12aeb1-4eec-4ba0-aa82-589d4a58d5db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b5141fa9-9015-4feb-ac90-99f499bb88d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cd5d3419-0376-4fc9-b107-db8ad444aaba" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b5141fa9-9015-4feb-ac90-99f499bb88d3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="clbs-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9284bae4-ad8f-4c90-9f23-94f282ca9622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_fdc4d487-b08a-4407-8adc-416b7aefd8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9284bae4-ad8f-4c90-9f23-94f282ca9622" xlink:to="loc_us-gaap_OperatingExpenses_fdc4d487-b08a-4407-8adc-416b7aefd8c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_337412ea-33e0-4b64-8228-2f582dfde11b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_f441b0a5-89d9-4344-a934-564238918e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_337412ea-33e0-4b64-8228-2f582dfde11b" xlink:to="loc_us-gaap_InvestmentIncomeNet_f441b0a5-89d9-4344-a934-564238918e40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6ea4c366-9015-4345-b19c-c5d3fde78988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_337412ea-33e0-4b64-8228-2f582dfde11b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6ea4c366-9015-4345-b19c-c5d3fde78988" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9b9ab460-73ac-42e2-9b5d-c602e6c5f695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1aa8425a-68e0-4c80-b7c0-88412d6b3b54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_9b9ab460-73ac-42e2-9b5d-c602e6c5f695" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1aa8425a-68e0-4c80-b7c0-88412d6b3b54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e0ab667b-5833-41b9-b8e4-1dcb2b261768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_9b9ab460-73ac-42e2-9b5d-c602e6c5f695" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e0ab667b-5833-41b9-b8e4-1dcb2b261768" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_25883736-3fe8-4c73-afc0-0bfe8de30eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_dab4998e-092a-42db-843c-d9636290136e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_25883736-3fe8-4c73-afc0-0bfe8de30eef" xlink:to="loc_us-gaap_OperatingIncomeLoss_dab4998e-092a-42db-843c-d9636290136e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1cb069f7-489b-4cee-a98e-88d67d869402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_25883736-3fe8-4c73-afc0-0bfe8de30eef" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1cb069f7-489b-4cee-a98e-88d67d869402" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_538c683c-615c-4f6e-9fec-5bcfe6f0351e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8189a5ce-1a42-4967-9d53-f147d822e16f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_538c683c-615c-4f6e-9fec-5bcfe6f0351e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8189a5ce-1a42-4967-9d53-f147d822e16f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_534fce93-cc77-4943-91ef-cf2132dccc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_538c683c-615c-4f6e-9fec-5bcfe6f0351e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_534fce93-cc77-4943-91ef-cf2132dccc1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_85e312dc-204f-442a-8e9d-37a63824220e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6ba4e2ef-586a-4698-a845-9f78b2cc2193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_85e312dc-204f-442a-8e9d-37a63824220e" xlink:to="loc_us-gaap_ProfitLoss_6ba4e2ef-586a-4698-a845-9f78b2cc2193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_43306d44-0e2b-4207-9748-f95cbf670068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_85e312dc-204f-442a-8e9d-37a63824220e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_43306d44-0e2b-4207-9748-f95cbf670068" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="clbs-20211231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d3909d7f-ad72-4191-b9c3-eabb6502fd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e905c022-d12c-498c-aaf1-257bf238a5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d3909d7f-ad72-4191-b9c3-eabb6502fd4b" xlink:to="loc_us-gaap_ProfitLoss_e905c022-d12c-498c-aaf1-257bf238a5f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_860f8801-f66e-4ef7-b5b5-dc066ab40f39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d3909d7f-ad72-4191-b9c3-eabb6502fd4b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_860f8801-f66e-4ef7-b5b5-dc066ab40f39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_47714cbc-54fa-4e7f-b972-d87fddd676a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a8bf290b-e892-45e5-8941-9273a1349ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_47714cbc-54fa-4e7f-b972-d87fddd676a9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a8bf290b-e892-45e5-8941-9273a1349ef5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8cbb289e-0d39-4727-8577-7eeaa8288f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_47714cbc-54fa-4e7f-b972-d87fddd676a9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_8cbb289e-0d39-4727-8577-7eeaa8288f8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f27d564b-6005-406a-bcee-7e96e26bd349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f95cf246-643e-4f4d-a01f-d1e1c0da3ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f27d564b-6005-406a-bcee-7e96e26bd349" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f95cf246-643e-4f4d-a01f-d1e1c0da3ce3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="clbs-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bbaa4351-cc65-4cb7-838c-db67cdf6fd92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_1bda066a-bf20-4d2a-b04a-33f4ba3123cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bbaa4351-cc65-4cb7-838c-db67cdf6fd92" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_1bda066a-bf20-4d2a-b04a-33f4ba3123cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_55ee0190-68f6-4b97-9b1b-9bdabbc74537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bbaa4351-cc65-4cb7-838c-db67cdf6fd92" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_55ee0190-68f6-4b97-9b1b-9bdabbc74537" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_da5e61e3-e2b7-4315-b36d-c3a009e8f1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bbaa4351-cc65-4cb7-838c-db67cdf6fd92" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_da5e61e3-e2b7-4315-b36d-c3a009e8f1f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15c4de47-03bb-4847-841f-df9faafafac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c4a69500-1673-4120-8400-f315aa396cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15c4de47-03bb-4847-841f-df9faafafac1" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c4a69500-1673-4120-8400-f315aa396cda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e3bea53f-e6be-4f37-b783-f5a5ba0a2032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15c4de47-03bb-4847-841f-df9faafafac1" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e3bea53f-e6be-4f37-b783-f5a5ba0a2032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7501e920-b0a8-4804-8003-a33e1610bc26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15c4de47-03bb-4847-841f-df9faafafac1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7501e920-b0a8-4804-8003-a33e1610bc26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6cb5caed-5db2-478b-8547-b088263bf863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_050eb265-3ba2-498f-8174-6d9e6bd7db72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6cb5caed-5db2-478b-8547-b088263bf863" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_050eb265-3ba2-498f-8174-6d9e6bd7db72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d22bace7-28d3-4e8b-bff8-71b89dc42ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6cb5caed-5db2-478b-8547-b088263bf863" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d22bace7-28d3-4e8b-bff8-71b89dc42ecb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2f86336-b89d-4d4e-9939-627b26d6c72b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6cb5caed-5db2-478b-8547-b088263bf863" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2f86336-b89d-4d4e-9939-627b26d6c72b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_29436cbe-4a33-47f4-9387-fe92db646d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6f7da1de-b8e9-4847-9f7a-543ab26bfa63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_29436cbe-4a33-47f4-9387-fe92db646d67" xlink:to="loc_us-gaap_ProfitLoss_6f7da1de-b8e9-4847-9f7a-543ab26bfa63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_e70918ce-7267-47d1-8564-abb4c80c005c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_29436cbe-4a33-47f4-9387-fe92db646d67" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_e70918ce-7267-47d1-8564-abb4c80c005c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_39e8842b-380b-4349-b521-c48dab00786a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_29436cbe-4a33-47f4-9387-fe92db646d67" xlink:to="loc_us-gaap_DepreciationAndAmortization_39e8842b-380b-4349-b521-c48dab00786a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2e87beb3-8424-4e34-9e15-d9d617d43d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_29436cbe-4a33-47f4-9387-fe92db646d67" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2e87beb3-8424-4e34-9e15-d9d617d43d18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0b6c6a71-2728-4577-9ba1-3586ec944425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_29436cbe-4a33-47f4-9387-fe92db646d67" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0b6c6a71-2728-4577-9ba1-3586ec944425" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_900144ba-a570-49af-ab70-3d77d831a105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_29436cbe-4a33-47f4-9387-fe92db646d67" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_900144ba-a570-49af-ab70-3d77d831a105" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_e09f5326-0a1b-456e-9c32-41ecdbd84c0e" xlink:href="clbs-20211231.xsd#clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_29436cbe-4a33-47f4-9387-fe92db646d67" xlink:to="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_e09f5326-0a1b-456e-9c32-41ecdbd84c0e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#AvailableforSaleSecuritiesSummaryDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f3f171b7-9e2f-4603-b847-610fedd547ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6382f398-de16-4ca8-b632-8592236c91cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f3f171b7-9e2f-4603-b847-610fedd547ad" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6382f398-de16-4ca8-b632-8592236c91cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_06043f87-b10a-4a0d-b64d-607b3d305750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f3f171b7-9e2f-4603-b847-610fedd547ad" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_06043f87-b10a-4a0d-b64d-607b3d305750" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7c04a0bc-e780-430f-9864-99492b632fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f3f171b7-9e2f-4603-b847-610fedd547ad" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7c04a0bc-e780-430f-9864-99492b632fba" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#AvailableforSaleSecuritiesContractualMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c063deec-5e54-428a-b015-a157b9fdbcd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_b5c2f6fe-1dd5-4875-b5f8-9aaf77584821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c063deec-5e54-428a-b015-a157b9fdbcd6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_b5c2f6fe-1dd5-4875-b5f8-9aaf77584821" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_38353d70-8bda-4a40-a606-ba3ac1e90e23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c063deec-5e54-428a-b015-a157b9fdbcd6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_38353d70-8bda-4a40-a606-ba3ac1e90e23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e665c929-ba7e-498e-b828-e8efdecb5a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a405003f-f1bb-4a79-a5b5-bf5891078c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e665c929-ba7e-498e-b828-e8efdecb5a75" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a405003f-f1bb-4a79-a5b5-bf5891078c71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ce987517-ca66-401e-b15a-389f024414a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e665c929-ba7e-498e-b828-e8efdecb5a75" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ce987517-ca66-401e-b15a-389f024414a1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#PropertyandEquipmentSummaryDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f3250d44-4586-4f63-b492-a695bebc1e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7a578294-fbc7-4ec8-897c-6dc439a2143d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f3250d44-4586-4f63-b492-a695bebc1e22" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7a578294-fbc7-4ec8-897c-6dc439a2143d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_49d4f91b-644c-4218-af12-e5284ec3be28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f3250d44-4586-4f63-b492-a695bebc1e22" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_49d4f91b-644c-4218-af12-e5284ec3be28" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_aab8d8b1-b8ec-45f1-88d9-0df046c86eac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_5f8bd528-820a-41d9-a152-f3c74e583b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_aab8d8b1-b8ec-45f1-88d9-0df046c86eac" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_5f8bd528-820a-41d9-a152-f3c74e583b5c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#AccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_9ad841b7-ac13-4a73-b0a8-a84a0259c1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_cb2d0524-e58d-42af-96f8-df7804b5528b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_9ad841b7-ac13-4a73-b0a8-a84a0259c1e5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_cb2d0524-e58d-42af-96f8-df7804b5528b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_55e3ce5d-0f48-464d-a37a-d3bca7d815ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_9ad841b7-ac13-4a73-b0a8-a84a0259c1e5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_55e3ce5d-0f48-464d-a37a-d3bca7d815ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_93d16fbd-4bca-44ae-90d9-0f050eff853a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_9ad841b7-ac13-4a73-b0a8-a84a0259c1e5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_93d16fbd-4bca-44ae-90d9-0f050eff853a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#OperatingLeasesBalanceSheetPresentationDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bc64bfd6-16dd-4539-9339-27edf23e6037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_53612129-026b-4734-9deb-dd7637efc278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_bc64bfd6-16dd-4539-9339-27edf23e6037" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_53612129-026b-4734-9deb-dd7637efc278" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_92dc56b3-3834-4646-8911-95ae300e6b00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_bc64bfd6-16dd-4539-9339-27edf23e6037" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_92dc56b3-3834-4646-8911-95ae300e6b00" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2b2b2dc3-49f9-483e-9da4-fe37d52bf31d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_debbff12-2c5c-4027-aa59-c51f33f8cdec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2b2b2dc3-49f9-483e-9da4-fe37d52bf31d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_debbff12-2c5c-4027-aa59-c51f33f8cdec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_62b0c9ea-7814-4944-8840-35861b64f5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2b2b2dc3-49f9-483e-9da4-fe37d52bf31d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_62b0c9ea-7814-4944-8840-35861b64f5e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d97f5a1e-ecba-4dae-bd3f-1d4917aa2da2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2b2b2dc3-49f9-483e-9da4-fe37d52bf31d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d97f5a1e-ecba-4dae-bd3f-1d4917aa2da2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0ca82e7d-da87-4beb-8cae-5b22173959c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2b2b2dc3-49f9-483e-9da4-fe37d52bf31d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0ca82e7d-da87-4beb-8cae-5b22173959c9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails_1" xlink:type="simple" xlink:href="clbs-20211231.xsd#OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails_1"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_25601e49-cf06-44b2-83c5-f95b42dcaeef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_83ba8a54-d1fb-42a4-aca1-80c5e9fea80c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_25601e49-cf06-44b2-83c5-f95b42dcaeef" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_83ba8a54-d1fb-42a4-aca1-80c5e9fea80c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3b830df8-c477-45ef-9c42-9255fc481811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_25601e49-cf06-44b2-83c5-f95b42dcaeef" xlink:to="loc_us-gaap_OperatingLeaseLiability_3b830df8-c477-45ef-9c42-9255fc481811" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6af14eb1-13d1-40b9-a53c-c07e4f5d6296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b716d5ba-e3ab-4d88-96d9-9d6b2fe61a58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6af14eb1-13d1-40b9-a53c-c07e4f5d6296" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b716d5ba-e3ab-4d88-96d9-9d6b2fe61a58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ec340d3e-8f71-4802-9704-77b3cd9672f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6af14eb1-13d1-40b9-a53c-c07e4f5d6296" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ec340d3e-8f71-4802-9704-77b3cd9672f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cdcba0a0-a228-480b-86fb-db41d5d4c444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_bffa56aa-7ee6-4504-96b1-aa37ea622012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_cdcba0a0-a228-480b-86fb-db41d5d4c444" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_bffa56aa-7ee6-4504-96b1-aa37ea622012" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_e7849282-177b-441e-b638-846487c55f56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_cdcba0a0-a228-480b-86fb-db41d5d4c444" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_e7849282-177b-441e-b638-846487c55f56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1ed41635-24c4-4e34-a5ac-25527e772e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4173bfa4-f4f1-4776-af02-beb9d33398b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1ed41635-24c4-4e34-a5ac-25527e772e85" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4173bfa4-f4f1-4776-af02-beb9d33398b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e5feae47-e248-4346-9430-01d236488604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1ed41635-24c4-4e34-a5ac-25527e772e85" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e5feae47-e248-4346-9430-01d236488604" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#IncomeTaxesEffectiveIncomeTaxReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8e83ab9a-8fe5-4487-96f7-1700bb05e9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_131830de-5033-49b3-8683-956fdd9a669a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8e83ab9a-8fe5-4487-96f7-1700bb05e9a9" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_131830de-5033-49b3-8683-956fdd9a669a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_edacc22e-f486-4830-888e-6f8e6bc26f03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8e83ab9a-8fe5-4487-96f7-1700bb05e9a9" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_edacc22e-f486-4830-888e-6f8e6bc26f03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount_17faade3-54d4-4d65-b069-8eda77592543" xlink:href="clbs-20211231.xsd#clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8e83ab9a-8fe5-4487-96f7-1700bb05e9a9" xlink:to="loc_clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount_17faade3-54d4-4d65-b069-8eda77592543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_ca7443b6-3e11-4936-97d1-c5cc507a9ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8e83ab9a-8fe5-4487-96f7-1700bb05e9a9" xlink:to="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_ca7443b6-3e11-4936-97d1-c5cc507a9ac4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_de6e9ce4-8d25-47ee-a0c4-4ed06e25116b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8e83ab9a-8fe5-4487-96f7-1700bb05e9a9" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_de6e9ce4-8d25-47ee-a0c4-4ed06e25116b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount_8f530cfd-a0ac-424f-9b47-8f466b7f73c0" xlink:href="clbs-20211231.xsd#clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8e83ab9a-8fe5-4487-96f7-1700bb05e9a9" xlink:to="loc_clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount_8f530cfd-a0ac-424f-9b47-8f466b7f73c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses_4e174f2d-2f40-4504-8490-fbdd83965678" xlink:href="clbs-20211231.xsd#clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8e83ab9a-8fe5-4487-96f7-1700bb05e9a9" xlink:to="loc_clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses_4e174f2d-2f40-4504-8490-fbdd83965678" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9e4d007a-41f1-4038-8712-be939b758660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8e83ab9a-8fe5-4487-96f7-1700bb05e9a9" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9e4d007a-41f1-4038-8712-be939b758660" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#IncomeTaxesComponentsofDeferredIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8623d8a8-33a5-4446-b44e-1ad0c33bcc99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_9121fcb4-8f35-43aa-afd5-9aa54bdee7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_8623d8a8-33a5-4446-b44e-1ad0c33bcc99" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_9121fcb4-8f35-43aa-afd5-9aa54bdee7f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_089ea12e-225b-4134-8b50-15ca17f2147e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_958f5ec6-ef83-48db-8456-f77712937ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_089ea12e-225b-4134-8b50-15ca17f2147e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_958f5ec6-ef83-48db-8456-f77712937ebd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_DeferredTaxAssetsRightOfUseLiability_20643546-9992-4be7-ac74-c6c50e238a61" xlink:href="clbs-20211231.xsd#clbs_DeferredTaxAssetsRightOfUseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_089ea12e-225b-4134-8b50-15ca17f2147e" xlink:to="loc_clbs_DeferredTaxAssetsRightOfUseLiability_20643546-9992-4be7-ac74-c6c50e238a61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_dd41052b-9efb-4b0b-9a64-b7a7d5398316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_089ea12e-225b-4134-8b50-15ca17f2147e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_dd41052b-9efb-4b0b-9a64-b7a7d5398316" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_07892123-4dd9-46b1-a4d1-96989d629084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_089ea12e-225b-4134-8b50-15ca17f2147e" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_07892123-4dd9-46b1-a4d1-96989d629084" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_DeferredTaxAssetsAccumulatedDepreciation_5c2da5fa-f16a-49e7-8c40-e24b11f60287" xlink:href="clbs-20211231.xsd#clbs_DeferredTaxAssetsAccumulatedDepreciation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_089ea12e-225b-4134-8b50-15ca17f2147e" xlink:to="loc_clbs_DeferredTaxAssetsAccumulatedDepreciation_5c2da5fa-f16a-49e7-8c40-e24b11f60287" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_de8b3a8a-509c-48bd-ac18-d5a49e6b5e13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_089ea12e-225b-4134-8b50-15ca17f2147e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_de8b3a8a-509c-48bd-ac18-d5a49e6b5e13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_c475604e-9805-4929-a9c2-b554d4f7b018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_089ea12e-225b-4134-8b50-15ca17f2147e" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_c475604e-9805-4929-a9c2-b554d4f7b018" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_NetDeferredTaxAssetsAndLiabilitiesGross_b2d62343-72b6-4e82-91f7-1a7223208e75" xlink:href="clbs-20211231.xsd#clbs_NetDeferredTaxAssetsAndLiabilitiesGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_692f5d07-ac4e-40b9-8a4a-8b17873bf6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_clbs_NetDeferredTaxAssetsAndLiabilitiesGross_b2d62343-72b6-4e82-91f7-1a7223208e75" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_692f5d07-ac4e-40b9-8a4a-8b17873bf6b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_829c0f7b-d521-4745-a448-b40e51322c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_clbs_NetDeferredTaxAssetsAndLiabilitiesGross_b2d62343-72b6-4e82-91f7-1a7223208e75" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_829c0f7b-d521-4745-a448-b40e51322c21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_762ef33e-ff9e-47c6-ad9d-94a3f4fca99b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_NetDeferredTaxAssetsAndLiabilitiesGross_76255dee-2e5f-45d0-9a29-8bc50d4b2bac" xlink:href="clbs-20211231.xsd#clbs_NetDeferredTaxAssetsAndLiabilitiesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_762ef33e-ff9e-47c6-ad9d-94a3f4fca99b" xlink:to="loc_clbs_NetDeferredTaxAssetsAndLiabilitiesGross_76255dee-2e5f-45d0-9a29-8bc50d4b2bac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5fcd1b57-431d-472a-8e99-8e27eca1ff2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_762ef33e-ff9e-47c6-ad9d-94a3f4fca99b" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5fcd1b57-431d-472a-8e99-8e27eca1ff2b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>clbs-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:845060b2-4e37-482c-8ae9-0e23a5d9619a,g:0f1463a6-505b-4611-9f37-25c6b798c5c1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="clbs-20211231.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="extended" id="i4a846d916c134b2eb5a80f884198d611_ConsolidatedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_05af0079-e9ff-4825-968b-23654e55c428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_05af0079-e9ff-4825-968b-23654e55c428" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0187dc07-0ab6-457c-86c9-25c80ed39de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_SharesOutstanding_0187dc07-0ab6-457c-86c9-25c80ed39de2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3277ebd2-8cf7-45f1-b211-a41c15855ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3277ebd2-8cf7-45f1-b211-a41c15855ea1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e9ab9180-2652-4b47-9ea2-a68ca1374692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_ProfitLoss_e9ab9180-2652-4b47-9ea2-a68ca1374692" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_23ef7a3f-0f71-4bd0-a316-8b311d74589a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_23ef7a3f-0f71-4bd0-a316-8b311d74589a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1209cc5d-ed41-4452-b238-b47d806ba8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1209cc5d-ed41-4452-b238-b47d806ba8ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b0a7d9c4-dc30-487f-9305-3ca07f38a71b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b0a7d9c4-dc30-487f-9305-3ca07f38a71b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eedd5569-c6d6-4306-892a-180d6aff7306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eedd5569-c6d6-4306-892a-180d6aff7306" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a0c9804d-5791-4577-8e32-07471f6cd717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a0c9804d-5791-4577-8e32-07471f6cd717" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c8adae18-9920-4e6b-9763-5ec5a74b9020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c8adae18-9920-4e6b-9763-5ec5a74b9020" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2c5c5ad7-00a4-4449-a24a-97ae2d87584b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2c5c5ad7-00a4-4449-a24a-97ae2d87584b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e874aec8-9852-4832-8d45-eb5a01aa5a86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b1c31a53-61de-4972-81cf-bf8d3c7207ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c0ec2df1-a39d-4ed8-af41-4f637ae392a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_05af0079-e9ff-4825-968b-23654e55c428" xlink:to="loc_us-gaap_StatementTable_c0ec2df1-a39d-4ed8-af41-4f637ae392a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_53f53346-5fcf-4799-9bcc-e48e992855c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c0ec2df1-a39d-4ed8-af41-4f637ae392a4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_53f53346-5fcf-4799-9bcc-e48e992855c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_53f53346-5fcf-4799-9bcc-e48e992855c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_53f53346-5fcf-4799-9bcc-e48e992855c5" xlink:to="loc_us-gaap_EquityComponentDomain_53f53346-5fcf-4799-9bcc-e48e992855c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2ae2690d-cf5b-4f31-9b84-550be0168fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_53f53346-5fcf-4799-9bcc-e48e992855c5" xlink:to="loc_us-gaap_EquityComponentDomain_2ae2690d-cf5b-4f31-9b84-550be0168fb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_81234089-dd7f-4052-9558-cd3fb5f2e243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2ae2690d-cf5b-4f31-9b84-550be0168fb0" xlink:to="loc_us-gaap_ParentMember_81234089-dd7f-4052-9558-cd3fb5f2e243" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_866a01d2-98e9-4ff2-a079-be4349ea9037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_81234089-dd7f-4052-9558-cd3fb5f2e243" xlink:to="loc_us-gaap_PreferredStockMember_866a01d2-98e9-4ff2-a079-be4349ea9037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9cb01ae7-1a40-4a57-a87e-ed899a431e50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_81234089-dd7f-4052-9558-cd3fb5f2e243" xlink:to="loc_us-gaap_CommonStockMember_9cb01ae7-1a40-4a57-a87e-ed899a431e50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ec16d31f-2a55-45e5-bb10-aadefce204cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_81234089-dd7f-4052-9558-cd3fb5f2e243" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ec16d31f-2a55-45e5-bb10-aadefce204cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2d192b7b-f84c-4025-a454-acad5c92b164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_81234089-dd7f-4052-9558-cd3fb5f2e243" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2d192b7b-f84c-4025-a454-acad5c92b164" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b37e7740-4a18-49fe-a784-392c140e24bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_81234089-dd7f-4052-9558-cd3fb5f2e243" xlink:to="loc_us-gaap_RetainedEarningsMember_b37e7740-4a18-49fe-a784-392c140e24bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_80a79514-7559-4b01-b495-dcc1adf2a1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_81234089-dd7f-4052-9558-cd3fb5f2e243" xlink:to="loc_us-gaap_TreasuryStockMember_80a79514-7559-4b01-b495-dcc1adf2a1ee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_d35845a1-4bd1-46d1-af0c-8f570581857b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2ae2690d-cf5b-4f31-9b84-550be0168fb0" xlink:to="loc_us-gaap_NoncontrollingInterestMember_d35845a1-4bd1-46d1-af0c-8f570581857b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TheBusinessDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#TheBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/TheBusinessDetails" xlink:type="extended" id="if9ec0a56f4e14d3298291757aee99268_TheBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9b374caf-bd86-4627-8dce-2e9e3d6208ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_970225f3-203c-40d8-bf81-caa0cca07e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9b374caf-bd86-4627-8dce-2e9e3d6208ee" xlink:to="loc_us-gaap_GrantsReceivable_970225f3-203c-40d8-bf81-caa0cca07e0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b97ab80e-fc6d-47bf-93a6-62c64050baf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9b374caf-bd86-4627-8dce-2e9e3d6208ee" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b97ab80e-fc6d-47bf-93a6-62c64050baf4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1c5f5af4-1ab9-47dd-a107-1803fc88c02a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b97ab80e-fc6d-47bf-93a6-62c64050baf4" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1c5f5af4-1ab9-47dd-a107-1803fc88c02a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_1c5f5af4-1ab9-47dd-a107-1803fc88c02a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1c5f5af4-1ab9-47dd-a107-1803fc88c02a" xlink:to="loc_us-gaap_ProjectMember_1c5f5af4-1ab9-47dd-a107-1803fc88c02a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_e463e2ad-1594-47dc-b919-bdc006d730d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1c5f5af4-1ab9-47dd-a107-1803fc88c02a" xlink:to="loc_us-gaap_ProjectMember_e463e2ad-1594-47dc-b919-bdc006d730d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CLBS16TreatmentOfCMDMember_e16ca443-33b4-4fad-b52f-e3e5b0f54838" xlink:href="clbs-20211231.xsd#clbs_CLBS16TreatmentOfCMDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_e463e2ad-1594-47dc-b919-bdc006d730d7" xlink:to="loc_clbs_CLBS16TreatmentOfCMDMember_e16ca443-33b4-4fad-b52f-e3e5b0f54838" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="iaa828cdb416142278ffde8a8b0cf2768_SummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_24e32422-779e-495d-96e9-fa8358378719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6d41b536-ef72-41fb-bd78-7fcf8864a314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_24e32422-779e-495d-96e9-fa8358378719" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6d41b536-ef72-41fb-bd78-7fcf8864a314" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a190e933-8106-4d2d-812b-68b478ed699b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_24e32422-779e-495d-96e9-fa8358378719" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a190e933-8106-4d2d-812b-68b478ed699b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bef6879f-4809-49f0-a0eb-16bade456d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a190e933-8106-4d2d-812b-68b478ed699b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bef6879f-4809-49f0-a0eb-16bade456d62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bef6879f-4809-49f0-a0eb-16bade456d62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bef6879f-4809-49f0-a0eb-16bade456d62" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bef6879f-4809-49f0-a0eb-16bade456d62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_37e81acc-ff8a-4d88-b801-3d6b425cf815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bef6879f-4809-49f0-a0eb-16bade456d62" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_37e81acc-ff8a-4d88-b801-3d6b425cf815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d9eea33c-1780-441e-8132-8c1926c8b84c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_37e81acc-ff8a-4d88-b801-3d6b425cf815" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d9eea33c-1780-441e-8132-8c1926c8b84c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d831a233-0261-4425-8d31-3afb582fc139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_37e81acc-ff8a-4d88-b801-3d6b425cf815" xlink:to="loc_us-gaap_ComputerEquipmentMember_d831a233-0261-4425-8d31-3afb582fc139" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_f85fc976-a482-40a6-9ceb-08c7233df711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_37e81acc-ff8a-4d88-b801-3d6b425cf815" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_f85fc976-a482-40a6-9ceb-08c7233df711" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#AvailableforSaleSecuritiesSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails" xlink:type="extended" id="i1484d9edfb794bd8b81070a9beb6237a_AvailableforSaleSecuritiesSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8c8a7227-e004-4800-aa48-2f8f60243ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_00cf49b3-a722-4a7e-8d6b-80de852f2f70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8c8a7227-e004-4800-aa48-2f8f60243ac4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_00cf49b3-a722-4a7e-8d6b-80de852f2f70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_086e2a28-d417-4bea-aa55-e9eac04f6c47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8c8a7227-e004-4800-aa48-2f8f60243ac4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_086e2a28-d417-4bea-aa55-e9eac04f6c47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_201f901e-ff76-428d-b35c-32cf2ac5254a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8c8a7227-e004-4800-aa48-2f8f60243ac4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_201f901e-ff76-428d-b35c-32cf2ac5254a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3ee50742-c423-46eb-8c39-82b6707f1039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8c8a7227-e004-4800-aa48-2f8f60243ac4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3ee50742-c423-46eb-8c39-82b6707f1039" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0e0f3b48-47c7-430c-9689-edcabd57cd76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8c8a7227-e004-4800-aa48-2f8f60243ac4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0e0f3b48-47c7-430c-9689-edcabd57cd76" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_24039a3c-938c-417a-8704-1f77a027051f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0e0f3b48-47c7-430c-9689-edcabd57cd76" xlink:to="loc_us-gaap_FinancialInstrumentAxis_24039a3c-938c-417a-8704-1f77a027051f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24039a3c-938c-417a-8704-1f77a027051f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_24039a3c-938c-417a-8704-1f77a027051f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24039a3c-938c-417a-8704-1f77a027051f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74ed7212-efdd-4801-94c5-61ea5d935b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_24039a3c-938c-417a-8704-1f77a027051f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74ed7212-efdd-4801-94c5-61ea5d935b45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6f175543-f892-4dd1-9966-e7fcd2063f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74ed7212-efdd-4801-94c5-61ea5d935b45" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6f175543-f892-4dd1-9966-e7fcd2063f51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_cfcf37c7-74fa-4ddd-a6ce-a0694e8777c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74ed7212-efdd-4801-94c5-61ea5d935b45" xlink:to="loc_us-gaap_MoneyMarketFundsMember_cfcf37c7-74fa-4ddd-a6ce-a0694e8777c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_1a7a49d9-c35f-4f4d-b25b-be166afa6a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74ed7212-efdd-4801-94c5-61ea5d935b45" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_1a7a49d9-c35f-4f4d-b25b-be166afa6a5f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationonConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#AvailableforSaleSecuritiesClassificationonConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationonConsolidatedBalanceSheetsDetails" xlink:type="extended" id="i4e3631ba312449359527fd44c592b547_AvailableforSaleSecuritiesClassificationonConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_dc3d271b-369a-4bd6-9821-7ce6dd44c8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_57addc31-1bbc-4447-9f68-51c631a4ece6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_dc3d271b-369a-4bd6-9821-7ce6dd44c8f5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_57addc31-1bbc-4447-9f68-51c631a4ece6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bb934fb8-a714-49a7-a227-cbcf89d60ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_dc3d271b-369a-4bd6-9821-7ce6dd44c8f5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bb934fb8-a714-49a7-a227-cbcf89d60ebe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3bf535cb-9b3a-4b68-8707-b23270a67d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bb934fb8-a714-49a7-a227-cbcf89d60ebe" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3bf535cb-9b3a-4b68-8707-b23270a67d42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3bf535cb-9b3a-4b68-8707-b23270a67d42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3bf535cb-9b3a-4b68-8707-b23270a67d42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3bf535cb-9b3a-4b68-8707-b23270a67d42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_870139c7-d514-4908-af31-bf2baa3b9e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3bf535cb-9b3a-4b68-8707-b23270a67d42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_870139c7-d514-4908-af31-bf2baa3b9e2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_66eaf030-4b6e-438f-8a07-0029bff635c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_870139c7-d514-4908-af31-bf2baa3b9e2f" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_66eaf030-4b6e-438f-8a07-0029bff635c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MarketableSecuritiesMember_64610be8-77b6-4f26-8f68-a3b102ba9c1e" xlink:href="clbs-20211231.xsd#clbs_MarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_870139c7-d514-4908-af31-bf2baa3b9e2f" xlink:to="loc_clbs_MarketableSecuritiesMember_64610be8-77b6-4f26-8f68-a3b102ba9c1e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#PropertyandEquipmentSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails" xlink:type="extended" id="i0bbc9950833a4040a6cce419e61532b9_PropertyandEquipmentSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_64971296-deed-4f77-b6e7-351eebee7620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5df0510c-4c77-4afe-a53d-cc700d7e6356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_64971296-deed-4f77-b6e7-351eebee7620" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5df0510c-4c77-4afe-a53d-cc700d7e6356" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_367edbf8-b676-4c03-81be-9c60807eb08e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_64971296-deed-4f77-b6e7-351eebee7620" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_367edbf8-b676-4c03-81be-9c60807eb08e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8d40343d-4759-4cc5-9045-87a2032d7b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_64971296-deed-4f77-b6e7-351eebee7620" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8d40343d-4759-4cc5-9045-87a2032d7b3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fbcddba6-677d-46dd-8abc-9db055af4dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_64971296-deed-4f77-b6e7-351eebee7620" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fbcddba6-677d-46dd-8abc-9db055af4dc4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_19ff6e96-525f-43d0-9c8b-c5c1eac6adf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fbcddba6-677d-46dd-8abc-9db055af4dc4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_19ff6e96-525f-43d0-9c8b-c5c1eac6adf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_19ff6e96-525f-43d0-9c8b-c5c1eac6adf3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_19ff6e96-525f-43d0-9c8b-c5c1eac6adf3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_19ff6e96-525f-43d0-9c8b-c5c1eac6adf3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee862a01-8eaa-4d29-ab6f-de8bd29b0d41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_19ff6e96-525f-43d0-9c8b-c5c1eac6adf3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee862a01-8eaa-4d29-ab6f-de8bd29b0d41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5e737a79-a5f7-47bd-b374-d608655d7019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee862a01-8eaa-4d29-ab6f-de8bd29b0d41" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5e737a79-a5f7-47bd-b374-d608655d7019" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_11e70072-f36e-4de2-94c8-fcdf433de8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee862a01-8eaa-4d29-ab6f-de8bd29b0d41" xlink:to="loc_us-gaap_ComputerEquipmentMember_11e70072-f36e-4de2-94c8-fcdf433de8e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d0a5a0a3-7b8b-41ba-bf25-c9a2c98ea79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee862a01-8eaa-4d29-ab6f-de8bd29b0d41" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d0a5a0a3-7b8b-41ba-bf25-c9a2c98ea79f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/LossPerShareDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#LossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/LossPerShareDetails" xlink:type="extended" id="id6173af6f2694cd684033bcb48440116_LossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a03c7d9c-6315-419e-ab00-cd25411f52c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_77db4e62-e4ad-4908-a680-c133b9ec16e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a03c7d9c-6315-419e-ab00-cd25411f52c2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_77db4e62-e4ad-4908-a680-c133b9ec16e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b0f72c2d-0a68-4a0b-86d7-2948cb34f818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a03c7d9c-6315-419e-ab00-cd25411f52c2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b0f72c2d-0a68-4a0b-86d7-2948cb34f818" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_edf8cc13-b962-46a0-8472-bbaa4b063e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b0f72c2d-0a68-4a0b-86d7-2948cb34f818" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_edf8cc13-b962-46a0-8472-bbaa4b063e60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_edf8cc13-b962-46a0-8472-bbaa4b063e60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_edf8cc13-b962-46a0-8472-bbaa4b063e60" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_edf8cc13-b962-46a0-8472-bbaa4b063e60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_da8130f6-be40-4f1e-b518-2cc510857c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_edf8cc13-b962-46a0-8472-bbaa4b063e60" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_da8130f6-be40-4f1e-b518-2cc510857c3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f33c2fd0-e7dc-4910-9469-d672fd03090c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_da8130f6-be40-4f1e-b518-2cc510857c3e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f33c2fd0-e7dc-4910-9469-d672fd03090c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_221ea354-3302-4a7d-bf99-384a420d2e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_da8130f6-be40-4f1e-b518-2cc510857c3e" xlink:to="loc_us-gaap_WarrantMember_221ea354-3302-4a7d-bf99-384a420d2e78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3ccd6acd-8b05-49fa-acf1-5331ce18e09f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_da8130f6-be40-4f1e-b518-2cc510857c3e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3ccd6acd-8b05-49fa-acf1-5331ce18e09f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="if3299338073f40b79b1bf55547bbd569_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c4295414-10f4-4fb7-87b4-8ed33ff38d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_c67ea93a-b0f8-47fb-9dd2-405ebc7bd6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c4295414-10f4-4fb7-87b4-8ed33ff38d48" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_c67ea93a-b0f8-47fb-9dd2-405ebc7bd6a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_04be93bd-b2ac-4652-a411-1fe86a591a36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c67ea93a-b0f8-47fb-9dd2-405ebc7bd6a1" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_04be93bd-b2ac-4652-a411-1fe86a591a36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1a6d8f7a-3e9e-4556-a641-7cc0ba0df4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c67ea93a-b0f8-47fb-9dd2-405ebc7bd6a1" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1a6d8f7a-3e9e-4556-a641-7cc0ba0df4c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83b7bfbb-68dd-4ed4-8d06-88aad0180716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c4295414-10f4-4fb7-87b4-8ed33ff38d48" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83b7bfbb-68dd-4ed4-8d06-88aad0180716" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5499ddef-89d8-4976-b3b3-9246e58eb431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83b7bfbb-68dd-4ed4-8d06-88aad0180716" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5499ddef-89d8-4976-b3b3-9246e58eb431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5499ddef-89d8-4976-b3b3-9246e58eb431_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5499ddef-89d8-4976-b3b3-9246e58eb431" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5499ddef-89d8-4976-b3b3-9246e58eb431_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6bd10ac5-375c-451b-b19a-66505a5a31c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5499ddef-89d8-4976-b3b3-9246e58eb431" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6bd10ac5-375c-451b-b19a-66505a5a31c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_fd159745-5b5f-4f0a-ba8a-98ecdcc4851d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6bd10ac5-375c-451b-b19a-66505a5a31c5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_fd159745-5b5f-4f0a-ba8a-98ecdcc4851d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09f56641-de66-4eb0-b347-db0dd9c074e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83b7bfbb-68dd-4ed4-8d06-88aad0180716" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09f56641-de66-4eb0-b347-db0dd9c074e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_09f56641-de66-4eb0-b347-db0dd9c074e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09f56641-de66-4eb0-b347-db0dd9c074e5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_09f56641-de66-4eb0-b347-db0dd9c074e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7755dd55-c9b6-41f4-a4e3-f765a0a14dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09f56641-de66-4eb0-b347-db0dd9c074e5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7755dd55-c9b6-41f4-a4e3-f765a0a14dca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1af238fe-20d8-44de-a1c5-ed42e87d0617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7755dd55-c9b6-41f4-a4e3-f765a0a14dca" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1af238fe-20d8-44de-a1c5-ed42e87d0617" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fd30bd8b-91e7-4711-831e-6a7d81620891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7755dd55-c9b6-41f4-a4e3-f765a0a14dca" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fd30bd8b-91e7-4711-831e-6a7d81620891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e58259df-7edc-4b08-b785-296fd419b1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7755dd55-c9b6-41f4-a4e3-f765a0a14dca" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e58259df-7edc-4b08-b785-296fd419b1c0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#StockholdersEquityEquityPlanDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails" xlink:type="extended" id="i337ffce93a9948689929650ba7e4218b_StockholdersEquityEquityPlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4862b2d0-1f0d-47cb-9c12-9eb8e85ccf21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4862b2d0-1f0d-47cb-9c12-9eb8e85ccf21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9e5fa60c-cddb-41b8-bfdf-69f4383a38f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9e5fa60c-cddb-41b8-bfdf-69f4383a38f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b3fd1b9e-a506-47c3-a5d2-2930b9cf86d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b3fd1b9e-a506-47c3-a5d2-2930b9cf86d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan_df64cbc2-5e45-405d-8a37-a67ad77eff13" xlink:href="clbs-20211231.xsd#clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan_df64cbc2-5e45-405d-8a37-a67ad77eff13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm_b3d4c7ac-9f5b-491e-a299-2e5581a68167" xlink:href="clbs-20211231.xsd#clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm_b3d4c7ac-9f5b-491e-a299-2e5581a68167" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent_c8973c93-a320-4775-8ef7-fd1cb07c8978" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent_c8973c93-a320-4775-8ef7-fd1cb07c8978" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee_729a2219-d868-4197-8216-e86b54675812" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee_729a2219-d868-4197-8216-e86b54675812" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate_5b2099d0-877f-4b1b-ae16-6dd5234d265e" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate_5b2099d0-877f-4b1b-ae16-6dd5234d265e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate_1887ec9f-f9a7-4cdd-8e0f-82cb34cc594f" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate_1887ec9f-f9a7-4cdd-8e0f-82cb34cc594f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ef9a7156-618a-4a6e-b49f-bea434020367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ef9a7156-618a-4a6e-b49f-bea434020367" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ee6e889-5833-45ef-8da7-6bb69861d649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ee6e889-5833-45ef-8da7-6bb69861d649" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3d2532f1-a729-44a1-8d93-86abb58de0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ee6e889-5833-45ef-8da7-6bb69861d649" xlink:to="loc_us-gaap_PlanNameAxis_3d2532f1-a729-44a1-8d93-86abb58de0dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3d2532f1-a729-44a1-8d93-86abb58de0dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_3d2532f1-a729-44a1-8d93-86abb58de0dd" xlink:to="loc_us-gaap_PlanNameDomain_3d2532f1-a729-44a1-8d93-86abb58de0dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ffb171b9-e1ca-48a2-bf32-7029cac71a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_3d2532f1-a729-44a1-8d93-86abb58de0dd" xlink:to="loc_us-gaap_PlanNameDomain_ffb171b9-e1ca-48a2-bf32-7029cac71a1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EquityIncentiveCompensationPlan2018Member_5cb4212c-0417-4981-84a9-154aaab8a983" xlink:href="clbs-20211231.xsd#clbs_EquityIncentiveCompensationPlan2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ffb171b9-e1ca-48a2-bf32-7029cac71a1e" xlink:to="loc_clbs_EquityIncentiveCompensationPlan2018Member_5cb4212c-0417-4981-84a9-154aaab8a983" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlanMember_fabd725d-fa34-4da0-abab-3d5c7be39adc" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ffb171b9-e1ca-48a2-bf32-7029cac71a1e" xlink:to="loc_clbs_EmployeeStockPurchasePlanMember_fabd725d-fa34-4da0-abab-3d5c7be39adc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlan2012Member_8c148aa5-fe1d-44b6-b734-303b097e548d" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlan2012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ffb171b9-e1ca-48a2-bf32-7029cac71a1e" xlink:to="loc_clbs_EmployeeStockPurchasePlan2012Member_8c148aa5-fe1d-44b6-b734-303b097e548d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlan2017Member_df158b66-e03c-4cb6-92e3-e15190e42bd3" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlan2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ffb171b9-e1ca-48a2-bf32-7029cac71a1e" xlink:to="loc_clbs_EmployeeStockPurchasePlan2017Member_df158b66-e03c-4cb6-92e3-e15190e42bd3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlan2017AmendedMember_f5aa8d55-53e6-436f-9978-f2b7e4865dc9" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlan2017AmendedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ffb171b9-e1ca-48a2-bf32-7029cac71a1e" xlink:to="loc_clbs_EmployeeStockPurchasePlan2017AmendedMember_f5aa8d55-53e6-436f-9978-f2b7e4865dc9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4bd6a4c2-33a4-4b78-8005-1b084f6afff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ee6e889-5833-45ef-8da7-6bb69861d649" xlink:to="loc_us-gaap_AwardTypeAxis_4bd6a4c2-33a4-4b78-8005-1b084f6afff9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4bd6a4c2-33a4-4b78-8005-1b084f6afff9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4bd6a4c2-33a4-4b78-8005-1b084f6afff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4bd6a4c2-33a4-4b78-8005-1b084f6afff9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72b7d393-5b3c-48ca-83a9-727fa6eb50e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4bd6a4c2-33a4-4b78-8005-1b084f6afff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72b7d393-5b3c-48ca-83a9-727fa6eb50e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_903e90c1-0672-4595-9a1d-c8be6f82f74f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72b7d393-5b3c-48ca-83a9-727fa6eb50e3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_903e90c1-0672-4595-9a1d-c8be6f82f74f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_694f55ba-006c-40b2-a1e8-273e324ca06b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ee6e889-5833-45ef-8da7-6bb69861d649" xlink:to="loc_us-gaap_VestingAxis_694f55ba-006c-40b2-a1e8-273e324ca06b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_694f55ba-006c-40b2-a1e8-273e324ca06b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_694f55ba-006c-40b2-a1e8-273e324ca06b" xlink:to="loc_us-gaap_VestingDomain_694f55ba-006c-40b2-a1e8-273e324ca06b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_386dc372-e7c7-4c11-a419-26221c7359d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_694f55ba-006c-40b2-a1e8-273e324ca06b" xlink:to="loc_us-gaap_VestingDomain_386dc372-e7c7-4c11-a419-26221c7359d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_20b9ea79-b763-44c9-acea-44d42f5cc60f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_386dc372-e7c7-4c11-a419-26221c7359d9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_20b9ea79-b763-44c9-acea-44d42f5cc60f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_45961a7c-55b2-413b-a18c-1214bacc1e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_386dc372-e7c7-4c11-a419-26221c7359d9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_45961a7c-55b2-413b-a18c-1214bacc1e55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_0565eb0f-6e27-4cb9-9d5e-58be32dba5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_386dc372-e7c7-4c11-a419-26221c7359d9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_0565eb0f-6e27-4cb9-9d5e-58be32dba5e8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#StockholdersEquityEquityIssuancesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="extended" id="i56f1afb094714de2bfb98b1f96857146_StockholdersEquityEquityIssuancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_2f47b314-21b1-4db8-9344-b54d9929ef95" xlink:href="clbs-20211231.xsd#clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_2f47b314-21b1-4db8-9344-b54d9929ef95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_89028d77-7d82-45e0-9926-d19f6ce02226" xlink:href="clbs-20211231.xsd#clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_89028d77-7d82-45e0-9926-d19f6ce02226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fa5c463d-4c04-4376-9a73-7caca6b27c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fa5c463d-4c04-4376-9a73-7caca6b27c18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_853d04b5-0847-47a2-ab72-e2504f76dd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_853d04b5-0847-47a2-ab72-e2504f76dd6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6593c21e-9a13-433a-b370-82299a2d593e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6593c21e-9a13-433a-b370-82299a2d593e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_TermOfAgreement_86b7689b-dabe-4191-a48e-39238e170b55" xlink:href="clbs-20211231.xsd#clbs_TermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_clbs_TermOfAgreement_86b7689b-dabe-4191-a48e-39238e170b55" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_181cb76f-657f-4a12-911b-b4c755f0e1f0" xlink:href="clbs-20211231.xsd#clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_181cb76f-657f-4a12-911b-b4c755f0e1f0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_7828fcba-a4d6-4d6f-8b88-d43877badbb3" xlink:href="clbs-20211231.xsd#clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_7828fcba-a4d6-4d6f-8b88-d43877badbb3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_347a77c9-cb38-4058-8bc1-4a205d32df21" xlink:href="clbs-20211231.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_347a77c9-cb38-4058-8bc1-4a205d32df21" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_38e712f3-418d-4704-8fcf-76f211872ee0" xlink:href="clbs-20211231.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_38e712f3-418d-4704-8fcf-76f211872ee0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_8fc53f47-9911-42fc-bb0d-4b6fc9c964a7" xlink:href="clbs-20211231.xsd#clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_8fc53f47-9911-42fc-bb0d-4b6fc9c964a7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice_826de393-2dd9-4f98-a2f1-62d12eb873b8" xlink:href="clbs-20211231.xsd#clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice_826de393-2dd9-4f98-a2f1-62d12eb873b8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent_c05c4ab9-d5d8-46b4-ad0b-c30b9d891b5e" xlink:href="clbs-20211231.xsd#clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent_c05c4ab9-d5d8-46b4-ad0b-c30b9d891b5e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_150a58e9-d0ae-426e-a810-4656ea0edb96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_150a58e9-d0ae-426e-a810-4656ea0edb96" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f1b05989-51a5-40f0-8030-d73daa9ce042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f1b05989-51a5-40f0-8030-d73daa9ce042" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_63f0fddd-ef59-457a-b3c8-f3ed155fa90e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_63f0fddd-ef59-457a-b3c8-f3ed155fa90e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_21136483-ebac-4b53-a613-4948526eaf19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_21136483-ebac-4b53-a613-4948526eaf19" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_572411e6-88ea-4004-b3bb-971809928ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_572411e6-88ea-4004-b3bb-971809928ed3" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2b719106-c0d9-407f-a7e5-b2efff509a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2b719106-c0d9-407f-a7e5-b2efff509a4e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_4ed5dcdb-9eab-4adc-b9f7-1a68881e2c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_4ed5dcdb-9eab-4adc-b9f7-1a68881e2c86" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_8d305b7a-7ce6-40f8-bc54-c2b93f7edb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_8d305b7a-7ce6-40f8-bc54-c2b93f7edb4e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c76fadc7-f271-4cd9-b7e4-81d4b4d1b781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c76fadc7-f271-4cd9-b7e4-81d4b4d1b781" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4d18a83a-0ddc-445f-93fe-e419b2ee2f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c76fadc7-f271-4cd9-b7e4-81d4b4d1b781" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4d18a83a-0ddc-445f-93fe-e419b2ee2f6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d18a83a-0ddc-445f-93fe-e419b2ee2f6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4d18a83a-0ddc-445f-93fe-e419b2ee2f6d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d18a83a-0ddc-445f-93fe-e419b2ee2f6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a5cf593-7582-4644-b3a5-70b716a62533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4d18a83a-0ddc-445f-93fe-e419b2ee2f6d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a5cf593-7582-4644-b3a5-70b716a62533" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LincolnParkAgreementMember_104893cc-3909-432a-82e7-3fa505c64b7f" xlink:href="clbs-20211231.xsd#clbs_LincolnParkAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a5cf593-7582-4644-b3a5-70b716a62533" xlink:to="loc_clbs_LincolnParkAgreementMember_104893cc-3909-432a-82e7-3fa505c64b7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_H.C.WainwrightSalesAmendedAgreementMember_929c26ba-eafd-4a6d-96b3-126384b8f197" xlink:href="clbs-20211231.xsd#clbs_H.C.WainwrightSalesAmendedAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a5cf593-7582-4644-b3a5-70b716a62533" xlink:to="loc_clbs_H.C.WainwrightSalesAmendedAgreementMember_929c26ba-eafd-4a6d-96b3-126384b8f197" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AtTheMarketOfferingAgreementMember_1d13037f-0ba4-4c10-8d34-961930c95a95" xlink:href="clbs-20211231.xsd#clbs_AtTheMarketOfferingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a5cf593-7582-4644-b3a5-70b716a62533" xlink:to="loc_clbs_AtTheMarketOfferingAgreementMember_1d13037f-0ba4-4c10-8d34-961930c95a95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_InstitutionalPurchaseAgreementMember_1971059a-2dd1-4049-b7a5-2bba63c18c90" xlink:href="clbs-20211231.xsd#clbs_InstitutionalPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a5cf593-7582-4644-b3a5-70b716a62533" xlink:to="loc_clbs_InstitutionalPurchaseAgreementMember_1971059a-2dd1-4049-b7a5-2bba63c18c90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AdditionalPurchaseAgreementMember_358e1fd2-edbb-4098-a17b-86e98216e7fb" xlink:href="clbs-20211231.xsd#clbs_AdditionalPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a5cf593-7582-4644-b3a5-70b716a62533" xlink:to="loc_clbs_AdditionalPurchaseAgreementMember_358e1fd2-edbb-4098-a17b-86e98216e7fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_January2021PurchaseAgreementMember_cd987d5e-cf69-458c-a7cd-5307b59085c7" xlink:href="clbs-20211231.xsd#clbs_January2021PurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a5cf593-7582-4644-b3a5-70b716a62533" xlink:to="loc_clbs_January2021PurchaseAgreementMember_cd987d5e-cf69-458c-a7cd-5307b59085c7" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="extended" id="ia88497524bd64178b3984f46dc9ace01_StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fc3bdf5-8062-4519-b8ce-a7d2b1ba6dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract_ee792d89-8393-4348-ba71-64868592d294" xlink:href="clbs-20211231.xsd#clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fc3bdf5-8062-4519-b8ce-a7d2b1ba6dc3" xlink:to="loc_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract_ee792d89-8393-4348-ba71-64868592d294" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_def7a308-9758-46dc-9757-25dcac0670f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract_ee792d89-8393-4348-ba71-64868592d294" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_def7a308-9758-46dc-9757-25dcac0670f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_af1017d6-64be-4efa-ba1a-fbdd0df6f5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract_ee792d89-8393-4348-ba71-64868592d294" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_af1017d6-64be-4efa-ba1a-fbdd0df6f5d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d5c31100-1286-40de-b9b7-de9eb8867432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract_ee792d89-8393-4348-ba71-64868592d294" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d5c31100-1286-40de-b9b7-de9eb8867432" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_61660bfa-6d79-423e-8799-a00cdaa57bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract_ee792d89-8393-4348-ba71-64868592d294" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_61660bfa-6d79-423e-8799-a00cdaa57bd9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31f42d7e-007e-4b5a-9da1-16e8f4a72087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fc3bdf5-8062-4519-b8ce-a7d2b1ba6dc3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31f42d7e-007e-4b5a-9da1-16e8f4a72087" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8dfec4b1-dbdc-4346-b400-ec8878bdd320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31f42d7e-007e-4b5a-9da1-16e8f4a72087" xlink:to="loc_us-gaap_AwardTypeAxis_8dfec4b1-dbdc-4346-b400-ec8878bdd320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8dfec4b1-dbdc-4346-b400-ec8878bdd320_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8dfec4b1-dbdc-4346-b400-ec8878bdd320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8dfec4b1-dbdc-4346-b400-ec8878bdd320_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2a54db4-e8a0-43c1-bd3f-bf096ad41605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8dfec4b1-dbdc-4346-b400-ec8878bdd320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2a54db4-e8a0-43c1-bd3f-bf096ad41605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_dd46870f-d8e5-48fb-8a35-ddfe81fdb7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2a54db4-e8a0-43c1-bd3f-bf096ad41605" xlink:to="loc_us-gaap_RestrictedStockMember_dd46870f-d8e5-48fb-8a35-ddfe81fdb7d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_30ad8883-b206-4709-8ed2-71f38c2c3b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2a54db4-e8a0-43c1-bd3f-bf096ad41605" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_30ad8883-b206-4709-8ed2-71f38c2c3b6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_38378fa9-a72b-40a2-ab9e-d77c20f1a04a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31f42d7e-007e-4b5a-9da1-16e8f4a72087" xlink:to="loc_srt_RangeAxis_38378fa9-a72b-40a2-ab9e-d77c20f1a04a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_38378fa9-a72b-40a2-ab9e-d77c20f1a04a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_38378fa9-a72b-40a2-ab9e-d77c20f1a04a" xlink:to="loc_srt_RangeMember_38378fa9-a72b-40a2-ab9e-d77c20f1a04a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_64977f9d-9879-42a3-966a-4a1b8e82041d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_38378fa9-a72b-40a2-ab9e-d77c20f1a04a" xlink:to="loc_srt_RangeMember_64977f9d-9879-42a3-966a-4a1b8e82041d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_63219f01-1f4c-4c3c-ae67-84de08d73d8f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_64977f9d-9879-42a3-966a-4a1b8e82041d" xlink:to="loc_srt_MinimumMember_63219f01-1f4c-4c3c-ae67-84de08d73d8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9497345e-18f9-4ef0-bc60-54273dff9a53" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_64977f9d-9879-42a3-966a-4a1b8e82041d" xlink:to="loc_srt_MaximumMember_9497345e-18f9-4ef0-bc60-54273dff9a53" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" id="if1c44de9a887449bb5a2ef5d21880050_ShareBasedCompensationShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_488a9e19-6444-4f92-a732-e3bf76f4d723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_de5f79b3-5aee-4937-8526-43eece5925d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_488a9e19-6444-4f92-a732-e3bf76f4d723" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_de5f79b3-5aee-4937-8526-43eece5925d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bbac356a-478a-4ec7-b1db-87c1b24abe2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_488a9e19-6444-4f92-a732-e3bf76f4d723" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bbac356a-478a-4ec7-b1db-87c1b24abe2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_94234faf-9aca-4e72-8712-4361532fa604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bbac356a-478a-4ec7-b1db-87c1b24abe2d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_94234faf-9aca-4e72-8712-4361532fa604" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_94234faf-9aca-4e72-8712-4361532fa604_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_94234faf-9aca-4e72-8712-4361532fa604" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_94234faf-9aca-4e72-8712-4361532fa604_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1ad6496d-f97d-4251-bb51-0bc8c93b118a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_94234faf-9aca-4e72-8712-4361532fa604" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1ad6496d-f97d-4251-bb51-0bc8c93b118a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9d976317-8841-4f50-9606-c9434dd4ca17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1ad6496d-f97d-4251-bb51-0bc8c93b118a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9d976317-8841-4f50-9606-c9434dd4ca17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_349b9335-c195-4504-bc59-567371574d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1ad6496d-f97d-4251-bb51-0bc8c93b118a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_349b9335-c195-4504-bc59-567371574d44" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#ShareBasedCompensationCompensationCostNotYetRecognizedDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="extended" id="i5c5429ecc6234bb5a2bf9544b0b5a864_ShareBasedCompensationCompensationCostNotYetRecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71bbe65f-033e-4903-abd0-520039968eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9b22037d-ff21-4398-a4e2-52bff4826395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71bbe65f-033e-4903-abd0-520039968eaf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9b22037d-ff21-4398-a4e2-52bff4826395" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_362d7b12-b137-4cc2-b69a-bfdda0e34a41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71bbe65f-033e-4903-abd0-520039968eaf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_362d7b12-b137-4cc2-b69a-bfdda0e34a41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a799654f-1b16-4898-ba3f-74960fe3d21a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71bbe65f-033e-4903-abd0-520039968eaf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a799654f-1b16-4898-ba3f-74960fe3d21a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1d0b88ad-d5d2-49cf-baf9-3b478d27416d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a799654f-1b16-4898-ba3f-74960fe3d21a" xlink:to="loc_us-gaap_AwardTypeAxis_1d0b88ad-d5d2-49cf-baf9-3b478d27416d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d0b88ad-d5d2-49cf-baf9-3b478d27416d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1d0b88ad-d5d2-49cf-baf9-3b478d27416d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d0b88ad-d5d2-49cf-baf9-3b478d27416d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7f9d9aaf-1538-4855-b9b8-e5f160cf6a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1d0b88ad-d5d2-49cf-baf9-3b478d27416d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7f9d9aaf-1538-4855-b9b8-e5f160cf6a78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fc7cf9ac-91ce-43a7-9c0b-d70ca1d88c64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7f9d9aaf-1538-4855-b9b8-e5f160cf6a78" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fc7cf9ac-91ce-43a7-9c0b-d70ca1d88c64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_05aa3963-ace5-4601-9b5f-0fd145ab67b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7f9d9aaf-1538-4855-b9b8-e5f160cf6a78" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_05aa3963-ace5-4601-9b5f-0fd145ab67b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_efc44995-b449-47da-83f3-53d3a9f2ac37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7f9d9aaf-1538-4855-b9b8-e5f160cf6a78" xlink:to="loc_us-gaap_RestrictedStockMember_efc44995-b449-47da-83f3-53d3a9f2ac37" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="extended" id="ia72ef5078af04f3eb4fc26ab5eac9187_ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cfc1bea-fb0b-4818-9587-e0ce76f888e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_79dc4ed7-2d46-400a-b8bb-a7f98ab38be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cfc1bea-fb0b-4818-9587-e0ce76f888e2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_79dc4ed7-2d46-400a-b8bb-a7f98ab38be3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_890f1875-ecd3-4c29-a639-6543ab030c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cfc1bea-fb0b-4818-9587-e0ce76f888e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_890f1875-ecd3-4c29-a639-6543ab030c2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b30453e7-96ff-46aa-9ee1-3c728af5c28b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cfc1bea-fb0b-4818-9587-e0ce76f888e2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b30453e7-96ff-46aa-9ee1-3c728af5c28b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c2217557-903c-4a5e-aa35-5018e37a7878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b30453e7-96ff-46aa-9ee1-3c728af5c28b" xlink:to="loc_us-gaap_AwardTypeAxis_c2217557-903c-4a5e-aa35-5018e37a7878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2217557-903c-4a5e-aa35-5018e37a7878_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c2217557-903c-4a5e-aa35-5018e37a7878" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2217557-903c-4a5e-aa35-5018e37a7878_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ba012f6-a493-4bca-96ce-b8de3c34f0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c2217557-903c-4a5e-aa35-5018e37a7878" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ba012f6-a493-4bca-96ce-b8de3c34f0cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a9f843d0-c299-4a17-9be3-7e6f265a4bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ba012f6-a493-4bca-96ce-b8de3c34f0cf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a9f843d0-c299-4a17-9be3-7e6f265a4bad" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#ShareBasedCompensationValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails" xlink:type="extended" id="ifed8086cd786428996e466382cd78a2b_ShareBasedCompensationValuationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2246c916-8f7a-40d2-9aec-2c2029fd0011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2b203397-64a3-42fc-b63c-7b866bcce94b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2246c916-8f7a-40d2-9aec-2c2029fd0011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2b203397-64a3-42fc-b63c-7b866bcce94b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e0bd6021-a42b-4834-8d8e-82b8ead5becc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2b203397-64a3-42fc-b63c-7b866bcce94b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e0bd6021-a42b-4834-8d8e-82b8ead5becc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_a95048c2-20bd-4b33-8d99-bdea663a7797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2b203397-64a3-42fc-b63c-7b866bcce94b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_a95048c2-20bd-4b33-8d99-bdea663a7797" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_17b0cc26-3fbf-4d74-8d23-3da4aa5f7d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2b203397-64a3-42fc-b63c-7b866bcce94b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_17b0cc26-3fbf-4d74-8d23-3da4aa5f7d78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_abbafd89-08f5-4304-98a4-1235f627f4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2b203397-64a3-42fc-b63c-7b866bcce94b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_abbafd89-08f5-4304-98a4-1235f627f4f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_decbea84-6056-4526-a7c0-c725526c11b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2b203397-64a3-42fc-b63c-7b866bcce94b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_decbea84-6056-4526-a7c0-c725526c11b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dba4f02c-0d3b-4950-b991-5f73c53b8ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2b203397-64a3-42fc-b63c-7b866bcce94b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dba4f02c-0d3b-4950-b991-5f73c53b8ef1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fc18106d-3433-4c95-8d11-2a7eef625caf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2b203397-64a3-42fc-b63c-7b866bcce94b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fc18106d-3433-4c95-8d11-2a7eef625caf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0176f0fd-7836-40e1-bad8-2194f294af70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2246c916-8f7a-40d2-9aec-2c2029fd0011" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0176f0fd-7836-40e1-bad8-2194f294af70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_404a235b-9017-4f48-83ed-79bcddfbd1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0176f0fd-7836-40e1-bad8-2194f294af70" xlink:to="loc_us-gaap_AwardTypeAxis_404a235b-9017-4f48-83ed-79bcddfbd1a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_404a235b-9017-4f48-83ed-79bcddfbd1a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_404a235b-9017-4f48-83ed-79bcddfbd1a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_404a235b-9017-4f48-83ed-79bcddfbd1a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac9abd70-58a6-4cfb-9281-c875da7ac185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_404a235b-9017-4f48-83ed-79bcddfbd1a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac9abd70-58a6-4cfb-9281-c875da7ac185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_945ca8aa-321f-48c9-8ad3-d9f195b5436b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac9abd70-58a6-4cfb-9281-c875da7ac185" xlink:to="loc_us-gaap_EmployeeStockOptionMember_945ca8aa-321f-48c9-8ad3-d9f195b5436b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_abb9c82b-79e5-41f7-9d56-71168693f6d6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0176f0fd-7836-40e1-bad8-2194f294af70" xlink:to="loc_srt_RangeAxis_abb9c82b-79e5-41f7-9d56-71168693f6d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_abb9c82b-79e5-41f7-9d56-71168693f6d6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_abb9c82b-79e5-41f7-9d56-71168693f6d6" xlink:to="loc_srt_RangeMember_abb9c82b-79e5-41f7-9d56-71168693f6d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b4d0f660-155a-4a32-baa9-978d61021d7b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_abb9c82b-79e5-41f7-9d56-71168693f6d6" xlink:to="loc_srt_RangeMember_b4d0f660-155a-4a32-baa9-978d61021d7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_312b9888-69ca-4bb9-9793-d72dedae7b8a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b4d0f660-155a-4a32-baa9-978d61021d7b" xlink:to="loc_srt_MinimumMember_312b9888-69ca-4bb9-9793-d72dedae7b8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_541ad866-3446-412a-a8b9-a3e08e7657c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b4d0f660-155a-4a32-baa9-978d61021d7b" xlink:to="loc_srt_MaximumMember_541ad866-3446-412a-a8b9-a3e08e7657c5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="id61b66e27f54441f8e8f381b3f57670f_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_8d97d55d-3dd1-4a24-b576-0947d70cfcb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3286fbe8-31f1-4967-bd94-4754e8057367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8d97d55d-3dd1-4a24-b576-0947d70cfcb3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3286fbe8-31f1-4967-bd94-4754e8057367" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown_c17be8d2-7b29-456b-8b16-c4facc20a02d" xlink:href="clbs-20211231.xsd#clbs_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8d97d55d-3dd1-4a24-b576-0947d70cfcb3" xlink:to="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown_c17be8d2-7b29-456b-8b16-c4facc20a02d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_eed24f5c-454d-41bd-b33a-359e4b4dfd30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8d97d55d-3dd1-4a24-b576-0947d70cfcb3" xlink:to="loc_us-gaap_OperatingLossCarryforwards_eed24f5c-454d-41bd-b33a-359e4b4dfd30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_186eb707-1e4c-452e-ae3f-5136a54f10fe" xlink:href="clbs-20211231.xsd#clbs_OperatingLossCarryforwardsSetToExpireWrittenDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8d97d55d-3dd1-4a24-b576-0947d70cfcb3" xlink:to="loc_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_186eb707-1e4c-452e-ae3f-5136a54f10fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_168a4478-844e-4993-a565-6613322c32c7" xlink:href="clbs-20211231.xsd#clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8d97d55d-3dd1-4a24-b576-0947d70cfcb3" xlink:to="loc_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_168a4478-844e-4993-a565-6613322c32c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_2ae5e589-a63e-41bc-aeb4-bc4b657ea5de" xlink:href="clbs-20211231.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8d97d55d-3dd1-4a24-b576-0947d70cfcb3" xlink:to="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_2ae5e589-a63e-41bc-aeb4-bc4b657ea5de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_ec1c928f-d66f-45d2-9c3b-d4ee8621c393" xlink:href="clbs-20211231.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8d97d55d-3dd1-4a24-b576-0947d70cfcb3" xlink:to="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_ec1c928f-d66f-45d2-9c3b-d4ee8621c393" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LossOnSaleOfNetOperatingLosses_bb4992b8-e7f5-4401-936b-369787eaf1c4" xlink:href="clbs-20211231.xsd#clbs_LossOnSaleOfNetOperatingLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8d97d55d-3dd1-4a24-b576-0947d70cfcb3" xlink:to="loc_clbs_LossOnSaleOfNetOperatingLosses_bb4992b8-e7f5-4401-936b-369787eaf1c4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_a3fd3435-87ab-4516-810c-6ed016db4845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8d97d55d-3dd1-4a24-b576-0947d70cfcb3" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_a3fd3435-87ab-4516-810c-6ed016db4845" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d7955022-179b-4f51-8c4b-1849f7f1b41e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_a3fd3435-87ab-4516-810c-6ed016db4845" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d7955022-179b-4f51-8c4b-1849f7f1b41e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d7955022-179b-4f51-8c4b-1849f7f1b41e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d7955022-179b-4f51-8c4b-1849f7f1b41e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d7955022-179b-4f51-8c4b-1849f7f1b41e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7ebf5c78-d303-48d6-8483-66a8beabe0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d7955022-179b-4f51-8c4b-1849f7f1b41e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7ebf5c78-d303-48d6-8483-66a8beabe0d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_e45a25a3-a20b-4e38-a797-f324fb121569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7ebf5c78-d303-48d6-8483-66a8beabe0d2" xlink:to="loc_us-gaap_DomesticCountryMember_e45a25a3-a20b-4e38-a797-f324fb121569" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_261cf2b0-5ed5-4023-94da-b598c24706b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7ebf5c78-d303-48d6-8483-66a8beabe0d2" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_261cf2b0-5ed5-4023-94da-b598c24706b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_77619531-defa-4dc5-85a4-d5e5c78440fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_a3fd3435-87ab-4516-810c-6ed016db4845" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_77619531-defa-4dc5-85a4-d5e5c78440fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_77619531-defa-4dc5-85a4-d5e5c78440fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_77619531-defa-4dc5-85a4-d5e5c78440fd" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_77619531-defa-4dc5-85a4-d5e5c78440fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_0cccc6d6-16ee-4b0a-bbe8-0af2f32d61a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_77619531-defa-4dc5-85a4-d5e5c78440fd" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_0cccc6d6-16ee-4b0a-bbe8-0af2f32d61a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_50bc98a2-f0a6-4795-a747-7049449707fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_0cccc6d6-16ee-4b0a-bbe8-0af2f32d61a8" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_50bc98a2-f0a6-4795-a747-7049449707fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_22a34394-93cc-49b4-a104-bad8175c63cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_0cccc6d6-16ee-4b0a-bbe8-0af2f32d61a8" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_22a34394-93cc-49b4-a104-bad8175c63cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_d54e9438-e06b-4817-8c4f-13586f7585a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_0cccc6d6-16ee-4b0a-bbe8-0af2f32d61a8" xlink:to="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_d54e9438-e06b-4817-8c4f-13586f7585a6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>clbs-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:845060b2-4e37-482c-8ae9-0e23a5d9619a,g:0f1463a6-505b-4611-9f37-25c6b798c5c1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_86c09f0b-7839-4856-942f-b860d1e94237_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from warrant exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_b6b69838-328d-4072-a22f-838ed5fc4710_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure of Cash Flow Information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses_bc28e426-b159-4f07-9c33-79e402dbf94e_terseLabel_en-US" xlink:label="lab_clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of New Jersey State NOLs</link:label>
    <link:label id="lab_clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses_label_en-US" xlink:label="lab_clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Sale Of State Net Operating Losses</link:label>
    <link:label id="lab_clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses_documentation_en-US" xlink:label="lab_clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Sale Of State Net Operating Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses" xlink:href="clbs-20211231.xsd#clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses" xlink:to="lab_clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_161a82bb-22ed-4b4c-ace6-be344d9aa8e4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. federal corporate income tax rate (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_62320e34-e85c-4131-a373-629f7cb5f840_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1cde44c8-a460-4555-bd09-990c6521141a_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_daacd01d-e4f4-43f1-b0fa-e1ec5c99b4a1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_6e230840-d6e9-4983-a35e-a5eb179a01e7_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_168f5bee-199f-40eb-938f-79ffc7cbe2c0_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Caladrius Biosciences, Inc. common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_02658346-128c-44d5-9eb8-3da68371346d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b4bc0984-944b-4ec5-90f6-4f9aceabd424_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e1f68094-5996-41ea-800f-37c015b2dbd9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated net operating losses (tax effected)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_839dfd8c-1ee8-4ced-8dd7-9f77616fc72c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_97d04874-6a8b-4e74-a53b-7244c9cbd132_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_Sharesvestedandexpectedtovest_163f0767-02e9-4c88-abac-22502375ca8b_terseLabel_en-US" xlink:label="lab_clbs_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants vested or expected to vest (shares)</link:label>
    <link:label id="lab_clbs_Sharesvestedandexpectedtovest_label_en-US" xlink:label="lab_clbs_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares, vested and expected to vest</link:label>
    <link:label id="lab_clbs_Sharesvestedandexpectedtovest_documentation_en-US" xlink:label="lab_clbs_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares, vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_Sharesvestedandexpectedtovest" xlink:href="clbs-20211231.xsd#clbs_Sharesvestedandexpectedtovest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_Sharesvestedandexpectedtovest" xlink:to="lab_clbs_Sharesvestedandexpectedtovest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_475f526c-381b-4eaa-9bd9-ff10ea1a2351_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_45f15e60-37b4-490c-902d-3f45919569c0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a2b98d3d-93ed-496b-aed0-7af0ebd616ad_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f9d60aa4-36bc-4026-956a-94966b9877dd_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c0221183-baa2-4cad-8d27-ea1912b67df7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term for operating leases (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ae0fb550-cd08-482e-83eb-b9e51165de7f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_30365928-eeb7-480a-9081-feb4aa3f1056_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_738ff61f-d9de-4db2-bb33-be3819c3ea96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2da38e18-52d5-4fef-8d8e-31e6b4582830_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for future grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fc9f4383-fe8e-42f1-90ea-f2ec6f67aa74_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_817e6391-93cd-4f8b-a7af-a378b94802be_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_2cd779bb-eec2-4a88-bb50-a26192017fb0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable_c89f9c69-1a09-479f-ae77-adbc4258dc5d_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercisable (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercisable</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageExercisePriceWarrantsExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice_9db75a4b-21ae-4caf-be7b-f972eba75f88_terseLabel_en-US" xlink:label="lab_clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated purchases specified floor price threshold for directed purchases</link:label>
    <link:label id="lab_clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice_label_en-US" xlink:label="lab_clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Accelerated Purchase Specified Stock Floor Price</link:label>
    <link:label id="lab_clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice_documentation_en-US" xlink:label="lab_clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Agreement, Accelerated Purchase Specified Stock Floor Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice" xlink:href="clbs-20211231.xsd#clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice" xlink:to="lab_clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8a6626c0-908b-4654-8ab4-8f93d675416f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_f5875a6d-e663-483a-a75b-95dc91837bc1_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_833c1f34-f455-423d-a4df-ed9b41ed8ed9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate for operating leases (percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_55d2f78e-0562-4ff1-a8bb-a3c46e711198_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from computation of loss per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_2a46f2ad-6252-41c6-b913-6e26b7031689_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_f999f776-30e2-40b6-8caf-6c2962b815dc_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares allowable to direct for Regular Purchase (shares)</link:label>
    <link:label id="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_label_en-US" xlink:label="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase</link:label>
    <link:label id="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_documentation_en-US" xlink:label="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:href="clbs-20211231.xsd#clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:to="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_04e01728-7be3-4682-8817-90e0f0039ee3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7101e4ef-8198-4e76-8251-6e94dcaca313_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average estimated fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c0d911b6-9127-4620-84de-86cd35fa9f0a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities - net unrealized loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_7a4e61e6-cd1f-4934-894c-c014a2b8c8b4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_07a7237a-e0ef-4b40-8388-f7064d786db8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_66401d94-b07b-40ba-8ba8-d248fcf2f219_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c209a309-a55e-4887-91d6-fc175f0d7b32_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_4eb8a2a7-16c0-47fc-86fc-16d1e1ad9af9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_66336172-6d85-467d-bbb6-dcc382b48588_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum obligation per directed purchase transaction for Regular Purchase</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_label_en-US" xlink:label="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_documentation_en-US" xlink:label="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:href="clbs-20211231.xsd#clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:to="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_166e574a-19d6-4507-9ad3-6a4a78bf8059_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Weighted Average Contractual Term and Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_07ba2592-b73b-4b80-8b7f-f5d118a2cd9c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2c6754d6-8c8f-41d6-8864-0b8b39ea4f82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested or expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_ec071b63-a585-48b4-91df-e12f86ab74b9_terseLabel_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal debt securities</link:label>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_label_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US States and Political Subdivisions Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_c7371467-7506-416f-b534-72427e16fc1d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_35d6ec55-4c32-4075-bb17-19f5a2f2c85d_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants vested or expected to vest (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_7aadbd9a-19f5-46c1-ab8d-875f20e23a89_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at December 31, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ec2f7fed-63dd-48d7-9495-187fff3622ae_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_ba10c4d6-abd8-439b-858d-8ac8db9f6ccd_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_label_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term warrant outstanding</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_documentation_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term warrant outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageRemainingContractualTermwarrantoutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:to="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a6d61568-b7b7-4745-a942-47436c9c0878_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b4c8a4c2-8f54-494f-80d6-dfa4ce314b78_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_TreasuryStockPolicyPolicyTextBlock_d484abec-debd-4f40-8380-5b9f459ab0a7_terseLabel_en-US" xlink:label="lab_clbs_TreasuryStockPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_clbs_TreasuryStockPolicyPolicyTextBlock_label_en-US" xlink:label="lab_clbs_TreasuryStockPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Policy [Policy Text Block]</link:label>
    <link:label id="lab_clbs_TreasuryStockPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_clbs_TreasuryStockPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_TreasuryStockPolicyPolicyTextBlock" xlink:href="clbs-20211231.xsd#clbs_TreasuryStockPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_TreasuryStockPolicyPolicyTextBlock" xlink:to="lab_clbs_TreasuryStockPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_22e62ce8-3746-4fcb-bac4-2b1b10a51c34_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6a8a658e-ba7e-41a2-821e-bfe96b945c25_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_f2f295a2-00e6-4224-b3b2-093b2f334943_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7572a28b-ff99-4e56-b877-d81cf0700612_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_19546397-58e8-4221-bc3e-ec4cf348a30f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return to actual</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bf142eec-d8b3-4033-8aba-8190e4a92b18_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_b1ba8bf3-0c16-4e14-b00d-d9c231ddb824_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_5aaddd3a-e1a5-436b-875d-dffdb4c43905_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components Deferred Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_743e50b6-bc74-4423-bea7-433e484618b5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_1db87ccb-cc08-4b1a-a7d5-749367b899af_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2da33461-0632-4345-876a-3ef0cad9c520_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_26b92216-05d0-4c18-8c07-4382b1a6c955_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_3676762d-3526-42a6-ba25-db108bee21a1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Funding</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3c93d8f3-1ea9-421c-aa89-810925e4a6cd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_c3649262-fe20-443c-88a7-98eef2d1985e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caladrius Biosciences, Inc. common shareholders - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d8a3a1b7-ed22-449d-87a3-8fd27f17963c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_71954997-06c9-4453-8f4e-b437ac8ea1a7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Greater than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense_d9438029-0774-4be3-9c02-d48c65b7f8b7_terseLabel_en-US" xlink:label="lab_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of accrued grant funding to offset expense</link:label>
    <link:label id="lab_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense_label_en-US" xlink:label="lab_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Accrued Grant Funding Liability To Offset Expense</link:label>
    <link:label id="lab_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense_documentation_en-US" xlink:label="lab_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Accrued Grant Funding Liability To Offset Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense" xlink:href="clbs-20211231.xsd#clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense" xlink:to="lab_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_59906b68-2e62-47f7-8802-b1942a57bf41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_H.C.WainwrightSalesAmendedAgreementMember_e20aafde-478f-4ba9-9133-2d0e809593e0_terseLabel_en-US" xlink:label="lab_clbs_H.C.WainwrightSalesAmendedAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">H.C. Wainwright Sales Amended Agreement</link:label>
    <link:label id="lab_clbs_H.C.WainwrightSalesAmendedAgreementMember_label_en-US" xlink:label="lab_clbs_H.C.WainwrightSalesAmendedAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">H.C. Wainwright Sales Amended Agreement [Member]</link:label>
    <link:label id="lab_clbs_H.C.WainwrightSalesAmendedAgreementMember_documentation_en-US" xlink:label="lab_clbs_H.C.WainwrightSalesAmendedAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">H.C. Wainwright Sales Amended Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_H.C.WainwrightSalesAmendedAgreementMember" xlink:href="clbs-20211231.xsd#clbs_H.C.WainwrightSalesAmendedAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_H.C.WainwrightSalesAmendedAgreementMember" xlink:to="lab_clbs_H.C.WainwrightSalesAmendedAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_0b3ac8c9-fd69-4069-aabc-a9cf0babbb08_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_979124a9-0d36-4c5e-bb12-2465eff002c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized for issuance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_EmployeeStockPurchasePlan2017AmendedMember_1b595791-e121-44e9-bad0-a57b5b606596_terseLabel_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlan2017AmendedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended 2017 ESPP</link:label>
    <link:label id="lab_clbs_EmployeeStockPurchasePlan2017AmendedMember_label_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlan2017AmendedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan 2017 Amended [Member]</link:label>
    <link:label id="lab_clbs_EmployeeStockPurchasePlan2017AmendedMember_documentation_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlan2017AmendedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan 2017 Amended [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlan2017AmendedMember" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlan2017AmendedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_EmployeeStockPurchasePlan2017AmendedMember" xlink:to="lab_clbs_EmployeeStockPurchasePlan2017AmendedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_f2b6d216-47ac-47f1-bf08-9997e09ade0e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_8df21272-c423-46ce-b477-119bc939ca43_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares allowed in Accelerated Purchase as percent of shares in Regular Purchase (percent)</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_label_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_documentation_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:href="clbs-20211231.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:to="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_64b4eed9-ed79-4c2b-b5b8-701aea79ad72_terseLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Federal</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_786f9fc9-4f6d-4298-9537-fa56c7d7f306_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_6cb1355c-d43c-474c-a0a1-3f5a49ef9a33_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_00f8db52-4b31-41a1-a066-45d131385ea8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_f413e864-7913-4e2e-80c5-70ddb1fc83f0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_81f34d32-0fe1-4991-ab96-1ffc824111ae_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_20e5b388-aeb6-4d52-82c2-09620ba428ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_abf9c135-3d11-4e16-b7b6-777eb6bc086f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_ad43798a-2093-468a-b039-f884bfb725ee_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_522cf6c1-267f-46e4-b0a0-ed441962ca63_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ad799c26-be5b-4194-a1f5-1eb5512d76cf_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b379b1f8-2e3e-48f3-9e0d-4eeb00163e16_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_7a932c61-7e77-4ad6-b656-2d08fb0c76c3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_2dee39d4-bce3-46c5-8962-ee4bc542a857_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0ea51227-7b0a-47cc-89da-4e123b5a8839_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, non-controlling interests and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_e83b61b2-a0b8-4cab-aabe-75b79fb70f08_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2812ec82-263b-4bf7-bc4b-cd0da33f5d55_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4215718d-422b-4bf3-8645-a22715832d31_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3a20e4db-29bc-4f17-8e5b-08f25748df69_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based award tranche one</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_adbf8a54-74ec-4cb4-9dce-8fab95753e56_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_fcd57e34-ceea-43cd-b622-4d666f3a5f20_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f9406c26-4395-435b-9b01-db4690010dd8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES, NON-CONTROLLING INTERESTS AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsGranted_2907e55f-958a-462f-8daa-6016a236006e_terseLabel_en-US" xlink:label="lab_clbs_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (shares)</link:label>
    <link:label id="lab_clbs_WarrantsGranted_label_en-US" xlink:label="lab_clbs_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Granted</link:label>
    <link:label id="lab_clbs_WarrantsGranted_documentation_en-US" xlink:label="lab_clbs_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsGranted" xlink:href="clbs-20211231.xsd#clbs_WarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsGranted" xlink:to="lab_clbs_WarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_86af38d1-d6db-4861-84c9-fb4953b5888c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_f3a3fdfb-e0b2-4f46-b6f4-e1dc15f82ecb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8ded3e57-2d2c-49c7-ac15-e6451211917c_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding_a8a4ad8e-8d63-4d48-9699-c689833510e5_periodStartLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding_bdb576dc-65b1-4a02-906e-b76ed2f5ed29_periodEndLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_32498ecd-8a30-4f3e-8e5c-b8d936701277_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from option exercises</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_5a08e21d-772a-4f83-a6c5-2fb0c7e24ba0_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_94cba1fc-fc27-4d0d-a87b-6af1c4d65214_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_9117ffd4-53f6-488d-86b7-e325c5ff4277_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_3839744f-30fd-48a7-ae64-6f21d9594827_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_dcc37496-1481-44fa-81a9-424db8a2cb36_terseLabel_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Possible additional NOLs for five years resulting from Net Unrealized Built-in Gain rules</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_label_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Annual Available, Five Years, Net Unrealized Built In Gain</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_documentation_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Annual Available, Five Years, Net Unrealized Built In Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" xlink:href="clbs-20211231.xsd#clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" xlink:to="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_3cf9fea6-458f-4c63-abc0-4761b4113dea_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_4f4b582f-68cf-4c88-a3f4-e1cd6ac6845d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_92bc12a1-01f8-47f7-a960-eec52770025b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_16df2529-0b43-48b2-b69c-63a7ace23a6b_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_94d4713c-581f-4528-8147-6bde908d9d9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_95c92c42-df8b-4f6b-b399-f6358bfc78cc_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cf61b50e-359c-42d0-8aff-25c9d05f11a9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_0bb5c108-6dc0-4d83-8c9b-b7419deec999_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_OperatingLeaseRightOfUseAssetAbstract_4f6ba139-070a-4218-96bd-63aac3e6fea8_terseLabel_en-US" xlink:label="lab_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of Use Assets:</link:label>
    <link:label id="lab_clbs_OperatingLeaseRightOfUseAssetAbstract_label_en-US" xlink:label="lab_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset [Abstract]</link:label>
    <link:label id="lab_clbs_OperatingLeaseRightOfUseAssetAbstract_documentation_en-US" xlink:label="lab_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:href="clbs-20211231.xsd#clbs_OperatingLeaseRightOfUseAssetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:to="lab_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7c618f2f-40bd-440f-a583-b0aebeb27dee_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_b8c63046-fbcf-47f0-b758-1ba8fb36f6f3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock and warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_354d7aab-4f55-48a9-9708-a372c64b2df9_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_3642d7c6-2520-40ef-9440-0a8ae5cdb82f_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_8a735865-981a-4521-8067-e22b5fb80755_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Provision for Income Taxes Based on Loss from Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_5fb4ae21-839c-4e4a-b1c1-ceb6f3d4222d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_ea8d3c25-20eb-4b74-9612-b291236ffdf7_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants vested or expected to vest, weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_label_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_documentation_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:to="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_41cf81d5-eac7-48e7-83f7-21065b3adc0a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_cef62840-a748-4431-a1de-050b81048fce_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_55729846-4f32-402b-87ea-47b132c399dd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract_0ea968c3-5ceb-493e-bb35-62da09120c0a_terseLabel_en-US" xlink:label="lab_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock and Restricted Stock Units</link:label>
    <link:label id="lab_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract_label_en-US" xlink:label="lab_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock And Restricted Stock Units Issued [Abstract]</link:label>
    <link:label id="lab_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract_documentation_en-US" xlink:label="lab_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock And Restricted Stock Units Issued [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract" xlink:href="clbs-20211231.xsd#clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract" xlink:to="lab_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_c878b8aa-2e3d-490d-a423-e20945de481f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d213663e-9e21-4de6-9208-2fcd9c8517a2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cf045dde-7638-47ad-b99e-727603ef98c0_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c538a13a-0c2a-4b87-845d-17ca7a9d81d7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_2379a7b4-2deb-480b-bb9d-a226be93a782_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale-Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_4d4bd2d4-bd59-42ae-8b02-1b2957edb9c2_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_10e0b803-f693-4746-b3ba-61ce6fcc63d6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_a07f81c0-cead-4678-8db9-1c15c613a8c8_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_631370db-6552-444f-91e6-60fdcdaf4a4c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2da69771-1bf4-4248-b1e5-d5e226ad2aa1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, authorized 500,000,000 shares; issued 59,800,792 and 19,389,413 shares, at December 31, 2021 and December 31, 2020, respectively; and outstanding, 59,789,712 and 19,378,333 shares, at December 31, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_5fdf4198-01da-4a5c-a183-897c686e0fa6_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3c9ac641-4643-459c-bffe-ee6bc063c08b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected weighted-average period in years of compensation cost to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8095237a-9e86-4928-b9d4-f8104a623e3b_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ce914ba4-4673-49c1-ac35-9dca32ccc08f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_eb141213-8968-48d4-937b-3a859b321b69_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_DeferredTaxAssetsRightOfUseLiability_65bc01c1-1a5b-4564-9ca1-cb8df20abffc_terseLabel_en-US" xlink:label="lab_clbs_DeferredTaxAssetsRightOfUseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use liability</link:label>
    <link:label id="lab_clbs_DeferredTaxAssetsRightOfUseLiability_label_en-US" xlink:label="lab_clbs_DeferredTaxAssetsRightOfUseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Right Of Use Liability</link:label>
    <link:label id="lab_clbs_DeferredTaxAssetsRightOfUseLiability_documentation_en-US" xlink:label="lab_clbs_DeferredTaxAssetsRightOfUseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Right Of Use Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_DeferredTaxAssetsRightOfUseLiability" xlink:href="clbs-20211231.xsd#clbs_DeferredTaxAssetsRightOfUseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_DeferredTaxAssetsRightOfUseLiability" xlink:to="lab_clbs_DeferredTaxAssetsRightOfUseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d15c8cc1-907d-4e92-921b-93792436bf1a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding_181a1b01-5cf6-4fae-9f11-713cc7b05d0b_terseLabel_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding_label_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants Outstanding</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding_documentation_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:href="clbs-20211231.xsd#clbs_AggregateIntrinsicValueWarrantsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:to="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d26ca420-418a-4e47-a03a-1c12e8f3ae32_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_0ab85454-151e-415d-a487-6a8619e86791_terseLabel_en-US" xlink:label="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment shares issued as consideration per agreement (shares)</link:label>
    <link:label id="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_label_en-US" xlink:label="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued As Consideration</link:label>
    <link:label id="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_documentation_en-US" xlink:label="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued As Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:href="clbs-20211231.xsd#clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:to="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_b7973054-c4fc-45d6-b59f-b50b22ef6fb0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_f8d05318-2811-49d1-ba89-688ec7efc816_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_46f4aafe-f496-4dfc-ae7a-d7c6722663da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions in Calculating Fair Values of Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a3c2c2c2-09fd-4ece-876b-ab14442b258a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_633cfea9-3f0c-4229-a21f-dc27ada68f18_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_26960e9c-e2ba-4acc-94ec-c50895bf5448_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_28721e35-2cc4-4dbc-8212-d2c306d6ae73_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AtTheMarketOfferingAgreementMember_c39edf93-8a71-4ec9-b736-271d1d01e2bd_terseLabel_en-US" xlink:label="lab_clbs_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Agreement</link:label>
    <link:label id="lab_clbs_AtTheMarketOfferingAgreementMember_label_en-US" xlink:label="lab_clbs_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Agreement [Member]</link:label>
    <link:label id="lab_clbs_AtTheMarketOfferingAgreementMember_documentation_en-US" xlink:label="lab_clbs_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AtTheMarketOfferingAgreementMember" xlink:href="clbs-20211231.xsd#clbs_AtTheMarketOfferingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AtTheMarketOfferingAgreementMember" xlink:to="lab_clbs_AtTheMarketOfferingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6d527ab3-7ae0-46f9-91ed-221f5e84a403_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_bb9d56a2-80bd-4c1d-8798-d5017e1ce776_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_14c14fb3-331e-4d33-95c6-7cc634d7a58f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Amounts representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_17109e3e-13fa-43cd-a3de-b4a485552be6_terseLabel_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey</link:label>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_label_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey Division of Taxation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:to="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_98f40c55-6482-4e99-bbc8-8f6efc41ec2d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a20d24bb-c967-485d-9e17-ed9482d153ef_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross price for stock transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CommonStockWarrantsShares_8d48b8c7-7625-45c1-b162-2c25fd918c15_periodStartLabel_en-US" xlink:label="lab_clbs_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance (shares)</link:label>
    <link:label id="lab_clbs_CommonStockWarrantsShares_d1615512-6b8d-4089-a3e9-54b447b60003_periodEndLabel_en-US" xlink:label="lab_clbs_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance (shares)</link:label>
    <link:label id="lab_clbs_CommonStockWarrantsShares_label_en-US" xlink:label="lab_clbs_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants, Shares</link:label>
    <link:label id="lab_clbs_CommonStockWarrantsShares_documentation_en-US" xlink:label="lab_clbs_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CommonStockWarrantsShares" xlink:href="clbs-20211231.xsd#clbs_CommonStockWarrantsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CommonStockWarrantsShares" xlink:to="lab_clbs_CommonStockWarrantsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_InstitutionalPurchaseAgreementMember_1b2abe42-305b-40cc-88c9-f2019a2e78b7_terseLabel_en-US" xlink:label="lab_clbs_InstitutionalPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Institutional Purchase Agreement</link:label>
    <link:label id="lab_clbs_InstitutionalPurchaseAgreementMember_label_en-US" xlink:label="lab_clbs_InstitutionalPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Institutional Purchase Agreement [Member]</link:label>
    <link:label id="lab_clbs_InstitutionalPurchaseAgreementMember_documentation_en-US" xlink:label="lab_clbs_InstitutionalPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Institutional Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_InstitutionalPurchaseAgreementMember" xlink:href="clbs-20211231.xsd#clbs_InstitutionalPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_InstitutionalPurchaseAgreementMember" xlink:to="lab_clbs_InstitutionalPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ac467d3-e120-44cc-9654-a778c7b53a7e_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_fbd83e70-1704-499a-9c7c-b8801c8de7cd_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e71662ef-5068-4185-b080-57be580a0cc2_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b2b5b4d3-0f23-48e3-94b7-1e00a4f4e1b5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_b4780553-bc07-4db0-bbc8-6dcf4bac80fe_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares per each warrant</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_8238f619-4597-4baf-a6a0-a89b7ea29d8e_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_644e0f77-8f76-47ea-9ebd-cbe93509338d_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_673f2397-a2bd-43ad-9bb4-f67e748ce2b2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_7f184f84-37ac-40c4-959a-7122bd515f16_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ec31463e-2b7e-4fb4-b124-1de0731966f6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_NetDeferredTaxAssetsAndLiabilitiesGross_8efc9d42-e0c6-4a34-9f19-1d68ade2ae13_totalLabel_en-US" xlink:label="lab_clbs_NetDeferredTaxAssetsAndLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets and liabilities</link:label>
    <link:label id="lab_clbs_NetDeferredTaxAssetsAndLiabilitiesGross_label_en-US" xlink:label="lab_clbs_NetDeferredTaxAssetsAndLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Deferred Tax Assets And Liabilities, Gross</link:label>
    <link:label id="lab_clbs_NetDeferredTaxAssetsAndLiabilitiesGross_documentation_en-US" xlink:label="lab_clbs_NetDeferredTaxAssetsAndLiabilitiesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Deferred Tax Assets And Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_NetDeferredTaxAssetsAndLiabilitiesGross" xlink:href="clbs-20211231.xsd#clbs_NetDeferredTaxAssetsAndLiabilitiesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_NetDeferredTaxAssetsAndLiabilitiesGross" xlink:to="lab_clbs_NetDeferredTaxAssetsAndLiabilitiesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_dca1279b-8dbc-4481-b6b0-f13975716cba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0316e4c6-e462-4d64-9aa9-bd75ec60d042_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9a844961-4303-4380-abb4-0f7a83359d8e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_MilestonePaymentOnGrantAwardCashReceived_73c77421-af18-4d07-a026-d2c08036be26_terseLabel_en-US" xlink:label="lab_clbs_MilestonePaymentOnGrantAwardCashReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment received on grant award</link:label>
    <link:label id="lab_clbs_MilestonePaymentOnGrantAwardCashReceived_label_en-US" xlink:label="lab_clbs_MilestonePaymentOnGrantAwardCashReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment On Grant Award, Cash Received</link:label>
    <link:label id="lab_clbs_MilestonePaymentOnGrantAwardCashReceived_documentation_en-US" xlink:label="lab_clbs_MilestonePaymentOnGrantAwardCashReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment On Grant Award, Cash Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MilestonePaymentOnGrantAwardCashReceived" xlink:href="clbs-20211231.xsd#clbs_MilestonePaymentOnGrantAwardCashReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_MilestonePaymentOnGrantAwardCashReceived" xlink:to="lab_clbs_MilestonePaymentOnGrantAwardCashReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm_7667b4fd-5cc5-4e5b-99c0-a1faed89fa1f_terseLabel_en-US" xlink:label="lab_clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of offering period</link:label>
    <link:label id="lab_clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm_label_en-US" xlink:label="lab_clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Periods, Employee Stock Purchase Plan, Term</link:label>
    <link:label id="lab_clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm_documentation_en-US" xlink:label="lab_clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering Periods, Employee Stock Purchase Plan, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm" xlink:href="clbs-20211231.xsd#clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm" xlink:to="lab_clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9bd747ca-94fa-4d15-aa0b-5e4789a6aed1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9dc56472-dae0-4cd1-bcea-b9998ab1931d_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e0cf76d6-40d6-4f20-937f-ebbe03c1455b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2c045178-b072-4e45-acb4-b6db31a8bf23_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Greater than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c4d10b5b-850b-49cf-a39c-40d156a058df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1fba1cc4-3abb-4492-b31d-7d0f9d3f8810_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f898d5e7-47cc-4738-8c8b-3f41243afd11_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsOtherDisclosuresAbstract_69e5409d-9111-45b5-b66c-e8d7eee6395c_terseLabel_en-US" xlink:label="lab_clbs_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Weighted Average Contractual Term and Intrinsic Value</link:label>
    <link:label id="lab_clbs_WarrantsOtherDisclosuresAbstract_label_en-US" xlink:label="lab_clbs_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Other Disclosures [Abstract]</link:label>
    <link:label id="lab_clbs_WarrantsOtherDisclosuresAbstract_documentation_en-US" xlink:label="lab_clbs_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsOtherDisclosuresAbstract" xlink:href="clbs-20211231.xsd#clbs_WarrantsOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract" xlink:to="lab_clbs_WarrantsOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_2923d7bf-b866-40b9-91e1-1644e3218a28_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1cf59b0b-1939-4b91-96be-0092ae8bd18e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ef629589-10ad-46e5-9708-39b0545a8534_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_04a651b3-9c38-4745-8265-064db180dd4b_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount_86ecaca8-ede3-4f36-aea8-43120eead901_terseLabel_en-US" xlink:label="lab_clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Section 382 NOL Limitation</link:label>
    <link:label id="lab_clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount_label_en-US" xlink:label="lab_clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Section 382 NOL Limitation, Amount</link:label>
    <link:label id="lab_clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount_documentation_en-US" xlink:label="lab_clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Section 382 NOL Limitation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount" xlink:href="clbs-20211231.xsd#clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount" xlink:to="lab_clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_e1ccd60f-4a4b-4fe5-83c7-fa7189334ca6_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_1a448d5e-42e9-4d7f-a8e2-7e362b97ed6e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_NumberOfOfficesUnderOperatingLeases_c996e3ce-61c3-408f-8bc4-9935d5475ca2_terseLabel_en-US" xlink:label="lab_clbs_NumberOfOfficesUnderOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of offices under operating leases</link:label>
    <link:label id="lab_clbs_NumberOfOfficesUnderOperatingLeases_label_en-US" xlink:label="lab_clbs_NumberOfOfficesUnderOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Offices Under Operating Leases</link:label>
    <link:label id="lab_clbs_NumberOfOfficesUnderOperatingLeases_documentation_en-US" xlink:label="lab_clbs_NumberOfOfficesUnderOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Offices Under Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_NumberOfOfficesUnderOperatingLeases" xlink:href="clbs-20211231.xsd#clbs_NumberOfOfficesUnderOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_NumberOfOfficesUnderOperatingLeases" xlink:to="lab_clbs_NumberOfOfficesUnderOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_bc108e19-6a11-44e9-ba86-51ae8cffe759_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_996a3fa2-d82e-499c-9bd4-318ec7e9c890_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares called by warrants issued</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_b78f2cb2-37cb-476d-a055-00203f5e537e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current, balance sheet line item</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9c4f63cc-734a-4dbe-aa60-e915a6e760fa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_MarketableSecuritiesMember_3e7eb22d-aac1-40f0-a84a-d87672ec24ab_terseLabel_en-US" xlink:label="lab_clbs_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_clbs_MarketableSecuritiesMember_label_en-US" xlink:label="lab_clbs_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:label id="lab_clbs_MarketableSecuritiesMember_documentation_en-US" xlink:label="lab_clbs_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MarketableSecuritiesMember" xlink:href="clbs-20211231.xsd#clbs_MarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_MarketableSecuritiesMember" xlink:to="lab_clbs_MarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9f1f808d-325a-43d8-9422-63e76950ace1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_PreferredStockSharesDesignated_1c0b0fe2-2547-4d24-9d63-28d5810f8132_terseLabel_en-US" xlink:label="lab_clbs_PreferredStockSharesDesignated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated (shares)</link:label>
    <link:label id="lab_clbs_PreferredStockSharesDesignated_label_en-US" xlink:label="lab_clbs_PreferredStockSharesDesignated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Designated</link:label>
    <link:label id="lab_clbs_PreferredStockSharesDesignated_documentation_en-US" xlink:label="lab_clbs_PreferredStockSharesDesignated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Designated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreferredStockSharesDesignated" xlink:href="clbs-20211231.xsd#clbs_PreferredStockSharesDesignated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_PreferredStockSharesDesignated" xlink:to="lab_clbs_PreferredStockSharesDesignated" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_673a9384-13ce-4f41-9741-f054bbbd7c38_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c599ef48-539d-45f6-9f38-1cf05546d025_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_8dcb0b2f-5b8e-4cbe-b678-95daa74fa39f_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantsReceivable_b83ad408-c4c8-4260-8fcc-c0098ecd8258_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants awarded</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_599af8ed-c87d-434a-b9ef-b7911f7a8cb1_verboseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants awarded</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_label_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable" xlink:to="lab_us-gaap_GrantsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b382f6e2-2cee-4cba-9059-1206ae462317_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_f5d223cf-508d-4599-b539-62ce684310b1_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9257b1dd-2d12-4496-9518-f3b130099d17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ed74c98b-289d-464d-aea1-cfa1ab24b67a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_45e1f197-81b0-4c75-a9a8-8e00845565ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_dd41032e-7dd6-490c-a774-2133bffcabf8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0a63f640-e2a0-4336-bb07-b89969c3f658_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_eed8f76b-9025-4cdc-85fe-a097dce9040f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments Under Lease Agreements</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_9ba8958d-bd07-4389-bb07-8795931cba62_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Caladrius Biosciences, Inc. stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_January2021PurchaseAgreementMember_c4383d8a-f80d-4828-b74c-6354b0d7f58d_terseLabel_en-US" xlink:label="lab_clbs_January2021PurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2021 Private Placement</link:label>
    <link:label id="lab_clbs_January2021PurchaseAgreementMember_label_en-US" xlink:label="lab_clbs_January2021PurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2021 Purchase Agreement [Member]</link:label>
    <link:label id="lab_clbs_January2021PurchaseAgreementMember_documentation_en-US" xlink:label="lab_clbs_January2021PurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2021 Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_January2021PurchaseAgreementMember" xlink:href="clbs-20211231.xsd#clbs_January2021PurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_January2021PurchaseAgreementMember" xlink:to="lab_clbs_January2021PurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_25d257fb-1c8c-44e5-aa83-44d807eb7f13_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_dabce654-48ab-4df3-9345-1d14289c8e5b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_d35bda58-7b6f-4257-89e9-7efe975ff8ce_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9ee6fc23-4a05-4a0d-b969-97e018ac50aa_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_c34b9108-a1f2-4e23-bd86-a4e667eb57b5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate_7623608e-b32d-4c52-a261-50f8339b5856_terseLabel_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price measurement as percent of closing price on exercise date</link:label>
    <link:label id="lab_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate_label_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Purchase Price, Percent Of Closing Price On Exercise Date</link:label>
    <link:label id="lab_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate_documentation_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Purchase Price, Percent Of Closing Price On Exercise Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate" xlink:to="lab_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_03faf0cd-396b-467c-895a-b7c5e383413f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_4ec70b2c-685d-4ea3-9756-7cfc852ad30e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_25254bce-d636-4bf4-b5bc-6efb60cd8437_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_b76517a1-a1a9-4251-97e9-17da43d82ebc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_7364c24f-6dc8-4f1b-a5f7-e9ae0af6026d_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_85422a4d-244b-4647-b5c1-c70490c6c200_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_b5f0fdb2-1345-46ba-929d-1c4a6d5309b3_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0ceb94a4-6477-430e-9de7-5e012841477d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate - minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_dd9d9709-15d2-42ff-a8bc-6185d302cf58_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_adeec649-eabb-4ee9-891f-b7eccd3385f0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_6d4a75e5-78ea-49fa-9518-e2c263fd3014_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_67faff85-7ca8-4622-8313-9f01786905a3_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current income tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_35c98748-e055-4bbb-8946-eeb1ea86fb67_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_f0699862-4c31-4b4c-89e2-eb7f015ca314_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based compensation expense</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_969e9c7b-66cf-408b-87b9-50589df58aea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility - maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_17740efb-7393-4bbd-92a8-8ea60860aead_terseLabel_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of NOLs, gross</link:label>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_label_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross</link:label>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_documentation_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:href="clbs-20211231.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:to="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5ba4e144-46ef-4f56-ba11-7a0efad636c7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_341d8b6e-653d-49b7-b812-6c3798efd456_terseLabel_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of NOLs</link:label>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_label_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Net Operating Losses, NJEDA Program</link:label>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_documentation_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Net Operating Losses, NJEDA Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:href="clbs-20211231.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:to="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercised_c69f570d-bd37-474e-bc64-f16b10ee4a65_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercised_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercised</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercised_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageExercisePriceWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c571d814-2ed6-4003-a695-6c1b88305d8d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_6bf011b3-5280-429e-adfe-93bfc8e8058f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_6c4c95bc-1ecf-4f95-8d35-bd2059b64290_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b866f981-33de-4f4e-a244-28edef906d67_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_dedee412-0057-446d-be74-63cd0ac6d31b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_EmployeeStockPurchasePlanMember_c987092f-7839-45aa-aedc-dabf68a66993_terseLabel_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_clbs_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_clbs_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlanMember" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_EmployeeStockPurchasePlanMember" xlink:to="lab_clbs_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_fe64ae2d-b27e-4004-881f-3f904ccbd177_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_17b01b75-d81d-4e6f-9e67-15cdc888dd57_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based award tranche two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_93572ffc-85dd-4cad-b656-2d89084cf805_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_cc9172cf-ce07-4d13-b20c-f81ffe547437_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_b00dc066-c494-4d9c-9064-d26a7ef97d05_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsExpired_62dbd1a7-7bee-49f4-95e6-45a8c9ae41f7_negatedTerseLabel_en-US" xlink:label="lab_clbs_WarrantsExpired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired (shares)</link:label>
    <link:label id="lab_clbs_WarrantsExpired_label_en-US" xlink:label="lab_clbs_WarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expired</link:label>
    <link:label id="lab_clbs_WarrantsExpired_documentation_en-US" xlink:label="lab_clbs_WarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExpired" xlink:href="clbs-20211231.xsd#clbs_WarrantsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsExpired" xlink:to="lab_clbs_WarrantsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_10bb15c3-2619-4208-9562-257baf29d1dd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less - net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsExercised_16a0f690-f18d-4da8-8fbd-fb0be31c0de7_negatedTerseLabel_en-US" xlink:label="lab_clbs_WarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (shares)</link:label>
    <link:label id="lab_clbs_WarrantsExercised_label_en-US" xlink:label="lab_clbs_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercised</link:label>
    <link:label id="lab_clbs_WarrantsExercised_documentation_en-US" xlink:label="lab_clbs_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExercised" xlink:href="clbs-20211231.xsd#clbs_WarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsExercised" xlink:to="lab_clbs_WarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_eb4fa388-7091-4590-822e-b0e149bdc8e9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_86a43a32-ec38-4266-91ae-e06a925ae606_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_44e72f1f-b808-455d-8718-bec682df6f19_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other true ups</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5ef093c7-3510-4fce-bf6a-b309487d78fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_eb879dcf-d6c0-4737-bca2-d48b677e161b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_920d6e69-83f9-411f-a8e5-a15173dda7e4_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c8b76efb-8488-46fe-abcc-e1ba23d9f767_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3f151617-db96-4772-8d97-aae60e413708_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a1c0fbce-9058-43db-9711-6978f929d77b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan_80e08bd2-b890-4f68-bd09-0336bdd79aad_terseLabel_en-US" xlink:label="lab_clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of offering periods</link:label>
    <link:label id="lab_clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Offering Periods, Employee Stock Purchase Plan</link:label>
    <link:label id="lab_clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Offering Periods, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan" xlink:href="clbs-20211231.xsd#clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan" xlink:to="lab_clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e946fe64-86f2-411a-87ad-1856b2be34b1_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_4b4168b4-a026-46b6-ba9d-7056c3750baf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5f68f7e7-d7b0-4506-8ba4-aa148ceecb2a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_4370d743-3d2b-4b4d-af63-379f28a55709_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab2e2966-49de-4b85-92ed-d26f9c876d05_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_35e4af45-bae7-4063-8b5d-212b874a4ff4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_d8479fd2-163a-4744-a5f4-58f48dfe0f0f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Progress payment amortized to related research and development over estimated award period</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_d8d16d97-2d60-42c3-88f1-6bae0267826b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_5e9ae509-988f-4210-b6cf-f74fb5ee9a3e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d98e5812-31b0-4f27-a778-a328f25e3618_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a994b2c5-fec7-4ddb-8660-ee63f6facb0f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_e6ed9571-9f58-431e-92ed-b5ad3a690402_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_7affed09-17bc-4d65-8e2a-d3a4d784611a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries, employee benefits and related taxes</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d2c286aa-ec19-4b77-b438-0f44ebe2bbe0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2acbaef3-0854-41d1-94b2-99fd08525896_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72d2c4a6-168d-4284-8380-dbfad01880cb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_b5dd14a2-b304-47b2-b579-aca1600715c0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_1095fd92-9c8c-45d0-b714-aaf108ef7e66_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_3ae3ee13-0089-4273-ab1e-c80e8f725b79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_2f0c2034-c8ec-4125-8414-5a760aceb1a6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsVested_5c49f6ef-61a1-4632-96db-0104917092b5_terseLabel_en-US" xlink:label="lab_clbs_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercisable (shares)</link:label>
    <link:label id="lab_clbs_WarrantsVested_label_en-US" xlink:label="lab_clbs_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested</link:label>
    <link:label id="lab_clbs_WarrantsVested_documentation_en-US" xlink:label="lab_clbs_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsVested" xlink:href="clbs-20211231.xsd#clbs_WarrantsVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsVested" xlink:to="lab_clbs_WarrantsVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3869a2e3-7150-4c4b-8253-87284d67d236_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_0d7e9b71-3e9c-4385-bc03-0bc6b6e6ceec_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_353b04e6-36b0-4c05-ae78-f084264caefd_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_79186fb4-6c63-47bb-a021-2c9b5e2af0b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average estimated fair value of shares granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b6254f83-b3ee-46a1-8176-a344c2588ecf_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_227108a4-4d90-4a39-86c5-401c0be03962_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_BusinessTextBlock_c82bd931-f3dd-461c-9553-732257544a5c_terseLabel_en-US" xlink:label="lab_clbs_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Business</link:label>
    <link:label id="lab_clbs_BusinessTextBlock_label_en-US" xlink:label="lab_clbs_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Business [Text Block]</link:label>
    <link:label id="lab_clbs_BusinessTextBlock_documentation_en-US" xlink:label="lab_clbs_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Business [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_BusinessTextBlock" xlink:href="clbs-20211231.xsd#clbs_BusinessTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_BusinessTextBlock" xlink:to="lab_clbs_BusinessTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9f5f4b7f-00be-44e3-9ddd-f103f14ec326_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_7e20324b-e486-42e6-ac4d-59943c65c357_terseLabel_en-US" xlink:label="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum beneficial ownership allowable per agreement (percent)</link:label>
    <link:label id="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_label_en-US" xlink:label="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty</link:label>
    <link:label id="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_documentation_en-US" xlink:label="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:href="clbs-20211231.xsd#clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:to="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_cadb1680-2986-4bbb-a8a4-faf958ff0f8b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee_72f59253-73e2-4505-ad96-1b35787dbc76_terseLabel_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual contribution per employee</link:label>
    <link:label id="lab_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee_label_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contribution Per Employee</link:label>
    <link:label id="lab_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee_documentation_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contribution Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee" xlink:to="lab_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_4aa72a02-9d8f-4acc-ab05-86e5a87c3688_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested_1802a41e-fe02-41c7-8be6-30409acd30e4_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercisable, weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested_label_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">weighted Average Remaining Contractual Term, warrants vested</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested_documentation_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">weighted Average Remaining Contractual Term, warrants vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageRemainingContractualTermwarrantsvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:to="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_54d9a7b8-4cc8-4a35-8491-1258878507f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0eb46610-e1ed-46cd-9ed5-83cc8cfcf309_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_92a9a30b-1235-4a97-813f-18b8b1e705ac_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82952b0e-64a0-4b5b-be3e-f18d69d3fab8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7881f0e7-240e-4107-9c6f-fc520887b0b7_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8dafcc43-bda3-4e98-9724-e33c18d09dde_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_31831b45-b923-42f7-bc8b-9b3928f5863e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_f243b7f2-1ba2-48ac-a02a-129c03c770d0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9bf1335f-2351-42f5-9474-a566d763aa86_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before benefit from income taxes and noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a2dab924-e40a-45e8-9beb-afa03f2b5057_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax book income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_12b8c5c0-5dfb-4089-845e-6bbb07dfbf78_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7186892b-3bb4-4306-814d-96f6ebc8785c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_39e2b8db-1c11-4e16-8464-bce11189fe31_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_06405d33-093d-4b67-bbd8-e5d5e5297e2c_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f30fade3-75df-4925-9aa4-4a57a40e223d_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_b79cff9e-a347-47ee-a553-15aa0bf902ab_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a3dfa12f-4659-49b1-98fb-220a824c263e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_aaa4bcf7-8f3d-4ecd-9b9d-053b7580e5ad_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9b15e0ec-d439-4816-bcf0-4b2d2ad2c0e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_078e230b-8fb3-4c37-97aa-90447c3b4526_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_5b298f1d-df46-4db2-ba9e-6e20cc68a8f8_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AdditionalPurchaseAgreementMember_ecfafeee-2ced-4687-bacd-06939c29a0b4_terseLabel_en-US" xlink:label="lab_clbs_AdditionalPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Purchase Agreement</link:label>
    <link:label id="lab_clbs_AdditionalPurchaseAgreementMember_label_en-US" xlink:label="lab_clbs_AdditionalPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Purchase Agreement [Member]</link:label>
    <link:label id="lab_clbs_AdditionalPurchaseAgreementMember_documentation_en-US" xlink:label="lab_clbs_AdditionalPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AdditionalPurchaseAgreementMember" xlink:href="clbs-20211231.xsd#clbs_AdditionalPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AdditionalPurchaseAgreementMember" xlink:to="lab_clbs_AdditionalPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_16c0af00-599e-492e-8a44-0c47d0489b6f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0bebead8-270f-4ee5-a8c6-4c62e349abf6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of capital stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_92543f48-d10f-4be9-ba20-ff4c0fc4ebb4_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_1fed198a-52d4-4246-b8c0-f2bc0ebae130_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_d83209a6-88ce-4afe-b043-de5412337b16_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_fe529968-b6f6-474b-93fe-5454f369de67_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_de86ecf7-c800-45a7-8eb1-8b3e78e28a38_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ac81416f-29cb-42ef-83e7-2d81b4365492_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_1a45be36-e8e6-4b0c-9a30-12920eb7a444_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- Controlling Interest in Subsidiary</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_297422e2-a0c1-4500-b14c-1dfdcebb0227_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExpired_65cd46e4-0e3b-4f63-888d-372d91f31ac9_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExpired_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Expired</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExpired_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageExercisePriceWarrantsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_cb770484-e0fc-4de4-91a1-c00690a4624c_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_TermOfAgreement_5742e407-b17a-402e-a754-b5494708ebf1_terseLabel_en-US" xlink:label="lab_clbs_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement (in months)</link:label>
    <link:label id="lab_clbs_TermOfAgreement_label_en-US" xlink:label="lab_clbs_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Of Agreement</link:label>
    <link:label id="lab_clbs_TermOfAgreement_documentation_en-US" xlink:label="lab_clbs_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_TermOfAgreement" xlink:href="clbs-20211231.xsd#clbs_TermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_TermOfAgreement" xlink:to="lab_clbs_TermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cb34d4d7-a9a7-4e4d-86d7-f357b8093b4f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_FundingOfGrantAwardCashReceived_417d3e40-8118-4768-8f64-a2d2df0fffd4_terseLabel_en-US" xlink:label="lab_clbs_FundingOfGrantAwardCashReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding of grant award</link:label>
    <link:label id="lab_clbs_FundingOfGrantAwardCashReceived_label_en-US" xlink:label="lab_clbs_FundingOfGrantAwardCashReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Of Grant Award, Cash Received</link:label>
    <link:label id="lab_clbs_FundingOfGrantAwardCashReceived_documentation_en-US" xlink:label="lab_clbs_FundingOfGrantAwardCashReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Of Grant Award, Cash Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_FundingOfGrantAwardCashReceived" xlink:href="clbs-20211231.xsd#clbs_FundingOfGrantAwardCashReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_FundingOfGrantAwardCashReceived" xlink:to="lab_clbs_FundingOfGrantAwardCashReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsCanceled_c0a836fe-f75a-43fb-b057-358b2ffc7ec7_negatedTerseLabel_en-US" xlink:label="lab_clbs_WarrantsCanceled" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants forfeited (shares)</link:label>
    <link:label id="lab_clbs_WarrantsCanceled_label_en-US" xlink:label="lab_clbs_WarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Canceled</link:label>
    <link:label id="lab_clbs_WarrantsCanceled_documentation_en-US" xlink:label="lab_clbs_WarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsCanceled" xlink:href="clbs-20211231.xsd#clbs_WarrantsCanceled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsCanceled" xlink:to="lab_clbs_WarrantsCanceled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_e4c702ce-cbce-4e09-8032-2db11d2615e0_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_74393406-3a13-4ecf-9742-dd084bc6cc5d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b5c98af-fff0-4954-8cca-178b8462d6c6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5a03067c-fd95-429a-aa2a-119308c311c3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_90f85ecc-c457-4a7b-98ad-0eb948ca5558_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_49f4c644-9ecb-4b05-b9dc-64d6eabc80c2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_514d5423-3521-4742-88db-6ecad8ab79ef_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b36084eb-ff70-4407-9941-7c81ab7c69ce_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caladrius Biosciences, Inc. common shareholders - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_a2815b0d-2f59-4ab0-b2f3-6355170a80db_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_46ed02f8-8d75-4fad-b5e3-0f0e823a6e42_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price of shares sold (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_c87c2f4c-95d1-433f-8fe4-47383e804791_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_87ce3840-f9e9-412e-a77d-0280d95a3a89_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent non deductible expenses for U.S. taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_f06b59e3-9da7-4a53-8132-e2a8bda4660f_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0e7e62b4-30b0-47e5-865f-d1922fd5bc75_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_EmployeeStockPurchasePlan2017Member_c3ea48de-fa2e-4526-b138-2a76a7ef73e1_terseLabel_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 ESPP</link:label>
    <link:label id="lab_clbs_EmployeeStockPurchasePlan2017Member_label_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan 2017 [Member]</link:label>
    <link:label id="lab_clbs_EmployeeStockPurchasePlan2017Member_documentation_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan 2017 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlan2017Member" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlan2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_EmployeeStockPurchasePlan2017Member" xlink:to="lab_clbs_EmployeeStockPurchasePlan2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0c7590f6-dc81-42d1-bde9-79c2da788917_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_982b8115-828b-4525-893e-ef92d0777b91_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_b692a4fe-0691-467d-bc0a-a4ef7a1a4c36_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost; 11,080 shares at December 31, 2021 and December 31, 2020 respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3300a606-08be-48e0-82ec-caaef38ba1d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting terms (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_ProgressPaymentOnGrantAwardCashReceived_7f410827-51c2-4b2d-b684-e0ab8acbf831_terseLabel_en-US" xlink:label="lab_clbs_ProgressPaymentOnGrantAwardCashReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Progress payment received on grant award</link:label>
    <link:label id="lab_clbs_ProgressPaymentOnGrantAwardCashReceived_label_en-US" xlink:label="lab_clbs_ProgressPaymentOnGrantAwardCashReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Progress Payment On Grant Award, Cash Received</link:label>
    <link:label id="lab_clbs_ProgressPaymentOnGrantAwardCashReceived_documentation_en-US" xlink:label="lab_clbs_ProgressPaymentOnGrantAwardCashReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Progress Payment On Grant Award, Cash Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProgressPaymentOnGrantAwardCashReceived" xlink:href="clbs-20211231.xsd#clbs_ProgressPaymentOnGrantAwardCashReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_ProgressPaymentOnGrantAwardCashReceived" xlink:to="lab_clbs_ProgressPaymentOnGrantAwardCashReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_ef4b0460-8776-463b-b148-a9a8dd4374db_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_de814c72-24a3-459e-9c6e-4a6bcb04cffa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Effective Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_78c3b6be-5094-4696-a2c6-d9a9fdf46740_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_16e2d29b-5af7-411d-9b0c-a8c9c3e0638b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_90c00b0f-916b-461d-99c5-8d049170f95f_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Caladrius Biosciences, Inc. Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_8b6ce8f5-a783-4d86-ad92-dfa65788481a_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering amount authorized per agreement</link:label>
    <link:label id="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_label_en-US" xlink:label="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</link:label>
    <link:label id="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_documentation_en-US" xlink:label="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:href="clbs-20211231.xsd#clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:to="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_949059de-34bd-4b48-8361-724069f2165b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Assets Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_03629ebd-f2fc-48c1-ae9d-6c400295de1b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a8bfe7dd-5cd0-42d3-9a7d-496014e10864_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_083ddd64-25f4-4529-a611-8f41e4412d5d_terseLabel_en-US" xlink:label="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued liabilities and other liabilities</link:label>
    <link:label id="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_label_en-US" xlink:label="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</link:label>
    <link:label id="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_documentation_en-US" xlink:label="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:href="clbs-20211231.xsd#clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:to="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e4d36022-fdeb-40b2-ad01-929c4be4a3c6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_598c9071-9b07-4bde-83b4-b01ba9b7e545_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_893e6b56-9cdd-48fd-9bbf-35d58cc9fc60_terseLabel_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write down of NOLs set to expire unutilized</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_label_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Set To Expire, Written Down</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_documentation_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Set To Expire, Written Down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" xlink:href="clbs-20211231.xsd#clbs_OperatingLossCarryforwardsSetToExpireWrittenDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" xlink:to="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown_86c3e2f0-3f53-4fb0-81ed-9db6e6399aa6_terseLabel_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards, prior to write down</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown_label_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Before Write Down</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown_documentation_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Before Write Down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:href="clbs-20211231.xsd#clbs_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:to="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward_fe84b69a-5e83-4203-a6ea-b407af04fdb7_terseLabel_en-US" xlink:label="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Weighted Average Exercise Price</link:label>
    <link:label id="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:href="clbs-20211231.xsd#clbs_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:to="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_982a9806-fe97-4fef-b122-9d6420f9c0dd_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_de62c61a-034d-4ecf-878a-828404383eb6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_2c09ea48-8bfd-4ca0-bf02-c0a8ea62269a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a5930bb4-9bcf-4e1b-ba56-7d742508d5f5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_557aca69-de33-4d39-ba14-1331065eb391_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount_63b5d022-b46b-4810-9da7-70b6a5b8b23e_terseLabel_en-US" xlink:label="lab_clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in state deferred</link:label>
    <link:label id="lab_clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount_label_en-US" xlink:label="lab_clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in State Deferred, Amount</link:label>
    <link:label id="lab_clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount_documentation_en-US" xlink:label="lab_clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in State Deferred, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount" xlink:href="clbs-20211231.xsd#clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount" xlink:to="lab_clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_22092465-f703-4f98-b8d2-d28c941a473a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_7b74c16d-6ce8-428a-80c7-5537dcbf9a53_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_f241e5ca-5462-42bc-ad94-33fc2760baec_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_f138e24b-4846-4e7e-aa95-f587bfa74270_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5de63b38-e16d-4941-8e40-255eca400ae0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_7cd5f6a8-2977-443e-930e-d8428de84f8c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities - available for sale</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_a12162c6-228c-45c7-9464-bb36d9aac1f7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_2cde1122-9ac8-4bd5-a668-84ea978d259b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_EmployeeStockPurchasePlan2012Member_1b2b7520-63d5-4085-811a-dc656667a26f_terseLabel_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlan2012Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2012 ESPP</link:label>
    <link:label id="lab_clbs_EmployeeStockPurchasePlan2012Member_label_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlan2012Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan 2012 [Member]</link:label>
    <link:label id="lab_clbs_EmployeeStockPurchasePlan2012Member_documentation_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlan2012Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan 2012 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlan2012Member" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlan2012Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_EmployeeStockPurchasePlan2012Member" xlink:to="lab_clbs_EmployeeStockPurchasePlan2012Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_bccbc1fd-3223-46c4-94ac-b412339a1090_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3a092c65-b529-402e-a6e2-bc5473c36262_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b5f95b5c-4244-4bcf-94d8-e53a166c8bd3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_c2928333-e10b-4dbd-924e-474922c8f914_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CLBS16TreatmentOfCMDMember_12b00462-257b-41b8-abb8-2e05e5238390_terseLabel_en-US" xlink:label="lab_clbs_CLBS16TreatmentOfCMDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CLBS16 Treatment Of CMD</link:label>
    <link:label id="lab_clbs_CLBS16TreatmentOfCMDMember_label_en-US" xlink:label="lab_clbs_CLBS16TreatmentOfCMDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CLBS16 Treatment Of CMD [Member]</link:label>
    <link:label id="lab_clbs_CLBS16TreatmentOfCMDMember_documentation_en-US" xlink:label="lab_clbs_CLBS16TreatmentOfCMDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CLBS16 Treatment Of CMD</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CLBS16TreatmentOfCMDMember" xlink:href="clbs-20211231.xsd#clbs_CLBS16TreatmentOfCMDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CLBS16TreatmentOfCMDMember" xlink:to="lab_clbs_CLBS16TreatmentOfCMDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_0cf2e8a1-0bd7-4c1a-9441-26a6c70a7503_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate_e50f65dc-c110-4a23-860e-5e4eda9ff79b_terseLabel_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price measurement as percent of closing price on enrollment date</link:label>
    <link:label id="lab_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate_label_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Purchase Price, Percent Of Closing Price On Enrollment Date</link:label>
    <link:label id="lab_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate_documentation_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Purchase Price, Percent Of Closing Price On Enrollment Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate" xlink:to="lab_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent_16551a5f-6771-49bc-9a14-7f28593c5668_terseLabel_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual contribution per employee as percent of annual salary</link:label>
    <link:label id="lab_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent_label_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contribution Per Employee, Percent</link:label>
    <link:label id="lab_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent_documentation_en-US" xlink:label="lab_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contribution Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent" xlink:to="lab_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e152f653-1194-41d4-b292-39acd8c03829_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_b3d4ca74-19ef-42e1-a592-f92464fd24b8_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e2e80f37-348e-4475-be8f-99ab945915f1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_0b8778d8-e613-48ab-bc34-91d2ef95dd5a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AuditInformationAbstract_label_en-US" xlink:label="lab_clbs_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_clbs_AuditInformationAbstract_documentation_en-US" xlink:label="lab_clbs_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AuditInformationAbstract" xlink:href="clbs-20211231.xsd#clbs_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AuditInformationAbstract" xlink:to="lab_clbs_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_LincolnParkAgreementMember_f2f7ac1a-75a8-4b5c-a6a6-1c047b59732a_terseLabel_en-US" xlink:label="lab_clbs_LincolnParkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park Agreement</link:label>
    <link:label id="lab_clbs_LincolnParkAgreementMember_label_en-US" xlink:label="lab_clbs_LincolnParkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park Agreement [Member]</link:label>
    <link:label id="lab_clbs_LincolnParkAgreementMember_documentation_en-US" xlink:label="lab_clbs_LincolnParkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LincolnParkAgreementMember" xlink:href="clbs-20211231.xsd#clbs_LincolnParkAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_LincolnParkAgreementMember" xlink:to="lab_clbs_LincolnParkAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_5b7ce3fa-912a-47d9-89ba-f80d7925c85c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_64acf468-d6ba-4a35-a51a-684306885c7a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a57f36a2-d6dd-4f92-8bd3-a9ae618a2bbd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_21aaf522-5d48-44b3-b040-f98f40c0372e_terseLabel_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants vested or expected to vest, aggregate intrinsic value</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_label_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested and expected to vest</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_documentation_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:href="clbs-20211231.xsd#clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:to="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0098fd85-7a34-43ef-8553-60e48c2eddce_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_9c9f260c-931d-4f02-b95b-9b4e329a3562_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, by Jurisdiction [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled_454dfaf9-b6c1-4457-aaa0-f7c04dbf9ceb_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants forfeited (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Canceled</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageExercisePriceWarrantsCanceled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentImpairment_24dc8817-1333-4cfd-bf8c-0edd3dfdeb58_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentImpairment_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Impairment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsGranted_9d56c864-40f7-4cd2-b6d7-3c9625f9b406_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsGranted_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Granted</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsGranted_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageExercisePriceWarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_88f898bc-4eb2-49e2-a01b-09b7d32a5d1c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested or expected to vest (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_e77e5efb-d574-45b8-a589-b0f3d352254c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_44e7de8f-a73c-400c-9ddd-9daa3fead02a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based award tranche three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_510edf88-aabe-4d67-91ce-521380722cf2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Shares Vested and Weighted Average Estimated Fair Values of Shares Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_EquityIncentiveCompensationPlan2018Member_52c42d2f-0a46-48fe-81c8-2a681c5787cc_terseLabel_en-US" xlink:label="lab_clbs_EquityIncentiveCompensationPlan2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_clbs_EquityIncentiveCompensationPlan2018Member_label_en-US" xlink:label="lab_clbs_EquityIncentiveCompensationPlan2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Compensation Plan 2018 [Member]</link:label>
    <link:label id="lab_clbs_EquityIncentiveCompensationPlan2018Member_documentation_en-US" xlink:label="lab_clbs_EquityIncentiveCompensationPlan2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Compensation Plan 2018 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EquityIncentiveCompensationPlan2018Member" xlink:href="clbs-20211231.xsd#clbs_EquityIncentiveCompensationPlan2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_EquityIncentiveCompensationPlan2018Member" xlink:to="lab_clbs_EquityIncentiveCompensationPlan2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f69ce8db-7d61-4c87-aac7-43d04c271f58_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_15e501d5-ce0e-4743-831b-0c6703aa9c35_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_1f7c6951-dba0-47cf-af32-ea5e5d213bd0_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_79df8a8d-2171-444f-acfd-95124cf4ab9e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, noncurrent, balance sheet line item</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_481e3439-1a2e-4730-b88b-ace711d8c7d9_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expiration term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c00d6f84-75a7-4242-b444-4f503946ecd6_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvested_19a52bf8-0418-40cf-abf4-141e839cfa02_terseLabel_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvested_label_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvested_documentation_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvested" xlink:href="clbs-20211231.xsd#clbs_AggregateIntrinsicValueWarrantsvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AggregateIntrinsicValueWarrantsvested" xlink:to="lab_clbs_AggregateIntrinsicValueWarrantsvested" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_4546c32c-6535-4fc6-be62-a5aaae3b531e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_2fa8184b-4b58-47a3-ae3d-c346bd735bd6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_5667c86b-b673-4e34-9f02-cc2b8d2311fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility - minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_84e8af27-85ec-4d2d-9a28-b4c9754a1201_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_75318088-4e7f-4297-a524-3a2f90387e95_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3f5438b4-6df6-4b4f-bd9f-b08513a5ec7c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization/accretion on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent_e94b3573-c7c4-4e5e-979d-cb8c1a2b7f23_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission on gross proceeds due to third party (percent)</link:label>
    <link:label id="lab_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent_label_en-US" xlink:label="lab_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission On Gross Proceeds Due To Third Party Upon, Percent</link:label>
    <link:label id="lab_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent_documentation_en-US" xlink:label="lab_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission On Gross Proceeds Due To Third Party Upon, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent" xlink:href="clbs-20211231.xsd#clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent" xlink:to="lab_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_fd45b8a7-b7c8-49bb-872c-4630b4c52e1b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c31708a9-5184-47aa-8dec-413741338e71_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_723cd433-74f6-473a-9660-07e9d3f853de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Benefit from Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_d8e8bfcb-0acb-4dca-bb3e-c0a8c9a1c1bd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon exercise of warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ec715801-6635-41e8-932f-aec70cac3b72_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a167d77a-38c5-4f5c-bb94-bb9af1f33b51_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8cf52ecb-e8c5-42b6-8df3-b918e1129ec3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares sold (shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2aadf1f5-6ebf-4687-a606-1ac5e1ec4b20_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_27f3b32e-8eb7-46e4-8bf8-64a7819352c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate - maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a940b811-9baf-440c-ae97-12b1e66cfe30_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_37c65ce6-fba4-4d90-bd99-6749f46ce292_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39af3b3a-92cf-4cbe-994f-83ec65e08ca4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_59ef1774-e404-4bed-b663-c49135033445_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockNumberOfSharesAndRestrictionDisclosuresAbstract_1d2cf434-00e6-418c-b080-2fdeaaf4064f_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockNumberOfSharesAndRestrictionDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockNumberOfSharesAndRestrictionDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_TreasuryStockNumberOfSharesAndRestrictionDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Number of Shares and Restriction Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockNumberOfSharesAndRestrictionDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockNumberOfSharesAndRestrictionDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockNumberOfSharesAndRestrictionDisclosuresAbstract" xlink:to="lab_us-gaap_TreasuryStockNumberOfSharesAndRestrictionDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_FundingAmountAwarded_e415ea95-1736-4b51-b387-4c128105ed3f_terseLabel_en-US" xlink:label="lab_clbs_FundingAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total funding amount awarded</link:label>
    <link:label id="lab_clbs_FundingAmountAwarded_label_en-US" xlink:label="lab_clbs_FundingAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Amount Awarded</link:label>
    <link:label id="lab_clbs_FundingAmountAwarded_documentation_en-US" xlink:label="lab_clbs_FundingAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Amount Awarded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_FundingAmountAwarded" xlink:href="clbs-20211231.xsd#clbs_FundingAmountAwarded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_FundingAmountAwarded" xlink:to="lab_clbs_FundingAmountAwarded" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_111166ee-5420-41a4-ba9c-c8bdde2928aa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10f68190-ebc4-4ffd-acbe-fa09937906c3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from option exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_93007b71-7e86-4fc7-b500-ddeda1f72942_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c9059bf4-f38e-4e30-b0ae-b7dcd1fc1a30_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_856515a7-aa2b-4710-9264-78cc0e3efcd8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax book income - United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7711b747-20ba-424a-ad0d-498dfbd7eb79_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_d3353202-c7a5-4b0a-a63a-2fff83665416_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_15bb1da0-f45c-4347-8d7c-8326516218b5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_DeferredTaxAssetsAccumulatedDepreciation_590c2f3c-37ad-4800-8fca-76e978f17a8e_terseLabel_en-US" xlink:label="lab_clbs_DeferredTaxAssetsAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_clbs_DeferredTaxAssetsAccumulatedDepreciation_label_en-US" xlink:label="lab_clbs_DeferredTaxAssetsAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Accumulated Depreciation</link:label>
    <link:label id="lab_clbs_DeferredTaxAssetsAccumulatedDepreciation_documentation_en-US" xlink:label="lab_clbs_DeferredTaxAssetsAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Accumulated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_DeferredTaxAssetsAccumulatedDepreciation" xlink:href="clbs-20211231.xsd#clbs_DeferredTaxAssetsAccumulatedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_DeferredTaxAssetsAccumulatedDepreciation" xlink:to="lab_clbs_DeferredTaxAssetsAccumulatedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a0c83412-1139-42e4-ad9a-d04b3ac2700d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options and Warrants Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bb38ce79-ff9f-4bd8-8bb1-a721cef820ed_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_298bce8c-c946-4442-be4f-c4982b80fa1f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_11d826ff-0f81-44d2-9eaf-c29c59a1a6ff_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_b728347d-c44f-4fcb-9f5a-f57a9439ce94_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_c0fdb3ba-f591-4ee1-b21c-5f05b3b8a9f0_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_5d24cf80-ae89-4b76-a7e4-c669163b7263_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_dd817b87-d00b-4136-a198-8501778ab455_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_893567d7-20c3-41d4-9b4e-3fcc23ab832d_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares allowed in Accelerated Purchase as percent of shares traded during specified period (percent)</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_label_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_documentation_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:href="clbs-20211231.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:to="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_e625ccab-42ff-4884-853a-5c3685ac3dde_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_916803ad-3452-4a43-816f-989eb40aee8c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e5316635-4fbc-458c-a0dd-30a31273e75a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d610e6b4-dc89-4e3e-bd21-ecfbe1ab42ae_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_daec6dc4-5bda-4f1c-95ac-4ea9888faa24_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_PreferredStockLiquidationPreferenceShare_737ae162-60c2-4258-80fa-5730b6b4c71c_terseLabel_en-US" xlink:label="lab_clbs_PreferredStockLiquidationPreferenceShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, liquidation preference (shares)</link:label>
    <link:label id="lab_clbs_PreferredStockLiquidationPreferenceShare_label_en-US" xlink:label="lab_clbs_PreferredStockLiquidationPreferenceShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Share</link:label>
    <link:label id="lab_clbs_PreferredStockLiquidationPreferenceShare_documentation_en-US" xlink:label="lab_clbs_PreferredStockLiquidationPreferenceShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreferredStockLiquidationPreferenceShare" xlink:href="clbs-20211231.xsd#clbs_PreferredStockLiquidationPreferenceShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_PreferredStockLiquidationPreferenceShare" xlink:to="lab_clbs_PreferredStockLiquidationPreferenceShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e5bd0e3e-3316-4635-8b19-9156d7162f83_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_93e5b8b3-37dd-4f3f-9466-235acd641d96_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_e4bc881c-046f-40d1-92b1-9f6a3fb205c7_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_09e64c8b-e0ce-4745-92ac-e78ed87c6587_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a1e6b7a2-f738-499d-9ee7-70427b983fc2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_af9f4fc3-b207-49a0-8cad-a190a46216c8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d46e3ecd-c40c-4828-aa09-173877b268cf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax withholding payments on net share settlement equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_d609bc6a-adf8-46e0-9b8f-541c1124a261_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ae03df1e-6148-4bd8-bb35-97f151f411f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested or expected to vest, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7b30898a-c377-4b67-8f6c-85285919211a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_61a03d6a-2697-4b31-9879-6e371cc2ad16_terseLabel_en-US" xlink:label="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York</link:label>
    <link:label id="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_label_en-US" xlink:label="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York State Division of Taxation and Finance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:to="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_1633dce7-2f6a-4812-8474-cd84121e5ce3_terseLabel_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_label_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_0b319ade-d665-4633-a369-4f0eeec3f8bf_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a9cd4854-aa3d-44c8-ad4d-e6ee656df57d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6ddc64d3-50d3-4260-adaf-ae55958297b6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_b52532f3-6414-4716-8019-3cd46ef9c086_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_780aa966-7e17-4732-ae38-26189504aa02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bcc14b3c-f0c9-4757-8878-c28b8d35194e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_3201c13b-f0a2-4528-8442-7c554844a73b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1a26dd02-00fa-4735-9b90-cdd1138002e8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Federal benefit at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_788c6d99-2cf7-44c4-b1e6-4369d4304e69_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_ffcbd98a-a62c-4fab-9080-83fad6dd2975_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, balance sheet line item</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AggregateIntrinsicValueOptionExercised_b23044ff-a133-45e0-82be-d05294375307_negatedTerseLabel_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueOptionExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised, aggregate intrinsic value</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueOptionExercised_label_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueOptionExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Option Exercised</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueOptionExercised_documentation_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueOptionExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueOptionExercised" xlink:href="clbs-20211231.xsd#clbs_AggregateIntrinsicValueOptionExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AggregateIntrinsicValueOptionExercised" xlink:to="lab_clbs_AggregateIntrinsicValueOptionExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_3268de19-659b-47de-9f79-8e2fae7f9b74_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_c42f71b8-2001-451f-82c4-d5cef624b51a_terseLabel_en-US" xlink:label="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet</link:label>
    <link:label id="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_label_en-US" xlink:label="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</link:label>
    <link:label id="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_documentation_en-US" xlink:label="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:href="clbs-20211231.xsd#clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:to="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_546d8500-bd05-41dd-b98a-d7d22ada4a75_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_LossOnSaleOfNetOperatingLosses_835516b4-a6f5-49c0-8a49-b5832e0c88f8_terseLabel_en-US" xlink:label="lab_clbs_LossOnSaleOfNetOperatingLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on sale of NOLs</link:label>
    <link:label id="lab_clbs_LossOnSaleOfNetOperatingLosses_label_en-US" xlink:label="lab_clbs_LossOnSaleOfNetOperatingLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss On Sale Of Net Operating Losses</link:label>
    <link:label id="lab_clbs_LossOnSaleOfNetOperatingLosses_documentation_en-US" xlink:label="lab_clbs_LossOnSaleOfNetOperatingLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss On Sale Of Net Operating Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LossOnSaleOfNetOperatingLosses" xlink:href="clbs-20211231.xsd#clbs_LossOnSaleOfNetOperatingLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_LossOnSaleOfNetOperatingLosses" xlink:to="lab_clbs_LossOnSaleOfNetOperatingLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_7dcdb316-cf0f-4f77-badb-7951ddc1f857_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_e5cfa6d7-6210-445c-ae8d-5e4beccbafc2_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_969c2ba9-2223-4646-9d54-ce24b33a346e_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_591d0d75-acc7-4954-8238-2b77df33846c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested or expected to vest, weighted average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>clbs-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:845060b2-4e37-482c-8ae9-0e23a5d9619a,g:0f1463a6-505b-4611-9f37-25c6b798c5c1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.caladrius.com/role/Cover" xlink:type="simple" xlink:href="clbs-20211231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_dcf733ed-0398-48bf-a31e-c9754ec960eb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_DocumentType_dcf733ed-0398-48bf-a31e-c9754ec960eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_f97e9bc0-a10e-44bb-ae23-017fdbf31582" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_DocumentAnnualReport_f97e9bc0-a10e-44bb-ae23-017fdbf31582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_543f84c1-e73a-44ac-883c-c3388710dc5c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_DocumentPeriodEndDate_543f84c1-e73a-44ac-883c-c3388710dc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_8ae0cf01-9ed5-40d9-95a6-2cd0be722b58" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_CurrentFiscalYearEndDate_8ae0cf01-9ed5-40d9-95a6-2cd0be722b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_22ca8f2c-be61-4b22-bd80-da2020113dd5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_DocumentTransitionReport_22ca8f2c-be61-4b22-bd80-da2020113dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_0d9a6b2b-08be-42cd-8a5b-f1fcc48b1ac0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_EntityFileNumber_0d9a6b2b-08be-42cd-8a5b-f1fcc48b1ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_cc56c00e-bc65-48a1-b2e4-6a6b660d6f1b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_EntityRegistrantName_cc56c00e-bc65-48a1-b2e4-6a6b660d6f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7ee64b2d-da2b-4b00-bb42-ae541d546f23" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_EntityCentralIndexKey_7ee64b2d-da2b-4b00-bb42-ae541d546f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_57fcfe32-dd50-426d-a17a-6368988c7105" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_DocumentFiscalYearFocus_57fcfe32-dd50-426d-a17a-6368988c7105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8bdab2b5-93c1-4d1d-8689-5d9865599f53" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8bdab2b5-93c1-4d1d-8689-5d9865599f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9b43ef11-494e-4019-b647-a4b74be02fb0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_AmendmentFlag_9b43ef11-494e-4019-b647-a4b74be02fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_6f5c863f-68f7-41db-b7fb-6bcfc1fbf139" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_EntityIncorporationStateCountryCode_6f5c863f-68f7-41db-b7fb-6bcfc1fbf139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4dde79b6-533d-4c88-84d9-3a512ba5fdcd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_EntityTaxIdentificationNumber_4dde79b6-533d-4c88-84d9-3a512ba5fdcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4b35aa99-63f4-4df4-936f-5d96f1277db9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_EntityAddressAddressLine1_4b35aa99-63f4-4df4-936f-5d96f1277db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_bdfa33f5-5ba5-466c-b814-d46938b5f625" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_EntityAddressCityOrTown_bdfa33f5-5ba5-466c-b814-d46938b5f625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e466276c-0640-4f4d-badc-ab932bbc4b70" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_EntityAddressStateOrProvince_e466276c-0640-4f4d-badc-ab932bbc4b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_681c3ff6-c1be-461e-b217-0dd8be807a16" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_EntityAddressPostalZipCode_681c3ff6-c1be-461e-b217-0dd8be807a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5531063b-9e3a-4c9d-b160-d94d2e995e45" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_CityAreaCode_5531063b-9e3a-4c9d-b160-d94d2e995e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ddf673be-6d62-4dcb-9ee4-69cfaae0892e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_LocalPhoneNumber_ddf673be-6d62-4dcb-9ee4-69cfaae0892e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3f205137-11fd-4edf-9aa9-4aa7c751a51f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_Security12bTitle_3f205137-11fd-4edf-9aa9-4aa7c751a51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7a557063-2935-480b-a63f-8fed144adb3b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_TradingSymbol_7a557063-2935-480b-a63f-8fed144adb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b1d3f058-5a09-4aa3-ad4e-98f181cd1abc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_SecurityExchangeName_b1d3f058-5a09-4aa3-ad4e-98f181cd1abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_b15d489d-7034-4073-8358-ab974eb8a768" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_b15d489d-7034-4073-8358-ab974eb8a768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_74619cfc-a556-47a4-b94a-d22c54df49db" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_EntityVoluntaryFilers_74619cfc-a556-47a4-b94a-d22c54df49db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3637e247-4ac5-4b54-a7f7-e64f8eb981d9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_EntityCurrentReportingStatus_3637e247-4ac5-4b54-a7f7-e64f8eb981d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d20c6c02-3f0c-46ab-8a4c-b0cfafa581ef" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_EntityInteractiveDataCurrent_d20c6c02-3f0c-46ab-8a4c-b0cfafa581ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_fb185e1b-9f47-4508-93e8-343d0a6474fa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_EntityFilerCategory_fb185e1b-9f47-4508-93e8-343d0a6474fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_df633464-3d6b-4ee5-9c5a-feae183179bd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_EntitySmallBusiness_df633464-3d6b-4ee5-9c5a-feae183179bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8ce03bdb-c903-489c-9362-87f136c95377" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_EntityEmergingGrowthCompany_8ce03bdb-c903-489c-9362-87f136c95377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_a5cbbf9e-53ed-4e5e-91e3-a9f83465c435" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_IcfrAuditorAttestationFlag_a5cbbf9e-53ed-4e5e-91e3-a9f83465c435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1fda2855-a362-4801-b5f0-2f5c3fbebc8b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_EntityShellCompany_1fda2855-a362-4801-b5f0-2f5c3fbebc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_bbf20ada-8adc-4209-acb9-129d6f7af2da" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_EntityPublicFloat_bbf20ada-8adc-4209-acb9-129d6f7af2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6b63a953-4aeb-47c8-9030-58f0abe6c876" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6b63a953-4aeb-47c8-9030-58f0abe6c876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_3f954849-d44a-473d-83a9-00a5a0315307" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d22799fe-c41c-44cd-9f53-e9a7e253ea51" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_3f954849-d44a-473d-83a9-00a5a0315307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AuditInformation" xlink:type="simple" xlink:href="clbs-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AuditInformationAbstract_18fcfdc6-1b0b-4b41-a03c-769c033dadaa" xlink:href="clbs-20211231.xsd#clbs_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_21487a74-b85d-4427-8aa1-82b9bb5e8349" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_AuditInformationAbstract_18fcfdc6-1b0b-4b41-a03c-769c033dadaa" xlink:to="loc_dei_AuditorName_21487a74-b85d-4427-8aa1-82b9bb5e8349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_06386305-51ff-4d29-ae2d-aed58dd66f70" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_AuditInformationAbstract_18fcfdc6-1b0b-4b41-a03c-769c033dadaa" xlink:to="loc_dei_AuditorLocation_06386305-51ff-4d29-ae2d-aed58dd66f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_c00a3e4a-5167-4d73-9ccc-40e97aa1d574" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_AuditInformationAbstract_18fcfdc6-1b0b-4b41-a03c-769c033dadaa" xlink:to="loc_dei_AuditorFirmId_c00a3e4a-5167-4d73-9ccc-40e97aa1d574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="clbs-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5af02a49-c212-48cc-a988-2b26d7ab6cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f042fdc8-dc75-46d2-bbc4-d15bd373626d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5af02a49-c212-48cc-a988-2b26d7ab6cc5" xlink:to="loc_us-gaap_AssetsAbstract_f042fdc8-dc75-46d2-bbc4-d15bd373626d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_939160c6-605e-49f0-8814-d107ac940d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f042fdc8-dc75-46d2-bbc4-d15bd373626d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_939160c6-605e-49f0-8814-d107ac940d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f3d543da-2fa9-488d-aca2-55e410747134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_939160c6-605e-49f0-8814-d107ac940d83" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f3d543da-2fa9-488d-aca2-55e410747134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_232d1d37-5813-423b-b7b2-13d3c698c95b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_939160c6-605e-49f0-8814-d107ac940d83" xlink:to="loc_us-gaap_MarketableSecurities_232d1d37-5813-423b-b7b2-13d3c698c95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1a85e500-4809-4405-bd2c-4f20f23a882a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_939160c6-605e-49f0-8814-d107ac940d83" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1a85e500-4809-4405-bd2c-4f20f23a882a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b9bedbd0-5856-4421-b40b-e669e6f2b5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_939160c6-605e-49f0-8814-d107ac940d83" xlink:to="loc_us-gaap_AssetsCurrent_b9bedbd0-5856-4421-b40b-e669e6f2b5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6f441c9f-1e29-4d35-bc31-f444db094948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f042fdc8-dc75-46d2-bbc4-d15bd373626d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6f441c9f-1e29-4d35-bc31-f444db094948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b58e3ac7-bc41-4e28-8561-90a83aadd5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f042fdc8-dc75-46d2-bbc4-d15bd373626d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b58e3ac7-bc41-4e28-8561-90a83aadd5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_579d5b32-6d9b-4c8c-a34f-888d4eec15a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f042fdc8-dc75-46d2-bbc4-d15bd373626d" xlink:to="loc_us-gaap_Assets_579d5b32-6d9b-4c8c-a34f-888d4eec15a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fb1390a8-fa82-4de5-8a11-c7aa1825ad81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5af02a49-c212-48cc-a988-2b26d7ab6cc5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fb1390a8-fa82-4de5-8a11-c7aa1825ad81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f7d0a4a6-af13-438c-a3b6-3f1c6e529c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fb1390a8-fa82-4de5-8a11-c7aa1825ad81" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f7d0a4a6-af13-438c-a3b6-3f1c6e529c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_975cad7e-9ae2-4596-943f-c623e45dbc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f7d0a4a6-af13-438c-a3b6-3f1c6e529c19" xlink:to="loc_us-gaap_AccountsPayableCurrent_975cad7e-9ae2-4596-943f-c623e45dbc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ab837fc3-0477-4808-bf5f-f898d86c1884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f7d0a4a6-af13-438c-a3b6-3f1c6e529c19" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ab837fc3-0477-4808-bf5f-f898d86c1884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a10a0175-2372-45de-9e11-cd0f2f633429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f7d0a4a6-af13-438c-a3b6-3f1c6e529c19" xlink:to="loc_us-gaap_LiabilitiesCurrent_a10a0175-2372-45de-9e11-cd0f2f633429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a4f0ee74-0463-478f-9921-3413a60b19c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f7d0a4a6-af13-438c-a3b6-3f1c6e529c19" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a4f0ee74-0463-478f-9921-3413a60b19c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_37386e1b-f4bc-4789-98ce-cbfcf4124010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f7d0a4a6-af13-438c-a3b6-3f1c6e529c19" xlink:to="loc_us-gaap_Liabilities_37386e1b-f4bc-4789-98ce-cbfcf4124010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d3b9055-05b2-49dc-a29b-47f6cee837ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fb1390a8-fa82-4de5-8a11-c7aa1825ad81" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d3b9055-05b2-49dc-a29b-47f6cee837ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a836da4d-adfc-4ace-be49-cf97957357f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fb1390a8-fa82-4de5-8a11-c7aa1825ad81" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a836da4d-adfc-4ace-be49-cf97957357f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_52d868f6-8671-4c1f-8641-57beef6854b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a836da4d-adfc-4ace-be49-cf97957357f5" xlink:to="loc_us-gaap_PreferredStockValue_52d868f6-8671-4c1f-8641-57beef6854b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f63edf4c-f8cc-4cf7-af2f-f8dfa0a5bb07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a836da4d-adfc-4ace-be49-cf97957357f5" xlink:to="loc_us-gaap_CommonStockValue_f63edf4c-f8cc-4cf7-af2f-f8dfa0a5bb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_351013f5-06d9-4983-b0eb-4fd12b450117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a836da4d-adfc-4ace-be49-cf97957357f5" xlink:to="loc_us-gaap_AdditionalPaidInCapital_351013f5-06d9-4983-b0eb-4fd12b450117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_674a254d-920e-4a31-b8d7-6f4855f31d41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a836da4d-adfc-4ace-be49-cf97957357f5" xlink:to="loc_us-gaap_TreasuryStockValue_674a254d-920e-4a31-b8d7-6f4855f31d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_20b9e833-b32b-440c-a74f-d39a372d5233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a836da4d-adfc-4ace-be49-cf97957357f5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_20b9e833-b32b-440c-a74f-d39a372d5233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3703c319-307f-4992-95a1-e0fe9beab96a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a836da4d-adfc-4ace-be49-cf97957357f5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3703c319-307f-4992-95a1-e0fe9beab96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e641b179-7402-46d7-b1cc-5eb5a1f12ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a836da4d-adfc-4ace-be49-cf97957357f5" xlink:to="loc_us-gaap_StockholdersEquity_e641b179-7402-46d7-b1cc-5eb5a1f12ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_5d7a61d3-69d1-4d1e-b707-f1664224a0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a836da4d-adfc-4ace-be49-cf97957357f5" xlink:to="loc_us-gaap_MinorityInterest_5d7a61d3-69d1-4d1e-b707-f1664224a0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0615791b-a6cf-4165-90a6-616a25bef612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a836da4d-adfc-4ace-be49-cf97957357f5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0615791b-a6cf-4165-90a6-616a25bef612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a00fe288-7930-4b1d-8012-b5f9d7f53ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fb1390a8-fa82-4de5-8a11-c7aa1825ad81" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a00fe288-7930-4b1d-8012-b5f9d7f53ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="clbs-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1f431e34-4587-4288-b053-cc4403a04c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_878f0392-e582-4e92-8926-8c14171148de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1f431e34-4587-4288-b053-cc4403a04c08" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_878f0392-e582-4e92-8926-8c14171148de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f1d7f3bd-ab0c-4f8e-98b5-340b66b9c4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_878f0392-e582-4e92-8926-8c14171148de" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f1d7f3bd-ab0c-4f8e-98b5-340b66b9c4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreferredStockLiquidationPreferenceShare_338e403e-147c-4ae4-88e8-3085f502436a" xlink:href="clbs-20211231.xsd#clbs_PreferredStockLiquidationPreferenceShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_878f0392-e582-4e92-8926-8c14171148de" xlink:to="loc_clbs_PreferredStockLiquidationPreferenceShare_338e403e-147c-4ae4-88e8-3085f502436a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8afdf5a9-98ce-410b-843d-120126e4ba5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_878f0392-e582-4e92-8926-8c14171148de" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8afdf5a9-98ce-410b-843d-120126e4ba5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreferredStockSharesDesignated_897530b7-8a9d-4c11-abc4-f780e97eacf2" xlink:href="clbs-20211231.xsd#clbs_PreferredStockSharesDesignated"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_878f0392-e582-4e92-8926-8c14171148de" xlink:to="loc_clbs_PreferredStockSharesDesignated_897530b7-8a9d-4c11-abc4-f780e97eacf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b0239f72-69d1-4648-a400-01826c2bf5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_878f0392-e582-4e92-8926-8c14171148de" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b0239f72-69d1-4648-a400-01826c2bf5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ed2cc269-ad28-472c-9a8e-26425ae7afcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_878f0392-e582-4e92-8926-8c14171148de" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ed2cc269-ad28-472c-9a8e-26425ae7afcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_724dca6b-b2d4-4ae7-b59e-2c45c6c6fead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1f431e34-4587-4288-b053-cc4403a04c08" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_724dca6b-b2d4-4ae7-b59e-2c45c6c6fead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6c63d4a1-36e2-41cd-8296-1b9f96b7cc75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_724dca6b-b2d4-4ae7-b59e-2c45c6c6fead" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6c63d4a1-36e2-41cd-8296-1b9f96b7cc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0a736a39-d206-4521-822c-e9fe279018e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_724dca6b-b2d4-4ae7-b59e-2c45c6c6fead" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0a736a39-d206-4521-822c-e9fe279018e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_690bfe83-5b41-4aa2-9c64-e9d723f7505a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_724dca6b-b2d4-4ae7-b59e-2c45c6c6fead" xlink:to="loc_us-gaap_CommonStockSharesIssued_690bfe83-5b41-4aa2-9c64-e9d723f7505a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_67e1eb5e-f629-402e-9e2b-2e1a5ac4d489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_724dca6b-b2d4-4ae7-b59e-2c45c6c6fead" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_67e1eb5e-f629-402e-9e2b-2e1a5ac4d489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockNumberOfSharesAndRestrictionDisclosuresAbstract_99344187-c256-4feb-8375-eeb5cd91f77c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockNumberOfSharesAndRestrictionDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1f431e34-4587-4288-b053-cc4403a04c08" xlink:to="loc_us-gaap_TreasuryStockNumberOfSharesAndRestrictionDisclosuresAbstract_99344187-c256-4feb-8375-eeb5cd91f77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_fc6d07f3-65ea-4ad2-938c-d620edb2c428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TreasuryStockNumberOfSharesAndRestrictionDisclosuresAbstract_99344187-c256-4feb-8375-eeb5cd91f77c" xlink:to="loc_us-gaap_TreasuryStockShares_fc6d07f3-65ea-4ad2-938c-d620edb2c428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="clbs-20211231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_46b2850b-d382-45fa-95d1-ab0b25b892a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_fde0a272-aa18-498e-bc92-14a87abde875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_46b2850b-d382-45fa-95d1-ab0b25b892a8" xlink:to="loc_us-gaap_OperatingExpensesAbstract_fde0a272-aa18-498e-bc92-14a87abde875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a5723dad-53d9-4afe-a9e6-3e0a0adc81e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fde0a272-aa18-498e-bc92-14a87abde875" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a5723dad-53d9-4afe-a9e6-3e0a0adc81e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b1e09bbb-c7f7-4358-9774-b2a39edc300c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fde0a272-aa18-498e-bc92-14a87abde875" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b1e09bbb-c7f7-4358-9774-b2a39edc300c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5e1921ed-6e7d-4369-96dd-6efbb95ffbcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fde0a272-aa18-498e-bc92-14a87abde875" xlink:to="loc_us-gaap_OperatingExpenses_5e1921ed-6e7d-4369-96dd-6efbb95ffbcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ae93be4c-c087-457a-b90f-1a026540410a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_46b2850b-d382-45fa-95d1-ab0b25b892a8" xlink:to="loc_us-gaap_OperatingIncomeLoss_ae93be4c-c087-457a-b90f-1a026540410a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9ed98be7-8f6c-4aeb-a6a9-0a8072bb62e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_46b2850b-d382-45fa-95d1-ab0b25b892a8" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9ed98be7-8f6c-4aeb-a6a9-0a8072bb62e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_b7ad981a-78f0-4758-a724-c492ff769260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9ed98be7-8f6c-4aeb-a6a9-0a8072bb62e9" xlink:to="loc_us-gaap_InvestmentIncomeNet_b7ad981a-78f0-4758-a724-c492ff769260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_70feb164-64a1-4686-bd08-9f421e794236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9ed98be7-8f6c-4aeb-a6a9-0a8072bb62e9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_70feb164-64a1-4686-bd08-9f421e794236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b421fa15-badb-49ef-b61e-2afb3c3193aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9ed98be7-8f6c-4aeb-a6a9-0a8072bb62e9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_b421fa15-badb-49ef-b61e-2afb3c3193aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ecad9c6-970b-40d2-b84e-3ddbcaf0e9be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_46b2850b-d382-45fa-95d1-ab0b25b892a8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ecad9c6-970b-40d2-b84e-3ddbcaf0e9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_17f9a7c4-4783-4451-863c-4c7ae78e8eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_46b2850b-d382-45fa-95d1-ab0b25b892a8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_17f9a7c4-4783-4451-863c-4c7ae78e8eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a8ce0c67-4b13-45fc-990a-f43be6978e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_46b2850b-d382-45fa-95d1-ab0b25b892a8" xlink:to="loc_us-gaap_ProfitLoss_a8ce0c67-4b13-45fc-990a-f43be6978e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_5fcafdb0-80f1-468a-8cab-69fb48a4c972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_46b2850b-d382-45fa-95d1-ab0b25b892a8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_5fcafdb0-80f1-468a-8cab-69fb48a4c972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c03616c6-8444-4424-9f30-9181d62bd445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_46b2850b-d382-45fa-95d1-ab0b25b892a8" xlink:to="loc_us-gaap_NetIncomeLoss_c03616c6-8444-4424-9f30-9181d62bd445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_80e9d46d-de99-4974-855c-66135b68caf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_46b2850b-d382-45fa-95d1-ab0b25b892a8" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_80e9d46d-de99-4974-855c-66135b68caf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_255d314c-3d89-43ff-b1ee-e0cea5c760d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_80e9d46d-de99-4974-855c-66135b68caf7" xlink:to="loc_us-gaap_EarningsPerShareBasic_255d314c-3d89-43ff-b1ee-e0cea5c760d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_787a7f6f-e15a-42eb-861c-7279e0d794d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_80e9d46d-de99-4974-855c-66135b68caf7" xlink:to="loc_us-gaap_EarningsPerShareDiluted_787a7f6f-e15a-42eb-861c-7279e0d794d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1b80ab0e-d700-4d77-b751-d06cf2780966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_46b2850b-d382-45fa-95d1-ab0b25b892a8" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1b80ab0e-d700-4d77-b751-d06cf2780966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1afdaa62-e63b-48f4-8bc6-3442e50e2b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1b80ab0e-d700-4d77-b751-d06cf2780966" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1afdaa62-e63b-48f4-8bc6-3442e50e2b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_43226840-b53e-4339-81b0-691c00a9f74d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1b80ab0e-d700-4d77-b751-d06cf2780966" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_43226840-b53e-4339-81b0-691c00a9f74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="clbs-20211231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_16f9a55c-1a6f-47bb-8756-c441eb747c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6d03297c-e14f-4d29-9625-7e9c16de36e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_16f9a55c-1a6f-47bb-8756-c441eb747c3f" xlink:to="loc_us-gaap_ProfitLoss_6d03297c-e14f-4d29-9625-7e9c16de36e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_81bcfd24-e48a-4fe3-a0e4-95b80a039b69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_16f9a55c-1a6f-47bb-8756-c441eb747c3f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_81bcfd24-e48a-4fe3-a0e4-95b80a039b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8ddae868-909c-4413-bc7e-70262a0db4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_81bcfd24-e48a-4fe3-a0e4-95b80a039b69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8ddae868-909c-4413-bc7e-70262a0db4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_873b0daa-9fd8-4106-8d7f-6a08906d1b76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_81bcfd24-e48a-4fe3-a0e4-95b80a039b69" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_873b0daa-9fd8-4106-8d7f-6a08906d1b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_384561f2-74f5-4edb-9a15-566e8b061a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_16f9a55c-1a6f-47bb-8756-c441eb747c3f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_384561f2-74f5-4edb-9a15-566e8b061a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_22c01954-f152-481c-bbab-86deeb44152e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_16f9a55c-1a6f-47bb-8756-c441eb747c3f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_22c01954-f152-481c-bbab-86deeb44152e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2fa53c99-1ee8-4fae-9a28-d207dad51554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_16f9a55c-1a6f-47bb-8756-c441eb747c3f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2fa53c99-1ee8-4fae-9a28-d207dad51554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="clbs-20211231.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9fb02617-2cae-4725-a462-cfa237732a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c0ec2df1-a39d-4ed8-af41-4f637ae392a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9fb02617-2cae-4725-a462-cfa237732a73" xlink:to="loc_us-gaap_StatementTable_c0ec2df1-a39d-4ed8-af41-4f637ae392a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_53f53346-5fcf-4799-9bcc-e48e992855c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c0ec2df1-a39d-4ed8-af41-4f637ae392a4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_53f53346-5fcf-4799-9bcc-e48e992855c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2ae2690d-cf5b-4f31-9b84-550be0168fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_53f53346-5fcf-4799-9bcc-e48e992855c5" xlink:to="loc_us-gaap_EquityComponentDomain_2ae2690d-cf5b-4f31-9b84-550be0168fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_81234089-dd7f-4052-9558-cd3fb5f2e243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2ae2690d-cf5b-4f31-9b84-550be0168fb0" xlink:to="loc_us-gaap_ParentMember_81234089-dd7f-4052-9558-cd3fb5f2e243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_866a01d2-98e9-4ff2-a079-be4349ea9037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_81234089-dd7f-4052-9558-cd3fb5f2e243" xlink:to="loc_us-gaap_PreferredStockMember_866a01d2-98e9-4ff2-a079-be4349ea9037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9cb01ae7-1a40-4a57-a87e-ed899a431e50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_81234089-dd7f-4052-9558-cd3fb5f2e243" xlink:to="loc_us-gaap_CommonStockMember_9cb01ae7-1a40-4a57-a87e-ed899a431e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ec16d31f-2a55-45e5-bb10-aadefce204cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_81234089-dd7f-4052-9558-cd3fb5f2e243" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ec16d31f-2a55-45e5-bb10-aadefce204cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2d192b7b-f84c-4025-a454-acad5c92b164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_81234089-dd7f-4052-9558-cd3fb5f2e243" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2d192b7b-f84c-4025-a454-acad5c92b164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b37e7740-4a18-49fe-a784-392c140e24bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_81234089-dd7f-4052-9558-cd3fb5f2e243" xlink:to="loc_us-gaap_RetainedEarningsMember_b37e7740-4a18-49fe-a784-392c140e24bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_80a79514-7559-4b01-b495-dcc1adf2a1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_81234089-dd7f-4052-9558-cd3fb5f2e243" xlink:to="loc_us-gaap_TreasuryStockMember_80a79514-7559-4b01-b495-dcc1adf2a1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_d35845a1-4bd1-46d1-af0c-8f570581857b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2ae2690d-cf5b-4f31-9b84-550be0168fb0" xlink:to="loc_us-gaap_NoncontrollingInterestMember_d35845a1-4bd1-46d1-af0c-8f570581857b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_05af0079-e9ff-4825-968b-23654e55c428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c0ec2df1-a39d-4ed8-af41-4f637ae392a4" xlink:to="loc_us-gaap_StatementLineItems_05af0079-e9ff-4825-968b-23654e55c428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_05af0079-e9ff-4825-968b-23654e55c428" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0187dc07-0ab6-457c-86c9-25c80ed39de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_SharesOutstanding_0187dc07-0ab6-457c-86c9-25c80ed39de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3277ebd2-8cf7-45f1-b211-a41c15855ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3277ebd2-8cf7-45f1-b211-a41c15855ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e9ab9180-2652-4b47-9ea2-a68ca1374692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_ProfitLoss_e9ab9180-2652-4b47-9ea2-a68ca1374692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_23ef7a3f-0f71-4bd0-a316-8b311d74589a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_23ef7a3f-0f71-4bd0-a316-8b311d74589a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1209cc5d-ed41-4452-b238-b47d806ba8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1209cc5d-ed41-4452-b238-b47d806ba8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b0a7d9c4-dc30-487f-9305-3ca07f38a71b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_b0a7d9c4-dc30-487f-9305-3ca07f38a71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eedd5569-c6d6-4306-892a-180d6aff7306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eedd5569-c6d6-4306-892a-180d6aff7306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a0c9804d-5791-4577-8e32-07471f6cd717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a0c9804d-5791-4577-8e32-07471f6cd717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c8adae18-9920-4e6b-9763-5ec5a74b9020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c8adae18-9920-4e6b-9763-5ec5a74b9020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2c5c5ad7-00a4-4449-a24a-97ae2d87584b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2c5c5ad7-00a4-4449-a24a-97ae2d87584b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e874aec8-9852-4832-8d45-eb5a01aa5a86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_SharesOutstanding_e874aec8-9852-4832-8d45-eb5a01aa5a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b1c31a53-61de-4972-81cf-bf8d3c7207ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_25e5c586-d454-4891-b279-5464552f3e0d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b1c31a53-61de-4972-81cf-bf8d3c7207ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="clbs-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_fabc31c8-a3a1-459b-9d36-7de41514133e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6aa8e0cb-193f-47cb-af1b-a931c1b1d1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fabc31c8-a3a1-459b-9d36-7de41514133e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6aa8e0cb-193f-47cb-af1b-a931c1b1d1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f1e55157-e3c9-4b8a-897b-4a7212fd76ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6aa8e0cb-193f-47cb-af1b-a931c1b1d1d2" xlink:to="loc_us-gaap_ProfitLoss_f1e55157-e3c9-4b8a-897b-4a7212fd76ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c6ca274-7ceb-4254-867d-58a7393a0db9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6aa8e0cb-193f-47cb-af1b-a931c1b1d1d2" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c6ca274-7ceb-4254-867d-58a7393a0db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_b8188b55-5f32-4d85-9b3b-3921716dbc95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c6ca274-7ceb-4254-867d-58a7393a0db9" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_b8188b55-5f32-4d85-9b3b-3921716dbc95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_ef7f0a31-3ea8-473a-be6a-0253e257da04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c6ca274-7ceb-4254-867d-58a7393a0db9" xlink:to="loc_us-gaap_DepreciationAndAmortization_ef7f0a31-3ea8-473a-be6a-0253e257da04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fd1d6c5c-4f2b-42b7-99d6-8dc92a96bade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5c6ca274-7ceb-4254-867d-58a7393a0db9" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fd1d6c5c-4f2b-42b7-99d6-8dc92a96bade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_968bc4b5-d45a-4202-a365-ac32777b46a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6aa8e0cb-193f-47cb-af1b-a931c1b1d1d2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_968bc4b5-d45a-4202-a365-ac32777b46a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cd0bfc5c-6cea-43a6-8cf2-6dfda92c6f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_968bc4b5-d45a-4202-a365-ac32777b46a6" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cd0bfc5c-6cea-43a6-8cf2-6dfda92c6f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_da88b72e-73ca-48bc-9c37-4eaa88556411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_968bc4b5-d45a-4202-a365-ac32777b46a6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_da88b72e-73ca-48bc-9c37-4eaa88556411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_1a03b577-2f69-4319-ab09-eb311e1e3be5" xlink:href="clbs-20211231.xsd#clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_968bc4b5-d45a-4202-a365-ac32777b46a6" xlink:to="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_1a03b577-2f69-4319-ab09-eb311e1e3be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12979394-8fdb-4b07-95db-f626ac92c686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6aa8e0cb-193f-47cb-af1b-a931c1b1d1d2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_12979394-8fdb-4b07-95db-f626ac92c686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ed1b3607-3024-470d-97fb-b5afe3ff71ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fabc31c8-a3a1-459b-9d36-7de41514133e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ed1b3607-3024-470d-97fb-b5afe3ff71ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ea248958-bfa7-4246-989d-b1831a81f486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ed1b3607-3024-470d-97fb-b5afe3ff71ef" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ea248958-bfa7-4246-989d-b1831a81f486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_61580e8f-4339-4029-b98f-959ad4102149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ed1b3607-3024-470d-97fb-b5afe3ff71ef" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_61580e8f-4339-4029-b98f-959ad4102149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3f90db11-550c-440f-ac80-0a0f3dcebf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ed1b3607-3024-470d-97fb-b5afe3ff71ef" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3f90db11-550c-440f-ac80-0a0f3dcebf2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d146d9e-0d67-45de-841c-11d33b28f3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ed1b3607-3024-470d-97fb-b5afe3ff71ef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d146d9e-0d67-45de-841c-11d33b28f3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f9493d0-81cb-445d-ab4f-e116dab1ba22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fabc31c8-a3a1-459b-9d36-7de41514133e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f9493d0-81cb-445d-ab4f-e116dab1ba22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d7df6eef-577f-413d-8433-2d5d7807dbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f9493d0-81cb-445d-ab4f-e116dab1ba22" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d7df6eef-577f-413d-8433-2d5d7807dbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_79a4e373-8bee-4c18-a4d6-bf0c77a2f27f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f9493d0-81cb-445d-ab4f-e116dab1ba22" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_79a4e373-8bee-4c18-a4d6-bf0c77a2f27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e1c80af7-45ac-458a-9e5d-9d252739f10e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6f9493d0-81cb-445d-ab4f-e116dab1ba22" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e1c80af7-45ac-458a-9e5d-9d252739f10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_108744b6-fd06-42bf-bb21-b15d4edbf585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fabc31c8-a3a1-459b-9d36-7de41514133e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_108744b6-fd06-42bf-bb21-b15d4edbf585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dc91bc93-3db6-4cc5-9c8b-21b69e17b080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fabc31c8-a3a1-459b-9d36-7de41514133e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dc91bc93-3db6-4cc5-9c8b-21b69e17b080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_78f57e86-9e3e-49a8-957b-2e5408b616e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fabc31c8-a3a1-459b-9d36-7de41514133e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_78f57e86-9e3e-49a8-957b-2e5408b616e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2a9f0e41-f707-4a3b-ae0a-07f04554bf9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fabc31c8-a3a1-459b-9d36-7de41514133e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2a9f0e41-f707-4a3b-ae0a-07f04554bf9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_024bbb22-30d0-4696-89e1-358ab23f2369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fabc31c8-a3a1-459b-9d36-7de41514133e" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_024bbb22-30d0-4696-89e1-358ab23f2369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_d73e4529-cc0f-46a0-93c9-3d64d24a637c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_024bbb22-30d0-4696-89e1-358ab23f2369" xlink:to="loc_us-gaap_InterestPaidNet_d73e4529-cc0f-46a0-93c9-3d64d24a637c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_0c6b945d-21c5-4ad8-a0e9-9fae50aab061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_024bbb22-30d0-4696-89e1-358ab23f2369" xlink:to="loc_us-gaap_IncomeTaxesPaid_0c6b945d-21c5-4ad8-a0e9-9fae50aab061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TheBusiness" xlink:type="simple" xlink:href="clbs-20211231.xsd#TheBusiness"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/TheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2aed01cf-9f06-4e60-ab31-d60ba9c71906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_BusinessTextBlock_eacea22d-1edd-425a-b42c-7624f8b9d3e8" xlink:href="clbs-20211231.xsd#clbs_BusinessTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2aed01cf-9f06-4e60-ab31-d60ba9c71906" xlink:to="loc_clbs_BusinessTextBlock_eacea22d-1edd-425a-b42c-7624f8b9d3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TheBusinessDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#TheBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/TheBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_582628fc-dacf-4dee-a0dc-ae00130390e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b97ab80e-fc6d-47bf-93a6-62c64050baf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_582628fc-dacf-4dee-a0dc-ae00130390e3" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b97ab80e-fc6d-47bf-93a6-62c64050baf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1c5f5af4-1ab9-47dd-a107-1803fc88c02a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b97ab80e-fc6d-47bf-93a6-62c64050baf4" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1c5f5af4-1ab9-47dd-a107-1803fc88c02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_e463e2ad-1594-47dc-b919-bdc006d730d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_1c5f5af4-1ab9-47dd-a107-1803fc88c02a" xlink:to="loc_us-gaap_ProjectMember_e463e2ad-1594-47dc-b919-bdc006d730d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CLBS16TreatmentOfCMDMember_e16ca443-33b4-4fad-b52f-e3e5b0f54838" xlink:href="clbs-20211231.xsd#clbs_CLBS16TreatmentOfCMDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_e463e2ad-1594-47dc-b919-bdc006d730d7" xlink:to="loc_clbs_CLBS16TreatmentOfCMDMember_e16ca443-33b4-4fad-b52f-e3e5b0f54838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9b374caf-bd86-4627-8dce-2e9e3d6208ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_b97ab80e-fc6d-47bf-93a6-62c64050baf4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9b374caf-bd86-4627-8dce-2e9e3d6208ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_970225f3-203c-40d8-bf81-caa0cca07e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_9b374caf-bd86-4627-8dce-2e9e3d6208ee" xlink:to="loc_us-gaap_GrantsReceivable_970225f3-203c-40d8-bf81-caa0cca07e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="clbs-20211231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_adbe1f59-3183-4f07-80a2-fa1a54cdc022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e2be77ba-e29d-45e8-b325-8c18f4a741e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_adbe1f59-3183-4f07-80a2-fa1a54cdc022" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e2be77ba-e29d-45e8-b325-8c18f4a741e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="clbs-20211231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0dc0ce07-abfc-4fec-89c5-b20d9d89115c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7fa9164b-67cc-4f4f-bad6-3df737f2ae31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0dc0ce07-abfc-4fec-89c5-b20d9d89115c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7fa9164b-67cc-4f4f-bad6-3df737f2ae31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_d0913b46-1944-492e-bf32-115a1c35c7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0dc0ce07-abfc-4fec-89c5-b20d9d89115c" xlink:to="loc_us-gaap_UseOfEstimates_d0913b46-1944-492e-bf32-115a1c35c7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_145d464d-7104-43ff-b324-360e76f38ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0dc0ce07-abfc-4fec-89c5-b20d9d89115c" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_145d464d-7104-43ff-b324-360e76f38ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_711ad056-e82a-421b-b5e1-4a805908c69e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0dc0ce07-abfc-4fec-89c5-b20d9d89115c" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_711ad056-e82a-421b-b5e1-4a805908c69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_4b341e3b-cda8-401a-a057-33fc3505ebe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0dc0ce07-abfc-4fec-89c5-b20d9d89115c" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_4b341e3b-cda8-401a-a057-33fc3505ebe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_17147eb3-76a1-432f-871e-69f90a982556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0dc0ce07-abfc-4fec-89c5-b20d9d89115c" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_17147eb3-76a1-432f-871e-69f90a982556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6120d64f-bb59-4f16-968a-3d0e6b6c0af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0dc0ce07-abfc-4fec-89c5-b20d9d89115c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6120d64f-bb59-4f16-968a-3d0e6b6c0af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment_9f229f17-9120-4c07-8118-14040e6f71e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0dc0ce07-abfc-4fec-89c5-b20d9d89115c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentImpairment_9f229f17-9120-4c07-8118-14040e6f71e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5f118929-f240-41e1-9712-73d6e0616049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0dc0ce07-abfc-4fec-89c5-b20d9d89115c" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5f118929-f240-41e1-9712-73d6e0616049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_0bf11cfc-0b15-4a46-99fe-9bf232835c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0dc0ce07-abfc-4fec-89c5-b20d9d89115c" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_0bf11cfc-0b15-4a46-99fe-9bf232835c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_TreasuryStockPolicyPolicyTextBlock_ffd33593-9571-4189-8749-3a9192db1d91" xlink:href="clbs-20211231.xsd#clbs_TreasuryStockPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0dc0ce07-abfc-4fec-89c5-b20d9d89115c" xlink:to="loc_clbs_TreasuryStockPolicyPolicyTextBlock_ffd33593-9571-4189-8749-3a9192db1d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_56438b87-3a83-4d36-9ebf-2067dbc60398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0dc0ce07-abfc-4fec-89c5-b20d9d89115c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_56438b87-3a83-4d36-9ebf-2067dbc60398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_57a8cb38-eee2-4751-8240-3222131276b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0dc0ce07-abfc-4fec-89c5-b20d9d89115c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_57a8cb38-eee2-4751-8240-3222131276b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="clbs-20211231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f5883f77-8375-406d-9636-7c491a3b3817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_502c6b29-ba6a-4709-bbca-1c99d445c840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f5883f77-8375-406d-9636-7c491a3b3817" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_502c6b29-ba6a-4709-bbca-1c99d445c840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aadd1100-0730-45d3-97b9-4b9749e11ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a190e933-8106-4d2d-812b-68b478ed699b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aadd1100-0730-45d3-97b9-4b9749e11ea3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a190e933-8106-4d2d-812b-68b478ed699b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bef6879f-4809-49f0-a0eb-16bade456d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a190e933-8106-4d2d-812b-68b478ed699b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bef6879f-4809-49f0-a0eb-16bade456d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_37e81acc-ff8a-4d88-b801-3d6b425cf815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bef6879f-4809-49f0-a0eb-16bade456d62" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_37e81acc-ff8a-4d88-b801-3d6b425cf815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d9eea33c-1780-441e-8132-8c1926c8b84c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_37e81acc-ff8a-4d88-b801-3d6b425cf815" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d9eea33c-1780-441e-8132-8c1926c8b84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d831a233-0261-4425-8d31-3afb582fc139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_37e81acc-ff8a-4d88-b801-3d6b425cf815" xlink:to="loc_us-gaap_ComputerEquipmentMember_d831a233-0261-4425-8d31-3afb582fc139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_f85fc976-a482-40a6-9ceb-08c7233df711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_37e81acc-ff8a-4d88-b801-3d6b425cf815" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_f85fc976-a482-40a6-9ceb-08c7233df711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_24e32422-779e-495d-96e9-fa8358378719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a190e933-8106-4d2d-812b-68b478ed699b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_24e32422-779e-495d-96e9-fa8358378719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6d41b536-ef72-41fb-bd78-7fcf8864a314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_24e32422-779e-495d-96e9-fa8358378719" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6d41b536-ef72-41fb-bd78-7fcf8864a314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecurities" xlink:type="simple" xlink:href="clbs-20211231.xsd#AvailableforSaleSecurities"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e0b4788c-eb85-4b21-88be-8e599cfd0675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_83f78b06-736a-4ff4-92a0-173971cec597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e0b4788c-eb85-4b21-88be-8e599cfd0675" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_83f78b06-736a-4ff4-92a0-173971cec597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" xlink:type="simple" xlink:href="clbs-20211231.xsd#AvailableforSaleSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2e1d43de-4759-41c5-97d9-adad4cbd37a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_93e4ea10-f65b-468e-a5e8-bdcb09f340b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2e1d43de-4759-41c5-97d9-adad4cbd37a1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_93e4ea10-f65b-468e-a5e8-bdcb09f340b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_e7ed7e75-1386-411a-b704-abe477732b03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2e1d43de-4759-41c5-97d9-adad4cbd37a1" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_e7ed7e75-1386-411a-b704-abe477732b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_bce8ed78-0e10-4d6a-a9f5-45ad556e40cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2e1d43de-4759-41c5-97d9-adad4cbd37a1" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_bce8ed78-0e10-4d6a-a9f5-45ad556e40cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#AvailableforSaleSecuritiesSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8f80a919-e3c4-4ba1-bffd-b9ca79515361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0e0f3b48-47c7-430c-9689-edcabd57cd76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8f80a919-e3c4-4ba1-bffd-b9ca79515361" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0e0f3b48-47c7-430c-9689-edcabd57cd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_24039a3c-938c-417a-8704-1f77a027051f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0e0f3b48-47c7-430c-9689-edcabd57cd76" xlink:to="loc_us-gaap_FinancialInstrumentAxis_24039a3c-938c-417a-8704-1f77a027051f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74ed7212-efdd-4801-94c5-61ea5d935b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_24039a3c-938c-417a-8704-1f77a027051f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74ed7212-efdd-4801-94c5-61ea5d935b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6f175543-f892-4dd1-9966-e7fcd2063f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74ed7212-efdd-4801-94c5-61ea5d935b45" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6f175543-f892-4dd1-9966-e7fcd2063f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_cfcf37c7-74fa-4ddd-a6ce-a0694e8777c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74ed7212-efdd-4801-94c5-61ea5d935b45" xlink:to="loc_us-gaap_MoneyMarketFundsMember_cfcf37c7-74fa-4ddd-a6ce-a0694e8777c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_1a7a49d9-c35f-4f4d-b25b-be166afa6a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74ed7212-efdd-4801-94c5-61ea5d935b45" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_1a7a49d9-c35f-4f4d-b25b-be166afa6a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8c8a7227-e004-4800-aa48-2f8f60243ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_0e0f3b48-47c7-430c-9689-edcabd57cd76" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8c8a7227-e004-4800-aa48-2f8f60243ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_00cf49b3-a722-4a7e-8d6b-80de852f2f70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8c8a7227-e004-4800-aa48-2f8f60243ac4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_00cf49b3-a722-4a7e-8d6b-80de852f2f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_086e2a28-d417-4bea-aa55-e9eac04f6c47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8c8a7227-e004-4800-aa48-2f8f60243ac4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_086e2a28-d417-4bea-aa55-e9eac04f6c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_201f901e-ff76-428d-b35c-32cf2ac5254a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8c8a7227-e004-4800-aa48-2f8f60243ac4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_201f901e-ff76-428d-b35c-32cf2ac5254a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3ee50742-c423-46eb-8c39-82b6707f1039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8c8a7227-e004-4800-aa48-2f8f60243ac4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3ee50742-c423-46eb-8c39-82b6707f1039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationonConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#AvailableforSaleSecuritiesClassificationonConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationonConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b3b58081-d881-404c-860f-94e08c5db018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bb934fb8-a714-49a7-a227-cbcf89d60ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b3b58081-d881-404c-860f-94e08c5db018" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bb934fb8-a714-49a7-a227-cbcf89d60ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3bf535cb-9b3a-4b68-8707-b23270a67d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bb934fb8-a714-49a7-a227-cbcf89d60ebe" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3bf535cb-9b3a-4b68-8707-b23270a67d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_870139c7-d514-4908-af31-bf2baa3b9e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3bf535cb-9b3a-4b68-8707-b23270a67d42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_870139c7-d514-4908-af31-bf2baa3b9e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_66eaf030-4b6e-438f-8a07-0029bff635c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_870139c7-d514-4908-af31-bf2baa3b9e2f" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_66eaf030-4b6e-438f-8a07-0029bff635c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MarketableSecuritiesMember_64610be8-77b6-4f26-8f68-a3b102ba9c1e" xlink:href="clbs-20211231.xsd#clbs_MarketableSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_870139c7-d514-4908-af31-bf2baa3b9e2f" xlink:to="loc_clbs_MarketableSecuritiesMember_64610be8-77b6-4f26-8f68-a3b102ba9c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_dc3d271b-369a-4bd6-9821-7ce6dd44c8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bb934fb8-a714-49a7-a227-cbcf89d60ebe" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_dc3d271b-369a-4bd6-9821-7ce6dd44c8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_57addc31-1bbc-4447-9f68-51c631a4ece6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_dc3d271b-369a-4bd6-9821-7ce6dd44c8f5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_57addc31-1bbc-4447-9f68-51c631a4ece6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#AvailableforSaleSecuritiesContractualMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f694a235-95c4-4c21-b9ab-3e2fc4134e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_34c09c33-b940-4f45-835f-60320f081795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f694a235-95c4-4c21-b9ab-3e2fc4134e9b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_34c09c33-b940-4f45-835f-60320f081795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_bad5c3b5-4d5b-4f10-981a-e5b39a06612a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_34c09c33-b940-4f45-835f-60320f081795" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_bad5c3b5-4d5b-4f10-981a-e5b39a06612a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_e2db9c1f-e7c9-4ccf-b737-6fd19f0db2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_34c09c33-b940-4f45-835f-60320f081795" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_e2db9c1f-e7c9-4ccf-b737-6fd19f0db2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_131dc2a5-e09e-482e-9e7f-79e580a78a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_34c09c33-b940-4f45-835f-60320f081795" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_131dc2a5-e09e-482e-9e7f-79e580a78a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_ac75759d-de8e-4b00-8a2d-f0cc49e48a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f694a235-95c4-4c21-b9ab-3e2fc4134e9b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_ac75759d-de8e-4b00-8a2d-f0cc49e48a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_34238147-2907-4b4c-b239-d1d51e8e1731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_ac75759d-de8e-4b00-8a2d-f0cc49e48a0d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_34238147-2907-4b4c-b239-d1d51e8e1731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_66e1a9a7-7e70-46a1-80ce-43e5cdf022f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_ac75759d-de8e-4b00-8a2d-f0cc49e48a0d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_66e1a9a7-7e70-46a1-80ce-43e5cdf022f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c1fe04d7-0785-4c06-85c3-b4d8508b96f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_ac75759d-de8e-4b00-8a2d-f0cc49e48a0d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c1fe04d7-0785-4c06-85c3-b4d8508b96f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="clbs-20211231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f787eb1f-7d2e-4dc2-a9e6-5b63aed05ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_bf8d1928-a325-472d-9b07-de6d254ed3af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f787eb1f-7d2e-4dc2-a9e6-5b63aed05ac4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_bf8d1928-a325-472d-9b07-de6d254ed3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="clbs-20211231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2bb9635d-0c9d-4ed8-b850-08911f0b9452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_a7d69f05-740b-4d92-96b8-b7e12c1e5885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2bb9635d-0c9d-4ed8-b850-08911f0b9452" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_a7d69f05-740b-4d92-96b8-b7e12c1e5885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#PropertyandEquipmentSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_64aae74f-0d02-46d0-bebf-a147a4bc4a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fbcddba6-677d-46dd-8abc-9db055af4dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_64aae74f-0d02-46d0-bebf-a147a4bc4a2c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fbcddba6-677d-46dd-8abc-9db055af4dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_19ff6e96-525f-43d0-9c8b-c5c1eac6adf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fbcddba6-677d-46dd-8abc-9db055af4dc4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_19ff6e96-525f-43d0-9c8b-c5c1eac6adf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee862a01-8eaa-4d29-ab6f-de8bd29b0d41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_19ff6e96-525f-43d0-9c8b-c5c1eac6adf3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee862a01-8eaa-4d29-ab6f-de8bd29b0d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_5e737a79-a5f7-47bd-b374-d608655d7019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee862a01-8eaa-4d29-ab6f-de8bd29b0d41" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_5e737a79-a5f7-47bd-b374-d608655d7019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_11e70072-f36e-4de2-94c8-fcdf433de8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee862a01-8eaa-4d29-ab6f-de8bd29b0d41" xlink:to="loc_us-gaap_ComputerEquipmentMember_11e70072-f36e-4de2-94c8-fcdf433de8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_d0a5a0a3-7b8b-41ba-bf25-c9a2c98ea79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee862a01-8eaa-4d29-ab6f-de8bd29b0d41" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_d0a5a0a3-7b8b-41ba-bf25-c9a2c98ea79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_64971296-deed-4f77-b6e7-351eebee7620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fbcddba6-677d-46dd-8abc-9db055af4dc4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_64971296-deed-4f77-b6e7-351eebee7620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5df0510c-4c77-4afe-a53d-cc700d7e6356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_64971296-deed-4f77-b6e7-351eebee7620" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5df0510c-4c77-4afe-a53d-cc700d7e6356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_367edbf8-b676-4c03-81be-9c60807eb08e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_64971296-deed-4f77-b6e7-351eebee7620" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_367edbf8-b676-4c03-81be-9c60807eb08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8d40343d-4759-4cc5-9045-87a2032d7b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_64971296-deed-4f77-b6e7-351eebee7620" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8d40343d-4759-4cc5-9045-87a2032d7b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_97e8cbb6-d1e2-4092-abf3-70848bdf77ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_dd47191a-6585-467e-9fb8-70a6c09356e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_97e8cbb6-d1e2-4092-abf3-70848bdf77ed" xlink:to="loc_us-gaap_Depreciation_dd47191a-6585-467e-9fb8-70a6c09356e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/LossPerShare" xlink:type="simple" xlink:href="clbs-20211231.xsd#LossPerShare"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/LossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a84e5ed7-64b9-4ec6-8633-fcfef220830b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_36b377ab-25a7-4e06-899a-619ef3e182e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a84e5ed7-64b9-4ec6-8633-fcfef220830b" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_36b377ab-25a7-4e06-899a-619ef3e182e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/LossPerShareTables" xlink:type="simple" xlink:href="clbs-20211231.xsd#LossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/LossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fc66251d-3c02-4213-832a-55827b0a3ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_277cbba3-cebe-4b51-8ba0-e64129760f54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc66251d-3c02-4213-832a-55827b0a3ea3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_277cbba3-cebe-4b51-8ba0-e64129760f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/LossPerShareDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#LossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/LossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7b8450e1-794e-4999-808c-15cebd6df3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b0f72c2d-0a68-4a0b-86d7-2948cb34f818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7b8450e1-794e-4999-808c-15cebd6df3f2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b0f72c2d-0a68-4a0b-86d7-2948cb34f818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_edf8cc13-b962-46a0-8472-bbaa4b063e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b0f72c2d-0a68-4a0b-86d7-2948cb34f818" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_edf8cc13-b962-46a0-8472-bbaa4b063e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_da8130f6-be40-4f1e-b518-2cc510857c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_edf8cc13-b962-46a0-8472-bbaa4b063e60" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_da8130f6-be40-4f1e-b518-2cc510857c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f33c2fd0-e7dc-4910-9469-d672fd03090c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_da8130f6-be40-4f1e-b518-2cc510857c3e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f33c2fd0-e7dc-4910-9469-d672fd03090c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_221ea354-3302-4a7d-bf99-384a420d2e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_da8130f6-be40-4f1e-b518-2cc510857c3e" xlink:to="loc_us-gaap_WarrantMember_221ea354-3302-4a7d-bf99-384a420d2e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3ccd6acd-8b05-49fa-acf1-5331ce18e09f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_da8130f6-be40-4f1e-b518-2cc510857c3e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3ccd6acd-8b05-49fa-acf1-5331ce18e09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a03c7d9c-6315-419e-ab00-cd25411f52c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b0f72c2d-0a68-4a0b-86d7-2948cb34f818" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a03c7d9c-6315-419e-ab00-cd25411f52c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_77db4e62-e4ad-4908-a680-c133b9ec16e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a03c7d9c-6315-419e-ab00-cd25411f52c2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_77db4e62-e4ad-4908-a680-c133b9ec16e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="clbs-20211231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e53c4d29-693c-4966-a536-3c07df314d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_4066dbbd-9158-4f7f-ae84-e13b34918477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e53c4d29-693c-4966-a536-3c07df314d8a" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_4066dbbd-9158-4f7f-ae84-e13b34918477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="clbs-20211231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7926c416-5445-4435-b5d2-360e19d0bce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_b95c5fdf-2ccb-4bcd-8029-3ece1039338f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7926c416-5445-4435-b5d2-360e19d0bce9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_b95c5fdf-2ccb-4bcd-8029-3ece1039338f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dda40a1e-912b-4773-9d7a-367289abe8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83b7bfbb-68dd-4ed4-8d06-88aad0180716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dda40a1e-912b-4773-9d7a-367289abe8a6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83b7bfbb-68dd-4ed4-8d06-88aad0180716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5499ddef-89d8-4976-b3b3-9246e58eb431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83b7bfbb-68dd-4ed4-8d06-88aad0180716" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5499ddef-89d8-4976-b3b3-9246e58eb431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6bd10ac5-375c-451b-b19a-66505a5a31c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5499ddef-89d8-4976-b3b3-9246e58eb431" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6bd10ac5-375c-451b-b19a-66505a5a31c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_fd159745-5b5f-4f0a-ba8a-98ecdcc4851d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6bd10ac5-375c-451b-b19a-66505a5a31c5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_fd159745-5b5f-4f0a-ba8a-98ecdcc4851d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09f56641-de66-4eb0-b347-db0dd9c074e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83b7bfbb-68dd-4ed4-8d06-88aad0180716" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09f56641-de66-4eb0-b347-db0dd9c074e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7755dd55-c9b6-41f4-a4e3-f765a0a14dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_09f56641-de66-4eb0-b347-db0dd9c074e5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7755dd55-c9b6-41f4-a4e3-f765a0a14dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1af238fe-20d8-44de-a1c5-ed42e87d0617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7755dd55-c9b6-41f4-a4e3-f765a0a14dca" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1af238fe-20d8-44de-a1c5-ed42e87d0617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fd30bd8b-91e7-4711-831e-6a7d81620891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7755dd55-c9b6-41f4-a4e3-f765a0a14dca" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fd30bd8b-91e7-4711-831e-6a7d81620891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e58259df-7edc-4b08-b785-296fd419b1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7755dd55-c9b6-41f4-a4e3-f765a0a14dca" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e58259df-7edc-4b08-b785-296fd419b1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c4295414-10f4-4fb7-87b4-8ed33ff38d48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83b7bfbb-68dd-4ed4-8d06-88aad0180716" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c4295414-10f4-4fb7-87b4-8ed33ff38d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_c67ea93a-b0f8-47fb-9dd2-405ebc7bd6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c4295414-10f4-4fb7-87b4-8ed33ff38d48" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_c67ea93a-b0f8-47fb-9dd2-405ebc7bd6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_04be93bd-b2ac-4652-a411-1fe86a591a36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c67ea93a-b0f8-47fb-9dd2-405ebc7bd6a1" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_04be93bd-b2ac-4652-a411-1fe86a591a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1a6d8f7a-3e9e-4556-a641-7cc0ba0df4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c67ea93a-b0f8-47fb-9dd2-405ebc7bd6a1" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1a6d8f7a-3e9e-4556-a641-7cc0ba0df4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="clbs-20211231.xsd#AccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_7554a53f-4685-445f-893d-770911e96abf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_aa2a3e23-704a-43a0-b87d-7375a013c83d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_7554a53f-4685-445f-893d-770911e96abf" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_aa2a3e23-704a-43a0-b87d-7375a013c83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="clbs-20211231.xsd#AccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_166c5af1-3de3-4e1a-acdb-ca52c6d65e74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_f3d761d4-2948-4374-9843-3110231319aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_166c5af1-3de3-4e1a-acdb-ca52c6d65e74" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_f3d761d4-2948-4374-9843-3110231319aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#AccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_b4eeac6b-01c1-4507-9230-b6559ea41329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_a0b802cf-ebe4-4cbd-95e6-584440488322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_b4eeac6b-01c1-4507-9230-b6559ea41329" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_a0b802cf-ebe4-4cbd-95e6-584440488322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_76fc9d20-6d4f-43f7-8552-a833a73ebe73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_b4eeac6b-01c1-4507-9230-b6559ea41329" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_76fc9d20-6d4f-43f7-8552-a833a73ebe73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_10202c67-817d-401a-a080-76662660a690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_b4eeac6b-01c1-4507-9230-b6559ea41329" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_10202c67-817d-401a-a080-76662660a690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_22de353c-fe42-475f-88a7-a8ec58aa4a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_b4eeac6b-01c1-4507-9230-b6559ea41329" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_22de353c-fe42-475f-88a7-a8ec58aa4a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeases" xlink:type="simple" xlink:href="clbs-20211231.xsd#OperatingLeases"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9539ca41-6e6e-4c1b-b89a-2b8a8197a892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_946ffe73-c963-4ecf-9f21-d010fb9136bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9539ca41-6e6e-4c1b-b89a-2b8a8197a892" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_946ffe73-c963-4ecf-9f21-d010fb9136bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesTables" xlink:type="simple" xlink:href="clbs-20211231.xsd#OperatingLeasesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c0c3596b-412c-418a-847e-c4b7bd36e492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_ddaa5924-dadd-4224-b0ba-c430e071618d" xlink:href="clbs-20211231.xsd#clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c0c3596b-412c-418a-847e-c4b7bd36e492" xlink:to="loc_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_ddaa5924-dadd-4224-b0ba-c430e071618d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_830a7ec3-7d06-4e23-a34d-a733c978a090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c0c3596b-412c-418a-847e-c4b7bd36e492" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_830a7ec3-7d06-4e23-a34d-a733c978a090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#OperatingLeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1d3a8ed2-431a-4d70-ab5f-532143af6b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_NumberOfOfficesUnderOperatingLeases_abb1ce7a-a0f7-4313-a9d0-1730f3cad483" xlink:href="clbs-20211231.xsd#clbs_NumberOfOfficesUnderOperatingLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1d3a8ed2-431a-4d70-ab5f-532143af6b96" xlink:to="loc_clbs_NumberOfOfficesUnderOperatingLeases_abb1ce7a-a0f7-4313-a9d0-1730f3cad483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_786792f0-c813-4fab-b425-22a2ff70729f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1d3a8ed2-431a-4d70-ab5f-532143af6b96" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_786792f0-c813-4fab-b425-22a2ff70729f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_22c1621e-9e83-425a-aa72-0773258c08f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1d3a8ed2-431a-4d70-ab5f-532143af6b96" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_22c1621e-9e83-425a-aa72-0773258c08f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#OperatingLeasesBalanceSheetPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7654c7e0-2d71-4156-954c-02ce6ab4739d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLeaseRightOfUseAssetAbstract_12421892-fdb6-4875-8e37-bd56bfc284bd" xlink:href="clbs-20211231.xsd#clbs_OperatingLeaseRightOfUseAssetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7654c7e0-2d71-4156-954c-02ce6ab4739d" xlink:to="loc_clbs_OperatingLeaseRightOfUseAssetAbstract_12421892-fdb6-4875-8e37-bd56bfc284bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e465bde6-7478-4500-afdc-2073cdd82cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_OperatingLeaseRightOfUseAssetAbstract_12421892-fdb6-4875-8e37-bd56bfc284bd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e465bde6-7478-4500-afdc-2073cdd82cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_f2cc3ea3-e9f3-42d1-ac52-7ef4501ef464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_OperatingLeaseRightOfUseAssetAbstract_12421892-fdb6-4875-8e37-bd56bfc284bd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_f2cc3ea3-e9f3-42d1-ac52-7ef4501ef464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_af837359-91c7-4de4-ada0-d315031abf62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7654c7e0-2d71-4156-954c-02ce6ab4739d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_af837359-91c7-4de4-ada0-d315031abf62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_12895b85-0641-434c-bd08-ac9d13a94228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_af837359-91c7-4de4-ada0-d315031abf62" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_12895b85-0641-434c-bd08-ac9d13a94228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7a252423-360d-424b-b01c-e61b46a239a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_af837359-91c7-4de4-ada0-d315031abf62" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7a252423-360d-424b-b01c-e61b46a239a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1605cdf5-7c24-46c8-969e-b7acbb3495e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_af837359-91c7-4de4-ada0-d315031abf62" xlink:to="loc_us-gaap_OperatingLeaseLiability_1605cdf5-7c24-46c8-969e-b7acbb3495e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_3710cabd-13c7-4852-82a3-610c8a2d4856" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_af837359-91c7-4de4-ada0-d315031abf62" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_3710cabd-13c7-4852-82a3-610c8a2d4856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_88896bb1-2291-4044-a576-b974fa2fb978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_af837359-91c7-4de4-ada0-d315031abf62" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_88896bb1-2291-4044-a576-b974fa2fb978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_eca784ea-56e2-43b4-83f4-dd8fe66a04ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6a8d7d7b-78b8-43b5-807c-65fe46b305f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_eca784ea-56e2-43b4-83f4-dd8fe66a04ed" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6a8d7d7b-78b8-43b5-807c-65fe46b305f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_09058ce5-2b4b-4b42-b065-16dc80767cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6a8d7d7b-78b8-43b5-807c-65fe46b305f5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_09058ce5-2b4b-4b42-b065-16dc80767cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bc80118b-e78b-4fb7-9af3-b15c1aa4b9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6a8d7d7b-78b8-43b5-807c-65fe46b305f5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bc80118b-e78b-4fb7-9af3-b15c1aa4b9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_29f01756-a5ad-466c-b1c1-0bb9229a4c43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6a8d7d7b-78b8-43b5-807c-65fe46b305f5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_29f01756-a5ad-466c-b1c1-0bb9229a4c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_aba9bc06-ee8b-4e2c-b71d-c4b0670af9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6a8d7d7b-78b8-43b5-807c-65fe46b305f5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_aba9bc06-ee8b-4e2c-b71d-c4b0670af9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_98c0d22d-f8b4-4d57-9d83-5ae3b74ae85b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6a8d7d7b-78b8-43b5-807c-65fe46b305f5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_98c0d22d-f8b4-4d57-9d83-5ae3b74ae85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4ed581a5-16d6-4654-a7f3-d01d185cde30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6a8d7d7b-78b8-43b5-807c-65fe46b305f5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4ed581a5-16d6-4654-a7f3-d01d185cde30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b40c4015-0f69-471a-88cb-a154782907d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6a8d7d7b-78b8-43b5-807c-65fe46b305f5" xlink:to="loc_us-gaap_OperatingLeaseLiability_b40c4015-0f69-471a-88cb-a154782907d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails_1" xlink:type="simple" xlink:href="clbs-20211231.xsd#OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails_1"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquity" xlink:type="simple" xlink:href="clbs-20211231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_313abb00-4d31-4590-8bbd-fc0da144fd1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8d5f7a07-ef2d-48bd-86a7-01c24ae6f3be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_313abb00-4d31-4590-8bbd-fc0da144fd1c" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8d5f7a07-ef2d-48bd-86a7-01c24ae6f3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="clbs-20211231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f825e3fd-73c2-45c3-a4a1-6d2296f56497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_daf8ef04-29f1-452b-9f2c-96ffa517ed1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f825e3fd-73c2-45c3-a4a1-6d2296f56497" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_daf8ef04-29f1-452b-9f2c-96ffa517ed1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_2087587b-4f0a-4db2-bcb6-fab9a00c1991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f825e3fd-73c2-45c3-a4a1-6d2296f56497" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_2087587b-4f0a-4db2-bcb6-fab9a00c1991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_f9b39718-6679-4e85-869f-7f4cc6a88ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f825e3fd-73c2-45c3-a4a1-6d2296f56497" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_f9b39718-6679-4e85-869f-7f4cc6a88ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#StockholdersEquityEquityPlanDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a95a3993-6731-43b2-86d8-c3ee3427b1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ee6e889-5833-45ef-8da7-6bb69861d649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a95a3993-6731-43b2-86d8-c3ee3427b1b7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ee6e889-5833-45ef-8da7-6bb69861d649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3d2532f1-a729-44a1-8d93-86abb58de0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ee6e889-5833-45ef-8da7-6bb69861d649" xlink:to="loc_us-gaap_PlanNameAxis_3d2532f1-a729-44a1-8d93-86abb58de0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ffb171b9-e1ca-48a2-bf32-7029cac71a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_3d2532f1-a729-44a1-8d93-86abb58de0dd" xlink:to="loc_us-gaap_PlanNameDomain_ffb171b9-e1ca-48a2-bf32-7029cac71a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EquityIncentiveCompensationPlan2018Member_5cb4212c-0417-4981-84a9-154aaab8a983" xlink:href="clbs-20211231.xsd#clbs_EquityIncentiveCompensationPlan2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ffb171b9-e1ca-48a2-bf32-7029cac71a1e" xlink:to="loc_clbs_EquityIncentiveCompensationPlan2018Member_5cb4212c-0417-4981-84a9-154aaab8a983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlanMember_fabd725d-fa34-4da0-abab-3d5c7be39adc" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ffb171b9-e1ca-48a2-bf32-7029cac71a1e" xlink:to="loc_clbs_EmployeeStockPurchasePlanMember_fabd725d-fa34-4da0-abab-3d5c7be39adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlan2012Member_8c148aa5-fe1d-44b6-b734-303b097e548d" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlan2012Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ffb171b9-e1ca-48a2-bf32-7029cac71a1e" xlink:to="loc_clbs_EmployeeStockPurchasePlan2012Member_8c148aa5-fe1d-44b6-b734-303b097e548d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlan2017Member_df158b66-e03c-4cb6-92e3-e15190e42bd3" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlan2017Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ffb171b9-e1ca-48a2-bf32-7029cac71a1e" xlink:to="loc_clbs_EmployeeStockPurchasePlan2017Member_df158b66-e03c-4cb6-92e3-e15190e42bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlan2017AmendedMember_f5aa8d55-53e6-436f-9978-f2b7e4865dc9" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlan2017AmendedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ffb171b9-e1ca-48a2-bf32-7029cac71a1e" xlink:to="loc_clbs_EmployeeStockPurchasePlan2017AmendedMember_f5aa8d55-53e6-436f-9978-f2b7e4865dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4bd6a4c2-33a4-4b78-8005-1b084f6afff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ee6e889-5833-45ef-8da7-6bb69861d649" xlink:to="loc_us-gaap_AwardTypeAxis_4bd6a4c2-33a4-4b78-8005-1b084f6afff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72b7d393-5b3c-48ca-83a9-727fa6eb50e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4bd6a4c2-33a4-4b78-8005-1b084f6afff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72b7d393-5b3c-48ca-83a9-727fa6eb50e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_903e90c1-0672-4595-9a1d-c8be6f82f74f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72b7d393-5b3c-48ca-83a9-727fa6eb50e3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_903e90c1-0672-4595-9a1d-c8be6f82f74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_694f55ba-006c-40b2-a1e8-273e324ca06b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ee6e889-5833-45ef-8da7-6bb69861d649" xlink:to="loc_us-gaap_VestingAxis_694f55ba-006c-40b2-a1e8-273e324ca06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_386dc372-e7c7-4c11-a419-26221c7359d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_694f55ba-006c-40b2-a1e8-273e324ca06b" xlink:to="loc_us-gaap_VestingDomain_386dc372-e7c7-4c11-a419-26221c7359d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_20b9ea79-b763-44c9-acea-44d42f5cc60f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_386dc372-e7c7-4c11-a419-26221c7359d9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_20b9ea79-b763-44c9-acea-44d42f5cc60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_45961a7c-55b2-413b-a18c-1214bacc1e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_386dc372-e7c7-4c11-a419-26221c7359d9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_45961a7c-55b2-413b-a18c-1214bacc1e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_0565eb0f-6e27-4cb9-9d5e-58be32dba5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_386dc372-e7c7-4c11-a419-26221c7359d9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_0565eb0f-6e27-4cb9-9d5e-58be32dba5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7ee6e889-5833-45ef-8da7-6bb69861d649" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4862b2d0-1f0d-47cb-9c12-9eb8e85ccf21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4862b2d0-1f0d-47cb-9c12-9eb8e85ccf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9e5fa60c-cddb-41b8-bfdf-69f4383a38f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9e5fa60c-cddb-41b8-bfdf-69f4383a38f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b3fd1b9e-a506-47c3-a5d2-2930b9cf86d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b3fd1b9e-a506-47c3-a5d2-2930b9cf86d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan_df64cbc2-5e45-405d-8a37-a67ad77eff13" xlink:href="clbs-20211231.xsd#clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan_df64cbc2-5e45-405d-8a37-a67ad77eff13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm_b3d4c7ac-9f5b-491e-a299-2e5581a68167" xlink:href="clbs-20211231.xsd#clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm_b3d4c7ac-9f5b-491e-a299-2e5581a68167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent_c8973c93-a320-4775-8ef7-fd1cb07c8978" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent_c8973c93-a320-4775-8ef7-fd1cb07c8978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee_729a2219-d868-4197-8216-e86b54675812" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee_729a2219-d868-4197-8216-e86b54675812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate_5b2099d0-877f-4b1b-ae16-6dd5234d265e" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate_5b2099d0-877f-4b1b-ae16-6dd5234d265e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate_1887ec9f-f9a7-4cdd-8e0f-82cb34cc594f" xlink:href="clbs-20211231.xsd#clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate_1887ec9f-f9a7-4cdd-8e0f-82cb34cc594f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ef9a7156-618a-4a6e-b49f-bea434020367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9462f4ef-75e0-4acf-8a18-3a2302e6d086" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ef9a7156-618a-4a6e-b49f-bea434020367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#StockholdersEquityEquityIssuancesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_61941841-5982-4c45-9d89-d140ebfbcfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c76fadc7-f271-4cd9-b7e4-81d4b4d1b781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_61941841-5982-4c45-9d89-d140ebfbcfc5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c76fadc7-f271-4cd9-b7e4-81d4b4d1b781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4d18a83a-0ddc-445f-93fe-e419b2ee2f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c76fadc7-f271-4cd9-b7e4-81d4b4d1b781" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4d18a83a-0ddc-445f-93fe-e419b2ee2f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a5cf593-7582-4644-b3a5-70b716a62533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4d18a83a-0ddc-445f-93fe-e419b2ee2f6d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a5cf593-7582-4644-b3a5-70b716a62533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LincolnParkAgreementMember_104893cc-3909-432a-82e7-3fa505c64b7f" xlink:href="clbs-20211231.xsd#clbs_LincolnParkAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a5cf593-7582-4644-b3a5-70b716a62533" xlink:to="loc_clbs_LincolnParkAgreementMember_104893cc-3909-432a-82e7-3fa505c64b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_H.C.WainwrightSalesAmendedAgreementMember_929c26ba-eafd-4a6d-96b3-126384b8f197" xlink:href="clbs-20211231.xsd#clbs_H.C.WainwrightSalesAmendedAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a5cf593-7582-4644-b3a5-70b716a62533" xlink:to="loc_clbs_H.C.WainwrightSalesAmendedAgreementMember_929c26ba-eafd-4a6d-96b3-126384b8f197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AtTheMarketOfferingAgreementMember_1d13037f-0ba4-4c10-8d34-961930c95a95" xlink:href="clbs-20211231.xsd#clbs_AtTheMarketOfferingAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a5cf593-7582-4644-b3a5-70b716a62533" xlink:to="loc_clbs_AtTheMarketOfferingAgreementMember_1d13037f-0ba4-4c10-8d34-961930c95a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_InstitutionalPurchaseAgreementMember_1971059a-2dd1-4049-b7a5-2bba63c18c90" xlink:href="clbs-20211231.xsd#clbs_InstitutionalPurchaseAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a5cf593-7582-4644-b3a5-70b716a62533" xlink:to="loc_clbs_InstitutionalPurchaseAgreementMember_1971059a-2dd1-4049-b7a5-2bba63c18c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AdditionalPurchaseAgreementMember_358e1fd2-edbb-4098-a17b-86e98216e7fb" xlink:href="clbs-20211231.xsd#clbs_AdditionalPurchaseAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a5cf593-7582-4644-b3a5-70b716a62533" xlink:to="loc_clbs_AdditionalPurchaseAgreementMember_358e1fd2-edbb-4098-a17b-86e98216e7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_January2021PurchaseAgreementMember_cd987d5e-cf69-458c-a7cd-5307b59085c7" xlink:href="clbs-20211231.xsd#clbs_January2021PurchaseAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2a5cf593-7582-4644-b3a5-70b716a62533" xlink:to="loc_clbs_January2021PurchaseAgreementMember_cd987d5e-cf69-458c-a7cd-5307b59085c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c76fadc7-f271-4cd9-b7e4-81d4b4d1b781" xlink:to="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_2f47b314-21b1-4db8-9344-b54d9929ef95" xlink:href="clbs-20211231.xsd#clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_2f47b314-21b1-4db8-9344-b54d9929ef95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_89028d77-7d82-45e0-9926-d19f6ce02226" xlink:href="clbs-20211231.xsd#clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_89028d77-7d82-45e0-9926-d19f6ce02226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fa5c463d-4c04-4376-9a73-7caca6b27c18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fa5c463d-4c04-4376-9a73-7caca6b27c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_853d04b5-0847-47a2-ab72-e2504f76dd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_853d04b5-0847-47a2-ab72-e2504f76dd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6593c21e-9a13-433a-b370-82299a2d593e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6593c21e-9a13-433a-b370-82299a2d593e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_TermOfAgreement_86b7689b-dabe-4191-a48e-39238e170b55" xlink:href="clbs-20211231.xsd#clbs_TermOfAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_clbs_TermOfAgreement_86b7689b-dabe-4191-a48e-39238e170b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_181cb76f-657f-4a12-911b-b4c755f0e1f0" xlink:href="clbs-20211231.xsd#clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_181cb76f-657f-4a12-911b-b4c755f0e1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_7828fcba-a4d6-4d6f-8b88-d43877badbb3" xlink:href="clbs-20211231.xsd#clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_7828fcba-a4d6-4d6f-8b88-d43877badbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_347a77c9-cb38-4058-8bc1-4a205d32df21" xlink:href="clbs-20211231.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_347a77c9-cb38-4058-8bc1-4a205d32df21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_38e712f3-418d-4704-8fcf-76f211872ee0" xlink:href="clbs-20211231.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_38e712f3-418d-4704-8fcf-76f211872ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_8fc53f47-9911-42fc-bb0d-4b6fc9c964a7" xlink:href="clbs-20211231.xsd#clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_8fc53f47-9911-42fc-bb0d-4b6fc9c964a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice_826de393-2dd9-4f98-a2f1-62d12eb873b8" xlink:href="clbs-20211231.xsd#clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice_826de393-2dd9-4f98-a2f1-62d12eb873b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent_c05c4ab9-d5d8-46b4-ad0b-c30b9d891b5e" xlink:href="clbs-20211231.xsd#clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent_c05c4ab9-d5d8-46b4-ad0b-c30b9d891b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_150a58e9-d0ae-426e-a810-4656ea0edb96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_150a58e9-d0ae-426e-a810-4656ea0edb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f1b05989-51a5-40f0-8030-d73daa9ce042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f1b05989-51a5-40f0-8030-d73daa9ce042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_63f0fddd-ef59-457a-b3c8-f3ed155fa90e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_63f0fddd-ef59-457a-b3c8-f3ed155fa90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_21136483-ebac-4b53-a613-4948526eaf19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_21136483-ebac-4b53-a613-4948526eaf19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_572411e6-88ea-4004-b3bb-971809928ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_572411e6-88ea-4004-b3bb-971809928ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2b719106-c0d9-407f-a7e5-b2efff509a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2b719106-c0d9-407f-a7e5-b2efff509a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_4ed5dcdb-9eab-4adc-b9f7-1a68881e2c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_4ed5dcdb-9eab-4adc-b9f7-1a68881e2c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_8d305b7a-7ce6-40f8-bc54-c2b93f7edb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_79bb43a1-3914-4401-9f27-c04f2c38d62f" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_8d305b7a-7ce6-40f8-bc54-c2b93f7edb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#StockholdersEquityStockOptionsandWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0cf9d6c0-a41f-463e-b034-70a601c87ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_14b2c8b1-1aea-49db-a737-476a7c1e4e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0cf9d6c0-a41f-463e-b034-70a601c87ea5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_14b2c8b1-1aea-49db-a737-476a7c1e4e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bf09ca51-4cde-4f48-b8ff-eaa2a1fcc000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_14b2c8b1-1aea-49db-a737-476a7c1e4e32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bf09ca51-4cde-4f48-b8ff-eaa2a1fcc000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e69c4fc7-819b-42e3-8f19-44870fc5d619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_14b2c8b1-1aea-49db-a737-476a7c1e4e32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e69c4fc7-819b-42e3-8f19-44870fc5d619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e791e7a8-c532-4357-8136-597eac29f7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_14b2c8b1-1aea-49db-a737-476a7c1e4e32" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e791e7a8-c532-4357-8136-597eac29f7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ebf9677e-37a2-4906-b989-7a586cbe690c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_14b2c8b1-1aea-49db-a737-476a7c1e4e32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ebf9677e-37a2-4906-b989-7a586cbe690c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_70c42afe-e1fa-407d-9317-7c64022ad441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_14b2c8b1-1aea-49db-a737-476a7c1e4e32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_70c42afe-e1fa-407d-9317-7c64022ad441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d30950ba-5cc8-495b-94b2-f0d2aa0ae17b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_14b2c8b1-1aea-49db-a737-476a7c1e4e32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d30950ba-5cc8-495b-94b2-f0d2aa0ae17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_41e56c5a-86a1-4bc0-aa9b-f390432d4e63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0cf9d6c0-a41f-463e-b034-70a601c87ea5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_41e56c5a-86a1-4bc0-aa9b-f390432d4e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_25868b14-6e9c-4410-a79b-f4b3ce70eddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0cf9d6c0-a41f-463e-b034-70a601c87ea5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_25868b14-6e9c-4410-a79b-f4b3ce70eddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a98507c-9dd1-4a39-8688-c1ed6ff663ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0cf9d6c0-a41f-463e-b034-70a601c87ea5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a98507c-9dd1-4a39-8688-c1ed6ff663ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_855f14b2-a5f3-4f22-b06d-879bb30077aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a98507c-9dd1-4a39-8688-c1ed6ff663ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_855f14b2-a5f3-4f22-b06d-879bb30077aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_007dd59a-9dcd-46c3-8bdc-617646151cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a98507c-9dd1-4a39-8688-c1ed6ff663ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_007dd59a-9dcd-46c3-8bdc-617646151cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_365ceec7-3abf-4e04-adec-2fe2a98f9f18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a98507c-9dd1-4a39-8688-c1ed6ff663ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_365ceec7-3abf-4e04-adec-2fe2a98f9f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b57f5fc2-390e-4c8c-b2a3-25b29c719da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a98507c-9dd1-4a39-8688-c1ed6ff663ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b57f5fc2-390e-4c8c-b2a3-25b29c719da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_539a0260-5348-40fe-b6bd-8d11a394d4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a98507c-9dd1-4a39-8688-c1ed6ff663ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_539a0260-5348-40fe-b6bd-8d11a394d4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_720f7706-33ae-48c9-93f5-0d0cca38a8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5a98507c-9dd1-4a39-8688-c1ed6ff663ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_720f7706-33ae-48c9-93f5-0d0cca38a8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9978e061-e21b-430f-8f2a-26998de89082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0cf9d6c0-a41f-463e-b034-70a601c87ea5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9978e061-e21b-430f-8f2a-26998de89082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_a1efba70-e2b6-4f3a-b50f-d11f1c5222ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0cf9d6c0-a41f-463e-b034-70a601c87ea5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_a1efba70-e2b6-4f3a-b50f-d11f1c5222ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f4c3143-e03b-4ac5-aff3-b287e4d959a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0cf9d6c0-a41f-463e-b034-70a601c87ea5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f4c3143-e03b-4ac5-aff3-b287e4d959a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e693674b-d36f-4e91-8fa7-9fd54af91589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f4c3143-e03b-4ac5-aff3-b287e4d959a2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e693674b-d36f-4e91-8fa7-9fd54af91589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_50ce49e1-733f-44d7-a059-82617ce43e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f4c3143-e03b-4ac5-aff3-b287e4d959a2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_50ce49e1-733f-44d7-a059-82617ce43e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_8db7be45-0836-4d0d-a422-204cb8b44a74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f4c3143-e03b-4ac5-aff3-b287e4d959a2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_8db7be45-0836-4d0d-a422-204cb8b44a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4208c53b-e225-467c-89aa-d74d6f32bc29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f4c3143-e03b-4ac5-aff3-b287e4d959a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4208c53b-e225-467c-89aa-d74d6f32bc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueOptionExercised_2648cc46-99e8-4d9b-b55f-831507ee8b7f" xlink:href="clbs-20211231.xsd#clbs_AggregateIntrinsicValueOptionExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f4c3143-e03b-4ac5-aff3-b287e4d959a2" xlink:to="loc_clbs_AggregateIntrinsicValueOptionExercised_2648cc46-99e8-4d9b-b55f-831507ee8b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bf5249fe-41e9-423a-87fa-4b248b526c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f4c3143-e03b-4ac5-aff3-b287e4d959a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bf5249fe-41e9-423a-87fa-4b248b526c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_25cf3010-2bd6-4334-ac7f-8f0f62079fda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_9f4c3143-e03b-4ac5-aff3-b287e4d959a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_25cf3010-2bd6-4334-ac7f-8f0f62079fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bbc40cb4-d4b5-4846-8d76-d31a2a1f8358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0cf9d6c0-a41f-463e-b034-70a601c87ea5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bbc40cb4-d4b5-4846-8d76-d31a2a1f8358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CommonStockWarrantsShares_71fe2328-844a-43ac-afe3-21c5caf43c16" xlink:href="clbs-20211231.xsd#clbs_CommonStockWarrantsShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bbc40cb4-d4b5-4846-8d76-d31a2a1f8358" xlink:to="loc_clbs_CommonStockWarrantsShares_71fe2328-844a-43ac-afe3-21c5caf43c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsGranted_c8a320a9-68da-4a33-be9c-7a56574c8f06" xlink:href="clbs-20211231.xsd#clbs_WarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bbc40cb4-d4b5-4846-8d76-d31a2a1f8358" xlink:to="loc_clbs_WarrantsGranted_c8a320a9-68da-4a33-be9c-7a56574c8f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExercised_37ec3943-537f-4ab4-a86c-1e7ef349da1a" xlink:href="clbs-20211231.xsd#clbs_WarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bbc40cb4-d4b5-4846-8d76-d31a2a1f8358" xlink:to="loc_clbs_WarrantsExercised_37ec3943-537f-4ab4-a86c-1e7ef349da1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsCanceled_409e9b8a-1f53-4b14-8031-4a3a5335bc01" xlink:href="clbs-20211231.xsd#clbs_WarrantsCanceled"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bbc40cb4-d4b5-4846-8d76-d31a2a1f8358" xlink:to="loc_clbs_WarrantsCanceled_409e9b8a-1f53-4b14-8031-4a3a5335bc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExpired_d18cd4a5-a25f-4bb9-b7d2-c43f1d2ccf10" xlink:href="clbs-20211231.xsd#clbs_WarrantsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bbc40cb4-d4b5-4846-8d76-d31a2a1f8358" xlink:to="loc_clbs_WarrantsExpired_d18cd4a5-a25f-4bb9-b7d2-c43f1d2ccf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CommonStockWarrantsShares_ddaf4147-ba99-44f7-afe7-79cdbca12650" xlink:href="clbs-20211231.xsd#clbs_CommonStockWarrantsShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bbc40cb4-d4b5-4846-8d76-d31a2a1f8358" xlink:to="loc_clbs_CommonStockWarrantsShares_ddaf4147-ba99-44f7-afe7-79cdbca12650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_Sharesvestedandexpectedtovest_eb73cb88-70eb-4fca-9f25-5e67bbad4ec9" xlink:href="clbs-20211231.xsd#clbs_Sharesvestedandexpectedtovest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0cf9d6c0-a41f-463e-b034-70a601c87ea5" xlink:to="loc_clbs_Sharesvestedandexpectedtovest_eb73cb88-70eb-4fca-9f25-5e67bbad4ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsVested_36cd5ee5-e140-4862-9e7d-1fd4bcfd517c" xlink:href="clbs-20211231.xsd#clbs_WarrantsVested"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0cf9d6c0-a41f-463e-b034-70a601c87ea5" xlink:to="loc_clbs_WarrantsVested_36cd5ee5-e140-4862-9e7d-1fd4bcfd517c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_4ffdac76-5656-4eb1-867e-40f4d0d00cea" xlink:href="clbs-20211231.xsd#clbs_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0cf9d6c0-a41f-463e-b034-70a601c87ea5" xlink:to="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_4ffdac76-5656-4eb1-867e-40f4d0d00cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_9f6dee1d-af7c-4fee-9eb3-10f55ba43b61" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_4ffdac76-5656-4eb1-867e-40f4d0d00cea" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_9f6dee1d-af7c-4fee-9eb3-10f55ba43b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsGranted_4ff1fca3-9655-4182-b636-0fa6a40d196e" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageExercisePriceWarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_4ffdac76-5656-4eb1-867e-40f4d0d00cea" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsGranted_4ff1fca3-9655-4182-b636-0fa6a40d196e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercised_6d0ace2d-bf40-4f46-a20a-6fdbf059cc54" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageExercisePriceWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_4ffdac76-5656-4eb1-867e-40f4d0d00cea" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsExercised_6d0ace2d-bf40-4f46-a20a-6fdbf059cc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled_f470d6e3-6c86-451b-861e-59075ed4413b" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageExercisePriceWarrantsCanceled"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_4ffdac76-5656-4eb1-867e-40f4d0d00cea" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled_f470d6e3-6c86-451b-861e-59075ed4413b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExpired_51680e6e-2cc9-4452-885f-e09438c669df" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageExercisePriceWarrantsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_4ffdac76-5656-4eb1-867e-40f4d0d00cea" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsExpired_51680e6e-2cc9-4452-885f-e09438c669df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_b6a8db9d-50dc-4ea4-9a1f-8860fe2c4f87" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_4ffdac76-5656-4eb1-867e-40f4d0d00cea" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_b6a8db9d-50dc-4ea4-9a1f-8860fe2c4f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_d5016f20-7367-4cf3-807e-bfd31982f2b8" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0cf9d6c0-a41f-463e-b034-70a601c87ea5" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_d5016f20-7367-4cf3-807e-bfd31982f2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable_fcba7c9d-a701-4953-8a18-d99fb8dd0470" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageExercisePriceWarrantsExercisable"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0cf9d6c0-a41f-463e-b034-70a601c87ea5" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable_fcba7c9d-a701-4953-8a18-d99fb8dd0470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsOtherDisclosuresAbstract_bbfe2de3-b766-4e0e-8fe5-206c03b5bcc3" xlink:href="clbs-20211231.xsd#clbs_WarrantsOtherDisclosuresAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0cf9d6c0-a41f-463e-b034-70a601c87ea5" xlink:to="loc_clbs_WarrantsOtherDisclosuresAbstract_bbfe2de3-b766-4e0e-8fe5-206c03b5bcc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_fe0ec287-caf1-4d27-99c1-f98634ea7142" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageRemainingContractualTermwarrantoutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_bbfe2de3-b766-4e0e-8fe5-206c03b5bcc3" xlink:to="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_fe0ec287-caf1-4d27-99c1-f98634ea7142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_d2e74e52-9878-4ce0-bae7-1d94ae5be9e3" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_bbfe2de3-b766-4e0e-8fe5-206c03b5bcc3" xlink:to="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_d2e74e52-9878-4ce0-bae7-1d94ae5be9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested_96c068a2-54f9-4d19-a6e5-d9fc8a220391" xlink:href="clbs-20211231.xsd#clbs_WeightedAverageRemainingContractualTermwarrantsvested"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_bbfe2de3-b766-4e0e-8fe5-206c03b5bcc3" xlink:to="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested_96c068a2-54f9-4d19-a6e5-d9fc8a220391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding_387ca401-ffbd-44ce-99b8-fe3959206c1e" xlink:href="clbs-20211231.xsd#clbs_AggregateIntrinsicValueWarrantsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_bbfe2de3-b766-4e0e-8fe5-206c03b5bcc3" xlink:to="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding_387ca401-ffbd-44ce-99b8-fe3959206c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_ff9e9b8e-8217-41a0-936c-c3e0377cb914" xlink:href="clbs-20211231.xsd#clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_bbfe2de3-b766-4e0e-8fe5-206c03b5bcc3" xlink:to="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_ff9e9b8e-8217-41a0-936c-c3e0377cb914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvested_28102260-956d-42db-b9a5-68ded7f2a230" xlink:href="clbs-20211231.xsd#clbs_AggregateIntrinsicValueWarrantsvested"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_bbfe2de3-b766-4e0e-8fe5-206c03b5bcc3" xlink:to="loc_clbs_AggregateIntrinsicValueWarrantsvested_28102260-956d-42db-b9a5-68ded7f2a230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_32946ff8-afc2-4c74-9666-f7e1d325c9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31f42d7e-007e-4b5a-9da1-16e8f4a72087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_32946ff8-afc2-4c74-9666-f7e1d325c9d4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31f42d7e-007e-4b5a-9da1-16e8f4a72087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8dfec4b1-dbdc-4346-b400-ec8878bdd320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31f42d7e-007e-4b5a-9da1-16e8f4a72087" xlink:to="loc_us-gaap_AwardTypeAxis_8dfec4b1-dbdc-4346-b400-ec8878bdd320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2a54db4-e8a0-43c1-bd3f-bf096ad41605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8dfec4b1-dbdc-4346-b400-ec8878bdd320" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2a54db4-e8a0-43c1-bd3f-bf096ad41605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_dd46870f-d8e5-48fb-8a35-ddfe81fdb7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2a54db4-e8a0-43c1-bd3f-bf096ad41605" xlink:to="loc_us-gaap_RestrictedStockMember_dd46870f-d8e5-48fb-8a35-ddfe81fdb7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_30ad8883-b206-4709-8ed2-71f38c2c3b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2a54db4-e8a0-43c1-bd3f-bf096ad41605" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_30ad8883-b206-4709-8ed2-71f38c2c3b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_38378fa9-a72b-40a2-ab9e-d77c20f1a04a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31f42d7e-007e-4b5a-9da1-16e8f4a72087" xlink:to="loc_srt_RangeAxis_38378fa9-a72b-40a2-ab9e-d77c20f1a04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_64977f9d-9879-42a3-966a-4a1b8e82041d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_38378fa9-a72b-40a2-ab9e-d77c20f1a04a" xlink:to="loc_srt_RangeMember_64977f9d-9879-42a3-966a-4a1b8e82041d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_63219f01-1f4c-4c3c-ae67-84de08d73d8f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_64977f9d-9879-42a3-966a-4a1b8e82041d" xlink:to="loc_srt_MinimumMember_63219f01-1f4c-4c3c-ae67-84de08d73d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9497345e-18f9-4ef0-bc60-54273dff9a53" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_64977f9d-9879-42a3-966a-4a1b8e82041d" xlink:to="loc_srt_MaximumMember_9497345e-18f9-4ef0-bc60-54273dff9a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fc3bdf5-8062-4519-b8ce-a7d2b1ba6dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31f42d7e-007e-4b5a-9da1-16e8f4a72087" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fc3bdf5-8062-4519-b8ce-a7d2b1ba6dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract_ee792d89-8393-4348-ba71-64868592d294" xlink:href="clbs-20211231.xsd#clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fc3bdf5-8062-4519-b8ce-a7d2b1ba6dc3" xlink:to="loc_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract_ee792d89-8393-4348-ba71-64868592d294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_def7a308-9758-46dc-9757-25dcac0670f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract_ee792d89-8393-4348-ba71-64868592d294" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_def7a308-9758-46dc-9757-25dcac0670f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_af1017d6-64be-4efa-ba1a-fbdd0df6f5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract_ee792d89-8393-4348-ba71-64868592d294" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_af1017d6-64be-4efa-ba1a-fbdd0df6f5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d5c31100-1286-40de-b9b7-de9eb8867432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract_ee792d89-8393-4348-ba71-64868592d294" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d5c31100-1286-40de-b9b7-de9eb8867432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_61660bfa-6d79-423e-8799-a00cdaa57bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract_ee792d89-8393-4348-ba71-64868592d294" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_61660bfa-6d79-423e-8799-a00cdaa57bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="clbs-20211231.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5ee69e94-9bf2-4748-9b7d-fc155c8af365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fe1f7c2b-8bba-4fc6-a443-62c11ba3d19c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5ee69e94-9bf2-4748-9b7d-fc155c8af365" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fe1f7c2b-8bba-4fc6-a443-62c11ba3d19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="clbs-20211231.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a559e90b-359d-4a87-a55c-e9127b433579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4b24a688-d7de-4379-a96e-313f2b50b588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a559e90b-359d-4a87-a55c-e9127b433579" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4b24a688-d7de-4379-a96e-313f2b50b588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1a09ffce-5238-4370-80f1-978970805e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a559e90b-359d-4a87-a55c-e9127b433579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1a09ffce-5238-4370-80f1-978970805e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_718925df-59ff-4002-a338-fb2118d80dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a559e90b-359d-4a87-a55c-e9127b433579" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_718925df-59ff-4002-a338-fb2118d80dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0427371-7d50-452c-b1d2-862e3d40f8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bbac356a-478a-4ec7-b1db-87c1b24abe2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e0427371-7d50-452c-b1d2-862e3d40f8fd" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bbac356a-478a-4ec7-b1db-87c1b24abe2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_94234faf-9aca-4e72-8712-4361532fa604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bbac356a-478a-4ec7-b1db-87c1b24abe2d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_94234faf-9aca-4e72-8712-4361532fa604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1ad6496d-f97d-4251-bb51-0bc8c93b118a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_94234faf-9aca-4e72-8712-4361532fa604" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1ad6496d-f97d-4251-bb51-0bc8c93b118a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9d976317-8841-4f50-9606-c9434dd4ca17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1ad6496d-f97d-4251-bb51-0bc8c93b118a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9d976317-8841-4f50-9606-c9434dd4ca17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_349b9335-c195-4504-bc59-567371574d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1ad6496d-f97d-4251-bb51-0bc8c93b118a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_349b9335-c195-4504-bc59-567371574d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_488a9e19-6444-4f92-a732-e3bf76f4d723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bbac356a-478a-4ec7-b1db-87c1b24abe2d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_488a9e19-6444-4f92-a732-e3bf76f4d723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_de5f79b3-5aee-4937-8526-43eece5925d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_488a9e19-6444-4f92-a732-e3bf76f4d723" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_de5f79b3-5aee-4937-8526-43eece5925d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#ShareBasedCompensationCompensationCostNotYetRecognizedDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5e96ddfa-0270-44a7-adb9-b8056ec1514e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a799654f-1b16-4898-ba3f-74960fe3d21a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5e96ddfa-0270-44a7-adb9-b8056ec1514e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a799654f-1b16-4898-ba3f-74960fe3d21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1d0b88ad-d5d2-49cf-baf9-3b478d27416d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a799654f-1b16-4898-ba3f-74960fe3d21a" xlink:to="loc_us-gaap_AwardTypeAxis_1d0b88ad-d5d2-49cf-baf9-3b478d27416d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7f9d9aaf-1538-4855-b9b8-e5f160cf6a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1d0b88ad-d5d2-49cf-baf9-3b478d27416d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7f9d9aaf-1538-4855-b9b8-e5f160cf6a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fc7cf9ac-91ce-43a7-9c0b-d70ca1d88c64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7f9d9aaf-1538-4855-b9b8-e5f160cf6a78" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fc7cf9ac-91ce-43a7-9c0b-d70ca1d88c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_05aa3963-ace5-4601-9b5f-0fd145ab67b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7f9d9aaf-1538-4855-b9b8-e5f160cf6a78" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_05aa3963-ace5-4601-9b5f-0fd145ab67b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_efc44995-b449-47da-83f3-53d3a9f2ac37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7f9d9aaf-1538-4855-b9b8-e5f160cf6a78" xlink:to="loc_us-gaap_RestrictedStockMember_efc44995-b449-47da-83f3-53d3a9f2ac37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71bbe65f-033e-4903-abd0-520039968eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a799654f-1b16-4898-ba3f-74960fe3d21a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71bbe65f-033e-4903-abd0-520039968eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9b22037d-ff21-4398-a4e2-52bff4826395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71bbe65f-033e-4903-abd0-520039968eaf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9b22037d-ff21-4398-a4e2-52bff4826395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_362d7b12-b137-4cc2-b69a-bfdda0e34a41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71bbe65f-033e-4903-abd0-520039968eaf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_362d7b12-b137-4cc2-b69a-bfdda0e34a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2f9a4c16-28cb-4792-b0a5-a7d60dc6be68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b30453e7-96ff-46aa-9ee1-3c728af5c28b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2f9a4c16-28cb-4792-b0a5-a7d60dc6be68" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b30453e7-96ff-46aa-9ee1-3c728af5c28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c2217557-903c-4a5e-aa35-5018e37a7878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b30453e7-96ff-46aa-9ee1-3c728af5c28b" xlink:to="loc_us-gaap_AwardTypeAxis_c2217557-903c-4a5e-aa35-5018e37a7878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ba012f6-a493-4bca-96ce-b8de3c34f0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c2217557-903c-4a5e-aa35-5018e37a7878" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ba012f6-a493-4bca-96ce-b8de3c34f0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a9f843d0-c299-4a17-9be3-7e6f265a4bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ba012f6-a493-4bca-96ce-b8de3c34f0cf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a9f843d0-c299-4a17-9be3-7e6f265a4bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cfc1bea-fb0b-4818-9587-e0ce76f888e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b30453e7-96ff-46aa-9ee1-3c728af5c28b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cfc1bea-fb0b-4818-9587-e0ce76f888e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_79dc4ed7-2d46-400a-b8bb-a7f98ab38be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cfc1bea-fb0b-4818-9587-e0ce76f888e2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_79dc4ed7-2d46-400a-b8bb-a7f98ab38be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_890f1875-ecd3-4c29-a639-6543ab030c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cfc1bea-fb0b-4818-9587-e0ce76f888e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_890f1875-ecd3-4c29-a639-6543ab030c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#ShareBasedCompensationValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3d5e51b7-1ea8-4329-810f-ab73dc910a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0176f0fd-7836-40e1-bad8-2194f294af70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3d5e51b7-1ea8-4329-810f-ab73dc910a5b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0176f0fd-7836-40e1-bad8-2194f294af70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_404a235b-9017-4f48-83ed-79bcddfbd1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0176f0fd-7836-40e1-bad8-2194f294af70" xlink:to="loc_us-gaap_AwardTypeAxis_404a235b-9017-4f48-83ed-79bcddfbd1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac9abd70-58a6-4cfb-9281-c875da7ac185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_404a235b-9017-4f48-83ed-79bcddfbd1a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac9abd70-58a6-4cfb-9281-c875da7ac185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_945ca8aa-321f-48c9-8ad3-d9f195b5436b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ac9abd70-58a6-4cfb-9281-c875da7ac185" xlink:to="loc_us-gaap_EmployeeStockOptionMember_945ca8aa-321f-48c9-8ad3-d9f195b5436b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_abb9c82b-79e5-41f7-9d56-71168693f6d6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0176f0fd-7836-40e1-bad8-2194f294af70" xlink:to="loc_srt_RangeAxis_abb9c82b-79e5-41f7-9d56-71168693f6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b4d0f660-155a-4a32-baa9-978d61021d7b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_abb9c82b-79e5-41f7-9d56-71168693f6d6" xlink:to="loc_srt_RangeMember_b4d0f660-155a-4a32-baa9-978d61021d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_312b9888-69ca-4bb9-9793-d72dedae7b8a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b4d0f660-155a-4a32-baa9-978d61021d7b" xlink:to="loc_srt_MinimumMember_312b9888-69ca-4bb9-9793-d72dedae7b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_541ad866-3446-412a-a8b9-a3e08e7657c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b4d0f660-155a-4a32-baa9-978d61021d7b" xlink:to="loc_srt_MaximumMember_541ad866-3446-412a-a8b9-a3e08e7657c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2246c916-8f7a-40d2-9aec-2c2029fd0011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0176f0fd-7836-40e1-bad8-2194f294af70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2246c916-8f7a-40d2-9aec-2c2029fd0011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2b203397-64a3-42fc-b63c-7b866bcce94b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2246c916-8f7a-40d2-9aec-2c2029fd0011" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2b203397-64a3-42fc-b63c-7b866bcce94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e0bd6021-a42b-4834-8d8e-82b8ead5becc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2b203397-64a3-42fc-b63c-7b866bcce94b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e0bd6021-a42b-4834-8d8e-82b8ead5becc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_a95048c2-20bd-4b33-8d99-bdea663a7797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2b203397-64a3-42fc-b63c-7b866bcce94b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_a95048c2-20bd-4b33-8d99-bdea663a7797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_17b0cc26-3fbf-4d74-8d23-3da4aa5f7d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2b203397-64a3-42fc-b63c-7b866bcce94b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_17b0cc26-3fbf-4d74-8d23-3da4aa5f7d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_abbafd89-08f5-4304-98a4-1235f627f4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2b203397-64a3-42fc-b63c-7b866bcce94b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_abbafd89-08f5-4304-98a4-1235f627f4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_decbea84-6056-4526-a7c0-c725526c11b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2b203397-64a3-42fc-b63c-7b866bcce94b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_decbea84-6056-4526-a7c0-c725526c11b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dba4f02c-0d3b-4950-b991-5f73c53b8ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2b203397-64a3-42fc-b63c-7b866bcce94b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dba4f02c-0d3b-4950-b991-5f73c53b8ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fc18106d-3433-4c95-8d11-2a7eef625caf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2b203397-64a3-42fc-b63c-7b866bcce94b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fc18106d-3433-4c95-8d11-2a7eef625caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchFunding" xlink:type="simple" xlink:href="clbs-20211231.xsd#ResearchFunding"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ResearchFunding" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_500f21db-d8c5-4245-bf21-d4b78f1755a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_7df627e4-5580-4b14-b93a-a663467d3bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_500f21db-d8c5-4245-bf21-d4b78f1755a0" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_7df627e4-5580-4b14-b93a-a663467d3bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchFundingDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#ResearchFundingDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ResearchFundingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_7774c98e-d9d0-48d6-9068-607b61817370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_af0777f5-eee8-4597-a017-5166f0b9c007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_7774c98e-d9d0-48d6-9068-607b61817370" xlink:to="loc_us-gaap_GrantsReceivable_af0777f5-eee8-4597-a017-5166f0b9c007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_FundingAmountAwarded_fc44b7de-876f-4d26-910d-c2089022fecb" xlink:href="clbs-20211231.xsd#clbs_FundingAmountAwarded"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_7774c98e-d9d0-48d6-9068-607b61817370" xlink:to="loc_clbs_FundingAmountAwarded_fc44b7de-876f-4d26-910d-c2089022fecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_FundingOfGrantAwardCashReceived_6e08145d-c9ed-4562-bb88-ca5437426135" xlink:href="clbs-20211231.xsd#clbs_FundingOfGrantAwardCashReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_7774c98e-d9d0-48d6-9068-607b61817370" xlink:to="loc_clbs_FundingOfGrantAwardCashReceived_6e08145d-c9ed-4562-bb88-ca5437426135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MilestonePaymentOnGrantAwardCashReceived_e6a861cb-58c1-4c94-9072-14337be17673" xlink:href="clbs-20211231.xsd#clbs_MilestonePaymentOnGrantAwardCashReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_7774c98e-d9d0-48d6-9068-607b61817370" xlink:to="loc_clbs_MilestonePaymentOnGrantAwardCashReceived_e6a861cb-58c1-4c94-9072-14337be17673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProgressPaymentOnGrantAwardCashReceived_fb9b0df2-995d-4604-b091-6e0643f1e7d6" xlink:href="clbs-20211231.xsd#clbs_ProgressPaymentOnGrantAwardCashReceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_7774c98e-d9d0-48d6-9068-607b61817370" xlink:to="loc_clbs_ProgressPaymentOnGrantAwardCashReceived_fb9b0df2-995d-4604-b091-6e0643f1e7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_454c20f3-877e-46b9-9a9c-754c0ba22528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_7774c98e-d9d0-48d6-9068-607b61817370" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred_454c20f3-877e-46b9-9a9c-754c0ba22528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense_227d0120-dd5b-4cdd-b5eb-0f37766087d7" xlink:href="clbs-20211231.xsd#clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_7774c98e-d9d0-48d6-9068-607b61817370" xlink:to="loc_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense_227d0120-dd5b-4cdd-b5eb-0f37766087d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxes" xlink:type="simple" xlink:href="clbs-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_df8b9cdc-b5a1-43a8-84ad-cd6a63f59636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a5ea1318-acfa-461e-a8a3-09a601bdecfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_df8b9cdc-b5a1-43a8-84ad-cd6a63f59636" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a5ea1318-acfa-461e-a8a3-09a601bdecfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="clbs-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f0535752-00f0-4c1a-8451-6678c7a1f77f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_b63f8b93-5ba0-4f7a-91e2-8e9e0fd9fa83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f0535752-00f0-4c1a-8451-6678c7a1f77f" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_b63f8b93-5ba0-4f7a-91e2-8e9e0fd9fa83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_bbc50bd3-beba-4b91-8066-4e9877c9946b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f0535752-00f0-4c1a-8451-6678c7a1f77f" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_bbc50bd3-beba-4b91-8066-4e9877c9946b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4a05f357-17bc-4e3c-a4b3-a4631b3916b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f0535752-00f0-4c1a-8451-6678c7a1f77f" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4a05f357-17bc-4e3c-a4b3-a4631b3916b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_5ddee1ac-b30d-4d46-ab0b-cc130f792ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f0535752-00f0-4c1a-8451-6678c7a1f77f" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_5ddee1ac-b30d-4d46-ab0b-cc130f792ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesLossfromOperationsBeforeProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#IncomeTaxesLossfromOperationsBeforeProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxesLossfromOperationsBeforeProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_25dd1a71-2251-4339-892f-a9bdcd7b0455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e79917d5-570f-44f4-91c2-0cbe7ccb7909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_25dd1a71-2251-4339-892f-a9bdcd7b0455" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e79917d5-570f-44f4-91c2-0cbe7ccb7909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2a0e71d9-d29a-40cb-b2c5-13248cf1cacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_25dd1a71-2251-4339-892f-a9bdcd7b0455" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2a0e71d9-d29a-40cb-b2c5-13248cf1cacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d20cb7b4-f9ab-468e-a54d-ed5ed7dce53a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_35472c8f-d0c4-4c6c-acb1-ad917a1b6335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d20cb7b4-f9ab-468e-a54d-ed5ed7dce53a" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_35472c8f-d0c4-4c6c-acb1-ad917a1b6335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_5af6ded4-f007-4c6d-a3a9-f0af62906a93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_35472c8f-d0c4-4c6c-acb1-ad917a1b6335" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_5af6ded4-f007-4c6d-a3a9-f0af62906a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_91344c27-7f33-4b45-bcbf-c0c5e6a4828d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_35472c8f-d0c4-4c6c-acb1-ad917a1b6335" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_91344c27-7f33-4b45-bcbf-c0c5e6a4828d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_339f6d7f-8d40-4baf-9d51-3fc73b17b838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_35472c8f-d0c4-4c6c-acb1-ad917a1b6335" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_339f6d7f-8d40-4baf-9d51-3fc73b17b838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_eaeb7e36-e7d7-47a5-9b01-d51c76f201a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d20cb7b4-f9ab-468e-a54d-ed5ed7dce53a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_eaeb7e36-e7d7-47a5-9b01-d51c76f201a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_46b1f701-7efc-49f5-9b95-969bbfdada4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_eaeb7e36-e7d7-47a5-9b01-d51c76f201a4" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_46b1f701-7efc-49f5-9b95-969bbfdada4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_cd9cb0c5-7556-4907-b8ad-5dda318f4874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_eaeb7e36-e7d7-47a5-9b01-d51c76f201a4" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_cd9cb0c5-7556-4907-b8ad-5dda318f4874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b85460a5-2b8a-4f79-bf66-2b75a59e6fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_eaeb7e36-e7d7-47a5-9b01-d51c76f201a4" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b85460a5-2b8a-4f79-bf66-2b75a59e6fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_b43537ef-37bc-41ac-955d-d128255163d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d20cb7b4-f9ab-468e-a54d-ed5ed7dce53a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_b43537ef-37bc-41ac-955d-d128255163d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_1f4af9e6-6ea4-410e-abb1-c4cc793672a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_b43537ef-37bc-41ac-955d-d128255163d8" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_1f4af9e6-6ea4-410e-abb1-c4cc793672a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_bd705b89-b5f2-49ab-a5d8-2e97d6b1b7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_b43537ef-37bc-41ac-955d-d128255163d8" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_bd705b89-b5f2-49ab-a5d8-2e97d6b1b7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_84029d82-befe-496e-981a-106dff7bcd93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_b43537ef-37bc-41ac-955d-d128255163d8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_84029d82-befe-496e-981a-106dff7bcd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#IncomeTaxesEffectiveIncomeTaxReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b3c65247-7a38-4cb1-aa82-5bb8f065749d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2bb2b384-9e85-4408-9651-edd594cb36f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b3c65247-7a38-4cb1-aa82-5bb8f065749d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2bb2b384-9e85-4408-9651-edd594cb36f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_cb3718ee-5dc2-4f90-bb88-8588c29ff673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2bb2b384-9e85-4408-9651-edd594cb36f3" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_cb3718ee-5dc2-4f90-bb88-8588c29ff673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_a104dba7-678d-4f39-8740-4a66950b40e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2bb2b384-9e85-4408-9651-edd594cb36f3" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_a104dba7-678d-4f39-8740-4a66950b40e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount_3c0f4114-1ee0-42b3-ade0-c8c423c8cf83" xlink:href="clbs-20211231.xsd#clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2bb2b384-9e85-4408-9651-edd594cb36f3" xlink:to="loc_clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount_3c0f4114-1ee0-42b3-ade0-c8c423c8cf83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_5e7535ce-30e3-4577-a02d-b27b7191e6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2bb2b384-9e85-4408-9651-edd594cb36f3" xlink:to="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_5e7535ce-30e3-4577-a02d-b27b7191e6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_ac0be3a3-b85f-4631-93fc-a992d413f7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2bb2b384-9e85-4408-9651-edd594cb36f3" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_ac0be3a3-b85f-4631-93fc-a992d413f7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount_c96e986f-a83a-4a3c-a9a1-1246d8e57e9a" xlink:href="clbs-20211231.xsd#clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2bb2b384-9e85-4408-9651-edd594cb36f3" xlink:to="loc_clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount_c96e986f-a83a-4a3c-a9a1-1246d8e57e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses_b514a6a9-cc9d-4d13-9175-a1ede0e15f87" xlink:href="clbs-20211231.xsd#clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2bb2b384-9e85-4408-9651-edd594cb36f3" xlink:to="loc_clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses_b514a6a9-cc9d-4d13-9175-a1ede0e15f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_22b5d191-6b7b-490a-b5bd-46eb8bb50b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2bb2b384-9e85-4408-9651-edd594cb36f3" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_22b5d191-6b7b-490a-b5bd-46eb8bb50b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dcf692b3-6e8d-4465-b375-a71386365abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2bb2b384-9e85-4408-9651-edd594cb36f3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dcf692b3-6e8d-4465-b375-a71386365abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#IncomeTaxesComponentsofDeferredIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9b04d392-a9fc-4e40-8d87-f6a100f72839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_09e9568c-2e4c-4ee2-9a7f-420ca509d7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9b04d392-a9fc-4e40-8d87-f6a100f72839" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_09e9568c-2e4c-4ee2-9a7f-420ca509d7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6540c8e6-cfac-4e2c-b226-a783fa30a204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_09e9568c-2e4c-4ee2-9a7f-420ca509d7bc" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6540c8e6-cfac-4e2c-b226-a783fa30a204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0cb22fff-4c70-4794-930b-49ed9775006c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6540c8e6-cfac-4e2c-b226-a783fa30a204" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0cb22fff-4c70-4794-930b-49ed9775006c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_DeferredTaxAssetsRightOfUseLiability_b96a324f-fbe4-4d29-87c1-1fd4dff04add" xlink:href="clbs-20211231.xsd#clbs_DeferredTaxAssetsRightOfUseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6540c8e6-cfac-4e2c-b226-a783fa30a204" xlink:to="loc_clbs_DeferredTaxAssetsRightOfUseLiability_b96a324f-fbe4-4d29-87c1-1fd4dff04add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_cfba105d-d26e-4ff0-b681-418dd82fcd35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6540c8e6-cfac-4e2c-b226-a783fa30a204" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_cfba105d-d26e-4ff0-b681-418dd82fcd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_a97465b3-709e-4ec9-bb9a-4e2bf7e47ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6540c8e6-cfac-4e2c-b226-a783fa30a204" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_a97465b3-709e-4ec9-bb9a-4e2bf7e47ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_DeferredTaxAssetsAccumulatedDepreciation_e8384a04-3f7d-46a9-89e8-353eb0e990d5" xlink:href="clbs-20211231.xsd#clbs_DeferredTaxAssetsAccumulatedDepreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6540c8e6-cfac-4e2c-b226-a783fa30a204" xlink:to="loc_clbs_DeferredTaxAssetsAccumulatedDepreciation_e8384a04-3f7d-46a9-89e8-353eb0e990d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_b30ce3fd-3df3-4234-ad02-d0ba71148c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6540c8e6-cfac-4e2c-b226-a783fa30a204" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_b30ce3fd-3df3-4234-ad02-d0ba71148c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_b7901d23-1141-4a44-a1cc-c4c7a25af070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6540c8e6-cfac-4e2c-b226-a783fa30a204" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_b7901d23-1141-4a44-a1cc-c4c7a25af070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_11f5f1cf-ef8c-4703-8f5f-7f1ad8b258fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6540c8e6-cfac-4e2c-b226-a783fa30a204" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_11f5f1cf-ef8c-4703-8f5f-7f1ad8b258fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_35611be7-1b08-4326-933b-663003ab4095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_09e9568c-2e4c-4ee2-9a7f-420ca509d7bc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_35611be7-1b08-4326-933b-663003ab4095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_a5fd4e51-a277-4f5e-b793-c8601f063bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_35611be7-1b08-4326-933b-663003ab4095" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_a5fd4e51-a277-4f5e-b793-c8601f063bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_70a34c68-78f1-455b-a37d-7ed393b25c03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_35611be7-1b08-4326-933b-663003ab4095" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_70a34c68-78f1-455b-a37d-7ed393b25c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_NetDeferredTaxAssetsAndLiabilitiesGross_32ee2917-9241-484e-b55f-445d4c065fef" xlink:href="clbs-20211231.xsd#clbs_NetDeferredTaxAssetsAndLiabilitiesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_09e9568c-2e4c-4ee2-9a7f-420ca509d7bc" xlink:to="loc_clbs_NetDeferredTaxAssetsAndLiabilitiesGross_32ee2917-9241-484e-b55f-445d4c065fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_034a1ac2-5259-4d21-99c6-4c3e318ef508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_09e9568c-2e4c-4ee2-9a7f-420ca509d7bc" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_034a1ac2-5259-4d21-99c6-4c3e318ef508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d31beeeb-bd75-43cf-9fdb-28ceb44a675e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_09e9568c-2e4c-4ee2-9a7f-420ca509d7bc" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d31beeeb-bd75-43cf-9fdb-28ceb44a675e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="clbs-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_29a3bc90-a7e1-463a-8fee-58a08419e2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_a3fd3435-87ab-4516-810c-6ed016db4845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_29a3bc90-a7e1-463a-8fee-58a08419e2ce" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_a3fd3435-87ab-4516-810c-6ed016db4845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d7955022-179b-4f51-8c4b-1849f7f1b41e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_a3fd3435-87ab-4516-810c-6ed016db4845" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d7955022-179b-4f51-8c4b-1849f7f1b41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7ebf5c78-d303-48d6-8483-66a8beabe0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d7955022-179b-4f51-8c4b-1849f7f1b41e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7ebf5c78-d303-48d6-8483-66a8beabe0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_e45a25a3-a20b-4e38-a797-f324fb121569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7ebf5c78-d303-48d6-8483-66a8beabe0d2" xlink:to="loc_us-gaap_DomesticCountryMember_e45a25a3-a20b-4e38-a797-f324fb121569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_261cf2b0-5ed5-4023-94da-b598c24706b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7ebf5c78-d303-48d6-8483-66a8beabe0d2" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_261cf2b0-5ed5-4023-94da-b598c24706b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_77619531-defa-4dc5-85a4-d5e5c78440fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_a3fd3435-87ab-4516-810c-6ed016db4845" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_77619531-defa-4dc5-85a4-d5e5c78440fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_0cccc6d6-16ee-4b0a-bbe8-0af2f32d61a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_77619531-defa-4dc5-85a4-d5e5c78440fd" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_0cccc6d6-16ee-4b0a-bbe8-0af2f32d61a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_50bc98a2-f0a6-4795-a747-7049449707fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_0cccc6d6-16ee-4b0a-bbe8-0af2f32d61a8" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_50bc98a2-f0a6-4795-a747-7049449707fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_22a34394-93cc-49b4-a104-bad8175c63cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_0cccc6d6-16ee-4b0a-bbe8-0af2f32d61a8" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_22a34394-93cc-49b4-a104-bad8175c63cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_d54e9438-e06b-4817-8c4f-13586f7585a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_0cccc6d6-16ee-4b0a-bbe8-0af2f32d61a8" xlink:to="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_d54e9438-e06b-4817-8c4f-13586f7585a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_8d97d55d-3dd1-4a24-b576-0947d70cfcb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_a3fd3435-87ab-4516-810c-6ed016db4845" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_8d97d55d-3dd1-4a24-b576-0947d70cfcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3286fbe8-31f1-4967-bd94-4754e8057367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8d97d55d-3dd1-4a24-b576-0947d70cfcb3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3286fbe8-31f1-4967-bd94-4754e8057367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown_c17be8d2-7b29-456b-8b16-c4facc20a02d" xlink:href="clbs-20211231.xsd#clbs_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8d97d55d-3dd1-4a24-b576-0947d70cfcb3" xlink:to="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown_c17be8d2-7b29-456b-8b16-c4facc20a02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_eed24f5c-454d-41bd-b33a-359e4b4dfd30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8d97d55d-3dd1-4a24-b576-0947d70cfcb3" xlink:to="loc_us-gaap_OperatingLossCarryforwards_eed24f5c-454d-41bd-b33a-359e4b4dfd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_186eb707-1e4c-452e-ae3f-5136a54f10fe" xlink:href="clbs-20211231.xsd#clbs_OperatingLossCarryforwardsSetToExpireWrittenDown"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8d97d55d-3dd1-4a24-b576-0947d70cfcb3" xlink:to="loc_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_186eb707-1e4c-452e-ae3f-5136a54f10fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_168a4478-844e-4993-a565-6613322c32c7" xlink:href="clbs-20211231.xsd#clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8d97d55d-3dd1-4a24-b576-0947d70cfcb3" xlink:to="loc_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_168a4478-844e-4993-a565-6613322c32c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_2ae5e589-a63e-41bc-aeb4-bc4b657ea5de" xlink:href="clbs-20211231.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8d97d55d-3dd1-4a24-b576-0947d70cfcb3" xlink:to="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_2ae5e589-a63e-41bc-aeb4-bc4b657ea5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_ec1c928f-d66f-45d2-9c3b-d4ee8621c393" xlink:href="clbs-20211231.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8d97d55d-3dd1-4a24-b576-0947d70cfcb3" xlink:to="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_ec1c928f-d66f-45d2-9c3b-d4ee8621c393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LossOnSaleOfNetOperatingLosses_bb4992b8-e7f5-4401-936b-369787eaf1c4" xlink:href="clbs-20211231.xsd#clbs_LossOnSaleOfNetOperatingLosses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_8d97d55d-3dd1-4a24-b576-0947d70cfcb3" xlink:to="loc_clbs_LossOnSaleOfNetOperatingLosses_bb4992b8-e7f5-4401-936b-369787eaf1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/Contingencies" xlink:type="simple" xlink:href="clbs-20211231.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7c016c19-fe48-4456-902b-630759414b71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5770df64-7d5e-4a1f-920b-e35b8c9affcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7c016c19-fe48-4456-902b-630759414b71" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5770df64-7d5e-4a1f-920b-e35b8c9affcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104231025656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 22, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CALADRIUS BIOSCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000320017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-2343568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">110 Allen Road, 2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Basking Ridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">842-0100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CLBS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,533,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant's Proxy Statement for the 2022 Annual Meeting of Stockholders. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant's fiscal year ended December 31, 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104232540792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">GRANT THORNTON LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">New York, New York<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104231088120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 24,647<span></span>
</td>
<td class="nump">$ 16,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">70,323<span></span>
</td>
<td class="nump">18,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">1,212<span></span>
</td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">96,182<span></span>
</td>
<td class="nump">35,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">764<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">97,008<span></span>
</td>
<td class="nump">36,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,934<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">2,589<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,523<span></span>
</td>
<td class="nump">3,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">485<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">5,008<span></span>
</td>
<td class="nump">3,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at December 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, authorized 500,000,000 shares; issued 59,800,792 and 19,389,413 shares, at December 31, 2021 and December 31, 2020, respectively; and outstanding, 59,789,712 and 19,378,333 shares, at December 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">545,988<span></span>
</td>
<td class="nump">458,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 11,080 shares at December 31, 2021 and December 31, 2020 respectively</a></td>
<td class="num">(708)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(453,016)<span></span>
</td>
<td class="num">(425,550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Caladrius Biosciences, Inc. stockholders' equity</a></td>
<td class="nump">92,254<span></span>
</td>
<td class="nump">32,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests</a></td>
<td class="num">(254)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">92,000<span></span>
</td>
<td class="nump">32,242<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, non-controlling interests and equity</a></td>
<td class="nump">$ 97,008<span></span>
</td>
<td class="nump">$ 36,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104232342200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_PreferredStockLiquidationPreferenceShare', window );">Preferred stock, liquidation preference (shares)</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_PreferredStockSharesDesignated', window );">Preferred stock, shares designated (shares)</a></td>
<td class="nump">825,000<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (shares)</a></td>
<td class="nump">59,800,792<span></span>
</td>
<td class="nump">19,389,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (shares)</a></td>
<td class="nump">59,789,712<span></span>
</td>
<td class="nump">19,378,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockNumberOfSharesAndRestrictionDisclosuresAbstract', window );"><strong>Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock (shares)</a></td>
<td class="nump">11,080<span></span>
</td>
<td class="nump">11,080<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_PreferredStockLiquidationPreferenceShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Liquidation Preference, Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_PreferredStockLiquidationPreferenceShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_PreferredStockSharesDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Shares Designated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_PreferredStockSharesDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockNumberOfSharesAndRestrictionDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockNumberOfSharesAndRestrictionDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104232403992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 17,680<span></span>
</td>
<td class="nump">$ 9,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">11,370<span></span>
</td>
<td class="nump">9,892<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">29,050<span></span>
</td>
<td class="nump">19,145<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(29,050)<span></span>
</td>
<td class="num">(19,145)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income, net</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(75)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before benefit from income taxes and noncontrolling interests</a></td>
<td class="num">(28,974)<span></span>
</td>
<td class="num">(19,013)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="num">(1,508)<span></span>
</td>
<td class="num">(10,872)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(27,466)<span></span>
</td>
<td class="num">(8,141)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less - net income attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Caladrius Biosciences, Inc. common shareholders</a></td>
<td class="num">$ (27,466)<span></span>
</td>
<td class="num">$ (8,150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Basic and diluted loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Caladrius Biosciences, Inc. common shareholders - basic (in dollars per share)</a></td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Caladrius Biosciences, Inc. common shareholders - diluted (in dollars per share)</a></td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic shares</a></td>
<td class="nump">55,313<span></span>
</td>
<td class="nump">15,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares</a></td>
<td class="nump">55,313<span></span>
</td>
<td class="nump">15,440<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104230857944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (27,466)<span></span>
</td>
<td class="num">$ (8,141)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Available for sale securities - net unrealized loss</a></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss</a></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(27,523)<span></span>
</td>
<td class="num">(8,156)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders</a></td>
<td class="num">$ (27,523)<span></span>
</td>
<td class="num">$ (8,165)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104230557448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total Caladrius Biosciences, Inc. Stockholders' Equity</div></th>
<th class="th"><div>Series B Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Non- Controlling Interest in Subsidiary</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,529,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 20,553<span></span>
</td>
<td class="nump">$ 20,816<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 438,911<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">$ (417,400)<span></span>
</td>
<td class="num">$ (708)<span></span>
</td>
<td class="num">$ (263)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(8,141)<span></span>
</td>
<td class="num">(8,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,807,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuance of common stock and warrants</a></td>
<td class="nump">18,728<span></span>
</td>
<td class="nump">18,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">18,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">19,389,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">32,242<span></span>
</td>
<td class="nump">32,496<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">458,748<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(425,550)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(27,466)<span></span>
</td>
<td class="num">(27,466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">517,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,757<span></span>
</td>
<td class="nump">1,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,888,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuance of common stock and warrants</a></td>
<td class="nump">$ 85,500<span></span>
</td>
<td class="nump">85,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">85,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from option exercises (in shares)</a></td>
<td class="nump">7,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from option exercises</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">59,801,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 92,000<span></span>
</td>
<td class="nump">$ 92,254<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 545,988<span></span>
</td>
<td class="num">$ (70)<span></span>
</td>
<td class="num">$ (453,016)<span></span>
</td>
<td class="num">$ (708)<span></span>
</td>
<td class="num">$ (254)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104230960584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (27,466)<span></span>
</td>
<td class="num">$ (8,141)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Equity-based compensation expense</a></td>
<td class="nump">2,005<span></span>
</td>
<td class="nump">1,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization/accretion on marketable securities</a></td>
<td class="nump">2,514<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="num">(453)<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(150)<span></span>
</td>
<td class="nump">466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities', window );">Accounts payable, accrued liabilities and other liabilities</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="num">(2,839)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(22,245)<span></span>
</td>
<td class="num">(8,823)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(179,775)<span></span>
</td>
<td class="num">(34,799)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales of marketable securities</a></td>
<td class="nump">124,939<span></span>
</td>
<td class="nump">27,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(54,896)<span></span>
</td>
<td class="num">(7,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding payments on net share settlement equity awards</a></td>
<td class="num">(248)<span></span>
</td>
<td class="num">(148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of capital stock</a></td>
<td class="nump">85,500<span></span>
</td>
<td class="nump">18,728<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">85,276<span></span>
</td>
<td class="nump">18,580<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">8,135<span></span>
</td>
<td class="nump">2,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">16,512<span></span>
</td>
<td class="nump">14,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">24,647<span></span>
</td>
<td class="nump">16,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104232492184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_BusinessTextBlock', window );">The Business</a></td>
<td class="text">The Business<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">OVERVIEW</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caladrius Biosciences, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Caladrius&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The Company is developing what are intended to be first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Its technology is intended to leverage these cells to enable the body's natural repair mechanisms using formulations unique to each medical indication.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's leadership team has decades of collective biopharmaceutical development experience. Its goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. The Company's current product candidates include: </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CLBS16), the subject of both a completed positive Phase 2a study (ESCaPE-CMD) and an ongoing follow-on Phase 2b study (FREEDOM Trial) in the United States for the treatment of coronary microvascular dysfunction (&#8220;CMD&#8221;); </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (CLBS12), recipient of SAKIGAKE designation pursuant to which early conditional approval in Japan for the treatment of critical limb ischemia (&#8220;CLI&#8221;) and Buerger&#8217;s disease is being sought based on the current results of a clinical trial executed in Japan. HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was the recipient of orphan drug designation in March 2021 from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for Buerger's disease; and </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with chronic kidney disease related to type 2 diabetes (diabetic kidney disease or &#8220;DKD&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ischemic Repair (CD34 Cell Technology)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CD34+ cell was discovered as a result of the deliberate search for a cell capable of stimulating the development and/or repair of blood vessels. All tissues in the body maintain their function by replacing cells over time. In addition to the maintenance function, the body must also be capable of building new blood vessels after injury. A CD34+ cell is an endothelial progenitor cell that has the ability to stimulate new blood vessel formation at the level of the microvasculature. No other native cell discovered to date has demonstrated this same capability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's proprietary cell technology using autologous (a patient&#8217;s own naturally occurring) CD34+ cells has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted or reduced. Through the administration of CD34+ cells, Caladrius seeks to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted area. The Company believes that a number of conditions caused by underlying ischemic injury can be improved through its CD34+ cell technology including, but not limited to, Buerger's disease, CLI, CMD, and DKD.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of Coronary Microvascular Dysfunction</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, with the assistance of a $1.9&#160;million grant from the National Institutes of Health (Award Number R44HL135889), the Company initiated its program for XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of CMD, a disease that afflicts as many as 1.6 million patients in the United States alone, with no current targeted treatment options. That study, the ESCaPE-CMD Trial, was a Phase 2a proof-of-concept open label study that enrolled patients at the Mayo Clinic in Rochester, MN and Cedars-Sinai Medical Center in Los Angeles, CA. Those data showed a positive therapeutic effect with a statistically significant improvement in angina frequency, coronary flow reserve, Canadian Cardiovascular Society Angina Class and Seattle Angina Questionnaire scores, as well as an acceptable safety profile. The full data set from that study was presented at the SCAI 2020 Scientific Sessions Virtual Conference on May 14, 2020 by Dr. Timothy Henry, FACC, of the Christ Hospital in Cincinnati, Ohio. In December 2020, the Company commenced enrollment in its Phase 2b FREEDOM Trial of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a double-blind, randomized and placebo-controlled clinical trial designed to further evaluate the efficacy and safety of intracoronary artery delivery of autologous CD34+ cells in subjects with CMD and without obstructive coronary artery disease. While early enrollment proceeded to plan with the first patient treated in January 2021, the impact of the COVID-19 pandemic contributed to a general slowing of enrollment. Protocol amendments to the initial FREEDOM Trial protocol, as agreed to by the FDA, were implemented with the goal of enhancing breadth and speed of subject enrollment.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of Critical Limb Ischemia</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's randomized, open-label, registration-eligible study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan for the treatment of CLI and Buerger's disease has, to date, demonstrated positive trends in both safety and efficacy. The HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> study's enrollment, however, has been significantly curtailed by the COVID-19 pandemic's impact in Japan, including the States of Emergency in Japan that have persisted for much of the past 18 months. Due to the significant and continued operational and financial burden incurred as a result of these COVID-19 delays, coupled with the unpredictability of the timing of site enrollment re-initiation, Caladrius</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suspended further enrollment and is focusing its efforts on consummating a partnership for the product in Japan. Such a partnership may become the basis for the completion of development and registration of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan and may include the completion of enrollment of the four remaining no-option CLI subjects stipulated in the original protocol, if necessary, and/or exploration of the possibility of submitting the existing data to Japan's Pharmaceuticals and Medical Devices Agency (&#8220;PMDA&#8221;) under Japan's regenerative medicine regulations, which allow for conditional approval of innovative regenerative medicine products. Despite receipt from FDA in March 2021 of orphan designation in the U.S. for CLBS12 as a potential treatment for Buerger's disease, based on a response from the FDA in October 2021 regarding a development plan for U.S. registration the Company decided not to pursue United States development in Buerger's disease at this time.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CLBS201 for Treatment of Diabetic Kidney Disease</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progressive kidney failure is associated with attrition of the microcirculation of the kidney. Pre-clinical studies in kidney disease and injury models have demonstrated that protection or replenishment of the microcirculation results in improved kidney function. Based on these observations, the Company has elected to move forward with a Phase 1, open-label, proof-of-concept trial evaluating CLBS201 dosed via intra-renal artery injections in subjects with DKD. This protocol, as approved by an Institutional Review Board (the &#8220;IRB&#8221;), is expected to include six subjects in total with the first two subjects sequentially dosed and followed for a two-week safety observation period. Clearance by the independent Data Safety Monitoring Board (&#8220;DSMB&#8221;) overseeing the study will then permit the treatment of the next four patients, with all patients being followed for safety and therapeutic effect. A read-out of data will occur after at the six-month follow-up visit for all patients. A key criterion for continued development of CLBS201 will be its ability to demonstrate a therapeutic effect that will make it competitive in the field of DKD treatment, i.e., kidney function regeneration, as indicated by increased glomerular filtration rate.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Out-licensing Opportunities and Pipeline Diversification</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. The Company's current long-term strategy focuses on advancing its therapies through development with the ultimate objective of obtaining market authorizations and entering commercialization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. The Company believes that it is well-positioned to realize potentially meaningful value increases within its own proprietary pipeline if it is successful in advancing its product candidates to their next significant development milestones.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company further desires to diversify its pipeline of development products candidates and is exploring a range of strategic transactions in furtherance of that goal. The Company has taken, and intends to continue to take, active steps to identify assets and/or companies for acquisition and/or partnership that would complement its current development programs and de-risk its overall development portfolio. Such assets potentially could target indications beyond cardiovascular disease as well as product categories outside of cell therapy. The range of possible transactions includes an acquisition, merger, business combination, in-license or other strategic transaction, any of which could result in the issuance of securities that could significantly dilute the shares of its existing stockholders. There can be no assurance that this exploration of strategic alternatives will result in Caladrius entering into or completing any transaction or that such transaction, if completed, will add to shareholder value.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus Considerations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of coronavirus (SARS-CoV-2), which causes COVID-19, was reported to have surfaced in China. In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic, and the world's economies began to experience pronounced effects. Despite the FDA approval of multiple COVID-19 vaccines in late 2020, there remains uncertainty around the extent and duration of disruption and any future related financial impact cannot reasonably be estimated at this time. In response to the COVID-19 pandemic, the Company implemented a universal work from home policy as well as stringent social distancing and other hygiene policies for employees when they must be in the office. The Company's clinical study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan has experienced significant delays in enrollment due to the States of Emergency in effect in Japan for most of 2020 and re-implemented from January 7, 2021 through March 21, 2021 covering Tokyo and other regions in response to an increased number of COVID-19 infections. Due to reported increases in COVID-19 cases and a low rate of vaccination in Japan, States of Emergency were renewed on April 25, 2021 through May 11, 2021 and then re-implemented in Tokyo from July 12, 2021 through September 30, 2021. With the Company's expectation that </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 in Japan would continue to impact negatively enrollment of patients in the HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trial, it elected to suspend trial enrollment, seek a development partner and consult with the Japanese regulatory authorities regarding the submission of patient data already accrued. Caladrius' phase 2b trial of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. has also experienced delays in enrolling patients as a result of COVID-19.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes  critical estimate and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_BusinessTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Business [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_BusinessTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104236423960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States.  Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (&#8220;R&amp;D&#8221;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive the Company&#8217;s cell therapy initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#8217;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.</span></div>New Accounting PronouncementsIn October 2019, the FASB issued ASU 2019-12, which affects general principles within Topic 740, Income Taxes. The amendments of&#160;ASU 2019-12&#160;are meant to simplify and reduce the cost of accounting for income taxes. For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company believes that the adoption of this new accounting guidance has not had a material impact on its financial statements and footnote disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104232212424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale-Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Available-for-Sale-Securities</a></td>
<td class="text">Available-for-Sale-Securities<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or debt marketable securities in the Company's Consolidated Balance Sheets (in thousands):</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:19.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,522&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,452&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,750&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,737&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on the Company's Consolidated Balance Sheets (in thousands):</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:67.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,737&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.324%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,522&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,737&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104236426888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:73.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.200%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The Company&#8217;s results included depreciation expense of approximately $0.1 million and $0.1 million for the years ended December&#160;31, 2021 and 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104232525976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share</a></td>
<td class="text">Loss Per Share<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021 and 2020, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss per share a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s they are anti-dilutive in the periods presented. At December&#160;31, 2021 and 2020, the Company excluded the following potentially dilutive securities (in thousands):</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:69.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104232205528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of December&#160;31, 2021 and December&#160;31, 2020 were as follows (in thousands):</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:21.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,061&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,061&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash, cash equivalents, accounts payable and accrued expenses approximate fair value at December&#160;31, 2021 and December&#160;31, 2020, due to the short maturity nature of these items.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104236467192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">Accrued Liabilities <div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities were as follow (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.360%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,486&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104236369944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text">Operating Leases<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and recognized leases with duration greater than 12 months on the balance sheet using the modified retrospective approach. The Company has operating leases for two </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ffices with terms that expire in 2023 and 2025, respectively. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. Each of the Company's leases includes options for the Company to extend the lease term and/or sub-lease space in whole or in part.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzItMC0xLTEtNzIwMg_0a058abe-d734-4c31-a82c-efb4e8bc4aad"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzItMC0xLTEtNzIwMg_d0558917-552f-48e0-95eb-612098e4b721">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzYtMC0xLTEtNzIwMg_3827fe5c-6ee8-4d37-a233-c3c99088f192"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzYtMC0xLTEtNzIwMg_bfd3c824-688d-44a3-a795-98776d67c466">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzctMC0xLTEtNzIwMg_430fdfa5-3899-44a5-b33b-301b103d665c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzctMC0xLTEtNzIwMg_95df09b8-b8ab-49d7-988b-87cfc081e730">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the weighted average remaining lease term for our operating leases was 2.50 years, and the weighted average discount rate for our operating leases was 9.625%. Future minimum lease payments under the lease agreements as of December&#160;31, 2021 were as follows (in thousands):</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.181%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104236369944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Plans</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has used long-term incentive plans for the purpose of granting equity awards to employees of the Company, including officers, and nonemployees, including consultants and nonemployee members of the Company's board of directors </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(collectively, the &#8220;Participants&#8221;). The Participants may receive awards as determined by a committee of independent members of the Company's board of directors or, to the extent authorized by such committee with respect to certain Participants, a duly authorized employee (collectively, the &#8220;Committee&#8221;). The incentive plan currently used by the Company is the 2018 Equity Incentive Compensation Plan (the &#8220;2018 Plan&#8221;), as adopted by the stockholders of the Company in June 2018, and subsequently increased by the stockholders of the Company in June 2021 with 6,000,000 shares authorized for issuance thereunder and in June of 2020 with&#160;2,500,000&#160;shares authorized for issuance thereunder, plus any shares awarded under the 2015 Equity Compensation Plan (the &#8220;2015 Plan&#8221;) or the Amended and Restated 2009 Equity Compensation Plan (the &#8220;2009 Plan&#8221;) that are not issued due to their subsequent forfeiture, cancellation, or other settlement thereof. Concurrent with the adoption of the 2018 Plan, no future awards will occur under the 2015 Plan or the 2009 Plan. The awards that may be made under the 2018 Plan include: (a) incentive stock options and nonqualified stock options, (b) shares of restricted stock, (c) restricted stock units, and (d) other kinds of equity-based compensation awards. All stock options under the 2015 Plan and 2009 Plan were granted and the 2018 Plan are granted at the fair market value of the common stock at the grant date. Stock options vest either on the date of grant, ratably over a period determined at time of grant, or upon the accomplishment of specified business milestones, and generally expire 2, 3, or 10 years from the grant date depending on the status of the recipient as a nonemployee, employee or director of the Company. As of December&#160;31, 2021, there were&#160;5,585,661&#160;shares available for future grants under the 2018 Plan.&#160;No&#160;additional awards may be made under the 2015 Plan or the 2009 Plan.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted an employee stock purchase plan effective January 1, 2013 and authorized 50,000 shares under the plan (the &#8220;2012 ESPP&#8221;). The plan has two six-month offering periods per year under which eligible employees may contribute up to 15% of their compensation toward the purchase of the Company's common stock per offering period (with a $25,000 cap per calendar year). The employee's purchase price is equal to (i) 85% of the closing price of a share of the Company's common stock on the enrollment date of such offering period or (ii) 85% of the closing price of a share of the Company's common stock on the Exercise Date of such Offering Period, whichever is lower. In May 2017, the Company's stockholders approved an amendment and restatement to the 2012 ESPP (the &#8220;2017 ESPP&#8221;) in order to effect an increase of authorized shares from 50,000 to 100,000. In June 2018, the Company's stockholders approved an amendment to the 2017 ESPP  (the &#8220;Amended 2017 ESPP&#8221;) in order to effect an increase of authorized shares from 100,000 to 500,000. During the year ended December&#160;31, 2021, 47,132 shares were issued under the Amended 2017 ESPP. At December&#160;31, 2021, the Company had 300,577 shares of the Company's common stock available for future grant in connection with this plan.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Issuances</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Agreement </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March&#160;2019, the Company and Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&#8217;s common stock having an aggregate value of up to $26.0 million, subject to certain limitations and conditions set forth in the Purchase Agreement (the &#8220;Offering&#8221;). As consideration for entering into the Purchase Agreement, the Company issued to Lincoln Park an additional 181,510 shares of common stock as commitment shares.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Purchase Agreement, upon commencement Lincoln Park purchased 250,000 shares of common stock, at a price of $4.00 per share for a total gross purchase price of $1,000,000 (the &#8220;Initial Purchase&#8221;) upon commencement. Thereafter, as often as every business day from and after one business day following the date of the Initial Purchase and over the 36-month term of the Purchase Agreement, the Company has the right, from time to time, at its sole discretion and subject to certain conditions, to direct Lincoln Park to purchase up to 100,000 shares of common stock, with such amount increasing as the closing sale price of the common stock increases; provided Lincoln Park&#8217;s obligation under any single such purchase will not exceed $2,500,000, unless the Company and Lincoln Park mutually agree to increase the maximum amount of such single purchase (each, a &#8220;Regular Purchase&#8221;).&#160;If the Company directs Lincoln Park to purchase the maximum number of shares of common stock it then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, the Company may direct Lincoln Park in an &#8220;accelerated purchase&#8221; to purchase an additional amount of common stock that may not exceed the lesser of (i)&#160;300% the number of shares purchased pursuant to the corresponding Regular Purchase or (ii)&#160;30% of the total number of shares of the Company&#8217;s common stock traded during a specified period on the applicable purchase date as set forth in the Purchase Agreement (each, an "Accelerated Purchase"). Under certain circumstances and in accordance with the Purchase Agreement, the Company may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company controls the timing and amount of any sales of its common stock to Lincoln Park.&#160;There is no upper limit on the price per share that Lincoln Park must pay for its common stock under the Purchase Agreement, but in no event will shares be sold to Lincoln Park on a day the closing price is less than the floor price specified in the Purchase Agreement. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the purchase agreement if it would result in Lincoln Park beneficially owning more than 9.99% of its common stock.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Purchase Agreement does not limit the Company&#8217;s ability to raise capital from other sources at the Company&#8217;s sole discretion, except that (subject to certain exceptions) the Company may not enter into any Variable Rate Transaction (as defined in the Purchase Agreement, including the issuance of any floating conversion rate or variable priced equity-like securities) during the 36 months after the date of the Purchase Agreement. The Company has the right to terminate the Purchase Agreement at any time, at no cost to the Company.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had not made any sales of common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase. In addition, the Company may not direct Lincoln Park to make Accelerated Purchases under the Purchase Agreement if the stock is below the specified floor price of $1.00.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock Sales Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a common stock sales agreement with H.C. Wainwright &amp; Co., LLC (&#8220;HCW&#8221;) as sales agent, which was subsequently amended in August 2018 (the &#8220;Sales Agreement&#8221;), in connection with an &#8220;at the market offering&#8221; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of not more than $25.0 million. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provided HCW with customary indemnification rights, and HCW was entitled to a commission at a fixed commission rate equal to 3.0% of the gross proceeds per share sold. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, the Company suspended the use of the at-the-market transactions facility and terminated the continuous offering pursuant to the Sales Agreement.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of the termination of the Sales Agreement on February 12, 2021, the Company had sold an aggregate 3,784,912 shares of its common stock pursuant to the Sales Agreement for net proceeds of $9.5 million since inception. For the year ended December&#160;31, 2021, the Company had not issued any shares under the Sales Agreement.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">At The Market Offering Agreement</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with HCW, as sales agent, in connection with an &#8220;at the market offering&#8221; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0&#160;million. During the twelve months ended December&#160;31, 2021, the Company had not issued any shares under the ATM Agreement. Having received a listing deficiency notice from Nasdaq on February 18, 2022 after the Company&#8217;s shares traded below $1.00 for 30 consecutive trading days, the Company will not be permitted to sell additional shares under the ATM Agreement until it re-establishes timely compliance. Compliance may be reestablished by various mechanisms, including stock price appreciation at or above $1.00 for a requisite period of time and reverse stock split.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Registered Direct Offerings</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company entered into a Securities Purchase Agreement (the &#8220;Institutional Purchase Agreement&#8221;) with certain institutional investors (the &#8220;Institutional Purchasers&#8221;). Pursuant to the terms of the Institutional Purchase Agreement, the Company sold to the Institutional Purchasers in a registered direct offering an aggregate of 24,906,134 shares of its common stock and warrants to purchase an aggregate of 12,453,067 shares of its common stock at a combined purchase price equal to $2.45 per share and associated warrant. Each warrant features an exercise price equal to $2.90 per share, is exercisable immediately upon issuance and will expire five years from the issuance date. Additionally, in a concurrent non-brokered registered direct offering, the Company entered into a Securities Purchase Agreement (the &#8220;Additional Purchase Agreement&#8221;) with certain accredited investors (the &#8220;Additional Purchasers&#8221;). Pursuant to the terms of the Additional Purchase Agreement, the Company sold to the Additional Purchasers an aggregate of 1,632,652 shares of its common stock and warrants to purchase an aggregate of 816,326 shares of its common stock at a combined purchase price equal to $2.45 per share and associated warrant. Each warrant features an exercise price equal to $2.90 per share, is exercisable immediately upon issuance and will expire five years from the issuance date. In connection with the registered direct offerings, the Company received gross proceeds of approximately $65.0 million.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Private Placement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a securities purchase agreement (the &#8220;January Private Placement&#8221;) with certain investors (the &#8220;January Purchasers&#8221;). Pursuant to the terms of the January Private Placement, the Company agreed to sell to the January Purchasers an aggregate of 12,500,000 shares of its common stock at a purchase price equal to $2.00 per share, along with warrants to purchase an aggregate of 6,250,000 shares of its common stock. In connection with the January Private Placement, the Company received gross proceeds of $25.0 million. Each warrant is exercisable for one share of common stock </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and features an exercise price equal to $2.90 per share. The warrants are exercisable immediately upon issuance and will expire five and one-half years from the issuance date.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Exercises</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company issued 801,148 shares of common stock for net proceeds of $1.8 million in connection with warrant exercises associated with the April 23, 2020 securities purchase agreement and the May 25, 2020 securities purchase agreement.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Warrants</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for stock options and warrants for the year ended December&#160;31, 2021:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:22.248%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">963,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,638,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the Year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,314,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,519,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(801,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,842)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109,549)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,131,849&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.97</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,356,600&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at December 31, 2021 or expected to vest in the future</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,120,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.96</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,356,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.37</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,122,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.70</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,356,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the Company issued restricted stock for services as follows ($ in thousands, except share data):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:69.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.187%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Restricted Stock Issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of Restricted Stock Issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average estimated fair value of restricted stock issued for services in the years ended December&#160;31, 2021 and 2020 was $1.43 and $3.28 per share, respectively. The fair value of the restricted stock was determined using the Company&#8217;s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEyNTk4_1483d86e-ff2f-4b87-a4f3-f6e1bf4d50d7">one</span> to four years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the Company issued restricted stock units for services as follows ($ in thousands, except share data):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:69.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.187%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Restricted Stock Units Issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of Restricted Stock Units Issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average estimated fair value of restricted stock units issued for services in the years ended December&#160;31, 2021 and 2020 was $1.59 and $2.65 per share, respectively. The fair value of the restricted stock units was determined using the </span></div>Company&#8217;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104232531560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes share-based compensation in the form of stock options, restricted stock, and restricted stock units. The following table summarizes the components of share-based compensation expense for the years ended December&#160;31, 2021 and 2020 ($ in thousands):</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:76.206%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.882%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at December&#160;31, 2021 were as follows ($ in thousands):</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.64</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.57</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the years ended December&#160;31, 2021 and 2020 were as follows ($ in thousands):</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:75.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.883%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Assumptions </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#8217;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. </span></div><div style="margin-bottom:8pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of assumptions made in calculating the fair values of stock options was as follow:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:75.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - minimum (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - maximum (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility - minimum</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility - maximum</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate - minimum</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.40%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate - maximum</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104236436104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Funding<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research Funding</a></td>
<td class="text">Research Funding<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">California Institute of Regenerative Medicine Grant Award</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) awarded the Company funds of up to $12.2 million to support The Sanford Project: T-Rex Study, a prospective, randomized, placebo-controlled, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of CLBS03 as a treatment for recent-onset type 1 diabetes. The funding is based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. Based on the actual number of subjects enrolled in California, the total amount of funding was revised to $8.6&#160;million, of which $8.2 million has been received through the grant project period completion. </span></div>The Company received $5.7&#160;million in initial funding in May 2017, a $1.9&#160;million milestone payment in December 2017, a $0.3&#160;million progress payment in March 2018, and a $0.2&#160;million progress payment in May 2019, of which the total was amortized over the estimated award period through July 2020 as a reduction to the related research and development expenses, with the final true up payment of $46&#160;thousand received in September 2020 and recorded as a reduction to the related research and development expenses. During the year ended December&#160;31, 2021 and December&#160;31, 2020 the Company amortized and recognized $0.0&#160;million and $1.6&#160;million in credits, respectively, to research and development related to CIRM funds received.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104232525144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision (benefit) for income taxes is based on loss from operations before provision for income taxes and noncontrolling interests as follows ($ in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax book income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,974)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,013)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,974)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,013)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:0.1%"/><td style="width:2.732%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:71.773%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision (benefit) from income taxes was as follows ($ in thousands):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:73.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Federal   </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;State and local</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Federal   </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;State and local</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,872)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Federal   </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;State and local</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,872)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The provision (benefit) for income taxes is determined by applying the U.S. Federal statutory rate of 21% to income before income taxes, and the components are set forth below ($ in thousands): </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:73.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal benefit at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,085)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,993)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent non deductible expenses for U.S. taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in state deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to actual</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other true ups</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 382 NOL Limitation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of New Jersey State NOLs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,979)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,521)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax provision (benefit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,872)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes at December&#160;31, 2021 and 2020 consist of the following ($ in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:73.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Tax Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated net operating losses (tax effected)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Tax Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,189&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,189)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, and 2020, the Company had approximately $281 million and $264 million, respectively, of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an ownership change of greater than 50% over a 3-year testing period on January 25, 2021.  As a result, $169&#160;million of the $281&#160;million of Federal NOLs will expire unutilized.  The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $112&#160;million of remaining Federal NOL.  The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on January 25, 2021 will be subject to an annual limitation of $173k under Internal Revenue Code Section 382, while losses incurred after January 25, 2021 will not be subject to limitations. The Company may be able to utilize additional NOLs of approximately $1.1&#160;million per year for the first five years after this ownership change as a result of the application of the Net Unrealized Built-in Gain rules.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company had State NOLs available in New Jersey of $97 million and $99 million, respectively, California of $70 million and $70 million, respectively, and New York City of $13 million and $13&#160;million, respectively, to offset future taxable income expiring from 2031 through 2041. In accordance with Section 382 of the Internal Revenue code, the usage of the Company&#8217;s state NOLs would be limited given the change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the FASB&#8217;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For years prior to 2018 the federal statute of limitations is closed for assessing tax. The Company&#8217;s state tax returns remain open to examination for a period of three to four years from date of filing.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company received preliminary approval from the New Jersey Economic Development Authority (&#8220;NJEDA&#8221;) to participate in the Technology Business Tax Certificate Transfer Program (the &#8220;Program&#8221;). The Program permits qualified companies to sell a percentage of their New Jersey net operating losses (&#8220;NJ NOLs&#8221;) to unrelated profitable corporations. On April 12, 2021, the Company received final approval from NJEDA to sell a portion of our NJ NOLs, which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $1.4&#160;million. The $1.5&#160;million of our NJ NOL related tax benefits (&#8220;NJ NOL Tax Benefits&#8221;) have been recorded as a benefit from income taxes and the loss on sale of $0.1&#160;million recorded in other income (expense) in the consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104236494552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">ContingenciesFrom time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104230540232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes  critical estimate and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsCash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risks</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States.  Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Long-lived Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span>The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text">Loss Per ShareBasic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_TreasuryStockPolicyPolicyTextBlock', window );">Treasury Stock</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (&#8220;R&amp;D&#8221;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive the Company&#8217;s cell therapy initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#8217;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text">New Accounting PronouncementsIn October 2019, the FASB issued ASU 2019-12, which affects general principles within Topic 740, Income Taxes. The amendments of&#160;ASU 2019-12&#160;are meant to simplify and reduce the cost of accounting for income taxes. For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company believes that the adoption of this new accounting guidance has not had a material impact on its financial statements and footnote disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_TreasuryStockPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_TreasuryStockPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104236457560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">The estimated useful lives of property and equipment are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:73.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.200%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104233647832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale-Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-Sale Securities Reconciliation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or debt marketable securities in the Company's Consolidated Balance Sheets (in thousands):</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:19.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.125%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,522&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,452&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,750&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,737&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on the Company's Consolidated Balance Sheets (in thousands):</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:67.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,737&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Available-for-Sale Securities by Contractual Maturity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:31.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.324%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,522&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,737&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104236485384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">The estimated useful lives of property and equipment are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:73.716%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.200%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104236486504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share</a></td>
<td class="text">At December&#160;31, 2021 and 2020, the Company excluded the following potentially dilutive securities (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:69.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104236497384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value of Assets Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of December&#160;31, 2021 and December&#160;31, 2020 were as follows (in thousands):</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:21.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,061&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,061&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104236387032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities were as follow (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.360%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,486&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104236436104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock', window );">Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzItMC0xLTEtNzIwMg_0a058abe-d734-4c31-a82c-efb4e8bc4aad"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzItMC0xLTEtNzIwMg_d0558917-552f-48e0-95eb-612098e4b721">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzYtMC0xLTEtNzIwMg_3827fe5c-6ee8-4d37-a233-c3c99088f192"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzYtMC0xLTEtNzIwMg_bfd3c824-688d-44a3-a795-98776d67c466">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzctMC0xLTEtNzIwMg_430fdfa5-3899-44a5-b33b-301b103d665c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzctMC0xLTEtNzIwMg_95df09b8-b8ab-49d7-988b-87cfc081e730">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments Under Lease Agreements</a></td>
<td class="text">Future minimum lease payments under the lease agreements as of December&#160;31, 2021 were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.181%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104233543912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options and Warrants Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for stock options and warrants for the year ended December&#160;31, 2021:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:22.248%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">963,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,638,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the Year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,314,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,519,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(801,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,842)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109,549)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,131,849&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.64&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.97</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,356,600&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at December 31, 2021 or expected to vest in the future</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,120,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.96</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,356,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.37</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,122,783&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.26&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.70</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,356,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.84&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Restricted Stock</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the Company issued restricted stock for services as follows ($ in thousands, except share data):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:69.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.187%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Restricted Stock Issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of Restricted Stock Issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the Company issued restricted stock units for services as follows ($ in thousands, except share data):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:69.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.187%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of Restricted Stock Units Issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of Restricted Stock Units Issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104233614952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text">The following table summarizes the components of share-based compensation expense for the years ended December&#160;31, 2021 and 2020 ($ in thousands):<div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:76.206%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.882%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at December&#160;31, 2021 were as follows ($ in thousands):</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.64</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.57</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Schedule of Fair Value of Shares Vested and Weighted Average Estimated Fair Values of Shares Granted</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the years ended December&#160;31, 2021 and 2020 were as follows ($ in thousands):</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:75.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.883%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions in Calculating Fair Values of Stock Options</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of assumptions made in calculating the fair values of stock options was as follow:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:75.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.191%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - minimum (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term - maximum (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility - minimum</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility - maximum</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate - minimum</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.40%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate - maximum</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.71%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104232765736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Income Taxes Based on Loss from Operations</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision (benefit) for income taxes is based on loss from operations before provision for income taxes and noncontrolling interests as follows ($ in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax book income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,974)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,013)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,974)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,013)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Benefit from Income Taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision (benefit) from income taxes was as follows ($ in thousands):</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:73.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Federal   </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;State and local</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Federal   </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;State and local</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,872)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. Federal   </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;State and local</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,872)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Effective Income Taxes</a></td>
<td class="text"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The provision (benefit) for income taxes is determined by applying the U.S. Federal statutory rate of 21% to income before income taxes, and the components are set forth below ($ in thousands): </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:73.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Federal benefit at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,085)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,993)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent non deductible expenses for U.S. taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in state deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to actual</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other true ups</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 382 NOL Limitation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of New Jersey State NOLs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,979)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,521)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax provision (benefit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,872)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components Deferred Income Taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes at December&#160;31, 2021 and 2020 consist of the following ($ in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:73.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Tax Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated net operating losses (tax effected)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Tax Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,189&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,189)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104231042552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The Business (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=clbs_CLBS16TreatmentOfCMDMember', window );">CLBS16 Treatment Of CMD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants awarded</a></td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=clbs_CLBS16TreatmentOfCMDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=clbs_CLBS16TreatmentOfCMDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104230832232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104229203672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 91,522<span></span>
</td>
<td class="nump">$ 30,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">91,452<span></span>
</td>
<td class="nump">30,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">53,135<span></span>
</td>
<td class="nump">8,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">53,070<span></span>
</td>
<td class="nump">8,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">18,124<span></span>
</td>
<td class="nump">7,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">18,124<span></span>
</td>
<td class="nump">7,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">20,263<span></span>
</td>
<td class="nump">14,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 20,258<span></span>
</td>
<td class="nump">$ 14,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104232355128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Classification on Consolidated Balance Sheets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 91,452<span></span>
</td>
<td class="nump">$ 30,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">21,129<span></span>
</td>
<td class="nump">12,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=clbs_MarketableSecuritiesMember', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 70,323<span></span>
</td>
<td class="nump">$ 18,061<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=clbs_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=clbs_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104229293480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Contractual Maturities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Less than one year</a></td>
<td class="nump">$ 91,522<span></span>
</td>
<td class="nump">$ 30,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Greater than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">91,522<span></span>
</td>
<td class="nump">30,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less than one year</a></td>
<td class="nump">91,452<span></span>
</td>
<td class="nump">30,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Greater than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">$ 91,452<span></span>
</td>
<td class="nump">$ 30,737<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104229096008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 430<span></span>
</td>
<td class="nump">$ 370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(368)<span></span>
</td>
<td class="num">(313)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104229281624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104228086296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of loss per share</a></td>
<td class="nump">2,132<span></span>
</td>
<td class="nump">964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of loss per share</a></td>
<td class="nump">21,357<span></span>
</td>
<td class="nump">2,638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of loss per share</a></td>
<td class="nump">604<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104229144440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">$ 70,323<span></span>
</td>
<td class="nump">$ 18,061<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">70,323<span></span>
</td>
<td class="nump">18,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">70,323<span></span>
</td>
<td class="nump">18,061<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">70,323<span></span>
</td>
<td class="nump">18,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104232408776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Salaries, employee benefits and related taxes</a></td>
<td class="nump">$ 2,034<span></span>
</td>
<td class="nump">$ 1,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 2,589<span></span>
</td>
<td class="nump">$ 2,486<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104407222168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>office</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_NumberOfOfficesUnderOperatingLeases', window );">Number of offices under operating leases</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating leases (in years)</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate for operating leases (percent)</a></td>
<td class="nump">9.625%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_NumberOfOfficesUnderOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Offices Under Operating Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_NumberOfOfficesUnderOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104231007480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Balance Sheet Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_OperatingLeaseRightOfUseAssetAbstract', window );"><strong>Right-of Use Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 724<span></span>
</td>
<td class="nump">$ 574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Right-of-use assets, balance sheet line item</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current</a></td>
<td class="nump">$ 229<span></span>
</td>
<td class="nump">$ 370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">485<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 714<span></span>
</td>
<td class="nump">$ 624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease liabilities, current, balance sheet line item</a></td>
<td class="text">Accrued liabilities<span></span>
</td>
<td class="text">Accrued liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease liabilities, noncurrent, balance sheet line item</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">Other long-term liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_OperatingLeaseRightOfUseAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_OperatingLeaseRightOfUseAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104229297144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Future Minimum Lease Payments Under Lease Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Future Minimum Lease Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amounts representing interest</a></td>
<td class="num">(122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 714<span></span>
</td>
<td class="nump">$ 624<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104230679704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Equity Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>offering_period </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2013 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=clbs_EquityIncentiveCompensationPlan2018Member', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant</a></td>
<td class="nump">5,585,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=clbs_EquityIncentiveCompensationPlan2018Member', window );">2018 Plan | Stock options | Share-based award tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=clbs_EquityIncentiveCompensationPlan2018Member', window );">2018 Plan | Stock options | Share-based award tranche two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=clbs_EquityIncentiveCompensationPlan2018Member', window );">2018 Plan | Stock options | Share-based award tranche three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=clbs_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan', window );">Number of offering periods | offering_period</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm', window );">Term of offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent', window );">Maximum annual contribution per employee as percent of annual salary</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee', window );">Maximum annual contribution per employee | $</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate', window );">Purchase price measurement as percent of closing price on enrollment date</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate', window );">Purchase price measurement as percent of closing price on exercise date</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=clbs_EmployeeStockPurchasePlan2012Member', window );">2012 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=clbs_EmployeeStockPurchasePlan2017Member', window );">2017 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=clbs_EmployeeStockPurchasePlan2017AmendedMember', window );">Amended 2017 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant</a></td>
<td class="nump">300,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="nump">47,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Maximum Annual Contribution Per Employee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Maximum Annual Contribution Per Employee, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Purchase Price, Percent Of Closing Price On Enrollment Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Purchase Price, Percent Of Closing Price On Exercise Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Offering Periods, Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering Periods, Employee Stock Purchase Plan, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=clbs_EquityIncentiveCompensationPlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=clbs_EquityIncentiveCompensationPlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=clbs_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=clbs_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=clbs_EmployeeStockPurchasePlan2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=clbs_EmployeeStockPurchasePlan2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=clbs_EmployeeStockPurchasePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=clbs_EmployeeStockPurchasePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=clbs_EmployeeStockPurchasePlan2017AmendedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=clbs_EmployeeStockPurchasePlan2017AmendedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104227582424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Equity Issuances (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
<th class="th"><div>Jun. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of capital stock</a></td>
<td class="nump">$ 65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,500,000<span></span>
</td>
<td class="nump">$ 18,728,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">801,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_LincolnParkAgreementMember', window );">Lincoln Park Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement', window );">Aggregate offering amount authorized per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration', window );">Commitment shares issued as consideration per agreement (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross price for stock transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_TermOfAgreement', window );">Term of agreement (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase', window );">Number of shares allowable to direct for Regular Purchase (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase', window );">Maximum obligation per directed purchase transaction for Regular Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase', window );">Maximum shares allowed in Accelerated Purchase as percent of shares in Regular Purchase (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod', window );">Maximum shares allowed in Accelerated Purchase as percent of shares traded during specified period (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty', window );">Maximum beneficial ownership allowable per agreement (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice', window );">Accelerated purchases specified floor price threshold for directed purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_H.C.WainwrightSalesAmendedAgreementMember', window );">H.C. Wainwright Sales Amended Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement', window );">Aggregate offering amount authorized per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent', window );">Commission on gross proceeds due to third party (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,784,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_AtTheMarketOfferingAgreementMember', window );">ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement', window );">Aggregate offering amount authorized per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_InstitutionalPurchaseAgreementMember', window );">Institutional Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (shares)</a></td>
<td class="nump">24,906,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold (in dollars per share)</a></td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants issued</a></td>
<td class="nump">12,453,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expiration term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_AdditionalPurchaseAgreementMember', window );">Additional Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (shares)</a></td>
<td class="nump">1,632,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold (in dollars per share)</a></td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants issued</a></td>
<td class="nump">816,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expiration term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_January2021PurchaseAgreementMember', window );">January 2021 Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares per each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Agreement, Accelerated Purchase Specified Stock Floor Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Commission On Gross Proceeds Due To Third Party Upon, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Issued As Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_LincolnParkAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=clbs_LincolnParkAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_H.C.WainwrightSalesAmendedAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=clbs_H.C.WainwrightSalesAmendedAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=clbs_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_InstitutionalPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=clbs_InstitutionalPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_AdditionalPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=clbs_AdditionalPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_January2021PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=clbs_January2021PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104228070696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Options and Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (shares)</a></td>
<td class="nump">963,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares)</a></td>
<td class="nump">1,314,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (shares)</a></td>
<td class="num">(7,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (shares)</a></td>
<td class="num">(29,842)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (shares)</a></td>
<td class="num">(109,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (shares)</a></td>
<td class="nump">2,131,849<span></span>
</td>
<td class="nump">963,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest (shares)</a></td>
<td class="nump">2,120,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Exercisable (shares)</a></td>
<td class="nump">1,122,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Stock Options, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 14.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">3.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">2.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">34.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">5.64<span></span>
</td>
<td class="nump">$ 14.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested or expected to vest (in dollars per share)</a></td>
<td class="nump">5.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 9.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Weighted Average Contractual Term and Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual term (in years)</a></td>
<td class="text">7 years 11 months 19 days<span></span>
</td>
<td class="text">5 years 10 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested or expected to vest, weighted average remaining contractual term (in years)</a></td>
<td class="text">7 years 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, weighted average remaining contractual term (in years)</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_AggregateIntrinsicValueOptionExercised', window );">Options exercised, aggregate intrinsic value</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested or expected to vest, aggregate intrinsic value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Warrants, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_CommonStockWarrantsShares', window );">Warrants outstanding, beginning balance (shares)</a></td>
<td class="nump">2,638,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WarrantsGranted', window );">Warrants granted (shares)</a></td>
<td class="nump">19,519,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WarrantsExercised', window );">Warrants exercised (shares)</a></td>
<td class="num">(801,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WarrantsCanceled', window );">Warrants forfeited (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WarrantsExpired', window );">Warrants expired (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_CommonStockWarrantsShares', window );">Warrants outstanding, ending balance (shares)</a></td>
<td class="nump">21,356,600<span></span>
</td>
<td class="nump">2,638,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_Sharesvestedandexpectedtovest', window );">Warrants vested or expected to vest (shares)</a></td>
<td class="nump">21,356,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WarrantsVested', window );">Warrants exercisable (shares)</a></td>
<td class="nump">21,356,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WarrantsWeightedAverageExercisePriceRollForward', window );"><strong>Warrants, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsOutstanding', window );">Warrants outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsGranted', window );">Warrants granted (in dollars per share)</a></td>
<td class="nump">2.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsExercised', window );">Warrants exercised (in dollars per share)</a></td>
<td class="nump">2.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsCanceled', window );">Warrants forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsExpired', window );">Warrants expired (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsOutstanding', window );">Warrants outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">2.84<span></span>
</td>
<td class="nump">$ 2.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest', window );">Warrants vested or expected to vest (in dollars per share)</a></td>
<td class="nump">2.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsExercisable', window );">Warrants exercisable (in dollars per share)</a></td>
<td class="nump">$ 2.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WarrantsOtherDisclosuresAbstract', window );"><strong>Warrants, Weighted Average Contractual Term and Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding', window );">Warrants outstanding, weighted average remaining contractual term (in years)</a></td>
<td class="text">4 years 4 months 13 days<span></span>
</td>
<td class="text">4 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest', window );">Warrants vested or expected to vest, weighted average remaining contractual term (in years)</a></td>
<td class="text">4 years 4 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_WeightedAverageRemainingContractualTermwarrantsvested', window );">Warrants exercisable, weighted average remaining contractual term (in years)</a></td>
<td class="text">4 years 4 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_AggregateIntrinsicValueWarrantsOutstanding', window );">Warrants outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest', window );">Warrants vested or expected to vest, aggregate intrinsic value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_AggregateIntrinsicValueWarrantsvested', window );">Warrants exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AggregateIntrinsicValueOptionExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Option Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AggregateIntrinsicValueOptionExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AggregateIntrinsicValueWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AggregateIntrinsicValueWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AggregateIntrinsicValueWarrantsvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants vested</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AggregateIntrinsicValueWarrantsvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants vested and expected to vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CommonStockWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrants, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CommonStockWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_Sharesvestedandexpectedtovest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>shares, vested and expected to vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_Sharesvestedandexpectedtovest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Canceled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Other Disclosures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants, Vested</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Weighted Average Exercise Price [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Canceled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Vested And Expected To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term warrant outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageRemainingContractualTermwarrantoutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageRemainingContractualTermwarrantsvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>weighted Average Remaining Contractual Term, warrants vested</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageRemainingContractualTermwarrantsvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104230638408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract', window );"><strong>Restricted Stock and Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of shares issued (shares)</a></td>
<td class="nump">612,950<span></span>
</td>
<td class="nump">156,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of shares issued</a></td>
<td class="nump">$ 877,700<span></span>
</td>
<td class="nump">$ 512,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value</a></td>
<td class="nump">$ 1.43<span></span>
</td>
<td class="nump">$ 3.28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract', window );"><strong>Restricted Stock and Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract', window );"><strong>Restricted Stock and Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract', window );"><strong>Restricted Stock and Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of shares issued (shares)</a></td>
<td class="nump">458,245<span></span>
</td>
<td class="nump">325,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of shares issued</a></td>
<td class="nump">$ 728,600<span></span>
</td>
<td class="nump">$ 863,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value</a></td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="nump">$ 2.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Stock And Restricted Stock Units Issued [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104231110872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 2,005<span></span>
</td>
<td class="nump">$ 1,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">760<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 1,245<span></span>
</td>
<td class="nump">$ 1,086<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104227863352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">1 year 7 months 20 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">1 year 6 months 25 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104232149256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details) - Stock Options - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of shares vested</a></td>
<td class="nump">$ 757<span></span>
</td>
<td class="nump">$ 536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value of shares granted (in dollars per share)</a></td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104227834712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Valuation Assumptions (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility - minimum</a></td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility - maximum</a></td>
<td class="nump">84.00%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted Average volatility</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate - minimum</a></td>
<td class="nump">0.63%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate - maximum</a></td>
<td class="nump">1.16%<span></span>
</td>
<td class="nump">1.71%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104227556328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Funding (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">41 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_FundingAmountAwarded', window );">Total funding amount awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_FundingOfGrantAwardCashReceived', window );">Funding of grant award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_MilestonePaymentOnGrantAwardCashReceived', window );">Milestone payment received on grant award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_ProgressPaymentOnGrantAwardCashReceived', window );">Progress payment received on grant award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred', window );">Progress payment amortized to related research and development over estimated award period</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense', window );">Amortization of accrued grant funding to offset expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Accrued Grant Funding Liability To Offset Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_FundingAmountAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding Amount Awarded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_FundingAmountAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_FundingOfGrantAwardCashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding Of Grant Award, Cash Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_FundingOfGrantAwardCashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_MilestonePaymentOnGrantAwardCashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment On Grant Award, Cash Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_MilestonePaymentOnGrantAwardCashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_ProgressPaymentOnGrantAwardCashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Progress Payment On Grant Award, Cash Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_ProgressPaymentOnGrantAwardCashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of customer funding recorded as an offset to costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104233647672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Loss from Operations Before Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Pre-tax book income - United States</a></td>
<td class="num">$ (28,974)<span></span>
</td>
<td class="num">$ (19,013)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pre-tax book income</a></td>
<td class="num">$ (28,974)<span></span>
</td>
<td class="num">$ (19,013)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104229266776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Benefit from Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">U.S. Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax provision (benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S. Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and local</a></td>
<td class="num">(1,508)<span></span>
</td>
<td class="num">(10,872)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred income tax provision (benefit)</a></td>
<td class="num">(1,508)<span></span>
</td>
<td class="num">(10,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">U.S. Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">State and local</a></td>
<td class="num">(1,508)<span></span>
</td>
<td class="num">(10,872)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax provision (benefit)</a></td>
<td class="num">$ (1,508)<span></span>
</td>
<td class="num">$ (10,872)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104232354952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Effective Income Tax Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. Federal benefit at statutory rate</a></td>
<td class="num">$ (6,085)<span></span>
</td>
<td class="num">$ (3,993)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Permanent non deductible expenses for U.S. taxes</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount', window );">Change in state deferred</a></td>
<td class="nump">622<span></span>
</td>
<td class="nump">5,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Return to actual</a></td>
<td class="nump">2,277<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other true ups</a></td>
<td class="nump">1,407<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount', window );">Section 382 NOL Limitation</a></td>
<td class="nump">35,438<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses', window );">Sale of New Jersey State NOLs</a></td>
<td class="num">(1,508)<span></span>
</td>
<td class="num">(10,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="num">(33,979)<span></span>
</td>
<td class="num">(1,521)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax provision (benefit)</a></td>
<td class="num">$ (1,508)<span></span>
</td>
<td class="num">$ (10,872)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change in State Deferred, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Sale Of State Net Operating Losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Section 382 NOL Limitation, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104227839128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Accumulated net operating losses (tax effected)</a></td>
<td class="nump">$ 36,281<span></span>
</td>
<td class="nump">$ 68,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_DeferredTaxAssetsRightOfUseLiability', window );">Right of use liability</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">3,086<span></span>
</td>
<td class="nump">5,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_DeferredTaxAssetsAccumulatedDepreciation', window );">Accumulated depreciation</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Accrued payroll</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">526<span></span>
</td>
<td class="nump">526<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">40,393<span></span>
</td>
<td class="nump">74,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right of use asset</a></td>
<td class="num">(204)<span></span>
</td>
<td class="num">(161)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(204)<span></span>
</td>
<td class="num">(161)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_NetDeferredTaxAssetsAndLiabilitiesGross', window );">Net deferred tax assets and liabilities</a></td>
<td class="nump">40,189<span></span>
</td>
<td class="nump">74,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(40,189)<span></span>
</td>
<td class="num">(74,169)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_DeferredTaxAssetsAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Accumulated Depreciation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_DeferredTaxAssetsAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_DeferredTaxAssetsRightOfUseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Right Of Use Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_DeferredTaxAssetsRightOfUseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_NetDeferredTaxAssetsAndLiabilitiesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Deferred Tax Assets And Liabilities, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_NetDeferredTaxAssetsAndLiabilitiesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140104228004520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 12, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal corporate income tax rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain', window );">Possible additional NOLs for five years resulting from Net Unrealized Built-in Gain rules</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram', window );">Proceeds from sale of NOLs</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross', window );">Proceeds from sale of NOLs, gross</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_LossOnSaleOfNetOperatingLosses', window );">Loss on sale of NOLs</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_OperatingLossCarryforwardsBeforeWriteDown', window );">Net operating loss carryforwards, prior to write down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.0<span></span>
</td>
<td class="nump">$ 264.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown', window );">Write down of NOLs set to expire unutilized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.0<span></span>
</td>
<td class="nump">99.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.0<span></span>
</td>
<td class="nump">$ 13.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_LossOnSaleOfNetOperatingLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss On Sale Of Net Operating Losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_LossOnSaleOfNetOperatingLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Annual Available, Five Years, Net Unrealized Built In Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_OperatingLossCarryforwardsBeforeWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Before Write Down</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_OperatingLossCarryforwardsBeforeWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Set To Expire, Written Down</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_OperatingLossCarryforwardsSetToExpireWrittenDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Net Operating Losses, NJEDA Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>clbs-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:clbs="http://www.caladrius.com/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="clbs-20211231.xsd" xlink:type="simple"/>
    <context id="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if90ca5338733460a971066d59766dc81_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibab4128b577c44a6906698d794637dfa_I20220322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2022-03-22</instant>
        </period>
    </context>
    <context id="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4277098eb8e941d8849e8e36535b5f36_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i79f6e5136b8641cfa6b0a6033d36e4f2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib68115849dea4da8a299b880b533d09e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i85f50c88c76b46fb9a9fdce9451675bd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i121f073fba6944229ad70a1d2216e933_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie0b6071a73644d039603573d50440ef9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib80ecf1156d64c119d881173740ad234_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibaaa7498b3d44ce1bcad37ed96000058_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i22fd97027cb3412289b307029b9c5d44_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i348737336b4d46088a36ffcdbf611676_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic33cdb661db24963b1bfc647608c3a94_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4ec6574cc7fc442f846e686e0a84ff71_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i35b1729b0f074c18b9bceadc165d9549_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib0ff61bf14d841cc822f4506607be1ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ief8aba9cebaa4b98af858420b6d60b7f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i041d14ec45c44c8fb3cc8034c61ca2ed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0b6458eb2d574b56bd1552b4ca244e6f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i09a9631d583b4e668c5ba6e87d883e35_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icf75562bf4d943e689edffa4d6485601_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia3f51b0ee3ea49bba7a5f4081d6ded24_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if085aac894864f8a99c23eb6f47d40df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic0e019f45caf44e48d650bf1abbafe32_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic49793f351ee420aad500948204d4e30_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b3b4197bf6b40bd9ea38bf539ff4783_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb8d59a888234a98a095e58d9743487f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i590074ecb1084218835cf2d097815608_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4c4ae4fba6464ce49a9062a34c2c26ce_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib1d500671ff149bcba1096235d4f0351_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i08c8bd3f15da40f487ae7ccc5cd6ce0b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i85b3581054004614935d85f02ba032eb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i138b992a9f394701a484d131a2d03699_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic4300a282ab74c7fafc35eaf54a4d1b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i281d8d9652bf482bb56d77de34f2b394_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie9b7f001d8d64dcf8ca8ba24c50737f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibb79bfd702f54177906acce5d83f1c8d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd0fb63052524135af561bfff992a6c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66d93ded2f34467d936905ead482129f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie8805752994c49a8983ffea360e4c657_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i62dba77d3e2d4497b9f85f984cfba083_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">clbs:CLBS16TreatmentOfCMDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i71b84bd2ef5e48a7bdb1280f312427a2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0be130c99cf043d29b10c289f1311bf5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i66e36ae7aaf0456e850ea8fbf00533f0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2c6296c462c944e98b58dc2225093cca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4bd83120aa4846998e97a3591fb90ade_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iccc34d3422ed44678794bda76d2eaf4b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8bb11fcb1dc24116a57364c1887e3eee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5468258328d0445fae4d4028b71bf1d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7dc62f8ee9d94752a5a99f633d893ab6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea9f8dda92dc4bd8a85d72b68a1c2034_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if63b1c1c78bf4e0282c0521dfe489b5b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i048ee8e3bbb048d3a2c27c95245f5f26_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">clbs:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ce00799bd1b413ea234f8cba5445fa0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">clbs:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a31510bd7f84ebd8c107e3f8ae7e451_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd367f49394e4ab892e5ef3d131cbacb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i310aef3fef4244c585bf799759419229_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib92b79ab0ccd455ead408147f405a076_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2d9629ce58cd4f72b9770fbf37dff34a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44c2bc8d551a45f1ac6ddf183da926e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia36b0d5241f648078a95606bbd0ff79d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i56f86dd405f8453396a3f70388a0570d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3bccb0f475cc4d218304cd754913183a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0919bea6d44b4365b7bf14cfc4143c4f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iecc81b9b2d6b49b0b19a54a285242744_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id672da1b89c34c4e9eff23a1f19e2531_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib9772fdb5cd8471f96f384eb173d43ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i63e392b1e77d4c5eac2465ca78a69cbd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4584a12f69824f27abd288e3a1a3d90f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i26b465f7839c460fad563a663abb5e53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5830c986cd0e460abfdcf8d771b6070f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6b6161f803dd4b47b8ed44fadd5ac665_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c5d1caf1a754f32a2b36182140d1778_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0fda5905c1054d06a90a8cbf51b93a97_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia3d14c5a5f224864ad0dabc919f68696_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EquityIncentiveCompensationPlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic520fa50fa274ec688df80ce26839e93_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EquityIncentiveCompensationPlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib349cdd63be447d58d8816ef0e5c45d5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EquityIncentiveCompensationPlan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6839ac3846014921bbf0418907b17b41_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EquityIncentiveCompensationPlan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5c3abe0816124623859688fce308ef7d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EquityIncentiveCompensationPlan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4ea30e24d2234509b67b4bb09c8f3d27_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EquityIncentiveCompensationPlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i125c01a6899241f092b94c8c6d510bcb_I20130101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EmployeeStockPurchasePlan2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-01-01</instant>
        </period>
    </context>
    <context id="id2c17509e40c431c93f98142b8bee4f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i28542dcef1334e33863c7a40beba93ac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5adb43718d3c4cdf96885dcfb77648d0_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EmployeeStockPurchasePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="ia54075aa02684beb8ab89afa65b0d48d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EmployeeStockPurchasePlan2017AmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i27caf2e77bc5468785bb299e95eb6191_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EmployeeStockPurchasePlan2017AmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i81fbec32b886419d9100b66971330fc6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">clbs:EmployeeStockPurchasePlan2017AmendedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaffc3258262f48dcbbf5775b82cf558e_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:LincolnParkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="iec24a6e53385419d9edb327599fc7c12_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:LincolnParkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic5e26195328b4591826e01006d17f63d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:LincolnParkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0ab769fd5384e5c8fa1c574d03e7274_I20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:H.C.WainwrightSalesAmendedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="i18cb5d7872684b26a43eaec5bc10e4bb_D20180801-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:H.C.WainwrightSalesAmendedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="ibe7b2ea590f64edea9436bb291dddfe3_D20180201-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:H.C.WainwrightSalesAmendedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="i2959d4ff885948268aa6c8327cf31262_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:H.C.WainwrightSalesAmendedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib26b46410f1947caaa269dc8c84bc533_I20210604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-04</instant>
        </period>
    </context>
    <context id="ieba8f73a7897435fbc5b3392cb6478cf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1ba1e218994d4ff1b3b3d3cdd3ea83a2_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:InstitutionalPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i9992345fcbc5433492a910eba1965518_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:InstitutionalPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="ib537ee905795476eb1a4ed13cf5100b1_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AdditionalPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i064784dc58ac445ab8485a53331724c5_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AdditionalPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i39237a1f42304c68bc922379c5cafbc9_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="ic237f5a9d962463dab8bf38d6a802419_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:January2021PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i58d1afa2bd9346fc97c1b81a5e0a4fd1_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:January2021PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i82ea1a2d86944a1c93f15ae19da0bc8e_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ib6d2e0cb9f694fe7a859d47739e7393e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i806c337fb61d4e69a7df6495c7be9795_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3c06d396aa1143d3b027ef1142d83cb5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i079cc5701e904396b3b89403166d381c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i60f3653ff42d4f0eaacf9c26102cfd38_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6bbaca2f02cc464a87710b12e3b26046_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie912ebfc1b8b4a6aa5f2e375f861d2c2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0ca74538c1c54566b186f58a6caf61e1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic1373d5ad1834c4abef25fae33e3348e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ife71a6468a004189ad68cb01a4d67fcf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iab051a0f20f54b90a2c3a2ae838bb8ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieba28787ca6743bebdb732d522992e81_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8097329850104783b37c8ae588e3f1f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1262c5aee83e44218db30c90579c58ff_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2f25e23ccf5e4e8b9996111cff5b1f1f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee4c1259461b4d82a4ed9b9423814c93_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2b81cf0af0d549cc9704b163fd97825f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0424a8b4b4e74dd6a974d18e483a0683_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib31c704f4b3d4411913b83a05612f827_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifac165fbd5294cbbae45708def42554a_I20170228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2017-02-28</instant>
        </period>
    </context>
    <context id="i61ed912a36714a0f8fa66f5c6f03cc72_D20170501-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i08b10f0993ca498595bc8f6e22708cd3_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i31c91a3c922742a393bcaf2e5965f1af_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="icb2942cf4b2d4251b0227854fee06098_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="iaa54ec01303049c2ac24d543660aa65d_D20190501-20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="id909ba1c9804438aafc38ea943a32300_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibb3d98988e62496d9a95ec85932a553d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd538497ecb94882951d52a7b78a623a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib03213178c1c439fbbcd57ce65f84a0a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3273942991694dcbb5315ec3f95ef5c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib4ffabf75b224124baa59142f55d7740_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i208a56199ea240e189c18fe67bc1738e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie9412c3333444df08e11f620932bee49_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iacc61b5e28ba4a56b04bcf5fece477a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i63593eb72a0c4883b9e50df4be109be4_D20210412-20210412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2021-04-12</startDate>
            <endDate>2021-04-12</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="office">
        <measure>clbs:office</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="offering_period">
        <measure>clbs:offering_period</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF80L2ZyYWc6NTdlN2Q3Njc4YjBjNGM2Mjk0M2FjNjA2NmU3MTM1ZDcvdGFibGU6YzU4ZjIzMTJhYjdmNDY4YWJhMGQwMjc3ZTA4Y2NiZGYvdGFibGVyYW5nZTpjNThmMjMxMmFiN2Y0NjhhYmEwZDAyNzdlMDhjY2JkZl8yLTEtMS0xLTcyMDI_54270153-0f69-4d14-b3dd-a275be190f36">0000320017</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF80L2ZyYWc6NTdlN2Q3Njc4YjBjNGM2Mjk0M2FjNjA2NmU3MTM1ZDcvdGFibGU6YzU4ZjIzMTJhYjdmNDY4YWJhMGQwMjc3ZTA4Y2NiZGYvdGFibGVyYW5nZTpjNThmMjMxMmFiN2Y0NjhhYmEwZDAyNzdlMDhjY2JkZl80LTEtMS0xLTcyMDI_448b8522-5499-4acb-b183-08fe66ca97fb">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF80L2ZyYWc6NTdlN2Q3Njc4YjBjNGM2Mjk0M2FjNjA2NmU3MTM1ZDcvdGFibGU6YzU4ZjIzMTJhYjdmNDY4YWJhMGQwMjc3ZTA4Y2NiZGYvdGFibGVyYW5nZTpjNThmMjMxMmFiN2Y0NjhhYmEwZDAyNzdlMDhjY2JkZl81LTEtMS0xLTcyMDI_771dec68-0a83-4721-8b20-76028c070ccb">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF80L2ZyYWc6NTdlN2Q3Njc4YjBjNGM2Mjk0M2FjNjA2NmU3MTM1ZDcvdGFibGU6YzU4ZjIzMTJhYjdmNDY4YWJhMGQwMjc3ZTA4Y2NiZGYvdGFibGVyYW5nZTpjNThmMjMxMmFiN2Y0NjhhYmEwZDAyNzdlMDhjY2JkZl82LTEtMS0xLTcyMDI_af1f2014-b355-451b-b9b5-f1123bf8d701">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzItMC0xLTEtNzIwMg_0a058abe-d734-4c31-a82c-efb4e8bc4aad">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzItMC0xLTEtNzIwMg_d0558917-552f-48e0-95eb-612098e4b721">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzYtMC0xLTEtNzIwMg_3827fe5c-6ee8-4d37-a233-c3c99088f192">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzYtMC0xLTEtNzIwMg_bfd3c824-688d-44a3-a795-98776d67c466">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzctMC0xLTEtNzIwMg_430fdfa5-3899-44a5-b33b-301b103d665c">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzctMC0xLTEtNzIwMg_95df09b8-b8ab-49d7-988b-87cfc081e730">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i3c06d396aa1143d3b027ef1142d83cb5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEyNTk4_1483d86e-ff2f-4b87-a4f3-f6e1bf4d50d7">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i58d1afa2bd9346fc97c1b81a5e0a4fd1_I20210131"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTIvZnJhZzpkNWMwNjExYmY2OWQ0MzEzODVhZWJiYTQ1YjY2MjNkYi90ZXh0cmVnaW9uOmQ1YzA2MTFiZjY5ZDQzMTM4NWFlYmJhNDViNjYyM2RiXzExMw_4eca3aec-2590-4ec9-a97a-9cf0403bfa89">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <dei:DocumentType
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zODk5_871cffc5-3e7f-4bee-aa87-2c79dc98e390">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6Nzk3NTc2NWM1OWYzNDc5Y2EwNDU1MjNlYzFmNjM4NDcvdGFibGVyYW5nZTo3OTc1NzY1YzU5ZjM0NzljYTA0NTUyM2VjMWY2Mzg0N18wLTAtMS0xLTcyMDI_eea465b7-3980-4f57-bb66-1ec7ee0331a4">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8xMzM_6116db35-ce55-4d66-a9a1-61bbb5716f48">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8xMzM_373a2eba-88d9-450e-8b4d-82d1ac282f1b">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6NjMzZjQzYWJmODM5NDFiY2JiZWQwMDYxYjQ5NDYzZTkvdGFibGVyYW5nZTo2MzNmNDNhYmY4Mzk0MWJjYmJlZDAwNjFiNDk0NjNlOV8wLTAtMS0xLTcyMDI_510c0fae-4804-4193-861a-14ebccaa5d0b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zOTA4_6878cf28-a763-49e5-a537-e9d91059d4ac">001-33650</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zODk2_d9e972e9-4d07-4aeb-9f6f-72a41369d405">CALADRIUS BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6NzRhNWE2MjNkYjNiNGQzMzlkOGE4ZjdjMzA5ZGNiNjcvdGFibGVyYW5nZTo3NGE1YTYyM2RiM2I0ZDMzOWQ4YThmN2MzMDlkY2I2N18wLTAtMS0xLTcyMDI_79c6f02a-caac-460d-856a-b1877692afb4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6NzRhNWE2MjNkYjNiNGQzMzlkOGE4ZjdjMzA5ZGNiNjcvdGFibGVyYW5nZTo3NGE1YTYyM2RiM2I0ZDMzOWQ4YThmN2MzMDlkY2I2N18wLTEtMS0xLTcyMDI_f43b6460-e480-4411-b259-c8e919726be6">22-2343568</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6NzRhNWE2MjNkYjNiNGQzMzlkOGE4ZjdjMzA5ZGNiNjcvdGFibGVyYW5nZTo3NGE1YTYyM2RiM2I0ZDMzOWQ4YThmN2MzMDlkY2I2N180LTAtMS0xLTcyMDIvdGV4dHJlZ2lvbjo4MmI1MzNiODlkZDk0Nzc3YWViMDBiYTIzNjUxNGVhY180_dba644f1-f0ba-47cc-8f72-395474a29021">110 Allen Road, 2nd Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6NzRhNWE2MjNkYjNiNGQzMzlkOGE4ZjdjMzA5ZGNiNjcvdGFibGVyYW5nZTo3NGE1YTYyM2RiM2I0ZDMzOWQ4YThmN2MzMDlkY2I2N180LTAtMS0xLTcyMDIvdGV4dHJlZ2lvbjo4MmI1MzNiODlkZDk0Nzc3YWViMDBiYTIzNjUxNGVhY184_d6221c47-428d-4ae5-99fe-a0a58cd9b350">Basking Ridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6NzRhNWE2MjNkYjNiNGQzMzlkOGE4ZjdjMzA5ZGNiNjcvdGFibGVyYW5nZTo3NGE1YTYyM2RiM2I0ZDMzOWQ4YThmN2MzMDlkY2I2N180LTAtMS0xLTcyMDIvdGV4dHJlZ2lvbjo4MmI1MzNiODlkZDk0Nzc3YWViMDBiYTIzNjUxNGVhY18xMg_9ffb8daa-2f48-4379-92e8-4714ba79f269">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6NzRhNWE2MjNkYjNiNGQzMzlkOGE4ZjdjMzA5ZGNiNjcvdGFibGVyYW5nZTo3NGE1YTYyM2RiM2I0ZDMzOWQ4YThmN2MzMDlkY2I2N180LTEtMS0xLTcyMDI_fd6bb5b9-1c3e-489b-9757-f455838d6664">07920</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zODk3_b2307616-1b6e-4641-a506-61bb8703c110">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zOTEx_57314f80-f343-4dcc-950a-1c720cd8d6f3">842-0100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6YjA2YjdlNjlmNzVmNDc0YmE0ZmQ2NzgwNGZmYjA1ZGIvdGFibGVyYW5nZTpiMDZiN2U2OWY3NWY0NzRiYTRmZDY3ODA0ZmZiMDVkYl8yLTAtMS0xLTcyMDI_e5e362d9-1d8a-4dd4-8820-f04cac56957e">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6YjA2YjdlNjlmNzVmNDc0YmE0ZmQ2NzgwNGZmYjA1ZGIvdGFibGVyYW5nZTpiMDZiN2U2OWY3NWY0NzRiYTRmZDY3ODA0ZmZiMDVkYl8yLTEtMS0xLTcyMDI_a21b8309-7abe-425e-bcf8-49a4a6513d3f">CLBS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6YjA2YjdlNjlmNzVmNDc0YmE0ZmQ2NzgwNGZmYjA1ZGIvdGFibGVyYW5nZTpiMDZiN2U2OWY3NWY0NzRiYTRmZDY3ODA0ZmZiMDVkYl8yLTItMS0xLTcyMDIvdGV4dHJlZ2lvbjo2YWQ2OTMwNmFkOWM0OTAxODlhNzcxNjViNmUyMjFjY184_5b2a71d7-f20a-4f97-b71d-1e9bdd6b805c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zOTA2_7a76e9af-b6a7-4943-bdc2-4ddf80a958ac">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zOTAx_87bd0584-84e5-4d05-adf2-124382b4cf76">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zOTA3_d3c1a926-3e31-4b40-b86d-0ffaf15c6f34">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zOTAy_a894b943-8a6e-4945-9b57-ddbeac56aea6">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6YWYyMTM3ZTc5MDY0NGZhOGJkNjVjZTEwMGFiODY5ZjUvdGFibGVyYW5nZTphZjIxMzdlNzkwNjQ0ZmE4YmQ2NWNlMTAwYWI4NjlmNV8xLTAtMS0xLTcyMDI_412bd350-96e2-436a-92c1-ca36ba097f48">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6YWYyMTM3ZTc5MDY0NGZhOGJkNjVjZTEwMGFiODY5ZjUvdGFibGVyYW5nZTphZjIxMzdlNzkwNjQ0ZmE4YmQ2NWNlMTAwYWI4NjlmNV8xLTQtMS0xLTcyMDI_80172f6b-c7fd-4186-9a86-19e80214e274">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6YWYyMTM3ZTc5MDY0NGZhOGJkNjVjZTEwMGFiODY5ZjUvdGFibGVyYW5nZTphZjIxMzdlNzkwNjQ0ZmE4YmQ2NWNlMTAwYWI4NjlmNV8yLTQtMS0xLTcyMDI_426a75fc-fdd7-4cfd-a31c-fbd0642b4838">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zOTAz_9fc5602c-871a-4c83-ad18-25837678100c">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zODk4_f2152671-2393-47d9-8cd7-6eebe36e31f3">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="if90ca5338733460a971066d59766dc81_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8yOTUw_a255e2d4-dc55-4d39-bab4-931f908bd4d6"
      unitRef="usd">95000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ibab4128b577c44a6906698d794637dfa_I20220322"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGFibGU6NmZmMmU3YmZkOWQ3NDM5Yjk2OTFiYzQxMjIwYjFhZjUvdGFibGVyYW5nZTo2ZmYyZTdiZmQ5ZDc0MzliOTY5MWJjNDEyMjBiMWFmNV8xLTEtMS0xLTcyMDI_bd061cd1-04aa-4254-9ce6-3b6156f4469b"
      unitRef="shares">60533064</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xL2ZyYWc6N2ViNGQyNDE3MGQ5NDZhZjhlN2YxZjUwODEwYjk2YTIvdGV4dHJlZ2lvbjo3ZWI0ZDI0MTcwZDk0NmFmOGU3ZjFmNTA4MTBiOTZhMl8zOTA0_33512705-d1e3-4404-bc7f-fa079448d139">The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant's Proxy Statement for the 2022 Annual Meeting of Stockholders. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant's fiscal year ended December 31, 2021.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82MS9mcmFnOjU5YTZkZjk5MGQxODRlNTFhNTg4Y2QyMzM1YWFlYzM1L3RhYmxlOmU1M2ZiZjIyNTBmYTQzNjU5ZmVjYjJmYzYyNmY2OTg2L3RhYmxlcmFuZ2U6ZTUzZmJmMjI1MGZhNDM2NTlmZWNiMmZjNjI2ZjY5ODZfMC0wLTEtMS0xMjkyMS90ZXh0cmVnaW9uOjVlM2M1MjllMWZiMzQzYmI4OGM0ZTdhNTg2MGVlMWZkXzEzMTk0MTM5NTMzNDY4_007ce07f-9a17-4335-857d-70190d316da9">248</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82NC9mcmFnOmNhNjQzOTI4ZjY1ZjQxYTBhNDI0ZmI3YWZlODE2OTFjL3RleHRyZWdpb246Y2E2NDM5MjhmNjVmNDFhMGE0MjRmYjdhZmU4MTY5MWNfMTMxOTQxMzk1NDYwNjk_78db1303-200a-48d6-827c-f3ccf4e6da78">GRANT THORNTON LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82NC9mcmFnOmNhNjQzOTI4ZjY1ZjQxYTBhNDI0ZmI3YWZlODE2OTFjL3RleHRyZWdpb246Y2E2NDM5MjhmNjVmNDFhMGE0MjRmYjdhZmU4MTY5MWNfMTMxOTQxMzk1NDYwNjg_554520cf-e204-43fc-bd1b-00bfecf9e64c">New York, New York</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMy0xLTEtMS03MjAy_1829b215-977c-4777-bd0b-29addddba4f2"
      unitRef="usd">24647000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMy0zLTEtMS03MjAy_1e56dad7-5364-4800-a0b7-ee58607ffcd2"
      unitRef="usd">16512000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfNC0xLTEtMS03MjAy_4175be86-e8d2-4755-9c99-91f539207516"
      unitRef="usd">70323000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfNC0zLTEtMS03MjAy_2f3f7d6f-63e5-4b76-9bf2-2b4db0f5692c"
      unitRef="usd">18061000</us-gaap:MarketableSecurities>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfNS0xLTEtMS03MjAy_af4df0ac-d721-4dc5-a17f-8226b1dd78c1"
      unitRef="usd">1212000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfNS0zLTEtMS03MjAy_5b218329-6d9e-40aa-a5f7-327c94fd3ec3"
      unitRef="usd">758000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfNi0xLTEtMS03MjAy_4f2165cd-7883-4c92-9a46-207d21a26d87"
      unitRef="usd">96182000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfNi0zLTEtMS03MjAy_76b199b0-0b45-44d9-a04b-c04b76e29d1d"
      unitRef="usd">35331000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfNy0xLTEtMS03MjAy_74d2a8ef-bfce-4a50-bff6-2b81a2789a02"
      unitRef="usd">62000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfNy0zLTEtMS03MjAy_74984b72-5098-4a31-9875-beed7d849b85"
      unitRef="usd">57000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfOS0xLTEtMS03MjAy_63644c24-e2ba-4f38-b8af-8900280d7a2e"
      unitRef="usd">764000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfOS0zLTEtMS03MjAy_e32e1a80-04e6-4ebd-9029-c29dd7d65291"
      unitRef="usd">614000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTAtMS0xLTEtNzIwMg_5e2d8a75-8e44-47d2-9679-b230533433a2"
      unitRef="usd">97008000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTAtMy0xLTEtNzIwMg_44a6b26f-3214-472a-b739-2ee8b9a71e0b"
      unitRef="usd">36002000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTMtMS0xLTEtNzIwMg_ec32a6b1-ae6c-4554-8aee-6c58393c3155"
      unitRef="usd">1934000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTMtMy0xLTEtNzIwMg_401c9c7b-e551-4d24-bb3a-ef766dd42266"
      unitRef="usd">1020000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTQtMS0xLTEtNzIwMg_4ec6ade4-0e5e-4d7e-8ad1-f862438a9341"
      unitRef="usd">2589000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTQtMy0xLTEtNzIwMg_a7452ac9-0d95-4b56-b6a3-871855d7d43e"
      unitRef="usd">2486000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTYtMS0xLTEtNzIwMg_8a0f545c-8158-4aed-b999-effe1d8508b4"
      unitRef="usd">4523000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTYtMy0xLTEtNzIwMg_f9ba36cc-dece-4e7d-aa61-d1315e3a9e69"
      unitRef="usd">3506000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTctMS0xLTEtNzIwMg_482f09df-968a-45fe-a46d-40512813fee8"
      unitRef="usd">485000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTctMy0xLTEtNzIwMg_8008a4a3-eb3f-4f35-b0c3-0f96fb001495"
      unitRef="usd">254000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTgtMS0xLTEtNzIwMg_b22c4346-7283-4eb6-8d39-f6be089d964e"
      unitRef="usd">5008000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTgtMy0xLTEtNzIwMg_2177e7ac-a707-4572-8b40-358e0d1da8c5"
      unitRef="usd">3760000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTktMS0xLTEtNzIwMg_a9020830-dd10-44d4-a904-4c703ebc787d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMTktMy0xLTEtNzIwMg_b10fd789-cbe1-4ced-8fe3-5cc571cd8d88"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzMz_3061b504-6e2b-40e7-b40f-9660cb5b1603"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzMz_5411d509-9867-4299-b838-89e18aa7f6e6"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <clbs:PreferredStockLiquidationPreferenceShare
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzExMA_144356d0-c693-4600-a8cb-53b2fd722878"
      unitRef="shares">0.001</clbs:PreferredStockLiquidationPreferenceShare>
    <clbs:PreferredStockLiquidationPreferenceShare
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzExMA_4ebb7a17-5b2b-43f1-b27f-b41e1280a9af"
      unitRef="shares">0.001</clbs:PreferredStockLiquidationPreferenceShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzEzNg_7a9cf515-337c-42a3-92d5-e213bbe680cf"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzEzNg_a5148ae2-a334-4844-9feb-c7844f008ab0"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <clbs:PreferredStockSharesDesignated
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzE1MA_61e855f6-3d20-4c9b-a0b6-4ad65f762de4"
      unitRef="shares">825000</clbs:PreferredStockSharesDesignated>
    <clbs:PreferredStockSharesDesignated
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzE1MA_cde9a514-289b-4918-82f0-3efc301dc8a6"
      unitRef="shares">825000</clbs:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzE5Ng_1d466493-e600-457a-aab9-6605d682fe7d"
      unitRef="shares">10000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzE5Ng_5304de99-9c0b-4dc9-821c-b81a0a70ec9b"
      unitRef="shares">10000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzE5Ng_7107ad7e-0a2b-4fe7-b8c3-c1e32fe61f5f"
      unitRef="shares">10000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOjg0MGUxOTgyY2ExODQxZjE4NzI0MDI2YzExNjY5OGFkXzE5Ng_72e373e8-a044-4e0f-9f05-f732c5037dd9"
      unitRef="shares">10000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMS0xLTEtNzIwMg_77f7c30b-65f5-4621-a832-2c93a10efab1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjEtMy0xLTEtNzIwMg_56012285-6440-46cc-984f-c0db5d5dfdf7"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjItMC0xLTEtNzIwMi90ZXh0cmVnaW9uOmJlZmE5ZTkyOTBjMzQyNWY4MWVjMGVjNmIxOTBmOGY3XzI0_2c0b95c3-8a20-401f-b5a0-e563082eb006"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjItMC0xLTEtNzIwMi90ZXh0cmVnaW9uOmJlZmE5ZTkyOTBjMzQyNWY4MWVjMGVjNmIxOTBmOGY3XzI0_38d45406-2da3-421e-ad59-4bd3eafa1f9b"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjItMC0xLTEtNzIwMi90ZXh0cmVnaW9uOmJlZmE5ZTkyOTBjMzQyNWY4MWVjMGVjNmIxOTBmOGY3XzQ5_6741c13e-4012-4308-b014-5bb8fa3a598a"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjItMC0xLTEtNzIwMi90ZXh0cmVnaW9uOmJlZmE5ZTkyOTBjMzQyNWY4MWVjMGVjNmIxOTBmOGY3XzQ5_9cb4e145-4f4c-4190-821a-7049ce97b4db"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjItMC0xLTEtNzIwMi90ZXh0cmVnaW9uOmJlZmE5ZTkyOTBjMzQyNWY4MWVjMGVjNmIxOTBmOGY3XzY3_e970de89-0094-41b8-9073-e0e12bf2b2ab"
      unitRef="shares">59800792</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjItMC0xLTEtNzIwMi90ZXh0cmVnaW9uOmJlZmE5ZTkyOTBjMzQyNWY4MWVjMGVjNmIxOTBmOGY3Xzc0_4da4ca45-57c2-44ab-9baa-e92cf2921f6a"
      unitRef="shares">19389413</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjItMC0xLTEtNzIwMi90ZXh0cmVnaW9uOmJlZmE5ZTkyOTBjMzQyNWY4MWVjMGVjNmIxOTBmOGY3XzE2MA_e5bd38e3-f0b3-4d72-872c-d054354199b6"
      unitRef="shares">59789712</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjItMC0xLTEtNzIwMi90ZXh0cmVnaW9uOmJlZmE5ZTkyOTBjMzQyNWY4MWVjMGVjNmIxOTBmOGY3XzE2Nw_ce66d863-21ae-4cbc-9a13-11e724cfaf52"
      unitRef="shares">19378333</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjItMS0xLTEtNzIwMg_53723f01-3709-4091-9efb-8ed4b3857f11"
      unitRef="usd">60000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjItMy0xLTEtNzIwMg_3f2d0f60-be30-4400-b2c1-9b6cfa2ee0d1"
      unitRef="usd">19000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjMtMS0xLTEtNzIwMg_ca5fb698-697d-4435-8f54-fe03756f154f"
      unitRef="usd">545988000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjMtMy0xLTEtNzIwMg_828b8cb0-a5c8-421a-b4c2-e014b5e6fc92"
      unitRef="usd">458748000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockShares
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjQtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOmQzYmYyMGY4NjA5NDQ1ZTI4YTgxYmZkZDVkYjA2MGRhXzI5_d300fdae-3974-4b48-bd0d-2ca38771a6e4"
      unitRef="shares">11080</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjQtMC0xLTEtNzIwMi90ZXh0cmVnaW9uOmQzYmYyMGY4NjA5NDQ1ZTI4YTgxYmZkZDVkYjA2MGRhXzI5_ee06c93a-41c2-4d7e-8507-059ed789c98f"
      unitRef="shares">11080</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjQtMS0xLTEtNzIwMg_52254bbd-c746-4765-a239-0726c8296b7e"
      unitRef="usd">708000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjQtMy0xLTEtNzIwMg_56f6c304-e468-4e6a-8fb5-bf87b469b5be"
      unitRef="usd">708000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjUtMS0xLTEtNzIwMg_1d395478-f7d9-4693-a9c0-dfbd09c5f383"
      unitRef="usd">-453016000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjUtMy0xLTEtNzIwMg_8a6dbd7c-6878-44ac-a590-f7a341adff12"
      unitRef="usd">-425550000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjYtMS0xLTEtNzIwMg_e43fa66c-4dc6-4cf2-9944-af6101053a7b"
      unitRef="usd">-70000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjYtMy0xLTEtNzIwMg_889e3c7b-2c55-4476-ac9b-b595aa964d00"
      unitRef="usd">-13000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjctMS0xLTEtNzIwMg_60c1447c-ed59-4f63-bc47-d2c0c300302e"
      unitRef="usd">92254000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjctMy0xLTEtNzIwMg_38e6893e-d71b-4d70-99e0-5b048e73013d"
      unitRef="usd">32496000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjgtMS0xLTEtNzIwMg_02749332-4d3d-4305-8e96-e75a59c1c88c"
      unitRef="usd">-254000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjgtMy0xLTEtNzIwMg_327cf681-58bb-4021-bed1-53c5a8de4754"
      unitRef="usd">-254000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjktMS0xLTEtNzIwMg_c7f37f10-0a17-4e5e-b7b7-556bcdd1908a"
      unitRef="usd">92000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMjktMy0xLTEtNzIwMg_57b95d17-9cb0-4657-bceb-709d96e6fe19"
      unitRef="usd">32242000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMzAtMS0xLTEtNzIwMg_cd6ab75e-89f5-4694-9d56-ca33e54b3d8d"
      unitRef="usd">97008000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF82Ny9mcmFnOjdiOGExYjAwZDJmYTRjYzg5NjBiZDEwODk2NWI5NjhlL3RhYmxlOjA5Mzc4MDQ0YzkwYTQ4MzI4Yzk4OTRhZDlmNjJlZGYwL3RhYmxlcmFuZ2U6MDkzNzgwNDRjOTBhNDgzMjhjOTg5NGFkOWY2MmVkZjBfMzAtMy0xLTEtNzIwMg_ba51c384-65c6-4866-89a2-5ec8728b5b38"
      unitRef="usd">36002000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMy0xLTEtMS03MjAy_0f6b600f-fcdc-4553-95f7-f5e993edd747"
      unitRef="usd">17680000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMy0zLTEtMS03MjAy_7d6064e0-5905-45ea-9ba6-d92709561407"
      unitRef="usd">9253000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfNC0xLTEtMS03MjAy_565e5af9-59ee-484a-8b98-8cf097095b92"
      unitRef="usd">11370000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfNC0zLTEtMS03MjAy_7cdcaf72-7083-4f5c-abc3-f645029de3bc"
      unitRef="usd">9892000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfNS0xLTEtMS03MjAy_e5eef8f9-fc42-47e9-b9f1-55ff8423d469"
      unitRef="usd">29050000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfNS0zLTEtMS03MjAy_6a07bb36-fa7b-45e6-a309-4dc3f7721dd9"
      unitRef="usd">19145000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfNy0xLTEtMS03MjAy_d02f3b4f-dedc-4f93-9f3e-4074a90491a3"
      unitRef="usd">-29050000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfNy0zLTEtMS03MjAy_731a7340-aaeb-49b9-90ec-68dddfb57e0b"
      unitRef="usd">-19145000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMTAtMS0xLTEtNzIwMg_00e5cb04-7108-4d1d-86d5-2930e03e466c"
      unitRef="usd">151000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMTAtMy0xLTEtNzIwMg_58c3ba68-23b0-4780-8e43-3561d4e21bd7"
      unitRef="usd">132000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMTEtMS0xLTEtNzIwMg_675db0ff-13ad-479f-be5b-9046543ce4f0"
      unitRef="usd">-75000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMTEtMy0xLTEtNzIwMg_2598f97b-b61d-446a-8f6a-ae994bd515b7"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMTItMS0xLTEtNzIwMg_8922a02c-ecf9-4f32-a354-6da939ed5ce9"
      unitRef="usd">76000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMTItMy0xLTEtNzIwMg_d8bfe987-c38d-41ef-8d5f-e02cf43223da"
      unitRef="usd">132000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMTgtMS0xLTEtNzIwMg_aedc7ac2-3efe-4f23-af10-3b6589d1103f"
      unitRef="usd">-28974000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMTgtMy0xLTEtNzIwMg_3e9830b1-6c6a-4310-b003-048806b4c059"
      unitRef="usd">-19013000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMTktMS0xLTEtNzIwMg_d9448699-b128-431d-9b20-3e8c878ce0cd"
      unitRef="usd">-1508000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMTktMy0xLTEtNzIwMg_633a8c09-cfb6-4c25-a9b3-0311674e13d2"
      unitRef="usd">-10872000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMjAtMS0xLTEtNzIwMg_ffe5aba0-1996-4681-954f-6090a17ec80d"
      unitRef="usd">-27466000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMjAtMy0xLTEtNzIwMg_a0ca2d3c-411c-4b46-97cc-70c7119c38cf"
      unitRef="usd">-8141000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMjEtMS0xLTEtNzIwMg_6921d416-0478-4029-9e1a-a771a0f65451"
      unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMjEtMy0xLTEtNzIwMg_19a16e50-9033-4362-a317-e2e89da9b9e5"
      unitRef="usd">9000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:NetIncomeLoss
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMjMtMS0xLTEtNzIwMg_525d3f9b-ad9f-4a07-8853-cb921023b42b"
      unitRef="usd">-27466000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMjMtMy0xLTEtNzIwMg_975be8da-9b78-4b9c-a4d8-4a1999cf1059"
      unitRef="usd">-8150000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMzQtMS0xLTEtNzIwMg_294888d0-f896-41ff-b838-30f11a501f24"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMzQtMS0xLTEtNzIwMg_2df6e165-7a5c-41b3-8d32-8c1ea67e67fb"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMzQtMy0xLTEtNzIwMg_3f62333d-e1a9-4033-bde6-b40c4f9e987f"
      unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfMzQtMy0xLTEtNzIwMg_63e299b7-937f-43bc-a82d-8a5e0666f8de"
      unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfNDItMS0xLTEtNzIwMg_2aa0aae4-4859-4169-a94c-02dc970118d5"
      unitRef="shares">55313000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfNDItMS0xLTEtNzIwMg_8e443810-0c41-4712-99f3-8d305e1efeb4"
      unitRef="shares">55313000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfNDItMy0xLTEtNzIwMg_2327bdc0-577e-4214-b88c-9b3720881096"
      unitRef="shares">15440000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83MC9mcmFnOjcxZGRmZTNlMjg4ODRjMzA5ZDYxNGQwNjgwODI4NzNkL3RhYmxlOjgwYTZhNTQ3MWU3MjQ3NGQ5ZWRjMjdmM2UwNjQ5MTJhL3RhYmxlcmFuZ2U6ODBhNmE1NDcxZTcyNDc0ZDllZGMyN2YzZTA2NDkxMmFfNDItMy0xLTEtNzIwMg_c5c6eca3-795d-4b47-8b6a-cf3fef99c9a8"
      unitRef="shares">15440000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfMi0xLTEtMS03MjAy_c5c1ea15-7b6b-422c-8115-4b68b9847315"
      unitRef="usd">-27466000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfMi0zLTEtMS03MjAy_7db494ec-0b29-4e98-8e15-907ace3a1794"
      unitRef="usd">-8141000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfNS0xLTEtMS03MjAy_e9833dc7-eb32-4403-91a4-320d5ee4b4cc"
      unitRef="usd">-57000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfNS0zLTEtMS03MjAy_d6061ee6-b820-4094-a7bd-cdcae151d89e"
      unitRef="usd">-15000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfNi0xLTEtMS03MjAy_0db41f86-6fdc-40af-a3cf-bbc4a4896cf6"
      unitRef="usd">-57000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfNi0zLTEtMS03MjAy_b30b51f7-92a4-4fac-a37e-c69225719427"
      unitRef="usd">-15000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfOC0xLTEtMS03MjAy_0776ffa1-a759-481c-bedc-edfe5e79e118"
      unitRef="usd">-27523000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfOC0zLTEtMS03MjAy_50da0e76-41d6-488e-b0c6-b2834e10ce48"
      unitRef="usd">-8156000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfMTAtMS0xLTEtNzIwMg_9605dc5d-ddae-498c-84ab-f8d1f5b34f37"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfMTAtMy0xLTEtNzIwMg_f90569c0-fe48-4c7b-99b1-2f92dd49b0a9"
      unitRef="usd">9000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfMTItMS0xLTEtNzIwMg_fe66077a-6fe9-49f6-9b86-65ef72ade123"
      unitRef="usd">-27523000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83My9mcmFnOmMxYWI5NzFmZDZhMTQ5NGM4OTBjMGMyNTQyNDJlZDM1L3RhYmxlOjkyMzdmYmU2NDhlMDQyMjM4NGI2MDA2OWUzYmNlNjU0L3RhYmxlcmFuZ2U6OTIzN2ZiZTY0OGUwNDIyMzg0YjYwMDY5ZTNiY2U2NTRfMTItMy0xLTEtNzIwMg_330127ea-1dc7-48d7-bbc5-b576f0e11d6a"
      unitRef="usd">-8165000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i79f6e5136b8641cfa6b0a6033d36e4f2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi0xLTEtMS03MjAy_0a5007c0-d70d-45a5-aff3-8b31832e331b"
      unitRef="shares">10000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i79f6e5136b8641cfa6b0a6033d36e4f2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi0zLTEtMS03MjAy_c8b110b9-8ec1-4210-a408-68c9992e17f1"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ib68115849dea4da8a299b880b533d09e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi01LTEtMS03MjAy_191ad754-b856-42a4-92f2-f4d6aa105f3f"
      unitRef="shares">10529000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib68115849dea4da8a299b880b533d09e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi03LTEtMS03MjAy_0d9e81aa-dc71-4ee8-983f-051315d961df"
      unitRef="usd">11000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i85f50c88c76b46fb9a9fdce9451675bd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi05LTEtMS03MjAy_e4f26d34-fb70-412e-8aef-f248e5c2fadb"
      unitRef="usd">438911000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i121f073fba6944229ad70a1d2216e933_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi0xMS0xLTEtNzIwMg_c5d9a4e4-b044-49e8-bfc0-6de97db72c1a"
      unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie0b6071a73644d039603573d50440ef9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi0xMy0xLTEtNzIwMg_01e172bf-928f-4f7a-a9d6-9921fa27422d"
      unitRef="usd">-417400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib80ecf1156d64c119d881173740ad234_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi0xNS0xLTEtNzIwMg_4846e2c4-90a4-4b24-b0d0-4a1922555844"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibaaa7498b3d44ce1bcad37ed96000058_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi0xNy0xLTEtNzIwMg_14f2be10-4825-4bd9-89da-b222301ca5e1"
      unitRef="usd">20816000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i22fd97027cb3412289b307029b9c5d44_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi0xOS0xLTEtNzIwMg_a76c2a38-f13f-43d8-ac31-196f79e104b5"
      unitRef="usd">-263000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i348737336b4d46088a36ffcdbf611676_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMi0yMS0xLTEtNzIwMg_13fde5e3-38d8-44a1-ac32-8bb230bc96fc"
      unitRef="usd">20553000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ic33cdb661db24963b1bfc647608c3a94_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNC0xMy0xLTEtNzIwMg_afb23392-9a7f-4f6d-9fcb-ff8a0d220636"
      unitRef="usd">-8150000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4ec6574cc7fc442f846e686e0a84ff71_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNC0xNy0xLTEtNzIwMg_586e4c6e-d5a0-4c3e-9fae-06250b4a6e76"
      unitRef="usd">-8150000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i35b1729b0f074c18b9bceadc165d9549_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNC0xOS0xLTEtNzIwMg_8d0516e2-9a60-4192-a2c8-6a07149f6585"
      unitRef="usd">9000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNC0yMS0xLTEtNzIwMg_aa0536bb-3f09-463e-8f68-f3df4fe3a5e8"
      unitRef="usd">-8141000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ib0ff61bf14d841cc822f4506607be1ee_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNS0xMS0xLTEtNzIwMg_5a7054bf-c30a-415d-8281-fa7a08c9b427"
      unitRef="usd">-15000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i4ec6574cc7fc442f846e686e0a84ff71_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNS0xNy0xLTEtNzIwMg_660a5b0f-6806-46ba-a65e-a54517f02098"
      unitRef="usd">-15000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNS0yMS0xLTEtNzIwMg_cff0ab4d-c7ff-49f0-b480-c3b9b45f92f9"
      unitRef="usd">-15000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ief8aba9cebaa4b98af858420b6d60b7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNi01LTEtMS03MjAy_8c01dadf-2842-4287-b131-718aa0cb4831"
      unitRef="shares">53000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ief8aba9cebaa4b98af858420b6d60b7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNi03LTEtMS03MjAy_3fece92f-fb91-427e-9cba-cf74e1fc9ce3"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i041d14ec45c44c8fb3cc8034c61ca2ed_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNi05LTEtMS03MjAy_3f0f7ba7-daf1-40a9-b90c-745261e8df5d"
      unitRef="usd">1117000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4ec6574cc7fc442f846e686e0a84ff71_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNi0xNy0xLTEtNzIwMg_461cb7f0-2f1b-47da-ae45-1cb716111846"
      unitRef="usd">1117000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNi0yMS0xLTEtNzIwMg_b340e89c-47ac-420c-b976-01ae2cbfa892"
      unitRef="usd">1117000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ief8aba9cebaa4b98af858420b6d60b7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNy01LTEtMS03MjAy_5c3fedf6-6bd4-4d36-9bf3-0b50c359fb84"
      unitRef="shares">8807000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ief8aba9cebaa4b98af858420b6d60b7f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNy03LTEtMS03MjAy_11aa347c-3843-4d2b-8cec-e3dacb8abc36"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i041d14ec45c44c8fb3cc8034c61ca2ed_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNy05LTEtMS03MjAy_202251f9-84d2-46d3-a626-b143494390fd"
      unitRef="usd">18720000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4ec6574cc7fc442f846e686e0a84ff71_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNy0xNy0xLTEtNzIwMg_b922c6ca-896e-4b33-93c1-8f7a79068605"
      unitRef="usd">18728000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfNy0yMS0xLTEtNzIwMg_32605de1-36a9-415e-99d6-e65d78e333d9"
      unitRef="usd">18728000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="i0b6458eb2d574b56bd1552b4ca244e6f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtMS0xLTEtNzIwMg_0684afc1-41f1-4763-97cc-4fe8eac8fadb"
      unitRef="shares">10000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b6458eb2d574b56bd1552b4ca244e6f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtMy0xLTEtNzIwMg_36b787d5-ed20-40d0-a06c-7347e1e4cc29"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i09a9631d583b4e668c5ba6e87d883e35_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtNS0xLTEtNzIwMg_51184ff8-87c4-4868-b238-2b1eb9aa83a8"
      unitRef="shares">19389000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i09a9631d583b4e668c5ba6e87d883e35_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtNy0xLTEtNzIwMg_c9602770-7461-4a9e-acc4-206f7c7724d8"
      unitRef="usd">19000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icf75562bf4d943e689edffa4d6485601_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtOS0xLTEtNzIwMg_073120f9-ef4b-44e9-8ea4-ad6da25a6192"
      unitRef="usd">458748000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia3f51b0ee3ea49bba7a5f4081d6ded24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtMTEtMS0xLTcyMDI_40c47b16-de23-4fb3-8881-fb09ae16e4e0"
      unitRef="usd">-13000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if085aac894864f8a99c23eb6f47d40df_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtMTMtMS0xLTcyMDI_c167eb6d-b4d5-4cd2-a23d-14d4b7ab4e2f"
      unitRef="usd">-425550000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic0e019f45caf44e48d650bf1abbafe32_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtMTUtMS0xLTcyMDI_b284ae83-c4e7-494f-a341-6aaf685abf27"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic49793f351ee420aad500948204d4e30_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtMTctMS0xLTcyMDI_b848987d-e359-4ee5-ab45-b62580a0102a"
      unitRef="usd">32496000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9b3b4197bf6b40bd9ea38bf539ff4783_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtMTktMS0xLTcyMDI_5ebe1e58-3e85-4884-b83e-b7750f514aa7"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTAtMjEtMS0xLTcyMDI_fafc4106-f329-4f45-94c0-9e7b1d097529"
      unitRef="usd">32242000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="idb8d59a888234a98a095e58d9743487f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTEtMTMtMS0xLTcyMDI_44740d76-40b6-41a4-b005-4064d0d2f739"
      unitRef="usd">-27466000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i590074ecb1084218835cf2d097815608_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTEtMTctMS0xLTcyMDI_99d3abbe-5300-4e7e-86dc-7d1ae70db473"
      unitRef="usd">-27466000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4c4ae4fba6464ce49a9062a34c2c26ce_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTEtMTktMS0xLTcyMDI_2b10789c-56b9-48a7-8810-02480a4c0c86"
      unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTEtMjEtMS0xLTcyMDI_40984fd6-2e16-43d3-a416-ffae47c181e2"
      unitRef="usd">-27466000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ib1d500671ff149bcba1096235d4f0351_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTItMTEtMS0xLTcyMDI_0fe89163-d404-43fb-af75-b4293b2b3923"
      unitRef="usd">-57000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i590074ecb1084218835cf2d097815608_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTItMTctMS0xLTcyMDI_34522ed5-72d3-4700-a412-7cfc982a5085"
      unitRef="usd">-57000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTItMjEtMS0xLTcyMDI_f709be12-f635-45e1-aaa8-de951746140e"
      unitRef="usd">-57000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i08c8bd3f15da40f487ae7ccc5cd6ce0b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTMtNS0xLTEtNzIwMg_99194cd7-033b-47d1-99a4-8e9acb5914f4"
      unitRef="shares">517000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i08c8bd3f15da40f487ae7ccc5cd6ce0b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTMtNy0xLTEtNzIwMg_b12899af-205e-4be1-af34-77870268e260"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i85b3581054004614935d85f02ba032eb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTMtOS0xLTEtNzIwMg_69b04176-6420-4bc1-9ca5-6526f8c37696"
      unitRef="usd">1757000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i590074ecb1084218835cf2d097815608_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTMtMTctMS0xLTcyMDI_f8f39ced-b5d8-4ef2-9956-fcbe29734c9c"
      unitRef="usd">1757000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTMtMjEtMS0xLTcyMDI_6c19304f-7d13-43fb-8219-56b0de9d9437"
      unitRef="usd">1757000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i08c8bd3f15da40f487ae7ccc5cd6ce0b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTQtNS0xLTEtNzIwMg_f1d7b697-8241-4c54-8b62-430314275f7a"
      unitRef="shares">39888000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i08c8bd3f15da40f487ae7ccc5cd6ce0b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTQtNy0xLTEtNzIwMg_e9cb7bb9-46aa-4231-8695-7907caa1ccd5"
      unitRef="usd">41000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i85b3581054004614935d85f02ba032eb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTQtOS0xLTEtNzIwMg_9e9fe7c3-a12d-4b44-b5f6-0a30523ff51b"
      unitRef="usd">85459000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i590074ecb1084218835cf2d097815608_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTQtMTctMS0xLTcyMDI_f501d3a4-4774-429e-b275-021295273425"
      unitRef="usd">85500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTQtMjEtMS0xLTcyMDI_ab375e35-62ed-44bc-9dcd-a45c5c013931"
      unitRef="usd">85500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i08c8bd3f15da40f487ae7ccc5cd6ce0b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTUtNS0xLTEtNzIwMg_63a25f5f-aa22-4ecb-b047-adf91b14efbe"
      unitRef="shares">7000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i08c8bd3f15da40f487ae7ccc5cd6ce0b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTUtNy0xLTEtNzIwMg_71ef0bce-7ed4-43ed-94a6-b75ac00c0b04"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i85b3581054004614935d85f02ba032eb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTUtOS0xLTEtNzIwMg_9b71d1e9-189e-4e00-be1c-0e59e9d16db0"
      unitRef="usd">24000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i590074ecb1084218835cf2d097815608_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTUtMTctMS0xLTcyMDI_85098b12-82c1-4455-bd01-15d7b1edbd52"
      unitRef="usd">24000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTUtMjEtMS0xLTcyMDI_5762f466-7b37-4736-ae69-f6cf434fe699"
      unitRef="usd">24000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharesOutstanding
      contextRef="i138b992a9f394701a484d131a2d03699_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctMS0xLTEtNzIwMg_304b7957-8ce6-4f17-9bfa-941c94ea50ca"
      unitRef="shares">10000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i138b992a9f394701a484d131a2d03699_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctMy0xLTEtNzIwMg_46d2584d-d8df-404d-b206-820f585bf50d"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ic4300a282ab74c7fafc35eaf54a4d1b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctNS0xLTEtNzIwMg_be18ec12-940e-445b-a1e6-269a18a36f49"
      unitRef="shares">59801000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic4300a282ab74c7fafc35eaf54a4d1b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctNy0xLTEtNzIwMg_dc859366-c028-4611-afc2-7a1923db3b47"
      unitRef="usd">60000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i281d8d9652bf482bb56d77de34f2b394_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctOS0xLTEtNzIwMg_9f521cc5-0793-4c63-bd03-88bdf9a650dc"
      unitRef="usd">545988000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie9b7f001d8d64dcf8ca8ba24c50737f0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctMTEtMS0xLTcyMDI_1caea614-3bcd-4add-ae92-ffe8e4dd7488"
      unitRef="usd">-70000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibb79bfd702f54177906acce5d83f1c8d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctMTMtMS0xLTcyMDI_db429daa-8ef7-43e6-8e5b-ff50d035d159"
      unitRef="usd">-453016000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifd0fb63052524135af561bfff992a6c8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctMTUtMS0xLTcyMDI_3ce72f2c-e3dc-4b9a-8a8f-fe40455f7edd"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66d93ded2f34467d936905ead482129f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctMTctMS0xLTcyMDI_99996e2c-a3ef-4761-a2c2-9c47278bc3f0"
      unitRef="usd">92254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie8805752994c49a8983ffea360e4c657_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctMTktMS0xLTcyMDI_91e9236a-729c-4ac5-b17b-31f5ce9e81c1"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83Ni9mcmFnOmFjMTg2M2M1ZDQwOTRiZTM4Njg3NDQ4ZmIxNTMwMjdlL3RhYmxlOjEyN2ZhODhmNDI3NTQwYjA5MzQyNDI5ZGU1MWMxODE1L3RhYmxlcmFuZ2U6MTI3ZmE4OGY0Mjc1NDBiMDkzNDI0MjlkZTUxYzE4MTVfMTctMjEtMS0xLTcyMDI_1fc49951-5019-4ecc-889d-d51abe2687dd"
      unitRef="usd">92000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMy0xLTEtMS03MjAy_0b36cb8e-dc6a-4d1a-81b3-e7094226c105"
      unitRef="usd">-27466000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMy0zLTEtMS03MjAy_55f738d8-5abf-42c6-a56a-a190a51b68ca"
      unitRef="usd">-8141000</us-gaap:ProfitLoss>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfNS0xLTEtMS03MjAy_8b0f2da9-508c-4238-9188-0cbc2422495c"
      unitRef="usd">2005000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfNS0zLTEtMS03MjAy_7036d2f2-576d-4c3c-ade1-98b8cff3713d"
      unitRef="usd">1265000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:DepreciationAndAmortization
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfNi0xLTEtMS03MjAy_e97dc218-422c-4f36-b0fd-c551aa18e027"
      unitRef="usd">55000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfNi0zLTEtMS03MjAy_d58ffb2b-6228-4200-8faa-81f7d14440e5"
      unitRef="usd">63000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTAtMS0xLTEtNzIwMg_25ec92a2-bb1c-4a3d-9f79-89c5f41b2be2"
      unitRef="usd">-2514000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTAtMy0xLTEtNzIwMg_60678175-d84f-4741-998a-637fcfe5efc7"
      unitRef="usd">-307000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTItMS0xLTEtNzIwMg_54cfb696-3423-407d-8c50-0df9e72a9367"
      unitRef="usd">453000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTItMy0xLTEtNzIwMg_354a24a6-be40-4183-89eb-2361c3f0d91c"
      unitRef="usd">-56000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTMtMS0xLTEtNzIwMg_9b875a74-092f-4755-bc3a-830299ed87e4"
      unitRef="usd">150000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTMtMy0xLTEtNzIwMg_46070325-6c4c-4cc0-aa19-d5f7fa5e07fe"
      unitRef="usd">-466000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTQtMS0xLTEtNzIwMg_1ab1d32b-d793-40b5-bcb8-653bb61349ca"
      unitRef="usd">1250000</clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities>
    <clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTQtMy0xLTEtNzIwMg_52747d7c-4173-4fce-aa76-ffaeefc6f445"
      unitRef="usd">-2839000</clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTUtMS0xLTEtNzIwMg_a7476dc0-eaf4-4023-80dd-b669f15ed602"
      unitRef="usd">-22245000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTUtMy0xLTEtNzIwMg_be3e9817-b806-4e9d-8cb8-205c2958bbe9"
      unitRef="usd">-8823000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTctMS0xLTEtNzIwMg_6309eaf2-7e9f-4e4f-8ab6-074271590848"
      unitRef="usd">179775000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTctMy0xLTEtNzIwMg_2a36cf43-bc9b-4217-b5c5-cf07b4c428e9"
      unitRef="usd">34799000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTgtMS0xLTEtNzIwMg_afc05e60-68f3-4064-8482-1d549e5f35d1"
      unitRef="usd">124939000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMTgtMy0xLTEtNzIwMg_09a8c76e-b600-4e4f-bfb7-033693ccef17"
      unitRef="usd">27542000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjAtMS0xLTEtNzIwMg_17c6cdac-ab91-438c-99b8-f30c1590f57e"
      unitRef="usd">60000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjAtMy0xLTEtNzIwMg_419c174b-f9cf-4206-82e0-847cb4f4491c"
      unitRef="usd">20000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjEtMS0xLTEtNzIwMg_7cb6aef7-6144-46d4-a3db-7a69a966c417"
      unitRef="usd">-54896000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjEtMy0xLTEtNzIwMg_e3827f2a-29c9-4970-9563-40c285750a6d"
      unitRef="usd">-7277000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjMtMS0xLTEtNzIwMg_6f74b533-257a-48c2-a6c9-7943c77c0bb1"
      unitRef="usd">24000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjMtMy0xLTEtNzIwMg_3ae57c77-02f7-419e-bba4-f7293476df81"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjQtMS0xLTEtNzIwMg_2e1c7b96-d343-455c-a670-6593c1ea32ed"
      unitRef="usd">248000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjQtMy0xLTEtNzIwMg_ad660cc2-cb9c-4946-8372-1ef9ac1057ff"
      unitRef="usd">148000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjUtMS0xLTEtNzIwMg_4671ea32-28ea-4a0f-ba58-8a63c1b564e3"
      unitRef="usd">85500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjUtMy0xLTEtNzIwMg_fa5f3063-54ca-43d9-a83d-e594b2434e52"
      unitRef="usd">18728000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjktMS0xLTEtNzIwMg_46883d25-c869-40bd-ae7f-b756d5130570"
      unitRef="usd">85276000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMjktMy0xLTEtNzIwMg_a19164b4-f753-4200-a5d4-3a5bff4f012c"
      unitRef="usd">18580000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMzAtMS0xLTEtNzIwMg_e169f9a3-fe8b-48fc-836a-403a7cbfc000"
      unitRef="usd">8135000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMzAtMy0xLTEtNzIwMg_bac09731-c558-4849-b69b-c654bb5ec376"
      unitRef="usd">2480000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMzEtMS0xLTEtNzIwMg_8ac64f41-8586-4be2-8af9-38f2f90ff364"
      unitRef="usd">16512000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i348737336b4d46088a36ffcdbf611676_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMzEtMy0xLTEtNzIwMg_d4e505d0-b730-435b-bc0f-dcf47b8c6306"
      unitRef="usd">14032000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMzItMS0xLTEtNzIwMg_b918a782-ab9f-41cb-9c22-b54bf1ff9361"
      unitRef="usd">24647000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMzItMy0xLTEtNzIwMg_cedac9c1-3e9a-4dd6-8ff2-37c7c1e95c53"
      unitRef="usd">16512000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMzYtMS0xLTEtNzIwMg_64f9d92a-deb8-4515-ad37-d336f563b896"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMzYtMy0xLTEtNzIwMg_85677d9d-1342-4591-b33c-95b46139d851"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMzctMS0xLTEtNzIwMg_e10a5ae5-e047-4b9e-9eec-6085805d5db5"
      unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF83OS9mcmFnOmQ4Zjk1YjQxMjJlNDQyMWY4NGYyNzk3MWRjYzk3MWYyL3RhYmxlOjU4MjBjMjI2MGI1YTQ2NDU5MDdmMmJhYTNkYTg0NWQxL3RhYmxlcmFuZ2U6NTgyMGMyMjYwYjVhNDY0NTkwN2YyYmFhM2RhODQ1ZDFfMzctMy0xLTEtNzIwMg_4864084d-83ca-463a-8bd8-bce8f975667f"
      unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <clbs:BusinessTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84NS9mcmFnOjEwMDRkMDFiZGM5MTRmYzQ4N2Y0MjhjMDVhMTFlMzIyL3RleHRyZWdpb246MTAwNGQwMWJkYzkxNGZjNDg3ZjQyOGMwNWExMWUzMjJfNDA5MA_d6286a51-bf67-4862-b53f-173997c60bec">The Business&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"&gt;OVERVIEW&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Caladrius Biosciences, Inc. (&#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; &#x201c;Caladrius&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The Company is developing what are intended to be first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Its technology is intended to leverage these cells to enable the body's natural repair mechanisms using formulations unique to each medical indication.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's leadership team has decades of collective biopharmaceutical development experience. Its goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. The Company's current product candidates include: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (CLBS16), the subject of both a completed positive Phase 2a study (ESCaPE-CMD) and an ongoing follow-on Phase 2b study (FREEDOM Trial) in the United States for the treatment of coronary microvascular dysfunction (&#x201c;CMD&#x201d;); &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt"&gt;HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (CLBS12), recipient of SAKIGAKE designation pursuant to which early conditional approval in Japan for the treatment of critical limb ischemia (&#x201c;CLI&#x201d;) and Buerger&#x2019;s disease is being sought based on the current results of a clinical trial executed in Japan. HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was the recipient of orphan drug designation in March 2021 from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) for Buerger's disease; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with chronic kidney disease related to type 2 diabetes (diabetic kidney disease or &#x201c;DKD&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ischemic Repair (CD34 Cell Technology)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CD34+ cell was discovered as a result of the deliberate search for a cell capable of stimulating the development and/or repair of blood vessels. All tissues in the body maintain their function by replacing cells over time. In addition to the maintenance function, the body must also be capable of building new blood vessels after injury. A CD34+ cell is an endothelial progenitor cell that has the ability to stimulate new blood vessel formation at the level of the microvasculature. No other native cell discovered to date has demonstrated this same capability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's proprietary cell technology using autologous (a patient&#x2019;s own naturally occurring) CD34+ cells has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted or reduced. Through the administration of CD34+ cells, Caladrius seeks to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted area. The Company believes that a number of conditions caused by underlying ischemic injury can be improved through its CD34+ cell technology including, but not limited to, Buerger's disease, CLI, CMD, and DKD.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; for Treatment of Coronary Microvascular Dysfunction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, with the assistance of a $1.9&#160;million grant from the National Institutes of Health (Award Number R44HL135889), the Company initiated its program for XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the treatment of CMD, a disease that afflicts as many as 1.6 million patients in the United States alone, with no current targeted treatment options. That study, the ESCaPE-CMD Trial, was a Phase 2a proof-of-concept open label study that enrolled patients at the Mayo Clinic in Rochester, MN and Cedars-Sinai Medical Center in Los Angeles, CA. Those data showed a positive therapeutic effect with a statistically significant improvement in angina frequency, coronary flow reserve, Canadian Cardiovascular Society Angina Class and Seattle Angina Questionnaire scores, as well as an acceptable safety profile. The full data set from that study was presented at the SCAI 2020 Scientific Sessions Virtual Conference on May 14, 2020 by Dr. Timothy Henry, FACC, of the Christ Hospital in Cincinnati, Ohio. In December 2020, the Company commenced enrollment in its Phase 2b FREEDOM Trial of XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a double-blind, randomized and placebo-controlled clinical trial designed to further evaluate the efficacy and safety of intracoronary artery delivery of autologous CD34+ cells in subjects with CMD and without obstructive coronary artery disease. While early enrollment proceeded to plan with the first patient treated in January 2021, the impact of the COVID-19 pandemic contributed to a general slowing of enrollment. Protocol amendments to the initial FREEDOM Trial protocol, as agreed to by the FDA, were implemented with the goal of enhancing breadth and speed of subject enrollment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; for Treatment of Critical Limb Ischemia&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's randomized, open-label, registration-eligible study of HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Japan for the treatment of CLI and Buerger's disease has, to date, demonstrated positive trends in both safety and efficacy. The HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; study's enrollment, however, has been significantly curtailed by the COVID-19 pandemic's impact in Japan, including the States of Emergency in Japan that have persisted for much of the past 18 months. Due to the significant and continued operational and financial burden incurred as a result of these COVID-19 delays, coupled with the unpredictability of the timing of site enrollment re-initiation, Caladrius&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;suspended further enrollment and is focusing its efforts on consummating a partnership for the product in Japan. Such a partnership may become the basis for the completion of development and registration of HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Japan and may include the completion of enrollment of the four remaining no-option CLI subjects stipulated in the original protocol, if necessary, and/or exploration of the possibility of submitting the existing data to Japan's Pharmaceuticals and Medical Devices Agency (&#x201c;PMDA&#x201d;) under Japan's regenerative medicine regulations, which allow for conditional approval of innovative regenerative medicine products. Despite receipt from FDA in March 2021 of orphan designation in the U.S. for CLBS12 as a potential treatment for Buerger's disease, based on a response from the FDA in October 2021 regarding a development plan for U.S. registration the Company decided not to pursue United States development in Buerger's disease at this time.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;CLBS201 for Treatment of Diabetic Kidney Disease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Progressive kidney failure is associated with attrition of the microcirculation of the kidney. Pre-clinical studies in kidney disease and injury models have demonstrated that protection or replenishment of the microcirculation results in improved kidney function. Based on these observations, the Company has elected to move forward with a Phase 1, open-label, proof-of-concept trial evaluating CLBS201 dosed via intra-renal artery injections in subjects with DKD. This protocol, as approved by an Institutional Review Board (the &#x201c;IRB&#x201d;), is expected to include six subjects in total with the first two subjects sequentially dosed and followed for a two-week safety observation period. Clearance by the independent Data Safety Monitoring Board (&#x201c;DSMB&#x201d;) overseeing the study will then permit the treatment of the next four patients, with all patients being followed for safety and therapeutic effect. A read-out of data will occur after at the six-month follow-up visit for all patients. A key criterion for continued development of CLBS201 will be its ability to demonstrate a therapeutic effect that will make it competitive in the field of DKD treatment, i.e., kidney function regeneration, as indicated by increased glomerular filtration rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Additional Out-licensing Opportunities and Pipeline Diversification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. The Company's current long-term strategy focuses on advancing its therapies through development with the ultimate objective of obtaining market authorizations and entering commercialization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. The Company believes that it is well-positioned to realize potentially meaningful value increases within its own proprietary pipeline if it is successful in advancing its product candidates to their next significant development milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company further desires to diversify its pipeline of development products candidates and is exploring a range of strategic transactions in furtherance of that goal. The Company has taken, and intends to continue to take, active steps to identify assets and/or companies for acquisition and/or partnership that would complement its current development programs and de-risk its overall development portfolio. Such assets potentially could target indications beyond cardiovascular disease as well as product categories outside of cell therapy. The range of possible transactions includes an acquisition, merger, business combination, in-license or other strategic transaction, any of which could result in the issuance of securities that could significantly dilute the shares of its existing stockholders. There can be no assurance that this exploration of strategic alternatives will result in Caladrius entering into or completing any transaction or that such transaction, if completed, will add to shareholder value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Coronavirus Considerations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, a novel strain of coronavirus (SARS-CoV-2), which causes COVID-19, was reported to have surfaced in China. In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic, and the world's economies began to experience pronounced effects. Despite the FDA approval of multiple COVID-19 vaccines in late 2020, there remains uncertainty around the extent and duration of disruption and any future related financial impact cannot reasonably be estimated at this time. In response to the COVID-19 pandemic, the Company implemented a universal work from home policy as well as stringent social distancing and other hygiene policies for employees when they must be in the office. The Company's clinical study of HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Japan has experienced significant delays in enrollment due to the States of Emergency in effect in Japan for most of 2020 and re-implemented from January 7, 2021 through March 21, 2021 covering Tokyo and other regions in response to an increased number of COVID-19 infections. Due to reported increases in COVID-19 cases and a low rate of vaccination in Japan, States of Emergency were renewed on April 25, 2021 through May 11, 2021 and then re-implemented in Tokyo from July 12, 2021 through September 30, 2021. With the Company's expectation that &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;COVID-19 in Japan would continue to impact negatively enrollment of patients in the HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; clinical trial, it elected to suspend trial enrollment, seek a development partner and consult with the Japanese regulatory authorities regarding the submission of patient data already accrued. Caladrius' phase 2b trial of XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the U.S. has also experienced delays in enrolling patients as a result of COVID-19.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes  critical estimate and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</clbs:BusinessTextBlock>
    <us-gaap:GrantsReceivable
      contextRef="i62dba77d3e2d4497b9f85f984cfba083_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84NS9mcmFnOjEwMDRkMDFiZGM5MTRmYzQ4N2Y0MjhjMDVhMTFlMzIyL3RleHRyZWdpb246MTAwNGQwMWJkYzkxNGZjNDg3ZjQyOGMwNWExMWUzMjJfMTY0OTI2NzQ1MDU4Mw_8ae55f51-0778-4d0b-994e-61f262ce463c"
      unitRef="usd">1900000</us-gaap:GrantsReceivable>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84NS9mcmFnOjEwMDRkMDFiZGM5MTRmYzQ4N2Y0MjhjMDVhMTFlMzIyL3RleHRyZWdpb246MTAwNGQwMWJkYzkxNGZjNDg3ZjQyOGMwNWExMWUzMjJfMTMxOTQxMzk1ODkzNzE_fce396f1-0b53-4a12-b100-fe68df6870eb">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84NS9mcmFnOjEwMDRkMDFiZGM5MTRmYzQ4N2Y0MjhjMDVhMTFlMzIyL3RleHRyZWdpb246MTAwNGQwMWJkYzkxNGZjNDg3ZjQyOGMwNWExMWUzMjJfMTMxOTQxMzk1ODkzNzI_51d40ebe-5414-4624-94f2-f371c7d7d354">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes  critical estimate and assumptions in determining stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84NS9mcmFnOjEwMDRkMDFiZGM5MTRmYzQ4N2Y0MjhjMDVhMTFlMzIyL3RleHRyZWdpb246MTAwNGQwMWJkYzkxNGZjNDg3ZjQyOGMwNWExMWUzMjJfMTMxOTQxMzk1ODkzNzM_113d00ae-e5c8-4241-93c6-be166b02019a">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODYzNg_754c2519-43dc-439f-a599-7b952b10ca3c">Summary of Significant Accounting Policies&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States.  Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#x2019;s restricted stock and restricted stock units is based on the closing market price of the Company&#x2019;s common stock on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To further drive the Company&#x2019;s cell therapy initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#x2019;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.&lt;/span&gt;&lt;/div&gt;New Accounting PronouncementsIn October 2019, the FASB issued ASU 2019-12, which affects general principles within Topic 740, Income Taxes. The amendments of&#160;ASU 2019-12&#160;are meant to simplify and reduce the cost of accounting for income taxes. For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company believes that the adoption of this new accounting guidance has not had a material impact on its financial statements and footnote disclosures.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODYzMA_1cd1e456-9731-425d-bc8d-c3c695585a87">Cash and Cash EquivalentsCash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODYwMg_7f712317-ff99-46c6-a873-4f7ad3e30315">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States.  Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODU5OA_e0a328d9-721c-49ef-83d4-865c5a15984d">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODU4Nw_75efcbcd-5222-4fc7-a6de-5c66bc4d8ea2">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODU3Mw_11bef7c0-88d3-47ab-bbd7-6ecc2e4332df">The estimated useful lives of property and equipment are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i71b84bd2ef5e48a7bdb1280f312427a2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RhYmxlOjEzNjNjNWViNTY0YjQ1YTY5ZmRjOGQ1YTM0MDZiZjVhL3RhYmxlcmFuZ2U6MTM2M2M1ZWI1NjRiNDVhNjlmZGM4ZDVhMzQwNmJmNWFfMC0xLTEtMS03MjAy_178bab3b-e3a0-47d1-b3cb-c105bbe262d6">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0be130c99cf043d29b10c289f1311bf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RhYmxlOjEzNjNjNWViNTY0YjQ1YTY5ZmRjOGQ1YTM0MDZiZjVhL3RhYmxlcmFuZ2U6MTM2M2M1ZWI1NjRiNDVhNjlmZGM4ZDVhMzQwNmJmNWFfMS0xLTEtMS03MjAy_daa60343-6758-469d-8f0b-391651d22c7b">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i66e36ae7aaf0456e850ea8fbf00533f0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RhYmxlOjEzNjNjNWViNTY0YjQ1YTY5ZmRjOGQ1YTM0MDZiZjVhL3RhYmxlcmFuZ2U6MTM2M2M1ZWI1NjRiNDVhNjlmZGM4ZDVhMzQwNmJmNWFfMi0xLTEtMS03MjAy_3a016b7c-289b-499a-a029-417f58e01350">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentImpairment
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODYyNg_21f6ad2b-c34d-4dab-8f39-e3807130ad02">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODY0NA_7c1832a2-d4ab-4df1-998a-7214ec204666">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#x2019;s restricted stock and restricted stock units is based on the closing market price of the Company&#x2019;s common stock on the date of grant.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODYzNQ_bad21df0-4011-492e-a1f4-13c912cd7425">Loss Per ShareBasic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented.</us-gaap:EarningsPerSharePolicyTextBlock>
    <clbs:TreasuryStockPolicyPolicyTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODYwNw_8e184f07-d6bc-4684-a696-e01888ac79ea">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.&lt;/span&gt;&lt;/div&gt;</clbs:TreasuryStockPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODU4OA_6cfe580a-1bbb-45a7-8b87-0c92527ad824">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To further drive the Company&#x2019;s cell therapy initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#x2019;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF84OC9mcmFnOjViY2JlOTk5OWEzMDQwNzY5YTgxZTU5MmJiMmFlODkyL3RleHRyZWdpb246NWJjYmU5OTk5YTMwNDA3NjlhODFlNTkyYmIyYWU4OTJfODYyOA_7f79040a-731c-4375-8fa1-d7829d1acb65">New Accounting PronouncementsIn October 2019, the FASB issued ASU 2019-12, which affects general principles within Topic 740, Income Taxes. The amendments of&#160;ASU 2019-12&#160;are meant to simplify and reduce the cost of accounting for income taxes. For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company believes that the adoption of this new accounting guidance has not had a material impact on its financial statements and footnote disclosures.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RleHRyZWdpb246ZTM5YjE1ZjdhZjY4NGVlZmJiYjJiNWRjMDU2MTJlMDRfNjMx_5e67da7d-fa5a-473c-b979-62df5d92e937">Available-for-Sale-Securities&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or debt marketable securities in the Company's Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on the Company's Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's portfolio of available-for-sale securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RleHRyZWdpb246ZTM5YjE1ZjdhZjY4NGVlZmJiYjJiNWRjMDU2MTJlMDRfNjQ1_c981522d-9cc1-4d43-b7db-6108aa29c4d3">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or debt marketable securities in the Company's Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2c6296c462c944e98b58dc2225093cca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMi0xLTEtMS03MjAy_65629fb4-0282-4258-98a0-1653acb64348"
      unitRef="usd">53135000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2c6296c462c944e98b58dc2225093cca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMi0zLTEtMS03MjAy_e99b07c2-9701-42ee-bf54-9acd0121da17"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2c6296c462c944e98b58dc2225093cca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMi01LTEtMS03MjAy_bf4e095c-fb5a-4d00-96fe-7da87d3850e1"
      unitRef="usd">65000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2c6296c462c944e98b58dc2225093cca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMi03LTEtMS03MjAy_be98369b-c63e-48b6-8c85-cff21ccbe6a2"
      unitRef="usd">53070000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4bd83120aa4846998e97a3591fb90ade_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMi05LTEtMS03MjAy_d26a6da5-4594-41fc-b974-eae84580634d"
      unitRef="usd">8406000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4bd83120aa4846998e97a3591fb90ade_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMi0xMS0xLTEtNzIwMg_aad57d91-79ca-4681-a635-7f227be806d7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4bd83120aa4846998e97a3591fb90ade_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMi0xMy0xLTEtNzIwMg_80abbfff-4560-4b0d-a219-80714d40331a"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4bd83120aa4846998e97a3591fb90ade_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMi0xNS0xLTEtNzIwMg_0b353c84-e3c7-4df3-83ba-9e86a0ea7df9"
      unitRef="usd">8399000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iccc34d3422ed44678794bda76d2eaf4b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMy0xLTEtMS03MjAy_f385c253-061d-406d-b6b5-5a33043c0964"
      unitRef="usd">18124000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iccc34d3422ed44678794bda76d2eaf4b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMy0zLTEtMS03MjAy_ced57992-bcf6-43e8-ad7a-1d06159674ba"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iccc34d3422ed44678794bda76d2eaf4b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMy01LTEtMS03MjAy_31cbfe07-f7b4-43a7-a280-60b6ab75774e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iccc34d3422ed44678794bda76d2eaf4b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMy03LTEtMS03MjAy_c84ca915-e08d-4c07-8f5b-7823f1bfc067"
      unitRef="usd">18124000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8bb11fcb1dc24116a57364c1887e3eee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMy05LTEtMS03MjAy_3f7d558f-f562-4e64-9a84-683d2c3df419"
      unitRef="usd">7591000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8bb11fcb1dc24116a57364c1887e3eee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMy0xMS0xLTEtNzIwMg_5be41360-e891-4c67-ae95-13c08e00e7be"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8bb11fcb1dc24116a57364c1887e3eee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMy0xMy0xLTEtNzIwMg_f4010b28-daf9-4ee9-bc60-c6fcc217afbd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8bb11fcb1dc24116a57364c1887e3eee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfMy0xNS0xLTEtNzIwMg_def6a1d3-02b3-49bc-8f46-faac66791372"
      unitRef="usd">7591000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5468258328d0445fae4d4028b71bf1d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNC0xLTEtMS03MjAy_57c5c4a8-e408-4662-8a95-cb297decce94"
      unitRef="usd">20263000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5468258328d0445fae4d4028b71bf1d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNC0zLTEtMS03MjAy_ff9c2bf0-e3c2-4ac2-ac07-80be7b7a17f4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5468258328d0445fae4d4028b71bf1d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNC01LTEtMS03MjAy_90d17830-c6e3-43fe-8022-3515b00a989b"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5468258328d0445fae4d4028b71bf1d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNC03LTEtMS03MjAy_cd2e4ff7-48d7-4745-8143-54a2f39a16d8"
      unitRef="usd">20258000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7dc62f8ee9d94752a5a99f633d893ab6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNC05LTEtMS03MjAy_ff63e3c3-0cc7-4437-9025-a0b4810b7d45"
      unitRef="usd">14753000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7dc62f8ee9d94752a5a99f633d893ab6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNC0xMS0xLTEtNzIwMg_b9f19011-8c18-4e85-81e8-69e4b522e429"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7dc62f8ee9d94752a5a99f633d893ab6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNC0xMy0xLTEtNzIwMg_a52432ed-8faf-458f-8773-6dd6eb498e57"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7dc62f8ee9d94752a5a99f633d893ab6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNC0xNS0xLTEtNzIwMg_a03b854a-8469-4bb4-ad85-3c6bd1a8be5d"
      unitRef="usd">14747000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNi0xLTEtMS03MjAy_86850d59-4337-4543-83d4-d6d1ab60762b"
      unitRef="usd">91522000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNi0zLTEtMS03MjAy_0eac2b26-5b81-460a-b9ec-adec240e833c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNi01LTEtMS03MjAy_869dd0a8-35a8-4582-80c8-f36bf5b11316"
      unitRef="usd">70000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNi03LTEtMS03MjAy_95f6b48d-161d-4120-8c23-95bd8c23f193"
      unitRef="usd">91452000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNi05LTEtMS03MjAy_8a6a1baf-9a07-451b-b867-37c4dfb4066c"
      unitRef="usd">30750000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNi0xMS0xLTEtNzIwMg_f7b7988a-cd8b-452b-91c3-91d24552739d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNi0xMy0xLTEtNzIwMg_21687c01-53fa-4900-9598-9454a3e5db6c"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjQ1NDkyMzk5YTYzYTRhYzNiMmEyNmQ3MWVkYTNhYWY3L3RhYmxlcmFuZ2U6NDU0OTIzOTlhNjNhNGFjM2IyYTI2ZDcxZWRhM2FhZjdfNi0xNS0xLTEtNzIwMg_6bf46668-eff3-4cdc-b33d-d25c81f2244f"
      unitRef="usd">30737000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RleHRyZWdpb246ZTM5YjE1ZjdhZjY4NGVlZmJiYjJiNWRjMDU2MTJlMDRfNjM0_8df7e313-f217-4eb2-bf6b-5ba71c7f98b8">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on the Company's Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iea9f8dda92dc4bd8a85d72b68a1c2034_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjdhMDRlM2VhODI1NTQwZTI5NjQ1YjVhNDFhMGU0MTYwL3RhYmxlcmFuZ2U6N2EwNGUzZWE4MjU1NDBlMjk2NDViNWE0MWEwZTQxNjBfMS0xLTEtMS03MjAy_00d47f30-387a-414b-8052-12214feec53e"
      unitRef="usd">21129000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if63b1c1c78bf4e0282c0521dfe489b5b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjdhMDRlM2VhODI1NTQwZTI5NjQ1YjVhNDFhMGU0MTYwL3RhYmxlcmFuZ2U6N2EwNGUzZWE4MjU1NDBlMjk2NDViNWE0MWEwZTQxNjBfMS0zLTEtMS03MjAy_3a997405-17de-4fcf-aadc-908b66347d85"
      unitRef="usd">12676000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i048ee8e3bbb048d3a2c27c95245f5f26_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjdhMDRlM2VhODI1NTQwZTI5NjQ1YjVhNDFhMGU0MTYwL3RhYmxlcmFuZ2U6N2EwNGUzZWE4MjU1NDBlMjk2NDViNWE0MWEwZTQxNjBfMi0xLTEtMS03MjAy_76f7aaef-4d1f-430e-89dc-d4aa51083794"
      unitRef="usd">70323000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5ce00799bd1b413ea234f8cba5445fa0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjdhMDRlM2VhODI1NTQwZTI5NjQ1YjVhNDFhMGU0MTYwL3RhYmxlcmFuZ2U6N2EwNGUzZWE4MjU1NDBlMjk2NDViNWE0MWEwZTQxNjBfMi0zLTEtMS03MjAy_14764d2c-24df-40ee-9232-fccf59b7e38f"
      unitRef="usd">18061000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjdhMDRlM2VhODI1NTQwZTI5NjQ1YjVhNDFhMGU0MTYwL3RhYmxlcmFuZ2U6N2EwNGUzZWE4MjU1NDBlMjk2NDViNWE0MWEwZTQxNjBfMy0xLTEtMS03MjAy_746c542a-b2ca-4873-b776-e47869be79bd"
      unitRef="usd">91452000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjdhMDRlM2VhODI1NTQwZTI5NjQ1YjVhNDFhMGU0MTYwL3RhYmxlcmFuZ2U6N2EwNGUzZWE4MjU1NDBlMjk2NDViNWE0MWEwZTQxNjBfMy0zLTEtMS03MjAy_a8adb5fe-60a1-4550-bca0-ee517d65c140"
      unitRef="usd">30737000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RleHRyZWdpb246ZTM5YjE1ZjdhZjY4NGVlZmJiYjJiNWRjMDU2MTJlMDRfNjI2_8def9d69-5967-4d17-a6e4-89e17d2a6a49">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's portfolio of available-for-sale securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfMi0xLTEtMS03MjAy_479b0601-0119-483d-baab-79add56aa8dc"
      unitRef="usd">91522000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfMi0zLTEtMS03MjAy_840fdafb-73dd-420c-870a-85b25c2b7278"
      unitRef="usd">91452000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfMi01LTEtMS03MjAy_0b526aaa-b396-4e8d-958c-202ec977bb76"
      unitRef="usd">30750000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfMi03LTEtMS03MjAy_a2a44d4b-f697-42a3-b0d3-6440bee0bc7f"
      unitRef="usd">30737000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfMy0xLTEtMS03MjAy_e9238660-3ddf-4183-a484-f27dd81b0791"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfMy0zLTEtMS03MjAy_c7592e9b-b315-41cb-90af-e91925d00f25"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfMy01LTEtMS03MjAy_1edd269e-aeda-4052-8645-3251c3ca67b6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfMy03LTEtMS03MjAy_9c7487a3-9e75-4661-a4a3-efb0ed2d7da9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfNC0xLTEtMS03MjAy_7f712e69-ecc6-40ba-b961-808548f8899d"
      unitRef="usd">91522000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfNC0zLTEtMS03MjAy_90f162f3-6b48-49ea-8256-78c70d7da2c7"
      unitRef="usd">91452000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfNC01LTEtMS03MjAy_55ed9dc7-7b4b-4852-a1e6-49ffd8b7f7a1"
      unitRef="usd">30750000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85MS9mcmFnOmUzOWIxNWY3YWY2ODRlZWZiYmIyYjVkYzA1NjEyZTA0L3RhYmxlOjA4YzYxMzk5MmNiNzRmMmJiZTFiMjliYWIxMmYzMzhlL3RhYmxlcmFuZ2U6MDhjNjEzOTkyY2I3NGYyYmJlMWIyOWJhYjEyZjMzOGVfNC03LTEtMS03MjAy_632613ee-1ee8-4976-9e25-77900606d266"
      unitRef="usd">30737000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RleHRyZWdpb246Y2RjYzg4YmEwZWQyNGNjYjliNWFmNjJlNDBiNzRlOTNfMjQw_ead9ea18-9797-42fc-9a97-4c47fa4655ad">Property and Equipment&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company&#x2019;s results included depreciation expense of approximately $0.1 million and $0.1 million for the years ended December&#160;31, 2021 and 2020, respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5a31510bd7f84ebd8c107e3f8ae7e451_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfMi0xLTEtMS03MjAy_f590a1a5-ec1e-4fad-994c-be7741e7b78c"
      unitRef="usd">26000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icd367f49394e4ab892e5ef3d131cbacb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfMi0zLTEtMS03MjAy_c266c418-902a-4d0e-966d-14f12f0f8486"
      unitRef="usd">26000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i310aef3fef4244c585bf799759419229_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfMy0xLTEtMS03MjAy_eb3982da-3b63-47e9-80d9-3f1a970f15a4"
      unitRef="usd">314000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib92b79ab0ccd455ead408147f405a076_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfMy0zLTEtMS03MjAy_4cc2b86d-b744-40b4-bdbc-966f052bdd67"
      unitRef="usd">254000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2d9629ce58cd4f72b9770fbf37dff34a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfNC0xLTEtMS03MjAy_557ad84c-e3eb-4e76-940e-cdafdfa02132"
      unitRef="usd">90000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i44c2bc8d551a45f1ac6ddf183da926e5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfNC0zLTEtMS03MjAy_9132265b-a7ce-41fe-831a-02c3dac30217"
      unitRef="usd">90000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfNS0xLTEtMS03MjAy_fc796252-1e3c-4a36-9efb-2aab9b50a292"
      unitRef="usd">430000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfNS0zLTEtMS03MjAy_e9d72128-4c0b-4d4b-969a-39c7cffe2e5b"
      unitRef="usd">370000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfNi0xLTEtMS03MjAy_6f4493fb-e8eb-456f-bec3-25fb71bc9f11"
      unitRef="usd">368000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfNi0zLTEtMS03MjAy_6545758e-edbc-4cbb-bc36-03c0add7ad2c"
      unitRef="usd">313000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfNy0xLTEtMS03MjAy_80555a15-1895-4f2a-b186-29a968621a8e"
      unitRef="usd">62000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RhYmxlOmVjOWNlMWQ4M2IxYjQ2OGU5OGI4ZGQ2YzdlNzFhZTM1L3RhYmxlcmFuZ2U6ZWM5Y2UxZDgzYjFiNDY4ZTk4YjhkZDZjN2U3MWFlMzVfNy0zLTEtMS03MjAy_15b24868-f12d-4972-b8f1-b410ce5de180"
      unitRef="usd">57000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RleHRyZWdpb246Y2RjYzg4YmEwZWQyNGNjYjliNWFmNjJlNDBiNzRlOTNfMTc3_c1d2737e-4edf-4d46-8d2b-8007a7463049"
      unitRef="usd">100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85NC9mcmFnOmNkY2M4OGJhMGVkMjRjY2I5YjVhZjYyZTQwYjc0ZTkzL3RleHRyZWdpb246Y2RjYzg4YmEwZWQyNGNjYjliNWFmNjJlNDBiNzRlOTNfMTg0_92533f08-d7a7-4672-bdea-58eb55dea6e8"
      unitRef="usd">100000</us-gaap:Depreciation>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85Ny9mcmFnOjFkODkyOWM5YTE1MDQ2NDk5Nzk5N2Y2ZmUzM2Y2MWEyL3RleHRyZWdpb246MWQ4OTI5YzlhMTUwNDY0OTk3OTk3ZjZmZTMzZjYxYTJfMzM0_ede7e22f-e61b-4c9b-a7dc-78a39f77eb05">Loss Per Share&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2021 and 2020, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;loss per share a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s they are anti-dilutive in the periods presented. At December&#160;31, 2021 and 2020, the Company excluded the following potentially dilutive securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85Ny9mcmFnOjFkODkyOWM5YTE1MDQ2NDk5Nzk5N2Y2ZmUzM2Y2MWEyL3RleHRyZWdpb246MWQ4OTI5YzlhMTUwNDY0OTk3OTk3ZjZmZTMzZjYxYTJfMzQw_34753760-fbaa-45f9-be6a-1e65adc04551">At December&#160;31, 2021 and 2020, the Company excluded the following potentially dilutive securities (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia36b0d5241f648078a95606bbd0ff79d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85Ny9mcmFnOjFkODkyOWM5YTE1MDQ2NDk5Nzk5N2Y2ZmUzM2Y2MWEyL3RhYmxlOmEwMThjNTQxNjI2ZTRlZTViZTBjY2JlYjc2ODk0YmZhL3RhYmxlcmFuZ2U6YTAxOGM1NDE2MjZlNGVlNWJlMGNjYmViNzY4OTRiZmFfMi0xLTEtMS03MjAy_60df90b6-3d3a-4553-bcf2-2bc54d2e185a"
      unitRef="shares">2132000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i56f86dd405f8453396a3f70388a0570d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85Ny9mcmFnOjFkODkyOWM5YTE1MDQ2NDk5Nzk5N2Y2ZmUzM2Y2MWEyL3RhYmxlOmEwMThjNTQxNjI2ZTRlZTViZTBjY2JlYjc2ODk0YmZhL3RhYmxlcmFuZ2U6YTAxOGM1NDE2MjZlNGVlNWJlMGNjYmViNzY4OTRiZmFfMi0zLTEtMS03MjAy_74291e67-50a6-40ce-9769-902011dfee4f"
      unitRef="shares">964000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3bccb0f475cc4d218304cd754913183a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85Ny9mcmFnOjFkODkyOWM5YTE1MDQ2NDk5Nzk5N2Y2ZmUzM2Y2MWEyL3RhYmxlOmEwMThjNTQxNjI2ZTRlZTViZTBjY2JlYjc2ODk0YmZhL3RhYmxlcmFuZ2U6YTAxOGM1NDE2MjZlNGVlNWJlMGNjYmViNzY4OTRiZmFfMy0xLTEtMS03MjAy_e331cbc7-a960-4c6f-8304-f63a6bcd1cb6"
      unitRef="shares">21357000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0919bea6d44b4365b7bf14cfc4143c4f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85Ny9mcmFnOjFkODkyOWM5YTE1MDQ2NDk5Nzk5N2Y2ZmUzM2Y2MWEyL3RhYmxlOmEwMThjNTQxNjI2ZTRlZTViZTBjY2JlYjc2ODk0YmZhL3RhYmxlcmFuZ2U6YTAxOGM1NDE2MjZlNGVlNWJlMGNjYmViNzY4OTRiZmFfMy0zLTEtMS03MjAy_79b0afc0-94bc-4593-b6e1-136db647601d"
      unitRef="shares">2638000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iecc81b9b2d6b49b0b19a54a285242744_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85Ny9mcmFnOjFkODkyOWM5YTE1MDQ2NDk5Nzk5N2Y2ZmUzM2Y2MWEyL3RhYmxlOmEwMThjNTQxNjI2ZTRlZTViZTBjY2JlYjc2ODk0YmZhL3RhYmxlcmFuZ2U6YTAxOGM1NDE2MjZlNGVlNWJlMGNjYmViNzY4OTRiZmFfNC0xLTEtMS03MjAy_0f9021d7-7708-43ef-aa02-4d64c144bd83"
      unitRef="shares">604000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id672da1b89c34c4e9eff23a1f19e2531_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF85Ny9mcmFnOjFkODkyOWM5YTE1MDQ2NDk5Nzk5N2Y2ZmUzM2Y2MWEyL3RhYmxlOmEwMThjNTQxNjI2ZTRlZTViZTBjY2JlYjc2ODk0YmZhL3RhYmxlcmFuZ2U6YTAxOGM1NDE2MjZlNGVlNWJlMGNjYmViNzY4OTRiZmFfNC0zLTEtMS03MjAy_5a41fe39-26e5-49c9-87b4-a437946f18e7"
      unitRef="shares">340000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90ZXh0cmVnaW9uOmRlNjEyNWI1ZGE2MjQzMDk4OWZlZDc1MTgwNzA2ZDkzXzE1OTU_cea12cf1-ce91-4cb7-96d1-7fd752daa0ba">Fair Value Measurements&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of December&#160;31, 2021 and December&#160;31, 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities - available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash, cash equivalents, accounts payable and accrued expenses approximate fair value at December&#160;31, 2021 and December&#160;31, 2020, due to the short maturity nature of these items.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90ZXh0cmVnaW9uOmRlNjEyNWI1ZGE2MjQzMDk4OWZlZDc1MTgwNzA2ZDkzXzE2MDA_aebce384-b5e6-46f5-8d7b-edb8c5bac5e6">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of December&#160;31, 2021 and December&#160;31, 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities - available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib9772fdb5cd8471f96f384eb173d43ab_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzMtMi0xLTEtNzIwMg_933a21fd-4ac6-498d-9ce6-1aee9bbdd65d"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i63e392b1e77d4c5eac2465ca78a69cbd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzMtNC0xLTEtNzIwMg_928b00b0-a92f-4e1d-8a0e-aac9101f0ce1"
      unitRef="usd">70323000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i4584a12f69824f27abd288e3a1a3d90f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzMtNi0xLTEtNzIwMg_68d667cb-c200-416b-a242-b175b5b6be33"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i26b465f7839c460fad563a663abb5e53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzMtOC0xLTEtNzIwMg_a982c655-d843-46de-a8f5-43fb8fd54146"
      unitRef="usd">70323000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i5830c986cd0e460abfdcf8d771b6070f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzMtMTAtMS0xLTcyMDI_d60691f1-ee0c-4e19-a08f-cbe6393bbe95"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6b6161f803dd4b47b8ed44fadd5ac665_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzMtMTItMS0xLTcyMDI_83f4e301-34ca-4e3b-ad20-9e908a5bb04e"
      unitRef="usd">18061000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i4c5d1caf1a754f32a2b36182140d1778_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzMtMTQtMS0xLTcyMDI_6e901d66-ced3-479a-8b09-668763c72318"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0fda5905c1054d06a90a8cbf51b93a97_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzMtMTYtMS0xLTcyMDI_ff70e175-15e7-46ff-a78e-6ffeefdacd34"
      unitRef="usd">18061000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib9772fdb5cd8471f96f384eb173d43ab_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzQtMi0xLTEtNzIwMg_4685d3c2-47cc-45e8-8cbf-f9cc199d4b08"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i63e392b1e77d4c5eac2465ca78a69cbd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzQtNC0xLTEtNzIwMg_5dfa0cb1-93a2-4453-aec0-8ed9bb7427af"
      unitRef="usd">70323000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4584a12f69824f27abd288e3a1a3d90f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzQtNi0xLTEtNzIwMg_0491a358-6734-47ee-8d75-38a476c4f1ca"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i26b465f7839c460fad563a663abb5e53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzQtOC0xLTEtNzIwMg_e09c55e7-0bf9-445c-80f0-74c9cf052e54"
      unitRef="usd">70323000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5830c986cd0e460abfdcf8d771b6070f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzQtMTAtMS0xLTcyMDI_dca30e38-5f4f-4da4-9b0b-83950227064b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6b6161f803dd4b47b8ed44fadd5ac665_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzQtMTItMS0xLTcyMDI_b7b0b64f-40d3-4ba4-8562-24d74a80a264"
      unitRef="usd">18061000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4c5d1caf1a754f32a2b36182140d1778_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzQtMTQtMS0xLTcyMDI_2fb61183-2089-479c-9bbc-a62ab28e108b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0fda5905c1054d06a90a8cbf51b93a97_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDAvZnJhZzpkZTYxMjViNWRhNjI0MzA5ODlmZWQ3NTE4MDcwNmQ5My90YWJsZTpjNjc2MGVhNWQwMzU0NTNiOTI0NzI3OGRkMjQxYjJiOC90YWJsZXJhbmdlOmM2NzYwZWE1ZDAzNTQ1M2I5MjQ3Mjc4ZGQyNDFiMmI4XzQtMTYtMS0xLTcyMDI_4ca19da6-0071-4766-9654-c681fa9e2983"
      unitRef="usd">18061000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDMvZnJhZzo0M2ZhODNlYjk1NmY0YTVkYTQ3ZTU4NDMxYjU3MGZiNC90ZXh0cmVnaW9uOjQzZmE4M2ViOTU2ZjRhNWRhNDdlNTg0MzFiNTcwZmI0Xzg4_9f85c440-ad81-47cd-b427-4679a819a08e">Accrued Liabilities &lt;div style="margin-bottom:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities were as follow (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries, employee benefits and related taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDMvZnJhZzo0M2ZhODNlYjk1NmY0YTVkYTQ3ZTU4NDMxYjU3MGZiNC90ZXh0cmVnaW9uOjQzZmE4M2ViOTU2ZjRhNWRhNDdlNTg0MzFiNTcwZmI0XzEwMA_d9cb8a1c-2cf2-4dbb-98ac-fd520fd82586">&lt;div style="margin-bottom:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities were as follow (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries, employee benefits and related taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDMvZnJhZzo0M2ZhODNlYjk1NmY0YTVkYTQ3ZTU4NDMxYjU3MGZiNC90YWJsZTpmNzQ0NjA1NWM5YjE0Y2I4OTRkZTk5MGQ2YzhlYzE2Zi90YWJsZXJhbmdlOmY3NDQ2MDU1YzliMTRjYjg5NGRlOTkwZDZjOGVjMTZmXzItMS0xLTEtNzIwMg_01280cd3-4fd5-4fe2-8a9c-4a3904ced28d"
      unitRef="usd">2034000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDMvZnJhZzo0M2ZhODNlYjk1NmY0YTVkYTQ3ZTU4NDMxYjU3MGZiNC90YWJsZTpmNzQ0NjA1NWM5YjE0Y2I4OTRkZTk5MGQ2YzhlYzE2Zi90YWJsZXJhbmdlOmY3NDQ2MDU1YzliMTRjYjg5NGRlOTkwZDZjOGVjMTZmXzItMy0xLTEtNzIwMg_b6fd3c9a-ac70-4f59-8782-46fbdbcf8856"
      unitRef="usd">1716000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDMvZnJhZzo0M2ZhODNlYjk1NmY0YTVkYTQ3ZTU4NDMxYjU3MGZiNC90YWJsZTpmNzQ0NjA1NWM5YjE0Y2I4OTRkZTk5MGQ2YzhlYzE2Zi90YWJsZXJhbmdlOmY3NDQ2MDU1YzliMTRjYjg5NGRlOTkwZDZjOGVjMTZmXzMtMS0xLTEtNzIwMg_097e2522-e62f-454f-8377-b11c2327ca84"
      unitRef="usd">229000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDMvZnJhZzo0M2ZhODNlYjk1NmY0YTVkYTQ3ZTU4NDMxYjU3MGZiNC90YWJsZTpmNzQ0NjA1NWM5YjE0Y2I4OTRkZTk5MGQ2YzhlYzE2Zi90YWJsZXJhbmdlOmY3NDQ2MDU1YzliMTRjYjg5NGRlOTkwZDZjOGVjMTZmXzMtMy0xLTEtNzIwMg_188f6f46-60c3-4fd2-999c-0738df01b023"
      unitRef="usd">370000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDMvZnJhZzo0M2ZhODNlYjk1NmY0YTVkYTQ3ZTU4NDMxYjU3MGZiNC90YWJsZTpmNzQ0NjA1NWM5YjE0Y2I4OTRkZTk5MGQ2YzhlYzE2Zi90YWJsZXJhbmdlOmY3NDQ2MDU1YzliMTRjYjg5NGRlOTkwZDZjOGVjMTZmXzUtMS0xLTEtNzIwMg_018ea700-600e-4d34-a0f8-26fdb9588c5d"
      unitRef="usd">326000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDMvZnJhZzo0M2ZhODNlYjk1NmY0YTVkYTQ3ZTU4NDMxYjU3MGZiNC90YWJsZTpmNzQ0NjA1NWM5YjE0Y2I4OTRkZTk5MGQ2YzhlYzE2Zi90YWJsZXJhbmdlOmY3NDQ2MDU1YzliMTRjYjg5NGRlOTkwZDZjOGVjMTZmXzUtMy0xLTEtNzIwMg_d55ffeb6-1602-4d03-ac90-51f28a5b5999"
      unitRef="usd">400000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDMvZnJhZzo0M2ZhODNlYjk1NmY0YTVkYTQ3ZTU4NDMxYjU3MGZiNC90YWJsZTpmNzQ0NjA1NWM5YjE0Y2I4OTRkZTk5MGQ2YzhlYzE2Zi90YWJsZXJhbmdlOmY3NDQ2MDU1YzliMTRjYjg5NGRlOTkwZDZjOGVjMTZmXzYtMS0xLTEtNzIwMg_98abc898-5426-4ec4-8a65-446346556cac"
      unitRef="usd">2589000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDMvZnJhZzo0M2ZhODNlYjk1NmY0YTVkYTQ3ZTU4NDMxYjU3MGZiNC90YWJsZTpmNzQ0NjA1NWM5YjE0Y2I4OTRkZTk5MGQ2YzhlYzE2Zi90YWJsZXJhbmdlOmY3NDQ2MDU1YzliMTRjYjg5NGRlOTkwZDZjOGVjMTZmXzYtMy0xLTEtNzIwMg_7912595f-5bc7-4ee0-9d16-5a1c763cc38a"
      unitRef="usd">2486000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90ZXh0cmVnaW9uOjc2NzhiNDM5YjNjYjRiMjk4NmExMDE5OTdiNmY4ZDNjXzEzNTI_0b3742c9-d44c-46f2-990f-9d62571bb2a5">Operating Leases&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted ASU No. 2016-02, Leases (Topic 842) on January 1, 2019 and recognized leases with duration greater than 12 months on the balance sheet using the modified retrospective approach. The Company has operating leases for two &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;o&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ffices with terms that expire in 2023 and 2025, respectively. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. Each of the Company's leases includes options for the Company to extend the lease term and/or sub-lease space in whole or in part.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of Use Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzItMC0xLTEtNzIwMg_0a058abe-d734-4c31-a82c-efb4e8bc4aad"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzItMC0xLTEtNzIwMg_d0558917-552f-48e0-95eb-612098e4b721"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Right-of-Use Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating Lease Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzYtMC0xLTEtNzIwMg_3827fe5c-6ee8-4d37-a233-c3c99088f192"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzYtMC0xLTEtNzIwMg_bfd3c824-688d-44a3-a795-98776d67c466"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzctMC0xLTEtNzIwMg_430fdfa5-3899-44a5-b33b-301b103d665c"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzctMC0xLTEtNzIwMg_95df09b8-b8ab-49d7-988b-87cfc081e730"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Operating Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the weighted average remaining lease term for our operating leases was 2.50 years, and the weighted average discount rate for our operating leases was 9.625%. Future minimum lease payments under the lease agreements as of December&#160;31, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <clbs:NumberOfOfficesUnderOperatingLeases
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90ZXh0cmVnaW9uOjc2NzhiNDM5YjNjYjRiMjk4NmExMDE5OTdiNmY4ZDNjXzEzMTk0MTM5NTM0NzE4_03ebe2ec-3da4-4b24-b412-e424ec87823e"
      unitRef="office">2</clbs:NumberOfOfficesUnderOperatingLeases>
    <clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90ZXh0cmVnaW9uOjc2NzhiNDM5YjNjYjRiMjk4NmExMDE5OTdiNmY4ZDNjXzEzNTM_2b2515c7-c597-44c7-9992-ef60afd40c88">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of Use Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzItMC0xLTEtNzIwMg_0a058abe-d734-4c31-a82c-efb4e8bc4aad"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzItMC0xLTEtNzIwMg_d0558917-552f-48e0-95eb-612098e4b721"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Right-of-Use Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating Lease Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzYtMC0xLTEtNzIwMg_3827fe5c-6ee8-4d37-a233-c3c99088f192"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzYtMC0xLTEtNzIwMg_bfd3c824-688d-44a3-a795-98776d67c466"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzctMC0xLTEtNzIwMg_430fdfa5-3899-44a5-b33b-301b103d665c"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzctMC0xLTEtNzIwMg_95df09b8-b8ab-49d7-988b-87cfc081e730"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Operating Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzItMS0xLTEtNzIwMg_67e6fba0-c331-4a84-83df-9a7082db7589"
      unitRef="usd">724000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzItMi0xLTEtNzIwMg_7440058f-fc57-4ef4-85c4-d14e4992562e"
      unitRef="usd">574000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzMtMS0xLTEtNzIwMg_ea07574d-11d8-4cd0-9497-9cfbc27defe6"
      unitRef="usd">724000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzMtMi0xLTEtNzIwMg_8b914bec-45ca-4667-883a-a1eb01929a65"
      unitRef="usd">574000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzYtMS0xLTEtNzIwMg_12504b25-d517-47fc-b32c-e886be790001"
      unitRef="usd">229000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzYtMi0xLTEtNzIwMg_6cffd52c-ed0a-4a32-a81b-d1732201b8e2"
      unitRef="usd">370000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzctMS0xLTEtNzIwMg_888bded4-0151-4e95-897e-2fd53eb5741c"
      unitRef="usd">485000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzctMi0xLTEtNzIwMg_26acc78b-ca91-4c07-940d-7c59bdea48c2"
      unitRef="usd">254000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzgtMS0xLTEtNzIwMg_6614b690-0296-4cda-bf1f-6389ac740f54"
      unitRef="usd">714000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpjOGMxYzY3ZTk4ZDc0MjAyYjcxYTk4YWVjNTg3NjlhZS90YWJsZXJhbmdlOmM4YzFjNjdlOThkNzQyMDJiNzFhOThhZWM1ODc2OWFlXzgtMi0xLTEtNzIwMg_20722765-b52e-4a92-81ce-01f7c0b9fc36"
      unitRef="usd">624000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90ZXh0cmVnaW9uOjc2NzhiNDM5YjNjYjRiMjk4NmExMDE5OTdiNmY4ZDNjXzExNzY_46d3749e-cb26-4bf3-9ca8-812da47f9a47">P2Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90ZXh0cmVnaW9uOjc2NzhiNDM5YjNjYjRiMjk4NmExMDE5OTdiNmY4ZDNjXzEyNDg_12508e1c-b4eb-4812-815c-cbd9823bb75d"
      unitRef="number">0.09625</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90ZXh0cmVnaW9uOjc2NzhiNDM5YjNjYjRiMjk4NmExMDE5OTdiNmY4ZDNjXzEzNjQ_36d9773f-5fb5-4a32-806d-c4a4aad4a59a">Future minimum lease payments under the lease agreements as of December&#160;31, 2021 were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpmOTdlM2E2YmIyNDk0OTI3ODkyOGY4YmFjOGFkMDg5ZC90YWJsZXJhbmdlOmY5N2UzYTZiYjI0OTQ5Mjc4OTI4ZjhiYWM4YWQwODlkXzEtMS0xLTEtNzIwMg_0df7ed8d-4f9b-4971-8e4c-97efc7733bbd"
      unitRef="usd">286000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpmOTdlM2E2YmIyNDk0OTI3ODkyOGY4YmFjOGFkMDg5ZC90YWJsZXJhbmdlOmY5N2UzYTZiYjI0OTQ5Mjc4OTI4ZjhiYWM4YWQwODlkXzItMS0xLTEtNzIwMg_5d85e546-ab91-478b-be42-92a577d29725"
      unitRef="usd">217000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpmOTdlM2E2YmIyNDk0OTI3ODkyOGY4YmFjOGFkMDg5ZC90YWJsZXJhbmdlOmY5N2UzYTZiYjI0OTQ5Mjc4OTI4ZjhiYWM4YWQwODlkXzMtMS0xLTEtNzIwMg_258819e6-48b2-409c-a83c-93f17bd5bf82"
      unitRef="usd">190000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpmOTdlM2E2YmIyNDk0OTI3ODkyOGY4YmFjOGFkMDg5ZC90YWJsZXJhbmdlOmY5N2UzYTZiYjI0OTQ5Mjc4OTI4ZjhiYWM4YWQwODlkXzQtMS0xLTEtOTQ3NQ_a5f166ab-3e66-4cb6-b8fe-07c3b72df433"
      unitRef="usd">143000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpmOTdlM2E2YmIyNDk0OTI3ODkyOGY4YmFjOGFkMDg5ZC90YWJsZXJhbmdlOmY5N2UzYTZiYjI0OTQ5Mjc4OTI4ZjhiYWM4YWQwODlkXzQtMS0xLTEtNzIwMg_e6c68fae-7f4f-4ae2-ba82-c58a9612746a"
      unitRef="usd">836000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpmOTdlM2E2YmIyNDk0OTI3ODkyOGY4YmFjOGFkMDg5ZC90YWJsZXJhbmdlOmY5N2UzYTZiYjI0OTQ5Mjc4OTI4ZjhiYWM4YWQwODlkXzUtMS0xLTEtNzIwMg_0c069fff-175d-42b2-8502-44049a4833fd"
      unitRef="usd">122000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDYvZnJhZzo3Njc4YjQzOWIzY2I0YjI5ODZhMTAxOTk3YjZmOGQzYy90YWJsZTpmOTdlM2E2YmIyNDk0OTI3ODkyOGY4YmFjOGFkMDg5ZC90YWJsZXJhbmdlOmY5N2UzYTZiYjI0OTQ5Mjc4OTI4ZjhiYWM4YWQwODlkXzYtMS0xLTEtNzIwMg_da76d0d0-549f-45a2-b04a-4437f4d52721"
      unitRef="usd">714000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEzMTkw_2aba03d8-c95f-4670-8d06-732a61120cbc">Stockholders' Equity&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has used long-term incentive plans for the purpose of granting equity awards to employees of the Company, including officers, and nonemployees, including consultants and nonemployee members of the Company's board of directors &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(collectively, the &#x201c;Participants&#x201d;). The Participants may receive awards as determined by a committee of independent members of the Company's board of directors or, to the extent authorized by such committee with respect to certain Participants, a duly authorized employee (collectively, the &#x201c;Committee&#x201d;). The incentive plan currently used by the Company is the 2018 Equity Incentive Compensation Plan (the &#x201c;2018 Plan&#x201d;), as adopted by the stockholders of the Company in June 2018, and subsequently increased by the stockholders of the Company in June 2021 with 6,000,000 shares authorized for issuance thereunder and in June of 2020 with&#160;2,500,000&#160;shares authorized for issuance thereunder, plus any shares awarded under the 2015 Equity Compensation Plan (the &#x201c;2015 Plan&#x201d;) or the Amended and Restated 2009 Equity Compensation Plan (the &#x201c;2009 Plan&#x201d;) that are not issued due to their subsequent forfeiture, cancellation, or other settlement thereof. Concurrent with the adoption of the 2018 Plan, no future awards will occur under the 2015 Plan or the 2009 Plan. The awards that may be made under the 2018 Plan include: (a) incentive stock options and nonqualified stock options, (b) shares of restricted stock, (c) restricted stock units, and (d) other kinds of equity-based compensation awards. All stock options under the 2015 Plan and 2009 Plan were granted and the 2018 Plan are granted at the fair market value of the common stock at the grant date. Stock options vest either on the date of grant, ratably over a period determined at time of grant, or upon the accomplishment of specified business milestones, and generally expire 2, 3, or 10 years from the grant date depending on the status of the recipient as a nonemployee, employee or director of the Company. As of December&#160;31, 2021, there were&#160;5,585,661&#160;shares available for future grants under the 2018 Plan.&#160;No&#160;additional awards may be made under the 2015 Plan or the 2009 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted an employee stock purchase plan effective January 1, 2013 and authorized 50,000 shares under the plan (the &#x201c;2012 ESPP&#x201d;). The plan has two six-month offering periods per year under which eligible employees may contribute up to 15% of their compensation toward the purchase of the Company's common stock per offering period (with a $25,000 cap per calendar year). The employee's purchase price is equal to (i) 85% of the closing price of a share of the Company's common stock on the enrollment date of such offering period or (ii) 85% of the closing price of a share of the Company's common stock on the Exercise Date of such Offering Period, whichever is lower. In May 2017, the Company's stockholders approved an amendment and restatement to the 2012 ESPP (the &#x201c;2017 ESPP&#x201d;) in order to effect an increase of authorized shares from 50,000 to 100,000. In June 2018, the Company's stockholders approved an amendment to the 2017 ESPP  (the &#x201c;Amended 2017 ESPP&#x201d;) in order to effect an increase of authorized shares from 100,000 to 500,000. During the year ended December&#160;31, 2021, 47,132 shares were issued under the Amended 2017 ESPP. At December&#160;31, 2021, the Company had 300,577 shares of the Company's common stock available for future grant in connection with this plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Issuances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Purchase Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March&#160;2019, the Company and Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;) entered into a purchase agreement (the &#x201c;Purchase Agreement&#x201d;) and a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&#x2019;s common stock having an aggregate value of up to $26.0 million, subject to certain limitations and conditions set forth in the Purchase Agreement (the &#x201c;Offering&#x201d;). As consideration for entering into the Purchase Agreement, the Company issued to Lincoln Park an additional 181,510 shares of common stock as commitment shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Purchase Agreement, upon commencement Lincoln Park purchased 250,000 shares of common stock, at a price of $4.00 per share for a total gross purchase price of $1,000,000 (the &#x201c;Initial Purchase&#x201d;) upon commencement. Thereafter, as often as every business day from and after one business day following the date of the Initial Purchase and over the 36-month term of the Purchase Agreement, the Company has the right, from time to time, at its sole discretion and subject to certain conditions, to direct Lincoln Park to purchase up to 100,000 shares of common stock, with such amount increasing as the closing sale price of the common stock increases; provided Lincoln Park&#x2019;s obligation under any single such purchase will not exceed $2,500,000, unless the Company and Lincoln Park mutually agree to increase the maximum amount of such single purchase (each, a &#x201c;Regular Purchase&#x201d;).&#160;If the Company directs Lincoln Park to purchase the maximum number of shares of common stock it then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, the Company may direct Lincoln Park in an &#x201c;accelerated purchase&#x201d; to purchase an additional amount of common stock that may not exceed the lesser of (i)&#160;300% the number of shares purchased pursuant to the corresponding Regular Purchase or (ii)&#160;30% of the total number of shares of the Company&#x2019;s common stock traded during a specified period on the applicable purchase date as set forth in the Purchase Agreement (each, an "Accelerated Purchase"). Under certain circumstances and in accordance with the Purchase Agreement, the Company may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company controls the timing and amount of any sales of its common stock to Lincoln Park.&#160;There is no upper limit on the price per share that Lincoln Park must pay for its common stock under the Purchase Agreement, but in no event will shares be sold to Lincoln Park on a day the closing price is less than the floor price specified in the Purchase Agreement. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the purchase agreement if it would result in Lincoln Park beneficially owning more than 9.99% of its common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Purchase Agreement does not limit the Company&#x2019;s ability to raise capital from other sources at the Company&#x2019;s sole discretion, except that (subject to certain exceptions) the Company may not enter into any Variable Rate Transaction (as defined in the Purchase Agreement, including the issuance of any floating conversion rate or variable priced equity-like securities) during the 36 months after the date of the Purchase Agreement. The Company has the right to terminate the Purchase Agreement at any time, at no cost to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had not made any sales of common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase. In addition, the Company may not direct Lincoln Park to make Accelerated Purchases under the Purchase Agreement if the stock is below the specified floor price of $1.00.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Common Stock Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, the Company entered into a common stock sales agreement with H.C. Wainwright &amp;amp; Co., LLC (&#x201c;HCW&#x201d;) as sales agent, which was subsequently amended in August 2018 (the &#x201c;Sales Agreement&#x201d;), in connection with an &#x201c;at the market offering&#x201d; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of not more than $25.0 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provided HCW with customary indemnification rights, and HCW was entitled to a commission at a fixed commission rate equal to 3.0% of the gross proceeds per share sold. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 12, 2021, the Company suspended the use of the at-the-market transactions facility and terminated the continuous offering pursuant to the Sales Agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of the termination of the Sales Agreement on February 12, 2021, the Company had sold an aggregate 3,784,912 shares of its common stock pursuant to the Sales Agreement for net proceeds of $9.5 million since inception. For the year ended December&#160;31, 2021, the Company had not issued any shares under the Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;At The Market Offering Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;ATM Agreement&#x201d;) with HCW, as sales agent, in connection with an &#x201c;at the market offering&#x201d; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0&#160;million. During the twelve months ended December&#160;31, 2021, the Company had not issued any shares under the ATM Agreement. Having received a listing deficiency notice from Nasdaq on February 18, 2022 after the Company&#x2019;s shares traded below $1.00 for 30 consecutive trading days, the Company will not be permitted to sell additional shares under the ATM Agreement until it re-establishes timely compliance. Compliance may be reestablished by various mechanisms, including stock price appreciation at or above $1.00 for a requisite period of time and reverse stock split.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Registered Direct Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the Company entered into a Securities Purchase Agreement (the &#x201c;Institutional Purchase Agreement&#x201d;) with certain institutional investors (the &#x201c;Institutional Purchasers&#x201d;). Pursuant to the terms of the Institutional Purchase Agreement, the Company sold to the Institutional Purchasers in a registered direct offering an aggregate of 24,906,134 shares of its common stock and warrants to purchase an aggregate of 12,453,067 shares of its common stock at a combined purchase price equal to $2.45 per share and associated warrant. Each warrant features an exercise price equal to $2.90 per share, is exercisable immediately upon issuance and will expire five years from the issuance date. Additionally, in a concurrent non-brokered registered direct offering, the Company entered into a Securities Purchase Agreement (the &#x201c;Additional Purchase Agreement&#x201d;) with certain accredited investors (the &#x201c;Additional Purchasers&#x201d;). Pursuant to the terms of the Additional Purchase Agreement, the Company sold to the Additional Purchasers an aggregate of 1,632,652 shares of its common stock and warrants to purchase an aggregate of 816,326 shares of its common stock at a combined purchase price equal to $2.45 per share and associated warrant. Each warrant features an exercise price equal to $2.90 per share, is exercisable immediately upon issuance and will expire five years from the issuance date. In connection with the registered direct offerings, the Company received gross proceeds of approximately $65.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Private Placement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company entered into a securities purchase agreement (the &#x201c;January Private Placement&#x201d;) with certain investors (the &#x201c;January Purchasers&#x201d;). Pursuant to the terms of the January Private Placement, the Company agreed to sell to the January Purchasers an aggregate of 12,500,000 shares of its common stock at a purchase price equal to $2.00 per share, along with warrants to purchase an aggregate of 6,250,000 shares of its common stock. In connection with the January Private Placement, the Company received gross proceeds of $25.0 million. Each warrant is exercisable for one share of common stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and features an exercise price equal to $2.90 per share. The warrants are exercisable immediately upon issuance and will expire five and one-half years from the issuance date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrant Exercises&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company issued 801,148 shares of common stock for net proceeds of $1.8 million in connection with warrant exercises associated with the April 23, 2020 securities purchase agreement and the May 25, 2020 securities purchase agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options and Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity for stock options and warrants for the year ended December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;963,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,638,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the Year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,314,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,519,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(801,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29,842)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,131,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,356,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at December 31, 2021 or expected to vest in the future&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,120,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,356,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,122,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,356,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021 and 2020, the Company issued restricted stock for services as follows ($ in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of Restricted Stock Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Value of Restricted Stock Issued &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average estimated fair value of restricted stock issued for services in the years ended December&#160;31, 2021 and 2020 was $1.43 and $3.28 per share, respectively. The fair value of the restricted stock was determined using the Company&#x2019;s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEyNTk4_1483d86e-ff2f-4b87-a4f3-f6e1bf4d50d7"&gt;one&lt;/span&gt; to four years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021 and 2020, the Company issued restricted stock units for services as follows ($ in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of Restricted Stock Units Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Value of Restricted Stock Units Issued &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average estimated fair value of restricted stock units issued for services in the years ended December&#160;31, 2021 and 2020 was $1.59 and $2.65 per share, respectively. The fair value of the restricted stock units was determined using the &lt;/span&gt;&lt;/div&gt;Company&#x2019;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ia3d14c5a5f224864ad0dabc919f68696_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzExNTQ0ODcyMTIyNDc5_82c8b080-8a01-4e56-8a86-ac5a49d3b685"
      unitRef="shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ic520fa50fa274ec688df80ce26839e93_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzg1Mw_cb905265-4cef-486f-94bd-0c603e7d8524"
      unitRef="shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ib349cdd63be447d58d8816ef0e5c45d5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzE4NDM_bf3f8212-5857-4cf5-b49e-3b0293972592">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i6839ac3846014921bbf0418907b17b41_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzE4NDc_7f945314-5677-480e-a45e-2d71d84614f2">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i5c3abe0816124623859688fce308ef7d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzE4NTQ_58eb4cf1-7da6-42c5-8fa2-cab4eed49b80">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i4ea30e24d2234509b67b4bb09c8f3d27_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzIwMDA_73ee18ba-915e-472a-9d62-7da83bf5c1d3"
      unitRef="shares">5585661</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i125c01a6899241f092b94c8c6d510bcb_I20130101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzIyMjM_8207457e-ec9a-453e-ba1c-886c6773ef92"
      unitRef="shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <clbs:NumberofOfferingPeriodsEmployeeStockPurchasePlan
      contextRef="id2c17509e40c431c93f98142b8bee4f8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzIyODA_125a1e10-30e1-44e8-aae8-51a0b59af823"
      unitRef="offering_period">2</clbs:NumberofOfferingPeriodsEmployeeStockPurchasePlan>
    <clbs:OfferingPeriodsEmployeeStockPurchasePlanTerm
      contextRef="i28542dcef1334e33863c7a40beba93ac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEzMTky_93a11fc7-235b-4dfa-bf6b-1caa2890a015">P6M</clbs:OfferingPeriodsEmployeeStockPurchasePlanTerm>
    <clbs:EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent
      contextRef="i28542dcef1334e33863c7a40beba93ac_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzIzNzA_2cbcbcc3-01d2-42e6-b2d1-0540d38b88a6"
      unitRef="number">0.15</clbs:EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent>
    <clbs:EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee
      contextRef="i28542dcef1334e33863c7a40beba93ac_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzI0NzM_89a3288c-3122-45a0-acea-ea824d8a188f"
      unitRef="usd">25000</clbs:EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee>
    <clbs:EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate
      contextRef="i28542dcef1334e33863c7a40beba93ac_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzI1NDY_215ec332-2d51-4323-9e90-fb1bf5e3c00d"
      unitRef="number">0.85</clbs:EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate>
    <clbs:EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate
      contextRef="i28542dcef1334e33863c7a40beba93ac_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzI2NjY_39249a8d-1d53-4e0d-8097-ec322bd17571"
      unitRef="number">0.85</clbs:EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i125c01a6899241f092b94c8c6d510bcb_I20130101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzI5Njc_e7bb43dc-d53f-4312-986e-dc131419bb3b"
      unitRef="shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i5adb43718d3c4cdf96885dcfb77648d0_I20170531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzI5NzM_df3035da-e391-497f-bc28-9106dc6fa804"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i5adb43718d3c4cdf96885dcfb77648d0_I20170531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzMxNDE_6a3d5561-43a2-4a37-aa51-e51acf18220d"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ia54075aa02684beb8ab89afa65b0d48d_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzMxNDc_4ccb7d6b-371e-4b2f-86e0-4936b71d4e69"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i27caf2e77bc5468785bb299e95eb6191_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzMxNzc_7c4314da-1f68-4354-b737-00dea991ed2b"
      unitRef="shares">47132</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i81fbec32b886419d9100b66971330fc6_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzMyNTE_d15841e1-b535-4e4a-a03a-1dc4596c5836"
      unitRef="shares">300577</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement
      contextRef="iaffc3258262f48dcbbf5775b82cf558e_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzM3NDA_85ecf67c-b140-443d-87f1-9dd6f952d062"
      unitRef="usd">26000000</clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement>
    <clbs:StockIssuedDuringPeriodSharesIssuedAsConsideration
      contextRef="iec24a6e53385419d9edb327599fc7c12_D20190301-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzM5NTI_688ec698-7550-462e-8db0-2d42afad7551"
      unitRef="shares">181510</clbs:StockIssuedDuringPeriodSharesIssuedAsConsideration>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iec24a6e53385419d9edb327599fc7c12_D20190301-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzQwNTk_1d5cbe89-b0ff-4903-9d30-fa832dde5db5"
      unitRef="shares">250000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="iaffc3258262f48dcbbf5775b82cf558e_I20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzQxMDA_3f75bbd1-fdae-4ba7-981c-7f16b5b12d55"
      unitRef="usdPerShare">4.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iec24a6e53385419d9edb327599fc7c12_D20190301-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzQxNTA_7ff27509-0a85-4ba5-9929-796738f4a207"
      unitRef="usd">1000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <clbs:TermOfAgreement
      contextRef="iec24a6e53385419d9edb327599fc7c12_D20190301-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzQzMjg_67e9b392-b372-49ee-bc29-c6ecf221a648">P36M</clbs:TermOfAgreement>
    <clbs:SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase
      contextRef="iaffc3258262f48dcbbf5775b82cf558e_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzQ1MTM_82aad2e0-b6de-4ac1-9f0a-cfaaef15cfc6"
      unitRef="shares">100000</clbs:SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase>
    <clbs:SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase
      contextRef="iaffc3258262f48dcbbf5775b82cf558e_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzQ3MDc_72825566-cdb3-4d9e-ab7f-52597399803c"
      unitRef="usd">2500000</clbs:SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase>
    <clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase
      contextRef="iaffc3258262f48dcbbf5775b82cf558e_I20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzUyNTI_00967e5a-cd9d-4121-9bb3-714a456e01c4"
      unitRef="number">3</clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase>
    <clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod
      contextRef="iaffc3258262f48dcbbf5775b82cf558e_I20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzUzNDI_23790afb-f07b-4c89-9edb-2724f82bc4c8"
      unitRef="number">0.30</clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod>
    <clbs:RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty
      contextRef="iaffc3258262f48dcbbf5775b82cf558e_I20190331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzYyNDI_5a5e52c4-b15d-4957-9346-228b08b56198"
      unitRef="number">0.0999</clbs:RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty>
    <clbs:TermOfAgreement
      contextRef="iec24a6e53385419d9edb327599fc7c12_D20190301-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzExNTQ0ODcyMTIyNDk5_167e26bc-c393-465c-bf6a-e000860bccd9">P36M</clbs:TermOfAgreement>
    <clbs:PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice
      contextRef="ic5e26195328b4591826e01006d17f63d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzExNTQ0ODcyMTIyNTA2_e37210eb-e498-4550-a025-b790bb67bb33"
      unitRef="usdPerShare">1.00</clbs:PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice>
    <clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement
      contextRef="ib0ab769fd5384e5c8fa1c574d03e7274_I20180831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzczNjA_5b53ccb0-df8b-4556-be14-f5eda6181020"
      unitRef="usd">25000000</clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement>
    <clbs:SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent
      contextRef="i18cb5d7872684b26a43eaec5bc10e4bb_D20180801-20180831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzE2NDkyNjc0NTUwMTM_c45cbe6c-8803-4e02-b6c6-310d2a2d40de"
      unitRef="number">0.030</clbs:SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ibe7b2ea590f64edea9436bb291dddfe3_D20180201-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzkwMTI_ea10e8b6-0e66-4400-89b1-adafe286b068"
      unitRef="shares">3784912</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ibe7b2ea590f64edea9436bb291dddfe3_D20180201-20210212"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzkwODQ_c976dbd6-5aba-4694-a206-182bc0fbe86f"
      unitRef="usd">9500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2959d4ff885948268aa6c8327cf31262_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzE2NDkyNjc0NTgxOTI_eedf1093-0a2b-41b9-96d3-5c5e6ff5d202"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement
      contextRef="ib26b46410f1947caaa269dc8c84bc533_I20210604"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzE2NDkyNjc0NTg4NzA_029b0950-b37d-4632-aea8-90059bd9ad7c"
      unitRef="usd">50000000</clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ieba8f73a7897435fbc5b3392cb6478cf_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzE2NDkyNjc0NTg5MTI_c15f1bcc-a80e-4c22-9fa3-85ddf3a8fdf0"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i1ba1e218994d4ff1b3b3d3cdd3ea83a2_D20210201-20210228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI4NzI_cdf3c1b4-e789-4c96-bff5-7d76064a6dee"
      unitRef="shares">24906134</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i9992345fcbc5433492a910eba1965518_I20210228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI4NzY_ae35b36a-70b9-45aa-bf1d-2101ec3d9181"
      unitRef="shares">12453067</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i9992345fcbc5433492a910eba1965518_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI4ODA_e7c0a4cb-1b28-46c0-8f1d-6bddab46191b"
      unitRef="usdPerShare">2.45</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i9992345fcbc5433492a910eba1965518_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI4ODQ_259ce8c1-e2c5-466e-a908-67c117370bf8"
      unitRef="usdPerShare">2.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i9992345fcbc5433492a910eba1965518_I20210228"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI4ODg_07e3bff7-36ba-45df-90d8-f487b55e725d">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ib537ee905795476eb1a4ed13cf5100b1_D20210201-20210228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI4OTI_d006e41d-39b9-4360-9e15-6ca8d0bc1565"
      unitRef="shares">1632652</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i064784dc58ac445ab8485a53331724c5_I20210228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI4OTY_2a7eaa33-e662-4643-acfd-9971e2e62e92"
      unitRef="shares">816326</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i064784dc58ac445ab8485a53331724c5_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI5MDA_c1fd4c93-bbb1-479f-b51e-381e17085251"
      unitRef="usdPerShare">2.45</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i064784dc58ac445ab8485a53331724c5_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI5MDQ_c4614554-7008-4cdd-928b-1b97f2827e4c"
      unitRef="usdPerShare">2.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i064784dc58ac445ab8485a53331724c5_I20210228"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI5MDg_af8cc0b7-0a27-44b1-962c-2cdcecf3ba00">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i39237a1f42304c68bc922379c5cafbc9_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTI5MTI_f9fbf785-9e09-42bc-afbc-fedc850504f9"
      unitRef="usd">65000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ic237f5a9d962463dab8bf38d6a802419_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTQzOTE_5ea8a029-bc59-4004-a7a8-8d8d82220bc2"
      unitRef="shares">12500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i58d1afa2bd9346fc97c1b81a5e0a4fd1_I20210131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTQzOTU_514623fb-e1ef-4166-907c-b56959ed171d"
      unitRef="usdPerShare">2.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i58d1afa2bd9346fc97c1b81a5e0a4fd1_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTQzOTk_84f5e517-c1db-487c-b420-b34c828c6559"
      unitRef="shares">6250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic237f5a9d962463dab8bf38d6a802419_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTQ0MDM_00917366-6416-401f-9af1-5bd33b8ebdab"
      unitRef="usd">25000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i58d1afa2bd9346fc97c1b81a5e0a4fd1_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzE2NDkyNjc0NjM0MTQ_eea51aad-e0d9-4474-8457-dfd1b025f56e"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i58d1afa2bd9346fc97c1b81a5e0a4fd1_I20210131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTQ0MDk_4850fb8b-cd3a-4c3c-86eb-273a37c399cd"
      unitRef="usdPerShare">2.90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="i82ea1a2d86944a1c93f15ae19da0bc8e_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTU1ODQ_ce13a409-47cc-4c3d-8e03-b326b05eb60f"
      unitRef="shares">801148</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i82ea1a2d86944a1c93f15ae19da0bc8e_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEwOTk1MTE2NTU1ODg_ef5de574-1cf5-4742-b20a-ec27ec9d630e"
      unitRef="usd">1800000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEzMTgx_38fa45d3-824d-45b3-907c-f4e099edbd82">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity for stock options and warrants for the year ended December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.716%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;963,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,638,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.98&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the Year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,314,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,519,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(801,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29,842)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,131,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,356,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at December 31, 2021 or expected to vest in the future&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,120,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.96&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,356,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,122,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.70&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,356,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzItMS0xLTEtNzIwMg_e0efc85e-e4c5-4a91-9e82-87c2d60a3aad"
      unitRef="shares">963700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzItMy0xLTEtNzIwMg_edf03c84-799a-451e-b993-998ea36731d2"
      unitRef="usdPerShare">14.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzItNS0xLTEtNzIwMg_9f6aae10-39b2-47ef-8f7a-b4151d8464f7">P5Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzItNy0xLTEtNzIwMg_4800b5bd-4fb8-42fe-8f86-b20f3b0de18f"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <clbs:CommonStockWarrantsShares
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzItOS0xLTEtNzIwMg_8fb13ff1-9331-4f08-b685-95f8522b6e82"
      unitRef="shares">2638355</clbs:CommonStockWarrantsShares>
    <clbs:WeightedAverageExercisePriceWarrantsOutstanding
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzItMTEtMS0xLTcyMDI_6df2a77f-9409-41ee-8e26-ec8365f51be9"
      unitRef="usdPerShare">2.18</clbs:WeightedAverageExercisePriceWarrantsOutstanding>
    <clbs:WeightedAverageRemainingContractualTermwarrantoutstanding
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzItMTMtMS0xLTcyMDI_d41143c6-36f0-44fa-abbf-f9ee4c367dd3">P4Y11M23D</clbs:WeightedAverageRemainingContractualTermwarrantoutstanding>
    <clbs:AggregateIntrinsicValueWarrantsOutstanding
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzItMTUtMS0xLTcyMDI_c21a3efe-2a22-4cf4-88ed-73d302731aff"
      unitRef="usd">0</clbs:AggregateIntrinsicValueWarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzUtMS0xLTEtNzIwMg_22ff3b5f-37f3-439a-a81b-be65437a83fe"
      unitRef="shares">1314790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzUtMy0xLTEtNzIwMg_cb37a7a2-acde-474c-aacd-566c1acfc19f"
      unitRef="usdPerShare">1.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <clbs:WarrantsGranted
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzUtOS0xLTEtNzIwMg_8991cdd2-2e10-441a-b72c-f071e6bc589d"
      unitRef="shares">19519393</clbs:WarrantsGranted>
    <clbs:WeightedAverageExercisePriceWarrantsGranted
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzUtMTEtMS0xLTcyMDI_b1f7ffef-ae0f-4eaa-a0bf-381d490d1d27"
      unitRef="usdPerShare">2.90</clbs:WeightedAverageExercisePriceWarrantsGranted>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzYtMS0xLTEtNzIwMg_cc251a3d-1331-4d08-9811-583c57308634"
      unitRef="shares">7250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzYtMy0xLTEtNzIwMg_1b49e23c-ddd4-4122-9b38-a64756b0c4e5"
      unitRef="usdPerShare">3.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <clbs:AggregateIntrinsicValueOptionExercised
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzYtNy0xLTEtODcxNQ_d7419e73-1b49-44f3-84bf-a60245056e0d"
      unitRef="usd">3000</clbs:AggregateIntrinsicValueOptionExercised>
    <clbs:WarrantsExercised
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzYtOS0xLTEtNzIwMg_1a482080-e0fb-40d4-aec5-c4764386decc"
      unitRef="shares">801148</clbs:WarrantsExercised>
    <clbs:WeightedAverageExercisePriceWarrantsExercised
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzYtMTEtMS0xLTcyMDI_5d2945c4-62f2-487b-9ce9-48972e23a364"
      unitRef="usdPerShare">2.19</clbs:WeightedAverageExercisePriceWarrantsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzctMS0xLTEtNzIwMg_efeb9dbe-ad0f-45ee-8775-9215f0fabf8f"
      unitRef="shares">29842</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzctMy0xLTEtNzIwMg_992f4862-d2d9-4984-8963-f5ce4575e416"
      unitRef="usdPerShare">2.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <clbs:WarrantsCanceled
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzctOS0xLTEtNzIwMg_895f6527-726c-4bcd-8706-df906e9cfffc"
      unitRef="shares">0</clbs:WarrantsCanceled>
    <clbs:WeightedAverageExercisePriceWarrantsCanceled
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzctMTEtMS0xLTcyMDI_f6bc8693-d475-4d7a-ae51-068658164a73"
      unitRef="usdPerShare">0</clbs:WeightedAverageExercisePriceWarrantsCanceled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzgtMS0xLTEtNzIwMg_063577c7-6d1b-497c-98b0-c146e8d490e2"
      unitRef="shares">109549</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzgtMy0xLTEtNzIwMg_47e4dc5a-abac-4ef0-b486-3fe5688332a4"
      unitRef="usdPerShare">34.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <clbs:WarrantsExpired
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzgtOS0xLTEtNzIwMg_5472e446-a83b-4cb3-8807-f386cb67f33b"
      unitRef="shares">0</clbs:WarrantsExpired>
    <clbs:WeightedAverageExercisePriceWarrantsExpired
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzgtMTEtMS0xLTcyMDI_fe172177-f9ad-4a15-bcc4-3ff88ea53184"
      unitRef="usdPerShare">0</clbs:WeightedAverageExercisePriceWarrantsExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzktMS0xLTEtNzIwMg_0ac24c13-0b36-4e6d-a873-017c470bb83d"
      unitRef="shares">2131849</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzktMy0xLTEtNzIwMg_998bd3e3-7d9e-4cb4-97ac-caa29895963e"
      unitRef="usdPerShare">5.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzktNS0xLTEtNzIwMg_b08a03c5-6dc9-4f69-876c-b1ad67140591">P7Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzktNy0xLTEtNzIwMg_0bd2a6d8-908f-4908-aeb8-d311b9d2bdc7"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <clbs:CommonStockWarrantsShares
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzktOS0xLTEtNzIwMg_2c612eea-3c3b-4e03-9817-c48182b5b476"
      unitRef="shares">21356600</clbs:CommonStockWarrantsShares>
    <clbs:WeightedAverageExercisePriceWarrantsOutstanding
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzktMTEtMS0xLTcyMDI_c75965c3-2647-4c62-9d24-e20342ad2f2c"
      unitRef="usdPerShare">2.84</clbs:WeightedAverageExercisePriceWarrantsOutstanding>
    <clbs:WeightedAverageRemainingContractualTermwarrantoutstanding
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzktMTMtMS0xLTcyMDI_613da3a1-438a-4b6b-9a5f-a90c17bbe741">P4Y4M13D</clbs:WeightedAverageRemainingContractualTermwarrantoutstanding>
    <clbs:AggregateIntrinsicValueWarrantsOutstanding
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzktMTUtMS0xLTcyMDI_8586a7b1-f426-419f-a928-889fdb2de997"
      unitRef="usd">0</clbs:AggregateIntrinsicValueWarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzEwLTEtMS0xLTcyMDI_dd67c59a-ca98-4863-831a-acbed45bffda"
      unitRef="shares">2120643</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzEwLTMtMS0xLTcyMDI_ce503352-9511-4712-aee4-e21c74794438"
      unitRef="usdPerShare">5.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzEwLTUtMS0xLTcyMDI_25741715-9ab6-4d3d-a165-10b495f8e4ac">P7Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzEwLTctMS0xLTcyMDI_25866074-ccdd-490d-8179-0bdb7f652cb1"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <clbs:Sharesvestedandexpectedtovest
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzEwLTktMS0xLTcyMDI_3bedcc28-4435-4bd9-a8c1-754c880f0a9c"
      unitRef="shares">21356600</clbs:Sharesvestedandexpectedtovest>
    <clbs:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzEwLTExLTEtMS03MjAy_86e624a8-a0e8-4d3e-9575-1477d413ef98"
      unitRef="usdPerShare">2.84</clbs:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest>
    <clbs:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzEwLTEzLTEtMS03MjAy_61e3e56b-4fb2-4f3c-a15b-8b0128095d77">P4Y4M13D</clbs:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest>
    <clbs:AggregateIntrinsicValueWarrantsvestedandexpectedtovest
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzEwLTE1LTEtMS03MjAy_29ca8cb6-c4a4-419c-88c8-b01cff9a8c11"
      unitRef="usd">0</clbs:AggregateIntrinsicValueWarrantsvestedandexpectedtovest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzExLTEtMS0xLTcyMDI_0dd2d2ae-6e3e-4c1d-a263-fc010bd1e322"
      unitRef="shares">1122783</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzExLTMtMS0xLTcyMDI_7b73cd2f-c715-48b9-b591-c8df3d38da7f"
      unitRef="usdPerShare">9.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzExLTUtMS0xLTcyMDI_c856564e-618a-4c0f-8d22-c5f1a55685a8">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzExLTctMS0xLTcyMDI_bab381b0-6c7f-4f25-8614-e123f15ff3ae"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <clbs:WarrantsVested
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzExLTktMS0xLTcyMDI_768cf14e-60ad-4fc4-b8be-313f73235d33"
      unitRef="shares">21356600</clbs:WarrantsVested>
    <clbs:WeightedAverageExercisePriceWarrantsExercisable
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzExLTExLTEtMS03MjAy_a1ef60d8-ea71-4a94-9c68-37067953b60f"
      unitRef="usdPerShare">2.84</clbs:WeightedAverageExercisePriceWarrantsExercisable>
    <clbs:WeightedAverageRemainingContractualTermwarrantsvested
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzExLTEzLTEtMS03MjAy_a6eafec9-8f0f-4592-836b-f99e1a5b0bae">P4Y4M13D</clbs:WeightedAverageRemainingContractualTermwarrantsvested>
    <clbs:AggregateIntrinsicValueWarrantsvested
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTo3M2RmYjA3MGQxODg0MGU4ODcxZjg3OGRlOTkxNWViMy90YWJsZXJhbmdlOjczZGZiMDcwZDE4ODQwZTg4NzFmODc4ZGU5OTE1ZWIzXzExLTE1LTEtMS03MjAy_d87af769-964e-4238-8ad8-35fe8f5a93e3"
      unitRef="usd">0</clbs:AggregateIntrinsicValueWarrantsvested>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEzMTgz_bf559167-9e78-4adc-8996-9adabde0d729">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021 and 2020, the Company issued restricted stock for services as follows ($ in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of Restricted Stock Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Value of Restricted Stock Issued &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ib6d2e0cb9f694fe7a859d47739e7393e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTpjOTQ5ODlmN2MwNTk0ZGQ0OGEyZjRjMmIzMTcxYzg3OS90YWJsZXJhbmdlOmM5NDk4OWY3YzA1OTRkZDQ4YTJmNGMyYjMxNzFjODc5XzItMS0xLTEtNzIwMg_f73618ee-0faf-4c65-828e-7783f3cbc535"
      unitRef="shares">612950</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i806c337fb61d4e69a7df6495c7be9795_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTpjOTQ5ODlmN2MwNTk0ZGQ0OGEyZjRjMmIzMTcxYzg3OS90YWJsZXJhbmdlOmM5NDk4OWY3YzA1OTRkZDQ4YTJmNGMyYjMxNzFjODc5XzItMy0xLTEtNzIwMg_d1f72a05-1e70-4296-bbc9-54ae187bd515"
      unitRef="shares">156184</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ib6d2e0cb9f694fe7a859d47739e7393e_D20210101-20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTpjOTQ5ODlmN2MwNTk0ZGQ0OGEyZjRjMmIzMTcxYzg3OS90YWJsZXJhbmdlOmM5NDk4OWY3YzA1OTRkZDQ4YTJmNGMyYjMxNzFjODc5XzMtMS0xLTEtNzIwMg_b7b861b7-c97a-49fc-8c07-313d3b2ab36d"
      unitRef="usd">877700</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i806c337fb61d4e69a7df6495c7be9795_D20200101-20201231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTpjOTQ5ODlmN2MwNTk0ZGQ0OGEyZjRjMmIzMTcxYzg3OS90YWJsZXJhbmdlOmM5NDk4OWY3YzA1OTRkZDQ4YTJmNGMyYjMxNzFjODc5XzMtMy0xLTEtNzIwMg_c7670a38-665e-49df-b3e1-8e010f20ccb1"
      unitRef="usd">512300</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib6d2e0cb9f694fe7a859d47739e7393e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzMyOTg1MzQ5MTIyMTU_4736de4c-747c-4ddc-bb04-6523131c1c50"
      unitRef="usdPerShare">1.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i806c337fb61d4e69a7df6495c7be9795_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzMyOTg1MzQ5MTIyMTA_93e6ac87-e810-4064-a7b8-a74f392d32b5"
      unitRef="usdPerShare">3.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i079cc5701e904396b3b89403166d381c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEyNjA0_b5c38a3e-c0ac-4d9c-b43c-77448f89e169">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEzMTc2_6da9cf63-35c3-4f13-a0c6-64cbb9a8587a">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021 and 2020, the Company issued restricted stock units for services as follows ($ in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of Restricted Stock Units Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Value of Restricted Stock Units Issued &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i60f3653ff42d4f0eaacf9c26102cfd38_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTpiZmRmODk2NGYwYjM0ZDViYjc4OTU3YTIwZjBmN2Y0NS90YWJsZXJhbmdlOmJmZGY4OTY0ZjBiMzRkNWJiNzg5NTdhMjBmMGY3ZjQ1XzItMS0xLTEtNzIwMg_a74a8be9-f9cc-4e9a-b7ce-a33e2b077d86"
      unitRef="shares">458245</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i6bbaca2f02cc464a87710b12e3b26046_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTpiZmRmODk2NGYwYjM0ZDViYjc4OTU3YTIwZjBmN2Y0NS90YWJsZXJhbmdlOmJmZGY4OTY0ZjBiMzRkNWJiNzg5NTdhMjBmMGY3ZjQ1XzItMy0xLTEtNzIwMg_a35fe29e-c059-4033-a1f7-812ba82df58f"
      unitRef="shares">325853</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i60f3653ff42d4f0eaacf9c26102cfd38_D20210101-20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTpiZmRmODk2NGYwYjM0ZDViYjc4OTU3YTIwZjBmN2Y0NS90YWJsZXJhbmdlOmJmZGY4OTY0ZjBiMzRkNWJiNzg5NTdhMjBmMGY3ZjQ1XzMtMS0xLTEtNzIwMg_62dde020-0189-4a8d-949e-4f39de031fed"
      unitRef="usd">728600</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i6bbaca2f02cc464a87710b12e3b26046_D20200101-20201231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90YWJsZTpiZmRmODk2NGYwYjM0ZDViYjc4OTU3YTIwZjBmN2Y0NS90YWJsZXJhbmdlOmJmZGY4OTY0ZjBiMzRkNWJiNzg5NTdhMjBmMGY3ZjQ1XzMtMy0xLTEtNzIwMg_45cf5a9e-c51e-4514-92e0-009959acc038"
      unitRef="usd">863000.0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i60f3653ff42d4f0eaacf9c26102cfd38_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEyODc1_c6dab52a-d428-4d5b-82b4-0dc1136149a3"
      unitRef="usdPerShare">1.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6bbaca2f02cc464a87710b12e3b26046_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEyODgy_062154fa-546b-4508-94db-7055e2237528"
      unitRef="usdPerShare">2.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i60f3653ff42d4f0eaacf9c26102cfd38_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMDkvZnJhZzo1N2YwYWJjMWMyZjM0OGRiYjUyOWFmYjk2ZjVhYmJiYi90ZXh0cmVnaW9uOjU3ZjBhYmMxYzJmMzQ4ZGJiNTI5YWZiOTZmNWFiYmJiXzEzMTAy_ab5704c6-aff4-42d5-bc6b-d77c43d18e51">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90ZXh0cmVnaW9uOjFkYjNlYzgyYWNhNTRlYjg5ZWZjZjhjMjEyYWFkYTFhXzExMjg_1dfd5731-76f0-40a4-97e7-d65d8cce61da">Share-Based Compensation&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes share-based compensation in the form of stock options, restricted stock, and restricted stock units. The following table summarizes the components of share-based compensation expense for the years ended December&#160;31, 2021 and 2020 ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at December&#160;31, 2021 were as follows ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized compensation cost &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected weighted-average period in years of compensation cost to be recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.70&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total fair value of shares vested and the weighted average estimated fair values of shares granted for the years ended December&#160;31, 2021 and 2020 were as follows ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average estimated fair value of shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation Assumptions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#x2019;s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The range of assumptions made in calculating the fair values of stock options was as follow:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term - minimum (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term - maximum (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility - minimum&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility - maximum&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate - minimum&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate - maximum&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.71%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90ZXh0cmVnaW9uOjFkYjNlYzgyYWNhNTRlYjg5ZWZjZjhjMjEyYWFkYTFhXzExMzg_99f6d5b9-b8c6-4549-8804-797232e611ec">The following table summarizes the components of share-based compensation expense for the years ended December&#160;31, 2021 and 2020 ($ in thousands):&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at December&#160;31, 2021 were as follows ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized compensation cost &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected weighted-average period in years of compensation cost to be recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.70&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie912ebfc1b8b4a6aa5f2e375f861d2c2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkY2E3YTQ4NDE4ZmI0N2Y3OWRmNTllZTAzZmI1MjIwMi90YWJsZXJhbmdlOmRjYTdhNDg0MThmYjQ3Zjc5ZGY1OWVlMDNmYjUyMjAyXzItMS0xLTEtNzIwMg_21551374-2e83-4472-97c2-82e1cd457194"
      unitRef="usd">760000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0ca74538c1c54566b186f58a6caf61e1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkY2E3YTQ4NDE4ZmI0N2Y3OWRmNTllZTAzZmI1MjIwMi90YWJsZXJhbmdlOmRjYTdhNDg0MThmYjQ3Zjc5ZGY1OWVlMDNmYjUyMjAyXzItMy0xLTEtNzIwMg_8a3bbf3a-1ccb-4677-91aa-414df30572cb"
      unitRef="usd">179000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic1373d5ad1834c4abef25fae33e3348e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkY2E3YTQ4NDE4ZmI0N2Y3OWRmNTllZTAzZmI1MjIwMi90YWJsZXJhbmdlOmRjYTdhNDg0MThmYjQ3Zjc5ZGY1OWVlMDNmYjUyMjAyXzMtMS0xLTEtNzIwMg_5a0773db-7e27-4aa7-a614-c30973d1c9cc"
      unitRef="usd">1245000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ife71a6468a004189ad68cb01a4d67fcf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkY2E3YTQ4NDE4ZmI0N2Y3OWRmNTllZTAzZmI1MjIwMi90YWJsZXJhbmdlOmRjYTdhNDg0MThmYjQ3Zjc5ZGY1OWVlMDNmYjUyMjAyXzMtMy0xLTEtNzIwMg_82f0dd99-a231-4637-a59d-c4244e4b84c2"
      unitRef="usd">1086000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkY2E3YTQ4NDE4ZmI0N2Y3OWRmNTllZTAzZmI1MjIwMi90YWJsZXJhbmdlOmRjYTdhNDg0MThmYjQ3Zjc5ZGY1OWVlMDNmYjUyMjAyXzUtMS0xLTEtNzIwMg_67c4ecbe-e33a-4346-94f2-cb4d7dac47e7"
      unitRef="usd">2005000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkY2E3YTQ4NDE4ZmI0N2Y3OWRmNTllZTAzZmI1MjIwMi90YWJsZXJhbmdlOmRjYTdhNDg0MThmYjQ3Zjc5ZGY1OWVlMDNmYjUyMjAyXzUtMy0xLTEtNzIwMg_a42f4fc1-0562-4a55-9019-9bda9848e303"
      unitRef="usd">1265000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="iab051a0f20f54b90a2c3a2ae838bb8ca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTo5ZTczYmIwMDRmYTA0ZjhmODZjYWUwN2FkZDY5YjhmYi90YWJsZXJhbmdlOjllNzNiYjAwNGZhMDRmOGY4NmNhZTA3YWRkNjliOGZiXzEtMS0xLTEtNzIwMg_8f237aaf-45aa-4d46-8325-9447378a846b"
      unitRef="usd">757000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ieba28787ca6743bebdb732d522992e81_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTo5ZTczYmIwMDRmYTA0ZjhmODZjYWUwN2FkZDY5YjhmYi90YWJsZXJhbmdlOjllNzNiYjAwNGZhMDRmOGY4NmNhZTA3YWRkNjliOGZiXzEtMy0xLTEtNzIwMg_6fa5e7b7-9f76-4bdd-9625-788e4e3d6a98"
      unitRef="usd">149000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i8097329850104783b37c8ae588e3f1f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTo5ZTczYmIwMDRmYTA0ZjhmODZjYWUwN2FkZDY5YjhmYi90YWJsZXJhbmdlOjllNzNiYjAwNGZhMDRmOGY4NmNhZTA3YWRkNjliOGZiXzEtNy0xLTEtNzIwMg_229f723f-c285-4849-9677-1bcc4d87f579"
      unitRef="usd">546000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1262c5aee83e44218db30c90579c58ff_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTo5ZTczYmIwMDRmYTA0ZjhmODZjYWUwN2FkZDY5YjhmYi90YWJsZXJhbmdlOjllNzNiYjAwNGZhMDRmOGY4NmNhZTA3YWRkNjliOGZiXzItMS0xLTEtNzIwMg_55745c11-dc43-4bbe-8069-c3cb89618666">P1Y7M20D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i60f3653ff42d4f0eaacf9c26102cfd38_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTo5ZTczYmIwMDRmYTA0ZjhmODZjYWUwN2FkZDY5YjhmYi90YWJsZXJhbmdlOjllNzNiYjAwNGZhMDRmOGY4NmNhZTA3YWRkNjliOGZiXzItMy0xLTEtNzIwMg_e8ec741f-8eeb-4268-b624-24e3caf9509f">P1Y6M25D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib6d2e0cb9f694fe7a859d47739e7393e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTo5ZTczYmIwMDRmYTA0ZjhmODZjYWUwN2FkZDY5YjhmYi90YWJsZXJhbmdlOjllNzNiYjAwNGZhMDRmOGY4NmNhZTA3YWRkNjliOGZiXzItNy0xLTEtNzIwMg_4532583f-3645-4d23-9bba-e16da0f1eceb">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90ZXh0cmVnaW9uOjFkYjNlYzgyYWNhNTRlYjg5ZWZjZjhjMjEyYWFkYTFhXzExMTQ_2e93c0a7-6a7f-4978-8963-a580edce8e9f">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total fair value of shares vested and the weighted average estimated fair values of shares granted for the years ended December&#160;31, 2021 and 2020 were as follows ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average estimated fair value of shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i1262c5aee83e44218db30c90579c58ff_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTo0NDkyMWNmMGMyY2I0NGZkOTk0MGIzZTc3NDc0NzM3ZS90YWJsZXJhbmdlOjQ0OTIxY2YwYzJjYjQ0ZmQ5OTQwYjNlNzc0NzQ3MzdlXzMtMi0xLTEtNzIwMg_0d6b6f19-d7af-498a-89d3-ae4b4d006c9c"
      unitRef="usd">757000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i2f25e23ccf5e4e8b9996111cff5b1f1f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTo0NDkyMWNmMGMyY2I0NGZkOTk0MGIzZTc3NDc0NzM3ZS90YWJsZXJhbmdlOjQ0OTIxY2YwYzJjYjQ0ZmQ5OTQwYjNlNzc0NzQ3MzdlXzMtNC0xLTEtNzIwMg_c6a84fb9-004b-479d-ad24-cdbe4435f8cb"
      unitRef="usd">536000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1262c5aee83e44218db30c90579c58ff_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTo0NDkyMWNmMGMyY2I0NGZkOTk0MGIzZTc3NDc0NzM3ZS90YWJsZXJhbmdlOjQ0OTIxY2YwYzJjYjQ0ZmQ5OTQwYjNlNzc0NzQ3MzdlXzQtMi0xLTEtNzIwMg_42f7c96f-4adb-4483-a650-7a035ae33d23"
      unitRef="usdPerShare">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2f25e23ccf5e4e8b9996111cff5b1f1f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTo0NDkyMWNmMGMyY2I0NGZkOTk0MGIzZTc3NDc0NzM3ZS90YWJsZXJhbmdlOjQ0OTIxY2YwYzJjYjQ0ZmQ5OTQwYjNlNzc0NzQ3MzdlXzQtNC0xLTEtNzIwMg_97769c79-47aa-4e19-af2b-2b77113ee2ef"
      unitRef="usdPerShare">2.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90ZXh0cmVnaW9uOjFkYjNlYzgyYWNhNTRlYjg5ZWZjZjhjMjEyYWFkYTFhXzExMTk_2c1984fb-6fe9-44d5-b5dd-ac7f4c3a6edb">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The range of assumptions made in calculating the fair values of stock options was as follow:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term - minimum (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term - maximum (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility - minimum&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility - maximum&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate - minimum&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate - maximum&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.71%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iee4c1259461b4d82a4ed9b9423814c93_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzMtMS0xLTEtNzIwMg_af52719d-c37f-42f1-a139-ba639460ad14">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2b81cf0af0d549cc9704b163fd97825f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzMtMy0xLTEtNzIwMg_abf61e9b-c372-43af-a594-5a9f55490f94">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0424a8b4b4e74dd6a974d18e483a0683_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzQtMS0xLTEtNzIwMg_530a22c7-7b95-4708-b96c-9d0beb04ae5b">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib31c704f4b3d4411913b83a05612f827_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzQtMy0xLTEtNzIwMg_f596b326-0b37-40bf-8b87-f2de9017ea06">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i1262c5aee83e44218db30c90579c58ff_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzUtMS0xLTEtNzIwMg_cbfa6ced-6d3a-445e-bda1-b8f1a9987b2a"
      unitRef="number">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i2f25e23ccf5e4e8b9996111cff5b1f1f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzUtMy0xLTEtNzIwMg_61c6b8a6-0e15-4ed6-9b34-b3cb0babd9fc"
      unitRef="number">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i1262c5aee83e44218db30c90579c58ff_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzYtMS0xLTEtNzIwMg_19e3e3dc-b04a-42c9-94b2-3f7fcf682e45"
      unitRef="number">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i2f25e23ccf5e4e8b9996111cff5b1f1f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzYtMy0xLTEtNzIwMg_1fd4629c-e4ab-46c4-93e6-3632383f1fdf"
      unitRef="number">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i1262c5aee83e44218db30c90579c58ff_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzctMS0xLTEtNzIwMg_41f69a6c-7500-4401-bdbd-4ca23cbe1540"
      unitRef="number">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i2f25e23ccf5e4e8b9996111cff5b1f1f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzctMy0xLTEtNzIwMg_969fc01f-13d9-4e2d-8fc9-77c4a18157e5"
      unitRef="number">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1262c5aee83e44218db30c90579c58ff_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzgtMS0xLTEtNzIwMg_c5ae4000-1044-4fbf-b9ac-3587f2b9fd7e"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i2f25e23ccf5e4e8b9996111cff5b1f1f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzgtMy0xLTEtNzIwMg_10f5f9bd-229b-46d8-a8e7-47fba98e977a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i1262c5aee83e44218db30c90579c58ff_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzktMS0xLTEtNzIwMg_8a1af986-618e-4817-8116-6c2e18c37668"
      unitRef="number">0.0063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i2f25e23ccf5e4e8b9996111cff5b1f1f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzktMy0xLTEtNzIwMg_51d1380d-e5cb-4680-a8be-61c168cae061"
      unitRef="number">0.0040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i1262c5aee83e44218db30c90579c58ff_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzEwLTEtMS0xLTcyMDI_52d6245f-b6e1-45df-9d1c-fded2fc89198"
      unitRef="number">0.0116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i2f25e23ccf5e4e8b9996111cff5b1f1f_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTUvZnJhZzoxZGIzZWM4MmFjYTU0ZWI4OWVmY2Y4YzIxMmFhZGExYS90YWJsZTpkN2NkNDA3ZjY2NDI0OGM0Yjk4MGY4ODRjYWQzMDIxNi90YWJsZXJhbmdlOmQ3Y2Q0MDdmNjY0MjQ4YzRiOTgwZjg4NGNhZDMwMjE2XzEwLTMtMS0xLTcyMDI_69b4fbe7-13e9-4e94-9620-3424c7109d16"
      unitRef="number">0.0171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzEyNTA_3eb915c1-48fe-49a1-b74c-dfcb31bc0bc0">Research Funding&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;California Institute of Regenerative Medicine Grant Award&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2017, the California Institute for Regenerative Medicine (&#x201c;CIRM&#x201d;) awarded the Company funds of up to $12.2 million to support The Sanford Project: T-Rex Study, a prospective, randomized, placebo-controlled, double-blind Phase 2 clinical trial to evaluate the safety and efficacy of CLBS03 as a treatment for recent-onset type 1 diabetes. The funding is based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. Based on the actual number of subjects enrolled in California, the total amount of funding was revised to $8.6&#160;million, of which $8.2 million has been received through the grant project period completion. &lt;/span&gt;&lt;/div&gt;The Company received $5.7&#160;million in initial funding in May 2017, a $1.9&#160;million milestone payment in December 2017, a $0.3&#160;million progress payment in March 2018, and a $0.2&#160;million progress payment in May 2019, of which the total was amortized over the estimated award period through July 2020 as a reduction to the related research and development expenses, with the final true up payment of $46&#160;thousand received in September 2020 and recorded as a reduction to the related research and development expenses. During the year ended December&#160;31, 2021 and December&#160;31, 2020 the Company amortized and recognized $0.0&#160;million and $1.6&#160;million in credits, respectively, to research and development related to CIRM funds received.</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:GrantsReceivable
      contextRef="ifac165fbd5294cbbae45708def42554a_I20170228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzIwNA_0963d191-470f-44c7-8cc7-ba4c22c1d81a"
      unitRef="usd">12200000</us-gaap:GrantsReceivable>
    <clbs:FundingAmountAwarded
      contextRef="ifac165fbd5294cbbae45708def42554a_I20170228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzUzOQ_04c8f222-1c48-4ffe-9248-b1c1ae0dffaf"
      unitRef="usd">8600000</clbs:FundingAmountAwarded>
    <clbs:FundingOfGrantAwardCashReceived
      contextRef="i61ed912a36714a0f8fa66f5c6f03cc72_D20170501-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzU1Mg_c9802143-4ff1-40ef-9eb7-ea2654997a4f"
      unitRef="usd">8200000</clbs:FundingOfGrantAwardCashReceived>
    <clbs:FundingOfGrantAwardCashReceived
      contextRef="i08b10f0993ca498595bc8f6e22708cd3_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzEwOTk1MTE2MzEwNzQ_4284f7bf-ba94-4792-a430-e4520d1a9ee7"
      unitRef="usd">5700000</clbs:FundingOfGrantAwardCashReceived>
    <clbs:MilestonePaymentOnGrantAwardCashReceived
      contextRef="i31c91a3c922742a393bcaf2e5965f1af_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzEwOTk1MTE2MzEwODE_71fb2653-68d2-4193-8c4e-30e6b06757ac"
      unitRef="usd">1900000</clbs:MilestonePaymentOnGrantAwardCashReceived>
    <clbs:ProgressPaymentOnGrantAwardCashReceived
      contextRef="icb2942cf4b2d4251b0227854fee06098_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzEwOTk1MTE2MzEwODg_7cab4979-2607-428f-ab3d-5dcccbd88a03"
      unitRef="usd">300000</clbs:ProgressPaymentOnGrantAwardCashReceived>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
      contextRef="iaa54ec01303049c2ac24d543660aa65d_D20190501-20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzEwOTk1MTE2MzEwOTU_6d222ed9-45b4-42c4-aba1-183c484ec90a"
      unitRef="usd">200000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
      contextRef="id909ba1c9804438aafc38ea943a32300_D20200901-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzEwOTk1MTE2MzExMDI_c22eedab-21c2-4a1a-ac56-b303358b3d60"
      unitRef="usd">46000</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred>
    <clbs:AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzMyOTg1MzQ4ODczNzM_f12a1062-03dc-4aef-a033-bcb80e85b065"
      unitRef="usd">0</clbs:AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense>
    <clbs:AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMTgvZnJhZzpmZGFiYTZlY2Y5Nzc0OTI4ODg5ZWM4Mzc3YmI3MGFkOC90ZXh0cmVnaW9uOmZkYWJhNmVjZjk3NzQ5Mjg4ODllYzgzNzdiYjcwYWQ4XzMyOTg1MzQ4ODczNDI_8fae7543-3de9-49a9-8eab-61f309fe9d99"
      unitRef="usd">1600000</clbs:AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzQxNDQ_742c2ede-9519-4dd2-966b-7af982be2a9f">Income Taxes&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision (benefit) for income taxes is based on loss from operations before provision for income taxes and noncontrolling interests as follows ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-tax book income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision (benefit) from income taxes was as follows ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. Federal   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. Federal   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. Federal   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The provision (benefit) for income taxes is determined by applying the U.S. Federal statutory rate of 21% to income before income taxes, and the components are set forth below ($ in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Federal benefit at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent non deductible expenses for U.S. taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in state deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return to actual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other true ups&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 382 NOL Limitation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale of New Jersey State NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax provision (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes at December&#160;31, 2021 and 2020 consist of the following ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated net operating losses (tax effected)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (NOLs), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, and 2020, the Company had approximately $281 million and $264 million, respectively, of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. The Company performed an analysis and determined that they had an ownership change of greater than 50% over a 3-year testing period on January 25, 2021.  As a result, $169&#160;million of the $281&#160;million of Federal NOLs will expire unutilized.  The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $112&#160;million of remaining Federal NOL.  The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on January 25, 2021 will be subject to an annual limitation of $173k under Internal Revenue Code Section 382, while losses incurred after January 25, 2021 will not be subject to limitations. The Company may be able to utilize additional NOLs of approximately $1.1&#160;million per year for the first five years after this ownership change as a result of the application of the Net Unrealized Built-in Gain rules.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, the Company had State NOLs available in New Jersey of $97 million and $99 million, respectively, California of $70 million and $70 million, respectively, and New York City of $13 million and $13&#160;million, respectively, to offset future taxable income expiring from 2031 through 2041. In accordance with Section 382 of the Internal Revenue code, the usage of the Company&#x2019;s state NOLs would be limited given the change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the FASB&#x2019;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant taxing authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For years prior to 2018 the federal statute of limitations is closed for assessing tax. The Company&#x2019;s state tax returns remain open to examination for a period of three to four years from date of filing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the Company received preliminary approval from the New Jersey Economic Development Authority (&#x201c;NJEDA&#x201d;) to participate in the Technology Business Tax Certificate Transfer Program (the &#x201c;Program&#x201d;). The Program permits qualified companies to sell a percentage of their New Jersey net operating losses (&#x201c;NJ NOLs&#x201d;) to unrelated profitable corporations. On April 12, 2021, the Company received final approval from NJEDA to sell a portion of our NJ NOLs, which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $1.4&#160;million. The $1.5&#160;million of our NJ NOL related tax benefits (&#x201c;NJ NOL Tax Benefits&#x201d;) have been recorded as a benefit from income taxes and the loss on sale of $0.1&#160;million recorded in other income (expense) in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzQxNDE_2da0c0fe-920d-4adf-9090-187497fc0167">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision (benefit) for income taxes is based on loss from operations before provision for income taxes and noncontrolling interests as follows ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-tax book income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyZWUxOGUwZjc5Mjk0YjUwOGEyNjIyMWEzMDlhMzQ3NS90YWJsZXJhbmdlOjJlZTE4ZTBmNzkyOTRiNTA4YTI2MjIxYTMwOWEzNDc1XzItMS0xLTEtNzIwMg_f3a314e5-190c-42fc-b2d5-4c2c8fb6fc5c"
      unitRef="usd">-28974000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyZWUxOGUwZjc5Mjk0YjUwOGEyNjIyMWEzMDlhMzQ3NS90YWJsZXJhbmdlOjJlZTE4ZTBmNzkyOTRiNTA4YTI2MjIxYTMwOWEzNDc1XzItMy0xLTEtNzIwMg_6deb6e21-b2a1-43df-b41b-751a25bbaeb8"
      unitRef="usd">-19013000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyZWUxOGUwZjc5Mjk0YjUwOGEyNjIyMWEzMDlhMzQ3NS90YWJsZXJhbmdlOjJlZTE4ZTBmNzkyOTRiNTA4YTI2MjIxYTMwOWEzNDc1XzMtMS0xLTEtNzIwMg_60b1425e-d4d3-4e5b-b3fd-f0b79135a607"
      unitRef="usd">-28974000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyZWUxOGUwZjc5Mjk0YjUwOGEyNjIyMWEzMDlhMzQ3NS90YWJsZXJhbmdlOjJlZTE4ZTBmNzkyOTRiNTA4YTI2MjIxYTMwOWEzNDc1XzMtMy0xLTEtNzIwMg_6e0162aa-b40b-4956-aed2-25b537a569dc"
      unitRef="usd">-19013000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzQxNDM_37337b80-761f-48cc-b514-32e4e7a03758">&lt;div style="margin-bottom:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision (benefit) from income taxes was as follows ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. Federal   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. Federal   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. Federal   &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzMtMi0xLTEtNzIwMg_a66ead18-f672-450f-be1b-13f82a0d8769"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzMtNC0xLTEtNzIwMg_6959d9b4-cd46-47f4-8237-a4564582ea56"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzQtMi0xLTEtNzIwMg_e8ecac32-3515-4ec7-93b6-b730e1393062"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzQtNC0xLTEtNzIwMg_54a33d1a-7696-4b02-acda-a8e8733d4155"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzUtMi0xLTEtNzIwMg_5013c63e-44ed-44ad-afdd-7f40a9cf4f17"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzUtNC0xLTEtNzIwMg_4cfea0a7-7794-4f45-8863-e5bc7023045b"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzgtMi0xLTEtNzIwMg_9fc3103f-131d-4da0-9eb1-2caeb2d67f70"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzgtNC0xLTEtNzIwMg_36dc2664-dfbd-4a31-ad83-7baa42a57b3c"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzktMi0xLTEtNzIwMg_f2e75f46-73f9-43fc-ba8d-fe5a29889563"
      unitRef="usd">-1508000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzktNC0xLTEtNzIwMg_24e65d5d-97c7-462a-aecf-b40a6c5a16dc"
      unitRef="usd">-10872000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzEwLTItMS0xLTcyMDI_243b40a6-d4aa-468e-84c2-3c956af60c17"
      unitRef="usd">-1508000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzEwLTQtMS0xLTcyMDI_fa2a95f2-4d3e-4e11-8927-c02329055a38"
      unitRef="usd">-10872000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzEzLTItMS0xLTcyMDI_0015fd12-0684-4826-aa43-c5c46226fb47"
      unitRef="usd">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzEzLTQtMS0xLTcyMDI_f4f46982-568e-45f9-99e1-cd45dec2397a"
      unitRef="usd">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzE0LTItMS0xLTcyMDI_37b04e9f-61c9-4537-b7c4-fa9219623784"
      unitRef="usd">-1508000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzE0LTQtMS0xLTcyMDI_c0fe9aa4-afde-4053-83ed-e61f45e1c362"
      unitRef="usd">-10872000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzE1LTItMS0xLTcyMDI_9cc56e88-89f5-4bec-bdc6-74898363472f"
      unitRef="usd">-1508000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZToyM2QzYjU1ZGU2OWM0OGE1YWRiNGY3NDk1N2RlOGEwOC90YWJsZXJhbmdlOjIzZDNiNTVkZTY5YzQ4YTVhZGI0Zjc0OTU3ZGU4YTA4XzE1LTQtMS0xLTcyMDI_b8969d52-b214-4c1c-ba5f-049c0ba13425"
      unitRef="usd">-10872000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzQxMjU_c66143b1-faff-4061-a730-dfbc434d4158">&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The provision (benefit) for income taxes is determined by applying the U.S. Federal statutory rate of 21% to income before income taxes, and the components are set forth below ($ in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Federal benefit at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent non deductible expenses for U.S. taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in state deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return to actual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other true ups&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 382 NOL Limitation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale of New Jersey State NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax provision (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzM4MQ_36af79e1-9d39-430a-a5b8-b7e831abb0e8"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzItMi0xLTEtNzIwMg_e7c27c39-7c18-46e4-bd74-5b1cbbd69a1b"
      unitRef="usd">-6085000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzItNC0xLTEtNzIwMg_1defef64-aa70-4102-96e9-e8c5e56844df"
      unitRef="usd">-3993000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzQtMi0xLTEtNzIwMg_3eb94609-8997-4ba5-b921-ec6852cb5573"
      unitRef="usd">320000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzQtNC0xLTEtNzIwMg_27daa9be-9f7f-4da9-8026-f7d28378e1b5"
      unitRef="usd">5000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <clbs:EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzYtMi0xLTEtNzIwMg_bd2933eb-dbbf-4186-b77a-997fc7a255a1"
      unitRef="usd">622000</clbs:EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount>
    <clbs:EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzYtNC0xLTEtNzIwMg_0ee67cc4-0f71-44ed-a0ef-e34285a01741"
      unitRef="usd">5122000</clbs:EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzctMi0xLTEtNzIwMg_c1fb0aea-4837-4d45-a508-a6a0a7ada667"
      unitRef="usd">2277000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzctNC0xLTEtNzIwMg_f8b0f803-799d-4a29-a905-1b416617a4de"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzgtMi0xLTEtNzIwMg_93125633-b82f-4843-b109-10fc5d81f7a5"
      unitRef="usd">1407000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzgtNC0xLTEtNzIwMg_6946e46a-45ba-4c1b-883e-c4f42fac4dca"
      unitRef="usd">387000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <clbs:EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzktMi0xLTEtNzIwMg_04ba94c4-10b2-4bdd-bbf9-a16928fc4b12"
      unitRef="usd">35438000</clbs:EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount>
    <clbs:EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzktNC0xLTEtNzIwMg_e9f636f9-3a9e-4829-9bda-328e81e37522"
      unitRef="usd">0</clbs:EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount>
    <clbs:EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzEwLTItMS0xLTcyMDI_2cc570c0-fbe3-4de2-be89-5a3b71b8b75b"
      unitRef="usd">-1508000</clbs:EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses>
    <clbs:EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzEwLTQtMS0xLTcyMDI_7ffb6980-d57a-4c56-bf1d-ea338a712ff6"
      unitRef="usd">-10872000</clbs:EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzExLTItMS0xLTcyMDI_df5ef0a4-5768-4aae-8647-193be52a9809"
      unitRef="usd">-33979000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzExLTQtMS0xLTcyMDI_37b6620f-d49c-49ee-8f61-6b4e6b3887fb"
      unitRef="usd">-1521000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzEyLTItMS0xLTcyMDI_5331e562-5bac-492c-9424-498cda5920ff"
      unitRef="usd">-1508000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i85d2d9f5c0e74e609e1d30033825b136_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTowNjMxZmM1NTYyZTk0ZDM5YTJlYzVmMDE1NTg1MTEzMC90YWJsZXJhbmdlOjA2MzFmYzU1NjJlOTRkMzlhMmVjNWYwMTU1ODUxMTMwXzEyLTQtMS0xLTcyMDI_9b4bd4c3-1db8-4e8a-9d64-04cc81c2b983"
      unitRef="usd">-10872000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzQxMTk_fda8b5a3-3471-4eb4-82b1-33dcaf1ffa84">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes at December&#160;31, 2021 and 2020 consist of the following ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated net operating losses (tax effected)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzMtMi0xLTEtNzIwMg_cab80750-a9a8-444a-b12b-72543b3f2c54"
      unitRef="usd">36281000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzMtNC0xLTEtNzIwMg_9d64f9dc-4930-4991-be68-839ed8f410ca"
      unitRef="usd">68286000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <clbs:DeferredTaxAssetsRightOfUseLiability
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzYtMi0xLTEtNzIwMg_67e34ebc-ea9a-45af-bb40-b8d7d227618b"
      unitRef="usd">201000</clbs:DeferredTaxAssetsRightOfUseLiability>
    <clbs:DeferredTaxAssetsRightOfUseLiability
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzYtNC0xLTEtNzIwMg_d0845d19-8bb4-4579-9bfc-ca6b425f7b20"
      unitRef="usd">176000</clbs:DeferredTaxAssetsRightOfUseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzctMi0xLTEtNzIwMg_8c345ae0-c704-4948-8a40-c62d09041454"
      unitRef="usd">3086000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzctNC0xLTEtNzIwMg_b6e57fd5-283e-4f61-8e90-0cd90d3dc479"
      unitRef="usd">5025000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzgtMi0xLTEtNzIwMg_7cf023ae-dc89-4d79-a43c-6c2be3e68759"
      unitRef="usd">97000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzgtNC0xLTEtNzIwMg_2992f53a-baf5-4572-b09c-cea426a8cf0b"
      unitRef="usd">131000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <clbs:DeferredTaxAssetsAccumulatedDepreciation
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzEzLTItMS0xLTcyMDI_3d9cc81c-cc98-48ab-9083-800ea6bbe734"
      unitRef="usd">26000</clbs:DeferredTaxAssetsAccumulatedDepreciation>
    <clbs:DeferredTaxAssetsAccumulatedDepreciation
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzEzLTQtMS0xLTcyMDI_a1b87fea-f003-4235-8ad6-4cac821dfb2f"
      unitRef="usd">19000</clbs:DeferredTaxAssetsAccumulatedDepreciation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzE0LTItMS0xLTcyMDI_390d5779-26f7-4dcf-ab56-17145178eb75"
      unitRef="usd">176000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzE0LTQtMS0xLTcyMDI_79ff3eda-ad16-48a1-a2f5-9a3f18bbba03"
      unitRef="usd">167000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzE2LTItMS0xLTcyMDI_c277bf18-1228-4b8b-9f58-21dfebaa9e3f"
      unitRef="usd">526000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzE2LTQtMS0xLTcyMDI_1836fd46-60ff-4f62-912e-c1037e2866ef"
      unitRef="usd">526000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzE3LTItMS0xLTcyMDI_121efa7f-2522-4f7d-a569-a4bd5e44282f"
      unitRef="usd">40393000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzE3LTQtMS0xLTcyMDI_129906d8-dcce-4d70-8b7d-592f468e4c64"
      unitRef="usd">74330000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzIwLTItMS0xLTcyMDI_a60b2a18-f910-4998-a1f4-ace96bc12b0e"
      unitRef="usd">204000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzIwLTQtMS0xLTcyMDI_04146628-ec2a-4a1c-8a3d-585525785a88"
      unitRef="usd">161000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzIyLTItMS0xLTcyMDI_567a507c-5393-4e94-857d-73e3c5f03984"
      unitRef="usd">204000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzIyLTQtMS0xLTcyMDI_d6312b64-0aab-4c33-ab18-6ee6b40963d0"
      unitRef="usd">161000</us-gaap:DeferredIncomeTaxLiabilities>
    <clbs:NetDeferredTaxAssetsAndLiabilitiesGross
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzIzLTItMS0xLTcyMDI_82cefcd2-9c69-4dfc-bfb0-fd302437483b"
      unitRef="usd">40189000</clbs:NetDeferredTaxAssetsAndLiabilitiesGross>
    <clbs:NetDeferredTaxAssetsAndLiabilitiesGross
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzIzLTQtMS0xLTcyMDI_f8809987-339c-4f46-ae5f-26625a94592c"
      unitRef="usd">74169000</clbs:NetDeferredTaxAssetsAndLiabilitiesGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzI0LTItMS0xLTcyMDI_c1dd8bbf-3a31-47e1-acae-98e70c31433e"
      unitRef="usd">40189000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzI0LTQtMS0xLTcyMDI_47a65d2d-1240-4f75-910f-6f5e30c09487"
      unitRef="usd">74169000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzI1LTItMS0xLTcyMDI_db59d379-be45-46bc-a316-b6adf4ab038b"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i4277098eb8e941d8849e8e36535b5f36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90YWJsZTo2MDM3MjE4ODgxNDM0MmQ0YTQ5OThjZTVjYWJiNTMzMi90YWJsZXJhbmdlOjYwMzcyMTg4ODE0MzQyZDRhNDk5OGNlNWNhYmI1MzMyXzI1LTQtMS0xLTcyMDI_aa0fcb44-1eb9-49f5-9b89-304f8a134cf2"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <clbs:OperatingLossCarryforwardsBeforeWriteDown
      contextRef="ibb3d98988e62496d9a95ec85932a553d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzEwNTk_9bbc6090-f910-4ddc-ab29-ecefa7c24a85"
      unitRef="usd">281000000</clbs:OperatingLossCarryforwardsBeforeWriteDown>
    <us-gaap:OperatingLossCarryforwards
      contextRef="icd538497ecb94882951d52a7b78a623a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzEwNjY_92f51f01-dfea-4a3b-bbc6-c757d5746c4e"
      unitRef="usd">264000000</us-gaap:OperatingLossCarryforwards>
    <clbs:OperatingLossCarryforwardsSetToExpireWrittenDown
      contextRef="ibb3d98988e62496d9a95ec85932a553d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzExNTQ0ODcyMTAxNDA2_772de455-684c-4e45-9030-4b1767aa5aa8"
      unitRef="usd">169000000</clbs:OperatingLossCarryforwardsSetToExpireWrittenDown>
    <clbs:OperatingLossCarryforwardsBeforeWriteDown
      contextRef="ibb3d98988e62496d9a95ec85932a553d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzEyMDk0NjI3OTE1MTcy_a57d6a38-dae6-49d5-864b-5b9d4aaee26f"
      unitRef="usd">281000000</clbs:OperatingLossCarryforwardsBeforeWriteDown>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ibb3d98988e62496d9a95ec85932a553d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzExNTQ0ODcyMTAxNDIw_58698af1-d5c8-481e-b884-8c65d3030a50"
      unitRef="usd">112000000</us-gaap:OperatingLossCarryforwards>
    <clbs:OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain
      contextRef="i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzEyMDk0NjI3OTE1MTg2_31ea7e6a-db4e-48a0-aa28-301cd59ea6e3"
      unitRef="usd">1100000</clbs:OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ib03213178c1c439fbbcd57ce65f84a0a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzEyNDg_b9f3a244-2359-4892-b3ef-80349071a68c"
      unitRef="usd">97000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i3273942991694dcbb5315ec3f95ef5c1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzEyNTU_799bbb9d-1d14-4b29-a212-e435c3de1d2c"
      unitRef="usd">99000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ib4ffabf75b224124baa59142f55d7740_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzEyODc_397c923e-c6fd-4b9b-af61-f8fb90e23f38"
      unitRef="usd">70000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i208a56199ea240e189c18fe67bc1738e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzEyOTQ_3a456e65-729b-4c4d-8a5e-8d83d509ee57"
      unitRef="usd">70000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ie9412c3333444df08e11f620932bee49_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzEzMzM_21491302-ffaa-4fec-8540-e0196dfc6be2"
      unitRef="usd">13000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="iacc61b5e28ba4a56b04bcf5fece477a5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzEzNDA_a5c58796-d057-4bc9-88d3-f7bd13c28d6a"
      unitRef="usd">13000000</us-gaap:OperatingLossCarryforwards>
    <clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgram
      contextRef="i63593eb72a0c4883b9e50df4be109be4_D20210412-20210412"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzE2NDkyNjc0NDY0Mzc_932ee4f7-a606-4364-9b6b-d5c016ce2112"
      unitRef="usd">1400000</clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgram>
    <clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross
      contextRef="i63593eb72a0c4883b9e50df4be109be4_D20210412-20210412"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzE2NDkyNjc0NDY0NDY_2f36abab-612c-4531-8b1a-e03dbcb0d565"
      unitRef="usd">1500000</clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross>
    <clbs:LossOnSaleOfNetOperatingLosses
      contextRef="i63593eb72a0c4883b9e50df4be109be4_D20210412-20210412"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjEvZnJhZzo0ODdmY2I4NGM5NDk0MTFlYWZjMzU1NTc3YTkzNTkxNC90ZXh0cmVnaW9uOjQ4N2ZjYjg0Yzk0OTQxMWVhZmMzNTU1NzdhOTM1OTE0XzE2NDkyNjc0NDY1ODM_75defb42-e85b-4e49-b679-2650ac24c459"
      unitRef="usd">100000</clbs:LossOnSaleOfNetOperatingLosses>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjdkMDQ5Mjg4YjgyZTQzOGM4NWQ1MDRjYzNlOWRjNTAwL3NlYzo3ZDA0OTI4OGI4MmU0MzhjODVkNTA0Y2MzZTlkYzUwMF8xMjQvZnJhZzplMTBiYjU0NzUyY2Y0ZmNkYWEwMDZlOWYwOWJiNDY3OC90ZXh0cmVnaW9uOmUxMGJiNTQ3NTJjZjRmY2RhYTAwNmU5ZjA5YmI0Njc4XzQyMw_530f351e-ecd9-4dec-82d5-f10cacac53c2">ContingenciesFrom time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MG']7&-3-B\\SM\SJIR8Q7X*I<W@,BTP57SR*&R/7^3> A31&)OEEQ!FXS#:
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M8$ VWQ^;&RWV]2>\!Z&U*.K+':.PCXT O-\(H5]NS%?!]BOPZG]02P,$%
M  @ 5(%V5&"R)(PY P  <PP  !@   !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6RE5UUOFS 4_2L6VD,K=0%#"% ED=94T_8P*6KV\>R"$ZP:3&V3M/OULPTE
MH220='D(_KCW^)R+KZ^9[AA_$BG&$KQD-!<S*Y6RN+5M$:<X0V+$"IRKF37C
M&9*JRS>V*#A&B7'*J.TZSL3.$,FM^=2,+?E\RDI)28Z7'(@RRQ!_O<.4[686
MM-X&'L@FE7K GD\+M,$K+'\52ZYZ=H.2D SG@K <<+R>65_@[0+ZVL%8_"9X
M)P[:0$MY9.Q)=[XG,\O1C##%L=002#VV>($IU4B*QW,-:C5K:L?#]AOZ5R->
MB7E$ B\8_4,2F<ZLT ()7J.2R@>V^X9K089@S*@P_V!7V?J!!>)22);5SHI!
M1O+JB5[J0!PXP/$)![=V<,]U\&H'SPBMF!E9]TBB^92S'>#:6J'IAHF-\59J
M2*Y?XTIR-4N4GYPO6"X8)0F2. %WB*(\QF"EX02X6B*.<YEB26)$K\%G\ G8
M0*1J5$QMJ5;7&'9<KW17K>2>6.D>QR/@P1O@.BX\XKXXW]UIN]M*<R/<;82[
M!L\[@;=4VP5SKE2O)(N?>A"]!M$SB.-!1*$1;^I( 53*E''R5TU<54/7QZ)7
M@4\,N$Z^[5REHOE-[>UAG,XP;/$?-_S'E_&GY+G4.T.G6V$FL=X=?2*J%8(#
M;L[(<> [!4-6+?I^0]^_C'Z!.-@B6BK&) <)HQ1Q 0K,JQ=SE'^U1-AF]I[^
M@%&+_:1A/_G0YDFP()O<9&=?W">=/1&Z?G?K#)JUN <-]^!#W(D0Y0#OH$,(
M'MGQ0U8MUF'#.OP0:U7KA$1Y0O)-+_7P+.I#5BWJ44,]ZCV[%BS+5$X.'5S0
MV1<!IS<6->!_)$Z]0#20^8-F;0$'50Q>(."R@[>&/GQ'OG/\Z#W+M"UA7X^@
M>[&$FW-RJ,9MD8I"QPDB]SW]KB6,O# :0^\$^WWM@_W%[SC[<W,)=FN:'P5A
M%,".A*ZEDA"$GG=*PK[\P7%O5OU4UV!1\M?AO-J7)-A?DQI($Y?^$/A=8= )
M.SMPR*QB:A_<"/5U_ ?B&Y(+0/%:^3FC0,'PZH9;=20KS"7QD4EUY33-5'T5
M8*X-U/R:,?G6T??.YCMC_@]02P,$%     @ 5(%V5'>U$WZ1!   X1   !@
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M(.CMKTR(,XOZZ^[J+\B"IE1:E-R<J#7,>+'FWQOS==LN_XF5?54_R5D.GSU
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MTTI5 V9F_,UX9C[;ZR/CCR(C1(+G(B_%]2R3LKI:+$22D0*+3ZPBI?JR9[S
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ML54GB72VI\W@JY)K,*<M9#9VBPP*8?\8X@$;F.N4K*%!ZBJ!@5 >X@1!O7,
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M0GUF-6TN'^>E<<T<"1-,$ES;@C6Q0)P<.8\;BR[U(7B!JG#LBS7DC<C 24;
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MI2PF=[4E"XW47L1WW=@0##QB4AXOV71JB:4+B+67T\/9%K24M16KVP,/,>/
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M<B]<EGHCZB<"[TA-2B]WB0R0OC6'$S1OW$Y1_:Q1RZKH?)X>*!?A>\GMU]0
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M:W-H965T<R]S:&5E=#$Q+GAM;+5666_;.!#^*P-ML!L#:G19/K*V@5S-%FB
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M->F?GT5@FC'4&$Y7H?77VM$@"<N2)C<:#Z#SC::BM89WT/T7S'X!4$L#!!0
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MQ??X*(F:;8U]<!4BP5.MM)M'%5$SC6.75U@+=V(:U+Q3&EL+8M-N8M=8%$4
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MW2PF)O;;<;XC674DV1LD:0;71E/EX),NL'A)$+.B7E:VE[7*CC)>8GX"PW0
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M85GQ+X?6!_!^:0SM#9^@_S<7?P!02P,$%     @ 5(%V5%&T!1+@!   90L
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MY%N1 ALX_H]_6$;1Z-DU+TH9RQTN08_&S\Y#DD[S%W"9>\"06*!$[$9!:(E
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MGW^^8F=6><UA7F] 'J2&B2\H@-<(P?WB3?WW>?.$"*;!!VXD%N&TU0*[)OH
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M'DBYX'*8:&(E[0)TV1\&F:M*K@E[+,O*Z-(0IQ98$0@A5@2.=(\3(,%7O%.
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M9 *CCP%R7A/Q?A$%QIF^^@U02P,$%     @ 5(%V5%H:VV<)#@  SR@  !D
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M#^<3M9@MYB/R'G:&>,CR'AZ1=VC%_SI?AN@!G'^/3/"HF^ 13_#HR 07.MA
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M684PO-TXXDBWK<CNN%GJ/P#CV-X*S3+8W&K?!C'B"3@AR\(Q18')X</$ZE+
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M4.G6$D /E"]RB30P/V405YH[6B&1-V53L/92;1$RO=G0=@.PF5[[GB9_P.;
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M2OY)1&L\#<!S4KJ]H FZ;QA?_P=02P,$%     @ 5(%V5)(!;I+B @  8P8
M !D   !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL?55M:^,P#/XK(NS#"F-Y
M:[==:0OM7KB#&Y1U=_?AN ]NHB1FCIW9SKK]^Y.=-NN@+137EJ7GD61)F6R4
M?C$5HH7W6D@S#2IKFW$8FJS"FIE+U:"DFT+IFEDZZC(TC4:6>Z-:A$D4784U
MXS*83;QLJ6<3U5K!)2XUF+:NF?Y8H%";:1 '.\$3+ROK!.%LTK 25VA_-4M-
MI[!'R7F-TG E06,Q#>;Q>#%T^E[A-\>-V=N#BV2MU(L[_,BG0>0<0H&9=0B,
M_M[P%H5P0.3&ZQ8SZ"F=X?Y^A_[@8Z=8ULS@K1)_>&ZK:7 30(X%:X5]4IOO
MN(UGY/ R)8Q?8=/ICI( LM9856^-R8.:R^Z?O6_SL&=P$QTQ2+8&B?>[(_)>
MWC'+9A.M-J"=-J&YC0_56Y-S7+I'65E-MYSL[&S5/0:H E:\E+S@&9,6YEFF
M6FFY+&&I!,\X&CA_9FN!9C )+1$[\S#;DBPZDN0(29S HY*V,G O<\R_ H3D
M<>]VLG-[D9Q$O,/L$M+X I(HB4_@I7T:4H^7'L$[%._?^=I8367S[P3!L"<8
M>H+AL3Q3-^6M0)?HI::>TO8#F,SA_K7E#56Y/936DYBN7\>F81E. VI(@_H-
M@]ESA8#&<BI8S*$U6+0"!%6^<=3-/C7NJ(%I!&:@4(*:U(SAH=62V]9)2:_@
M[VYO(([@ YDV<*OJIK6H]R#2[=5*%7;C\':"GTA-4RF1 Z^)_@V=.HEYX9,A
MW/77E'R"9HJZW[A 2--29)V'[IG.N22):@U9F,$8J"*P7I-+NZIP2W0LDC-(
MKKKE4"CQ$)+1\)CGWR+W.^SQ!91:&0/#-(+T.G)]U-:M\&^1([U2QIF?1N?I
MU<V UC@='(62-)//X"JA970-AXHPW&O\&G7IQYL!7\O=#.BE_02==X/C4[T;
MOX],EUP:>H^"3*/+ZU$ NAMIW<&JQH^1M;(TE/RVHJ\ :J= ]X52=G=P!/UW
M9?8?4$L#!!0    ( %2!=E12%K8M200   (,   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;+56VV[C-A#]%4(-VAC01C=+=E+;0&Z;+K !@B2[?2CZ
M0$MCFPA%>DG*7O?K.Z1L68DO&Q3;%YN<RYG#X<R(@Z54+WH&8,CWD@L]]&;&
MS"^"0.<S**D^DW,0J)E(55*#6S4-]%P!+9Q3R8,X#+.@I$QXHX&3/:C10%:&
M,P$/BNBJ+*E:70&7RZ$7>1O!(YO.C!4$H\&<3N$)S)?Y@\)=T* 4K 2AF11$
MP63H74875YFU=P9?&2QU:TWL2<92OMC-IV+HA980<,B-1:#XMX!KX-P"(8UO
M:TRO"6D=V^L-^D=W=CS+F&JXEOQ/5IC9T.M[I( )K;AYE,L_8'V>U.+EDFOW
M2Y:U;99Y)*^TD>7:&1F43-3_]/LZ#RV'?GC (5X[Q(YW'<BQO*&&C@9*+HFR
MUHAF%^ZHSAO),6$OY<DHU#+T,Z/+!66<CCE\P O^\$1Q\01YI9AAH,GILU7I
MSB P&,MZ!/D:]ZK&C0_@1C&YE\+,-+D5!12O 0(DV3"--TROXJ.(-Y"?D23R
M21S&T1&\I#EYXO"2 WB?Q *TP?HRVB<W,#:$BH+<?JN869%6#OZZ'&NCL'K^
M/A*TVP3MNJ#= T&?L*F*B@.1$[*;^G;81\BER!EGU%;OO@LX&LDV\X6>TQR&
M'G:K!K4 ;_0\ S*1'#N1B2DQ-CAAFM!-3UI:]!4M;6GI+2V%M!1>*&&"Y%3/
M7-+< C!S"[3&?!*IL#,PHXCY G68%@:Z&B1R+<LY%:O?-*Z$EIP5U"#P%>54
MY)@+6]-8@LY:5AH#Z<X%WE0.Y1A44PH[DA#QM"%W2FI-O@@<59S]@\!W.*+T
MKO@S[I'4K3:L= 0^4J;(5\HK^)E :BX52NN\M))Q0M+$CY(4%[_^TH^C^'=<
MG69II]:$O1 7?;\;9J\M>ATG3\[/;:/!:IUK,JDP3R3J^U'<;>PW_VMQST_/
MHQUE+;VO!,O9G/(=IG'HQUG2F)\B12M*^R3J^KVTI<DZ3M3MD6=I$.F$G$=^
M&L=O3A!V:DTWM9HD1)#PM4F4=-::I$>.M%_:M%_Z[O:[W];FMNWV]=E1R/U]
MMJV!B:V!A:T!_>/FH@K(% 0HROG*?6P*@E^NN6*Y=1\;+#R+J61)<EF6H'*&
MZ;5ZV\\VN+4\(_OZO&YQK%3MNB_G5&LV8;F;+Y:;E>[A][8,Y/_>O0?'R@F)
M(RS@<UQ$L9_ULO8EMBCV0C^)$UOM81:U:W!;:<?K*6OJ*?M)XWR\LGERWY$*
MV=Q38S6K??5V-.3[Y_J;^][>%PXB@\9,_K@@D77>8EVN6?^G:[TL,:X;E&ZJ
M[AV3[['Y#-J>B&+-"B KH*H]7W;'R?JV[W!.&^3SVO/M#'S[OS._#N+OJZ:@
M]2[#9IVZUZ?&E%;"U$^T1MH\<"_K=]W6O'X=8Z%/[5>'PP1=P[,>3B55OSCK
MC9%S]\H;2X-O1K><X2,=E#5 _41*L]G8 ,VS?_0O4$L#!!0    ( %2!=E3,
M&FN4T@(  %D&   9    >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;(55VV[;
M, S]%<+80P,4]35M%R0!DEZP 2L0--WV,.Q!L>E8J"RYDMRT?S]*3MP42#(@
MD"6*/.2A2&:\4?K95(@6WFHAS22HK&U&86CR"FMF+E2#DFY*I6MFZ:C7H6DT
MLL(;U2),HN@RK!F7P73L90L]':O6"BYQH<&T=<WT^QR%VDR".-@)'OFZLDX0
M3L<-6^,2[<]FH>D4]B@%KU$:KB1H+"?!+![-,Z?O%7YQW)B]/3@F*Z6>W>%[
M,0DB%Q *S*U#8/1YQ1L4P@%1&"];S*!WZ0SW]SOT>\^=N*R8P1LE?O/"5I/@
M.H "2]8*^Z@VWW#+9^CP<B6,7V'3Z6;D,6^-5?76F,XUE]V7O6WSL&=P'1TQ
M2+8&B8^[<^2CO&663<=:;4 [;4)S&T_56U-P7+I'65I-MYSL['2AZ7VU?0<F
M"[A[:7E#&;=P]L16 LU@'%IRXE3#? LX[P"3(X!Q @]*VLK G2RP^ P04G1]
MB,DNQ'ER$O$6\PM(XW-(HB0^@9?VE%./E_Z'\CDL!".NGYG_F:V,U50L?T^X
MRGI7F7>5'7&UI!XJ6H&@2CB<Z4,)/HGING1D&I;C)* V-*A?,9@^50AH+*<R
MQ0):@V4K0%"]&^>ZV7>-/56F$9B!4@EJ33."^U9+;ELG);V2O[F]@3B"=V3:
MP(VJF]:BWH-(MU=+5=J-P]L)?B"U2J5$ ;PF]Z_HU$G,2Y\,X:X_I^0#-%?4
M\\81(4U+S+H(N5S#&9<D4:TA"S,8 =4&UBL*:5<?;HF.,?D"R66W'*(29Y ,
MLV.1?XW<[W#$Y[#6RAC(T@C2JPAF>=[6K?!O42"]4LZ9GT%GZ>7U@-8X'1R%
MDC2)O\!E0LOP"@X58;C7[C7JM1]JAM+62MMU?B_MY^:L&Q<?ZMW0?6!ZS:6A
M]RC)-+JX&@:@NT'6':QJ_/!8*4NCR&\KFOVHG0+=ETK9W<$YZ/]-IO\ 4$L#
M!!0    ( %2!=E3T(24>C@(  ' %   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;(U474_;,!3]*U=Y JDB7Z6PJHW4 M,F#5'1,1ZF/;C)36/AV)GM
M4/CWNW;24"2H]I+8U_<<GWOMX]E.Z2=3(5IXJ84T\Z"RMIF&H<DKK)DY4PU*
M6BF5KIFEJ=Z&IM'("@^J19A$T22L&9=!-O.QE<YFJK6"2UQI,&U=,_VZ1*%V
M\R .]H%[OJVL"X39K&%;7*-]:%::9N' 4O :I>%*@L9R'BSBZ7+L\GW"+XX[
M<S &5\E&J2<W^5[,@\@)0H&Y=0R,?L]XA4(X(I+QM^<,ABT=\'"\9__J:Z=:
M-LS@E1*/O+#5/+@,H,"2M<+>J]TW[.LY=WRY$L9_8=?G1@'DK;&J[L&DH.:R
M^[.7O@__ TAZ0.)U=QMYE=?,LFRFU0ZTRR8V-_"E>C2)X](=RMIJ6N6$L]D/
M90RL4,.Z8AKAY"?;"#2GL] 2N4L)\YYHV1$EGQ#%"=PJ:2L#-[+ XCU!2*H&
M:<E>VC(YRGB-^1FD\0B2*(F/\*5#J:GG2S_ANV%:<KD]+/?W8F.LIIOQYPC_
M>. ?>_[Q)_QK,DS1"@15PD):7G#1NBL':\Q;S2U'ZLU++EIJ#Y1:U7"EZJ:U
MS%]/ KT_BX^.X*@ Y]^I:5B.\X ,:E _8Y M+% CL=X0[[Z9P&3A!M$(;(5>
M!I.O@'MQ+E@J08:E?D&C+%(Y3(A7&&HR;S6=<$D(U1IB-:?3#[9S6\':JOP)
M[AI7K8%D%*<)?)F,X9%IS:2E4#Q*SR]H99)>PCW2P?#<DIH.^" YY4RB,:3C
M"#XZKO# !37JK?>Z@5RUTG:&&*+#<[+H7/26WKU%MTQO.:D46!(T.KLX#T!W
M_NXF5C7>4QMER:%^6-&3B-HET'JIJ&G]Q&TP/++9/U!+ P04    " !4@794
M;LSS_<@"  !W!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6RE5=]O
MTS 0_E=. 0&3QO*CW5:5-E*[,8'$I&D;XP'QX"27QIIC!]MIM_^>LY.& EOW
MP$OL.]]]=]_9=YEME+XW%:*%AUI(,P\J:YMI&)J\PIJ9(]6@I)-2Z9I9$O4J
M-(U&5GBG6H1)%)V$->,R2&=>=Z73F6JMX!*O-)BVKIE^7*)0FWD0!UO%-5]5
MUBG"=-:P%=Z@_=I<:9+" :7@-4K#E02-Y3Q8Q-/EV-E[@SN.&[.S!\<D4^K>
M"9^+>1"YA%!@;AT"HV6-9RB$ Z(T?O:8P1#2.>[NM^@7GCMQR9C!,R6^\<)6
M\V 20($E:X6]5IM/V/,Y=GBY$L9_8=/9GE#$O#56U;TSR367W<H>^CKL.$RB
M9QR2WB'Q>7>!?);GS+)TIM4&M+,F-+?Q5+TW)<>ENY0;J^F4DY]-+QC7<,=$
MBW")S+0:J>+6P+M;E@DT![/04A1G&^8]XK)#3)Y!C!.X5-)6!C[* HL_ 4)*
M;\@QV>:X3/8BGF-^!*/X$)(HB??@C0;.(X\W>IGS.3>Y4(ZV@>^+S%A-S^3'
MGACC(<;8QQ@_$^.&NJ=H!8(J82<>20MCD K<5[L >IK7F+=:<[F")3/</%7S
MO=%<YTY-PW*<!]2:!O4:@_2V0CA3=</DXUL#)9=,YIP)8%T"3!8@.,NXX)83
M?5LQ"QO42)V2JU9:RHV:'DA;.@+KC@ U$C7C-M_,Y4N(CAA=$]89ZN&J?(B_
MM5$?@S)2@D8"/34N*;AJ#9F;@^D3./]B?,$U"HC[->G7$=PJ2PSWGW87,(5+
MIN_1NF<.QA'JRO >V)IQX=6.OF&T>0UO7DV2./E N]/H<)2,7E+%D\/H)'Y)
M];]83SW4<&<8U*A7?N09\%?:S85!.TS513=,?IMW(YDJM.+2@,"27*.CT^,
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M[&),);3-X]-LO*GBA;\VGIZ/N-S1>XTV*-#YQAA_V 0'W3^ ^5]02P,$%
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M0WE.<:-!F>X &7T?!Y/V@9EZ_+6V) ZX#U>-Y=AGSCCRP*=<^)2$INZ/*)Q
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M':41H/=+(?1V8PPT?P)F_P-02P,$%     @ 5(%V5&,C&-LN!0  T0T  !D
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M=7(CQ]<_PO>,&IG*"F!5#E/<T"VNZ4X:N%6*52NT]B6DLC**+A@8"3-4=E:
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MP;U LLAS+%YO@/+=U.D[^P\/9)TI\\&-HPU>PP+4X^9>Z)E;LZ0D!R8)9TC
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MWG//]7%\G6ZX>)(%@$(O)65RXA5*5>>^+[,"2BQ/>05,KZRX*+'20['V924
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M2%\(HBG3S4#QRE:Z1ZYTW;3=0C]M0!@#O;[B7&T')H![+$W_ E!+ P04
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MLY>U<'AMZD=94+6(/D108"G:FN[-[C/V?H+ W-0N?&'7K;T81Y"WCHSJP:Q
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MUH=)]LV!:O2?%*A^XYP;IMMS O6(JN.!ZEN^]6&^_8UD!>&O^LL"I/SL1UF
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MU?M*VM'.\1T(2<_')VZT=,PL7@-96E7_2IK%YL":ZK&9;!N^&&X"X';'IP^
M)F1L)N3ND#VC%8#;S2 $L>MYSBDM=\TT1K8F9VPFY]J(?B(TV] FYY8-Q] T
M16,S19\&^V"' +<I> "+9F+L6W+>Y=T!K!D6FTL1:S*TK@24PF8ET%^#$LW:
MQ)*U5V>W"Y3DD[*XIRE'-%,32Z9F%[0-E.S34KT/E*9M8DG;RPOZ!Z1-XCWA
M3#1]$TOZ9F<W$8@UE9-&(]^2RHU,:@^QHQ.%QOYI(T%-L]P3.BT0R[1@8E1[
M6SHZ64>V'*/4O$\L>9]=U%E0TGT[5)KRR?12FOW#I@+15$_,']W=P?AR->2
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M- UZ,U!\8WO<>ZYTQVQ?"WVI(<($Z.\KSM7SP"S079.6_P-02P,$%     @
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M[T&8 ;I_QKG:5\P$Y3^&X5]02P,$%     @ 5(%V5(.S%QB9 P  ? P  !D
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M"5P'J.<)8W(WT"^H>];P+U!+ P04    " !4@794"1HKIIH#  "L"@  &0
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M(*TO"_/- -(*S/-<"/T^L*?2[BMD]1M02P,$%     @ 5(%V5/?9_(K$ P
MU T  !D   !X;"]W;W)K<VAE971S+W-H965T-3DN>&ULK5?O;]LV$/U7"*$#
M$J"U1/EW81MH;'3+D&9!O:P8AGU@I+--E!(UDHZ<87_\CI(L.;',&5F^6*+$
M=_?N\?A,37*IONL-@"&[1*1ZZFV,R3[ZOHXVD##=D1FD^&8E5<(,#M7:UYD"
M%A>@1/AA$ S\A/'4FTV*9W=J-I%;(W@*=XKH;9(P]70%0N93CWK[!U_Y>F/L
M W\VR=@:EF#NLSN%([^.$O,$4LUE2A2LIMXG^G$1%H!BQF\<<GUP3VPI#U)^
MMX/K>.H%EA$(B(P-P?#R"',0PD9"'G]50;TZIP4>WN^C?RZ*QV(>F(:Y%-]X
M;#93;^21&%9L*\Q7F?\$54%]&R^20A>_)*_F!AZ)MMK(I (C@X2GY97M*B$.
M +1W A!6@/!<0+<"=,\%]"I KU"F+*708<$,FTV4S(FRLS&:O2G$+-!8/D_M
MNB^-PK<<<69VG48R ?(KVX$F'\@M4XK9E2 7"S","WV)3^^7"W+Q[I*\(SPE
M7[@0N&)ZXAO,;Z/X497KJLP5GLCU*5,=0L/W) Q"V@*?N^$+B#JD2T_"%^?#
M@^=P'T6KE0MKY<(B7O<<Y?ZXP;?DVD"B_W3$[M:QNT7LWHG8]YUEAZP@!L4$
MB:3*)*X*H/I%2L-VI!A?9* B2,UEFYCN#"'M!,$/#JJ]FFK/&>A.:LT?!! 6
MQ]QN961\^\N-)NA)9&4[Z0F8TN@1&K<B3]=DI61";M'2[E-T*L'_AIA<;;DP
M'["[?D2K(FHKH*V_YB45&A1<K*4]SF@'>^&QI8!^74#?78"2$4"L2UZ:82ER
M5930UN']-@:]=@:#FL'@E0S>D[5"?=N(E"%I^(Q(OYW(L"8R=!*YP5P$S?B_
M1!@>BQ"<6H91G7ODS/VY['9'1X[K2.,WWY@T:/PR</*TC8O_NM8EL9>%52Q"
MTWS"=L^9BG'),L6Q]8TDN>*X26.9IZUF5^89'(@8CDZ(2 _LG/XO>JU,Z!$3
M2L.:266NY:3^(=W!B<:GC8?2T$GW6RW1OM^(Q@I0/-AE7 '9IEO#"X]H91X>
M,Q^,3Y!JS)>ZO7%IK+G^@QZ5DY]!:7AR=4YCE+3W]GW9N!AUV]BK%KY_)-]X
M^'+=6^:<4K@Q/.IVO+W"<[1_))ARYM*@L2\Z?'N%&X.B;H=ZE<*C(_6&P4N%
MG7.>DVT\D([/[N'?\>3M.O TWA<&;ZYOV%A7^/;6%1Z[$NV^T-<]IR3K'YR@
M[??.%Z;6/-5$P I!06>(:%5^0I0#([/B4/T@#1[1B]L-?G:!LA/P_4I*LQ_8
M<WK](3?[%U!+ P04    " !4@794*P^#"SL#  #N$P  #0   'AL+W-T>6QE
M<RYX;6S=6&UKVS 0_BM&':.#$2?QZL9K$M@"A<$V"NV'?2M*+"<"6?)DI4OZ
MZZ>3'.>ENM#UPY;.H;%TC^ZY1W?G6NVP-FO!;A>,F6A5"EF/R,*8ZF,<U[,%
M*VG=4163%BF4+JFQ4SV/ZTHSFM?@5(JXW^VF<4FY)..A7);7I:FCF5I*,R)I
M:XK\[4L^(KWT XD\W43E;$3NS]_^7"IS]2;R][/W9V?=^W=7A_9S![PC<9#T
M8I_4K>UTNT!TWDXPY_09BCI=7%0'I[Y\'O51;I1\\"SR(]08<1;,YDXNG6/<
MU'L\+)3<ECTAWF"9:<FB!RI&9$(%GVH.7@4MN5A[<Q\,,R64CHSM-QNJ!Y;Z
MT<,]/X-6;'A*+I5VL7T$_SUMEA\ FQD(Y$*T OO$&\;#BAK#M+RV$[?8&9]
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M@L@ ]1F@/MXKA$S<!XL3]LGL%=YIEB5)FF(9G4R""B98WM(4?L)LF#;PP.)
MI#_+-5YMO$..]P%6TV,=@NT4[T1LIWBN 0GG#3RR+%QM+ YX8%7 >@?BA^-
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M*^JM!'HKZJT$>BOJK01Z&^IM!'H;ZFT$>AOJ;01ZVV2SA$!O0[V-0&]#O8U
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M#7^R7+T"4$L! A0#%     @ 5(%V5 =!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !4@7942:K,7^T
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 5(%V5-K@%FS5!0
M$18  !@              ("!3Q$  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( %2!=E1@LB2,.0,  ',,   8              " @5H7
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !4@794=[43
M?I$$  #A$   &               @(')&@  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ 5(%V5,[*FV,F P  +PD  !@
M ("!D!\  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( %2!
M=E0__>Y"] 4  /8:   8              " @>PB  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " !4@794KEK.DY@%  !;%0  &
M        @($6*0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( %2!=E2@K ^RSP(  !<&   9              "
M@=57  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 5(%V
M5+D*@OFH!   WPL  !D              ("!VUH  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " !4@794][F0C&8"  !#!0  &0
M        @(&Z7P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( %2!=E11M 42X 0  &4+   9              " @5=B  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ 5(%V5%]IHVA=$@  <#T
M !D              ("!;F<  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " !4@794$15JF+L$  !O#   &0              @($">@
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( %2!=E1>&N)>
MHP,  *$'   9              " @?1^  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ 5(%V5+%B93TP"P  *1T  !D
M ("!SH(  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !4
M@794KZ=8*:H"  #?!0  &0              @($UC@  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( %2!=E1:&MMG"0X  ,\H   9
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M970R-BYX;6Q02P$"% ,4    " !4@794;LSS_<@"  !W!@  &0
M    @(&]K   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M %2!=E1CVWIM=@(  $0%   9              " @;RO  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ 5(%V5(V@G==( P  #0@  !D
M             ("!:;(  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " !4@794R@<4'&L$  #7"P  &0              @('HM0  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( %2!=E013;5D8P0
M ! ,   9              " @8JZ  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ 5(%V5&,C&-LN!0  T0T  !D              ("!
M)+\  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !4@794
MA^410DX"  #*!0  &0              @(&)Q   >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( %2!=E1NB:.&<P(  'L'   9
M      " @0['  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ 5(%V5,CLC0_$ P  3A   !D              ("!N,D  'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !4@794]$I *Y<"  "]!P
M&0              @(&SS0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( %2!=E1F402=F@(  -X'   9              " @8'0  !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 5(%V5&9JMRS>
M @  'PH  !D              ("!4M,  'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " !4@79448[($#L"   B!0  &0
M@(%GU@  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( %2!
M=E0K?_*-SP(  #@)   9              " @=G8  !X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ 5(%V5!ICS[_* @  V H  !D
M         ("!W]L  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
M    " !4@794S-5BRFX"  !>!@  &0              @('@W@  >&PO=V]R
M:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( %2!=E1MU+>E-@(  $P%
M   9              " @87A  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL
M4$L! A0#%     @ 5(%V5+<))_G0 @  \ D  !D              ("!\N,
M 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " !4@794#,W$
M>9H"  !6!P  &0              @('YY@  >&PO=V]R:W-H965T<R]S:&5E
M=#0U+GAM;%!+ 0(4 Q0    ( %2!=E0^_I#:WP0   H7   9
M  " @<KI  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
M5(%V5$+Y<J1A!P  ^",  !D              ("!X.X  'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    " !4@7947Y_!;G8&  #/(P  &0
M            @(%X]@  >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( %2!=E27MCCY:P,  #(-   9              " @27]  !X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ 5(%V5-E7P4FK @
M*@@  !D              ("!QP ! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    " !4@794: BU0P8#  "&"@  &0              @(&I
M P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( %2!=E2G
M2:T$QP(  *0&   9              " @>8& 0!X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ 5(%V5/-NXL,5 P  /0P  !D
M     ("!Y D! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %2!=E2H4[. C@,  )$,   9              "
M@:L: 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ 5(%V
M5/?9_(K$ P  U T  !D              ("!<!X! 'AL+W=O<FMS:&5E=',O
M<VAE970U.2YX;6Q02P$"% ,4    " !4@794*P^#"SL#  #N$P  #0
M        @ %K(@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( %2!=E27BKL<
MP    !,"   +              "  =$E 0!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( %2!=E1D=RDRI@0   HG   /              "  ;HF 0!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " !4@794678!^/4!   X(P  &@
M    @ &-*P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" !4@794%\C,&]L!  #1(@  $P              @ &Z+0$ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     0P!# $P2  #&+P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>142</ContextCount>
  <ElementCount>328</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - The Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/TheBusiness</Role>
      <ShortName>The Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Available-for-Sale-Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecurities</Role>
      <ShortName>Available-for-Sale-Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/LossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2130109 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2136110 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2142111 - Disclosure - Research Funding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ResearchFunding</Role>
      <ShortName>Research Funding</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2144112 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2151113 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Available-for-Sale-Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesTables</Role>
      <ShortName>Available-for-Sale-Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AvailableforSaleSecurities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/PropertyandEquipment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/LossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/LossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2320305 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/FairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2323306 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AccruedLiabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2326307 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/OperatingLeases</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2331308 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/StockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2337309 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/ShareBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2345310 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - The Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/TheBusinessDetails</Role>
      <ShortName>The Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/TheBusiness</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Available-for-Sale-Securities - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails</Role>
      <ShortName>Available-for-Sale-Securities - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Available-for-Sale-Securities - Classification on Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationonConsolidatedBalanceSheetsDetails</Role>
      <ShortName>Available-for-Sale-Securities - Classification on Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Available-for-Sale-Securities - Contractual Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails</Role>
      <ShortName>Available-for-Sale-Securities - Contractual Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Property and Equipment - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails</Role>
      <ShortName>Property and Equipment - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Property and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/PropertyandEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/LossPerShareDetails</Role>
      <ShortName>Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/LossPerShareTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2424410 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2427411 - Disclosure - Operating Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesNarrativeDetails</Role>
      <ShortName>Operating Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2428412 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails</Role>
      <ShortName>Operating Leases - Balance Sheet Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2429413 - Disclosure - Operating Leases - Future Minimum Lease Payments Under Lease Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails</Role>
      <ShortName>Operating Leases - Future Minimum Lease Payments Under Lease Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2432414 - Disclosure - Stockholders' Equity - Equity Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails</Role>
      <ShortName>Stockholders' Equity - Equity Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2433415 - Disclosure - Stockholders' Equity - Equity Issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails</Role>
      <ShortName>Stockholders' Equity - Equity Issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2434416 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Stock Options and Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2435417 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails</Role>
      <ShortName>Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2438418 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2439419 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails</Role>
      <ShortName>Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2440420 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails</Role>
      <ShortName>Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2441421 - Disclosure - Share-Based Compensation - Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails</Role>
      <ShortName>Share-Based Compensation - Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2443422 - Disclosure - Research Funding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ResearchFundingDetails</Role>
      <ShortName>Research Funding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/ResearchFunding</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2446423 - Disclosure - Income Taxes - Loss from Operations Before Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxesLossfromOperationsBeforeProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Loss from Operations Before Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2447424 - Disclosure - Income Taxes - Components of Benefit from Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Components of Benefit from Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2448425 - Disclosure - Income Taxes - Effective Income Tax Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails</Role>
      <ShortName>Income Taxes - Effective Income Tax Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2449426 - Disclosure - Income Taxes - Components of Deferred Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="clbs-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2450427 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="clbs-20211231.htm">clbs-20211231.htm</File>
    <File>clbs-20211231.xsd</File>
    <File>clbs-20211231_cal.xml</File>
    <File>clbs-20211231_def.xml</File>
    <File>clbs-20211231_lab.xml</File>
    <File>clbs-20211231_pre.xml</File>
    <File>clbs-ex311_20211231xq4.htm</File>
    <File>clbs-ex32_20211231.htm</File>
    <File>exh23120211231.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="562">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "clbs-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 142,
   "dts": {
    "calculationLink": {
     "local": [
      "clbs-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "clbs-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "clbs-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "clbs-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "clbs-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "clbs-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 490,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 8,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 12
   },
   "keyCustom": 61,
   "keyStandard": 267,
   "memberCustom": 13,
   "memberStandard": 36,
   "nsprefix": "clbs",
   "nsuri": "http://www.caladrius.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.caladrius.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Available-for-Sale-Securities",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecurities",
     "shortName": "Available-for-Sale-Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Property and Equipment",
     "role": "http://www.caladrius.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Loss Per Share",
     "role": "http://www.caladrius.com/role/LossPerShare",
     "shortName": "Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Fair Value Measurements",
     "role": "http://www.caladrius.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Accrued Liabilities",
     "role": "http://www.caladrius.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Operating Leases",
     "role": "http://www.caladrius.com/role/OperatingLeases",
     "shortName": "Operating Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130109 - Disclosure - Stockholders' Equity",
     "role": "http://www.caladrius.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136110 - Disclosure - Share-Based Compensation",
     "role": "http://www.caladrius.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142111 - Disclosure - Research Funding",
     "role": "http://www.caladrius.com/role/ResearchFunding",
     "shortName": "Research Funding",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.caladrius.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144112 - Disclosure - Income Taxes",
     "role": "http://www.caladrius.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151113 - Disclosure - Contingencies",
     "role": "http://www.caladrius.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Available-for-Sale-Securities (Tables)",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables",
     "shortName": "Available-for-Sale-Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.caladrius.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - Loss Per Share (Tables)",
     "role": "http://www.caladrius.com/role/LossPerShareTables",
     "shortName": "Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320305 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.caladrius.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323306 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://www.caladrius.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326307 - Disclosure - Operating Leases (Tables)",
     "role": "http://www.caladrius.com/role/OperatingLeasesTables",
     "shortName": "Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://www.caladrius.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331308 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.caladrius.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337309 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345310 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.caladrius.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "ifac165fbd5294cbbae45708def42554a_I20170228",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GrantsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - The Business (Details)",
     "role": "http://www.caladrius.com/role/TheBusinessDetails",
     "shortName": "The Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i62dba77d3e2d4497b9f85f984cfba083_I20171231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GrantsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i71b84bd2ef5e48a7bdb1280f312427a2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i71b84bd2ef5e48a7bdb1280f312427a2_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Available-for-Sale-Securities - Summary (Details)",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails",
     "shortName": "Available-for-Sale-Securities - Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Available-for-Sale-Securities - Classification on Consolidated Balance Sheets (Details)",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationonConsolidatedBalanceSheetsDetails",
     "shortName": "Available-for-Sale-Securities - Classification on Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "iea9f8dda92dc4bd8a85d72b68a1c2034_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Available-for-Sale-Securities - Contractual Maturities (Details)",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails",
     "shortName": "Available-for-Sale-Securities - Contractual Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Property and Equipment - Summary (Details)",
     "role": "http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails",
     "shortName": "Property and Equipment - Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Property and Equipment - Narrative (Details)",
     "role": "http://www.caladrius.com/role/PropertyandEquipmentNarrativeDetails",
     "shortName": "Property and Equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "ia36b0d5241f648078a95606bbd0ff79d_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Loss Per Share (Details)",
     "role": "http://www.caladrius.com/role/LossPerShareDetails",
     "shortName": "Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "ia36b0d5241f648078a95606bbd0ff79d_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i26b465f7839c460fad563a663abb5e53_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.caladrius.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i26b465f7839c460fad563a663abb5e53_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424410 - Disclosure - Accrued Liabilities (Details)",
     "role": "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "clbs:NumberOfOfficesUnderOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "office",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427411 - Disclosure - Operating Leases - Narrative (Details)",
     "role": "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails",
     "shortName": "Operating Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "clbs:NumberOfOfficesUnderOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "office",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428412 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)",
     "role": "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails",
     "shortName": "Operating Leases - Balance Sheet Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429413 - Disclosure - Operating Leases - Future Minimum Lease Payments Under Lease Agreements (Details)",
     "role": "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails",
     "shortName": "Operating Leases - Future Minimum Lease Payments Under Lease Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "ia3d14c5a5f224864ad0dabc919f68696_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432414 - Disclosure - Stockholders' Equity - Equity Plan (Details)",
     "role": "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails",
     "shortName": "Stockholders' Equity - Equity Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "ia3d14c5a5f224864ad0dabc919f68696_I20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i39237a1f42304c68bc922379c5cafbc9_D20210201-20210228",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433415 - Disclosure - Stockholders' Equity - Equity Issuances (Details)",
     "role": "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails",
     "shortName": "Stockholders' Equity - Equity Issuances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i39237a1f42304c68bc922379c5cafbc9_D20210201-20210228",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i4277098eb8e941d8849e8e36535b5f36_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434416 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)",
     "role": "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails",
     "shortName": "Stockholders' Equity - Stock Options and Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "ib6d2e0cb9f694fe7a859d47739e7393e_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435417 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)",
     "role": "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
     "shortName": "Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "ib6d2e0cb9f694fe7a859d47739e7393e_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements of Operations",
     "role": "http://www.caladrius.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438418 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
     "shortName": "Share-Based Compensation - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "iab051a0f20f54b90a2c3a2ae838bb8ca_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439419 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
     "shortName": "Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "iab051a0f20f54b90a2c3a2ae838bb8ca_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1262c5aee83e44218db30c90579c58ff_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440420 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
     "shortName": "Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1262c5aee83e44218db30c90579c58ff_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1262c5aee83e44218db30c90579c58ff_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441421 - Disclosure - Share-Based Compensation - Valuation Assumptions (Details)",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails",
     "shortName": "Share-Based Compensation - Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1262c5aee83e44218db30c90579c58ff_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "ifac165fbd5294cbbae45708def42554a_I20170228",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GrantsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443422 - Disclosure - Research Funding (Details)",
     "role": "http://www.caladrius.com/role/ResearchFundingDetails",
     "shortName": "Research Funding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "ifac165fbd5294cbbae45708def42554a_I20170228",
      "decimals": "-5",
      "lang": "en-US",
      "name": "clbs:FundingAmountAwarded",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446423 - Disclosure - Income Taxes - Loss from Operations Before Provision for Income Taxes (Details)",
     "role": "http://www.caladrius.com/role/IncomeTaxesLossfromOperationsBeforeProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Loss from Operations Before Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447424 - Disclosure - Income Taxes - Components of Benefit from Income Taxes (Details)",
     "role": "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails",
     "shortName": "Income Taxes - Components of Benefit from Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448425 - Disclosure - Income Taxes - Effective Income Tax Reconciliation (Details)",
     "role": "http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails",
     "shortName": "Income Taxes - Effective Income Tax Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449426 - Disclosure - Income Taxes - Components of Deferred Income Taxes (Details)",
     "role": "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails",
     "shortName": "Income Taxes - Components of Deferred Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i1b0bd8da4fb44e1a9a41a8cdb938cb18_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450427 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.caladrius.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i79f6e5136b8641cfa6b0a6033d36e4f2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Equity",
     "role": "http://www.caladrius.com/role/ConsolidatedStatementsofEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i79f6e5136b8641cfa6b0a6033d36e4f2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:BusinessTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - The Business",
     "role": "http://www.caladrius.com/role/TheBusiness",
     "shortName": "The Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20211231.htm",
      "contextRef": "i0abd5c313f3e44caa002b1fc681e9aa9_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:BusinessTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 51,
   "tag": {
    "clbs_AdditionalPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Purchase Agreement",
        "label": "Additional Purchase Agreement [Member]",
        "terseLabel": "Additional Purchase Agreement"
       }
      }
     },
     "localname": "AdditionalPurchaseAgreementMember",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_AggregateIntrinsicValueOptionExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value, Option Exercised",
        "label": "Aggregate Intrinsic Value, Option Exercised",
        "negatedTerseLabel": "Options exercised, aggregate intrinsic value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueOptionExercised",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AggregateIntrinsicValueWarrantsOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value, Warrants Outstanding",
        "label": "Aggregate Intrinsic Value, Warrants Outstanding",
        "terseLabel": "Warrants outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueWarrantsOutstanding",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AggregateIntrinsicValueWarrantsvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value, Warrants vested",
        "label": "Aggregate Intrinsic Value, Warrants vested",
        "terseLabel": "Warrants exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueWarrantsvested",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value, Warrants vested and expected to vest",
        "label": "Aggregate Intrinsic Value, Warrants vested and expected to vest",
        "terseLabel": "Warrants vested or expected to vest, aggregate intrinsic value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueWarrantsvestedandexpectedtovest",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization Of Accrued Grant Funding Liability To Offset Expense",
        "label": "Amortization Of Accrued Grant Funding Liability To Offset Expense",
        "terseLabel": "Amortization of accrued grant funding to offset expense"
       }
      }
     },
     "localname": "AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/ResearchFundingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AtTheMarketOfferingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering Agreement",
        "label": "At The Market Offering Agreement [Member]",
        "terseLabel": "ATM Agreement"
       }
      }
     },
     "localname": "AtTheMarketOfferingAgreementMember",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.caladrius.com/20211231",
     "xbrltype": "stringItemType"
    },
    "clbs_BusinessTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Business [Text Block]",
        "label": "The Business [Text Block]",
        "terseLabel": "The Business"
       }
      }
     },
     "localname": "BusinessTextBlock",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/TheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clbs_CLBS16TreatmentOfCMDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CLBS16 Treatment Of CMD",
        "label": "CLBS16 Treatment Of CMD [Member]",
        "terseLabel": "CLBS16 Treatment Of CMD"
       }
      }
     },
     "localname": "CLBS16TreatmentOfCMDMember",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_CommonStockWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants, Shares",
        "label": "Common Stock Warrants, Shares",
        "periodEndLabel": "Warrants outstanding, ending balance (shares)",
        "periodStartLabel": "Warrants outstanding, beginning balance (shares)"
       }
      }
     },
     "localname": "CommonStockWarrantsShares",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_DeferredTaxAssetsAccumulatedDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Accumulated Depreciation",
        "label": "Deferred Tax Assets, Accumulated Depreciation",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "DeferredTaxAssetsAccumulatedDepreciation",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_DeferredTaxAssetsRightOfUseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Right Of Use Liability",
        "label": "Deferred Tax Assets, Right Of Use Liability",
        "terseLabel": "Right of use liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsRightOfUseLiability",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Change in State Deferred, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Change in State Deferred, Amount",
        "terseLabel": "Change in state deferred"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeinStateDeferredAmount",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Sale Of State Net Operating Losses",
        "label": "Effective Income Tax Rate Reconciliation, Sale Of State Net Operating Losses",
        "terseLabel": "Sale of New Jersey State NOLs"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationSaleOfStateNetOperatingLosses",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Section 382 NOL Limitation, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Section 382 NOL Limitation, Amount",
        "terseLabel": "Section 382 NOL Limitation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationSection382NOLLimitationAmount",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_EmployeeStockPurchasePlan2012Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan 2012 [Member]",
        "label": "Employee Stock Purchase Plan 2012 [Member]",
        "terseLabel": "2012 ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2012Member",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_EmployeeStockPurchasePlan2017AmendedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan 2017 Amended [Member]",
        "label": "Employee Stock Purchase Plan 2017 Amended [Member]",
        "terseLabel": "Amended 2017 ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2017AmendedMember",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_EmployeeStockPurchasePlan2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan 2017 [Member]",
        "label": "Employee Stock Purchase Plan 2017 [Member]",
        "terseLabel": "2017 ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2017Member",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Maximum Annual Contribution Per Employee",
        "label": "Employee Stock Purchase Plan, Maximum Annual Contribution Per Employee",
        "terseLabel": "Maximum annual contribution per employee"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployee",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Maximum Annual Contribution Per Employee, Percent",
        "label": "Employee Stock Purchase Plan, Maximum Annual Contribution Per Employee, Percent",
        "terseLabel": "Maximum annual contribution per employee as percent of annual salary"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionPerEmployeePercent",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Purchase Price, Percent Of Closing Price On Enrollment Date",
        "label": "Employee Stock Purchase Plan, Purchase Price, Percent Of Closing Price On Enrollment Date",
        "terseLabel": "Purchase price measurement as percent of closing price on enrollment date"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnEnrollmentDate",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Purchase Price, Percent Of Closing Price On Exercise Date",
        "label": "Employee Stock Purchase Plan, Purchase Price, Percent Of Closing Price On Exercise Date",
        "terseLabel": "Purchase price measurement as percent of closing price on exercise date"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanPurchasePricePercentOfClosingPriceOnExerciseDate",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_EquityIncentiveCompensationPlan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Compensation Plan 2018 [Member]",
        "label": "Equity Incentive Compensation Plan 2018 [Member]",
        "terseLabel": "2018 Plan"
       }
      }
     },
     "localname": "EquityIncentiveCompensationPlan2018Member",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_FundingAmountAwarded": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding Amount Awarded",
        "label": "Funding Amount Awarded",
        "terseLabel": "Total funding amount awarded"
       }
      }
     },
     "localname": "FundingAmountAwarded",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/ResearchFundingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_FundingOfGrantAwardCashReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding Of Grant Award, Cash Received",
        "label": "Funding Of Grant Award, Cash Received",
        "terseLabel": "Funding of grant award"
       }
      }
     },
     "localname": "FundingOfGrantAwardCashReceived",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/ResearchFundingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_H.C.WainwrightSalesAmendedAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "H.C. Wainwright Sales Amended Agreement [Member]",
        "label": "H.C. Wainwright Sales Amended Agreement [Member]",
        "terseLabel": "H.C. Wainwright Sales Amended Agreement"
       }
      }
     },
     "localname": "H.C.WainwrightSalesAmendedAgreementMember",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities",
        "label": "Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities",
        "terseLabel": "Accounts payable, accrued liabilities and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_InstitutionalPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Institutional Purchase Agreement",
        "label": "Institutional Purchase Agreement [Member]",
        "terseLabel": "Institutional Purchase Agreement"
       }
      }
     },
     "localname": "InstitutionalPurchaseAgreementMember",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_January2021PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January 2021 Purchase Agreement",
        "label": "January 2021 Purchase Agreement [Member]",
        "terseLabel": "January 2021 Private Placement"
       }
      }
     },
     "localname": "January2021PurchaseAgreementMember",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]",
        "label": "Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet"
       }
      }
     },
     "localname": "LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clbs_LincolnParkAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lincoln Park Agreement [Member]",
        "label": "Lincoln Park Agreement [Member]",
        "terseLabel": "Lincoln Park Agreement"
       }
      }
     },
     "localname": "LincolnParkAgreementMember",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_LossOnSaleOfNetOperatingLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss On Sale Of Net Operating Losses",
        "label": "Loss On Sale Of Net Operating Losses",
        "terseLabel": "Loss on sale of NOLs"
       }
      }
     },
     "localname": "LossOnSaleOfNetOperatingLosses",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_MarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities",
        "label": "Marketable Securities [Member]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesMember",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationonConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_MilestonePaymentOnGrantAwardCashReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment On Grant Award, Cash Received",
        "label": "Milestone Payment On Grant Award, Cash Received",
        "terseLabel": "Milestone payment received on grant award"
       }
      }
     },
     "localname": "MilestonePaymentOnGrantAwardCashReceived",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/ResearchFundingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_NetDeferredTaxAssetsAndLiabilitiesGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Deferred Tax Assets And Liabilities, Gross",
        "label": "Net Deferred Tax Assets And Liabilities, Gross",
        "totalLabel": "Net deferred tax assets and liabilities"
       }
      }
     },
     "localname": "NetDeferredTaxAssetsAndLiabilitiesGross",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_NumberOfOfficesUnderOperatingLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Offices Under Operating Leases",
        "label": "Number Of Offices Under Operating Leases",
        "terseLabel": "Number of offices under operating leases"
       }
      }
     },
     "localname": "NumberOfOfficesUnderOperatingLeases",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "clbs_NumberofOfferingPeriodsEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Offering Periods, Employee Stock Purchase Plan",
        "label": "Number of Offering Periods, Employee Stock Purchase Plan",
        "terseLabel": "Number of offering periods"
       }
      }
     },
     "localname": "NumberofOfferingPeriodsEmployeeStockPurchasePlan",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "clbs_OfferingPeriodsEmployeeStockPurchasePlanTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering Periods, Employee Stock Purchase Plan, Term",
        "label": "Offering Periods, Employee Stock Purchase Plan, Term",
        "terseLabel": "Term of offering period"
       }
      }
     },
     "localname": "OfferingPeriodsEmployeeStockPurchasePlanTerm",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clbs_OperatingLeaseRightOfUseAssetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Right-Of-Use Asset",
        "label": "Operating Lease, Right-Of-Use Asset [Abstract]",
        "terseLabel": "Right-of Use Assets:"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAbstract",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Annual Available, Five Years, Net Unrealized Built In Gain",
        "label": "Operating Loss Carryforwards, Annual Available, Five Years, Net Unrealized Built In Gain",
        "terseLabel": "Possible additional NOLs for five years resulting from Net Unrealized Built-in Gain rules"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_OperatingLossCarryforwardsBeforeWriteDown": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Before Write Down",
        "label": "Operating Loss Carryforwards, Before Write Down",
        "terseLabel": "Net operating loss carryforwards, prior to write down"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsBeforeWriteDown",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_OperatingLossCarryforwardsSetToExpireWrittenDown": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Set To Expire, Written Down",
        "label": "Operating Loss Carryforwards, Set To Expire, Written Down",
        "terseLabel": "Write down of NOLs set to expire unutilized"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsSetToExpireWrittenDown",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_PreferredStockLiquidationPreferenceShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Liquidation Preference, Share",
        "label": "Preferred Stock, Liquidation Preference, Share",
        "terseLabel": "Preferred stock, liquidation preference (shares)"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceShare",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_PreferredStockSharesDesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Shares Designated",
        "label": "Preferred Stock, Shares Designated",
        "terseLabel": "Preferred stock, shares designated (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesDesignated",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sale Of Net Operating Losses, NJEDA Program",
        "label": "Proceeds From Sale Of Net Operating Losses, NJEDA Program",
        "terseLabel": "Proceeds from sale of NOLs"
       }
      }
     },
     "localname": "ProceedsFromSaleOfNetOperatingLossesNJEDAProgram",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross",
        "label": "Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross",
        "terseLabel": "Proceeds from sale of NOLs, gross"
       }
      }
     },
     "localname": "ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_ProgressPaymentOnGrantAwardCashReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Progress Payment On Grant Award, Cash Received",
        "label": "Progress Payment On Grant Award, Cash Received",
        "terseLabel": "Progress payment received on grant award"
       }
      }
     },
     "localname": "ProgressPaymentOnGrantAwardCashReceived",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/ResearchFundingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement, Accelerated Purchase Specified Stock Floor Price",
        "label": "Purchase Agreement, Accelerated Purchase Specified Stock Floor Price",
        "terseLabel": "Accelerated purchases specified floor price threshold for directed purchases"
       }
      }
     },
     "localname": "PurchaseAgreementAcceleratedPurchaseSpecifiedStockFloorPrice",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty",
        "label": "Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty",
        "terseLabel": "Maximum beneficial ownership allowable per agreement (percent)"
       }
      }
     },
     "localname": "RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_RestrictedStockAndRestrictedStockUnitsIssuedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock And Restricted Stock Units Issued [Abstract]",
        "label": "Restricted Stock And Restricted Stock Units Issued [Abstract]",
        "terseLabel": "Restricted Stock and Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockAndRestrictedStockUnitsIssuedAbstract",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement",
        "label": "Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement",
        "terseLabel": "Aggregate offering amount authorized per agreement"
       }
      }
     },
     "localname": "SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase",
        "label": "Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase",
        "terseLabel": "Number of shares allowable to direct for Regular Purchase (shares)"
       }
      }
     },
     "localname": "SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Commission On Gross Proceeds Due To Third Party Upon, Percent",
        "label": "Sale Of Stock, Commission On Gross Proceeds Due To Third Party Upon, Percent",
        "terseLabel": "Commission on gross proceeds due to third party (percent)"
       }
      }
     },
     "localname": "SaleOfStockCommissionOnGrossProceedsDueToThirdPartyUponPercent",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase",
        "label": "Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase",
        "terseLabel": "Maximum obligation per directed purchase transaction for Regular Purchase"
       }
      }
     },
     "localname": "SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase",
        "label": "Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase",
        "terseLabel": "Maximum shares allowed in Accelerated Purchase as percent of shares in Regular Purchase (percent)"
       }
      }
     },
     "localname": "SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period",
        "label": "Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period",
        "terseLabel": "Maximum shares allowed in Accelerated Purchase as percent of shares traded during specified period (percent)"
       }
      }
     },
     "localname": "SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_Sharesvestedandexpectedtovest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "shares, vested and expected to vest",
        "label": "shares, vested and expected to vest",
        "terseLabel": "Warrants vested or expected to vest (shares)"
       }
      }
     },
     "localname": "Sharesvestedandexpectedtovest",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Issued As Consideration",
        "label": "Stock Issued During Period, Shares, Issued As Consideration",
        "terseLabel": "Commitment shares issued as consideration per agreement (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedAsConsideration",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_TermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Of Agreement",
        "label": "Term Of Agreement",
        "terseLabel": "Term of agreement (in months)"
       }
      }
     },
     "localname": "TermOfAgreement",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clbs_TreasuryStockPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury Stock, Policy [Policy Text Block]",
        "label": "Treasury Stock, Policy [Policy Text Block]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockPolicyPolicyTextBlock",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clbs_WarrantsCanceled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Canceled",
        "label": "Warrants Canceled",
        "negatedTerseLabel": "Warrants forfeited (shares)"
       }
      }
     },
     "localname": "WarrantsCanceled",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Exercised",
        "label": "Warrants Exercised",
        "negatedTerseLabel": "Warrants exercised (shares)"
       }
      }
     },
     "localname": "WarrantsExercised",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expired",
        "label": "Warrants Expired",
        "negatedTerseLabel": "Warrants expired (shares)"
       }
      }
     },
     "localname": "WarrantsExpired",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Granted",
        "label": "Warrants Granted",
        "terseLabel": "Warrants granted (shares)"
       }
      }
     },
     "localname": "WarrantsGranted",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Other Disclosures [Abstract]",
        "label": "Warrants Other Disclosures [Abstract]",
        "terseLabel": "Warrants, Weighted Average Contractual Term and Intrinsic Value"
       }
      }
     },
     "localname": "WarrantsOtherDisclosuresAbstract",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clbs_WarrantsVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Vested",
        "label": "Warrants, Vested",
        "terseLabel": "Warrants exercisable (shares)"
       }
      }
     },
     "localname": "WarrantsVested",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsWeightedAverageExercisePriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Weighted Average Exercise Price [Roll Forward]",
        "label": "Warrants Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Warrants, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "WarrantsWeightedAverageExercisePriceRollForward",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsCanceled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Canceled",
        "label": "Weighted Average Exercise Price, Warrants Canceled",
        "terseLabel": "Warrants forfeited (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsCanceled",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Exercisable",
        "label": "Weighted Average Exercise Price, Warrants Exercisable",
        "terseLabel": "Warrants exercisable (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsExercisable",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Exercised",
        "label": "Weighted Average Exercise Price, Warrants Exercised",
        "terseLabel": "Warrants exercised (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsExercised",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Expired",
        "label": "Weighted Average Exercise Price, Warrants Expired",
        "terseLabel": "Warrants expired (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsExpired",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Granted",
        "label": "Weighted Average Exercise Price, Warrants Granted",
        "terseLabel": "Warrants granted (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsGranted",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Outstanding",
        "label": "Weighted Average Exercise Price, Warrants Outstanding",
        "periodEndLabel": "Warrants outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Warrants outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsOutstanding",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest",
        "label": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest",
        "terseLabel": "Warrants vested or expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest",
        "label": "Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest",
        "terseLabel": "Warrants vested or expected to vest, weighted average remaining contractual term (in years)"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clbs_WeightedAverageRemainingContractualTermwarrantoutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Contractual Term warrant outstanding",
        "label": "Weighted Average Remaining Contractual Term warrant outstanding",
        "terseLabel": "Warrants outstanding, weighted average remaining contractual term (in years)"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermwarrantoutstanding",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clbs_WeightedAverageRemainingContractualTermwarrantsvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "weighted Average Remaining Contractual Term, warrants vested",
        "label": "weighted Average Remaining Contractual Term, warrants vested",
        "terseLabel": "Warrants exercisable, weighted average remaining contractual term (in years)"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermwarrantsvested",
     "nsuri": "http://www.caladrius.com/20211231",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r195",
      "r205",
      "r239",
      "r240",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r394",
      "r440",
      "r441",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r195",
      "r205",
      "r239",
      "r240",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r394",
      "r440",
      "r441",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r195",
      "r205",
      "r230",
      "r239",
      "r240",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r394",
      "r440",
      "r441",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r195",
      "r205",
      "r230",
      "r239",
      "r240",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r394",
      "r440",
      "r441",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r29",
      "r363"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization/accretion on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r407",
      "r431"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "totalLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Abstract]",
        "terseLabel": "Accrued Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r27",
      "r173"
     ],
     "calculation": {
      "http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r45",
      "r46",
      "r47",
      "r425",
      "r446",
      "r447"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r44",
      "r47",
      "r54",
      "r55",
      "r56",
      "r97",
      "r98",
      "r99",
      "r324",
      "r442",
      "r443",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r16",
      "r276",
      "r363"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r273",
      "r274",
      "r275",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r242",
      "r269",
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation of loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r91",
      "r135",
      "r137",
      "r141",
      "r159",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r319",
      "r325",
      "r344",
      "r361",
      "r363",
      "r402",
      "r424"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r41",
      "r91",
      "r159",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r319",
      "r325",
      "r344",
      "r361",
      "r363"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.caladrius.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets, fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r146",
      "r166"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails",
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Greater than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r150",
      "r152",
      "r419"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Greater than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r150",
      "r151",
      "r418"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r144",
      "r147",
      "r166",
      "r406"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Estimated fair value",
        "verboseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationonConsolidatedBalanceSheetsDetails",
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesContractualMaturitiesDetails",
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r244",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails",
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationonConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationonConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of California.",
        "label": "California Franchise Tax Board [Member]",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r24",
      "r83"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationonConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Available-for-Sale-Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r76",
      "r83",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r76",
      "r345"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of shares per each warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares called by warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r35",
      "r182",
      "r408",
      "r430"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r183",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15",
      "r363"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, authorized 500,000,000 shares; issued 59,800,792 and 19,389,413 shares, at December 31, 2021 and December 31, 2020, respectively; and outstanding, 59,789,712 and 19,378,333 shares, at December 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r50",
      "r52",
      "r53",
      "r63",
      "r415",
      "r436"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r50",
      "r52",
      "r62",
      "r317",
      "r318",
      "r329",
      "r414",
      "r435"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r50",
      "r52",
      "r61",
      "r316",
      "r329",
      "r413",
      "r434"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r128",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r231",
      "r238",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r297",
      "r304"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "U.S. Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r297",
      "r304",
      "r306"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current income tax provision (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r297",
      "r304"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationonConsolidatedBalanceSheetsDetails",
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r298",
      "r304"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "U.S. Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r81",
      "r92",
      "r298",
      "r304",
      "r305",
      "r306"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred income tax provision (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r12",
      "r13",
      "r288",
      "r403",
      "r423"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "clbs_NetDeferredTaxAssetsAndLiabilitiesGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r298",
      "r304"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "clbs_NetDeferredTaxAssetsAndLiabilitiesGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred Tax Assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r295",
      "r296"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Accumulated net operating losses (tax effected)"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r295",
      "r296"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "auth_ref": [
      "r295",
      "r296"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "terseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r295",
      "r296"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred Tax Liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r295",
      "r296"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofDeferredIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r81",
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r81",
      "r171"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r64",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r110",
      "r112",
      "r114",
      "r115",
      "r116",
      "r120",
      "r121",
      "r334",
      "r335",
      "r416",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Caladrius Biosciences, Inc. common shareholders - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Basic and diluted loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Weighted average common shares outstanding:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r64",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r112",
      "r114",
      "r115",
      "r116",
      "r120",
      "r121",
      "r334",
      "r335",
      "r416",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Caladrius Biosciences, Inc. common shareholders - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r94",
      "r284",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. federal corporate income tax rate (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r407",
      "r431"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Employee-related Liabilities",
        "terseLabel": "Salaries, employee benefits and related taxes"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected weighted-average period in years of compensation cost to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LossPerShareDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails",
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r54",
      "r55",
      "r56",
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r123",
      "r160",
      "r219",
      "r226",
      "r273",
      "r274",
      "r275",
      "r300",
      "r301",
      "r333",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r442",
      "r443",
      "r444",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Assets Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r196",
      "r198",
      "r199",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r337",
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r336",
      "r337",
      "r339",
      "r340",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r196",
      "r231",
      "r232",
      "r237",
      "r238",
      "r337",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r196",
      "r198",
      "r199",
      "r231",
      "r232",
      "r237",
      "r238",
      "r337",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r196",
      "r198",
      "r199",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r337",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r196",
      "r198",
      "r199",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r341",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r92",
      "r283"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations",
        "terseLabel": "U.S. Federal"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r153",
      "r154",
      "r156",
      "r157",
      "r158",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r167",
      "r168",
      "r169",
      "r170",
      "r197",
      "r217",
      "r332",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Grants awarded",
        "verboseLabel": "Grants awarded"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ResearchFundingDetails",
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "auth_ref": [
      "r314",
      "r316"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less - net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r93",
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Pre-tax book income - United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesLossfromOperationsBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r58",
      "r135",
      "r136",
      "r139",
      "r140",
      "r142",
      "r401",
      "r410",
      "r417",
      "r438"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Pre-tax book income",
        "totalLabel": "Net loss before benefit from income taxes and noncontrolling interests"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations",
      "http://www.caladrius.com/role/IncomeTaxesLossfromOperationsBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r176",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r94",
      "r285",
      "r287",
      "r292",
      "r302",
      "r309",
      "r311",
      "r312",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r95",
      "r108",
      "r109",
      "r134",
      "r283",
      "r303",
      "r310",
      "r439"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Benefit from income taxes",
        "totalLabel": "Tax provision (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations",
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails",
      "http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations, by Jurisdiction [Abstract]",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Valuation allowance for deferred tax assets"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "U.S. Federal benefit at statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Permanent non deductible expenses for U.S. taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other true ups"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount",
        "terseLabel": "Return to actual"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r78",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r74",
      "r77",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "verboseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r67",
      "r69"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Investment income, net"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Available-for-Sale Securities by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.caladrius.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Marketable securities - available for sale"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Equity-based compensation expense"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments Under Lease Agreements"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: Amounts representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r31",
      "r91",
      "r138",
      "r159",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r320",
      "r325",
      "r326",
      "r344",
      "r361",
      "r362"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r91",
      "r159",
      "r344",
      "r363",
      "r405",
      "r428"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, non-controlling interests and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES, NON-CONTROLLING INTERESTS AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r33",
      "r91",
      "r159",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r320",
      "r325",
      "r326",
      "r344",
      "r361",
      "r362",
      "r363"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r39",
      "r91",
      "r159",
      "r184",
      "r188",
      "r189",
      "r190",
      "r193",
      "r194",
      "r344",
      "r404",
      "r427"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r76",
      "r79",
      "r82"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r48",
      "r51",
      "r56",
      "r59",
      "r82",
      "r91",
      "r100",
      "r102",
      "r103",
      "r104",
      "r105",
      "r108",
      "r109",
      "r113",
      "r135",
      "r136",
      "r139",
      "r140",
      "r142",
      "r159",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r335",
      "r344",
      "r411",
      "r432"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to Caladrius Biosciences, Inc. common shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewJerseyDivisionOfTaxationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of New Jersey.",
        "label": "New Jersey Division of Taxation [Member]",
        "terseLabel": "New Jersey"
       }
      }
     },
     "localname": "NewJerseyDivisionOfTaxationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of New York.",
        "label": "New York State Division of Taxation and Finance [Member]",
        "terseLabel": "New York"
       }
      }
     },
     "localname": "NewYorkStateDivisionOfTaxationAndFinanceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r226",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- Controlling Interest in Subsidiary"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating Expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r135",
      "r136",
      "r139",
      "r140",
      "r142"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Future Minimum Lease Payments"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Operating lease liabilities",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails",
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsUnderLeaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Operating Lease Liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      },
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating lease liabilities, current, balance sheet line item"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating lease liabilities, noncurrent, balance sheet line item"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Right-of-use assets, balance sheet line item"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r357",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate for operating leases (percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r356",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term for operating leases (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r32"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r42",
      "r43",
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r49",
      "r52",
      "r54",
      "r55",
      "r57",
      "r60",
      "r219",
      "r346",
      "r351",
      "r352",
      "r412",
      "r433"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r42",
      "r45"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Available for sale securities - net unrealized loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Total Caladrius Biosciences, Inc. Stockholders' Equity"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Tax withholding payments on net share settlement equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r244",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14",
      "r363"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at December 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r22",
      "r23"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from issuance of capital stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r72",
      "r272"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Net proceeds from warrant exercises"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r48",
      "r51",
      "r56",
      "r75",
      "r91",
      "r100",
      "r108",
      "r109",
      "r135",
      "r136",
      "r139",
      "r140",
      "r142",
      "r159",
      "r184",
      "r185",
      "r186",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r316",
      "r322",
      "r323",
      "r328",
      "r329",
      "r335",
      "r344",
      "r417"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity",
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r27",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r177",
      "r450",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r26",
      "r172"
     ],
     "calculation": {
      "http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentImpairment": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.",
        "label": "Property, Plant and Equipment, Impairment [Policy Text Block]",
        "terseLabel": "Long-lived Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentImpairment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r174",
      "r363",
      "r421",
      "r429"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets",
      "http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r25",
      "r174",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r10",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentTables",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of customer funding recorded as an offset to costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.",
        "label": "Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred",
        "terseLabel": "Progress payment amortized to related research and development over estimated award period"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ResearchFundingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r280",
      "r395",
      "r455"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "Research Funding"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ResearchFunding"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LossPerShareDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r226",
      "r276",
      "r363",
      "r426",
      "r445",
      "r447"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r160",
      "r273",
      "r274",
      "r275",
      "r300",
      "r301",
      "r333",
      "r442",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Gross price for stock transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock, Name of Transaction [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares sold (shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price of shares sold (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationonConsolidatedBalanceSheetsDetails",
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Available-for-Sale Securities Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Provision for Income Taxes Based on Loss from Operations"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components Deferred Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Effective Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r242",
      "r268",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r242",
      "r268",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Benefit from Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r27",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/PropertyandEquipmentSummaryDetails",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/TheBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r244",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails",
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r251",
      "r258",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options and Warrants Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions in Calculating Fair Values of Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r36",
      "r89",
      "r124",
      "r125",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r208",
      "r212",
      "r217",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting terms (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average estimated fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Warrants, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Valuation Assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility - maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility - minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate - maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate - minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Weighted Average volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails",
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock Options, Weighted Average Contractual Term and Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Expired (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average estimated fair value of shares granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Shares Vested and Weighted Average Estimated Fair Values of Shares Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r253",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (shares)",
        "periodStartLabel": "Outstanding, beginning balance (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Stock Options, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Options exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Exercisable (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options vested or expected to vest, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested or expected to vest (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested or expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r241",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails",
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-based award tranche one"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Share-based award tranche three"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share-based award tranche two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r244",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r264",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, weighted average remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, weighted average remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested or expected to vest, weighted average remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r87",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r92",
      "r283",
      "r303"
     ],
     "calculation": {
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.",
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r38",
      "r54",
      "r55",
      "r56",
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r109",
      "r123",
      "r160",
      "r219",
      "r226",
      "r273",
      "r274",
      "r275",
      "r300",
      "r301",
      "r333",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r442",
      "r443",
      "r444",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Statement, Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r123",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r14",
      "r15",
      "r219",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued under ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r219",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issued (shares)",
        "verboseLabel": "Net proceeds from issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity",
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Shares issued upon exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r219",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Number of shares issued (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r219",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r219",
      "r226",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (shares)",
        "terseLabel": "Proceeds from option exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity",
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r219",
      "r226"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Net proceeds from issuance of common stock and warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r14",
      "r15",
      "r219",
      "r226"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "verboseLabel": "Value of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r226",
      "r243",
      "r259"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r219",
      "r226"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Proceeds from option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r19",
      "r20",
      "r91",
      "r143",
      "r159",
      "r344",
      "r363"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Caladrius Biosciences, Inc. stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r55",
      "r91",
      "r97",
      "r98",
      "r99",
      "r101",
      "r107",
      "r159",
      "r160",
      "r226",
      "r273",
      "r274",
      "r275",
      "r300",
      "r301",
      "r314",
      "r315",
      "r327",
      "r333",
      "r344",
      "r346",
      "r347",
      "r352",
      "r443",
      "r444",
      "r474"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets",
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r204",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r218",
      "r226",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Subsidiary, Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosure of Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r153",
      "r154",
      "r156",
      "r157",
      "r158",
      "r197",
      "r217",
      "r332",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r37",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockNumberOfSharesAndRestrictionDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Number of Shares and Restriction Disclosures [Abstract]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockNumberOfSharesAndRestrictionDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r37",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock (shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r37",
      "r227",
      "r228"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury stock, at cost; 11,080 shares at December 31, 2021 and December 31, 2020 respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "auth_ref": [
      "r231",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "terseLabel": "Municipal debt securities"
       }
      }
     },
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants expiration term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r111",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted shares"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r110",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic shares"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6806780-109447"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "http://asc.fasb.org/subtopic&trid=2197926"
  },
  "r457": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r458": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r459": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r460": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r461": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r462": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r463": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r464": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r465": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r466": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r467": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r468": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r469": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r470": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r471": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r472": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r473": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0000320017-22-000016-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000320017-22-000016-xbrl.zip
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M^)) Q?,2'8?$"Y5DG'I>%$M&X'LL8^4#H%8&*ABG@(7GV6  '*T%6P VW[)
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MB=@/2""E)@D(*[U$H<(-&$&G@\DX/9W3O^<S-TK69[7V;E(G$-;],]Y>W#S
M(JR;PY-!=F&,36_KGN!0JQA2](,D IH%"0CF@,^PI1Q+0L*B2! _),M4WVI%
MT>)QBE%*I21)>.@KQ;4'')UPI4.?QV!]1$P\<XM%M*@Z[ZTBAR QC:41@>9<
M<A;X,L0ZEBI1G'*F^#*5-%PA5'B<ZI9*153&TM.!Y+$DDL;"Y\*+?,P5Y/R9
M*UP]PE",\U2-JV-UNZ-T7&SO[*XBE]!!Z&E!910KQA4WL4D2CPF:T-AX/ENF
M2M0KC!J/4_P8['<OT=)7.N(A3>(@8>AZIB'3G(EER+D1:?Y)#"8 VW;9W0X'
MV,K-?R9FI"ZN^#'KF^=N+;81#7) DV\ ^$>F-/WX)RQ2Y.KPXCWF0GYA5JT1
MH&YA[Z!+XF4(F&&Q)ZD)0\V5;X3R>. K 39L$"NY!$?>5A2!O"5!(.Y'7% O
M">+(XXD7"JF]*#(@G@33,5F"8U]W 2UV#ZASS]C\5!#(PTZ ?A)&+%8\((G0
M?L!$ /])Z1N?+14"_2(P\R,\]A(%2A.#';UE@@?<=1A2;$)'EJ"2ZHI*C?M5
M.^[.8Q[(@ 8TB0C3FDL>R@ASQH'VM2]4$"Q!<&-%$>A^U8Z[0R#05355(J$B
M]'G"/.%)%M#(HYQH&H;14B'0L]KQ"#F.B19^3'R%Y<4T"41,1*0D%G6/F8C#
MI4*@U849MJZW ,N2)%5F"HMAN8PR9;"\5H]07ZJ_XQ#7AAM-<&G7AJNF!!]O
M,]J5(+"FP)6$GW@>%I@7FF@A54SC)(B"N$J:)0$C3Q6A,$[?$4,SEXQ9UEQH
MC12.?FK0.0=/6>\<W@T$$MVSRDH"EY$[H'?E>V!;^/"?AT5[@RC2H'XHXP5@
M>)BXJI3]#)[O).V[ H]D/%9:!TP:SD/M1]@>.3 ),;[BOEZFH_2?3#$&GGKE
M5+5U7XL"RV/,@+1Q)G+=R\4()MH=?:M,UN-BRJW?7B[J6H+/+Y+T@>Q$*!:!
M64QY[%$I$\)I%)-0TE#R9:HVO")H=-^$VSO+5A&1?<6$- 2X,/5XX+'(CT%H
M)LHP$IDD7*:DMF=$OATB'^9F)0N#<R,8,1[7GL>X3V(9 ">6DL0J2ICVEJ (
MVA/4_>[.FTP]7Q$J@BB.,866Q)Z,N8I4H/$P57D8AS+D-,L$GGGR_C#)U2&0
M7@68>W6R4;9(8C_3M\93- 1Z,9PHSJB*61)'E'LRDL;P9 GJ;7X/8)XNM<P[
M00SZ:SZ7]W_1&S)_TW<[,KS(YYY6)J&,<<-8%# 5"DZDD2)F0BVYX'\X\#^^
MX/.%EIR%--),<:43U.!\K1(9A@&/RO(B-"3^:D 0UW*OG#5TB7]')T9\3D)?
M".(%$0?"BO ,JDA$X$NB>55I>NF\45\#S :,H(U>$G>4%RJ1>"8,I<(2/6'D
M2^G%L8E](P,:+[L5_RB >GQV&-%$&L5 ?XD"3F,=4T)D$,0A2#J2J"6H:_%D
M@'DOAH!($H".'WF!EP 35%(F?ACZ,O)4XON1K5-&8\*>+GQV)K)(=2KRBQTQ
M,-W$ F4.6._3D<H&HP\B/]XX &O[OH\.T]@E[([**BF/B\#XH!#ZEGB,ELP+
M_3A.5*BH+6:,P+$L\1E*W\</2SC=BA]>!>E/\$/E&P^DF<^\2'(_ID!X!F0:
M"30-DX M0?+OTX#D_514($*&09QH'S/Z?14E@BH_Y)HP$WJA+6-&(Q(M+W#^
M7-]<WQ/IZ"Q/#P['>$]1R:N'X8V12Z([\F!%2OHZC$*KSGN!X,P(HWRI*#%<
MVD9U"*N2-SX#[:=8I07;[5CE%0C_S$$;$TK/8,90$G"CC8@Y"] FH%KKQ+ *
MPEYE$,#_O6<(_P2$O5L;!W K]>X PE[LQYHG213YV-8^B 2V% (-1V&_AF"9
MFC4\>0@_4B-@>]2 4Y+0F(.!+X07Q%I%"GBV KVVSM B?%D!NS'N'9JR@%ZW
M\@(_E-I# I?PNS SI(B2D(DPBD/._ 0@(QF+/24#'D8J62$R?%AH/3[]42FH
M\6@4QQP9+95,,LV4UJ L16S:#F<F0[UH64&+)9;3\:3J7EDY91X0N-\E/KWH
M#H ;QS$&UQ.%'E/&.';V!>470!X'OD^K6.$S3'^4O<Z#Z6>L2I^%QL3$#V.?
MAX&15( Z2YE*?'2&TA6BP;GVL;\" 1*4CUPK/Q**<U_(B$>^ +6&T1"[SBX_
M 3XH0.^%^D"/8:&@"?>PYE,0215[\$NL?"5 TXD?@?J6 K<5;%+BBQBK5_*
M:4!NF;!(!P),;D[C*THAH<NK%/XE1A.XB,MX!+9U>Z40;KV;%(5(4Y$(3^J8
M\2!1<:BHC*CP#1$\T57-[&>(_AC?HG?CWXP\(ZCP=!3$G N;"$9]86BL!9$J
M,H] ?TN!W!)[7Q$EXP0V+C&AB-#'%(8L-O ?N[IO3]F8_4(6\Y5:2T^)0]U9
MU@ )% /Y(P.JN0EB$>HDX+&O0FEB4*.7J?S64P#BXQ3=5"306(%54,J99I)X
MH4G@,S UIN0RG"\K\O'K;3$ZJ("'7]OI*!U.AO=\4N$7H'$".KCR0T+!-.:
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M)?5@U5&/[</.7M-K'W6.^T<=?/ZR?3DX[KYK\OTC#2;;AK__#GX_NA[U !N
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M'0 G&*;C,? .,P".D&<C],P,+AQS:O(+IX4N-*%LDFY#C$59MN@*9YR-,:_
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M^EX0PMZQF+D\U+$;*=!- F.D88%A%"OH?,NJ^7%:^$*_^*=/5'BJ41P<@)A
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MX231G+LIG%;,K;,LBV1K=)PLY!A-1E5WA3HT5)<E2H>5@F'3I>94G]RXE3?
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M4%P=NHTLCU@HQCFHE!B;3SM/R=9!8F61-BK5<_6(\#A9E8 [/Q2\\KK"8]U
M>/8:TQSNF<-_KZ6P&IE U?FGZW9/HSYZ]'=Y]*A1@F0E#)\/&#E +R*V7BJ7
MEX!FAF'\]'K51ENW:SY[V\;^59JKN>+F^'LY%#I C#MU.Z&FF)99/E<.<94E
MX6SH?IAI8Y,R++W,J?56I4.N:J;E83$/R&!^]SSGOC:E^O@C%NZN$P+JI58A
MJ74\!#,].(FGRB0ZBZ=,L*)?FVI>=<2#8>H27;6KNG1TTD7K\9H?OCIW63K:
M;'&-"N]TAE,X347I87/!>D$F6_J_8'=,U7'KFA\-<P_*O,-%]]%)M5B)1L\T
MRE3R[NVR>-[;#.=?BXK6]MM9:G]:5(WKJO9DE? LTO/9ZY$;9^@ION)L&Y]E
M<T+2.N3'55DYN\@RCP2%2J67"WP$,-4<3QV-,PA4!0+7G<V!$;F-L)5+0O*Q
M"A] OX&2<J=\MIW9?"O<W,4%-G;:TQ7:K+'"F%KF5K[WM#S':%\*(OFZ35J6
M%CT?ERI"'3:IHCEX+F,:22E/YBZL<\X&O1[RP%0R=-BYUAF:E,+?3L@F!U5I
M9Z5]<NY:LZ4^XS\Y <0!1:W<S+E)X)C'@.E5E=-L5$OQRIZYDNU4XV)=#_QJ
M7>H902+(K@=M+)':AX=8WRX=6T4+F*=5!BKAG:1F8#V1@+CSM5W3=;.^=I4T
MY]2)K&P&455LJ3*IJORB_\O>FS?';279XE\%,3.O6XX'TJ+DI6V_7T?0E&2S
M6PM_DMQ^\R=8A6*AA0)JL)"J_O3OYLG,>_,"*(J2+&Y=,1$]%JL*RUWRYG+R
MG'ER5CJ7NT$E9U&4ZD73HWY>5\*M.9\.Y][S>M5W>X''_17$A_HJ].^<*&/X
M$R$2%XJ;>W%D4:Z.66((UPDJFYX=;L8LQVPQ<5]RFP=I.K2KH40GY?-V0#!:
M1Z-,U:R&O&>0*?/^$6RJ/^',;HK):<JZ.MLC]<=$J-0W'(?F"#VS^;DD[&F_
M\=,6Z"]AV)K=I"%14#+G<E!)A<N,7B;HI;'N4=9W2V<*_V5%UI2$?4+C-"^8
M6)(JU'3$XG8:WJ:"#3POYOFX2(T/U?:1,AS?!-YT62SR/?<Z5'OAIY.@)2#[
MQ@C "^:[HK+JGH:A?!B)3$%P]-W)8K28P/KN38.7&0;C[$45H4H]M[Z+TN1^
M;3^C:(TN5 SG9@(!RBDCMPIP*-C,D9TVMP^H_ZW*V_O1(V5PUO"/-.$"A9+\
M<S0,?**&0V2.M"#6QTCS"24"."+R! K P0JBBAC6%=PWHEP5U0)N?(VW<HTO
MI-H"VW;YNHV$6<5\2 3ONR[XS T""_H%FQ3B]<Q\O+76[B+MF<&@B#T"3>\>
M$2WSZB5FM#(FZ?+F3K-1_)1V:S 1,,-+#.&9%\":Q4 ([Y4'2$.8)C?X;E+(
M;O5=2W9@8&0YI>[GR^W;ENHEET:L?W'_=U]SDH-E*B?/%Y3D0,;8RH $ 0[4
MG5NBL.$]TH:N7Z,9&Z?JYP7!C?'3';[9S.NW.WSS;7B4>XAOOKS$0>(V7FG%
MYXF=:S%[QYHW  OFX#]'$T0%$I^>#T9L<^01APGHH(Q;NH5:8=_^40H^GZ7>
M<T^B-U_Y.W('@3LW1?7XOCB#!A)X\ .!TR#A@F555($Y\+QHJ%/KS>'K-WM'
M]3_VB'=-SJH,T9 .$^-9F<Z"?7ZX<&X=+[(9EUN.G$^? 8_HJP8/&<;U>]VX
M<TR U*^:,^>FB2:SLR'.P\F9L,9Y,+#-2'SH] @3BB]$!X7G"[HJ%;J=RUBO
MZ- \S<\RM!D&HE3RE*JZ9R@D<B*FXJ$U!5LX65$<YS9">(+S;$85$]85A, \
M5:&(P)94+*F9D5!Q=2^/)2HI<!7[L*&=$]?T:\\8% G6<\4JE*ZETNX,!E4F
M#/V&&XD@[1-5(&C8?<%$JN:C(CXCU0U4+2,67F$X=L/YCH/#)=5*U\Z%G6VL
MSTG];,Z+=.^&)'1)K]1)+!:D'Y:;,S?P\GOUQG-WSWJ3YZ&?3OH\3WT2BJF2
M)$JW&>H=J.>/J[P2_"/LC?D@.H8P5%'9ZJO1@-J"[Y!$8X0;6M4MLI? .7,A
M?<\N.ZPR17M^GW(A3Y,K8CP.Y,_HAJ8E]K9^MZG-0J.2GH2:=N$C#:TYR-"Q
MZ/="42TD<>\1)MZJA0P%F3/]Q<SWCF8)@.M(\BS$+O@RJ(!BIH;I@LU&E5]P
M3>-PW11E\NC;T9MOD@-];[%RU7#LW)UX)'@0>V<5#AX-+O0F7W=L_1\_Y(]<
MT.VUP5!$$(43\@;,T,@<:F <(G&Q2%5^AI4?8WVMII?LYMU^_9S]&@/#)^M=
M JW1ZI7!>J%G>% +Y\R'0J?@/?J\):8\;SW.  K=G*1$)!H*[,*)K 148=JY
M,I*55"S90.VYIUYG=(QKLT&W:S+X0PSY&&U!1AU\"=:R#ZUYI.PW@,*I ;@5
ML/-+G?:WOSY-GAT_??XD>?4L.7KZ_'GB_O+Z\.2_[X7;_GH2J%,0J8'S#1G"
M*+ W2HC3U 7F#93?]??NW\O>/8]2"2B?!V6KR/UN^=@C C@*2)N5VYJA]GZX
MJF6WV_1B3+U@6O7=$W1$0N#S^O!*N:@(LDR3C4S1H1'^)7P).75RY3CGJ:91
MTS// 9\BQMFSJF8U#)S![JF70'_H"#%E25F<2PG%G97O^34A/>%\U*;C)4]U
MHS(WM!\T?*A=MN&\I7SL>3&G$M:9.T[7K694VZ#!!B7.!RNF5T#@K??E:V_6
M>?M5ZDD7-C06GHN%\_",))79@%=#_YFTF]8=W2TWT+D8'%M4WF6?:7"T>@;A
M$UT+>!U$;%Z?8]U 9RSERA!2 WW0+TF1#:C#HJ%>P%5VQGP5^/\\.?O)FX)3
M%7ER\,/W#]W4G%(QRNVLIKY(A4B"WL Y6T4I5:1FON=BZH+@#O1"GMJ#-"X(
M?PS2"+,(HTN:H"-<O5BM>O<='B"=$'EB02U3 T3MBXOD=U)C(3P=MR0)@<!=
MBWIS'ACTB\XH'4.YFI>H0:*KLQ#,!LF34 :$QA8!'PTD[]* ;!N3*GMMMV21
M=7%I[5Z8*\YJ@:+JHO:=5U"XR=M!&<)9D!]M'YIP9A(33U[,J(LLKU3/!ORZ
MI;@Z\'(SH,:)\W+N@OGF*R7.JEI"^0G%BDZJ5T(Q%=&V+LEG7?@$6+;*_34-
MH;J?PJ\\8Z4VPZWJN2_;IP,4BO.OW$([6]&6?%=12=.M7(&XA)=6.:.X.D-4
M9*8<'6B9!D4@,>%IDE.UE^E;YV*[)(N8ZZ]Y(!%@<[)"'0<I.8G59: /@WE@
MWY%(X-UNYBI,"V4CYL1KXV)YO^FB?9D.?^BME60_+80IY#'M^[?R>@+M49(<
M4&+A462UP);2<O )H3"1^K#P6&FN@U$WS1#^+)WWC9 T@QRW4:IU/X=^I4[/
MX;W8SO_(W#J(9ZV042&+-P&IX 5$+'5-AM.,?0ZE6[(-(K0J>*&X<Z>B5SJC
M=%2\QE,77_8-?R9'HMM[:SKFS44S>">< S"U4^U$M>GU5E?=F;/5E8ED)/.F
MH >KO(IH*X(]1!"I:$WSH2#+:%5P N(T[Q06QN-ADI% OKN!7$$QNZ$VU+)@
MCF[N@"DX.SA :_ )5:]62C>^Z(@[8(CA",ID;R6QZ=M]"M#]HC)A4CYNU==]
M,T.^@QP&3=EY=T32M&36P3_<,JW6>:8. 8:#OF[=.AXMR<Q043#9Y%D3X#,7
M.JH9IT= ^$7H3$IO='[7D4O5Y$N"^VQ'L7.6<M&XD:0$IM>2RUJ!/E(.E=._
M9&=HI(DG1$ 'LP9I%49"\B) 5BR49HI5X$T^EQTBCYUI&NGVATU/CWY]^>KY
MJU_^.WGUV]N]Y\='3U^^.7[Y2_+JY.35Z[>_O3Q^>_STS?VHZTSR1_[O$8'D
M%5_6B\7?J'T^^%9@=I/O(AR'PX-7PS(;JC%ZS/NLSKLMQ7YR^[R(O:D]]S1N
MAN\-! $YEPB5GBX \]@J1#QNSC00>F:]%,M"4!R+>7'?X(K3!9WGA@;?M&1$
MJ%CWI[P\SV\OX^DG%O&/+7KR1-&3)S*-MZP9_5ZX/+2E@MG'J0<^7[_NQ9]>
M9UV$[$*TWQ3MD'+\QZVC$@G\//[NPZ.R=X.Z:MD7ZF?Z>"FD'_:_PS"\I+,>
M?5D\%:C%DKC!TY[VB7O(WRJKB?#T-]]5(#]('D!EE 4$G,GYUN9Y9LY#Z"C+
M)9&E<YC8O]0?A_(.R(JR-'G=MVV1,:$W^:-_=__STT<<*K=D05QMGYS>F@5Q
M\%"TL<JL6+5<'/SB=/@?J?U0@'++?3F[R5H!83XF-)"E]*'X0C ZMX/>$71&
M5:;ON2*BC?= $<S%!S%).%P*_5>#4NR;)\_V#BC,^<?37YY17O<LQZX*3&*4
M+_P7XL,5;4'&0#;]*I7GX^A-N(PT:0"3C#*O<,LJ :W/E;A7Z@E.0$'79ONN
M_'>$27ZW@TG>AD>Y!ICDG3ME9K?GE#G8?_@]C<,QY4F%O\U%)"@PR<G#I@D1
ME)*/<?3DH?97),G.HCP9B7\FJTV-S!@H_Q99(R!-56FT'RM=N;-$W=[AB^/P
MK65.=2]I'DZW")Q*]X7ZNZ<-)XMA6(5&^\IBP7=NP<UOSX(3M^85I;1DH4G0
M86/TJ?(_=%@_-NZXV<%'.N-+D29<Y>Y;=OL'1E\;;$93L+V<=_7A_^O_.6V^
M_NO]2FB\X(['T Z[$6:0XQL%T7QLZN^VI2ZP?8Y]1-KY,BR*U>^!#BXWR>.'
M#U/W#(.B-%02T)!$==7H!]\>X/M:.S,=@ N 2]2]]KVI X>^4L$-[N&MUX:#
M8G"G[P:/)H;MZ6\X=/3)I\S=E9-^MWOZWD8UI;C2&Y68(AZ:UG;O:UL)9C[2
MYM ^2"^;*!=1@9X])MD)-3Y0$$SV'+8JN!6N2A=T8:(&;N;.'AX319,*H?!R
M0D43O950?MG7 3W@5K2 < 19(@/;HIU1C;H!9RW"4Z_+2P  JJ:!)T(*7S\2
M-B-%#7R]!'X!@!-P5<_UO^GV!I^RGWQA>.L'!01QA-U>S8)+5_ZX6J%+W4Q=
MBSH@SY]G?QI.4N -9! J,;5D](6\+>Y=<6#;6?KBR<>^Y\T;O^,I%"L?8[(X
MKGB.?",'A8N^#M+OIL\[$@NX #* T2235R:])BKQ$I@^?12N^DWZE_@LDA/J
M-.\NJ*S^S6,^,MV?#K[[3K_(7(1W;/V13?GX]>?BPWM1"9I:DBEE*%TH_QCS
M^PW8<?SB:G)1!/B8]?H]K1"_8NR*-UU=6Z]U\,C_?.PXW?+E-EU%?//T\,VK
MEX?/C]_>#P#W[[Z"'0&(P!2A/+7L0+7<TP=&DXI5 F\SB@1F^Y=7_WCZ^N6+
MIR_?)J^?_O+;\\.WQZ]>?LPQJ]%PPT,(3^7V3B:YZ"SK-V,,W-P]7P.T15UY
M>"):W98%C@YIH$&!$5\N\FV",^30(EVXGRCN[HQJ617#D;;TXJ0Q!4AQ#MZO
MV8P(BJ6CR\*VW/>%4XV!9\S"QN<@<:IP?P_(0K44RH^FK!<YM9>? 6$MKV$<
M]Y1@:?W"74DU!JWF!(]<@J%3JE&&MK$"KH#4@EHWT.P*(I[G[<PY>VKY#.R:
MV9NRBU8)>I4:-40[SB%VL6K5,3*E\6^SO3I_>U453II<>*.$()#>^M"T*\<$
MM$S.7C"$DE$D//)3J_#>[MSIPWP]'JG3,%*Z1FTRGN(/QEYK>)D*(14+=J#1
MO!-\HG,']KA00)EXF;2P/HUDB, S\SF6^C.$F$^:_HP#S:.Z7:&]Y=#=0?$,
MSY[\*5NM?SJB/WID0VB%7<BUL+\ZJ .[_^W5TD0$PFQF8A@M=>V<<7\[9)FH
M S>-]WK'\-%HTY.#Y%S%LYPT&2A@?I?G:WQ)&^I3QG7B;ZQAJOWO/$#X@-K(
M(>*"I!*&SS?DKP)S)+\)N9_X5>L&A"_,S2%0]@:;VGL6^5X,9WQJBK>L@$Y8
MR^LF2F7T2(C\//Y-2+^=*[&]OI]0/(.EC;6AY.0XZ4^=#5!6A#<B#&YG_>37
M-W;"]Y-?%;D^\=AB_Z@/<)7GG5CK!9CHV8K*5>=NJ?E>!'XX7IAAB?'KT*7,
M4C=KF7\5_<*\7\;0/4F="Y^??LC1/-&1$BF6>RIP.FM_,XU7M%H[B)31@$Z]
M,GO1^@V\V'YR6/&BGH.*132J)5Y;3]!UCW<YG44>^2V3D)",6=$(XBON@LWL
MDGCN"0H/3>U I_3GYX>!T=4YA+S[*(2 \2,S,/F[ET_,[\+ZBMD$^5D&[[,)
MB=RD+-Z!0M2-TB]\TI8B7V?K'-I2QAL.;\U*26AQ$N(QOT-Y+;CWHE%K"V?.
MLX8I W1>W-N])*&DT*:!DTQOLVUR)^B.]?+^YD3$)MZ4>8&9,R%H<D5>$Y5-
M]$AW%+72*@GDY_?V#'PFI-':FBC87[,IA1?=S"]Q\NN&SR3CN^'2-D'?16[,
MJE:?HXOAGSVA\8FN(^/]1J$S4]]YBI4F7_3$,L*&@>RD+[6YQ8'.5+>&A+9W
MWF07[-[0SO!GB:5*N\@:]#R4Z+9HS6&(YDL6$7#S/V-F/_E:ZM>O.[ RM,;J
M']J\^%</Y4!F4!;"0+P6>NU]SSO_0/B4XL.+*N=^"!9,&B-OCD<*/CY+EV4X
M;Z@'4IB@<1J>.2<^]\P*I%-(WZ*U[+QT/)ESCE<%AX_HZS@S;*)KHJF&9W^*
MG%9G7 ^_!Y_D]')ZC[_1VIUQ2^B35W]+ ZM=%)1@!Q5T!/Z&3>_=<B+W7K'6
M*HY/#ZQ<@86B#66)#?D/F;P=K3><,J>13S5^R_!*RI4CRYHN>.YLA[P^)UQT
M@9?Y&2*IL,)WBN#61'R_@X+=AD>Y)L:\NW5\'5:ZDZE[-\_?(0+08Y_X_L7_
MH;2#FF#40<FSB/W^2?]B.B_CS@YI$4?S+":)2&BO"O._"B#J$R;B"^-T/A+?
M#$?TNQLD0AG =[YA[%2L(.3"<=^RZF)0VG:43*,PEJ+XJE@9 0R6/VA6&M\8
M80Q<M8#7X1ESW$'Z9\K7U7-[Z36=YA3"N?7VR_,3&\=\7F/ [5LP=W%YF)!-
M",W('V(7\_CE$Z4]](S '#^+*IY?2D'0@[\.,P$+(3QHI_F"Z"R$?27B<6+0
MJ"HSWY,U\:D:1;=ME3S>Q^A8)DCT-\<2S6NO'RQ^-)H=:M*%(B61LSYKYAQV
M\@+PFBO.!1<"_U6-8H+5?I& ^)2D4=C1#_HOK>]H9FD54/WPT<7 &W:N/6%B
MH4D_S0RBN.233DRHR )>J2Y6=$8-WI15\T05V9V0N^5Z&Y?K.F_HW-*@.)N[
M8 <U(33IEJ55&Y\V240X,*/<;3CB<+ 9B\?'6K0P?SDZ"0N3TN#4RU,6[5(8
M-T;"KAZKT]1K* XA#3/MF8$PE):D_W)H%\:';'HCXE;*/2'8O2?K]&X?M6ZJ
M6JH1D%L4NV68-.=<=;'98IO#QJL3 H]\Y'O1JO.6EY+T9XT19 T,)5F7[9;!
MS2^#-;7J21,ADYIL]\!>TG\A!1BDTM8-G3R[F;SYF10')=APV&G6?,..GI\7
MK6QVDDW-<_*/<ZV)\432_!8V08>9=BXVZ;I5@4\*%^P  '61_:R![=BM@IM?
M!9>8=>O;LDAKNU9Y1 7*^+HQ:(VRF:AI-_K?",0[.=S-.DM5U,#=I.H$*%HO
MN!3/WU&^KE:46D81N\6)>%\%)7Y!E/Q"/L^+Z!%/IAR?V2\OC.>#\J&]PELF
M5O,_C7[Y]L2771]$&^&KU-=,^> +M%-^:$B2IEO6\];KGSNWKF72.Q6SCDKS
M4E[3RODZF[T3O7)$MMO=+]1^U9%D&DG"[.1V3N@]#K[_J14MIFY#4  W#&?=
M,DW<+S&UN"WIV6PN[U';[>!K.Y&SC99\3)W$K2$*%'/%9\UX_0^%$6CZPS%]
M%_'U__'7-VK"C#M*P!W-)ONZLBV+AJ0P)7I:9F-C1C-U1C,F[0%;F/R6)<[/
MB>'>.3Y4'!/Q+^Y>Z=<2Q5.Y,E7Z6-TV$.OH-L,3M_9].?O)"V=KF?UB $9
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MF";T&+VB+/!ER8C!!H<3#REVG8ZT'DFVVD4+A8J[:'3$2UP4;;YEJ'ELP^K
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MQG5&Z#]"[--2_?;A_Z(1>O3M_Z*?!EW/(3NP:$_D)HG^Z.'!]Z@(+K/>>Z!
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M;;W<M%!O=6YHN=AKE*+A0P^QG_S#>3:ATQVN;7QWN0G%M3TI.(.=ZG03$GY
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MB)M12UIP?O4PM< 6]X!L+?KZ142)*(VHUB,%?>,JF)*^X RE96FW5J[=6_R
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M/KLG6R/".<O(Q)!>(I]FKAKR4+=9,HE1P1U2K.##B8*[[: =5C44/6I"7'H
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M+U-!:12.ZZ6?8XCXGUN[J'9KZ7K74LB=##S&83/^!*#?_>A_B#*T4/47Q#<
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MGLG;'NN'[A+'-Q\B+[/S"&_+3</2BMP$\)]W).$BHEHK?B%Y:%W?"/:?G+=
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M'(W3Q9^NB'VS8C(])IB)B;Y6TML/$A^.)?:L:</;_\V%EF1'OD^9*4OY]EX
M'O[H0/X,BFW:C&_K=YN:N?@5FZ<48_;@!&2--]G<H/3\3BJJ!8=FS@8\Z?-
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MMLG;!+?1$X%>U>1\]R7-R4<F+U0\<LA#/)EJ_Q#S4.O;2K;D3B^C.-NJ4&B
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MF@C<A/-HG/V%T^?O(*AM>LC+/+L/(F:"E&%4/[<'^%,SU=&"'Q-N=L ':!M
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MCG&ZRN$HHP)(.[04-)V0Z87F).:XB4:6DCJAMD@@'8)>#W#:SO* 4M<\H@'
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MF)NL,;!U3=,DRDSYR"\^CK[]3T&2R6C263*L<!/_C[+)1X%,+.9U!IIVM_6
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MIF_L5,H54K1MAD0%MOR^$J'GVBU60JV\'9/G.$V(JI-L+U?7@8M]7C2-@'G
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M<J R@5BXRAO98?HFGZ=E]_!N+;O9UVP8/E+X4Y@5I1K3Q2+.3"**R;3LM1'
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M+HY>"(2BNL31BL+J20.[:QHC*BSXZV3HQ/^TM @T=-=&6[*ANOL-JUG3UX6
MDO*P$&ZR\PVA?9"C;U'>EP2<H=_S02'1G,YK(X^RPF/"*^'7$1\'O9-N2(*
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M))."U'?82BM9HBOEW4)/&?S2FGU@12FR=NV815+]UC+MP7E*-QO9_&8SU6N
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M]I\5;+ I-.^,!U8[GNKI@)[L1SV0*3/.3^"_T[[YLT)3!Q>7"7E50?40TDJ
MWK*?1S(H1!/0'M)6?;=O.&!F#8YS0H< -I.*_2:9!GOQU4QD%R[S(+GEQ@'
M3\D_(_$6!=]0K9-780GZ1GP2?P-%6MENU7CT6'?6>S-P<E!=,&'"W%'1MFCF
M%$HT*C21(K#H?6C _*AO>"T:<IIJR"0%T^S7:/ 8S.$^715CL==^1LB%Q[G-
MG$K!E$J!LUF(\;VLKGGQT6V$O&\H,)-8#R)WP%N;) VFK:^LZ):JG,ZCA)(Q
M"'3O#0N #K(EAQWJ"6E'_+C.)\)'N%#)7:HCM7>NNCW<?_S.K9EB@@YH)ZDR
MO&1.K9>\ND+!WI^<A71JQZ%"HR9?HOW>:V-=^&#94V4T>V;+T'!9/]PC[ *:
M2)1\\D)DACG^ K%E6"N\2]6=GD)'K:;7I10A->]O3US2D2L:WDZB%UMI:<V9
MYGLN&0N1VD:?1?%%J4 7),Q8=SQ/#'[CED-BC2Q2HKOM.,E/KDA;) 3:+?BW
MH:^Z!S8Z<H5LGE<V9.:4J":RZL&Q,&QQ$MS*;1WX!U2,>8,P10^F:-#N7K=D
M(X--\GMWHKRC<"*HQ?9S@20D LS!U^G?O78AB='JRJ>W)I9N-;R=[GJ#%J@"
M] $VQ^^&%GN1[;CS8W/E_!32 .U[CZ!A3&6&7'2R!HB(@.KT1 9;DG,.G)6?
MJ;G0UX8VIU1SA.$R/9/$_N,F<.#&6AP7TH/4K'A^PDNR*_-^V83M=<Y^_LP'
M0ZZ6!CL?:A'>Q/R.MX+.%<^G89[,(F9OH] ,5G4J2AF_HBN[A>_=556_[&K0
M"?%&S'MB'/.[XG]8%E6(Q!U1@(JJ& 7:>:GE>^\,7K=)30)*CN<8;9.[2?VB
MDXJ ;8#-)[7N@>RS:55/0^<$]QW(/O5'Z$J$TA%9%YH;X7:.)"L4$T!U18D^
M>-=;X7-==/J0$_59-8=)YR.W&=_:0*+.Z8#B:7]V<Y^R\->;L((1J)](T^*A
MC.M1B,6I!L1.K1XRC68&UP!)J&IA0PQ3/(06SG.#3S/@J4 .<!,/.'RDZ#R#
M@I\SA1U(H.$"TUL+<C[D"YJ<P1<:;>9*4#"E)DAV?BS:+1#N(8&-7C3*V-@B
MC0EY=Y[1ES6;-S26ZV$G,CC6R39(X9WS\F F3,.I7#R;UDP95?:K:K:B'%:!
M-BM\-M]-Z(.=4(32VH7E)U7"&1$?(:6T4%I(Y>A,4J#,ZYJ35+(J3"C>]R7@
M)YIFI2U-0I8[<])\O[A<-X4_T*5!13I1=PQ=;73=X0Y=]Q >98>N^\,8Q/XR
M%^ !"#E<L%M4;Z*JQ7)6A#(NDPEKC[QUJ%%O2?JJT=TB_4=H#^+8D>YR=O+J
M?'<2?JV)MQ@F2BV'0KN4"[DP.J]$[F'GN3RDC<JMPC0O_@Q+' NJ(8_]*:9M
M_0#.JGJWJ1$(P!\!J+_&;EZ_&KS9TBK=T$&8AA\1@]!IE*KO6>MAO&Y)O.*6
M7+^J$V[]G0WX:FN%V<M:@:;0I3-XV]2N9[NM_.5-M,$[B@3HI9LQ#HEW=4:A
MFZ81C4N$*L9].GEW$_;Q$X:L><TMF1:K;O @6P*V^8<AJ@*>H@R:#L!UBT0"
M_$#*/W3PT$D+C:!LS'J'G*MQ)-./:\Z#%9>VH^#PB_>8>L:I!VW-P\Q?=D3-
MQ 4O0%NTSF4IQX1T,:A0D1)SP-P*]4%K?/V47?;-L(6W$9G/(*@HLB*'Z/6.
MW54Q2KYFR)PX(>W>HPQWY53+H_2O5W<P+/X%QJ+](%P8,D+/O4?BLN-97LR;
M[&ADJQ#<N9J\0$TD!_,!C]P\'[=%4 #@7[K0=$T0(V #!"_[F0W-QLW7OU2\
MIY8M\_G7U#\3\'#VS?6ECP=F;CBKKEW]"/CG%95H<Q*1$;HF-@X\*XPU1GQA
MOZFQB%-@AU&@S:F&3WE *&QS@1-:@WZZBJ _$#<*XUXW+13R<ZZ*,:]E3/A
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MN]AO8YF\]$!/1U']T-ZYV!(^M7.E]AT('8:#AJD_&S5Z2^FK::2'?D/.T$!
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MF_G ;P\C+*W0?@_HS\F%!YC--!LA4X.Y3W>+$/PK;3M7CU3*:P>\L<";[W;
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MD3S9_U'%3A7(,P:)1\Y:.:ZNJ[IHY@$4IOBB238G4T%H(8/+&W&('L._^*'
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MQ[B+*_<QD\8[=.;R4%$+<N ]GK90'Z(:U$8^2A\:>.!W"^'+^M*,ZPXTOX/
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M:L7^>(S%E!QW<3D.<C!RA[!W"&3LT!]/V1<5CI^\^$9^TF4/\,S6OL\1+$?
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M<A?[/4_D_@ZIKD[KW/P0\OJ?KA3QI,*%'\INY=@7QYZ\>3P=<V47KNNKD3K
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M"7D"Z'S$3>1]NVEM\G7&NFXBIS0TO\L(=Q:K*=[L=2,C,28I1(!8!+5FO$!
MF#0!W&B:$,[B%*&=MVNK[[.A);NV6C77==,85/.QJCE[G4A2K&$:09 8XJKO
M0/L35E8_D\@>:-BX$ESN3"N1:KZR*N%[=M1NQ66[<BE;&K2Z%24O6T/9#D7"
MG[K?VWCI/]F5KW7WLW4/Y0#7!T@+O7"59&D2"0XB$6O@TK@!3QD%J8$D9E&*
M&$VM:4=95?!'%P -H4FEU>&U]7L+.OP,.CQ77!SSQ (M!)(I[JZ0)4BHPL!
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M"2 L0IH:C!+M8E!)N&Q]8?*7D[Z',X-78;(_H??-[4*CU^W-FN[C@)  0RO
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M5#%"0A&NTIVWO(KH8H93R>#ME3FY/IK!H )<&D7AXI+#8;^5C+(F5\/>>B\
M-]9J?MF$S+L\_'M3>];LS3KS#^W;YQO7ABCO!R+?8JJ&P$A3% %(8PXHQ +8
MTTL"&<=(PC1BE*$R1GD'5UG)0Q_7H_1!N5=3[EE:@X1$D6$0"+N1@)+(14JC
M&!ALN-!2),*PG;>B1&H=XJW*1['&\5;SS&I?MJ7NMT:#RKM6;Z!:IJO,H%JQ
MFK]KUZ+3L8CC.ZCF'>@?<^6[G7;R=EK#3^?MLY(82FP]Q<E1GZ>%##--4I$
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MGA@! U-<)SS69^!1H2BV>ZQ!0C4#5&D,)"8:(*II$LN$&IQ:JHA9E;'%N]6
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MSW@JO:4,I+7$H]7=$$U!C&.9TE3J- M<K3T7:ETFRRKO\)@0Y/Y1HQ7@'J4
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MR0R7*]D\7+?9O0HVY0 HPPU?@M*(F[+9=WMZA/MP<1!:,+Q;,#RY9.H--A'
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M"F0;AT-_C*] ^_?ZC$HWH8N#OW>W"55P+PB9O3JZKRS,N#9XZ@XHN!ZC088
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MC6@Q2\G1TH,OB2.:H^E9\R2ZN1"IT!F.]B$,I%VTSL\^%EY_61B*%EG,/\%
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MCM&M7X?<P"I^!*X8/T)Z&<RM=X',""7]JGY5I*0ZS'S"^V;HZKI,XNZ@?T*
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M^J,+XPW[9WO)>^E"[F%)26 T)]P;1DS(#!%&Y]3F04DCUSH>>/@Y+..H'&/
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MP3GG/3,1%%/WR^R^1#"#[>.)!<8>/%[XAZBK$182*PEC^/2_K&Y)Z 9(((R
MWAW;H$MW=576DT]FY>6]R*7<#D\.\GTO#DX\/MS_>C59LNJ YG' ^$[?7!Q^
M_G"Y^V[WY !@8_?SV]/=DS^:N]N_94AI[NWOIIV3#Q='T08P58E&1I41J<DC
M8_-/GJMDN13"]D$?-D ,6QEZ6?+$"P'?4X9;20R. O:"%B(YX:F<+'$U6(.R
MS=5P :9WVD1AL]%=5ZV,B,DF):2*V'*2F*$N@<Z!^]HH&0YK-WSO[@&//R#
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MG$6?:4/S<F,6$YFK(E.N[32"XK-+/2V*XG.6GE)WEYYZ3@6CQ(\J&/7&=EI
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M= S&.<6ILFE9!Z UF-9@6H/I#PESJUGIH^/H."O%W, 2"8VD8ARH:8RYRIY
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MV,_LX.3P=._=AZN#R\D@?T]WKXX;@"^ '[N  1\;.R=?^>[I&[C^&[&W'QJ
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M'-,M-V885K#/FV5R2O?<G4RD=C8;I[#_KA,[0!ZJ +ANSF#)2P*ZI5%Y:V>
MUN@6&2SR=4#.5K=,NF^$V-\X69&56[A?8*]]PW7'0:-/TR;W29;ZZVB]Q<A7
M])1;&05C6I3D*P;'J!+&)*\\H9GH9TDOB?ZTR$_&^]S*\ZO7M[J_CTY%3:]N
MD'8!KQ])K:.71B,E!$B[I!'IX#"B@5,P\ .\3-8VB2;K@MP</088.$ZHNOU<
MYU)TJP^]C&C-/T?4SDT[JDP.RL\?@4Z5,S"VFP:J=%$S9GD[:6C17"N0<1NE
MVDCO6_O @;O5X.IM-'L;?;C8W?]Z1(+P+FJ#'$X)<9A\T!<,@PQJ1D.((KC<
M N2.(,R);;2><\_L]8'?K00#<+!<NZ40#7J+I S.?/MW>[T+_ST'U+,$D^D"
M02G8[&.S"AE-/ +&()UPA)9-)OG&K%7/,2G5$6[6UA8@)?/S+YUV=RH8Y:[5
M7RY43+L^KI=_3+=^K(IKA+T:*>81&!C'D4J)YK!GA*T666 $,H8:I(Q43"=N
M*5:@<&^N1S!*!-^#"#1 9@9::&AT3:F@,MJI$\L*0.M5W]9>;.4?\FG_Y76N
M:K"7U3E2:;?ECQ?M5IQXO^SH.O -#Z)8\L^3 RJO4J;6YG=O"Q*^E\B.$,,<
M_+N79MLX@SC@,KSU]<G=%3S+D531.&8H<DQ1T% QYF-0@[P$<P>$QDJNUS:O
M:Z8/HG^KF."J9WQ_D>^R(L:,[_5^ EQ.H<Z<"?XM]5H#S/INNUFU'N_$*L6\
M*O8R:3E=6TIEC9TJZVV<4\'+0\2\(\QX]@'7O=3DE'$R8I"7]O>HU;V5]TS9
MT;J]73[![V6E[<Z9[?0N]]N#2?T8OYPW;6?P:PVF-P@UV=G/J2_6!AHQ<C*
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M]2EOTO-U_2Q>)P,,4<<E)S@1PY6WUE)I@M<>;%0O&!LT8,:\KI/Q-.C)<TL
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MNK,$P)B3:\)YD<-"GP>$Y:<8_^RT8P-$:>C8>+T8=AWN#??8V?]P%*,5Q-J
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M[3R?L'PYBDF$*,#6(3X)D!A.D:/8HNBIBMX$R7#,Y4EG",J@L,F,L@ #.WI
M;;IC<24##\X6$)YF05F9O(KO.),IJV"5I0T QL0\7UG5\JD+:JNJ7NK>V75G
MMP'S&G^^V\(FK O",\(2BYQ[:S&FCB0O-8G&VDGG595F/@'0_CB&\]+#GO'A
MM]QM*^N0V.J69+\<97^06R )WQJ]R_VRZ2B,XK=FZ<]Z;9OM:F?_R_<CII/E
M(C"D*0^("\<JEWOB$9M<$CYHX-\1,.DL6^>=\_B\&Q.,]&@N66KW_!0> 2Y2
M54JW?>$H%4JE6MHCLCTDNVG>ZDB_SKG-R?C,#7T?_5$._"D=L(LS46O:LV[\
M=?##/T*C>]:TE[\V6N53EU_ZQ_@-LM?A6^ST&J!=^C<I[U>]W7=(&+,A),D^
MB5X'_H3!C?ONBHW27?%++TR_1^D&Y?K&M_$&N?&]VRZK-Q2[WU5O?T\POO2Q
MJ@U%;GZW'FL]UGJLKV6L<JZK_E*B;(6T@.594?S_:VSMVKL<<@#HK[@@I<X<
M7&_X44JF/DO/OA<S=<DD^%>XOVQ-?*>W%T^1QJ&"G'RZ5S 14UQY&5)Q_=$^
M7^BUSS*_R EAC5 ,'FKAB8++/)&XE#;_''(RU_.^GGG[7/X"U'0+1F2_Q*%+
ML2B=Y/6$/GA"/\93VR@;9/X.7\Z^AWPZDB/VBY\.L@_[YWJ2%YWD82W"XCU,
M::/5;?CB;]L\C\5/[UO%_G'['"X>YIK9US=Y-5364+F:$UI#Y8I Y1WT<OI
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M,(NTZ+L?=[FN'/((Y&6\_$C=U&]9N#1.8V#9J95!(X-U0AS^1C8ZC0(CQ)E
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M?M\H_*5,T/.$Z><:<S6"U'7,U5(A>CSF2CG%?* )^1PQP;4SR E#D-<AL<!
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M#J?JT"'=<>H$*0^O^%$USM1%=^7#9/7@>@M-C?STH-TX--X_9FC$/4:FL%6
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M05I<EDOU;\/W"<'VQI5FEQ'WM\,:1WW-QI"[A.F'P?1L2\@L5SS-#>)44L3
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M0:U?-W=3$EX@FC-PM@!+;QQFF'")M0=OWF-NG)(V7WF3@<A;XI#? PN8CCL
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M.02;#X<HVHT3%BNTI&/\X;TSAQ(;%@$;J)S AM?P==XO-E3414*R$AE*9%A
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M,2XA&X8W!82*.O3";#3?73#;>:K_K.-*XH_NN3B8CGMC"#(^__1?4$L#!!0
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MOO'G^=GD<.%8\OX[&%L\M4E<N2OZ1C'DK0>ZUUT4I="L7F>LM*O-BXV$J+R
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MVR<?+@_AUT5=^J>D-.(,SX8QP1Q2$@+)*Z@W%!!8<,XAF.+0U";8A?5)9.T
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M PCJ@.0*LW4/7_K!K[CZ6L.S6"Y)JRKD5A61013%-KLO3GD&)>;LI#?:7#V
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MB"F%TB#5F%0:YR?T_$,D+@6J2I?"5/TPWIUI;K0+6:H8Y%BRQ.NTQV .XTA
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MK3Q>]WWH#\Y/8+2O2V^'[PL=Q^C/X ?>C(;C^8]M#_$?>9$HN5.22<)H+C?
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M*=$&1H)/EG#F9.9.^FSJ7.?[$"LT=]J$.8C)C[-"4U+I,3X*Q*$L1&9IB16
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M*AJHZWMUEZS;*A @G3UY4:J=FSXZ]R^&T[/6^R]/;29K%'%OP*#RPF:10@7
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M5E#P^BIL*[XGTD(;$ZOR$(\5M\)C]Z)62I4:C)Q6K-:F;4<A$Z)?Y6)==9]
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M+%;?M1?$E]6K^NR\3@8MRP=:KI^^K+I3I$_RZV9!R^[/>9YE=<U-& 52457
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M"R7ZW^=8,D)#FD*D\[[@-.>0).H'2@22B(J,YE9!#K<*-#4^Z)<P/=[G[4=
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M$-* $8@Y9;K0A(1IS-(L9VF0VQ6:<"O>5$VP!_JDV<N.I1R/G!FG/=]X>&;
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M(X6NSWD4PCC' C,1"@R9B#.(0RHA84$($0NS.)6"9=R. R_W-S6^^_V7S[^
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MB!TK#Q9E:G1\;0'L>B0,V784?'W3;'L0U/,C[\XW?FHU^;GV]&R5 3MMG":
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M8%F#V*;_J=GBG?C@ITZ!GT'1.B:W.OS?H NAUWJ 5A'[VL56PV1&RQ[!]TS
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MX_4/]"Q)L*L>=Z^.(X^K4N>OU^6VK%[W*A*^M;MV]<AX3HA4$(,\(P+ 7"%
M5(9!PO4KFT,DXC1W*F(P2)RIO>4W<@AZUXD;N&AVI[WQEB(PY7A8!?=R#%[
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M"E[]=Q];]:X79_5&?Z*;*G+Z;B6J?DK[,HH'=6 SR$@28T 3E0(H]1O+!$:
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MMZNM.5H)H;_VI3EEW6^^KO]:S>-,415S 3*"&("HX "3G )6\%QF.(-)9A7
MVS''U+;,6LRHD7,654?U]28RLMJ[*:X!>MMCX0&FT#M4'X2<7!DW,.CMU;@V
M[F@.CAN*'?HZ;GVTK]OC2MO WTNIGI8?%DK.H>1%S%(.$,ZU:2UI!DB1(U!P
MQ7&>4I'%CE<5-^><&@G4DD5++5J5%_TLZ<;]BN(VU+:>"J\ !O=&'/4:/6XU
M.HL::(W0/ET-U@AY=B?<GG=DEX$U$.=N ?M'?87![UQV:9[FD'$)!,H0@$Q!
MP'*F*4@JAK0!@F'F5JWTZE13HYI+P=U#@]X=/:%^P I,*PY!\$&\F;=!"AP7
M_S(^R-MJWXZ3]U0,[?V*KQ_E5_KS[FG[;6V2=#[J[\N;]2-=K.:L0'E2T 30
MA!(37V$::4H"DD)0TV@]E8R[$$C79%.CD%K62 L;[:2=14;>Z,]:8L?BZ)U(
MVW&*+_P"L\H0Z)PIQ 83KR32.>&H-&*C^BF16#W3TQ)9J^U?>J_09D[[XQOY
M0R[7E<%3]<5K<AJ*#$&>0@60,+VQ5,( S54!)*$RI@K%*;)*PG&>>6HDTTKK
M:)M8 VUIJH2 +[3ET@A:G81VOQR('55R>^P0W!LMOR:,]>SC6C2NH)P9.,X#
M](TU7QF7;UW&X?.B_/?KC12+K?EICG.8IA0*D$)H'+.PT.<EG@!>Q*9&'N(:
M&;=X\ZMS38V(CD0U=Y=&2,>DE"YH[8C($V"!J><8*R/<+*H%;7[YM%XN^'/T
M9_/_(#4.+*#R'(]^?;Z18])O*GX>EW[[D7YL\HKJ;P:77[Y)N?U@ULS4DS&]
MCUBN8B58"A*3L *1:6^7$@$2#BD2>183YI3H=FVBJ?%((V=4"1JUDO9J)G45
M6SLN\8%88"+I!Y8S5=Q"PBM/7)UL5)*XI?(I0]S\_,BE =_111,R5I9/CW7U
M*4-7[S92OE_I%UF6V\]T*YLJ1_.82T8@A4#;+*;P22P!$;( N8R3%,-$_]7M
M0#62X%.C+R,J4%I64W*^$C;:F H)('JL!1ZICJ#K^EN>\R:XJJ&/B<,K#AKE
MFS#? _5GE:T7&02B%H+(8#!K2X]-H!9ASW6;1H%"5^'_'E4+>RZ)MU*&?>?O
M>[OP0X]G)J_]CA_E=BX$$:2("4ARD0*8*@4H-K>2"<Y%%J=<Y4[%YR_,,;5M
M92^BWE>,C+-H)2VK[71!:7MK, B@X)<%.VS>-]A\[,"FQ_W 5>T]7PN<SS/R
M;<!51<\O :Y_=&C-EZ/"?Q^UZ$\;<WT\IT)*CB !DC(&H)0$8)(HP K)N<@R
MK$_,_4J_7)EQ:B2PKV:RK,J/+O?MJS4=[,3N6PCF&NYV'.$5S<",T55?].-M
M' <4B+F!3: Z,==F?:%R,3= N%XUYM:#_9AG9]#\ML_#T<;,?Y[DBC\WM^M(
M0%KD,@<%EA1 HFC=MEFF/$69TE9' EVXQV+.J;'/@:313M2>D0PVD-O1CF<@
M Q-/3PR="<<!%:^48S/OJ*3C ,0I[;@\VO,FL::O74"%Z3VR*N4KN9)JL9VC
M0E&EL.8<3C& *$T!SI(,$!4G!48DSFGF4HNX>SHGNAFM+G'#\,VA)]K2G]%W
MT^:S-!Z87U@MNFLIJV[8+2\:O8$9^JZQ0? @I*J1-?KEU2W\W"\5K6#Q>Z_8
M/>6X5XM6ZI_=+MH]U8]DWC19Y5=&?[U>:=/J25M7C9FU7NTK-F0Y)[B VLR)
M\QQ IH]=F$ $I&2)I!@IAIS"OP?(,C5KJ%7%C7J&+(8=+XT$<6#2:K7H9*U9
MM-<FVJL3),S< ZQ>26^(/*,RH@?@3NG2QY ]G=%E^61N>>]5%4U_MQ)_4.,P
MWY;OUILO<O-CP65YOWF]I(O'<JYBI+_G* 609XEF3VBR=&4*3)'B.,DYS=S.
MC$ZS3XTOZY2#YGZ,']ZCR7KU''W93BMAZ>4.A6]H_W<C=U58J"IE8"):6]DC
MM=Y$K?0F'[B6WZ-[O ]L?AWG3A*,ZU+O \Z9L[W7(!,(.&F;:?YKO=3#&*==
M=3%(?U8A!P0127C! $)< 1AC;5T6C( \SC$1*L=46M54'%_TR9%KV]KWQTY:
M$W!2"_N" 2?=Z_\"(2?>5O7O&W2R^Z[L,6BC3FY\7UXVZL1JZ:8;=](M_M\W
M\L1J68+&GMA)T*,JWJ?-FDLIRG<:P2]TJ;??CW)[U,) EA__Z^V;._W!APU]
M_'6C_S1/B@+&4C%09"0S/A,!2$HQP)*B&*-8;VKV[:%ZB3"UW:E5(C)?Q:BD
M=9?-C_<?-!L]&($=BJ#U6Y/NG68<I /O&#N0C0*1T<!4*C,]8XY[H)A0@4J/
MJ%%D%OTZRAHX%)T+OA8C%9@+MB9NE>0&P=E9-:[?R.-5B!ND^5$UN&$C]3N*
M?99;NEA)\99N5GJ2\H[K;^V3WN2D>"/5@B^V\YQ1*!,( 412'Z%4CK0QF"2@
MH'H+HJ9H"W=RT-^><FJ;RX&$D:A%=#OP6*!L=U#QBUW@[:(5-FJEC7XY1+(1
MV./%H#TZ7FUXBVE'M;WM83BUF1V>','6G6<P$9@A"5">"0 )*P##20H0SPJ"
MI1+0H="SZ^Q3(Z'K%FY LRJ$53LAANIM/(6$/* 1^_\G^_6%#-<@-NN$S54O
MENJ07>,/N7CXIC>@NQ]Z^ ?95CVNBB"W5Q3M'\6<(Z+RPG1.$ED!8 $E8!Q!
MH!+$DEA*2)%5;Q;WJ:>V7^SNYMIR_J(J9RK6RR7=5 T ZFYLEH%M/=;"8N\(
MAG#@C:.5.VH$WU=G;RJY[]#?21\,9H?](AC<(VT6/F%WVR9Z(=>Y1[B-.-X&
MT4O3H]VAWP@#KI+9;2\_._7RO_WY?5$'[GR2F\5:[QQYH4\;"02I% A #1N@
MB.3ZL)$PC+,X%]B].($/R::VL>SE,YN(%K!WF6Q_B^=PS3OVDDS_%O=@06OU
M/-_.^D3<_^6K%^G&OUOU">K%JU.O$_1U3I=;O6ELFW9EOZ\6V_+SE]^;JI&(
MJ3A)6 ;R%,< ID0"*I0$)&.*8XGC'%LU*+&:;6HDO!>V"<>KQ'7U2G?!:^N0
M]@1:<%_T);RB7[2LY3\"E-^TPL6S%[IKQI$=T!;*G_N>;1[JVWV ;BOB:J(;
M+U?,1QQR8CH/)-+$"BIM_&&1Y8")-,X)0YIBG'+_K6:=&K'LA-Y%^IX6WK=(
M?1BP"):6G&]H0UMI/E#MT;?  27/+0QL9AZYFX$#&.>-#5P>'M BI>XH_^9I
M8_J\5394W9SU:J>X<LXP0HI@O0:9D)JVH+:#4JC/L5@*J4B,A%L"74\Y)D=D
ME;S1HE(D>EKIA8C>?OGTJ4>#E1Z+8DMCP:$.3FS&F*I5B&H=FD/D;-> NJL'
MIL<<D8%@^F_ATD.6\?N[] ?L8O.7 </U;5WY;K&4F]>:GQ_6FV?]=R$E3%(0
MQWD!($0",%E @#(N8LJ1R!+FUK;R:/RIL5PM8E3)&+5"NO:J/$:PF[H\X!*8
MDMP@Z=&<\J+B QM3'H\Y<E/*BPJ=-Z2\_#&?K> ;UX,I"!"35($"9P3 G%)
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M)S%C2<XSD**$ )C&6-,;2D&:%XRJE(A$.&7R^1!J:M;?!UF6$3#]'=NV)_1
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M87T"1@B0A$H@8T1)FE.)8JO"F</$F!HY?7PR$26&C,JCW$ WTVO@TM@15GC
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M1%L1([7>1.*PQWN?TY2'U;/CPG'7)#!+VM?!J_4SM8\N=3S;+^M.R]'JY/5
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MWAJ7/M2_GK$I.+?>?%]OS/O_ZOFS80:IQ35!_%4,_SS+,Q9#B4"&3.T7'N>
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MV.U 9'8E$/E?5?M74X'CYW?)39F)M?G3VWV+;,M^LLE<F21V@C!@2"$ "\@
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M4Z,,(Y[)>Z"[=%%C&C[JT_\WVZ"+BQA:V'P#D E,"A4H]ZI7\O$I$ ZVV0!
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M>,GN?M80W6CB9S]./X9\(S4)Z_&_TI\'S0)WJ55QAE(B-16J5'$ ,4\ E40
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MRPTUA2*,T_(UW6R>U7IC,HW++W+[=:W-T,5&_K%9;+=R]6;]UVINBBPBEB-
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MQDW<\0;C6<J.OY'[!'0_?E^NGZ6L@JL^Z3?E&RVE\;"E<9(V;<D2EK(B3V.
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M<99E0"8Q U P 4@*)8 %)&G*L2()=#&#SF:8FNVSKV\O&PD=*V2<06A'/8.
M"<PO>TS>WL+$O>S$-;W]UH\XFV7<0A#7E#RKZ'#U@ST\>:\_O/J2H*\;2:O;
MYGOU^K<WK0,O97%LPO[3O-"O=<(PH$S_)Y5Q+O,TPYG=^?'&/%,S.VI)HYVH
MT;V*M+ .OJ<.3"V<=WZ0"ORV7P&ICZ>N RT'!YT?U$;RR[E^Q=R<<+>AZ/2]
M=3P^GLOMM@Y'GC:+CP\H27;0:?NCEOUIL]%SS&.N4HFIWDF8* #D"=5'-9B
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M>I5Z /%R/U,? _?PK?PA#8E+<?=#S_$@C[B^9?K75 .TE&(.<R@4500PQ!,
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MG8N]%N-D=@T&,<3&["4QIK!!:P&3Y4:MS9V&\>)_RZ6^]<+XVN*A7);FIJ;
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MPR:=I]4BYTSEBBB.H5Y+9GJR8!&DG E33B5B)(U1RJE+B/73(9Q(/EB7Y[9
MYO!"L2>PM&/GVQ :F55[PLU *YX_!CRONE?F.C%,4,8YK^8Q4USXYK WO&63
MZJ.LXTP^KSZS[_\H-U]-1X1R^>7U:GVZJL9<D%1BR4TUUXA#0F,*&8MRB+0/
MF65%G%*N!L3J#95GHK%YIGW<7WOQP6.K'M!^QU)NFBH1H)*;S:)Q0&334809
M=G<DF,&FM*.A42T3*(BD46%6=_7KR3X[[?3MYU]_C'8KBEYY;[ P0=GQ5LB.
M.?3F^PUCVG>KI?SQCJW_E)O7VZ6HNK[U:907/&60":47WZF,8%Y0!1.".$(Q
M87&*7!;?IX>9VL*YEA(\U&("9>1TX[HS8-HQV>T0C<Q3#3J-A* 6<81#O\LH
M>.69,T,%99'+ZAYSQ)5O3ZK:Y?UV4VW8TG#7W9<OZ]JY>;/<K,ME5?)Z=3AG
M,L)"(0E31&C3!*\H< +S3*$$*8*0RB=0_O*Z)E/CL:YQZ;>F#N)J#62O#.*W
MN@PBZU0!9:<+^&:4F43A3(NGQV$3<>K/Q/3W&.U*:_90F8$=+F '3+-+.?EJ
MF_;&_1G*;UIH\W^A'J>]T0(5Z'00R/V@O-UF>5U6G"W^*=GZU5*\U /,LP)'
M-*<,<IQE>DY-,TA5RB%-8IKD*(\18K;'Y><&F=ITU\H)&D&!D11H48&1U?[P
M_"RDUX_0?0 U=DC-$(R<#M2O@3#X6/WLC8,=KE]3K7_$?O6[0Q,A_OKG:OUG
MW=SF9?FMK.IF?9_9=];FW+TNETPKTBXY4\2T;ZW7[W&:&QK ".8TRV$J<88X
MCYE 3I&_;L-/C2"T],"([YKCX 2YG3\Z'I C$TB'(:A%!YWL)J:QD[[V"EOY
M1]@:& :=YXP&)Q$"9S,,@>=I)L.@NPR,&6:+4JW6RY*]ULX6_UI64H_TZTK[
M5NU+A5*,!9<9C)4F,T)1#"G)".2"$A0CF7#IE,QU=<2I4==>8,=@X:O0VO&5
M5\#&]G%VLH*=L/6A2BWN"(QD#8[?R.&KHX8-'[8%X4D,L?6% X\VZHU2TR!A
MW_9X'S ?:9\H9T)"D::)21/%D.$TAT1%4DJ.%2V<VM1?'&UJK-)O3[X7O-><
MW/'<XR+2EL<?OO ;^Q3D%%RC]F:W0L;OR<C%$<,>D-@H_^2<Q.JB&YL)UQ:?
MLYP+0A,"&<,"$L(I9(((*%,ITR05*LFL.IJ<OOWD>&/7]K9YX(?V!VZPL]S!
M'XS(V-OJUF ,;_E[H/,X37Z;(9ZGK>^!>F<;^1Y^:_#^R1WGJ^W2I&-_6*^6
M^D=>W[UJTI>.$^I2(7A*!(9)I/\@<1KI%YLIR&22Y F-\ZQPW4%Q$F!JK[Y9
M_^\5 (<:.&^LN-G">FME-(0#;*Z<!3=, N10]'SOK[@)$7J'91!$)_98AMUG
M&/6];"OUZ,7575V=MN[1/2^2.,&QPC EB$"2H132".40<Q-$JW(>42>".SW,
MU&BL%LJ-KL[@9T=*MZ,R,O5T M8;)8V(,W 9)6=NN0R"5P8Y,U10GKBL[C$;
M7/EVX*"N4[D[=TOQ3FZ^KL1JL?KR8U?0*:,18WF:PDRB3!,(CK5SA"F,4T3S
M)"*,1>X)FN/*/#4V,E*WH3A[T0,%8#E8VG*A-BW[C;WZ&RMQLSY%Z^D^2H6P
M@+::1HR4@]P_1S24NR&\Q3T-&'K8+/;JX7&Q^B'E)[G^5K8%)9\(_'ZU;.)<
M:]FJ.B^R__O?5M7F_6KS3[GY*/GJR[+\EQ3S@G-$"LRABGBNYZXD@Y1F%/*8
M%E3@!.7$J8O%:)).;<;Z?;G>R09XG_>XEMYMZAK/O'83UB2,%G":.I%"-@,[
M_;I9R2BD/]V 'W(#]CK-3(7XK<^DL]'A]SKSC"=MT/EF=-"/9YGQ!W2;6ZKU
M9O[1//YWW\MJCN,(<80+/0^P&)(DII 2$L.,)PG1/[$,%S;SP,%=I\;99B.]
MK#:E"?Q\)UFU7;?'%D98RR.<0]@N\^M@, (<V S P9K83NI]B83T!3T"TO\Z
M)I_#.P8ABI-*="_UZ5\.[CFV>C 1'^:57O)RT?21V'W<%J?\52ZE*C=WF]=2
MF"*6QHA;C?^/_?4F2!NQ.!4BBF%DVCN0S*21%7D$N1 (81I%L:2.;<G\23<U
M0OC];Y_^!EJ)0=&H -@&5)WT8&T=.C^..>T<N&<STLA$]4HIR>OJNHV$]=ZL
MD1$<*FILUIEQI]3Q-?X=MU%@]]T^S:.$H3NL^0?W1!.V$0896.OEH)-$&YR:
M4<I3D><PYBHS834$%DBFD. T%P1'1*9.J<&G!ID:*VL/V822_6IJ!'^3ZTUI
M(LJ..I\XUEXY!:T=M=X*V,@,>03+"+&]EP#P6^[DU$!A2YE<4/5)F9)+WQU&
M +LN"6]-/\B/Y9>OFWOU>R7KT[!=$-"]:C(/2K;XL*I*0U>OOF\T2YG7Y*UV
MZ^=*\4*8U$>6QAP2Q0J81S2"%"LFM',8YUGBPAF>Y)H:S=2*P)6"VTJV[6IG
MH&"+.FNG^BJEJ2:WE*#4^KG1C2]#VC'4,YAG9%+;]X>I59J!G:FT6LW9_ SL
MHPY7"NQT YURX(^]>N#5<OM0WW*U],B,GH'W2J:^9 O*OYX!/:9LW[<?T*_Q
M3 )\DT#_ZKM<\[(RIS*Q]NR(4I AC"%)I";ON)!01$F<$YPE.,H<JO<Y#&W%
M N$+]76%7&0GY\UU6US,<9F'?:,;J!WNN:HD78T3L)/:/Z .S1K] QNH5:,/
M@-WZ-+I!=;%+H^6MPO5H=-/MH$.CXZ4#<^S*Y6I=;G[H,:1^BC9S'*=42)3#
M-,D+2#(A8:ZR'%(9*R8SE1<9<4JK.QI@:M[T^]42:D-N]( +X[F5K9RN&73'
M.-KYP+>@,_IABUX?FN*5V@C_7K<.W_P =QO]*!;;)GUNLS*'SWWP.C4\YLZ=
M <AONMSQ(&$SY,ZH^"0I[MSW!OAS;Z7V'>6A8_EKLX3\9%:0'_0 W5139^_L
M<SDXB56&"JK!U$B2!"GMXW$"1<*E2F-2)'8%BFZ48VH\TL_(/5H'@EYY[3HX
M\.FRL*[<W"H.:LT=G)<;C&GA(88QT<ADUB@Q.[;,[!!ST-?%)278JTT<G,PP
MM@GD>(YL(S>?]'9D+_JI-]P^G.]Z.P8'_JR'VPWS<>_$_VRK39V>]7G5'9C)
M]W+3G(*]757Z<]=NV E)!4VB"!8B2B!!0L#"[%V+3,0Q$XPPM\WJ,82<VAS9
MT]$XC^M.R[IGP4)K:#XU/W/3@WO;M-WVT>U\E"? SL-_;KN.O1US:-*=@L"T
M4F\#&5X8)7\QOYY";_4Q#>)U53**H$%7-F-"?;PZ&G6L(2LL/>#]\A-;R'NE
MI=A/>_IS6<TI3A*4%@2R5.GI(^<1I(SDL$@HCF7$*556X6X68TUM%C!2F>5.
MQ9K5TOO[MY:;+3; VJQHO,$U]JK%('6_!$94<*]J3NUYQ[6X_I!S67=X0S#4
MVN(6)!U7#E;87%X=7+Y%P!6 E2Z'7K[=)0,]^6^L7)BE@>FFP_K5H5[*8O..
M;=I_F;X[Y?)^*4W]WEVVVSP37!08I9"K2$&BL@P63!0PRQ/MOW.D:.+4Q?XV
M<2;'R](XX%^9]KB7LNXXZ^ADWV8<2W<Z&.0C<[L1MU> ;@9VFD&U6D.C6S_!
M> 9:W7[H;RYJ"FJ[.'S2+Y<FM>[7=4'P65,?7*OOT6_V@KQ?#_DVD<+ZPE[@
M>^+U^KGKP.J_JX?'K68F<S;T:";Q-D!5)ERQ5&0PC5$$"4DX9)(*F$A22,X+
MYMCX^\PX4^//3LRZV>+CQ?Y^3G#:$:,'D$9FO!T^.Q''J.A[&0:_=7S/C!6V
M>N]EA9_4[+WR]=LJ5)W)/YCG:<[C@N4PCF,,24I2F(N$0"YC4F#,,$FE2W?G
M*^,Y,4.P5L^BBW@OFVVQ#?L.'LUF1%V&_T6;QO7+L-I6YY"W(P^/>([N-K4@
M]I*D6F'!BU^O03BX\-458$:I@'5NS&<IA74%@',UL:Y==D-QK"&-[:T;/OU#
MFB-Z_9UO>OGZ17Z4#ZQ<ZL]_,\$NC&^V;/%9KA_0/,F1B$260,:YZ5NO28W&
MIH96D65"84Q)RIUK:$U"M:FY5S8]$?]J=0.L40ZL.^T WZL'M+@/X$6YK!>Y
ME2/C3L="+F6])B'PA.:1YVFIV $%6J3 #BK0PPH8L#R7"IN4_?U7%)N&>N$+
MCTU#[S-.P 0E/.=O]-^VM_JG__JW[A/]AY'OO_[M_P-02P,$%     @ 5(%V
M5-?%#-[B>P  %\T% !4   !C;&)S+3(P,C$Q,C,Q7W!R92YX;6SLO5MW6\>2
M)OC>O\)S^G7B..^76E752Y:E4YJ6+2U+KM,U+UAYB930AP)4 "A+]>LG$N"=
M!(7+3NRDIQ],4R"Y=UR^C(R(C(SXY__Q]=/9#U]PL9S.9__R%_Y7]I<?<);F
M>3K[\"]_^?W]2W!_^1__^M_^VS__7P#_ZZ??7O_P\SR=?\+9ZH?G"PPKS#_\
M,5U]_.'O&9?_^*$LYI]^^/M\\8_IEP#PK^L_>C[__&TQ_?!Q]8-@0MS]Z>*?
MG-+,L"A H;2@G$C@ GI@*&30V1ONP__]X9]8X<K(8$ S'4$9SL$7^@.ADXG6
MNZ037S_T;#K[QS_5+S$L\0=B;K9<__-?_O)QM?K\3S_^^,<??_SU:UR<_76^
M^/"C8$S^>/G;?[GX]:_W?O\/N?YM[KW_<?W3JU]=3A_Z17HL__%__?+Z7?J(
MGP),9\M5F*7Z@N7TGY;K#U_/4UBM9?Y=NG[8^AOU7W#Y:U _ BY \K]^7>:_
M_.M_^^&'C3@6\S/\#<L/]?^___;JUBM3. MY,3U?_C7-/_U8?^/'YW/" ]&Z
M_MO5M\_X+W]93C]]/L/+SSXNL/S+7])97-([!>=B\\;_OOG#'Z]?_'F!2\+*
MFM'7],'%W]>W'$ $?EWA+..&L\M7G,W3K5\ZJW*=7_WE68AXMOYTDG$Z63_U
M65RN%B&M)ED(ZWU!2(HG4"IE I66@#Y8%%IBT/PVSY7F)1&]5L,2TU\_S+_\
M2 _^L<KA/U7]%C;?K@5R[Y4;X1Q&^^7*>T^_.\FI6"DQ Y/>T;*)!8+DQ(FW
M6F'RAF$\FO2;;[Q-^4W%/END'^:+C LR'Y>O#(MT3\FWH7OQ&S]^#@MZ$*2/
MT[-\^=?5C@RAL]5\ .EM5$/D_N4'XKK@8H'Y]48S6YE;<[8BHXKKWQQ"Z\]F
ML_-P]AM^GB]6D^(M^I@8!,Z0A! C!+*7P+@M.1;)M1.#:?_FFW="@>@?!0=+
MLQ,TO,7%=)Y?S/+/M =/M)+%*=H T<I # 3:0YU,D*1TSG*6:7<<# ZW7KT3
M'F3_>#A<GB,#XOGYHDKJY71)>^A_8%A<\D!.%$N%D9N$68-BV8/7Y#^)E%E$
M*T34[OB];<O;=X*%ZA<6@TBU$U/Q?A%FRVF5_86Y$R(%5\C/CF@XJ"@$Q.P8
MY$#:99S+G/5PKL.=M^^$#-TO,@:1ZLC(>#%;35??7D[/\-?S3Q$7$X)Q,%%$
M8"[2!DA@IAB,PJS"2TKD'?&0V-&(N/O6G9!@^D7"45+L @&_X8=I%<)L]6OX
MA).4M$F,/*"8#-DV%SA$@0H,<64,RZ;PXT.*A]Z\$Q)L[T@X0II=H.$YR6H1
MSEY1A/WU?^*WB44T9,9RM6"1#!IC$*,2Y!IKQ;-6I@@Y$!SNO'HG/+C>\7",
M/#MQ':[]GY?TR7*B;4D%I0#:RQA9.),I9+(!C#3..Y?(-1[.<[CS\IU X?L%
MQ1 R[0H6FY!IPX2+.=#.I\%+BII4YK3U$?F@LW=&:U\E-# P;KQ^M]04>RK8
M.%2P(Z/C&7&0UUR<A0\3'Y7$PHEFK\@98MQ#-,I"4-&JB$R4>+Q+>>N5NZ&@
MXPSEX0+LPG]X-4OS!85":Y&_(\GC\_DY;8'?GL\S3DS1R1E9P+AB@3:\"-&6
M"":FDGB)A4L_D#?Q*"&[H:3C#.;0PNX".^_#UU>9Q#<MT\VIV$5(I7)&ZZ,!
M+64&E9P#I[('2<(1,>B24QX(-5M(V TO'6<XAQ-P%TAYEC/I8'GQO]?3&?*)
MBE*'X#WY3$71)DE?O#2E;I(490EK<QS*MCSP^MT0TG&R<QC!]H2.Y_3MF\7[
M^1^S2<PE2%DT:$(S*&,21,<59&6\=%$7(XX/6;:\?#=D=)SL'$*H/>%BO5&^
M6;Q=S+],9PDG2*0+2]0SHRCV*BI###E!B%Z*&!.Y6D/E/1^F8#>$=)\$'4"\
M/<'D[7RY"F?_[_3SQIER/,E2#"1>T[J&(T3!+;"<743';+A6T# @N?7^W2#2
M?7;T:-&.?<Y:>5A@6-.MM>3,R @>Z_EP\@1L;AADK[) [S6JXS>5FV_<#00=
MIT0/%M_(:J]5>F=O/\YGEX<\.1=C):'59"/()4J5BYK6]ZF$@,QY@4>K_NY;
M=U-_Q\G/H\0X,@3>83I?$'PI'GH_79WA1!;!-)<6."\4,V$NX,E+!A6"359S
MDD$Y&@)WW[I;X57'.<ZCQ#@R!-XO0JV'?O?M4YR?36S0VI+] N%E/=EC$4)-
MMKB"F2L5<I3'GY/>>N5NRN\XM7FX #M9_"^^IH]A]@'71[N19UF8=J #6^-5
M0L@*P;O"R:/)/,3CR^T>>O-N..@X>7FT.+L($_Z.9V?_<T:!\#L,2]K3\JOE
M\IPVM<AU5HZ\&<ND L6L!">)+XIWK,+H@C7'E]P]2L)N .D^6SF$@+M RK_/
MS\Y) 8MUF=!B.;$4XY"'0R&PU@:4#0JB5P%(7$G7_)K/0Y78W'GU;LCH/DMY
MC$"[0,1%9>FF:+!NB:2$\^5$&DG<*TOF+]&6&+6"8(L%-*HXC-[Q/%0*^V$*
M=L-'][G* <3;!4Q>S>AI)([I%_PYK,(%6R0<EDQB FC#).&8$,$%E2 R"IM*
MT([C\:''8Q3L!I/N$Y8#B+<+F*RMX/.PP@_SQ;=)B=QIY!1*EPIUS1QXB0ZD
MDID%HZPJ8< RWJL7[P:*[E.4APNS"RR\^Q3.SGXZ7TYGN%Q.<C%2*J- 9A,I
MND8-/ND !0-R)[GU<:B3\ULOW@T+'6<JCQ5F%UAX\0D7'VC[^]MB_L?JX_/Y
MI\]A]FWB$C(9<X3DF:2XVZ=ZG"O V<*E25Y+:P?"Q(,$[(:-CM.80PEW9(R\
M2F7Q[#Q/Z3>>K5:XW.A@7746=(JQ> 1=;\<JU!2&<Z2 W!='*T G)8\_V=C^
M_MVN$W:<Y1Q(M%T8D7<?*0R_A#<O.0BG-80*:N48AZ@+ U%TDB5B3&ZHR/7F
M>W<#1,>9SR-%V040WI['LVEZ>38/JPE!6+"0 SG&F>0@F(>0H@<N?#;%AB+R
M4#[FC=?N!H..$Y_'";(+%!!\/]5:TWGZQ[N/)+;EF_-5;6M2$_L3$XT,M,=1
M@(WD(=E$WC*3#+0KC!YFDK-#%4D\1L=N..D^_SF8J#NY,+*\+E?&_-.WWRHE
M.$OX'K^N?J)?_L=$%J^54QZR4H&8DAD<<0F,!1V8Y%JRXUW3G<G9#48=)TO;
M"'XP-/WSC_<$^YH^.+AAT=KC>C4K\\6G]<-N$[Q;[Z)[SQBFC='CI!W9T:AR
M,;G[ABOP<%=2R<D CZQ>.%0<2*,)K/&)29EI\PG?D\JC;SCJMM#&25X?  JN
MG U6072:/&,E+&V*@8,3T<>HD=SCXY/?-UXX3BNCX91UZ]+0@7(<^[+8ANS7
M%TW0)LQ(9R33H'DIH++PM05/IB]9NYP->40#7!>[_=)Q>ADUA<%!\NP#"B^G
MBT^O\B31QB.1MB+-C27"K02?$NU]#+TE,&=MU5! V+QRG!9&36%P@"R[W=N?
MSV?+^=DTKST8^C%Y+Q1-XVIYR":__6%#-2W<B=@CM_WS)7P(X?-D76]?W;PW
MY>5T1B^;AK.W\TU7FBLHZ5"8".3@)<%KMH'T'[QS(*(PV89H4GHLHU?",JXU
M?O'2]:KZ$<]6R\M/UA(&QB_:3O[W?:@[U&Y<ON/9<DG"O>*U,"5HV3C(R=9[
M*5E O68 F>N8I96&6&["ZVTZQO$OFJ'BTL ,(/01MYK;U%^<^%XQX:7GAI'!
M-4PC*%\8N/6-)LYL2%ZQ[!YK8' L<NZ0,RZ CM'O@U Y1M@=(.9Y6'Y\-LOU
M?R_^\WSZ)9S5R/K9ZGE8++Y-9Q_^/9R=XZ3(K!7MS"!*+6)VCIRM% 1HC8KX
M4I;+QQR7PQ&T$WD](.HH&,Q;ZZ0#H/T2%O_ 58AG>%$G.\7E1$B1.:TST(Y+
M4$+6N_Q1 )=9)N-=\OJQ@Y?#<?40->.$3.U@=+3$.T#-VP5^#M/\XNMGG"V1
M%L6;U4=<W)+5A >G43-63YMH(2@*#&,6% D4P8J0P3GQV*G-X2#:@;AQXJ]V
MF!I:'QU [#;QT4?,,=<3AUISJTCQ45&8BL9X-$5$71XK<Q_(5QJGQ6P[V!PN
MX\,!,E^%LX%LT/PS+E;?WE+(NR+(USWY<XU!?L75Q!2E>/(%. H">Y8$]B0Y
MT,<J1^:55VWP\AA5/>QD@[C8@XF^ SMSPU+^.I^ER[6@'<J0+)&N."@4#FA1
M</ L.!E"SCH]=CQP.'X>)*>'[6H0X!PO[ X0LZ%_HJW/.DH!)OM8VQ@E"%(5
MLKXN*\3$=6@3?&W>W\->-&"\OI<X.]A]7D]#G)ZMG7<R@.NRB8_S,Q+ZLAK#
MU;=KT40N*Y"A!%=OG:,&%SB'5+/A3NB0W6/S7@Z'R:X4CKLK-<\<-E%4!U;H
M!E]W7<)B,PLJ& BE!I-RO92B 5EX,JB%3[S-YK6=IG%S06TPL!UHQRBD V@]
M2ZDV=ER^#=]JFN(R/O!6IY M@@](PM'>@%>R0#)"HM*9O+PV6:&'Z>D&4D=I
M^^YF>+SH^P#0XIS>>D]&DQ"=M"5)8,K6R7O,02RZ0''>96<2=ZZ1T[2-I'&W
MOW8P&D !'2#I(0XX"XR3FRFDK6LATZK :J,S*V)]:4J<:G<;-RYKA)TC1=Z!
M;[Z.,F^P<2/4#*HP1*L(_H8$8UT![TG;4G$9#(O<I\=JQH^,ZQ^D:=Q KA&(
M!E)!7Q9H0I&L,_5^;E$Q5=(]>)<04BRI*"X4XX]5# YB>L899G4ZF[.7D#LP
M-O7>Q'2U+GROA\/S66T!@13'$BLJR^B9UL!T'3;L:Q]24;,;MIB$6'?BQUHG
M''$^OYVH;OR==I'84"KIP/H\(J'@I,E!90BYI-ID!"%BS9$4;[VV4MO2JLCN
MJ%32*?RA=M@:2"$=0.OMY7O7+&V*5[2@&, 5 \Y8#BKQ0M\I#MI&Q&*<5H]V
MM3_JS/XN,6-7- ZCY_L']4<)O0/<W+@H>%'Q9"3FHA+%D+70.Q5++H"H(64N
M@04=XZ/WZ([;Y6Y2,G8FNPEBCA)W!W!YEO,ZF1_.WH9I?C5['CY/R?>:2,T9
MK_W\F<F>-F(G(;)ZN;1D+J+2C/,VJ-E"T+A[5R/P#"'\#C#T?H%A>;[X=F,5
M&*N"T"05+^K\]" Y1)<MF**<UD7RK-H<J]VG9=P OA%RCA3Y_J#Q&]#,\$.]
MR/)^,.S\AJLPG6%^$18S"@.6SU(Z_W1^5E_R,Y9IFJXF@D5/GC^M 5FG9"I&
M,8%5!;+T05J1M9!M"O&_3]NXT7XC; VLD@X,U T.UIFOVG9E@1]QMIQ^P7H?
M_A.^GB^7O^+J37D?ODZD93))[D$R6\C^>E%'NG- 5M!'#-&;-K6Q>Q(ZSKSL
MUIMB0V5U@,7[4IL@A1.16P]6,5'+<RQ$3LZCQDB,%"Y2.%6J8)RYVXT1=:3(
M.\AB_C*=S1>734IQN9KH;(/A68+Q>3T$EL1AF87"C5%"J, >;0Y\Q!60.Y2,
M,YB[,6".$G>7-H;LYMEY[17TMC9!)N6L5HMI/%_?<WD_K\<_\]F*J* G?KCB
MFAFNK>=U%$,BR\J-KC6?!@PWY&E&+.9Z*FICNW0(_>.,!S^Y+6NNV@[LW_=R
MQY/ :+<7SH'UDH&*=2@VXZ)VT?.9Q"D3MHD1OD=9-\?')ZFL.UXY@X'M9$TG
MWJXU\1%74_JKVVP<V8'B]I,;MZ-XA(U3]J;@14F.=92'=A9414UD6D)*%&7*
MP%1B;6X&G:(WQ>WCA<W<LS=ET\^/Y+_.XUS>#OQYNDQG\^4Y_>A*.,ZZPB0%
M.*CK*D7ZSGEAP"6NN.5<N?S8I+FASG_V)GSLLZ*!<??XJ5%;M7;@7=YF=\/F
ML_/51W*9_POSI'"RZ3*2=Q/KQ(3BZMBFJ$$J%HV)/JG4I@[Y<;K&Q>!)(?(H
M/(_2UXCH6W?'NLW*ZRGY%WFMP\T/<+V;$7\3*1W2ND7@RE87&Q4X5T<U,*>+
M9D+)NQF\+8T.=WWCN(>;8\"KG4*ZLW$DPC>+]3:2UZ)\BXL-5RZ47'2X*(%3
MG$5P2F;@@OQ;@RH&W::";#?ZQCTT[<?F#:*_OFS?1HP_XW+Z85;YFCAOM62Q
M]O?TN9:I<#+H24&QKO;VPY"*.,#BW7W/N/%L)W;N*.%W9]TVW*SG*>9)9$+Z
M8L5%IM,H!T$Q1B;("9-$+/K1<6+#>F\;FL8]9.W'BAVLITX1=[.#/6:1DC >
M0A8.E!4)?"!/5!@E=$ ;2CH=[/:='M#LA+4W[!VJL0X >*-.;W\Y6J%R"B9"
M%%E5Y]5"U)YX34HGDTS!T*:)Z#%4CUUNV3CI<C*%]@7>K:XL42VS"@0A4^\@
M\Y3!"5_;1?OB3;0IV39%!#L0-V[NY71(V0[10=36%Q+O)9)8L!3$2P]9,$-+
M6M0Q [0MH"\HK"?/!!NU.]U.U+A&L ?D':6F'A%WX0 ;SV)!)T'75O@J! $^
M&45L9"MDL9KI-C5Z6P@:-]?2#](.4$^/*+LU7LLBQZ@1BJDM\YBH]^M%!($\
MZ)!45JY-L=71<\V:)6+ZP=NABNH =+>*^&^+D<3W&Y*XIJEJ]"$A>B^5XN0V
M)U';@1:,X*35@"2 E#TOUJ;V-RSVI'KL6SR-8Y*3*;0W\&YXG)1D,K-%@M$8
M:&%G,OJUT4 V@F&.M+Y%F^*-!X@9-^8X'1(>@^ !:GD20W^N%O)R7MY\QL7Z
MZ4=/_]GRU.'KKG8A?Z":J\U]B:L77D%,F2B<9A&RK)E!70)XG>NI!8M"1^=%
M:+-2MQ!T=$^AC1AG'RYZK-_H?9J1!6$%U$+&>I<2(28O@*O@;(@97:.\R%:2
MQK5,0R#B7CNA0:3?P:9&AAF)@#I'Y&?\@F?S==OL"ZXF05/HDD,&+>NUW% 0
M@D<#DGAD(2?'&R4X'B5K7#@-I/I[5Q"'TD,'H'J'Z]K[O^&,1'5&+#W+GZ:S
M:173:OH%+[F*')F/,4*RA1Q/J1UX6R=WBB ]YB09:^/0[T;?N)FT-C!KH)D.
M\'9/5A.-W N.&0S:3 P8#][D^L\2H]>EQ$8EF?=(&3< ;(.BX^3=P>V:*P:N
M;]=. GH9426@<)<PKVV Z%D!'I@P6C'%69OTZ@/$C&MZFCI,!TJ\ ]#\.I_-
M;W-Q.=[H*HS%[%U$"ZZ8=<EGO6U6Y\@'QZR(T0ALDS;]+FGC6J$6@!I6&QUL
M8J]F7W"Y;A*X8:>.KHDV$ \\0"UK 65I'PY6*$C*BU*L\<*TZ>_Y #'C>MT#
MJWL^K.P[@,_Z[&&KE":6%8S<*##UZ%T99R!F1FY=4;1O6Z^$;-AG>"M=XVYT
M;4$UH$8ZP-=V1B+16P+7$$..Y$EB@6@X@@@EKON4R-#&<3H.5<UVN[:H&D8/
M';A3UX[@2Q+AIBGN.3%UG1_^"<M\<=$ YWWXBLL77TE^I+[I+"R^O2)G8KGE
MLK_&1,8[&8I:R;M0K(Y_<@I!YAQ3**RVR6F8[&W"U+C'WRU<N%X0T,UB(!8O
M%O-/.,,R74VX+3[8I&K;<0E*:0[.R-IETP:T#ATVNIRPA:!Q;R:T ^%QDN]@
M>WZ[F!/5F[#:)63)V-IW0E9I)/">!2B*HFWCB7;>ZF;!)0WC7B)H 9,#Y=N-
M:7G,RC[6/^<%_?KJVX28#"5'!HZ5M;,:P*40P?@2E0LJ>=NF,=(0U(_;XFV<
MG7-@G79@X2@FOY$[3$P:;FA_=TJI.AM:4> D&7CN>#8B9K+8;8*.FV2,VPNN
M25KM8"EW8.HN^[=>WC7X*2RGJ9ZH3L_.5YBO;XF1^Y>5R9#1UV[35H'3.H$Q
M7.IH:!64-JV^=R1PW#YN+6#50C,=V*0'V9H(K;/D*E&PX8@)62@0YXA 7@,&
MG:QAN4W5Q(/DC)NW;:+X7<"UEQ8ZA-*%@";6V6"+*8!<!U"BED8:GL *ZY%E
MZ]6)P'1!T+@9VS'@=(@F.@34'5%MO:O HV-DTA&R90Q4MA:BI>@W,Y.*L(YY
MT^:DX$""=[-O[$^T6PZBN@X0^G><?OA85^T7BEH^X.VB\1NW7#;VG%.P$H(1
M@$9&4*[0DH[DFDIR2U$S%-&T26OL16;7N^TPP)F?2HO]0O1"GO?O8RDIA'&*
M0=02R>F0'ARG$-MXGA@+OEC5IF_"GH1VO8N?$J:#:/+)72&Y-6%BG<BXQ<EQ
M-TGN/[SMA9+O,#-\+]_-EK^>Y'EO4,<U5DWQH;J</)#+J&PD;]%J TDICM$J
MFV2;[6I/0@<\>#"92>%M(@=9$<M9U")0H<&B3]QDE ;;C,#:\^#A%'UW!\?(
M(P<2^\B]@SUUEQDWM#-,YYD^KY?[\&?<_/\ZO.,QE2P4H'*AWA>4$!@J\K#K
M#L&DCZ9-H>7QM'?3I*@Y0D^LYXZ1_?N,V#JKO4C^;7Y6O8N_A>FLBN'-[!VF
M\\5FDL!BNJ0?_4S_G'W8R.5JXI/+.: S#CSS"4CV$F*R")8)(P++435*6+?B
M:.0K7"=&YHX+XZ0PZ7BYW!IVYJR,C$)&\"6[VK#6@,NV@ G,>68RC[9AX>H0
MX^C:71'K$\8'JZ^#$\0'V+EDY:"I0](I;7@18%71H#!'\+5$4QN#+C+#@VO6
MHVY(1KII8]+<:QD3 7TO@)W8%2(Q[K6"PK4 Y7B"&$,]*<F(D>2O19O*VR,)
M'WMF<A< 'US#'3@9C[ [$25HF;P'CDB;4PE(:U.XVB?0YI UU[I9_\9M1(T]
M8+D+(.ZEF2<Q0.UFPO)B3MZ *=>;D_>:Y5D?(GOXY.HC(_M\B13(< LB$1Z4
M%1J",@)2"4):*T6P;48>[D3>\2-,+U[ROIK?26*81"X<@JP#%I"\YU!J8\EB
MI THO0AM;--M.KI)J Z$B_O310^6>@>;VQ7U&XE4BSJ?U=7Z[.MT.=&R:"F5
M 5WJR%-+YM3'E&JLA]Z+6A#3:LKV(V1U@J@#]+T-.D<+OP,DW>'AY_FG,)U-
M1$!A/,NTE'0DH4A.3#@%6K.(C!M'*Z]-+=!#Y'2"G./5?;?<YVC9=P"@S335
M7[ >JT\<>2R*.0^YYGH4HT#!:^T@95FB+@*%:K-3WZ1BY%*<XY5Z]\3O4 GW
M@(Y;LU4N>3 F,%Y[<](:(6$4 8%97T>#2^4Q>";;G&H\1,W(TS(/UNVC0VP.
M$'0'8+G1\?J" 9\BX[5K-@^*@0K:0G 6@?9K[T-M7ZS;[$/W2!EYZN50,#E.
MQ =CY LNXGP@E#S+>=W'.IR]#=/\:O8\?)Y2/'_!#M;*!\D+B* U*(T:8N0,
M0LA8$@JF4IO>@H^2-?)XRJ'0,YSH.[ VSU(Z_W1^%BX+#Q](2UTP)C+W(MH(
MQ:E4F^W7.%,K""EDG>A'W+0)R7<F<>19E8/AJXE*.L#:;[@B+Q#S90'L!1=1
M6K1V;7;7O1AK>U=+7B&%GXDK1J**;8S5P_2,/'YR*!0-(.P.('.KO?VE5%BP
M7G,%5FORYVCCAJB\AIP2#[F(P+'-(=L#Q(P\+W(HL!PKY@Z0\O!YW04O66JG
M=&TT%M?34^M-I,(2N*(MTXX[;=LTQ'V,JI%O(0P>H0^F@0[0=)7N>DTV=-UI
M:<(T$5SC1O2%UI>CS=8;%T%(HQ5JW6S8R7U:.JFB'3")?)B8.P#*W=JR5[/[
M1S6_T8IX.5_\$19Y(B@@2-H9R-514\Z3517$K59&:2V*1-;FBM2>A':2;3X0
M%_<;QC134@<8O']]BW%G<V(66(AUYJ,E0VN2!Z&38YAIH6*;AD6'7;5K.?RD
MG>+OVK*CM' PC#ZO2UQIP2Q6 ^U\=P5T6.&?L!9C%N!2G:&@2Y4DITU"\<2U
MTQI#F]M0P] _>@OZT\'V]/KN!NLW;I&A#]%SQT"86M<7E06/04"HW3*XM,KX
M-A9SS]M[+;O4GPQS!\J]@ZWVL:K_9U_"]*PN$A+1NW"&-VZMY/]]OFFP?EWB
M)['8( NP8M=!$2/_F1MP47*>K=+.-YJW,1 'HS?D/1E:1]%Y!UA?2W0SWOGF
M?:N-GW/9N0#7!;(DEK7J)UPPGY+.@+F&@(K6=!32 :WK[)B)P84VN;D#B!V]
MF^]I]_B&FNP7K.O9U%LXC"S8[).".M&+)&H+>,DTR!3J]%07+&^3%-R?UM$[
M"H\-U:'TV"]2-XOQ5_QC_2-RC#!GK8V'9#(%C[)>'?0B /E*V812+'UR>DMZ
M1=_H787'1N0Q^NJB@N2QE7;-5F#).Z8R:$M"4]I:<"@%,*LL+R9ER]M4J>U$
MWN@=B,=&X1':ZMT4KG_XYO.ZG_>+K[A(4S+\D^1"#L@=>"_(V*.)X*V1H#'I
M8%7T3+2IA=N?UM'[&(\-SJ'TV"]2-V[)@PR*1.(,V0)CH38/5QZ"4(&X#"BR
ML]JI$;S+@W':M(7HV$ =2(T]X/3>(00ZJP(F6FAN?6&9=@-'D@.,.C >@@ZN
MD1]YV%'0G_0L:!\U')D??S'+/9T$19XD#UJ"X1EK,VKBG*<"L;@LDQ7,-AKB
M=,*3(/Y_CH(.4_B@4#]9_]"P_/CR;/['L'U#KQ[:N%_HP\0/?Y7]ZD770]=#
M)&20#0RR%H)I3SY?E@9L1L4U5US*5LGA[50-,)BG/O/M8OYE2O+[Z=OOY#:\
MFEU-_'Z65M,OFQ.!2SF8$!RR%(%[66]+TG>A</KB23H\\LQSF[/&_6GMI SH
M6#0],.>GI=(Z< 1O'+$6CEIS;0%EJH6\==*5MQ%4L(*+DJV);8X:>VE,VUK;
MVT^W]Q%]!Z"Y/K-<OI__AK2YI^D9WAJ*]7Z^KRAU,BD(J\ F),X%N27.V S:
M!2N]K(T9VW2K;<'-R!.[3PODT>'0P9*HR8(P2WC1@N79+/\]+!:!1%)/_''Q
M99HHT%L\/PO33\M)=-RYJ#7H0@&>RDZ#CS+6VS7<<I-C\FUZCNQ%YKC6>'Q4
MW:T.;J;B#O#[,]*;TW2CW5E^]JD&<O^U.3C%8@L+DL"$P9%MD $BF@!,:(E"
MVQQ8FQN=CQ UKH'M#IM#J:\#)#Y+:8%K/FXP44>0+-/\O#:2F>6W"_PT/?^T
M?#7[@A=JF!3:H4S2"50157K1@O>Y]M%-7@1/#E1N$S0>1N^X19S=X?<$2M\?
MVGX#[1E^J,F1]PWO EV)]:)'P'73-N-B4E'7-%V=IL<$A;%&0TBUD-I&94*;
MK/SN-(Z+Y!.[NHU4UX'9O<\9+;C/89I_OJ#GQ==:2E5;G:X+79\MET@K,&46
M2UV!)B%Q*8.IE?T"3"XY>)%,<6V.+P^CM[=K1L.@Y[L@'5R571O3RM.U =@P
MEP-YXU8@6)F(.1(N^"0M*"1KX+0VBK>Y9[0;?;W=(SH1+H]6U?@XK"<W#W!&
M#LW:<7D;OM5#L.K?G%\MO.7ERGL]#7%ZMMZ>)CPP&6LEEBBF3F+FODY!]8"U
MZA\YRHAW<@+W#XV&(J:W*T:#PG$4C76PP^_N*DVX\-9+3PY\R;'V]+!U+&^$
M8H0)J>X%C8I!=J=QW'M%)W8[&ZFN@TD:6SC;!'D/"Q(SC](07Y()18)D&;PM
M$:(.!64IEC<J%-F?UDX:<)SH6'0HI75@*VD3N,B./$O_>3Y=X"]A\0]<U[-<
M7]V;8!#*>>T@ED#^B5 &O/,9(G>2!\>+:F0F=R*OR\/4P3!RK^WOT H[UK4<
MZG@^(>;E2Y)OO3=*;L@O8579^?:F/,BBX=HQ=&4SC%DQX2%Z^J?7/F3%"4^J
MS3'JWJ1V>4;:#)]-%=FCQ22.R3U9?7M[%F8K8K=6"GZNOS*1Q;,<.:_=PNH
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M<GA,;5#)($3)(1L6@T^6^T;]EP<A_ZA;#Y?:>4\*^>ELG38-"8,0&3CF7*^
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M/CO/N6Y39-'.G/T4EE,*VN^\X-OFZ_6:L25X;E0$8U/E7)$'$;(!F8N5MHB
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M6%!Q\?Q3EE,\Q%+[8HJBG9/%4API+3E7S&3PIC;U2,KS( E-O$T*O%TQQ=9
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MWYN)-H >.L7312J9R.;2)PM9K\7#2%!%UKH8$4.0T:-HD[3?3M.XF!I&YSL
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M1@_=-G%\EM+B'&]N"X?4RSSPE&&J9+Y'WD"U,?=?\YQV0%RWXZ,-,5W\XZI
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M!1@'"'=$:*Q[)FRL]:M9;2(U_8(W%U7E2C#N?L':A&^B4U2B=@1EBEM0WI&
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M^!=[@6<2/:L7DXRM!UI>@P_U&HB+:(H3Q:HV;>FWDC1RBG)TM&P9!WR<ZCK
MX+_CLI;"KM>S\:IH'0,P9D@@+ H@O\:!L!*E4"DPT^:2S@TBQ@TH^]C"#]5)
M/W"Z6&'2F9PD+0.TM>%-XAR"XAZ$$8*GV@HGM_$*;Y$QKNDZ6)D/@^( R78
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M@XOI/$\\ZA(,2Y!RKA.+HX-8,NV*OBCI9)"NM!D],A@+(Y\(=; 23@Z$7E;
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M/KH(GP6*-P\@K<_7@:M??\<T+_-U&+1VA"'+RG)1R,#FKO9$8@I(TPO044;
M=58@[FQTM%SPQ"4@/0)]9"E/C7S2VGF]F;[V#.M-JM5-?O&*1S_@ LL\S</9
MNS\6]-)/\]^_66UTK-T^T&9$II9%6?!DCH$2)4&,M?M7-"7YY(T*PW*^HRYK
M&(I/)?LRG<2FQNIW&? ']/6;+J[9_?ILN3Q?1]IF3IB,=6Z!R-F#*O5V19VM
M:43F J.S,@YK.W'(*H8A\53R-$>3Q]3 NQ-*^_QYOEJ1Q-XM?CI?KE:_G"\3
M8EZ]NB0?]L.G^7G^I2K6;[^O.Q!<=<E@.JD0/62=R1(R44'(+$*J?:VR\SP.
MK,(_;!W#P'<".9ICRZ2'@/MC*=&W^,?Z5ZL9URQHAT05"TB[N4$(CC.B3QL,
M#'/TC3KM#5K?, 2>4CYG?+%T +9K]7E-'+PNDWU7JI8M%VN*9X5'IGUMNLQ#
M[916&#@F&60K<P@^(5-M6IP^N;1A$#NA-,ZXPN@ 71L6_2/42OZ+=^=K&_9;
MCAT3Z='%'%<OP]D9YA^^;OYNM?G#U<S(PDK.&;#H>M_1UDQ5<E D9JYU"9ZU
MR28>N/!AR#R!=-(4@NP5M]=]3*[:FI3[-/(9F7#2*"<!8TCD56D)P=0,JU=.
MTT$0"F\SS&FOY0[#Z EDGHXGM Z0>4W BT6^HN#=Y<7J(BPR&23K'I/:"L4Y
M&G"NCAYBK%X_CQ&\Y8YY+QS>GUH]$@B?6MDPO)U 6JB)*#J UHY[_(\A?;K[
MMS,1+?><&6)?]?.9+1 L:H@"2RF:^:"Z.*Z_7_HP<)Y EF<:87: WD?=LW<7
MG^JP+,PZITP*B"&""CE!],5"[;SK'$>16DWP>7)MP^YTGT#RI9$X.@#8;>=L
MHRK7QL5JYK)D.I)5:U,=3<^*@YBT@B2BE\62U]]HYWML5<- =0*YD-%%<$+-
MV&[-3UZ1;7%M=(S:E.V)=[1JSK8+:6V:M+%4?#:)U2EY!921")%)!98%PWAR
M%L-)-&G;MWWBAOFW#-?WR[.SU\OS^LL95Y'VX,AI1Z[VJZ>M.EA9KZR;8!-'
MA;+A<*/1Z>FJ-=PNR!MM*LMXXN[@/!Z1"U=V\2P6YE/0ZUI;!%44G2"N%, 0
M1. E)<98[WB_(N5$Q]N-B,]V*K,'6/;6EM^OC.:+<'[1A<ZLAS>MWFR&GJWS
MKS,T/JF2+#CNR8P7**&V62+3SEE6DLZF4=2S 3$G.@RO7[TY%# ]G#./>;*W
M3=AK5R3/T'J.-CA(6@I04E=:I0'MZ5A/@IS<H-JHQ,YK/='Q=@T1WU;<NP/:
M7P%ZL6Z]D#]T8S\1LPO.+R[7%\(WMV$Q%F^L19"UJE5Y9B#6;+4-VID42?-9
MZO(L>("8$QVFU^]9<"A@#E6=+K3F9G#L#1,L2TJ$VF^7EYHGLAF\Y!9L,HH)
M$;)2G8W5WD[,B4X"[%=K#@7,\SEPOO?!LF1>LQA I^1(+CJ")U%!85F$P )R
M&[M4G/T<]OYF$_:K-H>!Y4"'_<=%'X?-WW%%&OQB4<>58ZK*O*P??<\;Q5&;
MI ,X$SBH6..2@9RS(CU34F2%IE'/_"-1.*UCWU'LMPDD>O#2V_!EX^35:JH-
M7P09IK2G*3#HZZP$3GRQE2\JRH268<Y]GCE#*9PV(M"_JAP&B6>@*K?VBG]@
MO2I$3/J"Y^$CWKEL62V!LK$$=/!.,YO KUMD!^EI6W$.R C(IA1#<FTTY^?H
MM$X;-NA(?1K#Y*^C2#.G=:FV- 1="\V+$"1%D\'5NS22,6M#.&7M>3;9RB8X
MGT8M=P+=Z>0W5SOEJQYE$+$@YSKVP>>4:6]-$ES,"0RW1AFN>;K?\_Y86CD>
MD<\F']J%9DX$OE,X*9]BS;=KGH.X(XU.B,F"#)','F2UX!L3B(*"!%Q\:=5%
M^:AT/IO<[4EH9SL(/@<%?2"Y]RA_HK9%ER3JT#\$E5R"*(($H:/PR7*?&]V\
M/3:ESR:-?!)*VA*&ST%-'\@F/LH?+7U@PC#04M7&?@4AFDA>0.:<)*NR2A-%
M.T>F]-GDK4]"35O"\!34="0?W0I6K&4&I*R]9ESR=6ZS!I992D&ZX/)$+N@1
M T.GD!7O0BDG -U?)H_^*,>\MPZ9X8""1U"2%7!%!!#&>Y?1>>;ZK*,ZC.YI
MC]2.,B%'A,\S./R>3KL^RJW L<1@&7$K&E"E#C?1Q#*R% I/6@@1^TR6'$;W
MM$=E_\K6 C[/0-EN)A6_FJ_2V7)5/>=O<O1%)<F5!&2R=FA(&D(IDEQD$J'*
M7OO0Y\'U*%G33ESI2%7&$WXOFA"?9D;<V?Q]CW6N,WW^<KE8L^8RG-7^3J)6
MLDEC580L30WR>DXG<[#@2]8J%,^U:UCZ>%QB3SM)/R+4'U+"CG'W#%1S9_MY
M&^?X3+.$RB,'*R5Q3F4+@6GRLH7AEGXE435J =4-#TX[I]^O(D^$TN>KW]M-
M]NV<<SG:B*K.5I5UG!;+9%@)05JI4G11J6 ;55YWPX/3OA5P<OK=&J6]Z/<X
MD>4WQ(GY8C5/?P]GESA3@KFD290HA";OQR9P/@3(MD["DR(FT6?OD*TDG7:Z
MO['V38ZAJ8?+O/CX\7Q=5GN7ABL:;QI*"*-<2LJ ]^AH?_ 1HM8%G.2:6407
M;;FK%EN&R Q[WVGGOL?';"M1/9]2[*=MW2WLF\6BA?*E3J%&#TK( ,[6(O8H
ME(M:F'1_/E(G._[>))]V$KO?$^$X&'P&YM?3ANLV1@F=BF2<@8AU.+&4"D*R
M-?W(BA',^I)/-9=VB+(VRPW\Y91U9 R>LK)>Y87>+$A8E^LK=.LFZ1\^A<6&
MA6^7BR]K+MYNL1%C4BQ%!5E%,GX=&2(N6P-9\G4;2B?U1)4.H](Y[43Y'E)V
M[>$QM6]T:\S9=2?P-2M6,\L+"BD<.*7HE)8AT<:%$@1/.H6B9.)FD#NT]14G
MFMPZ BB6HTMH\F+1-2W7!*QK[LB/2RY(P8('XW*H-R_I7*S='&S01EN5Z+@9
MAK%[#S[1;,N1D76(-*;>MZ[7?A,3D!:3]&1H:4F&B@IUWJPS"3A:+%+Y''C8
M"4NGWJUU(C3M)Y'IHS1WB'A9AX">$0V*>?31!>!%2_)5N:JC/]>WQ(.64L?$
M^$ZHNG[RB8:L)P+57O+H#%/K\ALB(7.7L@KD!PI-:A&CAVBS@*1DX5FD5#C;
M<:-:/_A$ \J3;5.[2Z,30&VW"',FLX\K"S'XVMJ]V&H16K ^Y9@"%T8/@]9A
M-GM_<=5N;/9=)#1Q'<^:DJME7[$F+#)N DD7R_K1#*.5*3I'7CA&4"6%.E9,
M@T9C8PQ98?*#\/;H:P9AKMF4R!'B$"-SLA?;^RJ\.),F98VH ;EBI"5&@$>;
MZ80FM4DE:V[33N?9U7.'10>:#6<<2^P',*L7.3]51WF]7:I2<DBT/Y*[:$!A
MY.",Q5HY7&_;,)9P-P]LX(N'(:7G&6/-V3TYE!ZAZ9KN6SG$F2\F(_),AZ--
MM!TBDII$"9P5K6-0,IJ!;M=N+YXF)-E>_,LCR:*3,., "J^#7L1&3J>M!&\T
MV7C<"8A&&F EF*!8YMX\.=MSUY=.$Y[L#V7[R. 4=K*;$)C)+"04&6*IQWTA
M#R((%L"4' O3/B6M1D/7Q '+_O"UGQQ. 6'?XF%%698-2C#)$?\TC\0_CJ ]
MLQKK2!(91P/8M+'+_O"UEQ1. 5[7P3'-C6-H$$1*-5JA!3BG"R#S2KIDC,_#
MKL3N\-)IPIC]@6L?&9P"MFZ;EM$$EZ//H%DFTQ*# A_(:W+.L((BJ>+L9&;^
MZ%',_C"VKRQZB$P.H6_+!;A9UHR;(AA8:2RH5"0X1DR-)4ONG2@BNM%PMV41
MPUS-GJ?C'%4,I["UW;I8.2LI!IM(G8)EO Z^(MH"=Y"]+]'ES,AD&-ORKR\>
M!JN>)\DT9_?D4+K>?6L.ZJ$[PS'2AIO)G(S6U#V?(;B"FL!!K)11QY3D,.P\
M\:9A8.EY;LKX#)T<'</J6?^XHGEYZP0O1%<2SD(*A70@"PO>)P[%.R/I0+=<
MB7VVG.%+Z"!\.@X&'MF*&@GD1&!W]T@/UT?ZQ>9 %V@5DH?BG75TH".#&- "
MSUX%U!$]#MRX1EA-!U'6R< XGIA.!)<;[=ODUV>>V&A<$*!5(:<Y<P_!$'^S
M+XD^%DSZO?)'PU[?0?QUZFUP'T%,#;4MQ5 /.<O2V10469JEQ R*5(AV]NB@
MH/3:5U[R85FCX>_L(.@Z/J@:L;QS)&V[!%3*^G(K,4]P\H=Y8."E29 D,FEM
MBIX/RQ;M]_X.(J]'1]@8HC@)M,V$XTS4;OY>&](?D2-$'W0M]L!LBPA"#@M(
M#'I=!Q'6B;"T$Z-'@\[_^:_O&/TS?;#^U?HW]5^]Q_(_Z_]_>__FSO-3. OY
M?'ZY^M]I^?GJ^>N[JY^69R2GU96;_IZH.Y]7%5G_CE3FWB>_+>87JU=X$>9G
MJ[OTK>:??S][\CP\])7_=4/L?39LWOP=QEH3CG]>(&TM^7\=5MY\+TXBA5>F
M% >ASM!1R2KPAI!<+/(LA4X^MVFW=G<=!Q=MIT^8+\_P7=E_LLF'=?!/\D)J
M9A%8C1ZKJ.N$OL"!&W1%!2O8_3326/788Y$P;2GL ?CZKM1Z$J%VT(+@:N7T
MQR_^G*]F+A=,*G+(=3ZDDLI 5(P!)D<N=\S$1M8$D7>6,7&!]3106(XEEPY
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MERAZM?P<YHN9Q5ATL@ZR9)+<D4RL44Z2%QU<1'H0R^)(.+I:42>;T@'2?A)
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MVYSRA8\QRM_P:8C_2*7_7U!+ P04    " !4@794>@*57@L%  "_%@  %@
M &-L8G,M97@S,E\R,#(Q,3(S,2YH=&WM6&UOVS80_KY?<570- %LO<>)9==
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M7_(5W_%':WU?K6[.X]\!4$L! A0#%     @ 5(%V5 Q!C0CIJP( A348 !$
M             ( !     &-L8G,M,C R,3$R,S$N:'1M4$L! A0#%     @
M5(%V5.?D5AUK$0  #[\  !$              ( !&*P" &-L8G,M,C R,3$R
M,S$N>'-D4$L! A0#%     @ 5(%V5..&&^2['0  [B,! !4
M ( !LKT" &-L8G,M,C R,3$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( %2!=E0J
MIBF-S30  !Q% @ 5              "  :#; @!C;&)S+3(P,C$Q,C,Q7V1E
M9BYX;6Q02P$"% ,4    " !4@7948&_4]>GE  !OV D %0
M@ &@$ , 8VQB<RTR,#(Q,3(S,5]L86(N>&UL4$L! A0#%     @ 5(%V5-?%
M#-[B>P  %\T% !4              ( !O/8# &-L8G,M,C R,3$R,S%?<')E
M+GAM;%!+ 0(4 Q0    ( %2!=E1B!38W>0<  /\B   :              "
M =%R! !C;&)S+65X,S$Q7S(P,C$Q,C,Q>'$T+FAT;5!+ 0(4 Q0    ( %2!
M=E1Z I5>"P4  +\6   6              "  8)Z! !C;&)S+65X,S)?,C R
M,3$R,S$N:'1M4$L! A0#%     @ 5(%V5#.9#?*T P  E L  !(
M     ( !P7\$ &5X:#(S,3(P,C$Q,C,Q+FAT;5!+!08     "0 ) %8"  "E
%@P0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
